"companyid","keydevid","transcriptid","headline","mostimportantdateutc","keydeveventtypename","companyname","speakertypename","componenttextpreview","word_count","componenttext"
265621,321831219,920733,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Operator","My name is Leo, and I will be your conference facilitator this morning. At this time, I would like to welcome everyone to Danaher Corporation's fourth quarter 2015 earnings results conference call. [Operator Instructions] I will now turn the call over to",57,"My name is Leo, and I will be your conference facilitator this morning. At this time, I would like to welcome everyone to Danaher Corporation's fourth quarter 2015 earnings results conference call. [Operator Instructions] I will now turn the call over to Mr. Matt Gugino, Vice President of Investor Relations. Mr. Gugino, you may begin your conference."
265621,321831219,920733,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","Thank you, Leo. Good morning, everyone, and thanks for joining us on the call. With us today are Tom Joyce, our President and Chief Executive Officer; and Dan Comas, our Executive Vice President and Chief Financial Officer. I'd like to point out that our",325,"Thank you, Leo. Good morning, everyone, and thanks for joining us on the call. With us today are Tom Joyce, our President and Chief Executive Officer; and Dan Comas, our Executive Vice President and Chief Financial Officer. I'd like to point out that our earnings release, the slide presentation supplementing today's call and other information required by SEC Regulation G relating to any non-GAAP financial measures provided during the call are all available on the investors section of our website, www.danaher.com, under the heading Financial Information. The audio portion of this call will be archived on the Investors section of our website later today under the heading Events & Presentations and will remain archived until our next quarterly call. A replay of this call will also be available until February 2, 2016. The replay number is (888) 203-1112 within the U.S. or (719) 457-0820 outside the U.S. and the confirmation code is 9714607. 
During the presentation, we will describe certain of the more significant factors that impacted year-over-year performance. The supplemental materials describe additional factors that impacted year-over-year performance. Unless otherwise noted, all references in these remarks and supplemental materials to company-specific financial metrics continuing operations of the company in [ph] the fourth quarter of 2015, and all references to period to period increases or decreases in financial metrics are year-over-year. 
During the call, we will make forward-looking statements within the meaning of the federal stimulus laws, including statements regarding events or developments that we believe or anticipate will or may occur in the future. These forward-looking statements are subject to a number of risks and uncertainties, including those set forth in our SEC filings and actual results might differ materially from any forward-looking statements that we make today. These forward-looking statements speak only as of the date that they are made, and we do not assume any obligation to update any forward-looking statements. 
With that, I'd like to turn the call over to Tom."
265621,321831219,920733,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","Thanks, Matt, and good morning, everyone. We are pleased with our results for the fourth quarter, in which the team delivered double-digit earnings growth, strong core operating margin expansion and record free cash flow. Despite the more challenging econ",2253,"Thanks, Matt, and good morning, everyone. We are pleased with our results for the fourth quarter, in which the team delivered double-digit earnings growth, strong core operating margin expansion and record free cash flow. Despite the more challenging economic landscape, particularly in our industrially oriented markets, we continue to build our competitive advantage and drove share gains across a number of our businesses. As always, the Danaher Business System is the foundation for our team's outstanding execution. 
We also made meaningful progress toward establishing a new industrial growth company, Fortive, which will be spun out of Danaher later this year. At our year-end investor meeting, we announced Fortive name, branding, future operating structure and additional leadership position. We also achieved an important milestone in December, filing Fortive Form 10 registration statement with the Securities and Exchange Commission. We are confident that Fortive will launch with a strong foundation and will be poised for success upon completion of the separation in the third quarter of 2016. 
For the full year, our investments in organic growth initiatives helped drive solid 3% core revenue growth. With the addition of our recent acquisitions and other portfolio moves, our total annual revenues are now over $20 billion. 
From an M&A perspective, 2015 was a historic year for Danaher. Including Pall, we announced and closed 14 acquisitions for nearly $14.5 billion, expanding our capabilities across the portfolio. Looking forward, our funnels at both Danaher and Fortive are strong, and we'll continue to focus on small and midsized transactions throughout the separation process.
In 2015, we generated a record $3.2 billion of free cash flow, including over $1 billion in the fourth quarter. Our free cash flow to net income conversion ratio in 2015 was 123%, representing the 24th consecutive year in which our free cash flow has exceeded net income. We recognize the importance of this metric, particularly in a more challenging macroenvironment as strong free cash flow is a fuel used to fund both our organic and inorganic growth initiatives. 
Now turning to the fourth quarter. Sales grew 12.5% to $5.9 billion, while core revenue was roughly flat. Core revenue growth, particularly for our consumables businesses, was negatively impacted by 4 fewer selling days in the quarter. In addition, the impact of currency translation eased this quarter but still decreased revenues by 5%, while acquisitions increased revenues by 17.5%.
In a weakening global macroenvironment, the Danaher Business System helped protect and expand many of our market-leading positions, driving share gains at Hach, ChemTreat, Matco, Gilbarco, Radiometer, SCIEX and Videojet. 
In the high-growth markets, declines in Latin America, Russia and the Middle East were more than offset by double-digit growth in India and high single-digit growth in China. Notably, annual revenues in China exceeded $2 billion for the first time, and we remain well positioned in the most attractive sectors in the market. 
In the developed markets, revenues were down slightly due to incremental softness in the U.S. and Western Europe.
Gross margin for the quarter was 51.2%. For the full year, our gross margin was 52.3% and our gross profit increased by almost $900 million. In the quarter, core operating margin increased 120 basis points, with all 5 segments improving by 60 basis points or better. Our reported operating margin was flat at 16.6%, negatively affected by the dilutive impact of recent acquisitions and acquisition-related transaction costs.
Fourth quarter adjusted diluted net EPS was $1.27, which represents an increase of 13.5% over last year. For the full year, adjusted diluted net EPS was $4.30, up 8.5% from 2014.
Turning to our 5 operating segments. Test & Measurement revenues decreased 9%, while core revenues were down 5%. Core operating margin increased 110 basis points, primarily due to new product introductions and good cost management. Core revenue in our Instruments platform decreased at a high single-digit rate, with declines across most major geographies. Food core revenues were down high single digits as industrial markets continued to weaken in North America, Latin America and the Middle East. In December, Fluke acquired Pacific Laser Systems, a leader in handheld laser alignment tools, to enhance its product offerings for professional contractors, electricians and general maintenance customers. At Tektronix, core sales declined high single digits. Declines in North America, Latin America and the Middle East more than offset growth in China that resulted from solid execution by our local sales team. The team's continued investments in innovation placed Tek in a position of technology leadership within its industry. This quarter, Tek launched the MDO 4000C, a Mixed Domain Oscilloscope that combines up to 6 instruments in 1 unit. The new MDO 4000C is completely customizable and upgradable, allowing engineers to start with a high-performance oscilloscope and add functionality over time as needs change or budgets allow. 
Matco, a business that will be a significant contributor to Fortive's results, delivered its third consecutive year of double-digit core growth in 2015. Even after 3 decades as part of the Danaher portfolio, Matco continues to find new ways to improve using DBS. By deploying such DBS tools as web marketing, Accelerated Product Development and lean conversion, the team continues to expand its franchise distribution network, gain market share and expand margins.
Turning now to our Environmental segment. Revenues grew 1%, with core revenues up 4%. Core operating margin expanded 60 basis points, and reported operating margin expanded 260 basis points to 21.8%. Water Quality core revenues increased at a low single-digit rate, a combination of fewer selling days and forward demand from our more Industrial customers in the developed markets resulted in essentially flat core growth at Hach, while ChemTreat grew slightly. Trojan had another very good quarter driven by healthy demand and increased bidding activity in the North American Muni market. Hach delivered another impressive year in 2015. In addition to mid single-digit organic growth, Hach continued its healthy cadence of bolt-on acquisitions. The team has done a terrific job implementing DBS in newly acquired businesses to help improve sales and drive innovation. One such example is BioTector, which was acquired in 2014 and had double-digit growth in the quarter. BioTector provides online total organic carbon analyzers that help our customers monitor water quality in real time and reduce waste.  BioTector's early and effective application of DBS tools such as lean conversion and pharma management led to more than 200 basis points of margin expansion, significant inventory reductions and market share gains in the chemical and dairy segments. 
Gilbarco Veeder-Root's core revenues grew high single digits, with strength across the platform. In the U.S, point-of-sale solutions and dispensers increased over 20% as our customers continued to upgrade their payment systems to comply with EMV security requirements. We expect EMV-related demand to continue to accelerate for the next several years. Moving to Life Science & Diagnostics, core revenues grew 2% with reported revenues up 34.5%,  largely due to our recent Pall, Microscan and Devicor acquisitions. Core operating margin expanded 75 basis points. 
Core revenues in our Diagnostics platform increased low single digits, with growth in the high-growth markets, partially offset by slight declines in developed markets. As previously mentioned, fewer selling days in the quarter negatively impact our recurring revenue streams across the platform. 
At Beckman Coulter, core revenues increased at a low single-digit rate, led by our immunoassay and urinalysis solutions. Utilization rates in Asia remain healthy, leading to high single-digit growth across the region. In Europe, we celebrated our first orders with the commercial launch of our Veris molecular diagnostic system. Veris is streamlined sample in result out workflow offers breakthrough ease-of-use in a market that is experiencing a shortage of skilled technicians. In short, it's helping our lab customers process more tests, reduce training requirements and save money. And thus far, customer feedback has been extremely positive.
Radiometer's core revenues grew up slightly, a deceleration from previous quarters due to the effect of fewer selling days and a difficult comparison in Instrument sales. Geographically, we saw healthy growth in China and Japan, while Latin America and the Middle East declined. 
Leica Biosystems had a good finish to the year, delivering low single-digit core growth as strong demand across most major product lines was partially offset by the impact of -- from fewer selling days. Notably, the team delivered a record year of placements for our BOND advanced staining instrument. 
Last December, we closed the acquisition of Devicor, a leading provider of breast biopsy devices and markers that move Leica further upstream in the anatomical workflow. Devicor continues to track well and has exceeded our expectations, posting high single-digit core growth or better in each quarter since acquisition. 
Core revenues in our Life Science platform were up low single digits with growth in both developed and high-growth markets. SCIEX core revenues grew mid-single digits, with continued strength in our clinical and applied end markets. 2015  marked the fifth year since our acquisition of SCIEX. Since then, SCIEX has proven to be a remarkable example of how thoughtful application of DBS principles can drive tremendous financial results. The team has taken the business that was growing below market rates to mid to high single-digit growth and share gains. We've seen significant improvements on the cost side as well, which has enabled SCIEX to invest those savings into higher impact growth initiatives. Progress at SCIEX continues today, and 2015 marked one of the most important product innovation years in SCIEX's history, with the launch of its X series mass spectrometry platform. The X series introduced an entirely new design, easy-to-use software and custom models for targeted applications in routine food, environmental and forensic testing labs.
Leica Microsystems core revenues were essentially flat as strong performance in China and Japan was offset by declines in Europe, the Middle East and Latin America.
Turning now to Dental. Segment revenues increased 17%, largely due to our Nobel Biocare acquisition. Core revenues were up slightly. Core operating margins increased by over 500 basis points in the quarter, primarily due to consistent DBS implementation across a number of operational areas. Reported operating margins were 15.8%.
Revenues in our consumables business were negatively impacted by fewer selling days in the quarter, but our team continued to execute well and saw strong demand for several product lines throughout the year. In particular, our investment in innovation have provided us with truly differentiated technologies such as SonicFill, TF Adaptive and elementsfree, which all launched in 2014. In Dental technology, we saw our first quarter of positive growth since the fourth quarter of 2014. Top line results continue to be impacted by destocking within our U.S. distribution channels, but to a much lesser degree than in previous quarters. 
December marked the one-year anniversary of our acquisition of Nobel Biocare. The team has quickly embraced growth, lean and leadership tools of DBS, helping to not only accelerate growth but also improve operating margins by over 300 basis points since the acquisition.
Moving to Industrial Technologies. Revenues declined 8.5%, while core revenues were down 4.5%. Core operating margin expanded 80 basis points, and reported operating margin expanded 120 basis points to 21.6%. Automation core revenues decreased at a high single-digit rate due to weakening in industrial markets in China and North America. Despite the challenging market and revenue decline, the team continues to identify cost saving opportunities and delivered solid core margin expansion in the quarter. 
Core revenues in our Product Identification platform were up slightly. In the fourth quarter, we continued to extend our reach into new Product ID adjacencies with the acquisition of Laetus, a leading supplier of track and trace inspection systems for pharmaceutical packaging plants. Increasingly, pharmaceutical tracking is becoming a regulatory and public safety concern and Laetus gives us exposure to this important vertical. I'm more excited to welcome Laetus to the Danaher team. 
At Videojet, core revenues were up low single digits as strong performance in Europe and North America was somewhat offset by weakness in the high-growth markets. Results were negatively impacted by fewer selling days in the quarter. Throughout the full year, Videojet has placed a major focus on digital investments, driving key innovations in areas such as network monitoring remote service-enabled printers and predictive maintenance. As a result, we achieved record new equipment vitality of over 40% for the year. These tremendous technology capabilities have not only certified Videojet's leadership position in the market, they've also meaningfully improved our customers' experiences.
So to wrap up. We are pleased with our record fourth quarter results. During the quarter, the team delivered double-digit earnings growth, significantly expanded core operating margins, generated record free cash flow and announced several bolt-on acquisitions. Despite the more challenging economic landscape, particularly in our industrially oriented markets, we continue to execute well. 
Looking back, 2015 was a remarkable year for Danaher. We completed the largest acquisition in our history with Pall, announced our pending separation into 2 independent publicly traded companies with Fortive and drove excellent overall financial results. With the Danaher Business System as our foundation, we believe we'll continue to deliver earnings outperformance and create long-term shareholder value in 2016 and for years to come. 
We are initiating first quarter adjusted diluted net EPS guidance between $1 and $1.04, which assumes approximately flat core revenue growth. As we announced at our annual investor event in December, we continue to expect full-year 2016 core revenue growth of 2% to 3% and adjusted diluted net earnings per share to be in the range of $4.80 to $4.95, which would represent a 12% to 15% increase year-on-year."
265621,321831219,920733,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","Thanks, Tom. That concludes our formal remarks. Leo, we are now ready for questions.",14,"Thanks, Tom. That concludes our formal remarks. Leo, we are now ready for questions."
265621,321831219,920733,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Operator","[Operator Instructions] We'll take our first question from Scott Davis of Barclays.",12,"[Operator Instructions] We'll take our first question from Scott Davis of Barclays."
265621,321831219,920733,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Analysts","I think -- I mean, given that it's been a month since you gave the last guidance in mid-December, formal guidance, I guess, things seemed to have degraded a bit on the macro side. I mean, what confidence do you have? I mean, now that you've seen, I guess,",81,"I think -- I mean, given that it's been a month since you gave the last guidance in mid-December, formal guidance, I guess, things seemed to have degraded a bit on the macro side. I mean, what confidence do you have? I mean, now that you've seen, I guess, most of January, I mean have things stabilized? I mean, your guidance seems to indicate that you think that was a bit of a blip, I suppose. Just a little color there."
265621,321831219,920733,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","Sure, Scott. I think, Scott, what we're assuming is that what we saw was some of the slowing in December is essentially the environment that we're going to see in the near term here. It's clearly impacting our more industrial businesses more than our othe",225,"Sure, Scott. I think, Scott, what we're assuming is that what we saw was some of the slowing in December is essentially the environment that we're going to see in the near term here. It's clearly impacting our more industrial businesses more than our other businesses. So we are not immune to this slowdown. But I think we took some appropriate actions in the fourth quarter. Those actions are going to pay off here certainly from a margin standpoint. But I think the other thing to keep in mind is that the portfolio that we have today truly does differentiate us. And I think when we look at the opportunities that we have in our Life Science businesses, our Diagnostic businesses, some improvement that we're seeing here in our Dental businesses, continued good progress at GVR, while we remain cautious in some respects around the macroenvironment and are not assuming things get materially better there, we are playing offense in a number of areas that I think will bode well. So I don't think there's anything particularly optimistic in our outlook around the macro, but I think some of the things that we're doing from an investment standpoint and across our growth initiatives should continue to position a very good portfolio and a differentiated portfolio and continue to move it into an even better place."
265621,321831219,920733,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Analysts","Yes, makes sense. And then just as a follow-up, the emerging-market currencies have degraded a fair amount. Are you able to get local price to offset that? I mean, how do you manage that volatility just given the exposure you guys have?",42,"Yes, makes sense. And then just as a follow-up, the emerging-market currencies have degraded a fair amount. Are you able to get local price to offset that? I mean, how do you manage that volatility just given the exposure you guys have?"
265621,321831219,920733,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","Yes. It's an issue, I'd probably bifurcate the answer. Where we have the aftermarket business, the consumables, the service, we're typically able to get price. With equipment and instruments, we are not able to. And we've taken a little bit of a margin hi",71,"Yes. It's an issue, I'd probably bifurcate the answer. Where we have the aftermarket business, the consumables, the service, we're typically able to get price. With equipment and instruments, we are not able to. And we've taken a little bit of a margin hit there. Fortunately, the euro stabilized so the overall currency impact is not what it was in '15, but it's a little bit of a negative right now."
265621,321831219,920733,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Operator","And we'll take our next question from Nigel Coe of Morgan Stanley.",13,"And we'll take our next question from Nigel Coe of Morgan Stanley."
265621,321831219,920733,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Analysts","Just on the $0.40 from Pall, can you maybe just first of all comment on how Pall's tracking, how it tracked through the quarter, maybe commented on the industrial business Life Sciences side? And how does the composition of the $0.40 in the plan changed a",53,"Just on the $0.40 from Pall, can you maybe just first of all comment on how Pall's tracking, how it tracked through the quarter, maybe commented on the industrial business Life Sciences side? And how does the composition of the $0.40 in the plan changed at all in the last couple of months?"
265621,321831219,920733,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","Nigel, we are very, very happy with how we've gotten started with Pall. Starting with the team that we have in place, a terrific team, both the Pall leadership team, many of whom have taken on added responsibilities. But in addition, the added resources t",398,"Nigel, we are very, very happy with how we've gotten started with Pall. Starting with the team that we have in place, a terrific team, both the Pall leadership team, many of whom have taken on added responsibilities. But in addition, the added resources that we put in place and the leadership that we have brought to bear in the business, I think, together, that team is off to a terrific start. We'll talk to the $0.40 and the cost opportunities that we have here in just a minute. But coming to the growth side of the house, about what we expected, continued very good progress and growth rates on the Life Science side, keeping in mind that, that business has an exceptional position in the biopharma market in Life Science. So we're seeing continued good growth there. We're also seeing outstanding growth in single use technologies, which are a key part and a key growth driver of the biopharma segment of Life Science business as time goes on. On the industrial side, again, what we would have expected, which is a slowing on that side of the house, we've seen that those businesses impacted far more than obviously on the more Life Science-oriented side of the house. But I think it's also important to keep in mind that, that business is also strongly skewed towards consumables. In total, the portfolio is about 70% aftermarket consumables primarily. And so that's a strong foundation and I think continues to give us confidence that while we'll have some segments that are challenged, the business overall will continue to perform quite well. Relative to the cost side of the house, again, off to a very good start. You heard us in December, take the 2016 number up to $100 million because we've gotten off to an earlier start. We're getting the kinds of cost reductions that you would expect us to get out of a public company in the early going. The public company costs, beginning to get after some of the indirect cost leverage that we get and some of the procurement cost leverage that we get by consolidating procurement across our other businesses where appropriate. And over time, we'll see some of the benefits coming from -- on the gross margin side as we look to the operational footprint, but that will obviously take a little bit more time."
265621,321831219,920733,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Analysts","Okay. That's helpful. And then on the balance sheet, you've taken down a lot of impressive amount of debt since the acquisition of Pall, I think about $3 billion of debt paydown. Given the bit more challenging macro, is there a changing bias toward deleve",47,"Okay. That's helpful. And then on the balance sheet, you've taken down a lot of impressive amount of debt since the acquisition of Pall, I think about $3 billion of debt paydown. Given the bit more challenging macro, is there a changing bias toward delevering this year?"
265621,321831219,920733,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","Nigel, I think we remain in that kind of $2 billion target for M&A this year. We are incrementally encouraged we are able to get some deals done in December. Granted they were small, but we actually saw a flurry of deals get done towards the end of the ye",117,"Nigel, I think we remain in that kind of $2 billion target for M&A this year. We are incrementally encouraged we are able to get some deals done in December. Granted they were small, but we actually saw a flurry of deals get done towards the end of the year. Clearly, what's going on, the high-yield market has made it very difficult for the private equity parties let alone industrial companies have a lower credit rating. So some of the anxiety out here definitely helping some of the conversation. So on the margin, we're a little bit more encouraged than we were at 60, 90 days ago on the M&A front I hope I didn't [indiscernible], Nigel."
265621,321831219,920733,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Operator","Our next question is from Steve Tusa of JPMorgan.",9,"Our next question is from Steve Tusa of JPMorgan."
265621,321831219,920733,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Analysts","Can you just maybe talk a little bit more specifically about Pall Industrial trends? I mean, what is the organic -- what kind of organic are you seeing there and what are you expecting for 2016 a little more kind of precisely?",42,"Can you just maybe talk a little bit more specifically about Pall Industrial trends? I mean, what is the organic -- what kind of organic are you seeing there and what are you expecting for 2016 a little more kind of precisely?"
265621,321831219,920733,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","So Steve, for the 4 months that we owned the business on a constant currency basis, Pall grew about 4% on a combined basis. Really, would have been accretive to our core growth here. Life Science was up high single digits, Industrial was down low to mid-s",88,"So Steve, for the 4 months that we owned the business on a constant currency basis, Pall grew about 4% on a combined basis. Really, would have been accretive to our core growth here. Life Science was up high single digits, Industrial was down low to mid-single digits. We see that for the near term, not a bad way to be looking at the business. Clearly, the Industrial piece is more challenged but more than making up for with a very strong growth on the Life Science side."
265621,321831219,920733,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Analysts","And then what was Pall's contribution to free cash flow in the quarter?",14,"And then what was Pall's contribution to free cash flow in the quarter?"
265621,321831219,920733,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","So on the working capital side where we contributed north of $300 million of cash out of working capital, Pall was a nice piece of it but maybe 15%. The working capital improvements were very broad-based, really exceptional performance across all the 5 se",57,"So on the working capital side where we contributed north of $300 million of cash out of working capital, Pall was a nice piece of it but maybe 15%. The working capital improvements were very broad-based, really exceptional performance across all the 5 segments. So it was a nice contributor, but it was not an overwhelming piece."
265621,321831219,920733,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Analysts","Okay. Great. And then just 1 last question. What's the kind of the restructuring contingency look like in '16? Is there any change to that as you kind of exited the year a bit of a weaker rate? Or are you kind of in kind of normal day-to-day planning? H",61,"Okay. Great. 
And then just 1 last question. What's the kind of the restructuring contingency look like in '16? Is there any change to that as you kind of exited the year a bit of a weaker rate? Or are you kind of in kind of normal day-to-day planning? How kind of extreme things around some of the more Industrial businesses?"
265621,321831219,920733,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","We learned from 2015 and we're pleased about it that we did a number of things throughout the course the year from productivity perspective. And I think particularly in an environment like this, it's important that we stay cognizant of the fact that there",164,"We learned from 2015 and we're pleased about it that we did a number of things throughout the course the year from productivity perspective. And I think particularly in an environment like this, it's important that we stay cognizant of the fact that there may be opportunities that present themselves and things that we may need to do. So we're going to keep the teams active at looking for opportunities thought the course of the year and we'll take advantage of those as they come up. So I think we got a lot done in 2015. We got a lot more done in December than we anticipated, probably $20 million north of what we thought in December. So that's a good thing, sets us up well a little bit more than we would have anticipated. But again, I think it's important that we stay cognizant of the environment business by business and look for opportunities to take action where good projects present themselves."
265621,321831219,920733,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Operator","We'll take our next question from Steven Winoker of Bernstein.",11,"We'll take our next question from Steven Winoker of Bernstein."
265621,321831219,920733,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Analysts","What was the Fortive versus Danaher corporate if you split it that way for the quarter?",16,"What was the Fortive versus Danaher corporate if you split it that way for the quarter?"
265621,321831219,920733,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","Sure. Looking at Fortive, probably being rough down 2 to 3. And Danaher go forward up 1, 1.5. So that's roughly the way it would split.",26,"Sure. Looking at Fortive, probably being rough down 2 to 3. And Danaher go forward up 1, 1.5. So that's roughly the way it would split."
265621,321831219,920733,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Analysts","And just a couple of things.",6,"And just a couple of things."
265621,321831219,920733,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","Steve, I'm sorry, Steve, sorry to interrupt, just want to make one other quick point just for clarification on that. It's important to recognize on the Danaher side of the house that 1 to 1.5, that side of the house has a higher percentage of consumables",118,"Steve, I'm sorry, Steve, sorry to interrupt, just want to make one other quick point just for clarification on that. It's important to recognize on the Danaher side of the house that 1 to 1.5, that side of the house has a higher percentage of consumables and recurring revenue than you do on the Fortive side. And a result of that, the fewer selling days in the fourth quarter has a little bit greater impact on the Danaher side. So when you normalize for the days impact on the Danaher side, that's going to be potentially could be 1.5%, 2%, maybe on that side. Again, rough numbers, but it has a little bit more of an impact there."
265621,321831219,920733,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Analysts","Just on a couple of the segments. So I think this was the at least 11 quarters since I've seen Fluke go negative, so maybe a little commentary on the what's going on in the industrial environment, specifically on Fluke? And then also Life Sciences & Diagn",87,"Just on a couple of the segments. So I think this was the at least 11 quarters since I've seen Fluke go negative, so maybe a little commentary on the what's going on in the industrial environment, specifically on Fluke? And then also Life Sciences & Diagnostics, it's the lowest I think I've seen in 14 quarters. So we you went through a lot of detail there, but to what extent should we be concerned about any kind of bleedover from the broader environment into their markets?"
265621,321831219,920733,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","Sure, sure. So Fluke. Fluke clearly impacted by the downshift in the macroenvironment in the quarter, fluke being one of our more industrially oriented businesses. I think the macroenvironment, while it had its impact on us on a broad basis also had an in",144,"Sure, sure. So Fluke. Fluke clearly impacted by the downshift in the macroenvironment in the quarter, fluke being one of our more industrially oriented businesses. I think the macroenvironment, while it had its impact on us on a broad basis also had an influence on the way our distributors were thinking about inventories during the course of the quarter. So I think one of the things but we don't have all the numbers right now for full transparency on what happened to channel inventories, it's a pretty good hypothesis right now based on some early data we have that would suggest that there were some inventory control that went on in the channel that certainly would have had some impact as well. So I think those 2 factors combined, again broad-based macro on sellout and probably some impact on sell-in based on inventory contraction."
265621,321831219,920733,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","On the Diagnostic side, Steve, so the bigger piece is obviously Diagnostics that's largely consumables. Diagnostics were up 4% organically for the year. And as you remember, Q1 really had the extra days, we're up 6%. Q4 when we had the fewer days, we are",70,"On the Diagnostic side, Steve, so the bigger piece is obviously Diagnostics that's largely consumables. Diagnostics were up 4% organically for the year. And as you remember, Q1 really had the extra days, we're up 6%. Q4 when we had the fewer days, we are up 2%. So actually on a days adjusted basis, Diagnostics tracked pretty close to that 3% or 4% rate all year including the fourth quarter."
265621,321831219,920733,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","Maybe one other thing to add there is that best we can tell, Steve, we didn't see any year-end budget flush there in the fourth quarter. That's a little bit more Life Science-oriented phenomena than a Diagnostic-oriented phenomena. But in some past fourth",116,"Maybe one other thing to add there is that best we can tell, Steve, we didn't see any year-end budget flush there in the fourth quarter. That's a little bit more Life Science-oriented phenomena than a Diagnostic-oriented phenomena. But in some past fourth quarters, we've seen the impact that. We didn't see any of that in the fourth. Good news and bad news on that front, it has an impact on the fourth quarter. Sometimes, that budget flush can drive some inventories out then create some go forward weakness as you start the new year. We're hoping we -- in the early numbers coming out here in January, look like we're off to a decent start."
265621,321831219,920733,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Operator","We'll take our next question from Jeff Sprague of Vertical Research.",12,"We'll take our next question from Jeff Sprague of Vertical Research."
265621,321831219,920733,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Analysts","I wanted to ask that question a little bit more broadly, to what extent do you think kind of the more industrially oriented organic growth rates kind of clearly reflect end demand versus maybe broader channel liquidation? I don't know if you have any good",59,"I wanted to ask that question a little bit more broadly, to what extent do you think kind of the more industrially oriented organic growth rates kind of clearly reflect end demand versus maybe broader channel liquidation? I don't know if you have any good insight into your other channels or any even anecdotal color there would be helpful."
265621,321831219,920733,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","I don't have much there, Jeff. I know the teams are still out talking to customers and trying to get a better sense of that. One reason for a little bit more insight on Fluke than and less so, Fluke a little bit more concentrated with some big distributor",91,"I don't have much there, Jeff. I know the teams are still out talking to customers and trying to get a better sense of that. One reason for a little bit more insight on Fluke than and less so, Fluke a little bit more concentrated with some big distributor partners that get a little bit more transparency a little bit more quickly. Some of the more automation controls businesses and so on, more fragmented channels than not, just taken us a little longer to get any sense of channel inventories."
265621,321831219,920733,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Analysts","And just shifting gears a little bit. Any thoughts on how the device tax place through? Do you see any change in demand there or any change in the way people are pricing competitively and maybe just size what you think the impact could be to your business",50,"And just shifting gears a little bit. Any thoughts on how the device tax place through? Do you see any change in demand there or any change in the way people are pricing competitively and maybe just size what you think the impact could be to your business this year?"
265621,321831219,920733,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","Sure. Jeff, when the device tax was first put in place, the impact of that was fairly modest on us. There's money at stake, but overall not a huge number. So what comes back in terms of a little bit of a lift to operating margins is also modest. I mean, n",136,"Sure. Jeff, when the device tax was first put in place, the impact of that was fairly modest on us. There's money at stake, but overall not a huge number. So what comes back in terms of a little bit of a lift to operating margins is also modest. I mean, net, net, it's a good thing for the industry. We didn't see much impact in the market from a pricing standpoint when it all -- I should say from a competitive standpoint. We did get some of that back in price over time, and probably some competitors did as well. But in terms of real impact to competitive dynamics, I think it's too modest a change certainly to the scale of our business and maybe to the scale of others to really impact the competitive."
265621,321831219,920733,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","Jeff, I think we said in '13 it was about a nickel hit. We recovered some of that i n price. So I think it will be less than a nickel, but maybe $0.03 benefit here in the year.",39,"Jeff, I think we said in '13 it was about a nickel hit. We recovered some of that i n price. So I think it will be less than a nickel, but maybe $0.03 benefit here in the year."
265621,321831219,920733,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Operator","We'll move next to Ross Muken of Evercore ISI.",10,"We'll move next to Ross Muken of Evercore ISI."
265621,321831219,920733,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Analysts","Maybe on Dental, can you just give us a little bit more color just sort of on the progress you made throughout the year. It looks like ending the year you had some of your best results obviously adjusting for the days. And so as we sort of now roll Nobel",88,"Maybe on Dental, can you just give us a little bit more color just sort of on the progress you made throughout the year. It looks like ending the year you had some of your best results obviously adjusting for the days. And so as we sort of now roll Nobel into the sort of core and we think about the margin progression of that business over the year, help us think through kind of the pushes and pulls and how happy you are with the progress made?"
265621,321831219,920733,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","Sure. Thanks, Ross. I think 2015 was a year of a very good progress across the platform. You mentioned Nobel, let me just start with that. We have a tremendous team of folks at Nobel, largely the leadership team that was in place when we acquired the busi",318,"Sure. Thanks, Ross. I think 2015 was a year of a very good progress across the platform. You mentioned Nobel, let me just start with that. We have a tremendous team of folks at Nobel, largely the leadership team that was in place when we acquired the business. They have really embraced DBS and are off to a terrific start both in terms of continuing to use DBS tools to drive growth but also as in my comments earlier some great progress on operating margins. And now as that goes core to the Dental platform, we'll see some impact of that to the good. On the business that existed prior to 2015, I think again 2015 was a year of a lot of progress. I've mentioned a couple of times that we've had outstanding relationships with our distribution partners. We work in a collaborative way with them on channel inventories throughout the course of the year. That was obviously somewhat of a painful process to go through in a sense that the impact on core growth. But net-net, a very good process in terms of positioning the channel efficiently. So we are pleased that the vast majority of that is behind us. There can always be a little bit of a tail to that of stuff we are still moving out and so are moving inventories. But again, I think a ton of progress. We've also got a very good leadership team in place in our Dental platform today with some new players in place that I think are doing some wonderful things in terms of driving innovation. It was a very good year of new product introductions, and I think we'll see the benefit of that as core growth improves this year. So we know we still have work to do there, but good news is that there's opportunities for value creation as we go on here."
265621,321831219,920733,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Analysts","Great. And maybe just quickly a little more color on the M&A pipeline. Can you just give us a sense? I mean there's obviously been a ton of equity market volatility. We're seeing obviously a shift in how the private equity folks are also sort of transacti",114,"Great. And maybe just quickly a little more color on the M&A pipeline. Can you just give us a sense? I mean there's obviously been a ton of equity market volatility. We're seeing obviously a shift in how the private equity folks are also sort of transacting. Just give us a feel for maybe healthcare versus industrial-oriented assets and the like, whether there's more activity at one side of the spectrum versus the other and how sort of the valuation dislocations have been kind of digested by the various groups? Because you're obviously doing smaller things at this point and it's obviously the large end of the market that's probably been the most impacted."
265621,321831219,920733,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","Sure. Well, I'll let Dan comment in a second on kind of the environment that we're seeing. But if you just look at what we did in the fourth quarter, which I think is a bit instructive, we got 4, 5  small deals done in the fourth quarter. And by the way,",168,"Sure. Well, I'll let Dan comment in a second on kind of the environment that we're seeing. But if you just look at what we did in the fourth quarter, which I think is a bit instructive, we got 4, 5  small deals done in the fourth quarter. And by the way, a couple -- 2 or 3 of those deals were Fortive-related. I mentioned specific laser systems in my earlier comments, but there are a couple of other smaller situations that we were able to complete during the quarter for Fortive's benefit along with a couple on the Danaher side. So I think the fourth quarter was indicative perhaps of some things opening up a bit. I think the environment is generally a favorable one for businesses like ours with a balance sheet that's ready to deploy into small and midsize situations. And I think to your question, there are some folks who are perhaps a bit more on the sidelines right now than in previous days."
265621,321831219,920733,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Operator","Our next question comes from Shannon O'Callaghan of UBS.",10,"Our next question comes from Shannon O'Callaghan of UBS."
265621,321831219,920733,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Analysts","So Test & Measurement and Industrial, Tek are both generating pretty good core margin expansion here despite these mid-single-digit declines. Can you give a little more color on how they're managing to do that, I mean both have some pretty good leverage i",61,"So Test & Measurement and Industrial, Tek are both generating pretty good core margin expansion here despite these mid-single-digit declines. Can you give a little more color on how they're managing to do that, I mean both have some pretty good leverage in the model, so that's a lot to offset? And what's going on in those businesses and can it continue?"
265621,321831219,920733,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","Yes. Shannon, it is a real testament to those businesses given the challenging environment they're in from a core growth perspective that they are getting the operating margin lift that they're getting without the benefit of the top line dropping that thr",191,"Yes. Shannon, it is a real testament to those businesses given the challenging environment they're in from a core growth perspective that they are getting the operating margin lift that they're getting without the benefit of the top line dropping that through. I think it is a testament to the strength of the Danaher Business System, the tools that we use not just in newly acquired businesses, but in businesses with long histories with Danaher that have gotten a lot done using DBS in the past and are still getting it done. If you think about some of the businesses in T&M, be it Fluke and the associated acquisitions around Fluke that have been done quite a number of years ago, think about other businesses like, like some of the business in our automation Sensors and Controls areas, those guys are using DBS, whether those are lean tools specifically in the plants or deploying those tools into areas of SG&A, they are just demonstrating that those tools are still highly effective in businesses with long histories with Danaher. So it's kudos to those guys and they continue to get her done."
265621,321831219,920733,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Analysts","Okay. And then you talked a little bit about the Diagnostic content things, but Radiometer, that's the one that seemed like it was just going to grow to the sky forever in the equipment business, was a little weaker there. So maybe a little just color? An",52,"Okay. And then you talked a little bit about the Diagnostic content things, but Radiometer, that's the one that seemed like it was just going to grow to the sky forever in the equipment business, was a little weaker there. So maybe a little just color? Anything there to be concerned about?"
265621,321831219,920733,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","Yes -- no. Radiometer is a tremendous business with a long track record of high single-digit growth at Danaher. I'm sure Matt or Dan can find how many quarters it's been, but it's quite a number of them in a row that we've been high single digits and taki",193,"Yes -- no. Radiometer is a tremendous business with a long track record of high single-digit growth at Danaher. I'm sure Matt or Dan can find how many quarters it's been, but it's quite a number of them in a row that we've been high single digits and taking share. It's a high consumables business. It's probably in the 80% neighborhood of consumables, so the days impact was fairly significant there. They also had a challenging comp in the fourth quarter, on the Instrumentation side, a couple of big orders that had some impact there. So I think Radiometer is in as good a shape today as it's ever been, no meaningful shift in the competitive dynamics there. So we still feel very good about it. I think if there was anything there, Shannon, would be unique to Radiometer. It's simply the fact that some of the growth that we've seen in high-growth markets while still strong in places like China and India are still now very weak in Latin America, in Russia, in the Middle East. And so even our best businesses are probably going to feel a little bit impact there."
265621,321831219,920733,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Operator","Our next question comes from Brandon Couillard of Jefferies.",9,"Our next question comes from Brandon Couillard of Jefferies."
265621,321831219,920733,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Analysts","Just back on the Dental business. Dan, can you give us the impact of the fewer days on core growth overall? And how should we think about margin expansion for the year?",32,"Just back on the Dental business. Dan, can you give us the impact of the fewer days on core growth overall? And how should we think about margin expansion for the year?"
265621,321831219,920733,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","Well, it has less of an impact on equipment. We were up slightly in the quarter, it's first time we've been up, albeit modestly. But it impacts consumables probably [indiscernible] probably 1.5, 2 points when it comes to consumables. Good progress on the",102,"Well, it has less of an impact on equipment. We were up slightly in the quarter, it's first time we've been up, albeit modestly. But it impacts consumables probably [indiscernible] probably 1.5, 2 points when it comes to consumables. Good progress on the margin side, granted we had a pretty weak performance a year ago, so part of it was a calm, but we've also took part of our incremental restructuring here in Q4 was at Dental, so we should see some continued margin expansion coming out of Dental. Hopefully, with a little better growth than what we've seen here in '15."
265621,321831219,920733,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Operator","Our next question comes from Julian Mitchell of Crdit Suisse.",10,"Our next question comes from Julian Mitchell of Crdit Suisse."
265621,321831219,920733,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Analysts","Just a question around Western Europe. I think I heard you say that sales were down slightly in Q4, having been up sort of rather mid single digit pace in the nine-month period. I think a lot of companies have been sort of saying Europe is okay, so maybe",66,"Just a question around Western Europe. I think I heard you say that sales were down slightly in Q4, having been up sort of rather mid single digit pace in the nine-month period. I think a lot of companies have been sort of saying Europe is okay, so maybe just talk a little bit about what you saw there, specific countries or segments that slowed down?"
265621,321831219,920733,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","Julian, I think that was one of the areas first what we expected at the beginning of the quarter that surprised us a little bit to the downside. Wasn't dramatic. Clearly, our consumable business is over there. We're impacted by the selling days and maybe",132,"Julian, I think that was one of the areas first what we expected at the beginning of the quarter that surprised us a little bit to the downside. Wasn't dramatic. Clearly, our consumable business is over there. We're impacted by the selling days and maybe we were not as well calibrated, we should have been. But having gone through most of the business here in the first couple weeks here, the total in Europe is still decent. So it doesn't feel like the stepdown at our numbers in Q4 would suggest. And we think we'll get back to sort of modest growth here pretty quickly in 2016. Watching that carefully because it probably caught us a little bit by surprise in the fourth quarter, but again the tone still seems pretty good."
265621,321831219,920733,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Analysts","And you laid out the overall EPS seasonality through the year about just over a month ago. Maybe just talk a little bit about the Pall seasonality of that $0.40, particularly given the industrial organic sales trend in that business right now and how you",53,"And you laid out the overall EPS seasonality through the year about just over a month ago. Maybe just talk a little bit about the Pall seasonality of that $0.40, particularly given the industrial organic sales trend in that business right now and how you would contrast that $0.40 impact versus overall Danaher?"
265621,321831219,920733,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","Well, the $0.40 should ramp during the year as we go after cost. Again, we were able to get some more things done in December, and that was inclusive of Pall as well. So we're getting out of the gate a little bit faster in  in Q1 from a margin perspective",80,"Well, the $0.40 should ramp during the year as we go after cost. Again, we were able to get some more things done in December, and that was inclusive of Pall as well. So we're getting out of the gate a little bit faster in  in Q1 from a margin perspective. I think the offset, as you suggest, is the Industrial side. So I think we'll get nice accretion here in Q1, but it will clearly ramp through the year."
265621,321831219,920733,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Operator","Our next question comes from Andrew Kaplowitz of Citigroup.",9,"Our next question comes from Andrew Kaplowitz of Citigroup."
265621,321831219,920733,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Analysts","Obviously, good performance in margin in the quarter. Are raw materials, raw materials costs helping at all with price costs. Did the price cost stable in the 4Q versus 3Q? Did it improve? I know you mentioned covering FX, but are raw materials helping at",46,"Obviously, good performance in margin in the quarter. Are raw materials, raw materials costs helping at all with price costs. Did the price cost stable in the 4Q versus 3Q? Did it improve? I know you mentioned covering FX, but are raw materials helping at all?"
265621,321831219,920733,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","I don't have any great analysis on that yet. Given our gross margin in raw materials tends to be less of a factor for us than a lot of other companies you might cover, we are continuing to get price, still getting 60, 70 basis points. And it's hard for no",70,"I don't have any great analysis on that yet. Given our gross margin in raw materials tends to be less of a factor for us than a lot of other companies you might cover, we are continuing to get price, still getting 60, 70 basis points. And it's hard for not to think raw materials are helping us a little bit, but for us, it's really on the margin."
265621,321831219,920733,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Analysts","Okay. Got it. And then how do you get visibility forecast for example on the Middle East. I mean, the reason looks like it inflected down a bit in 4Q and with the oils recent down, how difficult is it to get visibility? And what do you forecast for 2016?",50,"Okay. Got it. And then how do you get visibility forecast for example on the Middle East. I mean, the reason looks like it inflected down a bit in 4Q and with the oils recent down, how difficult is it to get visibility? And what do you forecast for 2016?"
265621,321831219,920733,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","Well, Andrew, there's a couple of different ways to come at that in the Middle East. One is simply conversations with distribution partners, and a lot of what we do in the Middle East does involve some form of a distributor partner. And making sure that w",232,"Well, Andrew, there's a couple of different ways to come at that in the Middle East. One is simply conversations with distribution partners, and a lot of what we do in the Middle East does involve some form of a distributor partner. And making sure that we have transparency as much as we possibly can into the opportunity funnels that those distributors are seeing as well as making sure that the conversations we're having with our own sales team around those funnels that they roll up to our leadership team are as well pressure-tested as possible. The key thing about markets like the Middle East is, particularly in businesses like ours, you have a fairly high level of project or tender-related business we saw on the equipment side. And so really making sure that we understand opportunity funnels and are not overly optimistic about the timing within which funding will be released as in many cases that funding has some governmental influence to it is really important. It is easy to have a sales team get overly optimistic that the timing of funding release is going to be the same as it was a year ago or 2 years ago when the reality is, things may have slowed down and tenders may be being let at a much slower pace. So being diligent about how we pressure test those funnels is key."
265621,321831219,920733,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Analysts","So it's fair to say you're being pretty conservative with the Middle East forecast.",15,"So it's fair to say you're being pretty conservative with the Middle East forecast."
265621,321831219,920733,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","We're trying to be increasingly conservative as you see how government funding is being influenced. I think what's interesting watching the course of the year, oil continued to drop throughout the course of the year and yet we actually saw our Middle East",99,"We're trying to be increasingly conservative as you see how government funding is being influenced. I think what's interesting watching the course of the year, oil continued to drop throughout the course of the year and yet we actually saw our Middle East numbers hang in there reasonably well throughout the middle part of the year. It wasn't until the latter part of the year that we saw more acute shift in the Middle East. And so there was a little bit of a lag there and taking a bit of time for the team to fully recalibrate."
265621,321831219,920733,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Operator","And we'll take our final question from Deane Dray of RBC Capital Markets.",14,"And we'll take our final question from Deane Dray of RBC Capital Markets."
265621,321831219,920733,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Analysts","Just a quick question on R&D spending overall, came in lighter year-over-year and versus our estimates. Did you throttle back on any spending? Is it just timing of some of the projects?",33,"Just a quick question on R&D spending overall, came in lighter year-over-year and versus our estimates. Did you throttle back on any spending? Is it just timing of some of the projects?"
265621,321831219,920733,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","As you probably saw in the numbers that we put out, Deane, we are showing R&D down about 20 basis points. But the reality is that, that was primarily influenced by Pall and R&D spending to normalize for the Pall influence was actually up on the quarter. S",90,"As you probably saw in the numbers that we put out, Deane, we are showing R&D down about 20 basis points. But the reality is that, that was primarily influenced by Pall and R&D spending to normalize for the Pall influence was actually up on the quarter. So we are continuing to make sure that innovation is a key priority for the businesses and that R&D spending is maintained to the greatest extent possible for the opportunities that we think have the greatest impact in the next year or 2."
265621,321831219,920733,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Analysts","And then just last question for me is the, the incremental restructuring done in December, did you say what portion of that was Danaher versus Fortive?",26,"And then just last question for me is the, the incremental restructuring done in December, did you say what portion of that was Danaher versus Fortive?"
265621,321831219,920733,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","It was roughly the split you'd expect, 70%, 30%. And that 70% Danaher is inclusive of the Pall.",19,"It was roughly the split you'd expect, 70%, 30%. And that 70% Danaher is inclusive of the Pall."
265621,321831219,920733,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Operator","And I'd be happy to turn the program back over to our host.",14,"And I'd be happy to turn the program back over to our host."
265621,321831219,920733,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","Thanks, Leo. Thanks, everyone, for joining us. We're around all day for questions.",13,"Thanks, Leo. Thanks, everyone, for joining us. We're around all day for questions."
265621,321831219,920733,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Operator","Thank you. This does conclude today's Danaher Corporation's fourth quarter 2015 earnings results conference call. You may now all disconnect your lines, and everyone, have a great day.",28,"Thank you. This does conclude today's Danaher Corporation's fourth quarter 2015 earnings results conference call. You may now all disconnect your lines, and everyone, have a great day."
265621,321831219,920905,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Operator","My name is Leo, and I will be your conference facilitator this morning. At this time, I would like to welcome everyone to Danaher Corporation's Fourth Quarter 2015 Earnings Results Conference Call. [Operator Instructions] I will now turn the call over t",57,"My name is Leo, and I will be your conference facilitator this morning. At this time, I would like to welcome everyone to Danaher Corporation's Fourth Quarter 2015 Earnings Results Conference Call. [Operator Instructions] 
I will now turn the call over to Mr. Matt Gugino, Vice President of Investor Relations. Mr. Gugino, you may begin your conference."
265621,321831219,920905,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","Thank you, Leo. Good morning, everyone, and thanks for joining us on the call. With us today are Tom Joyce, our President and Chief Executive Officer; and Dan Comas, our Executive Vice President and Chief Financial Officer. I'd like to point out that ou",325,"Thank you, Leo. Good morning, everyone, and thanks for joining us on the call. With us today are Tom Joyce, our President and Chief Executive Officer; and Dan Comas, our Executive Vice President and Chief Financial Officer. 
I'd like to point out that our earnings release, the slide presentation supplementing today's call and other information required by SEC Regulation G relating to any non-GAAP financial measures provided during the call are all available on the investors section of our website, www.danaher.com, under the heading Financial Information. 
The audio portion of this call will be archived on the Investors section of our website later today under the heading Events & Presentations and will remain archived until our next quarterly call. A replay of this call will also be available until February 2, 2016. The replay number is (888) 203-1112 within the U.S. or (719) 457-0820 outside the U.S., and the confirmation code is 9714607. 
During the presentation, we will describe certain of the more significant factors that impacted year-over-year performance. The supplemental materials describe additional factors that impacted year-over-year performance. Unless otherwise noted, all references in these remarks and supplemental materials to company-specific financial metrics relate to the continuing operations of the company in the fourth quarter of 2015, and all references to period-to-period increases or decreases in financial metrics are year-over-year. 
During the call, we will make forward-looking statements within the meaning of the federal securities laws, including statements regarding events or developments that we believe or anticipate will or may occur in the future. These forward-looking statements are subject to a number of risks and uncertainties, including those set forth in our SEC filings, and actual results might differ materially from any forward-looking statements that we make today. These forward-looking statements speak only as of the date that they are made, and we do not assume any obligation to update any forward-looking statements. 
With that, I'd like to turn the call over to Tom."
265621,321831219,920905,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","Thanks, Matt, and good morning, everyone. We are pleased with our results for the fourth quarter, in which the team delivered double-digit earnings growth, strong core operating margin expansion and record free cash flow. Despite the more challenging econ",2253,"Thanks, Matt, and good morning, everyone. We are pleased with our results for the fourth quarter, in which the team delivered double-digit earnings growth, strong core operating margin expansion and record free cash flow. Despite the more challenging economic landscape, particularly in our industrially oriented markets, we continue to build our competitive advantage and drove share gains across a number of our businesses. As always, the Danaher Business System is the foundation for our team's outstanding execution. 
We also made meaningful progress toward establishing a new industrial growth company, Fortive, which will be spun out of Danaher later this year. At our year-end investor meeting, we announced Fortive's name, branding, future operating structure and additional leadership positions. We also achieved an important milestone in December, filing Fortive's Form 10 registration statement with the Securities and Exchange Commission. We are confident that Fortive will launch with a strong foundation and will be poised for success upon completion of the separation in the third quarter of 2016. 
For the full year, our investments in organic growth initiatives helped to drive solid 3% core revenue growth. With the addition of our recent acquisitions and other portfolio moves, our total annual revenues are now over $20 billion. 
From an M&A perspective, 2015 was a historic year for Danaher. Including Pall, we announced and closed 14 acquisitions for nearly $14.5 billion, expanding our capabilities across the portfolio. Looking forward, our funnels at both Danaher and Fortive are strong, and we'll continue to focus on small and midsized transactions throughout the separation process.
In 2015, we generated a record $3.2 billion of free cash flow, including over $1 billion in the fourth quarter. Our free cash flow to net income conversion ratio in 2015 was 123%, representing the 24th consecutive year in which our free cash flow has exceeded net income. We recognize the importance of this metric, particularly in a more challenging macro environment, as strong free cash flow is the fuel used to fund both our organic and inorganic growth initiatives. 
Now turning to the fourth quarter. Sales grew 12.5% to $5.9 billion, while core revenue was roughly flat. Core revenue growth, particularly for our consumables businesses, was negatively impacted by 4 fewer selling days in the quarter. In addition, the impact of currency translation eased this quarter but still decreased revenues by 5%, while acquisitions increased revenues by 17.5%.
In a weakening global macro environment, the Danaher Business System helped to protect and expand many of our market-leading positions, driving share gains at Hach, ChemTreat, Matco, Gilbarco, Radiometer, SCIEX and Videojet. In the high-growth markets, declines in Latin America, Russia and the Middle East were more than offset by double-digit growth in India and high single-digit growth in China. Notably, annual revenues in China exceeded $2 billion for the first time, and we remain well-positioned in the most attractive sectors in the market. In the developed markets, revenues were down slightly due to incremental softness in the U.S. and Western Europe.
Gross margin for the quarter was 51.2%. For the full year, our gross margin was 52.3%, and our gross profit increased by almost $900 million. In the quarter, core operating margin increased 120 basis points, with all 5 segments improving by 60 basis points or better. Our reported operating margin was flat at 16.6%, negatively affected by the dilutive impact of recent acquisitions and acquisition-related transaction costs.
Fourth quarter adjusted diluted net EPS was $1.27, which represents an increase of 13.5% over last year. For the full year, adjusted diluted net EPS was $4.30, up 8.5% from 2014.
Turning to our 5 operating segments. Test & Measurement revenues decreased 9%, while core revenues were down 5%. Core operating margin increased 110 basis points, primarily due to new product introductions and good cost management. Core revenue in our Instruments platform decreased at a high single-digit rate, with declines across most major geographies. Fluke core revenues were down high single digits as industrial markets continued to weaken in North America, Latin America and the Middle East. In December, Fluke acquired Pacific Laser Systems, a leader in handheld laser alignment tools, to enhance its product offerings for professional contractors, electricians and general maintenance customers. 
At Tektronix, core sales declined high single digits. Declines in North America, Latin America and the Middle East more than offset growth in China that resulted from solid execution by our local sales team. The team's continued investments in innovation placed Tek in a position of technology leadership within its industry. This quarter, Tek launched the MDO4000C, a Mixed Domain Oscilloscope that combines up to 6 instruments in 1 unit. The new MDO4000C is completely customizable and upgradable, allowing engineers to start with a high-performance oscilloscope and add functionality over time as needs change or budgets allow. 
Matco, a business that will be a significant contributor to Fortive's results, delivered its third consecutive year of double-digit core growth in 2015. Even after 3 decades as part of the Danaher portfolio, Matco continues to find new ways to improve using DBS. By deploying such DBS tools as web marketing, accelerated product development and lean conversion, the team continues to expand its franchise distribution network, gain market share and expand margins.
Turning now to our Environmental segment. Revenues grew 1%, with core revenues up 4%. Core operating margin expanded 60 basis points, and reported operating margin expanded 260 basis points to 21.8%. Water Quality core revenues increased at a low single-digit rate, a combination of fewer selling days and slower demand from our more industrial customers in the developed markets resulted in essentially flat core growth at Hach, while ChemTreat grew slightly. Trojan had another very good quarter, driven by healthy demand and increased bidding activity in the North American muni market. 
Hach delivered another impressive year in 2015. In addition to mid-single digit organic growth, Hach continued its healthy cadence of bolt-on acquisitions. The team has done a terrific job implementing DBS in newly acquired businesses to help improve sales and drive innovation. One such example is BioTector, which was acquired in 2014 and had double-digit growth in the quarter. BioTector provides online total organic carbon analyzers that help our customers monitor water quality in real time and reduce waste. BioTector's early and effective application of DBS tools such as lean conversion and pharma management led to more than 200 basis points of margin expansion, significant inventory reductions and market share gains in the chemical and dairy segments. 
Gilbarco Veeder-Root's core revenues grew high single digits, with strength across the platform. In the U.S, point-of-sale solutions and dispensers increased over 20%, as our customers continued to upgrade their payment systems to comply with EMV security requirements. We expect EMV-related demand to continue to accelerate for the next several years. 
Moving to Life Science & Diagnostics, core revenues grew 2%, with reported revenues up 34.5%, largely due to our recent Pall, Microscan and Devicor acquisitions. Core operating margin expanded 75 basis points. 
Core revenues in our Diagnostics platform increased low single digits, with growth in the high-growth markets, partially offset by slight declines in developed markets. As previously mentioned, fewer selling days in the quarter negatively impact our recurring revenue streams across the platform. 
At Beckman Coulter, core revenues increased at a low single-digit rate, led by our immunoassay and urinalysis solutions. Utilization rates in Asia remain healthy, leading to high single-digit growth across the region. 
In Europe, we celebrated our first orders with the commercial launch of our Veris molecular diagnostic system. Veris is streamlined sample-in result-out workflow, offers breakthrough ease of use in a market that is experiencing a shortage of skilled technicians. In short, it's helping our lab customers process more tests, reduce training requirements and save money. And thus far, customer feedback has been extremely positive.
Radiometer's core revenues grew up slightly, a deceleration from previous quarters due to the effect of fewer selling days and a difficult comparison in Instrument sales. Geographically, we saw healthy growth in China and Japan, while Latin America and the Middle East declined. 
Leica Biosystems had a good finish to the year, delivering low single-digit core growth as strong demand across most major product lines was partially offset by the impact of -- from fewer selling days. Notably, the team delivered a record year of placements for our BOND advanced staining instrument. 
Last December, we closed the acquisition of Devicor, a leading provider of breast biopsy devices and markers. That move Leica further upstream in the anatomical pedagogy workflow. Devicor continues to track well and has exceeded our expectations, posting high single-digit core growth or better in each quarter since acquisition. 
Core revenues in our Life Science platform were up low single digits with growth in both developed and high-growth markets. SCIEX core revenues grew mid-single digits, with continued strength in our clinical and applied end markets. 2015 marked the fifth year since our acquisition of SCIEX. Since then, SCIEX has proven to be a remarkable example of how thoughtful application of DBS principles can drive tremendous financial results. The team has taken the business that was growing below market rates to mid to high single-digit growth and share gains. We've seen significant improvements on the cost side as well, which has enabled SCIEX to invest those savings into higher impact growth initiatives. Progress at SCIEX continues today, and 2015 marked one of the most important product innovation years in SCIEX's history, with the launch of its X-Series mass spectrometry platform. The X-Series introduced an entirely new design, easy-to-use software and custom models for targeted applications in routine food, environmental and forensic testing labs.
Leica Microsystems core revenues were essentially flat as strong performance in China and Japan was offset by declines in Europe, the Middle East and Latin America.
Turning now to Dental. Segment revenues increased 17%, largely due to our Nobel Biocare acquisition. Core revenues were up slightly. Core operating margins increased by over 500 basis points in the quarter, primarily due to consistent DBS implementation across a number of operational areas. Reported operating margins were 15.8%.
Revenues in our consumables business were negatively impacted by fewer selling days in the quarter, but our team continued to execute well and saw strong demand for several product lines throughout the year. In particular, our investments in innovation have provided us with truly differentiated technologies such as SonicFill, TF Adaptive and elementsfree, which all launched in 2014. In Dental technology, we saw our first quarter of positive growth since the fourth quarter of 2014. Top line results continue to be impacted by destocking within our U.S. distribution channels, but to a much lesser degree than in previous quarters. 
December marked the one-year anniversary of our acquisition of Nobel Biocare. The team has quickly embraced growth, lean and leadership tools of DBS, helping to not only accelerate growth but also improve operating margins by over 300 basis points since the acquisition.
Moving to Industrial Technologies. Revenues declined 8.5%, while core revenues were down 4.5%. Core operating margin expanded 80 basis points, and reported operating margin expanded 120 basis points to 21.6%. Automation core revenues decreased at a high single-digit rate due to weakening in industrial markets in China and North America. Despite the challenging market and revenue decline, the team continues to identify cost-savings opportunities and delivered solid core margin expansion in the quarter. 
Core revenues in our Product Identification platform were up slightly. In the fourth quarter, we continued to extend our reach into new Product ID adjacencies with the acquisition of Laetus, a leading supplier of track and trace inspection systems for pharmaceutical packaging plants. Increasingly, pharmaceutical tracking is becoming a regulatory and public safety concern, and Laetus gives us exposure to this important vertical. I'm more excited to welcome Laetus to the Danaher team. 
At Videojet, core revenues were up low single digits as strong performance in Europe and North America was somewhat offset by weakness in the high-growth markets. Results were negatively impacted by fewer selling days in the quarter. Throughout the full year, Videojet has placed a major focus on digital investments, driving key innovations in areas such as network monitoring, remote service-enabled printers and predictive maintenance. As a result, we achieved record new equipment vitality of over 40% for the year. These tremendous technology capabilities have not only certified Videojet's leadership position in the market, they've also meaningfully improved our customers' experiences.
So to wrap up. We are pleased with our record fourth quarter results. During the quarter, the team delivered double-digit earnings growth, significantly expanded core operating margins, generated record free cash flow and announced several bolt-on acquisitions. Despite the more challenging economic landscape, particularly in our industrially oriented markets, we continue to execute well. 
Looking back, 2015 was a remarkable year for Danaher. We completed the largest acquisition in our history with Pall, announced our pending separation into 2 independent publicly traded companies with Fortive and drove excellent overall financial results. With the Danaher Business System as our foundation, we believe we'll continue to deliver earnings outperformance and create long-term shareholder value in 2016 and for years to come. 
We are initiating first quarter adjusted diluted net EPS guidance between $1 and $1.04, which assumes approximately flat core revenue growth. As we announced at our annual investor event in December, we continue to expect full year 2016 core revenue growth of 2% to 3% and adjusted diluted net earnings per share to be in the range of $4.80 to $4.95, which would represent a 12% to 15% increase year-on-year."
265621,321831219,920905,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","Thanks, Tom. That concludes our formal remarks. Leo, we are now ready for questions.",14,"Thanks, Tom. That concludes our formal remarks. Leo, we are now ready for questions."
265621,321831219,920905,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Operator","[Operator Instructions] We'll take our first question from Scott Davis of Barclays.",12,"[Operator Instructions] We'll take our first question from Scott Davis of Barclays."
265621,321831219,920905,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Analysts","I think -- I mean, given that it's been about a month since you gave the last guidance in mid-December, the formal guidance, I guess. Things seemed to have degraded a bit on the macro side. I mean, what confidence do you have? I mean, now that you've seen",84,"I think -- I mean, given that it's been about a month since you gave the last guidance in mid-December, the formal guidance, I guess. Things seemed to have degraded a bit on the macro side. I mean, what confidence do you have? I mean, now that you've seen, I guess, most of January, I mean have things stabilized? I mean, your guidance seems to indicate that you think that was a bit of a blip, I suppose. So just a little color there."
265621,321831219,920905,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","Sure, Scott. I think, Scott, we're -- what we're assuming is that what we saw was some of the slowing in December is essentially the environment that we're going to see in the near term here. It's clearly impacting our more industrial businesses more than",228,"Sure, Scott. I think, Scott, we're -- what we're assuming is that what we saw was some of the slowing in December is essentially the environment that we're going to see in the near term here. It's clearly impacting our more industrial businesses more than our other businesses. So we are not immune to this slowdown. But I think we took some appropriate actions in the fourth quarter. Those actions are going to pay off here certainly from a margin standpoint. But I think the other thing to keep in mind is that the portfolio that we have today truly does differentiate us. And I think when we look at the opportunities that we have in our Life Science businesses, our Diagnostic businesses, some improvement that we're seeing here in our Dental businesses, continued good progress at GVR. While we remain cautious in some respects around the macro environment and are not assuming things get materially better there, we are playing offense in a number of areas that, I think, will bode well. So I don't think there's anything particularly optimistic in our outlook around the macro, but I think some of the things that we're doing from an investment standpoint and across our growth initiatives should continue to position a very good portfolio and a differentiated portfolio and continue to move it into an even better place."
265621,321831219,920905,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Analysts","Yes, makes sense. And then just as a follow-up, the emerging-market currencies have degraded a fair amount. I mean, are you able to get local price to offset that? I mean, how do you manage that volatility just typically just given the exposure you guys h",46,"Yes, makes sense. And then just as a follow-up, the emerging-market currencies have degraded a fair amount. I mean, are you able to get local price to offset that? I mean, how do you manage that volatility just typically just given the exposure you guys have?"
265621,321831219,920905,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","Yes. I mean, it's an issue. I'd probably bifurcate the answer. Where we have the aftermarket business, the consumables, the service, we're typically able to get price. With equipment and instruments, we are not able to. And we've taken a little bit of a m",73,"Yes. I mean, it's an issue. I'd probably bifurcate the answer. Where we have the aftermarket business, the consumables, the service, we're typically able to get price. With equipment and instruments, we are not able to. And we've taken a little bit of a margin hit there. Fortunately, the euro stabilized so the overall currency impact is not what it was in '15, but it's a little bit of a negative right now."
265621,321831219,920905,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Operator","And we'll take our next question from Nigel Coe of Morgan Stanley.",13,"And we'll take our next question from Nigel Coe of Morgan Stanley."
265621,321831219,920905,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Analysts","So just on the $0.40 from Pall, can you maybe just first of all comment on how Pall is tracking? How it tracked through the quarter? Maybe comment then on the industrial business Life Sciences side? And how does the composition of the $0.40 in the plan ch",56,"So just on the $0.40 from Pall, can you maybe just first of all comment on how Pall is tracking? How it tracked through the quarter? Maybe comment then on the industrial business Life Sciences side? And how does the composition of the $0.40 in the plan changed at all in the last couple of months?"
265621,321831219,920905,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","Nigel, we are very, very happy with how we've gotten started with Pall. Starting with the team that we have in place, a terrific team, both the Pall leadership team, many of whom have taken on added responsibilities. But in addition, the added resources t",400,"Nigel, we are very, very happy with how we've gotten started with Pall. Starting with the team that we have in place, a terrific team, both the Pall leadership team, many of whom have taken on added responsibilities. But in addition, the added resources that we put in place and the leadership that we have brought to bear in the business, I think, together, that team is off to a terrific start. We'll talk to the $0.40 and the cost opportunities we have here in just a minute. But coming to the growth side of the house, about what we expected, continued very good progress and growth rates on the Life Science side, keeping in mind that, that business has an exceptional position in the biopharma market in Life Science. So we're seeing continued good growth there. We're also seeing outstanding growth in single-use technologies, which are a key part and a key growth driver of the biopharma segment of Life Science business as time goes on. On the industrial side, again, what you -- what we would have expected, which is a slowing on that side of the house, we've seen that those businesses impacted far more than, obviously, on the more Life Science-oriented side of the house. But I think it's also important to keep in mind that, that business is also strongly skewed towards consumables. In total, the portfolio is about 70% aftermarket consumables, primarily. And so that's a strong foundation, and I think continues to give us confidence that while we'll have some segments that are challenged, the business overall will continue to perform quite well. Relative to the cost side of the house, again, off to a very good start. You heard us in December, take the 2016 number up to $100 million because we had gotten off to an earlier start. We're getting the kinds of cost reductions that you would expect us to get out of a public company in the early going. The public company costs beginning to get after some of the indirect cost leverage that we get and some of the procurement cost leverage that we get by consolidating procurement across our other businesses where appropriate. And over time, we'll see some of the benefits coming from -- on the gross margin side as we look at the operational footprint, but that will obviously take a little bit more time."
265621,321831219,920905,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Analysts","Okay. But that's helpful. And then on the balance sheet, you've taken down a lot of impressive amount of debt since the acquisition of Pall, I think about $3 billion of debt pay down. Given the bit more challenging macro, is there a changing bias toward d",49,"Okay. But that's helpful. And then on the balance sheet, you've taken down a lot of impressive amount of debt since the acquisition of Pall, I think about $3 billion of debt pay down. Given the bit more challenging macro, is there a changing bias toward delevering this year?"
265621,321831219,920905,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","Nigel, I think, we remain in that kind of $2 billion target for M&A this year. We are incrementally encouraged. We are able to get some deals done in December, granted they were small, but we actually saw a flurry of deals get done towards the end of the",118,"Nigel, I think, we remain in that kind of $2 billion target for M&A this year. We are incrementally encouraged. We are able to get some deals done in December, granted they were small, but we actually saw a flurry of deals get done towards the end of the year. Clearly, what's going on, the high-yield market has made it very difficult for the private equity parties, let alone industrial companies have a lower credit rating. So some of the anxiety out here definitely helping some of the conversation. So on the margin, we're a little bit more encouraged than we were at 60, 90 days ago on the M&A front. I hope I didn't scare you, Nigel."
265621,321831219,920905,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Operator","Our next question is from Steve Tusa of JPMorgan.",9,"Our next question is from Steve Tusa of JPMorgan."
265621,321831219,920905,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Analysts","Can you just maybe talk a little bit more specifically about Pall industrial trends? I mean, what is the organic -- what kind of organic are you seeing there? And what are you expecting for 2016, a little more kind of precisely?",42,"Can you just maybe talk a little bit more specifically about Pall industrial trends? I mean, what is the organic -- what kind of organic are you seeing there? And what are you expecting for 2016, a little more kind of precisely?"
265621,321831219,920905,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","So Steve, for the 4 months that we owned the business on a constant currency basis, Pall grew about 4% on a combined basis. Really, would have been accretive to our core growth here. Life Science was up high single digits. Industrial was down low to mid-s",88,"So Steve, for the 4 months that we owned the business on a constant currency basis, Pall grew about 4% on a combined basis. Really, would have been accretive to our core growth here. Life Science was up high single digits. Industrial was down low to mid-single digits. We see that for the near term, not a bad way to be looking at the business. Clearly, the Industrial piece is more challenged, but more than making up for with a very strong growth on the Life Science side."
265621,321831219,920905,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Analysts","And then what was Pall's contribution to free cash flow in the quarter?",14,"And then what was Pall's contribution to free cash flow in the quarter?"
265621,321831219,920905,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","On the working capital side, where we contributed north of $300 million of cash out of working capital, Pall was a nice piece of it, but maybe 15%. The working capital improvements were very broad-based, really exceptional performance across all the 5 seg",56,"On the working capital side, where we contributed north of $300 million of cash out of working capital, Pall was a nice piece of it, but maybe 15%. The working capital improvements were very broad-based, really exceptional performance across all the 5 segments. So it was a nice contributor, but it was not an overwhelming piece."
265621,321831219,920905,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Analysts","Okay. Great. And then just one last question. What's the kind of the restructuring contingency look like in '16? Is there any change to that as you kind of exited the year at a bit of a weaker rate? Or are you kind of in kind of normal day-to-day planning",63,"Okay. Great. And then just one last question. What's the kind of the restructuring contingency look like in '16? Is there any change to that as you kind of exited the year at a bit of a weaker rate? Or are you kind of in kind of normal day-to-day planning? How kind of extreme are things around some of the more industrial businesses?"
265621,321831219,920905,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","Steve, I think, one of the things that we learned from 2015, and we're pleased about is this. We did a number of things throughout the course of the year from productivity perspective. And I think particularly in an environment like this, it's important t",170,"Steve, I think, one of the things that we learned from 2015, and we're pleased about is this. We did a number of things throughout the course of the year from productivity perspective. And I think particularly in an environment like this, it's important that we stay cognizant of the fact that there may be opportunities that present themselves and things that we may need to do. So we're going to keep the teams active at looking for opportunities throughout the course of the year, and we'll take advantage of those as they come up. So I think we've got a lot done in 2015. We got a lot more done in December than we anticipated, probably $20 million north of what we thought in December. So that's a good thing, sets us up well a little bit more than we would have anticipated. But again, I think it's important that we stay cognizant of the environment business-by-business and look for opportunities to take action where good projects present themselves."
265621,321831219,920905,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Operator","We'll take our next question from Steven Winoker of Bernstein.",11,"We'll take our next question from Steven Winoker of Bernstein."
265621,321831219,920905,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Analysts","What was the Fortive versus Danaher corporate, if you split it that way, for the quarter?",16,"What was the Fortive versus Danaher corporate, if you split it that way, for the quarter?"
265621,321831219,920905,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","Sure. Looking at Fortive, probably being rough down 2 to 3, and Danaher go forward up 1, 1.5. So I think that's roughly the way it would split.",28,"Sure. Looking at Fortive, probably being rough down 2 to 3, and Danaher go forward up 1, 1.5. So I think that's roughly the way it would split."
265621,321831219,920905,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Analysts","Okay. And just a couple of things.",7,"Okay. And just a couple of things."
265621,321831219,920905,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","And Steve -- I'm sorry, Steve, sorry to interrupt. Just wanted to make one other quick point just for clarification on that. It's important to recognize on the Danaher side of the house that 1 to 1.5, that side of the house has a higher percentage of cons",124,"And Steve -- I'm sorry, Steve, sorry to interrupt. Just wanted to make one other quick point just for clarification on that. It's important to recognize on the Danaher side of the house that 1 to 1.5, that side of the house has a higher percentage of consumables and recurring revenue than you do on the Fortive side. And as a result of that, the fewer selling days in the fourth quarter has a little bit greater impact on the Danaher side. So when you normalize for the days impact on the Danaher side, that's going to be potentially -- it could be 1.5%, 2%, maybe even on that side. Again, rough numbers, but it has a little bit more of an impact there."
265621,321831219,920905,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Analysts","Okay. All right. And then just on a couple of the segments. So I think this was the -- it's at least 11 quarters since I've seen Fluke go negative. So maybe a little commentary on the -- what's going on in the industrial environment, specifically on Fluke",100,"Okay. All right. And then just on a couple of the segments. So I think this was the -- it's at least 11 quarters since I've seen Fluke go negative. So maybe a little commentary on the -- what's going on in the industrial environment, specifically on Fluke? And then also Life Sciences & Diagnostics, it's the lowest, I think, I've seen in 14 quarters. So we -- you went through a lot of detail there, but to what extent are we -- should we be concerned about any kind of bleed over from the broader environment into their markets?"
265621,321831219,920905,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","Sure, sure. So Fluke -- Fluke clearly impacted by the downshift in the macro environment in the quarter, Fluke being one of our more industrially oriented businesses. I think the macro environment, while it had its impact on us on a broad basis, also had",149,"Sure, sure. So Fluke -- Fluke clearly impacted by the downshift in the macro environment in the quarter, Fluke being one of our more industrially oriented businesses. I think the macro environment, while it had its impact on us on a broad basis, also had an influence on the way our distributors were thinking about inventories during the course of the quarter. So I think, one of the things that -- but we don't have all the numbers right now for full transparency on what happened to channel inventories, it's a pretty good hypothesis right now based on some early data we have that would suggest that there were some inventory control that went on in the channel that certainly would have had some impact as well. So I think those 2 factors combined, again, broad-based macro on sellout and probably some impact on sell-in based on inventory contraction."
265621,321831219,920905,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","On the Diagnostic side, Steve, so -- the bigger piece is, obviously, Diagnostics, that's largely consumables. Diagnostics were up 4% organically for the year. And as you remember, Q1 really had the extra days were up 6%. Q4, when we had the fewer days, we",70,"On the Diagnostic side, Steve, so -- the bigger piece is, obviously, Diagnostics, that's largely consumables. Diagnostics were up 4% organically for the year. And as you remember, Q1 really had the extra days were up 6%. Q4, when we had the fewer days, were up 2%. So actually on a days adjusted basis, Diagnostics tracked pretty close to that 3% to 4% rate all year including the fourth quarter."
265621,321831219,920905,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","Maybe one other thing to add there is that, best we can tell, Steve, we didn't see any year-end budget flush there in the fourth quarter. That's a little bit more a Life Science-oriented phenomena than a Diagnostic-oriented phenomena. But in some past fou",117,"Maybe one other thing to add there is that, best we can tell, Steve, we didn't see any year-end budget flush there in the fourth quarter. That's a little bit more a Life Science-oriented phenomena than a Diagnostic-oriented phenomena. But in some past fourth quarters, we've seen the impact that. We didn't see any of that in the fourth. Good news and bad news on that front, it has an impact on the fourth quarter. Sometimes that budget flush can drive some inventories out, but then create some go-forward weakness as you start the New Year. We're hoping we -- and the early numbers coming out here in January, look like we're off to a decent start."
265621,321831219,920905,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Operator","We'll take our next question from Jeff Sprague of Vertical Research.",12,"We'll take our next question from Jeff Sprague of Vertical Research."
265621,321831219,920905,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Analysts","Thanks for that color on Fluke. I wanted to ask that question a little bit more broadly. To what extent do you think kind of the more industrially oriented organic growth rates kind of clearly reflect end demand versus maybe broader channel liquidation? I",66,"Thanks for that color on Fluke. I wanted to ask that question a little bit more broadly. To what extent do you think kind of the more industrially oriented organic growth rates kind of clearly reflect end demand versus maybe broader channel liquidation? I don't know if you have any good insight into your other channels or any -- even anecdotal color there would be helpful."
265621,321831219,920905,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","I don't have much there, Jeff. I know the teams are still out, talking to customers and trying to get a better sense of that. One reason for a little bit more insight on Fluke than and less so, Fluke's a little bit more concentrated with some big distribu",98,"I don't have much there, Jeff. I know the teams are still out, talking to customers and trying to get a better sense of that. One reason for a little bit more insight on Fluke than and less so, Fluke's a little bit more concentrated with some big distributor partners, that we can get a little bit more transparency a little bit more quickly. More -- some of the more automation Sensors and Controls businesses and so on, more fragmented channels and not. It's just taken us a little longer to get any sense of channel inventories."
265621,321831219,920905,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Analysts","And just shifting gears a little bit. Any thoughts on how the device tax place through? Do you see any change in demand there? Or any change in the way people are pricing competitively? And maybe to size, what you think the impact could be to your busines",50,"And just shifting gears a little bit. Any thoughts on how the device tax place through? Do you see any change in demand there? Or any change in the way people are pricing competitively? And maybe to size, what you think the impact could be to your business this year?"
265621,321831219,920905,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","Sure. Jeff, when the device tax was first put in place, the impact of that was fairly modest on us. There's money at stake, but overall not a huge number. So what comes back in terms of a little bit of a lift to operating margins is also modest. I mean, n",135,"Sure. Jeff, when the device tax was first put in place, the impact of that was fairly modest on us. There's money at stake, but overall not a huge number. So what comes back in terms of a little bit of a lift to operating margins is also modest. I mean, net-net, it's a good thing for the industry. We didn't see much impact in the market from a pricing standpoint when it all happened, I should say from a competitive standpoint. We did get some of that back in price over time, and probably some competitors did as well. But in terms of real impact to competitive dynamics, I think it's too modest a change certainly to the scale of our business and maybe to the scale of others to really impact the competitive."
265621,321831219,920905,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","Jeff, I think, we said in '13 it was about a nickel hit. We recovered some of that in price. So I think it will be less than a $0.05, but maybe $0.03 benefit here in the year.",38,"Jeff, I think, we said in '13 it was about a nickel hit. We recovered some of that in price. So I think it will be less than a $0.05, but maybe $0.03 benefit here in the year."
265621,321831219,920905,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Operator","We'll move next to Ross Muken of Evercore ISI.",10,"We'll move next to Ross Muken of Evercore ISI."
265621,321831219,920905,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Analysts","Maybe on Dental, can you just give us a little bit more color just sort of on the progress you made throughout the year. It looks like ending the year you had some of your best results, obviously, adjusting for the days. And so as we sort of now roll Nobe",88,"Maybe on Dental, can you just give us a little bit more color just sort of on the progress you made throughout the year. It looks like ending the year you had some of your best results, obviously, adjusting for the days. And so as we sort of now roll Nobel into the sort of core and we think about the margin progression of that business over the year, help us think through kind of the pushes and pulls, and how happy you are with the progress made?"
265621,321831219,920905,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","Sure. Yes, thanks, Ross. I think, 2015 was a year of a very good progress across the platform. You mentioned Nobel, let me just start with that. We have a tremendous team of folks at Nobel. Largely, the leadership team that was in place when we acquired t",320,"Sure. Yes, thanks, Ross. I think, 2015 was a year of a very good progress across the platform. You mentioned Nobel, let me just start with that. We have a tremendous team of folks at Nobel. Largely, the leadership team that was in place when we acquired the business, they have really embraced DBS and are off to a terrific start both in terms of continuing to use DBS tools to drive growth, but also, as in my comments earlier, some great progress on operating margins. And now as that goes core to the Dental platform, we'll see some impact to that to the good. On the business that existed prior to 2015, I think, again, 2015 was a year of a lot of progress. I've mentioned a couple of times that we've had outstanding relationships with our distribution partners. We worked in a collaborative way with them on channel inventories throughout the course of the year. That was, obviously, somewhat of a painful process to go through in a sense of the impact on core growth, but net-net a very good process in terms of positioning the channel efficiently. So we are pleased that the vast majority of that's behind us. There can always be a little bit of a tail to that of stuff we're still moving out and so are moving inventories but, again I think, a ton of progress. We've also got a very good leadership team in place on our -- in our Dental platform today, with some new players in place that, I think, are doing some wonderful things in terms of driving innovation. It was a very good year of new product introductions. And I think we'll see the benefit of that as core growth improves this year. So we know we still have work to do there, but good news is that there's opportunities for value creation as we go on here."
265621,321831219,920905,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Analysts","Great. And maybe just quickly a little color more on the M&A pipeline. Can you just give us a sense? And there's obviously been a ton of equity market volatility. We're seeing, obviously, a shift in how the private equity folks are also sort of transactin",111,"Great. And maybe just quickly a little color more on the M&A pipeline. Can you just give us a sense? And there's obviously been a ton of equity market volatility. We're seeing, obviously, a shift in how the private equity folks are also sort of transacting. Just give us a feel for maybe healthcare versus industrial-oriented assets and the like. Whether there's more activity at one side of the spectrum versus the other, and how? So the valuation dislocations have been kind of digested by the various groups, because you're obviously doing smaller things at this point, and it's, obviously, the large end of the market that's probably been most impacted."
265621,321831219,920905,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","Sure. Well, I'll let Dan comment in a second on kind of the environment that we're seeing. But if you just look at what we did in the fourth quarter, which I think is a bit instructive, we've got 4, 5  small deals done in the fourth quarter. And by the wa",168,"Sure. Well, I'll let Dan comment in a second on kind of the environment that we're seeing. But if you just look at what we did in the fourth quarter, which I think is a bit instructive, we've got 4, 5  small deals done in the fourth quarter. And by the way, a couple -- 2 or 3 of those deals were Fortive-related. I mentioned Pacific Laser Systems in my earlier comments, but there were a couple of other smaller situations that we were able to complete during the quarter for Fortive's benefit along with a couple on the Danaher side. So I think the fourth quarter was indicative perhaps of some things opening up a bit. I think, the environment is generally a favorable one for businesses like ours with a balance sheet that's ready to deploy into small and midsize situations. And I think to your question, there are some folks who are perhaps a bit more on the sidelines right now than in previous days."
265621,321831219,920905,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Operator","Next question comes from Shannon O'Callaghan of UBS.",9,"Next question comes from Shannon O'Callaghan of UBS."
265621,321831219,920905,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Analysts","So Test & Measurement and Industrial, Tek are both generating pretty good core margin expansion here, despite these mid-single-digit declines. Can you give a little more color on how they're managing to do that? I mean, both of them have pretty good lever",62,"So Test & Measurement and Industrial, Tek are both generating pretty good core margin expansion here, despite these mid-single-digit declines. Can you give a little more color on how they're managing to do that? I mean, both of them have pretty good leverage in the model, so that's a lot to offset. And what's going on in those businesses, and can it continue?"
265621,321831219,920905,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","Yes. It's -- Shannon, it is the real testament to those businesses given the challenging environment they're in from a core growth perspective. That they are getting the operating margin lift that they're getting without the benefit of the top line droppi",196,"Yes. It's -- Shannon, it is the real testament to those businesses given the challenging environment they're in from a core growth perspective. That they are getting the operating margin lift that they're getting without the benefit of the top line dropping that through. I think, it is a testament to the strength of the Danaher Business System, the tools that we use not just in newly acquired businesses, but in businesses with long histories with Danaher that have gotten a lot done using DBS in the past and are still getting it done. If you think about some of the businesses in T&M, be it Fluke and the associated acquisitions around Fluke that have been done quite a number of years ago, think about other businesses like Qualitrol, like some of the businesses in our automation Sensors and Controls areas, those guys are using DBS, whether those are lean tools specifically in the plants or deploying those tools into -- in areas of SG&A, they are just demonstrating that those tools are still highly effective in businesses with long histories with Danaher. So it's kudos to those guys, and they continue to get her done."
265621,321831219,920905,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Analysts","Okay. And then you talked a little bit about the Diagnostic content things, but Radiometer, that's been one that seemed like it was just going to grow to the sky forever in the equipment business. It was a little weaker there, so maybe a little just color",53,"Okay. And then you talked a little bit about the Diagnostic content things, but Radiometer, that's been one that seemed like it was just going to grow to the sky forever in the equipment business. It was a little weaker there, so maybe a little just color? Anything there to be concerned about?"
265621,321831219,920905,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","Yes. No. We -- Radiometer is a tremendous business with a long track record of high single-digit growth at Danaher. I'm sure Matt or Dan can find how many quarters it's been, but it's quite a number of them in a row that we've been high single digits and",195,"Yes. No. We -- Radiometer is a tremendous business with a long track record of high single-digit growth at Danaher. I'm sure Matt or Dan can find how many quarters it's been, but it's quite a number of them in a row that we've been high single digits and taking share. It's a high consumables business. It's probably in the 80% neighborhood of consumables, so the days impact was fairly significant there. They also had a challenging comp in the fourth quarter on the Instrumentation side. Couple of big orders that had some impact there. So I think Radiometer is in as good a shape today as it's ever been, no meaningful shift in the competitive dynamics there. So we still feel very good about it. I think, if there was anything there, Shannon, would be unique to Radiometer, it's simply the fact that some of the growth that we've seen in the high-growth markets, while still strong in places like China and India, are still now very weak in Latin America, in Russia, in the Middle East. And so even our best businesses are probably going to feel a little bit of impact there."
265621,321831219,920905,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Operator","Our next question comes from Brandon Couillard of Jefferies.",9,"Our next question comes from Brandon Couillard of Jefferies."
265621,321831219,920905,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Analysts","Just -- back on the Dental business. Dan, can you give us the impact of the fewer days on core growth overall? And how should we think about margin expansion for the year?",33,"Just -- back on the Dental business. Dan, can you give us the impact of the fewer days on core growth overall? And how should we think about margin expansion for the year?"
265621,321831219,920905,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","Well, it has less of an impact on equipment. We were up slightly in the quarter, it's first time we've been up, albeit modestly. But it impacts consumables probably up in a -- as Tom alluded to, probably 1.5, 2 points when it comes to consumables. Good pr",110,"Well, it has less of an impact on equipment. We were up slightly in the quarter, it's first time we've been up, albeit modestly. But it impacts consumables probably up in a -- as Tom alluded to, probably 1.5, 2 points when it comes to consumables. Good progress on the margin side, granted we had a pretty weak performance a year ago. So part of it was a calm, but we've also took -- part of our incremental restructuring here in Q4 was at Dental, so we should see some continued margin expansion coming out of Dental. Hopefully, with a little better growth than what we've seen here in '15."
265621,321831219,920905,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Operator","Our next question comes from Julian Mitchell of Crdit Suisse.",10,"Our next question comes from Julian Mitchell of Crdit Suisse."
265621,321831219,920905,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Analysts","Just a question around Western Europe. I think, I heard you say that sales were down slightly in Q4, having been up sort of rather mid-single-digit pace in the nine-months period. I think a lot of other companies have sort of been saying Europe is okay, s",65,"Just a question around Western Europe. I think, I heard you say that sales were down slightly in Q4, having been up sort of rather mid-single-digit pace in the nine-months period. I think a lot of other companies have sort of been saying Europe is okay, so maybe just talk a little bit about what you saw there, specific countries or segments that slowed down?"
265621,321831219,920905,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","Julian, I mean, I think that was one of the areas worse what we expected at the beginning of the quarter that surprised us a little bit to the downside. It wasn't dramatic. Clearly, our consumable business is over there. We're impacted by the selling days",140,"Julian, I mean, I think that was one of the areas worse what we expected at the beginning of the quarter that surprised us a little bit to the downside. It wasn't dramatic. Clearly, our consumable business is over there. We're impacted by the selling days and maybe we were not as well calibrated, we should have been. But having gone through all -- most of the business here in the first couple weeks here, the total in Europe is still decent, and -- so it doesn't feel like the step-down at our numbers in Q4 would suggest. And we think we'll get back to sort of modest growth here pretty quickly in 2016. Watching that carefully because it probably caught us a little bit by surprise here in the fourth quarter, but again the tone still seems pretty good."
265621,321831219,920905,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Analysts","Understood. And you laid out the overall EPS seasonality through the year about just over a month ago. Maybe just talk a little bit about the Pall, seasonality of that $0.40, particularly given the industrial organic sales trend in that business right now",54,"Understood. And you laid out the overall EPS seasonality through the year about just over a month ago. Maybe just talk a little bit about the Pall, seasonality of that $0.40, particularly given the industrial organic sales trend in that business right now? And how you would contrast that $0.40 impact versus overall Danaher?"
265621,321831219,920905,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","Well, the $0.40 should ramp during the year as we go after cost. Again, we were able to get some more things done in December, and that was inclusive of Pall as well. So we're getting out of the gate a little bit faster in Q1 from a margin perspective. I",79,"Well, the $0.40 should ramp during the year as we go after cost. Again, we were able to get some more things done in December, and that was inclusive of Pall as well. So we're getting out of the gate a little bit faster in Q1 from a margin perspective. I think the offset, as you suggest, is the Industrial side. So I think we'll get nice accretion here in Q1, but it will clearly ramp through the year."
265621,321831219,920905,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Operator","Our next question comes from Andrew Kaplowitz of Citigroup.",9,"Our next question comes from Andrew Kaplowitz of Citigroup."
265621,321831219,920905,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Analysts","Obviously, good performance in margin in the quarter. Are raw materials, little raw materials costs helping at all with price costs? Did the price cost was stable in 4Q versus 3Q? Did it improve? I know you mentioned covering FX, but are raw materials hel",47,"Obviously, good performance in margin in the quarter. Are raw materials, little raw materials costs helping at all with price costs? Did the price cost was stable in 4Q versus 3Q? Did it improve? I know you mentioned covering FX, but are raw materials helping at all?"
265621,321831219,920905,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","I don't have any great analysis on that yet. Given our gross margin, raw materials tends to be less of a factor for us than a lot of other companies you might cover. We are continuing to get price, still getting 60, 70 basis points. And it's hard not to t",68,"I don't have any great analysis on that yet. Given our gross margin, raw materials tends to be less of a factor for us than a lot of other companies you might cover. We are continuing to get price, still getting 60, 70 basis points. And it's hard not to think raw materials are helping us a little bit, but for us it's really on the margin."
265621,321831219,920905,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Analysts","Okay, got it. And then how do you get visibility into what to forecast, for example, on the Middle East? I mean, the region looks like it inflected down a bit in 4Q, and with the oils recently down, how difficult is it to get visibility? And what do you f",53,"Okay, got it. And then how do you get visibility into what to forecast, for example, on the Middle East? I mean, the region looks like it inflected down a bit in 4Q, and with the oils recently down, how difficult is it to get visibility? And what do you forecast for 2016?"
265621,321831219,920905,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","Well, there's -- Andrew, there's a couple of different ways to come at that in the Middle East. One is simply conversations with distribution partners, and a lot of what we do in the Middle East does involve some form of a distributor partner. And making",235,"Well, there's -- Andrew, there's a couple of different ways to come at that in the Middle East. One is simply conversations with distribution partners, and a lot of what we do in the Middle East does involve some form of a distributor partner. And making sure that we have transparency as much as we possibly can into the opportunity funnels that those distributors are seeing as well as making sure that the conversations we're having with our own sales team around those funnels as they roll up to our leadership team are as well pressure-tested as possible. The key thing about markets like the Middle East is, particularly in businesses like ours, you have a fairly high level of project or tender-related business, and we saw on the equipment side. And so really making sure that we understand opportunity funnels and are not overly optimistic about the timing within which funding will be released, as in many cases that funding has some governmental influence to it, is really important. It is easy to have a sales team get overly optimistic that the timing of funding release is going to be the same as it was 1 year ago or 2 years ago when the reality is, things may have slowed down and tenders may be being let at a much slower pace. So being diligent about how we pressure test those funnels is key."
265621,321831219,920905,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Analysts","So it's fair to say you're being pretty conservative with the Middle East forecast.",15,"So it's fair to say you're being pretty conservative with the Middle East forecast."
265621,321831219,920905,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","We're trying to be increasingly conservative as we see how government funding is being influenced. I think, it was interesting watching the course of the year. Oil continued to drop, as you know, throughout the course of the year and yet, we actually saw",104,"We're trying to be increasingly conservative as we see how government funding is being influenced. I think, it was interesting watching the course of the year. Oil continued to drop, as you know, throughout the course of the year and yet, we actually saw our Middle East numbers hang in there reasonably well throughout the middle part of the year. It wasn't until the latter part of the year that we saw more acute shift in the Middle East. And so there was a little bit of a lag there and it's taking a bit of time for the team to fully recalibrate."
265621,321831219,920905,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Operator","And we'll take our final question from Deane Dray of RBC Capital Markets.",14,"And we'll take our final question from Deane Dray of RBC Capital Markets."
265621,321831219,920905,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Analysts","Just a quick question on R&D spending overall, came in lighter year-over-year and versus our estimates. Did you throttle back on any spending? Is it just timing of some of the projects?",33,"Just a quick question on R&D spending overall, came in lighter year-over-year and versus our estimates. Did you throttle back on any spending? Is it just timing of some of the projects?"
265621,321831219,920905,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","As you probably saw in the numbers that we put out, Deane, we are showing R&D down about 20 basis points. But the reality is that, that was primarily influenced by Pall and R&D spending normalized for the Pall influence was actually up on the quarter. So",89,"As you probably saw in the numbers that we put out, Deane, we are showing R&D down about 20 basis points. But the reality is that, that was primarily influenced by Pall and R&D spending normalized for the Pall influence was actually up on the quarter. So we are continuing to make sure that innovation is a key priority for the businesses and that R&D spending is maintained to the greatest extent possible for the opportunities that we think have the greatest impact in the next year or 2."
265621,321831219,920905,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Analysts","And then just last question for me is the, the incremental restructuring done in December, did you say what portion of that was Danaher versus Fortive?",26,"And then just last question for me is the, the incremental restructuring done in December, did you say what portion of that was Danaher versus Fortive?"
265621,321831219,920905,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","It was roughly the split you'd expect, 70%, 30%. And that 70% Danaher, inclusive of Pall.",17,"It was roughly the split you'd expect, 70%, 30%. And that 70% Danaher, inclusive of Pall."
265621,321831219,920905,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Operator","And I'd be happy to turn the program back over to our hosts.",14,"And I'd be happy to turn the program back over to our hosts."
265621,321831219,920905,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","Thanks, Leo. Thanks, everyone, for joining us. We're around all day for questions.",13,"Thanks, Leo. Thanks, everyone, for joining us. We're around all day for questions."
265621,321831219,920905,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Operator","Thank you. This does conclude today's Danaher Corporation's Fourth Quarter 2015 Earnings Results Conference Call. You may now all disconnect your lines, and everyone, have a great day.",28,"Thank you. This does conclude today's Danaher Corporation's Fourth Quarter 2015 Earnings Results Conference Call. You may now all disconnect your lines, and everyone, have a great day."
265621,321831219,920969,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Operator","My name is Leo, and I will be your conference facilitator this morning. At this time, I would like to welcome everyone to Danaher Corporation's Fourth Quarter 2015 Earnings Results Conference Call. [Operator Instructions] I will now turn the call over t",57,"My name is Leo, and I will be your conference facilitator this morning. At this time, I would like to welcome everyone to Danaher Corporation's Fourth Quarter 2015 Earnings Results Conference Call. [Operator Instructions] 
I will now turn the call over to Mr. Matt Gugino, Vice President of Investor Relations. Mr. Gugino, you may begin your conference."
265621,321831219,920969,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","Thank you, Leo. Good morning, everyone, and thanks for joining us on the call. With us today are Tom Joyce, our President and Chief Executive Officer; and Dan Comas, our Executive Vice President and Chief Financial Officer. I'd like to point out that ou",326,"Thank you, Leo. Good morning, everyone, and thanks for joining us on the call. With us today are Tom Joyce, our President and Chief Executive Officer; and Dan Comas, our Executive Vice President and Chief Financial Officer. 
I'd like to point out that our earnings release, the slide presentation supplementing today's call and other information required by SEC Regulation G relating to any non-GAAP financial measures provided during the call are all available on the investors section of our website, www.danaher.com, under the heading Financial Information. 
The audio portion of this call will be archived on the Investors section of our website later today under the heading Events & Presentations and will remain archived until our next quarterly call. A replay of this call will also be available until February 2, 2016. The replay number is (888) 203-1112 within the U.S. or (719) 457-0820 outside the U.S., and the confirmation code is 9714607. 
During the presentation, we will describe certain of the more significant factors that impacted the year-over-year performance. The supplemental materials describe additional factors that impacted year-over-year performance. Unless otherwise noted, all references in these remarks and supplemental materials to company-specific financial metrics relate to the continuing operations of the company in the fourth quarter of 2015, and all references to period-to-period increases or decreases in financial metrics are year-over-year. 
During the call, we will make forward-looking statements within the meaning of the federal securities laws, including statements regarding events or developments that we believe or anticipate will or may occur in the future. These forward-looking statements are subject to a number of risks and uncertainties, including those set forth in our SEC filings, and actual results might differ materially from any forward-looking statements that we make today. These forward-looking statements speak only as of the date that they are made, and we do not assume any obligation to update any forward-looking statements. 
With that, I'd like to turn the call over to Tom."
265621,321831219,920969,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","Thanks, Matt, and good morning, everyone. We are pleased with our results for the fourth quarter, in which the team delivered double-digit earnings growth, strong core operating margin expansion and record free cash flow. Despite the more challenging econ",2250,"Thanks, Matt, and good morning, everyone. We are pleased with our results for the fourth quarter, in which the team delivered double-digit earnings growth, strong core operating margin expansion and record free cash flow. Despite the more challenging economic landscape, particularly in our industrially oriented markets, we continued to build our competitive advantage and drove share gains across a number of our businesses. As always, the Danaher Business System is the foundation for our team's outstanding execution. 
We also made meaningful progress toward establishing a new industrial growth company, Fortive, which will be spun out of Danaher later this year. At our year-end investor meeting, we announced Fortive's name, branding, future operating structure and additional leadership positions. We also achieved an important milestone in December, filing Fortive's Form 10 registration statement with the Securities and Exchange Commission. We are confident that Fortive will launch with a strong foundation and will be poised for success upon completion of the separation in the third quarter of 2016. 
For the full year, our investments in organic growth initiatives helped drive solid 3% core revenue growth. With the addition of our recent acquisitions and other portfolio moves, our total annual revenues are now over $20 billion. 
From an M&A perspective, 2015 was a historic year for Danaher. Including Pall, we announced or closed 14 acquisitions for nearly $14.5 billion, expanding our capabilities across the portfolio. Looking forward, our funnels at both Danaher and Fortive are strong, and we'll continue to focus on small and midsized transactions throughout the separation process.
In 2015, we generated a record $3.2 billion of free cash flow, including over $1 billion in the fourth quarter. Our free cash flow to net income conversion ratio in 2015 was 123%, representing the 24th consecutive year in which our free cash flow has exceeded net income. We recognize the importance of this metric, particularly in a more challenging macro environment, as strong free cash flow is the fuel used to fund both our organic and inorganic growth initiatives. 
Now turning to the fourth quarter. Sales grew 12.5% to $5.9 billion, while core revenue was roughly flat. Core revenue growth, particularly for our consumables businesses, was negatively impacted by 4 fewer selling days in the quarter. In addition, the impact of currency translation eased this quarter but still decreased revenues by 5%, while acquisitions increased revenues by 17.5%.
In a weakening global macro environment, the Danaher Business System helped protect and expand many of our market-leading positions, driving share gains at Hach, ChemTreat, Matco, Gilbarco, Radiometer, SCIEX and Videojet. In the high-growth markets, declines in Latin America, Russia and the Middle East were more than offset by double-digit growth in India and high single-digit growth in China. Notably, annual revenues in China exceeded $2 billion for the first time, and we remain well-positioned in the most attractive sectors in the market. In the developed markets, revenues were down slightly due to incremental softness in the U.S. and Western Europe.
Gross margin for the quarter was 51.2%. For the full year, our gross margin was 52.3%, and our gross profit increased by almost $900 million. In the quarter, core operating margin increased 120 basis points, with all 5 segments improving by 60 basis points or better. Our reported operating margin was flat at 16.6%, negatively affected by the dilutive impact of recent acquisitions and acquisition-related transaction costs.
Fourth quarter adjusted diluted net EPS was $1.27, which represents an increase of 13.5% over last year. For the full year, adjusted diluted net EPS was $4.30, up 8.5% from 2014.
Turning to our 5 operating segments. Test & Measurement revenues decreased 9%, while core revenues were down 5%. Core operating margin increased 110 basis points, primarily due to new product introductions and good cost management. Core revenue in our Instruments platform decreased at a high single-digit rate, with declines across most major geographies. Fluke core revenues were down high single digits as industrial markets continued to weaken in North America, Latin America and the Middle East. In December, Fluke acquired Pacific Laser Systems, a leader in handheld laser alignment tools, to enhance its product offerings for professional contractors, electricians and general maintenance customers. 
At Tektronix, core sales declined high single digits. Declines in North America, Latin America and the Middle East more than offset growth in China that resulted from solid execution by our local sales team. The team's continued investments in innovation placed Tek in a position of technology leadership within its industry. This quarter, Tek launched the MDO4000C, a Mixed Domain Oscilloscope that combines up to 6 instruments in 1 unit. The new MDO4000C is completely customizable and upgradable, allowing engineers to start with a high-performance oscilloscope and add functionality over time as needs change or budgets allow. 
Matco, a business that will be a significant contributor to Fortive's results, delivered its third consecutive year of double-digit core growth in 2015. Even after 3 decades as part of the Danaher portfolio, Matco continues to find new ways to improve using DBS. By deploying such DBS tools as web marketing, accelerated product development and lean conversion, the team continues to expand its franchise distribution network, gain market share and expand margins.
Turning now to our Environmental segment. Revenues grew 1%, with core revenues up 4%. Core operating margin expanded 60 basis points, and reported operating margin expanded 260 basis points to 21.8%. Water Quality core revenues increased at a low single-digit rate, a combination of fewer selling days and slower demand from our more industrial customers in the developed markets resulted in essentially flat core growth at Hach, while ChemTreat grew slightly. Trojan had another very good quarter, driven by healthy demand and increased bidding activity in the North American muni market. 
Hach delivered another impressive year in 2015. In addition to mid-single digit organic growth, Hach continued its healthy cadence of bolt-on acquisitions. The team has done a terrific job implementing DBS in newly acquired businesses to help improve sales and drive innovation. One such example is BioTector, which was acquired in 2014 and had double-digit growth in the quarter. BioTector provides online total organic carbon analyzers that help our customers monitor water quality in real time and reduce waste. BioTector's early and effective application of DBS tools such as lean conversion and funnel management led to more than 200 basis points of margin expansion, significant inventory reductions and market share gains in the chemical and dairy segments. 
Gilbarco Veeder-Root's core revenues grew high single digits, with strength across the platform. In the U.S, point-of-sale solutions and dispensers increased over 20%, as our customers continued to upgrade their payment systems to comply with EMV security requirements. We expect EMV-related demand to continue to accelerate for the next several years. 
Moving to Life Science & Diagnostics, core revenues grew 2%, with reported revenues up 34.5%, largely due to our recent Pall, Microscan and Devicor acquisitions. Core operating margin expanded 75 basis points. 
Core revenues in our Diagnostics platform increased low single digits, with growth in the high-growth markets, partially offset by slight declines in developed markets. As previously mentioned, fewer selling days in the quarter negatively impact our recurring revenue streams across the platform. 
At Beckman Coulter, core revenues increased at a low single-digit rate, led by our immunoassay and urinalysis solutions. Utilization rates in Asia remain healthy, leading to high single-digit growth across the region. 
In Europe, we celebrated our first orders with the commercial launch of our Veris molecular diagnostic system. Veris' streamlined sample-in result-out workflow, offers breakthrough ease of use in a market that is experiencing a shortage of skilled technicians. In short, it's helping our lab customers process more tests, reduce training requirements and save money. And thus far, customer feedback has been extremely positive.
Radiometer's core revenues were up slightly, a deceleration from previous quarters due to the effect of fewer selling days and a difficult comparison in Instrument sales. Geographically, we saw healthy growth in China and Japan, while Latin America and the Middle East declined. 
Leica Biosystems had a good finish to the year, delivering low single-digit core growth as strong demand across most major product lines was partially offset by the impact from fewer selling days. Notably, the team delivered a record year of placements for our BOND advanced staining instrument. 
Last December, we closed the acquisition of Devicor, a leading provider of breast biopsy devices and markers. That move Leica further upstream in the anatomical pedology workflow. Devicor continues to track well and has exceeded our expectations, posting high single-digit core growth or better in each quarter since acquisition. 
Core revenues in our Life Science platform were up low single digits with growth in both developed and high-growth markets. SCIEX core revenues grew mid-single digits, with continued strength in our clinical and applied end markets. 2015 marked the fifth year since our acquisition of SCIEX. Since then, SCIEX has proven to be a remarkable example of how thoughtful application of DBS principles can drive tremendous financial results. The team has taken a business that was growing below market rates to mid- to high single-digit growth and share gains. We've seen significant improvement on the cost side as well, which has enabled SCIEX to invest those savings into higher impact growth initiatives. Progress at SCIEX continues today, and 2015 marked one of the most important product innovation years in SCIEX's history, with the launch of its X-Series mass spectrometry platform. The X-Series introduces an entirely new design, easy-to-use software and custom models for targeted application in routine food, environmental and forensic testing labs.
Leica Microsystems core revenues were essentially flat as strong performance in China and Japan was offset by declines in Europe, the Middle East and Latin America.
Turning now to Dental. Segment revenues increased 17%, largely due to our Nobel Biocare acquisition. Core revenues were up slightly. Core operating margins increased by over 500 basis points in the quarter, primarily due to consistent DBS implementation across a number of operational areas. Reported operating margins were 15.8%.
Revenues in our consumables business were negatively impacted by fewer selling days in the quarter, but our team continued to execute well and saw strong demand for several product lines throughout the year. In particular, our investments in innovation have provided us with truly differentiated technologies such as SonicFill, TF Adaptive and elementsfree, which all launched in 2014. In Dental technology, we saw our first quarter of positive growth since the fourth quarter of 2014. Top line results continued to be impacted by destocking within our U.S. distribution channels, but to a much lesser degree than in previous quarters. 
December marked the one-year anniversary of our acquisition of Nobel Biocare. The team has quickly embraced growth, lean and leadership tools of DBS, helping to not only accelerate growth but also improve operating margins by over 300 basis points since the acquisition.
Moving to Industrial Technologies. Revenues declined 8.5%, while core revenues were down 4.5%. Core operating margin expanded 80 basis points, and reported operating margin expanded 120 basis points to 21.6%. Automation core revenues decreased at a high single-digit rate due to weakening in the industrial markets in China and North America. Despite the challenging market and revenue decline, the team continues to identify cost-savings opportunities and delivered solid core margin expansion in the quarter. 
Core revenues in our Product Identification platform were up slightly. In the fourth quarter, we continued to extend our reach into new Product ID adjacencies with the acquisition of Laetus, a leading supplier of track and trace inspection systems for pharmaceutical packaging plants. Increasingly, pharmaceutical tracking is becoming a regulatory and public safety concern, and Laetus gives us exposure to this important vertical. And we're excited to welcome Laetus to the Danaher team. 
At Videojet, core revenues were up low single digits as strong performance in Europe and North America was somewhat offset by weakness in the high-growth markets. Results were negatively impacted by fewer selling days in the quarter. Throughout the full year, Videojet has placed a major focus on digital investments, driving key innovations in areas such as network monitoring, remote service-enabled printers and predictive maintenance. As a result, we achieved record new equipment vitality of over 40% for the year. These tremendous technology capabilities have not only solidified Videojet's leadership position in the market, they have also meaningfully improved our customers' experiences.
So to wrap up. We are pleased with our record fourth quarter results. During the quarter, the team delivered double-digit earnings growth, significantly expanded core operating margins, generated record free cash flow and announced several bolt-on acquisitions. Despite the more challenging economic landscape, particularly in our industrially oriented markets, we continue to execute well. 
Looking back, 2015 was a remarkable year for Danaher. We completed the largest acquisition in our history with Pall, announced our pending separation into 2 independent publicly traded companies with Fortive and drove excellent overall financial results. With the Danaher Business System as our foundation, we believe we'll continue to deliver earnings outperformance and create long-term shareholder value in 2016 and for years to come. 
We are initiating first quarter adjusted diluted net EPS guidance between $1 and $1.04, which assumes approximately flat core revenue growth. As we announced at our annual investor event in December, we continue to expect full year 2016 core revenue growth of 2% to 3% and adjusted diluted net earnings per share to be in the range of $4.80 to $4.95, which would represent a 12% to 15% increase year-on-year."
265621,321831219,920969,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","Thanks, Tom. That concludes our formal remarks. Leo, we are now ready for questions.",14,"Thanks, Tom. That concludes our formal remarks. Leo, we are now ready for questions."
265621,321831219,920969,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Operator","[Operator Instructions] We'll take our first question from Scott Davis of Barclays.",12,"[Operator Instructions] We'll take our first question from Scott Davis of Barclays."
265621,321831219,920969,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Analysts","I think -- I mean, given that it's been about a month since you gave the last guidance in mid-December, the formal guidance, I guess. Things seemed to have degraded a bit on the macro side. I mean, what confidence do you have? I mean, now that you've seen",84,"I think -- I mean, given that it's been about a month since you gave the last guidance in mid-December, the formal guidance, I guess. Things seemed to have degraded a bit on the macro side. I mean, what confidence do you have? I mean, now that you've seen, I guess, most of January, I mean have things stabilized? I mean, your guidance seems to indicate that you think that was a bit of a blip, I suppose. So just a little color there."
265621,321831219,920969,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","Sure, Scott. I think, Scott, we're -- what we're assuming is that what we saw with some of the slowing in December is essentially the environment that we're going to see in the near term here. It's clearly impacting our more industrial businesses more tha",227,"Sure, Scott. I think, Scott, we're -- what we're assuming is that what we saw with some of the slowing in December is essentially the environment that we're going to see in the near term here. It's clearly impacting our more industrial businesses more than our other businesses. So we're not immune to the slowdown. But I think we took some appropriate actions in the fourth quarter. Those actions are going to pay off here certainly from a margin standpoint. But I think the other thing to keep in mind is that the portfolio that we have today truly does differentiate us. And I think when we look at the opportunities that we have in our Life Science businesses, our Diagnostic businesses, some improvement that we're seeing here in our Dental businesses, continued good progress at GVR. While we remain cautious in some respects around the macro environment and are not assuming things get materially better there, we are playing offense in a number of areas that, I think, will bode well. So I don't think there's anything particularly optimistic in our outlook around the macro, but I think some of the things that we're doing from an investment standpoint and across our growth initiatives should continue to position a very good portfolio and a differentiated portfolio and continue to move it into an even better place."
265621,321831219,920969,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Analysts","Yes, makes sense. And then just as a follow-up, the emerging-market currencies have degraded a fair amount. I mean, are you able to get local price to offset that? I mean, how do you manage that volatility, specifically, just given the exposure you guys h",45,"Yes, makes sense. And then just as a follow-up, the emerging-market currencies have degraded a fair amount. I mean, are you able to get local price to offset that? I mean, how do you manage that volatility, specifically, just given the exposure you guys have?"
265621,321831219,920969,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","Yes. I mean, it's an issue. I'd probably bifurcate the answer. Where we have the aftermarket business, the consumables, the service, we're typically able to get price. With equipment and instruments, we are not able to. And we're taking a little bit of a",73,"Yes. I mean, it's an issue. I'd probably bifurcate the answer. Where we have the aftermarket business, the consumables, the service, we're typically able to get price. With equipment and instruments, we are not able to. And we're taking a little bit of a margin hit there. Fortunately, the euro stabilized so the overall currency impact is not what it was in '15, but it's a little bit of a negative right now."
265621,321831219,920969,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Operator","And we'll take our next question from Nigel Coe of Morgan Stanley.",13,"And we'll take our next question from Nigel Coe of Morgan Stanley."
265621,321831219,920969,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Analysts","So just on the $0.40 from Pall, can you maybe just first of all comment on how Pall is tracking? Or how it tracked through the quarter? Maybe commenting on the industrial versus Life Sciences sides? And how has the composition of the $0.40 in the plan cha",56,"So just on the $0.40 from Pall, can you maybe just first of all comment on how Pall is tracking? Or how it tracked through the quarter? Maybe commenting on the industrial versus Life Sciences sides? And how has the composition of the $0.40 in the plan changed at all in the last couple of months?"
265621,321831219,920969,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","Nigel, we are very, very happy with how we've gotten started with Pall. Starting with the team that we have in place, a terrific team, both the Pall leadership team, many of whom have taken on added responsibilities. But in addition, the added resources t",403,"Nigel, we are very, very happy with how we've gotten started with Pall. Starting with the team that we have in place, a terrific team, both the Pall leadership team, many of whom have taken on added responsibilities. But in addition, the added resources that we put in place and the leadership that we have brought to bear in the business, I think, together, that team is off to a terrific start. We'll talk to the $0.40 and the cost opportunities that we have here in just a minute. But coming to the growth side of the house, about what we expected, continued very good progress and growth rates on the Life Science side, keeping in mind that, that business has an exceptional position in the biopharma market in Life Science. So we're seeing continued good growth there. We're also seeing outstanding growth in single-use technologies, which are a key part and a key growth driver of the biopharma segment of the Life Science business as time goes on. On the industrial side, again, what you -- what we would have expected, which is a slowing on that side of the house, we've seen that -- those businesses impacted far more than, obviously, on the more Life Science-oriented side of the house. But I think it's also important to keep in mind that, that business is also strongly skewed towards consumables. In total, the portfolio is about 70% aftermarket consumables, primarily. And so that's a strong foundation, and I think continues to give us confidence that while we'll have some segments that are challenged, the business overall will continue to perform quite well. Relative to the cost side of the house, again, off to a very good start. You heard us in December, take the 2016 number up to $100 million because we had gotten off to an earlier start. We're getting the kinds of cost reductions that you would expect us to get out of a public company in the early going. The public company costs beginning to get after some of the indirect cost leverage that we get and some of the procurement cost leverage that we get by consolidating procurement across our other businesses where appropriate. And over time, we'll see some of the benefits coming from -- on the gross margin side as we look at the operational footprint, but that will obviously take a little bit more time."
265621,321831219,920969,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Analysts","Okay. But that's helpful. And then on the balance sheet, you've taken down a lot of -- an impressive amount of debt since the acquisition of Pall, I think about $3 billion of debt pay down. Given the bit more challenging macro, is there a change in your b",53,"Okay. But that's helpful. And then on the balance sheet, you've taken down a lot of -- an impressive amount of debt since the acquisition of Pall, I think about $3 billion of debt pay down. Given the bit more challenging macro, is there a change in your bias towards delevering this year?"
265621,321831219,920969,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","Nigel, I think, we remain in that kind of $2 billion target for M&A this year. We are incrementally encouraged. We were able to get some deals done in December, granted they were small, but we actually saw a flurry of deals get done towards the end of the",118,"Nigel, I think, we remain in that kind of $2 billion target for M&A this year. We are incrementally encouraged. We were able to get some deals done in December, granted they were small, but we actually saw a flurry of deals get done towards the end of the year. Clearly, what's going on, the high-yield market has made it very difficult for the private equity parties, let alone industrial companies have a lower credit rating. So some of the anxiety out here definitely helping some of the conversation. So on the margin, we're a little bit more encouraged than we were at 60, 90 days ago on the M&A front. I hope I didn't offend you, Nigel."
265621,321831219,920969,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Operator","Our next question is from Steve Tusa of JPMorgan.",9,"Our next question is from Steve Tusa of JPMorgan."
265621,321831219,920969,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Analysts","Can you just maybe talk a little bit more specifically about Pall industrial trends? I mean, what is the organic -- what kind of organic are you seeing there? And what are you expecting for 2016, a little more kind of precisely?",42,"Can you just maybe talk a little bit more specifically about Pall industrial trends? I mean, what is the organic -- what kind of organic are you seeing there? And what are you expecting for 2016, a little more kind of precisely?"
265621,321831219,920969,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","So Steve, for the 4 months that we owned the business on a constant currency basis, Pall grew about 4% on a combined basis. Clearly, it would have been accretive to our core growth here. Life Science was up high single digits. Industrial was down low to m",90,"So Steve, for the 4 months that we owned the business on a constant currency basis, Pall grew about 4% on a combined basis. Clearly, it would have been accretive to our core growth here. Life Science was up high single digits. Industrial was down low to mid-single digits. We see that for the near term, not a bad way to be looking at the business. Clearly, the Industrial piece is more challenged, but more than making up for it with a very strong growth on the Life Science side."
265621,321831219,920969,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Analysts","And then what was Pall's contribution to free cash flow in the quarter?",14,"And then what was Pall's contribution to free cash flow in the quarter?"
265621,321831219,920969,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","On the working capital side, where we contributed north of $300 million of cash out of working capital, Pall was a nice piece of it, but maybe 15%. The working capital improvements were very broad-based, really exceptional performance across all the 5 seg",56,"On the working capital side, where we contributed north of $300 million of cash out of working capital, Pall was a nice piece of it, but maybe 15%. The working capital improvements were very broad-based, really exceptional performance across all the 5 segments. So it was a nice contributor, but it was not an overwhelming piece."
265621,321831219,920969,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Analysts","Okay. Great. And then just one last question. What's kind of the restructuring contingency look like in '16? Is there any change to that as you kind of exited the year at a bit of a weaker rate? Or have you been kind of -- kind of normal day-to-day planni",63,"Okay. Great. And then just one last question. What's kind of the restructuring contingency look like in '16? Is there any change to that as you kind of exited the year at a bit of a weaker rate? Or have you been kind of -- kind of normal day-to-day planning? How kind of extreme are things around some of the more industrial businesses?"
265621,321831219,920969,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","Steve, I think, one of the things that we learned from 2015, and we're pleased about is this. We did a number of things throughout the course of the year from a productivity perspective. And I think particularly in an environment like this, it's important",171,"Steve, I think, one of the things that we learned from 2015, and we're pleased about is this. We did a number of things throughout the course of the year from a productivity perspective. And I think particularly in an environment like this, it's important that we stay cognizant of the fact that there may be opportunities that present themselves, some things that we may need to do. So we're going to keep the teams active at looking for opportunities throughout the course of the year, and we'll take advantage of those as they come up. So I think we got a lot done in 2015. We got a lot more done in December than we anticipated, probably $20 million north of what we thought in December. So that's a good thing, sets us up well a little bit more than we would have anticipated. But again, I think it's important that we stay cognizant of the environment business-by-business and look for opportunities to take action where good projects present themselves."
265621,321831219,920969,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Operator","We'll take our next question from Steven Winoker of Bernstein.",11,"We'll take our next question from Steven Winoker of Bernstein."
265621,321831219,920969,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Analysts","What was the Fortive versus Danaher corporate, if you split it that way, for the quarter?",16,"What was the Fortive versus Danaher corporate, if you split it that way, for the quarter?"
265621,321831219,920969,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","Sure. Looking at Fortive, probably being rough down 2 to 3, and Danaher go forward up 1, 1.5. So I think that's roughly the way it would split.",28,"Sure. Looking at Fortive, probably being rough down 2 to 3, and Danaher go forward up 1, 1.5. So I think that's roughly the way it would split."
265621,321831219,920969,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Analysts","Okay. And just a couple of things.",7,"Okay. And just a couple of things."
265621,321831219,920969,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","And Steve -- I'm sorry, Steve, sorry to interrupt. Just wanted to make one other quick point just for clarification on that. It's important to recognize on the Danaher side of the house that 1 to 1.5, that side of the house has a higher percentage of cons",124,"And Steve -- I'm sorry, Steve, sorry to interrupt. Just wanted to make one other quick point just for clarification on that. It's important to recognize on the Danaher side of the house that 1 to 1.5, that side of the house has a higher percentage of consumables and recurring revenue than you do on the Fortive side. And as a result of that, the fewer selling days in the fourth quarter has a little bit greater impact on the Danaher side. So when you normalize for the days impact on the Danaher side, that's going to be potentially -- it could be 1.5%, 2%, maybe even on that side. Again, rough numbers, but it has a little bit more of an impact there."
265621,321831219,920969,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Analysts","Okay. All right. And then just on a couple of the segments. So I think this was the -- it's been at least 11 quarters since I've seen Fluke go negative. So maybe a little commentary on the -- what's going on in the industrial environment, specifically on",102,"Okay. All right. And then just on a couple of the segments. So I think this was the -- it's been at least 11 quarters since I've seen Fluke go negative. So maybe a little commentary on the -- what's going on in the industrial environment, specifically on Fluke? And then also Life Sciences & Diagnostics, it's the lowest, I think, I've seen in 14 quarters. So are we -- you went through a lot of detail there, but to what extent are we -- should we be concerned about any kind of bleed over from the broader environment into their markets?"
265621,321831219,920969,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","Sure, sure. Let's start with Fluke. Fluke clearly impacted by the downshift in the macro environment in the quarter, Fluke being one of our more industrially oriented businesses. I think the macro environment, while it had its impact on us on a broad basi",150,"Sure, sure. Let's start with Fluke. Fluke clearly impacted by the downshift in the macro environment in the quarter, Fluke being one of our more industrially oriented businesses. I think the macro environment, while it had its impact on us on a broad basis, also had an influence on the way our distributors were thinking about inventories during the course of the quarter. So I think, one of the things that -- although, we don't have all the numbers right now for full transparency on what happened to channel inventories, it's a pretty good hypothesis right now based on some early data we have that would suggest that there was some inventory control that went on in the channel that certainly would have had some impact as well. So I think those 2 factors combined, again, broad-based macro on sellout and probably some impact on sell-in based on inventory contraction."
265621,321831219,920969,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","On the Diagnostic side, Steve, so -- the bigger piece is, obviously, Diagnostics, that's largely consumables. Diagnostics were up 4% organically for the year. And as you remember, Q1 when we had the extra days we were up 6%. Q4, when we had the fewer days",73,"On the Diagnostic side, Steve, so -- the bigger piece is, obviously, Diagnostics, that's largely consumables. Diagnostics were up 4% organically for the year. And as you remember, Q1 when we had the extra days we were up 6%. Q4, when we had the fewer days, we were up 2%. So actually on a days adjusted basis, Diagnostics tracked pretty close to that 3% to 4% rate all year including the fourth quarter."
265621,321831219,920969,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","Maybe one other thing to add there is that, best we can tell, Steve, we didn't see any year-end budget flush there in the fourth quarter. That's a little bit more of a Life Science-oriented phenomena than a Diagnostic-oriented phenomena. But in some past",119,"Maybe one other thing to add there is that, best we can tell, Steve, we didn't see any year-end budget flush there in the fourth quarter. That's a little bit more of a Life Science-oriented phenomena than a Diagnostic-oriented phenomena. But in some past fourth quarters, we've seen the impact of that. We didn't see any of that in the fourth. Good news and bad news on that front, it has an impact on the fourth quarter. Sometimes that budget flush can drive some inventories out that then creates some go-forward weakness as you start the New Year. We're hoping we -- and the early numbers coming out here in January, look like we're off to a decent start."
265621,321831219,920969,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Operator","We'll take our next question from Jeff Sprague of Vertical Research.",12,"We'll take our next question from Jeff Sprague of Vertical Research."
265621,321831219,920969,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Analysts","Thanks for that color on Fluke. I wanted to ask that question a little bit more broadly. To what extent do you think kind of the more industrially oriented organic growth rates kind of clearly reflect end demand versus maybe a broader channel liquidation?",67,"Thanks for that color on Fluke. I wanted to ask that question a little bit more broadly. To what extent do you think kind of the more industrially oriented organic growth rates kind of clearly reflect end demand versus maybe a broader channel liquidation? I don't know if you have any good insight into your other channels or any -- even anecdotal color there would be helpful."
265621,321831219,920969,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","I don't have much there, Jeff. I know the teams are still out talking to customers and trying to get a better sense of that. One reason for a little bit more insight on Fluke than -- and less so, Fluke's a little bit more concentrated with some big distri",98,"I don't have much there, Jeff. I know the teams are still out talking to customers and trying to get a better sense of that. One reason for a little bit more insight on Fluke than -- and less so, Fluke's a little bit more concentrated with some big distributor partners, that we can get a little bit more transparency a little bit more quickly. More -- some of the more automation Sensors and Controls businesses and so on, more fragmented channels and it's just taken us a little longer to get any sense of channel inventories."
265621,321831219,920969,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Analysts","And just shifting gears a little bit. Any thoughts on how the device tax plays through? Do you see any change in demand there? Or any change in the way people are pricing competitively? And maybe just size what you think the impact could be to your busine",50,"And just shifting gears a little bit. Any thoughts on how the device tax plays through? Do you see any change in demand there? Or any change in the way people are pricing competitively? And maybe just size what you think the impact could be to your business this year?"
265621,321831219,920969,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","Sure. Jeff, when the device tax was first put in place, the impact of that was fairly modest on us. There's money at stake, but overall not a huge number. So what comes back in terms of a little bit of a lift to operating margins is also modest. I mean, n",136,"Sure. Jeff, when the device tax was first put in place, the impact of that was fairly modest on us. There's money at stake, but overall not a huge number. So what comes back in terms of a little bit of a lift to operating margins is also modest. I mean, net-net, it's a good thing for the industry. We didn't see much impact in the market from a pricing standpoint when it all happened, I should say from a competitive standpoint. We did get some of that back in price over time, and probably some competitors did as well. But in terms of real impact to competitive dynamics, I think it's too modest a change certainly to the scale of our business and maybe to the scale of others to really impact the competitive world."
265621,321831219,920969,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","Jeff, I think, we said in '13 it was about a nickel hit. We've recovered some of that in price. So I think it will be less than a $0.05, but maybe a $0.03 benefit here in the year.",39,"Jeff, I think, we said in '13 it was about a nickel hit. We've recovered some of that in price. So I think it will be less than a $0.05, but maybe a $0.03 benefit here in the year."
265621,321831219,920969,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Operator","We'll move next to Ross Muken of Evercore ISI.",10,"We'll move next to Ross Muken of Evercore ISI."
265621,321831219,920969,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Analysts","Maybe on Dental, can you just give us a little bit more color just sort of on the progress you made throughout the year. It looks like ending the year you had some of your best results, obviously, adjusting for the days. And so as we sort of now roll Nobe",88,"Maybe on Dental, can you just give us a little bit more color just sort of on the progress you made throughout the year. It looks like ending the year you had some of your best results, obviously, adjusting for the days. And so as we sort of now roll Nobel into the sort of core and we think about the margin progression in that business over the year, help us think through kind of the pushes and pulls, and how happy you are with the progress made?"
265621,321831219,920969,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","Sure. Yes, thanks, Ross. I think, 2015 was a year of very good progress across the platform. You mentioned Nobel, let me just start with that. We have a tremendous team of folks at Nobel. Largely, the leadership team that was in place when we acquired the",318,"Sure. Yes, thanks, Ross. I think, 2015 was a year of very good progress across the platform. You mentioned Nobel, let me just start with that. We have a tremendous team of folks at Nobel. Largely, the leadership team that was in place when we acquired the business, they have really embraced DBS and are off to a terrific start both in terms of continuing to use DBS tools to drive growth, but also, as in my comments earlier, some great progress on operating margins. And now as that goes core to the Dental platform, we'll see some impact to that to the good. On the business that existed prior to 2015, I think, again, 2015 was a year of a lot of progress. I've mentioned a couple of times that we've had outstanding relationships with our distribution partners. We worked in a collaborative way with them on channel inventories throughout the course of the year. That was, obviously, somewhat of a painful process to go through in the sense of the impact on core growth, but net-net a very good process in terms of positioning the channel efficiently. So we are pleased that the vast majority of that's behind us. There can always be a little bit of a tail to that of stuff we're still moving out in slower moving inventories but, again I think, a ton of progress. We've also got a very good leadership team in place on our -- in our Dental platform today, with some new players in place that, I think, are doing some wonderful things in terms of driving innovation. It was a very good year of new product introductions. And I think we'll see the benefit of that as core growth improves this year. So we know we still have work to do there, but good news is that there's opportunities for value creation as we go on here."
265621,321831219,920969,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Analysts","Great. And maybe just quickly a little color more on the M&A pipeline. Can you just give us a sense? I mean there's obviously been a ton of equity market volatility. We've seen, obviously, a shift in how the private equity folks are also sort of transacti",112,"Great. And maybe just quickly a little color more on the M&A pipeline. Can you just give us a sense? I mean there's obviously been a ton of equity market volatility. We've seen, obviously, a shift in how the private equity folks are also sort of transacting. Just give us a feel for maybe healthcare versus industrial-oriented assets and the like. Whether there's more activity at one side of the spectrum versus the other, and how? So the valuation dislocations have been kind of digested by the various groups, because you're obviously doing smaller things at this point, and it's, obviously, the large end of the market that's probably been most impacted."
265621,321831219,920969,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","Sure. Well, I'll let Dan comment in a second on kind of the environment that we're seeing. But if you just look at what we did in the fourth quarter, which I think is a bit instructive, we got 4, 5 small deals done in the fourth quarter. And by the way, a",168,"Sure. Well, I'll let Dan comment in a second on kind of the environment that we're seeing. But if you just look at what we did in the fourth quarter, which I think is a bit instructive, we got 4, 5 small deals done in the fourth quarter. And by the way, a couple -- 2 or 3 of those deals were Fortive-related. I mentioned Pacific Laser Systems in my earlier comments, but there were a couple of other smaller situations that we were able to complete during the quarter for Fortive's benefit along with a couple on the Danaher side. So I think the fourth quarter was indicative perhaps of some things opening up a bit. I think, the environment is generally a favorable one for businesses like ours with a balance sheet that's ready to deploy into small and midsize situations. And I think to your question, there are some folks who are perhaps a bit more on the sidelines right now than in previous days."
265621,321831219,920969,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Operator","Next question comes from Shannon O'Callaghan of UBS.",9,"Next question comes from Shannon O'Callaghan of UBS."
265621,321831219,920969,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Analysts","So Test & Measurement and Industrial Tech are both generating pretty good core margin expansion here, despite these mid-single-digit declines. Can you give a little more color on how they're managing to do that? I mean, both of them have pretty good lever",62,"So Test & Measurement and Industrial Tech are both generating pretty good core margin expansion here, despite these mid-single-digit declines. Can you give a little more color on how they're managing to do that? I mean, both of them have pretty good leverage in the model, so that's a lot to offset. And what's going on in those businesses, and can it continue?"
265621,321831219,920969,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","Yes. It's -- Shannon, it is a real testament to those businesses given the challenging environment they're in from a core growth perspective. That they are getting the operating margin lift that they're getting without the benefit of the top line dropping",197,"Yes. It's -- Shannon, it is a real testament to those businesses given the challenging environment they're in from a core growth perspective. That they are getting the operating margin lift that they're getting without the benefit of the top line dropping that through. I think, it is a testament to the strength of the Danaher Business System, the tools that we use not just in newly acquired businesses, but in businesses with long histories with Danaher that have gotten a lot done using DBS in the past and are still getting it done. If you think about some of the businesses in T&M, be it Fluke and the associated acquisitions around Fluke that have been done quite a number of years ago, think about other businesses like Qualitrol, like some of the businesses in our automation and Sensors and Controls areas, those guys are using DBS, whether those are lean tools specifically in the plants or deploying those tools into -- in areas of SG&A, they are just demonstrating that those tools are still highly effective in businesses with long histories with Danaher. So it's kudos to those guys, and they continue to get 'er done."
265621,321831219,920969,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Analysts","Okay. And then you talked a little bit about the Diagnostic comps and things, but Radiometer, that's been one that seemed like it was just going to grow to the sky forever in the equipment business. It was a little weaker there, so maybe a little just col",54,"Okay. And then you talked a little bit about the Diagnostic comps and things, but Radiometer, that's been one that seemed like it was just going to grow to the sky forever in the equipment business. It was a little weaker there, so maybe a little just color? Anything there to be concerned about?"
265621,321831219,920969,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","Yes. No. We -- Radiometer is a tremendous business with a long track record of high single-digit growth at Danaher. I'm sure Matt or Dan can find how many quarters it's been, but it's quite a number of them in a row that we've been high single digits and",198,"Yes. No. We -- Radiometer is a tremendous business with a long track record of high single-digit growth at Danaher. I'm sure Matt or Dan can find how many quarters it's been, but it's quite a number of them in a row that we've been high single digits and taking share. It's a high consumables business. It's probably in the 80% neighborhood of consumables, so the days impact was fairly significant there. They also had a challenging comp in the fourth quarter on the Instrumentation side. Couple of big orders that had some impact there. So I think Radiometer is in as good a shape today as it's ever been, no meaningful shift in the competitive dynamics there. So we still feel very good about it. I think, if there was anything there, Shannon, and it wouldn't be unique to Radiometer, it's simply the fact that some of the growth that we have seen in the high-growth markets, while still strong in places like China and India, are still now very weak in Latin America, in Russia, in the Middle East. And so even our best businesses are probably going to feel a little bit of impact there."
265621,321831219,920969,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Operator","Our next question comes from Brandon Couillard of Jefferies.",9,"Our next question comes from Brandon Couillard of Jefferies."
265621,321831219,920969,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Analysts","Just -- back on the Dental business. Dan, any chance you could give us the impact of the fewer days on core growth overall? And how should we think about margin expansion for the year?",35,"Just -- back on the Dental business. Dan, any chance you could give us the impact of the fewer days on core growth overall? And how should we think about margin expansion for the year?"
265621,321831219,920969,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","Well, it has less of an impact on equipment. We were up slightly in the quarter, it's first time we've been up, albeit modestly. But it impacts consumables probably up in a -- as Tom alluded to, probably 1.5, 2 points when it comes to consumables. Good pr",111,"Well, it has less of an impact on equipment. We were up slightly in the quarter, it's first time we've been up, albeit modestly. But it impacts consumables probably up in a -- as Tom alluded to, probably 1.5, 2 points when it comes to consumables. Good progress on the margin side, granted we had a pretty weak performance a year ago. So part of it was the comp, but we've also took -- part of our incremental restructuring here in Q4 was at Dental, so we should see some continued margin expansion coming out of Dental. Hopefully, with a little bit better growth than what we've seen here in '15."
265621,321831219,920969,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Operator","Our next question comes from Julian Mitchell of Crdit Suisse.",10,"Our next question comes from Julian Mitchell of Crdit Suisse."
265621,321831219,920969,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Analysts","Just a question around Western Europe. I think, I heard you say that sales were down slightly in Q4, having been up sort of around a mid-single-digit pace in the nine-months period. I think a lot of other companies have sort of been saying Europe is okay,",66,"Just a question around Western Europe. I think, I heard you say that sales were down slightly in Q4, having been up sort of around a mid-single-digit pace in the nine-months period. I think a lot of other companies have sort of been saying Europe is okay, so maybe just talk a little bit about what you saw there, specific countries or segments that slowed down?"
265621,321831219,920969,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","Julian, I mean, I think that was one of the areas versus what we expected at the beginning of the quarter that surprised us a little bit to the downside. It wasn't dramatic. Clearly, our consumable businesses over there were impacted by the selling days a",140,"Julian, I mean, I think that was one of the areas versus what we expected at the beginning of the quarter that surprised us a little bit to the downside. It wasn't dramatic. Clearly, our consumable businesses over there were impacted by the selling days and maybe we were not as well calibrated as we should have been. But having gone through all -- most of the business here in the first couple weeks here, the tone in Europe is still decent, and -- so it doesn't feel like the step-down that our numbers in Q4 would suggest. And we think we'll get back to sort of modest growth here pretty quickly in 2016. Watching that carefully because it probably caught us a little bit by surprise here in the fourth quarter, but again the tone still seems pretty good."
265621,321831219,920969,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Analysts","Understood. And you laid out the overall EPS seasonality through the year about just over a month ago. Maybe just talk a little bit about the Pall, seasonality of that $0.40, particularly given the industrial organic sales trend in that business right now",54,"Understood. And you laid out the overall EPS seasonality through the year about just over a month ago. Maybe just talk a little bit about the Pall, seasonality of that $0.40, particularly given the industrial organic sales trend in that business right now? And how you would contrast that $0.40 impact versus overall Danaher?"
265621,321831219,920969,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","Well, the $0.40 should ramp during the year as we go after cost. Again, we were able to get some more things done in December, and that was inclusive of Pall as well. So we're getting out of the gate a little bit faster in Q1 from a margin perspective. I",79,"Well, the $0.40 should ramp during the year as we go after cost. Again, we were able to get some more things done in December, and that was inclusive of Pall as well. So we're getting out of the gate a little bit faster in Q1 from a margin perspective. I think the offset, as you suggest, is the Industrial side. So I think we'll get nice accretion here in Q1, but it will clearly ramp through the year."
265621,321831219,920969,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Operator","Our next question comes from Andrew Kaplowitz of Citigroup.",9,"Our next question comes from Andrew Kaplowitz of Citigroup."
265621,321831219,920969,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Analysts","Obviously, good performance in margin in the quarter. Are raw materials -- lower raw material costs helping at all with price costs? Did the price costs -- was it stable in 4Q versus 3Q? Did it improve? I know you mentioned covering FX, but are raw materi",50,"Obviously, good performance in margin in the quarter. Are raw materials -- lower raw material costs helping at all with price costs? Did the price costs -- was it stable in 4Q versus 3Q? Did it improve? I know you mentioned covering FX, but are raw materials helping at all?"
265621,321831219,920969,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","I don't have any great analysis on that yet. Given our gross margin, raw materials tends to be less of a factor for us than a lot of other companies you might cover. We are continuing to get price, still getting 60, 70 basis points. And it's hard not to t",68,"I don't have any great analysis on that yet. Given our gross margin, raw materials tends to be less of a factor for us than a lot of other companies you might cover. We are continuing to get price, still getting 60, 70 basis points. And it's hard not to think raw materials are helping us a little bit, but for us it's really on the margin."
265621,321831219,920969,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Analysts","Okay, got it. And then how do you get visibility into what to forecast, for example, on the Middle East? I mean, the region looks like it inflected down a bit in 4Q, and with oil's recent leg down, how difficult is it to get visibility? And what do you fo",53,"Okay, got it. And then how do you get visibility into what to forecast, for example, on the Middle East? I mean, the region looks like it inflected down a bit in 4Q, and with oil's recent leg down, how difficult is it to get visibility? And what do you forecast for 2016?"
265621,321831219,920969,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","Well, there's -- Andrew, there's a couple of different ways to come at that in the Middle East. One is simply conversations with distribution partners, and a lot of what we do in the Middle East does involve some form of a distributor partner. And making",236,"Well, there's -- Andrew, there's a couple of different ways to come at that in the Middle East. One is simply conversations with distribution partners, and a lot of what we do in the Middle East does involve some form of a distributor partner. And making sure that we have transparency as much as we possibly can into the opportunity funnels that those distributors are seeing as well as making sure that the conversations we're having with our own sales team around those funnels as they roll up to our leadership team are as well pressure-tested as possible. The key thing about markets like the Middle East is, particularly in the businesses like ours, you have a fairly high level of project or tender-related business, and we saw on the equipment side. And so really making sure that we understand opportunity funnels and are not overly optimistic about the timing within which funding will be released, as in many cases that funding has some governmental influence to it, is really important. It is easy to have a sales team get overly optimistic that the timing of funding release is going to be the same as it was 1 year ago or 2 years ago when the reality is, things may have slowed down and tenders may be being let at a much slower pace. So being diligent about how we pressure test those funnels is key."
265621,321831219,920969,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Analysts","So it's fair to say you're being pretty conservative with the Middle East forecast.",15,"So it's fair to say you're being pretty conservative with the Middle East forecast."
265621,321831219,920969,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","We're trying to be increasingly conservative as we see how government funding is being influenced. I think, it was interesting watching the course of the year. Oil continued to drop, as you know, throughout the course of the year and yet, we actually saw",105,"We're trying to be increasingly conservative as we see how government funding is being influenced. I think, it was interesting watching the course of the year. Oil continued to drop, as you know, throughout the course of the year and yet, we actually saw our Middle East numbers hang in there reasonably well throughout the middle part of the year. And It wasn't until the latter part of the year that we saw more acute shift in the Middle East. And so there was a little bit of a lag there and it's taken a bit of time for the team to fully recalibrate."
265621,321831219,920969,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Operator","And we'll take our final question from Deane Dray of RBC Capital Markets.",14,"And we'll take our final question from Deane Dray of RBC Capital Markets."
265621,321831219,920969,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Analysts","Just a quick question on R&D spending overall, came in lighter year-over-year and versus our estimates. Did you throttle back on any spending? Is it just timing of some of the projects?",33,"Just a quick question on R&D spending overall, came in lighter year-over-year and versus our estimates. Did you throttle back on any spending? Is it just timing of some of the projects?"
265621,321831219,920969,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","As you probably saw in the numbers that we put out, Deane, we are showing R&D down about 20 basis points. But the reality is that, that was primarily influenced by Pall and R&D spending normalized for the Pall influence was actually up on the quarter. So",89,"As you probably saw in the numbers that we put out, Deane, we are showing R&D down about 20 basis points. But the reality is that, that was primarily influenced by Pall and R&D spending normalized for the Pall influence was actually up on the quarter. So we are continuing to make sure that innovation is a key priority for the businesses and that R&D spending is maintained to the greatest extent possible for the opportunities that we think have the greatest impact in the next year or 2."
265621,321831219,920969,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Analysts","And then just last question for me is the -- the incremental restructuring done in December, did you say what portion of that was Danaher versus Fortive?",27,"And then just last question for me is the -- the incremental restructuring done in December, did you say what portion of that was Danaher versus Fortive?"
265621,321831219,920969,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","It was roughly the split you'd expect, 70%, 30%. And that 70% Danaher, inclusive of Pall.",17,"It was roughly the split you'd expect, 70%, 30%. And that 70% Danaher, inclusive of Pall."
265621,321831219,920969,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Operator","And I'd be happy to turn the program back over to our hosts.",14,"And I'd be happy to turn the program back over to our hosts."
265621,321831219,920969,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","Thanks, Leo. Thanks, everyone, for joining us. We're around all day for questions.",13,"Thanks, Leo. Thanks, everyone, for joining us. We're around all day for questions."
265621,321831219,920969,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Operator","Thank you. This does conclude today's Danaher Corporation's Fourth Quarter 2015 Earnings Results Conference Call. You may now all disconnect your lines, and everyone, have a great day.",28,"Thank you. This does conclude today's Danaher Corporation's Fourth Quarter 2015 Earnings Results Conference Call. You may now all disconnect your lines, and everyone, have a great day."
265621,321831219,921165,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Operator","My name is Leo, and I will be your conference facilitator this morning. At this time, I would like to welcome everyone to Danaher Corporation's Fourth Quarter 2015 Earnings Results Conference Call. [Operator Instructions] I will now turn the call over t",57,"My name is Leo, and I will be your conference facilitator this morning. At this time, I would like to welcome everyone to Danaher Corporation's Fourth Quarter 2015 Earnings Results Conference Call. [Operator Instructions] 
I will now turn the call over to Mr. Matt Gugino, Vice President of Investor Relations. Mr. Gugino, you may begin your conference."
265621,321831219,921165,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","Thank you, Leo. Good morning, everyone, and thanks for joining us on the call. With us today are Tom Joyce, our President and Chief Executive Officer; and Dan Comas, our Executive Vice President and Chief Financial Officer. I'd like to point out that ou",326,"Thank you, Leo. Good morning, everyone, and thanks for joining us on the call. With us today are Tom Joyce, our President and Chief Executive Officer; and Dan Comas, our Executive Vice President and Chief Financial Officer. 
I'd like to point out that our earnings release, the slide presentation supplementing today's call and other information required by SEC Regulation G relating to any non-GAAP financial measures provided during the call are all available on the investors section of our website, www.danaher.com, under the heading Financial Information. 
The audio portion of this call will be archived on the Investors section of our website later today under the heading Events & Presentations and will remain archived until our next quarterly call. A replay of this call will also be available until February 2, 2016. The replay number is (888) 203-1112 within the U.S. or (719) 457-0820 outside the U.S., and the confirmation code is 9714607. 
During the presentation, we will describe certain of the more significant factors that impacted the year-over-year performance. The supplemental materials describe additional factors that impacted year-over-year performance. Unless otherwise noted, all references in these remarks and supplemental materials to company-specific financial metrics relate to the continuing operations of the company in the fourth quarter of 2015, and all references to period-to-period increases or decreases in financial metrics are year-over-year. 
During the call, we will make forward-looking statements within the meaning of the federal securities laws, including statements regarding events or developments that we believe or anticipate will or may occur in the future. These forward-looking statements are subject to a number of risks and uncertainties, including those set forth in our SEC filings, and actual results might differ materially from any forward-looking statements that we make today. These forward-looking statements speak only as of the date that they are made, and we do not assume any obligation to update any forward-looking statements. 
With that, I'd like to turn the call over to Tom."
265621,321831219,921165,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","Thanks, Matt, and good morning, everyone. We are pleased with our results for the fourth quarter, in which the team delivered double-digit earnings growth, strong core operating margin expansion and record free cash flow. Despite the more challenging econ",2250,"Thanks, Matt, and good morning, everyone. We are pleased with our results for the fourth quarter, in which the team delivered double-digit earnings growth, strong core operating margin expansion and record free cash flow. Despite the more challenging economic landscape, particularly in our industrially oriented markets, we continued to build our competitive advantage and drove share gains across a number of our businesses. As always, the Danaher Business System is the foundation for our team's outstanding execution. 
We also made meaningful progress toward establishing a new industrial growth company, Fortive, which will be spun out of Danaher later this year. At our year-end investor meeting, we announced Fortive's name, branding, future operating structure and additional leadership positions. We also achieved an important milestone in December, filing Fortive's Form 10 registration statement with the Securities and Exchange Commission. We are confident that Fortive will launch with a strong foundation and will be poised for success upon completion of the separation in the third quarter of 2016. 
For the full year, our investments in organic growth initiatives helped drive solid 3% core revenue growth. With the addition of our recent acquisitions and other portfolio moves, our total annual revenues are now over $20 billion. 
From an M&A perspective, 2015 was a historic year for Danaher. Including Pall, we announced or closed 14 acquisitions for nearly $14.5 billion, expanding our capabilities across the portfolio. Looking forward, our funnels at both Danaher and Fortive are strong, and we'll continue to focus on small and midsized transactions throughout the separation process.
In 2015, we generated a record $3.2 billion of free cash flow, including over $1 billion in the fourth quarter. Our free cash flow to net income conversion ratio in 2015 was 123%, representing the 24th consecutive year in which our free cash flow has exceeded net income. We recognize the importance of this metric, particularly in a more challenging macro environment, as strong free cash flow is the fuel used to fund both our organic and inorganic growth initiatives. 
Now turning to the fourth quarter. Sales grew 12.5% to $5.9 billion, while core revenue was roughly flat. Core revenue growth, particularly for our consumables businesses, was negatively impacted by 4 fewer selling days in the quarter. In addition, the impact of currency translation eased this quarter but still decreased revenues by 5%, while acquisitions increased revenues by 17.5%.
In a weakening global macro environment, the Danaher Business System helped protect and expand many of our market-leading positions, driving share gains at Hach, ChemTreat, Matco, Gilbarco, Radiometer, SCIEX and Videojet. In the high-growth markets, declines in Latin America, Russia and the Middle East were more than offset by double-digit growth in India and high single-digit growth in China. Notably, annual revenues in China exceeded $2 billion for the first time, and we remain well-positioned in the most attractive sectors in the market. In the developed markets, revenues were down slightly due to incremental softness in the U.S. and Western Europe.
Gross margin for the quarter was 51.2%. For the full year, our gross margin was 52.3%, and our gross profit increased by almost $900 million. In the quarter, core operating margin increased 120 basis points, with all 5 segments improving by 60 basis points or better. Our reported operating margin was flat at 16.6%, negatively affected by the dilutive impact of recent acquisitions and acquisition-related transaction costs.
Fourth quarter adjusted diluted net EPS was $1.27, which represents an increase of 13.5% over last year. For the full year, adjusted diluted net EPS was $4.30, up 8.5% from 2014.
Turning to our 5 operating segments. Test & Measurement revenues decreased 9%, while core revenues were down 5%. Core operating margin increased 110 basis points, primarily due to new product introductions and good cost management. Core revenue in our Instruments platform decreased at a high single-digit rate, with declines across most major geographies. Fluke core revenues were down high single digits as industrial markets continued to weaken in North America, Latin America and the Middle East. In December, Fluke acquired Pacific Laser Systems, a leader in handheld laser alignment tools, to enhance its product offerings for professional contractors, electricians and general maintenance customers. 
At Tektronix, core sales declined high single digits. Declines in North America, Latin America and the Middle East more than offset growth in China that resulted from solid execution by our local sales team. The team's continued investments in innovation placed Tek in a position of technology leadership within its industry. This quarter, Tek launched the MDO4000C, a Mixed Domain Oscilloscope that combines up to 6 instruments in 1 unit. The new MDO4000C is completely customizable and upgradable, allowing engineers to start with a high-performance oscilloscope and add functionality over time as needs change or budgets allow. 
Matco, a business that will be a significant contributor to Fortive's results, delivered its third consecutive year of double-digit core growth in 2015. Even after 3 decades as part of the Danaher portfolio, Matco continues to find new ways to improve using DBS. By deploying such DBS tools as web marketing, accelerated product development and lean conversion, the team continues to expand its franchise distribution network, gain market share and expand margins.
Turning now to our Environmental segment. Revenues grew 1%, with core revenues up 4%. Core operating margin expanded 60 basis points, and reported operating margin expanded 260 basis points to 21.8%. Water Quality core revenues increased at a low single-digit rate, a combination of fewer selling days and slower demand from our more industrial customers in the developed markets resulted in essentially flat core growth at Hach, while ChemTreat grew slightly. Trojan had another very good quarter, driven by healthy demand and increased bidding activity in the North American muni market. 
Hach delivered another impressive year in 2015. In addition to mid-single digit organic growth, Hach continued its healthy cadence of bolt-on acquisitions. The team has done a terrific job implementing DBS in newly acquired businesses to help improve sales and drive innovation. One such example is BioTector, which was acquired in 2014 and had double-digit growth in the quarter. BioTector provides online total organic carbon analyzers that help our customers monitor water quality in real time and reduce waste. BioTector's early and effective application of DBS tools such as lean conversion and funnel management led to more than 200 basis points of margin expansion, significant inventory reductions and market share gains in the chemical and dairy segments. 
Gilbarco Veeder-Root's core revenues grew high single digits, with strength across the platform. In the U.S, point-of-sale solutions and dispensers increased over 20%, as our customers continued to upgrade their payment systems to comply with EMV security requirements. We expect EMV-related demand to continue to accelerate for the next several years. 
Moving to Life Science & Diagnostics, core revenues grew 2%, with reported revenues up 34.5%, largely due to our recent Pall, Microscan and Devicor acquisitions. Core operating margin expanded 75 basis points. 
Core revenues in our Diagnostics platform increased low single digits, with growth in the high-growth markets, partially offset by slight declines in developed markets. As previously mentioned, fewer selling days in the quarter negatively impact our recurring revenue streams across the platform. 
At Beckman Coulter, core revenues increased at a low single-digit rate, led by our immunoassay and urinalysis solutions. Utilization rates in Asia remain healthy, leading to high single-digit growth across the region. 
In Europe, we celebrated our first orders with the commercial launch of our Veris molecular diagnostic system. Veris' streamlined sample-in result-out workflow, offers breakthrough ease of use in a market that is experiencing a shortage of skilled technicians. In short, it's helping our lab customers process more tests, reduce training requirements and save money. And thus far, customer feedback has been extremely positive.
Radiometer's core revenues were up slightly, a deceleration from previous quarters due to the effect of fewer selling days and a difficult comparison in Instrument sales. Geographically, we saw healthy growth in China and Japan, while Latin America and the Middle East declined. 
Leica Biosystems had a good finish to the year, delivering low single-digit core growth as strong demand across most major product lines was partially offset by the impact from fewer selling days. Notably, the team delivered a record year of placements for our BOND advanced staining instrument. 
Last December, we closed the acquisition of Devicor, a leading provider of breast biopsy devices and markers. That move Leica further upstream in the anatomical pathology workflow. Devicor continues to track well and has exceeded our expectations, posting high single-digit core growth or better in each quarter since acquisition. 
Core revenues in our Life Science platform were up low single digits with growth in both developed and high-growth markets. SCIEX core revenues grew mid-single digits, with continued strength in our clinical and applied end markets. 2015 marked the fifth year since our acquisition of SCIEX. Since then, SCIEX has proven to be a remarkable example of how thoughtful application of DBS principles can drive tremendous financial results. The team has taken a business that was growing below market rates to mid- to high single-digit growth and share gains. We've seen significant improvement on the cost side as well, which has enabled SCIEX to invest those savings into higher impact growth initiatives. Progress at SCIEX continues today, and 2015 marked one of the most important product innovation years in SCIEX's history, with the launch of its X-Series mass spectrometry platform. The X-Series introduces an entirely new design, easy-to-use software and custom models for targeted application in routine food, environmental and forensic testing labs.
Leica Microsystems core revenues were essentially flat as strong performance in China and Japan was offset by declines in Europe, the Middle East and Latin America.
Turning now to Dental. Segment revenues increased 17%, largely due to our Nobel Biocare acquisition. Core revenues were up slightly. Core operating margins increased by over 500 basis points in the quarter, primarily due to consistent DBS implementation across a number of operational areas. Reported operating margins were 15.8%.
Revenues in our consumables business were negatively impacted by fewer selling days in the quarter, but our team continued to execute well and saw strong demand for several product lines throughout the year. In particular, our investments in innovation have provided us with truly differentiated technologies such as SonicFill, TF Adaptive and elementsfree, which all launched in 2014. In Dental technology, we saw our first quarter of positive growth since the fourth quarter of 2014. Top line results continued to be impacted by destocking within our U.S. distribution channels, but to a much lesser degree than in previous quarters. 
December marked the one-year anniversary of our acquisition of Nobel Biocare. The team has quickly embraced growth, lean and leadership tools of DBS, helping to not only accelerate growth but also improve operating margins by over 300 basis points since the acquisition.
Moving to Industrial Technologies. Revenues declined 8.5%, while core revenues were down 4.5%. Core operating margin expanded 80 basis points, and reported operating margin expanded 120 basis points to 21.6%. Automation core revenues decreased at a high single-digit rate due to weakening in the industrial markets in China and North America. Despite the challenging market and revenue decline, the team continues to identify cost-savings opportunities and delivered solid core margin expansion in the quarter. 
Core revenues in our Product Identification platform were up slightly. In the fourth quarter, we continued to extend our reach into new Product ID adjacencies with the acquisition of Laetus, a leading supplier of track and trace inspection systems for pharmaceutical packaging plants. Increasingly, pharmaceutical tracking is becoming a regulatory and public safety concern, and Laetus gives us exposure to this important vertical. And we're excited to welcome Laetus to the Danaher team. 
At Videojet, core revenues were up low single digits as strong performance in Europe and North America was somewhat offset by weakness in the high-growth markets. Results were negatively impacted by fewer selling days in the quarter. Throughout the full year, Videojet has placed a major focus on digital investments, driving key innovations in areas such as network monitoring, remote service-enabled printers and predictive maintenance. As a result, we achieved record new equipment vitality of over 40% for the year. These tremendous technology capabilities have not only solidified Videojet's leadership position in the market, they have also meaningfully improved our customers' experiences.
So to wrap up. We are pleased with our record fourth quarter results. During the quarter, the team delivered double-digit earnings growth, significantly expanded core operating margins, generated record free cash flow and announced several bolt-on acquisitions. Despite the more challenging economic landscape, particularly in our industrially oriented markets, we continue to execute well. 
Looking back, 2015 was a remarkable year for Danaher. We completed the largest acquisition in our history with Pall, announced our pending separation into 2 independent publicly traded companies with Fortive and drove excellent overall financial results. With the Danaher Business System as our foundation, we believe we'll continue to deliver earnings outperformance and create long-term shareholder value in 2016 and for years to come. 
We are initiating first quarter adjusted diluted net EPS guidance between $1 and $1.04, which assumes approximately flat core revenue growth. As we announced at our annual investor event in December, we continue to expect full year 2016 core revenue growth of 2% to 3% and adjusted diluted net earnings per share to be in the range of $4.80 to $4.95, which would represent a 12% to 15% increase year-on-year."
265621,321831219,921165,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","Thanks, Tom. That concludes our formal remarks. Leo, we are now ready for questions.",14,"Thanks, Tom. That concludes our formal remarks. Leo, we are now ready for questions."
265621,321831219,921165,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Operator","[Operator Instructions] We'll take our first question from Scott Davis of Barclays.",12,"[Operator Instructions] We'll take our first question from Scott Davis of Barclays."
265621,321831219,921165,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Analysts","I think -- I mean, given that it's been about a month since you gave the last guidance in mid-December, the formal guidance, I guess. Things seemed to have degraded a bit on the macro side. I mean, what confidence do you have? I mean, now that you've seen",84,"I think -- I mean, given that it's been about a month since you gave the last guidance in mid-December, the formal guidance, I guess. Things seemed to have degraded a bit on the macro side. I mean, what confidence do you have? I mean, now that you've seen, I guess, most of January, I mean have things stabilized? I mean, your guidance seems to indicate that you think that was a bit of a blip, I suppose. So just a little color there."
265621,321831219,921165,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","Sure, Scott. I think, Scott, we're -- what we're assuming is that what we saw with some of the slowing in December is essentially the environment that we're going to see in the near term here. It's clearly impacting our more industrial businesses more tha",227,"Sure, Scott. I think, Scott, we're -- what we're assuming is that what we saw with some of the slowing in December is essentially the environment that we're going to see in the near term here. It's clearly impacting our more industrial businesses more than our other businesses. So we're not immune to the slowdown. But I think we took some appropriate actions in the fourth quarter. Those actions are going to pay off here certainly from a margin standpoint. But I think the other thing to keep in mind is that the portfolio that we have today truly does differentiate us. And I think when we look at the opportunities that we have in our Life Science businesses, our Diagnostic businesses, some improvement that we're seeing here in our Dental businesses, continued good progress at GVR. While we remain cautious in some respects around the macro environment and are not assuming things get materially better there, we are playing offense in a number of areas that, I think, will bode well. So I don't think there's anything particularly optimistic in our outlook around the macro, but I think some of the things that we're doing from an investment standpoint and across our growth initiatives should continue to position a very good portfolio and a differentiated portfolio and continue to move it into an even better place."
265621,321831219,921165,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Analysts","Yes, makes sense. And then just as a follow-up, the emerging-market currencies have degraded a fair amount. I mean, are you able to get local price to offset that? I mean, how do you manage that volatility, specifically, just given the exposure you guys h",45,"Yes, makes sense. And then just as a follow-up, the emerging-market currencies have degraded a fair amount. I mean, are you able to get local price to offset that? I mean, how do you manage that volatility, specifically, just given the exposure you guys have?"
265621,321831219,921165,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","Yes. I mean, it's an issue. I'd probably bifurcate the answer. Where we have the aftermarket business, the consumables, the service, we're typically able to get price. With equipment and instruments, we are not able to. And we're taking a little bit of a",73,"Yes. I mean, it's an issue. I'd probably bifurcate the answer. Where we have the aftermarket business, the consumables, the service, we're typically able to get price. With equipment and instruments, we are not able to. And we're taking a little bit of a margin hit there. Fortunately, the euro stabilized so the overall currency impact is not what it was in '15, but it's a little bit of a negative right now."
265621,321831219,921165,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Operator","And we'll take our next question from Nigel Coe of Morgan Stanley.",13,"And we'll take our next question from Nigel Coe of Morgan Stanley."
265621,321831219,921165,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Analysts","So just on the $0.40 from Pall, can you maybe just first of all comment on how Pall is tracking? Or how it tracked through the quarter? Maybe commenting on the industrial versus Life Sciences sides? And how has the composition of the $0.40 in the plan cha",56,"So just on the $0.40 from Pall, can you maybe just first of all comment on how Pall is tracking? Or how it tracked through the quarter? Maybe commenting on the industrial versus Life Sciences sides? And how has the composition of the $0.40 in the plan changed at all in the last couple of months?"
265621,321831219,921165,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","Nigel, we are very, very happy with how we've gotten started with Pall. Starting with the team that we have in place, a terrific team, both the Pall leadership team, many of whom have taken on added responsibilities. But in addition, the added resources t",403,"Nigel, we are very, very happy with how we've gotten started with Pall. Starting with the team that we have in place, a terrific team, both the Pall leadership team, many of whom have taken on added responsibilities. But in addition, the added resources that we put in place and the leadership that we have brought to bear in the business, I think, together, that team is off to a terrific start. We'll talk to the $0.40 and the cost opportunities that we have here in just a minute. But coming to the growth side of the house, about what we expected, continued very good progress and growth rates on the Life Science side, keeping in mind that, that business has an exceptional position in the biopharma market in Life Science. So we're seeing continued good growth there. We're also seeing outstanding growth in single-use technologies, which are a key part and a key growth driver of the biopharma segment of the Life Science business as time goes on. On the industrial side, again, what you -- what we would have expected, which is a slowing on that side of the house, we've seen that -- those businesses impacted far more than, obviously, on the more Life Science-oriented side of the house. But I think it's also important to keep in mind that, that business is also strongly skewed towards consumables. In total, the portfolio is about 70% aftermarket consumables, primarily. And so that's a strong foundation, and I think continues to give us confidence that while we'll have some segments that are challenged, the business overall will continue to perform quite well. Relative to the cost side of the house, again, off to a very good start. You heard us in December, take the 2016 number up to $100 million because we had gotten off to an earlier start. We're getting the kinds of cost reductions that you would expect us to get out of a public company in the early going. The public company costs beginning to get after some of the indirect cost leverage that we get and some of the procurement cost leverage that we get by consolidating procurement across our other businesses where appropriate. And over time, we'll see some of the benefits coming from -- on the gross margin side as we look at the operational footprint, but that will obviously take a little bit more time."
265621,321831219,921165,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Analysts","Okay. But that's helpful. And then on the balance sheet, you've taken down a lot of -- an impressive amount of debt since the acquisition of Pall, I think about $3 billion of debt pay down. Given the bit more challenging macro, is there a change in your b",53,"Okay. But that's helpful. And then on the balance sheet, you've taken down a lot of -- an impressive amount of debt since the acquisition of Pall, I think about $3 billion of debt pay down. Given the bit more challenging macro, is there a change in your bias towards delevering this year?"
265621,321831219,921165,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","Nigel, I think, we remain in that kind of $2 billion target for M&A this year. We are incrementally encouraged. We were able to get some deals done in December, granted they were small, but we actually saw a flurry of deals get done towards the end of the",118,"Nigel, I think, we remain in that kind of $2 billion target for M&A this year. We are incrementally encouraged. We were able to get some deals done in December, granted they were small, but we actually saw a flurry of deals get done towards the end of the year. Clearly, what's going on, the high-yield market has made it very difficult for the private equity parties, let alone industrial companies have a lower credit rating. So some of the anxiety out here definitely helping some of the conversation. So on the margin, we're a little bit more encouraged than we were at 60, 90 days ago on the M&A front. I hope I didn't offend you, Nigel."
265621,321831219,921165,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Operator","Our next question is from Steve Tusa of JPMorgan.",9,"Our next question is from Steve Tusa of JPMorgan."
265621,321831219,921165,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Analysts","Can you just maybe talk a little bit more specifically about Pall industrial trends? I mean, what is the organic -- what kind of organic are you seeing there? And what are you expecting for 2016, a little more kind of precisely?",42,"Can you just maybe talk a little bit more specifically about Pall industrial trends? I mean, what is the organic -- what kind of organic are you seeing there? And what are you expecting for 2016, a little more kind of precisely?"
265621,321831219,921165,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","So Steve, for the 4 months that we owned the business on a constant currency basis, Pall grew about 4% on a combined basis. Clearly, it would have been accretive to our core growth here. Life Science was up high single digits. Industrial was down low to m",90,"So Steve, for the 4 months that we owned the business on a constant currency basis, Pall grew about 4% on a combined basis. Clearly, it would have been accretive to our core growth here. Life Science was up high single digits. Industrial was down low to mid-single digits. We see that for the near term, not a bad way to be looking at the business. Clearly, the Industrial piece is more challenged, but more than making up for it with a very strong growth on the Life Science side."
265621,321831219,921165,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Analysts","And then what was Pall's contribution to free cash flow in the quarter?",14,"And then what was Pall's contribution to free cash flow in the quarter?"
265621,321831219,921165,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","On the working capital side, where we contributed north of $300 million of cash out of working capital, Pall was a nice piece of it, but maybe 15%. The working capital improvements were very broad-based, really exceptional performance across all the 5 seg",56,"On the working capital side, where we contributed north of $300 million of cash out of working capital, Pall was a nice piece of it, but maybe 15%. The working capital improvements were very broad-based, really exceptional performance across all the 5 segments. So it was a nice contributor, but it was not an overwhelming piece."
265621,321831219,921165,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Analysts","Okay. Great. And then just one last question. What's kind of the restructuring contingency look like in '16? Is there any change to that as you kind of exited the year at a bit of a weaker rate? Or have you been kind of -- kind of normal day-to-day planni",63,"Okay. Great. And then just one last question. What's kind of the restructuring contingency look like in '16? Is there any change to that as you kind of exited the year at a bit of a weaker rate? Or have you been kind of -- kind of normal day-to-day planning? How kind of extreme are things around some of the more industrial businesses?"
265621,321831219,921165,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","Steve, I think, one of the things that we learned from 2015, and we're pleased about is this. We did a number of things throughout the course of the year from a productivity perspective. And I think particularly in an environment like this, it's important",171,"Steve, I think, one of the things that we learned from 2015, and we're pleased about is this. We did a number of things throughout the course of the year from a productivity perspective. And I think particularly in an environment like this, it's important that we stay cognizant of the fact that there may be opportunities that present themselves, some things that we may need to do. So we're going to keep the teams active at looking for opportunities throughout the course of the year, and we'll take advantage of those as they come up. So I think we got a lot done in 2015. We got a lot more done in December than we anticipated, probably $20 million north of what we thought in December. So that's a good thing, sets us up well a little bit more than we would have anticipated. But again, I think it's important that we stay cognizant of the environment business-by-business and look for opportunities to take action where good projects present themselves."
265621,321831219,921165,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Operator","We'll take our next question from Steven Winoker of Bernstein.",11,"We'll take our next question from Steven Winoker of Bernstein."
265621,321831219,921165,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Analysts","What was the Fortive versus Danaher corporate, if you split it that way, for the quarter?",16,"What was the Fortive versus Danaher corporate, if you split it that way, for the quarter?"
265621,321831219,921165,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","Sure. Looking at Fortive, probably being rough down 2 to 3, and Danaher go forward up 1, 1.5. So I think that's roughly the way it would split.",28,"Sure. Looking at Fortive, probably being rough down 2 to 3, and Danaher go forward up 1, 1.5. So I think that's roughly the way it would split."
265621,321831219,921165,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Analysts","Okay. And just a couple of things.",7,"Okay. And just a couple of things."
265621,321831219,921165,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","And Steve -- I'm sorry, Steve, sorry to interrupt. Just wanted to make one other quick point just for clarification on that. It's important to recognize on the Danaher side of the house that 1 to 1.5, that side of the house has a higher percentage of cons",124,"And Steve -- I'm sorry, Steve, sorry to interrupt. Just wanted to make one other quick point just for clarification on that. It's important to recognize on the Danaher side of the house that 1 to 1.5, that side of the house has a higher percentage of consumables and recurring revenue than you do on the Fortive side. And as a result of that, the fewer selling days in the fourth quarter has a little bit greater impact on the Danaher side. So when you normalize for the days impact on the Danaher side, that's going to be potentially -- it could be 1.5%, 2%, maybe even on that side. Again, rough numbers, but it has a little bit more of an impact there."
265621,321831219,921165,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Analysts","Okay. All right. And then just on a couple of the segments. So I think this was the -- it's been at least 11 quarters since I've seen Fluke go negative. So maybe a little commentary on the -- what's going on in the industrial environment, specifically on",102,"Okay. All right. And then just on a couple of the segments. So I think this was the -- it's been at least 11 quarters since I've seen Fluke go negative. So maybe a little commentary on the -- what's going on in the industrial environment, specifically on Fluke? And then also Life Sciences & Diagnostics, it's the lowest, I think, I've seen in 14 quarters. So are we -- you went through a lot of detail there, but to what extent are we -- should we be concerned about any kind of bleed over from the broader environment into their markets?"
265621,321831219,921165,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","Sure, sure. Let's start with Fluke. Fluke clearly impacted by the downshift in the macro environment in the quarter, Fluke being one of our more industrially oriented businesses. I think the macro environment, while it had its impact on us on a broad basi",150,"Sure, sure. Let's start with Fluke. Fluke clearly impacted by the downshift in the macro environment in the quarter, Fluke being one of our more industrially oriented businesses. I think the macro environment, while it had its impact on us on a broad basis, also had an influence on the way our distributors were thinking about inventories during the course of the quarter. So I think, one of the things that -- although, we don't have all the numbers right now for full transparency on what happened to channel inventories, it's a pretty good hypothesis right now based on some early data we have that would suggest that there was some inventory control that went on in the channel that certainly would have had some impact as well. So I think those 2 factors combined, again, broad-based macro on sellout and probably some impact on sell-in based on inventory contraction."
265621,321831219,921165,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","On the Diagnostic side, Steve, so -- the bigger piece is, obviously, Diagnostics, that's largely consumables. Diagnostics were up 4% organically for the year. And as you remember, Q1 when we had the extra days we were up 6%. Q4, when we had the fewer days",73,"On the Diagnostic side, Steve, so -- the bigger piece is, obviously, Diagnostics, that's largely consumables. Diagnostics were up 4% organically for the year. And as you remember, Q1 when we had the extra days we were up 6%. Q4, when we had the fewer days, we were up 2%. So actually on a days adjusted basis, Diagnostics tracked pretty close to that 3% to 4% rate all year including the fourth quarter."
265621,321831219,921165,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","Maybe one other thing to add there is that, best we can tell, Steve, we didn't see any year-end budget flush there in the fourth quarter. That's a little bit more of a Life Science-oriented phenomena than a Diagnostic-oriented phenomena. But in some past",119,"Maybe one other thing to add there is that, best we can tell, Steve, we didn't see any year-end budget flush there in the fourth quarter. That's a little bit more of a Life Science-oriented phenomena than a Diagnostic-oriented phenomena. But in some past fourth quarters, we've seen the impact of that. We didn't see any of that in the fourth. Good news and bad news on that front, it has an impact on the fourth quarter. Sometimes that budget flush can drive some inventories out that then creates some go-forward weakness as you start the New Year. We're hoping we -- and the early numbers coming out here in January, look like we're off to a decent start."
265621,321831219,921165,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Operator","We'll take our next question from Jeff Sprague of Vertical Research.",12,"We'll take our next question from Jeff Sprague of Vertical Research."
265621,321831219,921165,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Analysts","Thanks for that color on Fluke. I wanted to ask that question a little bit more broadly. To what extent do you think kind of the more industrially oriented organic growth rates kind of clearly reflect end demand versus maybe a broader channel liquidation?",67,"Thanks for that color on Fluke. I wanted to ask that question a little bit more broadly. To what extent do you think kind of the more industrially oriented organic growth rates kind of clearly reflect end demand versus maybe a broader channel liquidation? I don't know if you have any good insight into your other channels or any -- even anecdotal color there would be helpful."
265621,321831219,921165,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","I don't have much there, Jeff. I know the teams are still out talking to customers and trying to get a better sense of that. One reason for a little bit more insight on Fluke than -- and less so, Fluke's a little bit more concentrated with some big distri",98,"I don't have much there, Jeff. I know the teams are still out talking to customers and trying to get a better sense of that. One reason for a little bit more insight on Fluke than -- and less so, Fluke's a little bit more concentrated with some big distributor partners, that we can get a little bit more transparency a little bit more quickly. More -- some of the more automation Sensors and Controls businesses and so on, more fragmented channels and it's just taken us a little longer to get any sense of channel inventories."
265621,321831219,921165,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Analysts","And just shifting gears a little bit. Any thoughts on how the device tax plays through? Do you see any change in demand there? Or any change in the way people are pricing competitively? And maybe just size what you think the impact could be to your busine",50,"And just shifting gears a little bit. Any thoughts on how the device tax plays through? Do you see any change in demand there? Or any change in the way people are pricing competitively? And maybe just size what you think the impact could be to your business this year?"
265621,321831219,921165,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","Sure. Jeff, when the device tax was first put in place, the impact of that was fairly modest on us. There's money at stake, but overall not a huge number. So what comes back in terms of a little bit of a lift to operating margins is also modest. I mean, n",136,"Sure. Jeff, when the device tax was first put in place, the impact of that was fairly modest on us. There's money at stake, but overall not a huge number. So what comes back in terms of a little bit of a lift to operating margins is also modest. I mean, net-net, it's a good thing for the industry. We didn't see much impact in the market from a pricing standpoint when it all happened, I should say from a competitive standpoint. We did get some of that back in price over time, and probably some competitors did as well. But in terms of real impact to competitive dynamics, I think it's too modest a change certainly to the scale of our business and maybe to the scale of others to really impact the competitive world."
265621,321831219,921165,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","Jeff, I think, we said in '13 it was about a nickel hit. We've recovered some of that in price. So I think it will be less than a $0.05, but maybe a $0.03 benefit here in the year.",39,"Jeff, I think, we said in '13 it was about a nickel hit. We've recovered some of that in price. So I think it will be less than a $0.05, but maybe a $0.03 benefit here in the year."
265621,321831219,921165,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Operator","We'll move next to Ross Muken of Evercore ISI.",10,"We'll move next to Ross Muken of Evercore ISI."
265621,321831219,921165,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Analysts","Maybe on Dental, can you just give us a little bit more color just sort of on the progress you made throughout the year? It looks like ending the year you had some of your best results, obviously, adjusting for the days. And so as we sort of now roll Nobe",88,"Maybe on Dental, can you just give us a little bit more color just sort of on the progress you made throughout the year? It looks like ending the year you had some of your best results, obviously, adjusting for the days. And so as we sort of now roll Nobel into the sort of core and we think about the margin progression in that business over the year, help us think through kind of the pushes and pulls, and how happy you are with the progress made?"
265621,321831219,921165,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","Sure. Yes, thanks, Ross. I think, 2015 was a year of very good progress across the platform. You mentioned Nobel, let me just start with that. We have a tremendous team of folks at Nobel. Largely, the leadership team that was in place when we acquired the",318,"Sure. Yes, thanks, Ross. I think, 2015 was a year of very good progress across the platform. You mentioned Nobel, let me just start with that. We have a tremendous team of folks at Nobel. Largely, the leadership team that was in place when we acquired the business, they have really embraced DBS and are off to a terrific start both in terms of continuing to use DBS tools to drive growth, but also, as in my comments earlier, some great progress on operating margins. And now as that goes core to the Dental platform, we'll see some impact to that to the good. On the business that existed prior to 2015, I think, again, 2015 was a year of a lot of progress. I've mentioned a couple of times that we've had outstanding relationships with our distribution partners. We worked in a collaborative way with them on channel inventories throughout the course of the year. That was, obviously, somewhat of a painful process to go through in the sense of the impact on core growth, but net-net a very good process in terms of positioning the channel efficiently. So we are pleased that the vast majority of that's behind us. There can always be a little bit of a tail to that of stuff we're still moving out in slower moving inventories but, again I think, a ton of progress. We've also got a very good leadership team in place on our -- in our Dental platform today, with some new players in place that, I think, are doing some wonderful things in terms of driving innovation. It was a very good year of new product introductions. And I think we'll see the benefit of that as core growth improves this year. So we know we still have work to do there, but good news is that there's opportunities for value creation as we go on here."
265621,321831219,921165,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Analysts","Great. And maybe just quickly a little color more on the M&A pipeline. Can you just give us a sense? I mean there's obviously been a ton of equity market volatility. We've seen, obviously, a shift in how the private equity folks are also sort of transacti",112,"Great. And maybe just quickly a little color more on the M&A pipeline. Can you just give us a sense? I mean there's obviously been a ton of equity market volatility. We've seen, obviously, a shift in how the private equity folks are also sort of transacting. Just give us a feel for maybe healthcare versus industrial-oriented assets and the like. Whether there's more activity at one side of the spectrum versus the other, and how? So the valuation dislocations have been kind of digested by the various groups, because you're obviously doing smaller things at this point, and it's, obviously, the large end of the market that's probably been most impacted."
265621,321831219,921165,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","Sure. Well, I'll let Dan comment in a second on kind of the environment that we're seeing. But if you just look at what we did in the fourth quarter, which I think is a bit instructive, we got 4, 5 small deals done in the fourth quarter. And by the way, a",168,"Sure. Well, I'll let Dan comment in a second on kind of the environment that we're seeing. But if you just look at what we did in the fourth quarter, which I think is a bit instructive, we got 4, 5 small deals done in the fourth quarter. And by the way, a couple -- 2 or 3 of those deals were Fortive-related. I mentioned Pacific Laser Systems in my earlier comments, but there were a couple of other smaller situations that we were able to complete during the quarter for Fortive's benefit along with a couple on the Danaher side. So I think the fourth quarter was indicative perhaps of some things opening up a bit. I think, the environment is generally a favorable one for businesses like ours with a balance sheet that's ready to deploy into small and midsize situations. And I think to your question, there are some folks who are perhaps a bit more on the sidelines right now than in previous days."
265621,321831219,921165,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Operator","Next question comes from Shannon O'Callaghan of UBS.",9,"Next question comes from Shannon O'Callaghan of UBS."
265621,321831219,921165,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Analysts","So Test & Measurement and Industrial Tech are both generating pretty good core margin expansion here, despite these mid-single-digit declines. Can you give a little more color on how they're managing to do that? I mean, both of them have pretty good lever",62,"So Test & Measurement and Industrial Tech are both generating pretty good core margin expansion here, despite these mid-single-digit declines. Can you give a little more color on how they're managing to do that? I mean, both of them have pretty good leverage in the model, so that's a lot to offset. And what's going on in those businesses, and can it continue?"
265621,321831219,921165,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","Yes. It's -- Shannon, it is a real testament to those businesses given the challenging environment they're in from a core growth perspective. That they are getting the operating margin lift that they're getting without the benefit of the top line dropping",197,"Yes. It's -- Shannon, it is a real testament to those businesses given the challenging environment they're in from a core growth perspective. That they are getting the operating margin lift that they're getting without the benefit of the top line dropping that through. I think, it is a testament to the strength of the Danaher Business System, the tools that we use not just in newly acquired businesses, but in businesses with long histories with Danaher that have gotten a lot done using DBS in the past and are still getting it done. If you think about some of the businesses in T&M, be it Fluke and the associated acquisitions around Fluke that have been done quite a number of years ago, think about other businesses like Qualitrol, like some of the businesses in our automation and Sensors and Controls areas, those guys are using DBS, whether those are lean tools specifically in the plants or deploying those tools into -- in areas of SG&A, they are just demonstrating that those tools are still highly effective in businesses with long histories with Danaher. So it's kudos to those guys, and they continue to get her done."
265621,321831219,921165,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Analysts","Okay. And then you talked a little bit about the Diagnostic comps and things, but Radiometer, that's been one that seemed like it was just going to grow to the sky forever in the equipment business. It was a little weaker there, so maybe a little just col",54,"Okay. And then you talked a little bit about the Diagnostic comps and things, but Radiometer, that's been one that seemed like it was just going to grow to the sky forever in the equipment business. It was a little weaker there, so maybe a little just color? Anything there to be concerned about?"
265621,321831219,921165,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","Yes. No. We -- Radiometer is a tremendous business with a long track record of high single-digit growth at Danaher. I'm sure Matt or Dan can find how many quarters it's been, but it's quite a number of them in a row that we've been high single digits and",198,"Yes. No. We -- Radiometer is a tremendous business with a long track record of high single-digit growth at Danaher. I'm sure Matt or Dan can find how many quarters it's been, but it's quite a number of them in a row that we've been high single digits and taking share. It's a high consumables business. It's probably in the 80% neighborhood of consumables, so the days impact was fairly significant there. They also had a challenging comp in the fourth quarter on the Instrumentation side. Couple of big orders that had some impact there. So I think Radiometer is in as good a shape today as it's ever been, no meaningful shift in the competitive dynamics there. So we still feel very good about it. I think, if there was anything there, Shannon, and it wouldn't be unique to Radiometer, it's simply the fact that some of the growth that we have seen in the high-growth markets, while still strong in places like China and India, are still now very weak in Latin America, in Russia, in the Middle East. And so even our best businesses are probably going to feel a little bit of impact there."
265621,321831219,921165,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Operator","Our next question comes from Brandon Couillard of Jefferies.",9,"Our next question comes from Brandon Couillard of Jefferies."
265621,321831219,921165,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Analysts","Just -- back on the Dental business. Dan, any chance you could give us the impact of the fewer days on core growth overall? And how should we think about margin expansion for the year?",35,"Just -- back on the Dental business. Dan, any chance you could give us the impact of the fewer days on core growth overall? And how should we think about margin expansion for the year?"
265621,321831219,921165,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","Well, it has less of an impact on equipment. We were up slightly in the quarter, it's first time we've been up, albeit modestly. But it impacts consumables probably up in a -- as Tom alluded to, probably 1.5, 2 points when it comes to consumables. Good pr",111,"Well, it has less of an impact on equipment. We were up slightly in the quarter, it's first time we've been up, albeit modestly. But it impacts consumables probably up in a -- as Tom alluded to, probably 1.5, 2 points when it comes to consumables. Good progress on the margin side, granted we had a pretty weak performance a year ago. So part of it was the comp, but we've also took -- part of our incremental restructuring here in Q4 was at Dental, so we should see some continued margin expansion coming out of Dental. Hopefully, with a little bit better growth than what we've seen here in '15."
265621,321831219,921165,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Operator","Our next question comes from Julian Mitchell of Crdit Suisse.",10,"Our next question comes from Julian Mitchell of Crdit Suisse."
265621,321831219,921165,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Analysts","Just a question around Western Europe. I think, I heard you say that sales were down slightly in Q4, having been up sort of around a mid-single-digit pace in the 9-months period. I think a lot of other companies have sort of been saying Europe is okay, so",66,"Just a question around Western Europe. I think, I heard you say that sales were down slightly in Q4, having been up sort of around a mid-single-digit pace in the 9-months period. I think a lot of other companies have sort of been saying Europe is okay, so maybe just talk a little bit about what you saw there, specific countries or segments that slowed down?"
265621,321831219,921165,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","Julian, I mean, I think that was one of the areas versus what we expected at the beginning of the quarter that surprised us a little bit to the downside. It wasn't dramatic. Clearly, our consumable businesses over there were impacted by the selling days a",140,"Julian, I mean, I think that was one of the areas versus what we expected at the beginning of the quarter that surprised us a little bit to the downside. It wasn't dramatic. Clearly, our consumable businesses over there were impacted by the selling days and maybe we were not as well calibrated as we should have been. But having gone through all -- most of the business here in the first couple weeks here, the tone in Europe is still decent, and -- so it doesn't feel like the step-down that our numbers in Q4 would suggest. And we think we'll get back to sort of modest growth here pretty quickly in 2016. Watching that carefully because it probably caught us a little bit by surprise here in the fourth quarter, but again the tone still seems pretty good."
265621,321831219,921165,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Analysts","Understood. And you laid out the overall EPS seasonality through the year about just over a month ago. Maybe just talk a little bit about the Pall, seasonality of that $0.40, particularly given the industrial organic sales trend in that business right now",54,"Understood. And you laid out the overall EPS seasonality through the year about just over a month ago. Maybe just talk a little bit about the Pall, seasonality of that $0.40, particularly given the industrial organic sales trend in that business right now? And how you would contrast that $0.40 impact versus overall Danaher?"
265621,321831219,921165,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","Well, the $0.40 should ramp during the year as we go after cost. Again, we were able to get some more things done in December, and that was inclusive of Pall as well. So we're getting out of the gate a little bit faster in Q1 from a margin perspective. I",79,"Well, the $0.40 should ramp during the year as we go after cost. Again, we were able to get some more things done in December, and that was inclusive of Pall as well. So we're getting out of the gate a little bit faster in Q1 from a margin perspective. I think the offset, as you suggest, is the Industrial side. So I think we'll get nice accretion here in Q1, but it will clearly ramp through the year."
265621,321831219,921165,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Operator","Our next question comes from Andrew Kaplowitz of Citigroup.",9,"Our next question comes from Andrew Kaplowitz of Citigroup."
265621,321831219,921165,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Analysts","Obviously, good performance in margin in the quarter. Are raw materials -- lower raw material costs helping at all with price costs? Did the price costs -- was it stable in 4Q versus 3Q? Did it improve? I know you mentioned covering FX, but are raw materi",50,"Obviously, good performance in margin in the quarter. Are raw materials -- lower raw material costs helping at all with price costs? Did the price costs -- was it stable in 4Q versus 3Q? Did it improve? I know you mentioned covering FX, but are raw materials helping at all?"
265621,321831219,921165,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","I don't have any great analysis on that yet. Given our gross margin, raw materials tends to be less of a factor for us than a lot of other companies you might cover. We are continuing to get price, still getting 60, 70 basis points. And it's hard not to t",68,"I don't have any great analysis on that yet. Given our gross margin, raw materials tends to be less of a factor for us than a lot of other companies you might cover. We are continuing to get price, still getting 60, 70 basis points. And it's hard not to think raw materials are helping us a little bit, but for us it's really on the margin."
265621,321831219,921165,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Analysts","Okay, got it. And then how do you get visibility into what to forecast, for example, on the Middle East? I mean, the region looks like it inflected down a bit in 4Q, and with oil's recent leg down, how difficult is it to get visibility? And what do you fo",53,"Okay, got it. And then how do you get visibility into what to forecast, for example, on the Middle East? I mean, the region looks like it inflected down a bit in 4Q, and with oil's recent leg down, how difficult is it to get visibility? And what do you forecast for 2016?"
265621,321831219,921165,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","Well, there's -- Andrew, there's a couple of different ways to come at that in the Middle East. One is simply conversations with distribution partners, and a lot of what we do in the Middle East does involve some form of a distributor partner. And making",236,"Well, there's -- Andrew, there's a couple of different ways to come at that in the Middle East. One is simply conversations with distribution partners, and a lot of what we do in the Middle East does involve some form of a distributor partner. And making sure that we have transparency as much as we possibly can into the opportunity funnels that those distributors are seeing as well as making sure that the conversations we're having with our own sales team around those funnels as they roll up to our leadership team are as well pressure-tested as possible. The key thing about markets like the Middle East is, particularly in the businesses like ours, you have a fairly high level of project or tender-related business, and we saw on the equipment side. And so really making sure that we understand opportunity funnels and are not overly optimistic about the timing within which funding will be released, as in many cases that funding has some governmental influence to it, is really important. It is easy to have a sales team get overly optimistic that the timing of funding release is going to be the same as it was 1 year ago or 2 years ago when the reality is, things may have slowed down and tenders may be being let at a much slower pace. So being diligent about how we pressure test those funnels is key."
265621,321831219,921165,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Analysts","So it's fair to say you're being pretty conservative with the Middle East forecast.",15,"So it's fair to say you're being pretty conservative with the Middle East forecast."
265621,321831219,921165,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","We're trying to be increasingly conservative as we see how government funding is being influenced. I think, it was interesting watching the course of the year. Oil continued to drop, as you know, throughout the course of the year and yet, we actually saw",105,"We're trying to be increasingly conservative as we see how government funding is being influenced. I think, it was interesting watching the course of the year. Oil continued to drop, as you know, throughout the course of the year and yet, we actually saw our Middle East numbers hang in there reasonably well throughout the middle part of the year. And it wasn't until the latter part of the year that we saw more acute shift in the Middle East. And so there was a little bit of a lag there and it's taken a bit of time for the team to fully recalibrate."
265621,321831219,921165,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Operator","And we'll take our final question from Deane Dray of RBC Capital Markets.",14,"And we'll take our final question from Deane Dray of RBC Capital Markets."
265621,321831219,921165,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Analysts","Just a quick question on R&D spending overall, came in lighter year-over-year and versus our estimates. Did you throttle back on any spending? Is it just timing of some of the projects?",33,"Just a quick question on R&D spending overall, came in lighter year-over-year and versus our estimates. Did you throttle back on any spending? Is it just timing of some of the projects?"
265621,321831219,921165,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","As you probably saw in the numbers that we put out, Deane, we are showing R&D down about 20 basis points. But the reality is that, that was primarily influenced by Pall and R&D spending normalized for the Pall influence was actually up on the quarter. So",89,"As you probably saw in the numbers that we put out, Deane, we are showing R&D down about 20 basis points. But the reality is that, that was primarily influenced by Pall and R&D spending normalized for the Pall influence was actually up on the quarter. So we are continuing to make sure that innovation is a key priority for the businesses and that R&D spending is maintained to the greatest extent possible for the opportunities that we think have the greatest impact in the next year or 2."
265621,321831219,921165,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Analysts","And then just last question for me is the -- the incremental restructuring done in December, did you say what portion of that was Danaher versus Fortive?",27,"And then just last question for me is the -- the incremental restructuring done in December, did you say what portion of that was Danaher versus Fortive?"
265621,321831219,921165,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","It was roughly the split you'd expect, 70%, 30%. And that 70% Danaher, inclusive of Pall.",17,"It was roughly the split you'd expect, 70%, 30%. And that 70% Danaher, inclusive of Pall."
265621,321831219,921165,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Operator","And I'd be happy to turn the program back over to our hosts.",14,"And I'd be happy to turn the program back over to our hosts."
265621,321831219,921165,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","Thanks, Leo. Thanks, everyone, for joining us. We're around all day for questions.",13,"Thanks, Leo. Thanks, everyone, for joining us. We're around all day for questions."
265621,321831219,921165,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Operator","Thank you. This does conclude today's Danaher Corporation's Fourth Quarter 2015 Earnings Results Conference Call. You may now all disconnect your lines, and everyone, have a great day.",28,"Thank you. This does conclude today's Danaher Corporation's Fourth Quarter 2015 Earnings Results Conference Call. You may now all disconnect your lines, and everyone, have a great day."
265621,321831219,956827,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Operator","My name is Leo, and I will be your conference facilitator this morning. At this time, I would like to welcome everyone to Danaher Corporation's Fourth Quarter 2015 Earnings Results Conference Call. [Operator Instructions] I will now turn the call over t",57,"My name is Leo, and I will be your conference facilitator this morning. At this time, I would like to welcome everyone to Danaher Corporation's Fourth Quarter 2015 Earnings Results Conference Call. [Operator Instructions] 
I will now turn the call over to Mr. Matt Gugino, Vice President of Investor Relations. Mr. Gugino, you may begin your conference."
265621,321831219,956827,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","Thank you, Leo. Good morning, everyone, and thanks for joining us on the call. With us today are Tom Joyce, our President and Chief Executive Officer; and Dan Comas, our Executive Vice President and Chief Financial Officer. I'd like to point out that ou",325,"Thank you, Leo. Good morning, everyone, and thanks for joining us on the call. With us today are Tom Joyce, our President and Chief Executive Officer; and Dan Comas, our Executive Vice President and Chief Financial Officer. 
I'd like to point out that our earnings release, the slide presentation supplementing today's call and other information required by SEC Regulation G relating to any non-GAAP financial measures provided during the call are all available on the Investor section of our website, www.danaher.com, under the heading Financial Information. The audio portion of this call will be archived on the Investor section of our website later today under the heading Events & Presentations and will remain archived until our next quarterly call. A replay of this call will also be available until February 2, 2016. The replay number is (888) 203-1112 within the U.S. or (719) 457-0820 outside the U.S., and the confirmation code is 9714607. 
During the presentation, we will describe certain of the more significant factors that impacted year-over-year performance. The supplemental materials describe additional factors that impacted year-over-year performance. Unless otherwise noted, all references in these remarks and supplemental material to company-specific financial metrics relate to the continuing operations of the company and the fourth quarter of 2015, and all references to period-to-period increases or decreases in financial metrics are year-over-year. 
During the call, we will make forward-looking statements within the meaning of the federal securities laws, including statements regarding events or developments that we believe or anticipate will or may occur in the future. These forward-looking statements are subject to a number of risks and uncertainties, including those set forth in our SEC filings, and actual results might differ materially from any forward-looking statements that we make today. These forward-looking statements speak only as of the date that they are made, and we do not assume any obligation to update any forward-looking statements. 
With that, I'd like to turn the call over to Tom."
265621,321831219,956827,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","Thanks, Matt, and good morning, everyone. We're pleased with our results for the fourth quarter, in which the team delivered double-digit earnings growth, strong core operating margin expansion and record free cash flow. Despite the more challenging econo",2256,"Thanks, Matt, and good morning, everyone. We're pleased with our results for the fourth quarter, in which the team delivered double-digit earnings growth, strong core operating margin expansion and record free cash flow. Despite the more challenging economic landscape, particularly in our industrially oriented markets, we continued to build our competitive advantage and drove share gains across a number of our businesses. As always, the Danaher Business System is the foundation for our team's outstanding execution. 
We also made meaningful progress toward establishing a new industrial growth company, Fortive, which will be spun out of Danaher later this year. At our year-end investor meeting, we announced Fortive's name, branding, future operating structure and additional leadership positions. We also achieved an important milestone in December, filing Fortive's Form 10 registration statement with the Securities and Exchange Commission. We are confident that Fortive will launch with a strong foundation and will be poised for success upon completion of the separation in the third quarter of 2016. For the full year, our investments in organic growth initiatives helped drive solid 3% core revenue growth. With the addition of our recent acquisitions and other portfolio moves, our total annual revenues are now over $20 billion. 
From an M&A perspective, 2015 was a historic year for Danaher. Including Pall, we announced or closed 14 acquisitions for nearly $14.5 billion, expanding our capabilities across the portfolio. Looking forward, our funnels at both Danaher and Fortive are strong, and we'll continue to focus on small and mid-sized transactions throughout the separation process.
In 2015, we generated a record $3.2 billion of free cash flow, including over $1 billion in the fourth quarter. Our free cash flow to net income conversion ratio in 2015 was 123%, representing the 24th consecutive year in which our free cash flow has exceeded net income. We recognize the importance of this metric, particularly in a more challenging macro environment, as strong free cash flow is the fuel used to fund both our organic and inorganic growth initiatives. 
Now turning to the fourth quarter. Sales grew 12.5% to $5.9 billion, while core revenue was roughly flat. Core revenue growth, particularly for our consumables businesses, was negatively impacted by 4 fewer selling days in the quarter. In addition, the impact of currency translation eased this quarter but still decreased revenues by 5%, while acquisitions increased revenues by 17.5%.
In a weakening global macro environment, the Danaher Business System helped protect and expand many of our market-leading positions, driving share gains at Hach, ChemTreat, Matco, Gilbarco, Radiometer, SCIEX and Videojet. In the high growth markets, declines in Latin America, Russia and the Middle East were more than offset by double-digit growth in India and high single-digit growth in China. Notably, annual revenues in China exceeded $2 billion for the first time, and we remain well positioned in the most attractive sectors in the market. In the developed markets, revenues were down slightly due to incremental softness in the U.S. and Western Europe.
Gross margin for the quarter was 51.2%. For the full year, our gross margin was 52.3%, and our gross profit increased by almost $900 million. In the quarter, core operating margin increased 120 basis points, with all 5 segments improving by 60 basis points or better. Our reported operating margin was flat at 16.6%, negatively affected by the dilutive impact of recent acquisitions and acquisition related transaction costs.
Fourth quarter adjusted diluted net EPS was $1.27, which represents an increase of 13.5% over last year. For the full year, adjusted diluted net EPS was $4.30, up 8.5% from 2014.
Turning to our 5 operating segments. Test & Measurement revenues decreased 9%, while core revenues were down 5%. Core operating margin increased 110 basis points, primarily due to new product introductions and good cost management. Core revenue in our Instruments platform decreased at a high single-digit rate, with declines across most major geographies. Fluke core revenues were down high single digits as industrial markets continued to weaken in North America, Latin America and the Middle East. In December, Fluke acquired Pacific Laser Systems, a leader in handheld laser alignment tools, to enhance its product offerings for professional contractors, electricians and general maintenance customers. 
At Tektronix, core sales declined high single digits. Declines in North America, Latin America and the Middle East more than offset growth in China that resulted from solid execution by our local sales team. The team's continued investments in innovation placed Tek in a position of technology leadership within its industry. This quarter, Tek launched the MDO4000C, a Mixed Domain Oscilloscope that combines up to 6 instruments in 1 unit. The new MDO4000C is completely customizable and upgradable, allowing engineers to start with a high performance oscilloscope and add functionality over time as needs change or budgets allow. 
Matco, a business that will be a significant contributor to Fortive's results, delivered its third consecutive year of double-digit core growth in 2015. Even after 3 decades as part of the Danaher portfolio, Matco continues to find new ways to improve using DBS. By deploying such DBS tools as web marketing, accelerated product development and lean conversion, the team continues to expand its franchise distribution network, gain market share and expand margins.
Turning now to our Environmental segment. Revenues grew 1%, with core revenues up 4%. Core operating margin expanded 60 basis points, and reported operating margin expanded 260 basis points to 21.8%. Water Quality core revenues increased at a low single-digit rate, a combination of fewer selling days and slower demand from our more industrial customers in the developed markets resulted in essentially flat core growth at Hach, while ChemTreat grew slightly. Trojan had another very good quarter, driven by healthy demand and increased bidding activity in the North American muni market. 
Hach delivered another impressive year in 2015. In addition to mid-single-digit organic growth, Hach continued its healthy cadence of bolt-on acquisitions. The team has done a terrific job implementing DBS in newly acquired businesses to help improve sales and drive innovation. One such example is BioTector, which was acquired in 2014 and had double-digit growth in the quarter. BioTector provides online total organic carbon analyzers that help our customers monitor water quality in real time and reduce waste. BioTector's early and effective application of DBS tools such as lean conversion and funnel management led to more than 200 basis points of margin expansion, significant inventory reductions and market share gains in the chemical and dairy segments. 
Gilbarco Veeder-Root's core revenues grew high single digits, with strength across the platform. In the U.S., point-of-sale solutions and dispensers increased over 20% as our customers continued to upgrade their payment systems to comply with EMV security requirements. We expect EMV related demand to continue to accelerate for the next several years. 
Moving to Life Science & Diagnostics. Core revenues grew 2%, with reported revenues up 34.5%, largely due to our recent Pall, Microscan and Devicor acquisitions. Core operating margin expanded 75 basis points. 
Core revenues in our Diagnostics platform increased low single digits, with growth in the high growth markets, partially offset by slight declines in developed markets. As previously mentioned, fewer selling days in the quarter negatively impact our recurring revenue streams across the platform. 
At Beckman Coulter, core revenues increased at a low single-digit rate, led by our immunoassay and urinalysis solutions. Utilization rates in Asia remain healthy, leading to high single-digit growth across the region. 
In Europe, we celebrated our first orders with the commercial launch of our Veris molecular diagnostic system. Veris' streamlined sample-in result-out workflow offers breakthrough ease of use in a market that is experiencing a shortage of skilled technicians. In short, it's helping our lab customers process more tests, reduce training requirements and save money. And thus far, customer feedback has been extremely positive.
Radiometer's core revenues were up slightly, a deceleration from previous quarters due to the effect of fewer selling days and a difficult comparison in Instrument sales. Geographically, we saw healthy growth in China and Japan, while Latin America and the Middle East declined. 
Leica Biosystems had a good finish to the year, delivering low single-digit core growth as strong demand across most major product lines was partially offset by the impact from fewer selling days. Notably, the team delivered a record year of placements for our BOND advanced staining instrument. 
Last December, we closed the acquisition of Devicor, a leading provider of breast biopsy devices and markers that move Leica further upstream in the anatomical pathology workflow. Devicor continues to track well and has exceeded our expectations, posting high single-digit core growth or better in each quarter since acquisition. 
Core revenues in our Life Science platform were up low single digits, with growth in both developed and high growth markets. SCIEX core revenues grew mid-single digits, with continued strength in our clinical and applied end markets. 2015 marked the fifth year since our acquisition of SCIEX. Since then, SCIEX has proven to be a remarkable example of how thoughtful application of DBS principles can drive tremendous financial results. The team has taken a business that was growing below market rates to mid- to high single-digit growth and share gains. 
We've seen significant improvement on the cost side as well, which has enabled SCIEX to invest those savings into higher impact growth initiatives. Progress at SCIEX continues today, and 2015 marked one of the most important product innovation years in SCIEX's history, with the launch of its X-Series mass spectrometry platform. The X-Series introduces an entirely new design, easy-to-use software and custom models for targeted application in routine food, environmental and forensic testing labs.
Leica Microsystems core revenues were essentially flat as strong performance in China and Japan was offset by declines in Europe, the Middle East and Latin America.
Turning now to Dental. Segment revenues increased 17%, largely due to our Nobel Biocare acquisition. Core revenues were up slightly. Core operating margins increased by over 500 basis points in the quarter, primarily due to consistent DBS implementation across a number of operational areas. Reported operating margins were 15.8%.
Revenues in our consumables business were negatively impacted by fewer selling days in the quarter, but our team continued to execute well and saw strong demand for several product lines throughout the year. In particular, our investments in innovation have provided us with truly differentiated technologies such as SonicFill, TF Adaptive and elementsfree, which all launched in 2014. In Dental technology, we saw our first quarter of positive growth since the fourth quarter of 2014. Top line results continued to be impacted by destocking within our U.S. distribution channels, but to a much lesser degree than in previous quarters. 
December marked the 1-year anniversary of our acquisition of Nobel Biocare. The team has quickly embraced growth, lean and leadership tools of DBS, helping to not only accelerate growth but also improve operating margins by over 300 basis points since the acquisition.
Moving to Industrial Technologies. Revenues declined 8.5%, while core revenues were down 4.5%. Core operating margin expanded 80 basis points, and reported operating margin expanded 120 basis points to 21.6%. Automation core revenues decreased at a high single-digit rate due to weakening in industrial markets in China and North America. Despite the challenging market and revenue decline, the team continues to identify cost savings opportunities and delivered solid core margin expansion in the quarter. 
Core revenues in our Product Identification platform were up slightly. In the fourth quarter, we continued to extend our reach into new Product ID adjacencies with the acquisition of Laetus, a leading supplier of track and trace inspection systems for pharmaceutical packaging plants. Increasingly, pharmaceutical tracking is becoming a regulatory and public safety concern, and Laetus gives us exposure to this important vertical. And we're excited to welcome Laetus to the Danaher team. 
At Videojet, core revenues were up low single digits as strong performance in Europe and North America was somewhat offset by weakness in the high growth markets. Results were negatively impacted by fewer selling days in the quarter. Throughout the full year, Videojet has placed a major focus on digital investments, driving key innovations in areas such as network monitoring, remote service enabled printers and predictive maintenance. As a result, we achieved record new equipment vitality of over 40% for the year. These tremendous technology capabilities have not only solidified Videojet's leadership position in the market, they have also meaningfully improved our customers' experiences.
So to wrap up, we're pleased with our record fourth quarter results. During the quarter, the team delivered double-digit earnings growth, significantly expanded core operating margins, generated record free cash flow and announced several bolt-on acquisitions. Despite the more challenging economic landscape, particularly in our industrially oriented markets, we continue to execute well. 
Looking back, 2015 was a remarkable year for Danaher. We completed the largest acquisition in our history with Pall, announced our pending separation into 2 independent publicly traded companies with Fortive and drove excellent overall financial results. With the Danaher Business System as our foundation, we believe we'll continue to deliver earnings outperformance and create long-term shareholder value in 2016 and for years to come. 
We are initiating first quarter adjusted diluted net EPS guidance between $1 and $1.04, which assumes approximately flat core revenue growth. As we announced at our annual investor event in December, we continue to expect full year 2016 core revenue growth of 2% to 3% and adjusted diluted net earnings per share to be in the range of $4.80 to $4.95, which would represent a 12% to 15% increase year-on-year."
265621,321831219,956827,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","Thanks, Tom. That concludes our formal remarks. Leo, we're now ready for questions.",13,"Thanks, Tom. That concludes our formal remarks. Leo, we're now ready for questions."
265621,321831219,956827,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Operator","[Operator Instructions] We'll take our first question from Scott Davis of Barclays.",12,"[Operator Instructions] We'll take our first question from Scott Davis of Barclays."
265621,321831219,956827,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Analysts","I think -- I mean, given that it's been about a month since you gave the last guidance in mid-December, the formal guidance, I guess. Things seem to have degraded a bit on the macro side. I mean, what confidence do you have? I mean, now that you've seen,",84,"I think -- I mean, given that it's been about a month since you gave the last guidance in mid-December, the formal guidance, I guess. Things seem to have degraded a bit on the macro side. I mean, what confidence do you have? I mean, now that you've seen, I guess, most of January, I mean have things stabilized? I mean, your guidance seems to indicate that you think that was a bit of a blip, I suppose. So just a little color there."
265621,321831219,956827,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","Sure, Scott. I think, Scott, we're -- what we're assuming is that what we saw with some of the slowing in December is essentially the environment that we're going to see in the near term here. It's clearly impacting our more industrial businesses more tha",226,"Sure, Scott. I think, Scott, we're -- what we're assuming is that what we saw with some of the slowing in December is essentially the environment that we're going to see in the near term here. It's clearly impacting our more industrial businesses more than our other businesses, so we're not immune to the slowdown. But I think we took some appropriate actions in the fourth quarter. Those actions are going to pay off here certainly from a margin standpoint. But I think the other thing to keep in mind is that the portfolio that we have today truly does differentiate us. And I think when we look at the opportunities that we have in our Life Science businesses, our Diagnostic businesses, some improvement that we're seeing here in our Dental businesses, continued good progress at GVR. While we remain cautious in some respects around the macro environment and are not assuming things get materially better there, we're playing offense in a number of areas that I think will bode well. So I don't think there's anything particularly optimistic in our outlook around the macro, but I think some of the things that we're doing from an investment standpoint and across our growth initiatives should continue to position a very good portfolio and a differentiated portfolio and continue to move it into an even better place."
265621,321831219,956827,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Analysts","Yes, makes sense. And then just as a follow-up, emerging market currencies have degraded a fair amount. I mean, are you able to get local price to offset that? I mean, how do you manage that volatility specifically, just given the exposure you guys have?",45,"Yes, makes sense. And then just as a follow-up, emerging market currencies have degraded a fair amount. I mean, are you able to get local price to offset that? I mean, how do you manage that volatility specifically, just given the exposure you guys have?"
265621,321831219,956827,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","Yes. I mean, it's an issue. I'd probably bifurcate the answer. Where we have the aftermarket business, the consumables, the service, we're typically able to get price. With equipment and instruments, we're not able to and we're taking a little bit of a ma",72,"Yes. I mean, it's an issue. I'd probably bifurcate the answer. Where we have the aftermarket business, the consumables, the service, we're typically able to get price. With equipment and instruments, we're not able to and we're taking a little bit of a margin hit there. Fortunately, the euro stabilized so the overall currency impact is not what it was in '15, but it's a little bit of a negative right now."
265621,321831219,956827,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Operator","And we'll take our next question from Nigel Coe of Morgan Stanley.",13,"And we'll take our next question from Nigel Coe of Morgan Stanley."
265621,321831219,956827,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Analysts","So just on the $0.40 and Pall, can you maybe just, first of all, comment on how Pall is tracking? Or how it tracked through the quarter? Maybe commenting on the industrial business, Life Sciences side? And has the composition of the $0.40 in the plan chan",54,"So just on the $0.40 and Pall, can you maybe just, first of all, comment on how Pall is tracking? Or how it tracked through the quarter? Maybe commenting on the industrial business, Life Sciences side? And has the composition of the $0.40 in the plan changed at all in the last couple months?"
265621,321831219,956827,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","Nigel, we're very, very happy with how we've gotten started with Pall. Starting with the team that we have in place, a terrific team, both the Pall leadership team, many of whom have taken on added responsibilities. But in addition, the added resources th",403,"Nigel, we're very, very happy with how we've gotten started with Pall. Starting with the team that we have in place, a terrific team, both the Pall leadership team, many of whom have taken on added responsibilities. But in addition, the added resources that we put in place and the leadership that we have brought to bear in the business. I think together that team is off to a terrific start. We'll talk to the $0.40 and the cost opportunities that we have here in just a minute. But coming to the growth side of the house, about what we expected, continued very good progress and growth rates on the Life Science side, keeping in mind that, that business has an exceptional position in the biopharma market in Life Science, so we're seeing continued good growth there. We're also seeing outstanding growth in single-use technologies, which are a key part and a key growth driver of the biopharma segment of the Life Science business as time goes on. On the industrial side, again, what you -- what we would have expected, which is a slowing on that side of the house. We've seen that -- those businesses impacted far more than, obviously, on the more Life Science oriented side of the house. But I think it's also important to keep in mind that, that business is also strongly skewed towards consumables. In total, the portfolio is about 70% aftermarket consumables primarily. And so that's a strong foundation, and I think continues to give us confidence that while we'll have some segments that are challenged, the business overall will continue to perform quite well. Relative to the cost side of the house, again, off to a very good start. You heard us in December, take the 2016 number up to $100 million because we had gotten off to an earlier start. We're getting the kinds of cost reductions that you would expect us to get out of a public company in the early going. The public company costs beginning to get after some of the indirect cost leverage that we get and some of the procurement cost leverage that we get by consolidating procurement across our other businesses where appropriate. And over time, we'll see some of the benefits coming from -- on the gross margin side as we look at the operational footprint, but that will obviously take a little bit more time."
265621,321831219,956827,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Analysts","Okay. That's helpful. And then on the balance sheet, you've taken down a lot of -- impressive amount of debt since the acquisition of Pall, I think about $3 billion of debt pay down. Given the bit more challenging macro, is there a change in your bias tow",51,"Okay. That's helpful. And then on the balance sheet, you've taken down a lot of -- impressive amount of debt since the acquisition of Pall, I think about $3 billion of debt pay down. Given the bit more challenging macro, is there a change in your bias towards delevering this year?"
265621,321831219,956827,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","Nigel, I think we remain in that kind of $2 billion target for M&A this year. We are incrementally encouraged. We're able to get some deals done in December, granted they were small, but we actually saw a flurry of deals get done towards the end of the ye",119,"Nigel, I think we remain in that kind of $2 billion target for M&A this year. We are incrementally encouraged. We're able to get some deals done in December, granted they were small, but we actually saw a flurry of deals get done towards the end of the year. Clearly, what's going on in the high yield market has made it very difficult for the private equity parties, let alone industrial companies have a lower credit rating. So some of the anxiety out here is definitely helping some of the conversation. So on the margin, we're a little bit more encouraged than we were at 60, 90 days ago on the M&A front. Hope I didn't offend you, Nigel."
265621,321831219,956827,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Operator","Our next question is from Steve Tusa of JPMorgan.",9,"Our next question is from Steve Tusa of JPMorgan."
265621,321831219,956827,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Analysts","Can you just maybe talk a little bit more specifically about Pall industrial trends? I mean, what is the organic -- what kind of organic are you seeing there? And what are you expecting for 2016, a little more kind of precisely?",42,"Can you just maybe talk a little bit more specifically about Pall industrial trends? I mean, what is the organic -- what kind of organic are you seeing there? And what are you expecting for 2016, a little more kind of precisely?"
265621,321831219,956827,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","So Steve, for the 4 months that we owned the business, on a constant currency basis, Pall grew about 4% on a combined basis, clearly would have been accretive to our core growth here. Life Science was up high single digits. Industrial was down low to mid-",89,"So Steve, for the 4 months that we owned the business, on a constant currency basis, Pall grew about 4% on a combined basis, clearly would have been accretive to our core growth here. Life Science was up high single digits. Industrial was down low to mid-single digits. We see that for the near term, not a bad way to be looking at the business. Clearly, the industrial piece is more challenged, but more than making up for it with a very strong growth on the Life Science side."
265621,321831219,956827,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Analysts","And then what was Pall's contribution to free cash flow in the quarter?",14,"And then what was Pall's contribution to free cash flow in the quarter?"
265621,321831219,956827,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","On the working capital side, where we contributed north of $300 million of cash out of working capital, Pall was a nice piece of it, but maybe 15%. The working capital improvements were very broad based, really exceptional performance across all of the 5",58,"On the working capital side, where we contributed north of $300 million of cash out of working capital, Pall was a nice piece of it, but maybe 15%. The working capital improvements were very broad based, really exceptional performance across all of the 5 segments. So it was a nice contributor, but it was not an overwhelming piece."
265621,321831219,956827,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Analysts","Okay, great. And then just one last question, what's kind of the restructuring contingency look like in '16? Is there any change to that as you kind of exited the year at a bit of a weaker rate? Or are you kind of in normal day-to-day planning? How kind o",60,"Okay, great. And then just one last question, what's kind of the restructuring contingency look like in '16? Is there any change to that as you kind of exited the year at a bit of a weaker rate? Or are you kind of in normal day-to-day planning? How kind of extreme are things around some of the more industrial businesses?"
265621,321831219,956827,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","Steve, I think one of the things that we've learned from 2015 and we're pleased about is this, we did a number of things throughout the course of the year from a productivity perspective. And I think particularly in an environment like this, it's importan",171,"Steve, I think one of the things that we've learned from 2015 and we're pleased about is this, we did a number of things throughout the course of the year from a productivity perspective. And I think particularly in an environment like this, it's important that we stay cognizant of the fact that there may be opportunities that present themselves and things that we may need to do. So we're going to keep the teams active at looking for opportunities throughout the course of the year, and we'll take advantage of those as they come up. So I think we got a lot done in 2015. We got a lot more done in December than we anticipated, probably $20 million north of what we thought in December. So that's a good thing, sets us up well, a little bit more than we would have anticipated. But again, I think it's important that we stay cognizant of the environment business-by-business and look for opportunities to take action where good projects present themselves."
265621,321831219,956827,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Operator","We'll take our next question from Steven Winoker of Bernstein.",11,"We'll take our next question from Steven Winoker of Bernstein."
265621,321831219,956827,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Analysts","What was the Fortive versus Danaher core growth if you split it that way, for the quarter?",17,"What was the Fortive versus Danaher core growth if you split it that way, for the quarter?"
265621,321831219,956827,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","Sure. Looking at Fortive, probably being rough down 2% to 3% and Danaher go forward up 1%, 1.5%, so I think that's roughly the way it would split.",28,"Sure. Looking at Fortive, probably being rough down 2% to 3% and Danaher go forward up 1%, 1.5%, so I think that's roughly the way it would split."
265621,321831219,956827,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Analysts","Okay. And just a couple of things.",7,"Okay. And just a couple of things."
265621,321831219,956827,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","And Steve -- I'm sorry, Steve, sorry to interrupt. Just wanted to make one other quick point just for clarification on that. It's important to recognize on the Danaher side of the house that 1% to 1.5%, that side of the house has a higher percentage of co",124,"And Steve -- I'm sorry, Steve, sorry to interrupt. Just wanted to make one other quick point just for clarification on that. It's important to recognize on the Danaher side of the house that 1% to 1.5%, that side of the house has a higher percentage of consumables and recurring revenue than you do on the Fortive side. And as a result of that, the fewer selling days in the fourth quarter had a little bit greater impact on the Danaher side. So when you normalize for the days impact on the Danaher side, that's going to be potentially -- it could be 1.5%, 2%, maybe even on that side. Again, rough numbers, but it has a little bit more of an impact there."
265621,321831219,956827,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Analysts","Okay. All right. And then just on a couple of the segments. So I think this was, what -- it's been at least 11 quarters since I've seen Fluke go negative. So maybe a little commentary on the -- what's going on in the industrial environment, specifically o",102,"Okay. All right. And then just on a couple of the segments. So I think this was, what -- it's been at least 11 quarters since I've seen Fluke go negative. So maybe a little commentary on the -- what's going on in the industrial environment, specifically on Fluke? And then also Life Sciences & Diagnostics is the lowest, I think, I've seen in 14 quarters. So are we -- you went through a lot of detail there, but to what extent are we -- should we be concerned about any kind of bleed over from the broader environment into their markets?"
265621,321831219,956827,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","Sure, sure. Let's start with Fluke. Fluke clearly impacted by the downshift in the macro environment in the quarter, Fluke being one of our more industrially oriented businesses. I think the macro environment, while it had its impact on us on a broad basi",151,"Sure, sure. Let's start with Fluke. Fluke clearly impacted by the downshift in the macro environment in the quarter, Fluke being one of our more industrially oriented businesses. I think the macro environment, while it had its impact on us on a broad basis, also had an influence on the way our distributors were thinking about inventories during the course of the quarter. So I think one of the things that, although we don't have all the numbers right now for full transparency on what happened to channel inventories, it's a pretty good hypothesis right now based on some early data we have that would suggest that there was some inventory control that went on in the channel that certainly would have had some impact as well. So I think those 2 factors combined, again, broad-based macro on sell out and probably some impact on sell in based on inventory contraction."
265621,321831219,956827,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","On the Diagnostics side, Steve, so we -- the bigger piece is obviously Diagnostics, that's largely consumables. Diagnostics were up 4% organically for the year. And as you remember, Q1 when we had the extra days, we were up 6%. Q4, when we had the fewer d",74,"On the Diagnostics side, Steve, so we -- the bigger piece is obviously Diagnostics, that's largely consumables. Diagnostics were up 4% organically for the year. And as you remember, Q1 when we had the extra days, we were up 6%. Q4, when we had the fewer days, we were up 2%. So actually on a days adjusted basis, Diagnostics tracked pretty close to that 3% to 4% rate all year including the fourth quarter."
265621,321831219,956827,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","Maybe one other thing to add there is that, best we can tell, Steve, we didn't see any year-end budget flush there in the fourth quarter. That's a little bit more of a Life Science oriented phenomena than a Diagnostic oriented phenomena. But in some past",121,"Maybe one other thing to add there is that, best we can tell, Steve, we didn't see any year-end budget flush there in the fourth quarter. That's a little bit more of a Life Science oriented phenomena than a Diagnostic oriented phenomena. But in some past fourth quarters, we've seen the impact of that. We didn't see any of that in the fourth. Good news and bad news on that front, it has an impact on the fourth quarter. Sometimes that budget flush can drive some inventories out that then creates some go-forward weakness as you start the New Year. We're hoping we -- and the early numbers coming out here in January, look like we're off to a decent start."
265621,321831219,956827,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Operator","We'll take our next question from Jeff Sprague of Vertical Research.",12,"We'll take our next question from Jeff Sprague of Vertical Research."
265621,321831219,956827,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Analysts","Thanks for that color on Fluke. I wanted to ask that question a little bit more broadly. To what extent do you think kind of the more industrially oriented organic growth rates kind of clearly reflect end demand versus maybe a broader channel liquidation?",67,"Thanks for that color on Fluke. I wanted to ask that question a little bit more broadly. To what extent do you think kind of the more industrially oriented organic growth rates kind of clearly reflect end demand versus maybe a broader channel liquidation? I don't know if you have any good insight into your other channels or any -- even anecdotal color there would be helpful."
265621,321831219,956827,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","I don't have much there, Jeff. I know the teams are still out talking to customers and trying to get a better sense of that. One reason for a little bit more insight on Fluke than -- and less so, Fluke's a little bit more concentrated with some big distri",98,"I don't have much there, Jeff. I know the teams are still out talking to customers and trying to get a better sense of that. One reason for a little bit more insight on Fluke than -- and less so, Fluke's a little bit more concentrated with some big distributor partners that we can get a little bit more transparency a little bit more quickly. More -- some of the more automation Sensors and Controls businesses and so on, more fragmented channels and it's just taking us a little longer to get any sense of channel inventories."
265621,321831219,956827,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Analysts","And just shifting gears a little bit, any thoughts on how the device tax plays through? Do you see any change in demand there? Or any change in the way people are pricing competitively? And maybe just size what you think the impact could be to your busine",50,"And just shifting gears a little bit, any thoughts on how the device tax plays through? Do you see any change in demand there? Or any change in the way people are pricing competitively? And maybe just size what you think the impact could be to your business this year?"
265621,321831219,956827,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","Sure. Jeff, when the device tax was first put in place, the impact of that was fairly modest on us. There's money at stake, but overall not a huge number. So what comes back in terms of a little bit of a lift to operating margins is also modest. I mean, n",137,"Sure. Jeff, when the device tax was first put in place, the impact of that was fairly modest on us. There's money at stake, but overall not a huge number. So what comes back in terms of a little bit of a lift to operating margins is also modest. I mean, net-net, it's a good thing for the industry. We didn't see much impact in the market from a pricing standpoint when it all happened -- I should say from a competitive standpoint. We did get some of that back in price over time, and probably some competitors did as well. But in terms of real impact to competitive dynamics, I think it's too modest a change certainly to the scale of our business and maybe to the scale of others to really impact the competitive world."
265621,321831219,956827,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","Jeff, I think we said in '13, it was about $0.05 hit. We've uncovered some of that in price. So I think it'll be less than $0.05, but maybe $0.03 benefit here in the year.",35,"Jeff, I think we said in '13, it was about $0.05 hit. We've uncovered some of that in price. So I think it'll be less than $0.05, but maybe $0.03 benefit here in the year."
265621,321831219,956827,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Operator","We'll move next to Ross Muken of Evercore ISI.",10,"We'll move next to Ross Muken of Evercore ISI."
265621,321831219,956827,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Analysts","Maybe on Dental, can you just give us a little bit more color just sort of on the progress you made throughout the year? It looks like ending the year you had some of your best results, obviously, adjusting for the days. And so as we sort of now roll Nobe",88,"Maybe on Dental, can you just give us a little bit more color just sort of on the progress you made throughout the year? It looks like ending the year you had some of your best results, obviously, adjusting for the days. And so as we sort of now roll Nobel into the sort of core and we think about the margin progression in that business over the year, help us think through kind of the pushes and pulls and how happy you are with the progress made?"
265621,321831219,956827,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","Sure. Yes, thanks, Ross. I think 2015 was a year of very good progress across the platform. You mentioned Nobel, let me just start with that. We have a tremendous team of folks at Nobel. Largely, the leadership team that was in place when we acquired the",316,"Sure. Yes, thanks, Ross. I think 2015 was a year of very good progress across the platform. You mentioned Nobel, let me just start with that. We have a tremendous team of folks at Nobel. Largely, the leadership team that was in place when we acquired the business, they have really embraced DBS and are off to a terrific start both in terms of continuing to use DBS tools to drive growth, but also, as in my comments earlier, some great progress on operating margins. And now as that goes core to the Dental platform, we'll see some impact of that to the good. On the business that existed prior to 2015, I think, again, 2015 was a year of a lot of progress. I've mentioned a couple times that we've had outstanding relationships with our distribution partners. We worked in a collaborative way with them on channel inventories throughout the course of the year. That was, obviously, somewhat of a painful process to go through in the sense of the impact on core growth, but net-net a very good process in terms of positioning the channel efficiently. So we're pleased that the vast majority of that's behind us. There can always be a little bit of a tail to that of stuff we're still moving out in slower moving inventories, but again, I think a ton of progress. We've also got a very good leadership team in place on our -- in our Dental platform today, with some new players in place that I think are doing some wonderful things in terms of driving innovation. It was a very good year of new product introductions, and I think we'll see the benefit of that as core growth improves this year. So we know we still have work to do there, but good news is that there's opportunities for value creation as we go on here."
265621,321831219,956827,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Analysts","Great. And maybe just quickly a little color more on the M&A pipeline. Can you just give us a sense -- there's obviously been a ton of equity market volatility. We've seen, obviously, a shift in how the private equity folks are also sort of transacting. J",112,"Great. And maybe just quickly a little color more on the M&A pipeline. Can you just give us a sense -- there's obviously been a ton of equity market volatility. We've seen, obviously, a shift in how the private equity folks are also sort of transacting. Just give us a feel for maybe healthcare versus industrial oriented assets and the like, whether there's more activity at one side of the spectrum versus the other, and how? So the valuation dislocations have been kind of digested by the various groups because you're obviously doing smaller things at this point, and it's obviously the large end of the market that's probably been most impacted."
265621,321831219,956827,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","Sure. Well, I'll let Dan comment in a second on kind of the environment that we're seeing. But if you just look at what we did in the fourth quarter, which I think is a bit instructive, we got 4 or 5 small deals done in the fourth quarter. And by the way,",169,"Sure. Well, I'll let Dan comment in a second on kind of the environment that we're seeing. But if you just look at what we did in the fourth quarter, which I think is a bit instructive, we got 4 or 5 small deals done in the fourth quarter. And by the way, a couple -- 2 or 3 of those deals were Fortive related. I mentioned Pacific Laser Systems in my earlier comments, but there were a couple other smaller situations that we were able to complete during the quarter for Fortive's benefit along with a couple on the Danaher side. So I think the fourth quarter was indicative perhaps of some things opening up a bit. I think the environment is generally a favorable one for businesses like ours with a balance sheet that's ready to deploy into small and mid-size situations. And I think to your question, there are some folks who are perhaps a bit more on the sidelines right now than in previous days."
265621,321831219,956827,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Operator","Our next question comes from Shannon O'Callaghan of UBS.",10,"Our next question comes from Shannon O'Callaghan of UBS."
265621,321831219,956827,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Analysts","So Test & Measurement and Industrial Tech are both generating pretty good core margin expansion here despite these mid-single-digit declines. Can you give a little more color on how they're managing to do that? I mean, both of them have pretty good levera",62,"So Test & Measurement and Industrial Tech are both generating pretty good core margin expansion here despite these mid-single-digit declines. Can you give a little more color on how they're managing to do that? I mean, both of them have pretty good leverage in the model, so that's a lot to offset. And what's going on in those businesses, and can it continue?"
265621,321831219,956827,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","Yes. It's -- Shannon, it is a real testament to those businesses given the challenging environment they're in from a core growth perspective. That they are getting the operating margin lifted, they're getting without the benefit of the top line dropping t",195,"Yes. It's -- Shannon, it is a real testament to those businesses given the challenging environment they're in from a core growth perspective. That they are getting the operating margin lifted, they're getting without the benefit of the top line dropping that through. I think it is a testament to the strength of the Danaher Business System, the tools that we use, not just in newly acquired businesses, but in businesses with long histories with Danaher that have gotten a lot done using DBS in the past and are still getting it done. If you think about some of the businesses in T&M, be it Fluke and the associated acquisitions around Fluke that have been done quite a number of years ago, think about other businesses like Qualitrol, like some of the businesses in our automation and Sensors and Controls areas, those guys are using DBS, whether those are lean tools specifically in the plants or deploying those tools into -- in areas of SG&A, they're just demonstrating that those tools are still highly effective in businesses with long histories with Danaher. So it's kudos to those guys, and they continue to get her done."
265621,321831219,956827,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Analysts","Okay. And then you talked a little bit about the Diagnostic comps and things, but Radiometer, that's been one that seemed like it was just going to grow to the sky forever and the equipment business was a little weaker there, so maybe a little just color,",53,"Okay. And then you talked a little bit about the Diagnostic comps and things, but Radiometer, that's been one that seemed like it was just going to grow to the sky forever and the equipment business was a little weaker there, so maybe a little just color, anything there to be concerned about?"
265621,321831219,956827,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","Yes. No. We -- Radiometer is a tremendous business with a long track record of high single-digit growth at Danaher. I'm sure Matt or Dan can find how many quarters it's been, but it's quite a number of them in a row that we've been high single digits and",198,"Yes. No. We -- Radiometer is a tremendous business with a long track record of high single-digit growth at Danaher. I'm sure Matt or Dan can find how many quarters it's been, but it's quite a number of them in a row that we've been high single digits and taking share. It's a high consumables business. It's probably in the 80% neighborhood of consumables, so the days impact was fairly significant there. They also had a challenging comp in the fourth quarter on the Instrumentation side, a couple big orders that had some impact there. So I think Radiometer is in as good a shape today as it's ever been, no meaningful shift in the competitive dynamics there, so we still feel very good about it. I think if there was anything there, Shannon, it wouldn't be unique to Radiometer, it's simply the fact that some of the growth that we have seen in the high growth markets, while still strong in places like China and India, are still now very weak in Latin America, in Russia, in the Middle East, and so even our best businesses are probably going to feel a little bit of impact there."
265621,321831219,956827,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Operator","Our next question comes from Brandon Couillard of Jefferies.",9,"Our next question comes from Brandon Couillard of Jefferies."
265621,321831219,956827,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Analysts","Just back on the Dental business, Dan, any chance you could give us the impact of the fewer days on core growth overall? And how should we think about margin expansion for the year?",34,"Just back on the Dental business, Dan, any chance you could give us the impact of the fewer days on core growth overall? And how should we think about margin expansion for the year?"
265621,321831219,956827,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","Well, it has less of an impact on equipment. We were up slightly in the quarter, it's first time we've been up, albeit modestly. But it impacts consumables probably up in a -- as Tom alluded to, probably 1.5 points, 2 points when it comes to consumables.",110,"Well, it has less of an impact on equipment. We were up slightly in the quarter, it's first time we've been up, albeit modestly. But it impacts consumables probably up in a -- as Tom alluded to, probably 1.5 points, 2 points when it comes to consumables. Good progress on the margin side. Granted, we had a pretty weak performance a year ago, so part of it was the comp, but we've also took -- part of our incremental restructuring here in Q4 was at Dental, so we should see some continued margin expansion coming out of Dental, hopefully with little better growth than what we've seen here in '15."
265621,321831219,956827,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Operator","Our next question comes from Julian Mitchell of Crdit Suisse.",10,"Our next question comes from Julian Mitchell of Crdit Suisse."
265621,321831219,956827,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Analysts","Just a question around Western Europe. I think I heard you say that sales were down slightly in Q4, having been up sort of around a mid-single-digit pace in the 9-months period. I think a lot of other companies have sort of been saying Europe is okay, so",66,"Just a question around Western Europe. I think I heard you say that sales were down slightly in Q4, having been up sort of around a mid-single-digit pace in the 9-months period. I think a lot of other companies have sort of been saying Europe is okay, so maybe just talk a little bit about what you saw there, specific countries or segments that slowed down."
265621,321831219,956827,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","Julian, I mean, I think that was one of the areas versus what we expected at the beginning of the quarter that surprised us a little bit to the downside. It wasn't dramatic. Clearly, our consumable businesses over there were impacted by the selling days a",140,"Julian, I mean, I think that was one of the areas versus what we expected at the beginning of the quarter that surprised us a little bit to the downside. It wasn't dramatic. Clearly, our consumable businesses over there were impacted by the selling days and maybe we were not as well calibrated as we should have been. But having gone through all -- most of the business here in the first couple weeks here, the tone in Europe is still decent, and so it doesn't feel like the step down that our numbers in Q4 would suggest. And we think we'll get back to sort of modest growth here pretty quickly in 2016. Watching that carefully because it probably caught us a little bit by surprise here in the fourth quarter, but again the tone still seems pretty good."
265621,321831219,956827,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Analysts","Understood. And you'd laid out the overall EPS seasonality through the year about just over a month ago. Maybe just talk a little bit about the Pall seasonality of that $0.40, particularly given the industrial organic sales trend in that business right no",54,"Understood. And you'd laid out the overall EPS seasonality through the year about just over a month ago. Maybe just talk a little bit about the Pall seasonality of that $0.40, particularly given the industrial organic sales trend in that business right now? And how you would contrast that $0.40 impact versus overall Danaher?"
265621,321831219,956827,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","Well, the $0.40 should ramp during the year as we go after cost. Again, we were able to get some more things done in December, and that was inclusive of Pall as well. So we're getting it out of the gate a little bit faster in Q1 from a margin perspective.",80,"Well, the $0.40 should ramp during the year as we go after cost. Again, we were able to get some more things done in December, and that was inclusive of Pall as well. So we're getting it out of the gate a little bit faster in Q1 from a margin perspective. I think the offset, as you suggest, is the industrial side. So I think we'll get nice accretion here in Q1, but it will clearly ramp through the year."
265621,321831219,956827,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Operator","Our next question comes from Andrew Kaplowitz of Citigroup.",9,"Our next question comes from Andrew Kaplowitz of Citigroup."
265621,321831219,956827,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Analysts","Obviously, good performance in margin in the quarter. Are raw materials -- lower raw material costs helping at all with price costs? Did price costs -- was it stable in 4Q versus 3Q? Did it improve? I know you mentioned covering FX, but are raw materials",49,"Obviously, good performance in margin in the quarter. Are raw materials -- lower raw material costs helping at all with price costs? Did price costs -- was it stable in 4Q versus 3Q? Did it improve? I know you mentioned covering FX, but are raw materials helping at all?"
265621,321831219,956827,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","I don't have any great analysis on that yet. Given our gross margin, raw materials tend to be less of a factor for us than a lot of other companies you might cover. We are continuing to get price, still getting 60, 70 basis points, and it's hard not to th",68,"I don't have any great analysis on that yet. Given our gross margin, raw materials tend to be less of a factor for us than a lot of other companies you might cover. We are continuing to get price, still getting 60, 70 basis points, and it's hard not to think raw materials are helping us a little bit, but for us it's really on the margin."
265621,321831219,956827,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Analysts","Okay, got it. And then how do you get visibility into what to forecast, for example, in the Middle East? I mean, the region looks like it inflected down a bit in 4Q, and with oil's recent lag down, how difficult is it to get visibility? And what do you fo",53,"Okay, got it. And then how do you get visibility into what to forecast, for example, in the Middle East? I mean, the region looks like it inflected down a bit in 4Q, and with oil's recent lag down, how difficult is it to get visibility? And what do you forecast for 2016?"
265621,321831219,956827,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","Well, there's -- Andrew, there's a couple of different ways to come at that in the Middle East. One is simply conversations with distribution partners, and a lot of what we do in the Middle East does involve some form of a distributor partner. And making",238,"Well, there's -- Andrew, there's a couple of different ways to come at that in the Middle East. One is simply conversations with distribution partners, and a lot of what we do in the Middle East does involve some form of a distributor partner. And making sure that we have transparency as much as we possibly can into the opportunity funnels that those distributors are seeing as well as making sure that the conversations we're having with our own sales team around those funnels as they roll up to our leadership team are as well pressure tested as possible. The key thing about markets like the Middle East is, particularly in the businesses like ours, you have a fairly high level of project or tender related business and we saw on the equipment side. And so really making sure that we understand opportunity funnels and are not overly optimistic about the timing within which funding will be released, as in many cases, that funding has some governmental influence to it, is really important. It is easy to have a sales team get overly optimistic that the timing of funding release is going to be the same as it was a year ago or 2 years ago when the reality is things may have slowed down and tenders may be being let at a much slower pace. So being diligent about how we pressure test those funnels is key."
265621,321831219,956827,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Analysts","So it's fair to say you're being pretty conservative with the Middle East forecast.",15,"So it's fair to say you're being pretty conservative with the Middle East forecast."
265621,321831219,956827,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","We're trying to be increasingly conservative as we see how government funding is being influenced. I think it was interesting watching the course of the year. Oil continued to drop, as you know, throughout the course of the year and yet, we actually saw o",106,"We're trying to be increasingly conservative as we see how government funding is being influenced. I think it was interesting watching the course of the year. Oil continued to drop, as you know, throughout the course of the year and yet, we actually saw our Middle East numbers hang in there reasonably well throughout the middle part of the year. And it wasn't until the latter part of the year that we saw a more acute shift in the Middle East. And so there was a little bit of a lag there and it's taken a bit of time for the team to fully recalibrate."
265621,321831219,956827,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Operator","And we'll take our final question from Deane Dray of RBC Capital Markets.",14,"And we'll take our final question from Deane Dray of RBC Capital Markets."
265621,321831219,956827,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Analysts","Just a quick question on R&D spending overall, came in lighter year-over-year and versus our estimates. Did you throttle back on any spending? Is it just timing of some of the projects?",33,"Just a quick question on R&D spending overall, came in lighter year-over-year and versus our estimates. Did you throttle back on any spending? Is it just timing of some of the projects?"
265621,321831219,956827,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","As you probably saw in the numbers that we put out, Deane, we're showing R&D down about 20 basis points. But the reality is that, that was primarily influenced by Pall and R&D spending normalized for the Pall influence was actually up on the quarter. So w",87,"As you probably saw in the numbers that we put out, Deane, we're showing R&D down about 20 basis points. But the reality is that, that was primarily influenced by Pall and R&D spending normalized for the Pall influence was actually up on the quarter. So we're continuing to make sure that innovation is a key priority for the businesses and that R&D spending is maintained to the greatest extent possible for the opportunities that we think have the greatest impact in the next year or 2."
265621,321831219,956827,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Analysts","And then just last question for me is the incremental restructuring done in December, did you say what portion of that was Danaher versus Fortive?",25,"And then just last question for me is the incremental restructuring done in December, did you say what portion of that was Danaher versus Fortive?"
265621,321831219,956827,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","It was roughly the split you'd expect, 70-30, and that 70% Danaher inclusive of Pall.",16,"It was roughly the split you'd expect, 70-30, and that 70% Danaher inclusive of Pall."
265621,321831219,956827,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Operator","And I'd be happy to turn the program back over to our hosts.",14,"And I'd be happy to turn the program back over to our hosts."
265621,321831219,956827,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Executives","Thanks, Leo. Thanks, everyone, for joining us. We're around all day for questions.",13,"Thanks, Leo. Thanks, everyone, for joining us. We're around all day for questions."
265621,321831219,956827,"Danaher Corp., Q4 2015 Earnings Call, Jan 26, 2016",2016-01-26,"Earnings Calls","Danaher Corporation","Operator","Thank you. This does conclude today's Danaher Corporation's Fourth Quarter 2015 Earnings Results Conference Call. You may now all disconnect your lines, and everyone, have a great day.",28,"Thank you. This does conclude today's Danaher Corporation's Fourth Quarter 2015 Earnings Results Conference Call. You may now all disconnect your lines, and everyone, have a great day."
265621,329307690,960455,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Operator","My name is Issa, and I will be your conference facilitator today. At this time, I would like to welcome everyone to the Danaher Corporation first quarter 2016 earnings results conference call. [Operator Instructions] I will now turn the call over to Mr. M",56,"My name is Issa, and I will be your conference facilitator today. At this time, I would like to welcome everyone to the Danaher Corporation first quarter 2016 earnings results conference call. [Operator Instructions] I will now turn the call over to Mr. Matt Gugino, Vice President of Investor Relations. Mr. Gugino, please begin your conference."
265621,329307690,960455,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","Thank you, Issa,  and good morning, everyone, and thanks for joining us on the call. With us today are Tom Joyce, our President and Chief Executive Officer; and Dan Comas, our Executive Vice President and Chief Financial Officer. I like to point out that",335,"Thank you, Issa,  and good morning, everyone, and thanks for joining us on the call. With us today are Tom Joyce, our President and Chief Executive Officer; and Dan Comas, our Executive Vice President and Chief Financial Officer. I like to point out that our earnings release, the slide presentation supplementing today's call, our first quarter Form 10-Q and the reconciliations and other information required by SEC Regulation G relating to any non-GAAP financial measures provided during the call are all available on the Investors section of our website, www.danaher.com, under the heading Financial Information. The audio portion of this call will be archived on the Investors section of our website later today under the heading Events and Presentations and will remain archived until our next quarterly call. A replay of this call will also be available until April 28, 2016. The replay number is (888) 203-1112 within the U.S. or (719) 457-0820 outside the U.S. and the confirmation code is 464-3245. 
During the presentation, we will describe certain of the more significant factors that impact the year-over-year performance. The supplemental materials describe additional factors that impacted year-over-year performance. 
Unless otherwise noted, all references in these remarks and supplemental materials to company-specific financial metrics relate to the continuing operations of the company in the first quarter of 2016 and all references to period-to-period increases or decreases in financial metrics are year-over-year. 
During the call, we will make forward-looking statements within the meaning of the federal securities laws including statements regarding events or developments that we believe or anticipate will or may occur in the future. These forward-looking statements are subject to a number of risks and uncertainties, including those set forth in our SEC filings and actual results might differ materially from any forward-looking statements that we make today. These forward-looking statements speak only as of the date that they are made, and we do not assume any obligation to update any forward-looking statements. 
With that, I'd like to turn the call over to Tom."
265621,329307690,960455,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","Thanks, Matt, and good morning, everyone. We are pleased with our start to 2016 as our team continued to outperform in the face of uncertain and challenging economic conditions. In the quarter, we delivered high teens earnings growth, healthy operating ma",2371,"Thanks, Matt, and good morning, everyone. We are pleased with our start to 2016 as our team continued to outperform in the face of uncertain and challenging economic conditions. In the quarter, we delivered high teens earnings growth, healthy operating margin expansion and free cash flow that was up over 50% year-on-year. The Danaher Business System remained the driving force behind our performance, equipping our team with the tools to strengthen our competitive position, the focus to invest in higher impact growth opportunities and the flexibility to position our businesses for long-term success. 
This will be an exciting year as we anticipate the upcoming launch of Fortive Corporation, which we expect to spin out of Danaher in the third quarter. Since our last update in January, we continue to build a highly experienced leadership team that named additional members to Fortive's Board of Directors. The team has also made great progress solidifying Fortive's financial, legal and organizational structures. This separation is a unique opportunity for Danaher and Fortive to optimize our respective portfolios and build long-term shareholder value. We look forward to sharing more information with you at our investor and analyst event in May at Gilbarco Veeder-Root.
Now turning to the details of the quarter. Adjusted diluted net EPS was $1.08, an increase of 18.5% over last year. Sales grew 15% to $5.4 billion, and core revenue increased 50 basis points as the number of our businesses were negatively impacted by tough prior-year comparisons and 1 less selling day. 
Clearly, the economic environment remains challenging in many verticals and geographies, but we were encouraged by signs of sales and order stabilization through the quarter. Our team's focus on portfolio optimization and diligent execution using DBS helped improve and sustain many of our market-leading positions. Finally, the impact of currency translation eased this quarter but still decreased revenues by 2%, while acquisitions increased revenues by 16.5%.
Geographically, the developed markets grew slightly with stability in the U.S. and Europe. High-growth markets were up low single digits as continued growth in India was offset by declines in Latin America and Russia. In China, our teams are well-positioned to compete in several attractive markets and delivered mid-single-digit core growth in the quarter.
Gross margin for the first quarter was 53.1%, an increase of 50 basis points from last year. Along with the productivity initiatives undertaken in 2015, our gross margin expansion has enabled us to sustain and expand our growth investments in new product development and sales and marketing.
Core operating margin expanded 45 basis points, with reported operating margin at 16.4%. 
Free cash flow is one of the most important metrics at Danaher as it provides us with the agility to invest in both organic and inorganic growth initiatives across our entire portfolio. We had a strong quarter on this front, generating $622 million of free cash flow, a significant increase over last year.
Coming off a historic year of M&A, we closed 6 bolt-on acquisitions in the first quarter, deploying over $100 million in capital. These deals will strengthen our capabilities across many of our businesses. Both Danaher and Fortive have strong and active funnels, and we'll continue to focus on small and midsized transactions for both companies through the separation process.
Now let's take a look at our 5 operating segments, starting with Test & Measurement. Revenues decreased 5.5%, with core revenues down 5%. Core operating margin decreased 135 basis points, with reported operating margin coming in at 20.9%. Core revenues for our Instruments platform declined high single digits as we continue to face a challenging global market environment. All major geographies saw declines except for China and India. Fluke core revenues decreased mid-single digits due to declines in the U.S., Western Europe and Latin America, partially offset by increases in China. 
While still a difficult environment, we did see some signs of stabilization in certain geographies and industrial end markets during the quarter. A few weeks ago, Fluke announced the launch of the Fluke 279 FC thermal multimeter, the world's first test tool that integrates a full-featured digital multimeter with a thermal camera in 1 device. This combination enables technicians to check for hotspots on high-voltage equipment and analyze problems at a safe distance. By combining these important test tools into one, Fluke is helping our customers troubleshoot electrical issues more quickly, safely and thoroughly.
At Tektronix, core revenues declined low double digits as growth in China and India was more than offset by declines in all other major geographies. The Matco team continued to execute well, delivering high single-digit core growth in the quarter. Notably, Matco has posted mid-single-digit growth or better for 23 of the last 25 quarters and continues to improve its market position. In February, Matco hosted its Annual Tool Expo in Las Vegas. The expo provides Matco franchisees with an opportunity to see new products, attend training sessions and stock their businesses for the upcoming year. This year, almost 3/4 of Matco's franchisees participated, resulting in record attendance and event-driven sales.
Turning to our Environmental segment. Revenues grew 4%, with core revenues up 3.5%. Reported operating margin declined 220 basis points to 17.3%. Core operating margin declined 155 basis points and was negatively impacted by incremental investments, including EMV-related spend at Gilbarco Veeder-Root. We anticipate segment margins to return to more normalized levels in the second quarter. 
The Water Quality platform's core revenues grew slightly as 1 less selling day and a tough prior-year comparison had a negative impact. 
At Hach, positive momentum in the U.S. municipal market continued, but softness in high-growth markets resulted in flat core growth for the quarter. 
Trojan also saw strong municipal demand globally and delivered another good quarter. 
Finally, at ChemTreat, the team grew revenue slightly in the quarter despite headwinds in its industrial- and commodity-oriented markets. 
One of the ways that we continue to augment growth, build our capabilities and better serve our customers is through M&A. Our Water Quality platform has acquired more than 40 businesses since 1996 and continued its healthy cadence of bolt-on this quarter, with the Hach's acquisition of Loopmess [ph] in January. Loop's long-standing precision centers, long-lasting precision centers are a key part of weather-measuring networks along roads, railways and airports and enable us to deliver value to a wider range of customers around the world. The Hach team does an exceptional job of implementing DBS in newly acquired businesses, and this is well underway already at Loop. DBS lean and growth tools are helping us drive more efficient production, strengthen key account relationships and improve funnel management.
At Gilbarco Veeder-Root, core revenue grew high single digits for the third consecutive quarter. EMV-related demand in the U.S. drove double-digit growth in point-of-sale solutions and dispenser systems, and we believe we continue to gain share on both fronts. Many of our customers are still in the process of upgrading indoor payment systems for last October's credit card liability shift. Additionally, we are well-positioned to benefit from the upcoming outdoor liability shift, and the Gilbarco team is already collaborating with a number of customers to phase in outdoor upgrades. You'll hear more about EMV and GVR's other opportunities at our investor and analyst event next month.
Moving now to Life Sciences & Diagnostics. Core revenues grew 2.5%, with reported revenues up 42%, largely due to our recent Pall and Microscan acquisitions. Core operating margin expanded 205 basis points, thanks to the team's solid execution using DBS. Core revenues in our Diagnostics platform increased low single digits, led by healthy demand in high-growth markets. At Beckman Coulter, core revenue increased at a low single-digit rate. We saw strong demand for our immunoassay solutions and use our well-established installed base to help drive increased sales in India and China. Our consumable streams remain solid, and we're seeing healthy utilization rates globally. Radiometer and Leica Biosystems both increased core revenues in the quarter, with growth in China and India offset by declines in other high-growth markets. 
Our team is focused on improving our customers' experience every day and shows that commitment by expanding our product offering through both innovation and adjacent bolt-on acquisitions. Beckman Coulter's first major bolt-on, IRIS, closed in 2012 and extended our footprint beyond blood testing in the urinalysis. Since then, IRIS has delivered double-digit growth and expanded operating margins over 1,000 basis points. More recently, the acquisition of Microscan expanded Beckman's already strong presence in hospital and reference labs into the microbiology space. It has been 1 year since we closed the deal, and we achieved double-digit core revenue growth in the quarter. Both IRIS and Microscan are helping us serve our customers better, and we believe that adjacent acquisitions, combined with our consistent application of DBS, will continue to enhance our comprehensive workflow solutions across our diagnostic businesses. 
In our Life Science platform, core revenue was up low single digits, with growth in both developed and high-growth markets. Leica Microsystems core revenues were up low single digits as strong performance in North America and China was offset by declines in Japan and Latin America.
At SCIEX, core revenues grew low single digits, driven by demand in China and the Middle East. We also saw healthy sales growth in certain applied end markets and our service business. The SCIEX team has placed a strong focus on improving our customer's experience by pairing service contracts with instrument sales. This has driven record contract capture rates, including over 500 basis points of improvement in year-over-year attachment rates in the first quarter alone. 
SCIEX is a great example of how we use new products to help our customers' most critical challenges. In the quarter, we launched the x500R, the first model within our X-Series product family, which was the SCIEX team's largest ever development project. The x500R is a robust instrument that was specifically designed to serve customers in food and environmental testing labs to the fastest growing end markets in mass spectrometry. Going forward, we expect this to be a significant contributor to our future growth.
Turning to Pall. We are very pleased with our early progress. This quarter, the Pall team delivered mid-single-digit core revenue growth, led by double-digit growth in our Life Science business due to demand for our biopharmaceutical solutions, including single-use technologies. Our Industrial business was down low single digits as we face challenging market conditions. The team's enthusiastic application of DBS, including over 100 kaizen events since closed, has led to meaningful process improvements and several new product introduction across Pall's Life Sciences and Industrial businesses. As a result of our growth and productivity initiatives, year-on-year operating margins were up over 250 basis points. 
As we move on to Dental, core revenues increased by 0.5% due to strong demand for consumables and implants in North America and the high-growth markets as well as healthy orthodontic sales in China. These gains were negatively impacted by 1 less selling day.  Over the last several quarters, the Dental team's focus on execution and a disciplined spending has paid off in margin expansion. This quarter, the team grew core operating margins by 250 basis points and reported operating margins by over 500 basis points to 14.5%. Our continued investments in innovation have resulted in a number of differentiated product offerings for our Dental customers. At the Chicago Midwinter Dental Show in February, we launched over 15 [ph] new products, including [indiscernible], a revolutionary new cement for dental restoration that changes color to indicate the correct time for a dentist to remove any excess material. The first-in-class color indicator simplifies the dentist's procedure and reduces clinical risk.
At Nobel Biocare, the team drove mid-single-digit average daily sales of implant systems this quarter. Since the acquisition closed, Nobel has achieved over 400 basis points of operating margin improvement and is focused on reinvesting those savings into future growth opportunities.
Moving now to Industrial Technologies. Revenues declined 1.5%, while core revenues were also down 1.5%. Despite the revenue decline, core operating margin expanded 25 basis points, while reported operating margin declined 30 basis points to 24.3%. The Automation platform's core revenues decreased at a high single-digit rate due to the weakness in global industrial markets and a difficult prior-year comparison. While we expect this dynamic to largely persist in the near term, we were encouraged by signs of stabilization in the quarter. 
Product Identification core revenues grew at a low single-digit rate as increased demand for marking and coding [ph] was offset by softer demand for the businesses packaging and color solutions. 
Videojet's core revenues increased mid-single digits, driven by what we believe to be continuing share gains in North America and Europe, while high-growth markets remain softer. The Videojet team has delivered mid-single-digit growth or better for 9 of the past 10 quarters.
Last quarter, we announced the acquisition of Laetus [ph] which extends our Product ID offerings into track and trace inspection systems for pharmaceutical packaging plants. We're off to a good start with Laetus. The team's early adoption of DBS tools is already driving key process improvements as quicker service deployment and improved on-time delivery are ensuring that our customers receive the best possible support.
So to wrap up, our team executed well in the face of challenging economic conditions, and we are pleased with our start to 2016. The Danaher Business System remained the driving force behind our performance this quarter, helping to deliver high teens earnings growth, healthy operating margin expansion and 50% year-on-year free cash flow growth. We are also off to a great start at Pall, where the team drove meaningful process improvements and delivered mid-single-digit revenue growth in the quarter. We continue to make progress preparing for the launch of Fortive Corporation, which remains on track to close in the third quarter. Our teams are excited about the unique opportunity to continue developing 2 separate portfolios of market-leading businesses that we believe will create shareholder value for years to come.
We are initiating second quarter adjusted diluted net EPS guidance between $1.19 and $1.23, which assumes approximately 2% core revenue growth. We are increasing our full-year adjusted EPS guidance from $4.80 to $4.95 to $4.85 to $4.98, which would represent a 13% to 16% increase from 2015 adjusted EPS."
265621,329307690,960455,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","Thanks, Tom. That concludes our formal remarks. Issa, we're now ready to take questions.",14,"Thanks, Tom. That concludes our formal remarks. Issa, we're now ready to take questions."
265621,329307690,960455,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Operator","[Operator Instructions] We will now take our first question from Scott Davis from Barclays.",14,"[Operator Instructions] We will now take our first question from Scott Davis from Barclays."
265621,329307690,960455,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Analysts","China was up [indiscernible] for you guys, and I know last quarter was, I mean, track pretty comparable last quarter as well, but it sounded like things may have firmed up a little bit. I mean, Fluke -- is Fluke or canary in a coal mine in China having th",70,"China was up [indiscernible] for you guys, and I know last quarter was, I mean, track pretty comparable last quarter as well, but it sounded like things may have firmed up a little bit. I mean, Fluke -- is Fluke or canary in a coal mine in China having that business back in positive territory for the quarter? Maybe just a little color on what you guys are seeing there."
265621,329307690,960455,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","Sure. Thanks, Scott. Good morning. China, unquestionably, remains a very good market for us despite much of the headlines that certainly suggest that there's slowing in various areas. We're very pleased with the performance in China. And I think it was re",236,"Sure. Thanks, Scott. Good morning. China, unquestionably, remains a very good market for us despite much of the headlines that certainly suggest that there's slowing in various areas. We're very pleased with the performance in China. And I think it was relatively broad based. If you looked at Danaher versus Fortive, let's say, Danaher was up high single digits in China and Fortive was up mid-single digits in China. So I think a number of good examples where China remains a very attractive market for us. Relative to your specific question on Fluke, Fluke is just an exceptional business overall. We've had -- it's probably one of our most advanced businesses in terms of both go-to market as well as local production and product development in China. And while there's clearly still some softness around various industrial segments in the Chinese market, Fluke is a very strong brand in that market and has very strong share position. So I think we're encouraged by some of the stabilization we see in some of the markets. And in other of those markets, we just continue to see very strong growth. Our Dental business continues to perform exceptionally well in China. Life Sciences & Diagnostics broadly continuing to perform well there. So again, while clearly the headlines would show that, that market has pulled back a little bit in the aggregate, it's still a very good place to be."
265621,329307690,960455,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Analysts","Okay. That's helpful, Tom. And then just wanted to ask where you stand in Pall versus the deal model, kind of help us now that we are a year in or so, I mean, give us a sense of how -- what's working? What's not working? What -- Industrial is probably far",105,"Okay. That's helpful, Tom. And then just wanted to ask where you stand in Pall versus the deal model, kind of help us now that we are a year in or so, I mean, give us a sense of how -- what's working? What's not working? What -- Industrial is probably far weaker than you thought it was, but the Environmental or the I should say the life sciences [indiscernible] probably stronger than you thought it would be. So how are you managing that variability? And how does it all really stack up at the end of the day versus what your prior expectations were?"
265621,329307690,960455,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","Scott, it's Dan, we're off to a very good start there. We had mid-single-digit growth in the quarter. As Tom alluded, that was a combination of double-digit growth in the Life Science side and a slight decline on the Industrial side. Clearly, that would h",148,"Scott, it's Dan, we're off to a very good start there. We had mid-single-digit growth in the quarter. As Tom alluded, that was a combination of double-digit growth in the Life Science side and a slight decline on the Industrial side. Clearly, that would have been a contributor to our overall organic growth at Danaher. From a margin perspective, we are ahead of schedule. We talked about north of $100 million a benefit here this year on the margin side, continue to track very well to the ultimate target of $300 million. In addition to this, we are getting favorable mix giving the Life Science business is more profitable, and we really saw that play out exceedingly well in the first quarter. It will likely create some opportunities where we'll be able to accelerate some investments here at Pall during [ph] this year given we're tracking so well."
265621,329307690,960455,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","Just to follow on Dan's comment a little bit, the team at Pall has just done a tremendous job. As we've mentioned before, it's a great combination of both some seasoned Danaher leaders as well as an exceptional group of folks who have been at Pall for a l",136,"Just to follow on Dan's comment a little bit, the team at Pall has just done a tremendous job. As we've mentioned before, it's a great combination of both some seasoned Danaher leaders as well as an exceptional group of folks who have been at Pall for a long time, who, together, have really brought DBS to life in that business in rapid fashion. You heard me mention about the 100 kaizens that have gone on, those have gone on literally around the world. And it's just one indication of the rapid rate at which the Pall team has adopted the tools of DBS and really that has truly contributed to not only the growth dynamics that we're seeing but certainly has assisted in us getting ahead on the cost takeouts in the margin side."
265621,329307690,960455,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Operator","Our next question comes from Steve Tusa from JPMorgan.",9,"Our next question comes from Steve Tusa from JPMorgan."
265621,329307690,960455,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Analysts","Just back to Pall, just a follow-up on that. I think you were doing a little bit better than $100 million in R&D a year, and R&D year-over-year was up, I think, about $20 million. Is that a little bit of a decline in the core R&D? Or are you kind of getti",97,"Just back to Pall, just a follow-up on that. I think you were doing a little bit better than $100 million in R&D a year, and R&D year-over-year was up, I think, about $20 million. Is that a little bit of a decline in the core R&D? Or are you kind of getting efficiencies there on the Pall side? You also mentioned you're kind of walking away from some business there, I think, in your 10-Q at Pall. Could you just give us a degree of magnitude on that front? And then I have one quick follow-up."
265621,329307690,960455,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","Steve, on walking away some business, that's something that Pall had started prior even to our acquisition. It's down to a relatively nominal amount here and will be, I think, largely done by the middle of this year.",38,"Steve, on walking away some business, that's something that Pall had started prior even to our acquisition. It's down to a relatively nominal amount here and will be, I think, largely done by the middle of this year."
265621,329307690,960455,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Analysts","Okay. And then on the R&D front, what was kind of Pall's R&D? I think it was greater than $100 million. Are you guys getting more efficiency there? Do you expect to maintain that R&D budget? Increase it?",38,"Okay. And then on the R&D front, what was kind of Pall's R&D? I think it was greater than $100 million. Are you guys getting more efficiency there? Do you expect to maintain that R&D budget? Increase it?"
265621,329307690,960455,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","I would -- right now, we are sustaining and I suspect over time that will get increase.",17,"I would -- right now, we are sustaining and I suspect over time that will get increase."
265621,329307690,960455,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","I would just add to that. I think we've mentioned this maybe once before, but if you think back to the playbook that we ran post the Beckman acquisition, I think the playbook here at Pall is very similar, which is, there's a number of opportunities to get",192,"I would just add to that. I think we've mentioned this maybe once before, but if you think back to the playbook that we ran post the Beckman acquisition, I think the playbook here at Pall is very similar, which is, there's a number of opportunities to get cost out of the business broadly defined and we are working on those obviously, start to see the margins coming up. But the playbook is to then redeploy some of that cost takeout into investments in sales and marketing and R&D. You see us do that broadly across Danaher with gross margins going up and sales and marketing and R&D on the quarter for the Danaher in total, up 30 basis points. We did that at Beckman, R&D lifted over time, we started to get the innovation engine going. Innovation at Pall has always been a strong suit there, but we think we can take it up another level. So some of those cost takeouts will ultimately translate into either higher spending or potentially more efficient spending as we find opportunities to do a better job innovating at the same cost rate. We'll see."
265621,329307690,960455,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Analysts","Okay. And then just lastly on the free cash flow, a very strong quarter obviously, you're paying down some debt, beginning to delever here a little bit. Is there anything about the timing of that free cash flow? Or should we think about kind of normal sea",80,"Okay. And then just lastly on the free cash flow, a very strong quarter obviously, you're paying down some debt, beginning to delever here a little bit. Is there anything about the timing of that free cash flow? Or should we think about kind of normal seasonality off of that base? I know there were some accruals year-over-year, accruals were less of a drag, maybe there's just some timing. Maybe bottom line, what's kind of the annual free cash guide?"
265621,329307690,960455,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","We don't give a specific guide, but we're off to a very good start. There was a little bit of timing benefit around some tax payments, but broadly our cash flow was quite strong. As you know, we ended last year with a record number and [ph] a very strong",85,"We don't give a specific guide, but we're off to a very good start. There was a little bit of timing benefit around some tax payments, but broadly our cash flow was quite strong. As you know, we ended last year with a record number and [ph] a very strong second half of free cash flow. We expect that trend to continue. We're not going to be up 40% year-on-year, but we expect a very healthy double-digit increase in free cash flow this year."
265621,329307690,960455,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","Our first quarter last year was [ph] .",8,"Our first quarter last year was [ph] ."
265621,329307690,960455,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","We are a little bit light.",6,"We are a little bit light."
265621,329307690,960455,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","A little bit lighter last first quarter. So a little bit of benefit there from a comp standpoint.",18,"A little bit lighter last first quarter. So a little bit of benefit there from a comp standpoint."
265621,329307690,960455,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Operator","Our next question comes from Nigel Coe from Morgan Stanley.",10,"Our next question comes from Nigel Coe from Morgan Stanley."
265621,329307690,960455,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Analysts","Tom, so you mentioned you're seeing signs of stability. I think that was in relation to Fluke specifically. But maybe just broaden that to the conversation to maybe some of the more typical businesses within Industrial Tek, Tektronix. What are you seeing",51,"Tom, so you mentioned you're seeing signs of stability. I think that was in relation to Fluke specifically. But maybe just broaden that to the conversation to maybe some of the more typical businesses within Industrial Tek, Tektronix. What are you seeing today compared to what you saw back in January?"
265621,329307690,960455,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","Sure. Thanks, Nigel. Our comments about stability were not exclusively associated with Fluke. In fact, I think there are some pockets even around the Fluke business where we've seen stability but we've also seen still some real headwinds. But I think we h",210,"Sure. Thanks, Nigel. Our comments about stability were not exclusively associated with Fluke. In fact, I think there are some pockets even around the Fluke business where we've seen stability but we've also seen still some real headwinds. But I think we have seen stability in some other areas. You asked specifically about on the Industrial Tek side. The Automation businesses, our Sensors and Controls businesses, as we look at those throughout the course of the quarter, February and March, we saw indications of stability. We saw those order rates kind of firm up a little bit. And while we wouldn't call it an upward trajectory, we would call those a bit more stable than we had seen in the trajectory of [ph] the fourth quarter and maybe at the very opening of the year. You mentioned Tektronix. I wouldn't necessarily put Tektronix quite in that category yet, it had one of the more challenging quarters. It's in one of the tougher markets probably that we face today. And so I think while we are very encouraged by the new product flow at Tektronix and we expect to see those new products drive some improved performance in the back half of the year, Tek remains in a pretty challenging environment."
265621,329307690,960455,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Analysts","Okay. That's helpful. And then switching to Environmental margins, obviously, a lot of noise this quarter. You called out investment spending. I'm wondering if you can maybe help us size that impact? And it seems that this quarter you had a negative mix o",64,"Okay. That's helpful. And then switching to Environmental margins, obviously, a lot of noise this quarter. You called out investment spending. I'm wondering if you can maybe help us size that impact? And it seems that this quarter you had a negative mix of consumables versus GVR growth. Is that true? And would you expect that to normalize over the balance of the year?"
265621,329307690,960455,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","Well, I'll need you to clarify that last question. I'm not exactly sure what you meant by negative mix relative to GVR growth unless you're talking about Water Quality versus GVR within Environmental? Is that...",35,"Well, I'll need you to clarify that last question. I'm not exactly sure what you meant by negative mix relative to GVR growth unless you're talking about Water Quality versus GVR within Environmental? Is that..."
265621,329307690,960455,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Analysts","Exactly [indiscernible] GVR margin.",4,"Exactly [indiscernible] GVR margin."
265621,329307690,960455,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","Absolutely right. Thanks, Nigel, you're right on. If you look at Environmental, which, as all of you know, both has our GVR business as well as our Water Quality businesses, GVR had stronger growth during the course of the quarter, very encouraging signs",215,"Absolutely right. Thanks, Nigel, you're right on. If you look at Environmental, which, as all of you know, both has our GVR business as well as our Water Quality businesses, GVR had stronger growth during the course of the quarter, very encouraging signs of the EMV dynamic taking hold. And GVR comes through that with a lower margin mix relative to our Water Quality platform, which has higher margins and specifically Hach. So a little bit softer Hack business, a little bit stronger GVR business during the course of the quarter together caused us some of that headwind that you saw on the margin line there. The reference to investment spend is specific to what we need to do to build the capacity to step up to the demand associated with EMV. And so we see that specifically in our GVR business. And those are investments that clearly will pay off as we continue to ramp our capabilities. And as we go into the second quarter and beyond, we would expect those margins overall in the segment to return closer to normal levels. Obviously, some continued investment there, but we expect Water Quality to come up a bit. So overall, I think there were just a couple of unique factors here in the first quarter."
265621,329307690,960455,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Operator","Our next question comes from Shannon O'Callaghan from UBS.",10,"Our next question comes from Shannon O'Callaghan from UBS."
265621,329307690,960455,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Analysts","Tom, you mentioned execution and disciplined spending at Dental with the big margin improvement there. I mean, that's the segment you've always targeted getting to much higher margins over the year, but it's been more of a challenge. I mean, is this somet",57,"Tom, you mentioned execution and disciplined spending at Dental with the big margin improvement there. I mean, that's the segment you've always targeted getting to much higher margins over the year, but it's been more of a challenge. I mean, is this something of a breakthrough here? Or how should we read the performance in those comments?"
265621,329307690,960455,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","Well, you're absolutely right, Shannon, it's been a challenge in the past, and we did set our sights and commit to making a difference there. We have some new leadership in place over the platform. Many of you have met Amir Aghdaei [ph] who's lead a numbe",210,"Well, you're absolutely right, Shannon, it's been a challenge in the past, and we did set our sights and commit to making a difference there. We have some new leadership in place over the platform. Many of you have met Amir Aghdaei [ph] who's lead a number of our businesses over the last several years and some of our more challenging businesses. And he's really put a terrific team together. They set their sights on specific margin improvements over time. There was some outstanding execution, some disciplined cost control. But similar to the comments I made earlier around the playbook, I made reference to the Beckman playbook and how that applies to Pall, while we'll continue to drive margin improvement at Dental, one of the team's leadership, we'll also take some of that improvement and continue to invest in sales and marketing and in R&D because we do have opportunities for improvement in terms of our innovation cadence. You saw some modest improvement there in our core growth and the platform during the quarter. But we know there's opportunities to continue to improve that. We expect it to continue to step up. But some additional investment over time with some of that cost takeout will certainly be a help [ph]."
265621,329307690,960455,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Analysts","Okay. Great. And then, Dan, maybe a question for you on tax. Obviously, a lot of new tax policies being contemplated and put into place that impact a lot of multinationals. Any just thoughts on that in general and potential impacts on Danaher as well as h",62,"Okay. Great. And then, Dan, maybe a question for you on tax. Obviously, a lot of new tax policies being contemplated and put into place that impact a lot of multinationals. Any just thoughts on that in general and potential impacts on Danaher as well as how should we think about kind of the 2 NewCo tax rates and any differentials there?"
265621,329307690,960455,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","Sure, Shannon. Obviously, it's something we're spending a lot of time on trying to understand better. I mean, our initial read of this is, this is not going to be an impact to us, a material impact to us in the near term. That over time, we could see some",166,"Sure, Shannon. Obviously, it's something we're spending a lot of time on trying to understand better. I mean, our initial read of this is, this is not going to be an impact to us, a material impact to us in the near term. That over time, we could see some rate creep because of it. Now that assumes nothing else happens and there's no other opportunities. So sitting here right now, it's not something that worries us a great deal but obviously a potential risk kind of going forward. I don't think there's a big change in how we think about the tax rates of the 2 entities. We've talked about Fortive likely coming out close to the kind of a high 20 tax rate. Again, I think as they begin to do some acquisitions, they'll have an opportunity to bring that down. And I would expect that Danaher would be at our current rate or lower. Danaher RemainCo will be at current rate or lower."
265621,329307690,960455,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Operator","Our next question comes from Steven Winoker from Bernstein.",9,"Our next question comes from Steven Winoker from Bernstein."
265621,329307690,960455,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Analysts","Could you maybe just clarify. You talked about Fortive versus Danaher core growth in China. What was it globally for the quarter?",22,"Could you maybe just clarify. You talked about Fortive versus Danaher core growth in China. What was it globally for the quarter?"
265621,329307690,960455,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","The Danaher was up a couple of points, and Fortive was down 1 to 2 points, say [ph] 1.5%, I believe.",21,"The Danaher was up a couple of points, and Fortive was down 1 to 2 points, say [ph] 1.5%, I believe."
265621,329307690,960455,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Analysts","Okay. And well I guess everybody, what are you thinking about in terms of current thinking, I should say, on capital structure for the 2 entities? Were you still heading for, I know, there have been some private conversations but don't have a sense for wh",49,"Okay. And well I guess everybody, what are you thinking about in terms of current thinking, I should say, on capital structure for the 2 entities? Were you still heading for, I know, there have been some private conversations but don't have a sense for what that is now."
265621,329307690,960455,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","I don't think much has changed versus what we communicated a year ago. We would expect Fortive to come out as an investment grade company. Likely they're not going to be an A rated company, but triple -- something in the BBB range where they would be stro",64,"I don't think much has changed versus what we communicated a year ago. We would expect Fortive to come out as an investment grade company. Likely they're not going to be an A rated company, but triple -- something in the BBB range where they would be strong investment grade and clearly have a fair amount of latitude to actually choose [ph] M&A."
265621,329307690,960455,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Analysts","Okay. Great. And if I could just one more, Tom, in terms of R&D profile, I know you talked a little bit about it before specifically with Pall. But I guess, overall, for the company, where is -- what level of R&D are we talking about for just -- for the n",77,"Okay. Great. And if I could just one more, Tom, in terms of R&D profile, I know you talked a little bit about it before specifically with Pall. But I guess, overall, for the company, where is -- what level of R&D are we talking about for just -- for the new Danaher going forward? And do you see an opportunity to accelerate that at all as you think about also accelerating core growth in new Danaher?"
265621,329307690,960455,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","Sure. Thanks, Steve. I've said for a long time, I've always believed that there is no magic number for a business with the diverse portfolio that we have today. We really look at continuing to invest in R&D to certain levels, specifically at an operating",217,"Sure. Thanks, Steve. I've said for a long time, I've always believed that there is no magic number for a business with the diverse portfolio that we have today. We really look at continuing to invest in R&D to certain levels, specifically at an operating company level, and that's obviously relevant for -- relative to what's important to those markets, what's important for our competitiveness, what yields the greatest levels of competitive advantage from an innovation perspective. So we really look at it sort of operating company by operating company. Our track record is a great one, and it will continue of taking R&D up year-on-year pretty consistently. We've used our operating margin expansion, that's been driven by improvements in gross margin, to put some of that back into not only R&D, but into sales and marketing as well. And again, we've done that very consistently, I would expect that we will continue to do that. One of our 5 core values is Innovation Defines Our Future, and we represent that in our metrics by continuing to see that percent of R&D go up year-on-year. So again, it will vary in terms of the number that we achieve year-on-year by operating company or even by platform, but using innovation to drive competitiveness is key to our strategy."
265621,329307690,960455,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Analysts","What was it in the quarter, at least just for the current or for the new Danaher?",17,"What was it in the quarter, at least just for the current or for the new Danaher?"
265621,329307690,960455,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","Probably in the same -- Steve, we have the dynamic around Pall where a lot of the application expertise they bring to their customers which is a big part of their value add, they included sales and marketing and R&D. The fact that you saw R&D as a percent",107,"Probably in the same -- Steve, we have the dynamic around Pall where a lot of the application expertise they bring to their customers which is a big part of their value add, they included sales and marketing and R&D. The fact that you saw R&D as a percent of our overall revenues go down 40, 50 basis points year-on-year, that's entirely driven by the Pall dynamic. But I would say, Danaher is probably in that zone where you've got some higher R&D businesses but because of the way Pall accounts for their R&D, it probably averages to where Danaher is today around that [indiscernible] percent range."
265621,329307690,960455,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Operator","Your next question comes from Ross Muken from Evercore ISI.",10,"Your next question comes from Ross Muken from Evercore ISI."
265621,329307690,960455,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Analysts","Maybe on the Life Science business, just a little bit more color commentary. You called out pharma as sort of a strong end market. It seems like on the SCIEX side, that market has been running hot for a while. I mean how do you see that trajectory there?",100,"Maybe on the Life Science business, just a little bit more color commentary. You called out pharma as sort of a strong end market. It seems like on the SCIEX side, that market has been running hot for a while. I mean how do you see that trajectory there? And then secondarily on the Pall side, biotech there's obviously been a lot of concern in the market, particularly with the smaller companies on funding and the like. And have you seen anything in that side of the business, particularly with small to midsized biotechs in terms of any relevant slowdown?"
265621,329307690,960455,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","Thanks, Ross. Yes, no question, the pharma market is an important driver of our growth across the Life Science portfolio. And we have exposure to that growing market across virtually every one of our Life Science businesses. Pall, specific to your questio",223,"Thanks, Ross. Yes, no question, the pharma market is an important driver of our growth across the Life Science portfolio. And we have exposure to that growing market across virtually every one of our Life Science businesses. Pall, specific to your question around biotech and small and midsized, continues to perform exceptionally well across the biotech market. Just to go back and talk about a few things about what's going on in that market, pall has $1 billion business today that's oriented toward biopharmaceuticals. And the combination of the solutions that they've had for a number of years along with the newer products and single-use technologies, continue to drive the exceptional growth that we see there. That growth, as I think many of you know, Ross, and others know, is really driven by this move, the growth and the transition from small molecule drugs to large molecule drugs. And not only are those the fastest-growing segment of the market, but they're also the drugs that are most significantly represented in the pipelines of both small as well as large pharmaceutical companies today. So we remain optimistic and bullish on that market. And I think there's every reason to believe that we'll continue to see good growth, not only from Pall but from our other Life Science business that have exposure to that market."
265621,329307690,960455,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Analysts","Great. And maybe just quickly on the capital allocation side. So a lot of equity market volatility to start the year. Private equity's probably have been more of a net seller than buyer. I mean, how has it sort of impacted as prices on the private side in",129,"Great. And maybe just quickly on the capital allocation side. So a lot of equity market volatility to start the year. Private equity's probably have been more of a net seller than buyer. I mean, how has it sort of impacted as prices on the private side in terms of what you're looking at? And does it make sellers more apt to maybe approach a process given they saw equity prices up, down, up again, maybe they are afraid they go down again and so they want to take advantage of maybe an open and the sort of credit markets where larger companies can acquire. I'm just trying to get a feel for kind of how all these volatilities maybe help you a little bit on the deal front?"
265621,329307690,960455,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","Volatility is a net positive for us as a well-capitalized acquirer. Your comment about private equity is get a little better for them, but it's -- the leverage markets are still pretty tough. So I think all those factors play to our benefit. Now granted t",78,"Volatility is a net positive for us as a well-capitalized acquirer. Your comment about private equity is get a little better for them, but it's -- the leverage markets are still pretty tough. So I think all those factors play to our benefit. Now granted there are a number of other well-capitalized corporate player here, but we are happy to sort of compete in this sort of environment where there's a little bit more volatility and uncertainty."
265621,329307690,960455,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Operator","Next question comes from Jeffrey Sprague from Vertical Research Partners.",10,"Next question comes from Jeffrey Sprague from Vertical Research Partners."
265621,329307690,960455,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Analysts","Just a couple. First on SG&A, I guess, Dan, kind of partially answered it speaking to the Pall R&D. But the SG&A moving up as a percent of sales, is there anything to flag there? And do you expect that sort of upward pressure over the balance of the year?",50,"Just a couple. First on SG&A, I guess, Dan, kind of partially answered it speaking to the Pall R&D. But the SG&A moving up as a percent of sales, is there anything to flag there? And do you expect that sort of upward pressure over the balance of the year?"
265621,329307690,960455,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","If we first just take Pall out of the equation entirely, R&D as a percent of sales was flat year-on-year, but sales and marketing was up 30 basis points and that was intentional. We've stepped up some investments. We've talked about some of the opportunit",167,"If we first just take Pall out of the equation entirely, R&D as a percent of sales was flat year-on-year, but sales and marketing was up 30 basis points and that was intentional. We've stepped up some investments. We've talked about some of the opportunities in high-growth markets where we see people pulling back, and we see there was some opportunity. I think some of the success Fortive is having in China right now is probably a little bit of an example of that. And Pall brings in a pretty high sales and marketing expense when you've kind of layer that in. That probably sustains itself. We see that as important part of their go-to market, not only their go-to market, but as mentioned also sort of part of their R&D as well. So we don't see ourselves sort of cutting back in those investments, if anything, given we have a little bit more strength here early in the year, we may step some of that up."
265621,329307690,960455,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Analysts","And on tax, you mentioned creep and maybe there could be some offsets. Have you guys looked at this FASB change on stock comp and determined what if any benefit you'll have when you choose to adopt that?",38,"And on tax, you mentioned creep and maybe there could be some offsets. Have you guys looked at this FASB change on stock comp and determined what if any benefit you'll have when you choose to adopt that?"
265621,329307690,960455,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","We don't think it would be meaningful.",8,"We don't think it would be meaningful."
265621,329307690,960455,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Analysts","And then just finally, the 6 small deals, were any of those in Fortive? And if so, what?",18,"And then just finally, the 6 small deals, were any of those in Fortive? And if so, what?"
265621,329307690,960455,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","One was Fortive.",3,"One was Fortive."
265621,329307690,960455,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Analysts","What kind of that.",4,"What kind of that."
265621,329307690,960455,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","It was an acquisition for Gilbarco.",6,"It was an acquisition for Gilbarco."
265621,329307690,960455,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","And that's on top of a couple of more we did late last year. So in the last 4, 5 months, it's 3 deals, Jeff.",26,"And that's on top of a couple of more we did late last year. So in the last 4, 5 months, it's 3 deals, Jeff."
265621,329307690,960455,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Operator","Our next question comes from Deane Dray from RBC.",9,"Our next question comes from Deane Dray from RBC."
265621,329307690,960455,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Analysts","Just like to go back to the 2016 guide and just to clarify, has there been any change to the core revenue outlook for 2% to 3%? And then maybe a bit on the cadence of that through the year? And how might that split with Fortive?",47,"Just like to go back to the 2016 guide and just to clarify, has there been any change to the core revenue outlook for 2% to 3%? And then maybe a bit on the cadence of that through the year? And how might that split with Fortive?"
265621,329307690,960455,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","Deane, no real change to our view of the full year. It's 2% to 3%. I think our comments referring to some stabilization that we've seen here in the last couple of months, I think, suggests -- as well as by the way, how that was represented in the order ra",85,"Deane, no real change to our view of the full year. It's 2% to 3%. I think our comments referring to some stabilization that we've seen here in the last couple of months, I think, suggests -- as well as by the way, how that was represented in the order rates, not just the sellout, but the order rates in the last couple of months, suggests that we still feel pretty good about the 2% to 3%. So I think we're going to stay there."
265621,329307690,960455,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Analysts","And how about the expectations for Fortive in the second quarter?",11,"And how about the expectations for Fortive in the second quarter?"
265621,329307690,960455,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","We would expect that Fortive would be in the same zone, maybe a little bit better, Danaher ex Fortive would be slightly better and that would roll up to be approximately 2% versus the 0.5% of core we delivered in the first quarter.",43,"We would expect that Fortive would be in the same zone, maybe a little bit better, Danaher ex Fortive would be slightly better and that would roll up to be approximately 2% versus the 0.5% of core we delivered in the first quarter."
265621,329307690,960455,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Analysts","Great. And then maybe some clarification on Hach. The softness in the high-growth markets, is there anything specific there? Is it tougher comps? Why might there be some slowing there?",30,"Great. And then maybe some clarification on Hach. The softness in the high-growth markets, is there anything specific there? Is it tougher comps? Why might there be some slowing there?"
265621,329307690,960455,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","Well, it certainly was a very challenging comp year-on-year. The platform, overall, I think, comp 10% versus last year, Deane. So it was probably among the platforms that we have probably the toughest comp perhaps across the entire corporation. So that wa",142,"Well, it certainly was a very challenging comp year-on-year. The platform, overall, I think, comp 10% versus last year, Deane. So it was probably among the platforms that we have probably the toughest comp perhaps across the entire corporation. So that was certainly challenge. We have seen some delays in some key projects in a couple of the high-growth markets. So that was certainly a factor there. In certain of those high-growth market, we actually have a little bit more industrial exposure than purely municipal exposure. And that, obviously, had an impact on those markets. Again, we don't --  that business, you know it well, Deane, is just one of our exceptional franchises, and we're confident that business continues to -- will continue to grow over time, and we'll see that business as core growth rate improve here in the second quarter."
265621,329307690,960455,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Analysts","Great. And then just last one, and still on the topic of Hach. I don't recall ever there being a time where Water Quality has been more front page news in the U.S. with Flint, Michigan. Just what's your expectation about the longer-term implications on Wa",54,"Great. And then just last one, and still on the topic of Hach. I don't recall ever there being a time where Water Quality has been more front page news in the U.S. with Flint, Michigan. Just what's your expectation about the longer-term implications on Water Quality, water test? And how is Hach positioned?"
265621,329307690,960455,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","Sure. Well, believe me, we wish we had an answer today to the infrastructure challenges that lead pipes represent in that situation. It's just terrible to see the challenges that, that community has gone through. But I think, if we try to look on the brig",141,"Sure. Well, believe me, we wish we had an answer today to the infrastructure challenges that lead pipes represent in that situation. It's just terrible to see the challenges that, that community has gone through. But I think, if we try to look on the bright side from the standpoint of the overall market dynamics, situations like that always turn the spotlight up on the importance of regulatory oversight in municipalities around the country, and frankly, throughout the world. And so as those regulatory drivers continue to be strengthened, to be pointed at the greatest vulnerabilities in municipal and industrial systems, that, again, while challenging for those communities, ultimately benefits consumers and certainly benefits us. Regulatory drivers have always been a key macro driver for that platform and they will continue to be so for as long as we can anticipate."
265621,329307690,960455,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Operator","Our next question comes from Andrew Obin from Bank of America Merrill Lynch.",13,"Our next question comes from Andrew Obin from Bank of America Merrill Lynch."
265621,329307690,960455,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Analysts","I guess on the Q, you sort of indicated that you're still on track to pay the $3 billion dividend from Fortive to Danaher. Is there any flexibility around that number if Fortive discovers a good acquisition? How flexible are you there?",42,"I guess on the Q, you sort of indicated that you're still on track to pay the $3 billion dividend from Fortive to Danaher. Is there any flexibility around that number if Fortive discovers a good acquisition? How flexible are you there?"
265621,329307690,960455,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","Well that's something obviously the board would need to determine depending on obviously the size of the acquisition and what else they have in the pipeline.",27,"Well that's something obviously the board would need to determine depending on obviously the size of the acquisition and what else they have in the pipeline."
265621,329307690,960455,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Analysts","But is it fair to assume that there's some flexibility there?",12,"But is it fair to assume that there's some flexibility there?"
265621,329307690,960455,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","Nothing set until it's set.",6,"Nothing set until it's set."
265621,329307690,960455,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Analysts","And then just going back to GVR, the EMV investment and both growth and investment, is it fair to assume that investment is going to be front-end loaded Q1 and Q2, but you might see growth throughout the year? Is that the right way of thinking about it?",48,"And then just going back to GVR, the EMV investment and both growth and investment, is it fair to assume that investment is going to be front-end loaded Q1 and Q2, but you might see growth throughout the year? Is that the right way of thinking about it?"
265621,329307690,960455,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","Yes. There's clearly some upfront cost, and as Tom alluded, we also had some onetime items in the quarter, and that will normalize as we get through the year.",29,"Yes. There's clearly some upfront cost, and as Tom alluded, we also had some onetime items in the quarter, and that will normalize as we get through the year."
265621,329307690,960455,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Operator","We'll now take our next question from Julian Mitchell from Crdit Suisse.",13,"We'll now take our next question from Julian Mitchell from Crdit Suisse."
265621,329307690,960455,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Analysts","Just a question on Dental first. The growth rate was lower than I thought, particularly as Nobel should have automatically pushed up the organic growth a little bit and the comp was pretty easy. So I saw you called out Middle East and Africa equipment, bu",68,"Just a question on Dental first. The growth rate was lower than I thought, particularly as Nobel should have automatically pushed up the organic growth a little bit and the comp was pretty easy. So I saw you called out Middle East and Africa equipment, but I wouldn't have thought that was a very sizable piece of the business. So maybe just give a bit more color there."
265621,329307690,960455,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","Sure. Our Dental growth, overall, Julian, at 0.5%, was basically in line with our expectations, modest improvement from where we've been over the last few quarters. And obviously, as we talked just a few minutes ago, we are very pleased within the OMX up",212,"Sure. Our Dental growth, overall, Julian, at 0.5%, was basically in line with our expectations, modest improvement from where we've been over the last few quarters. And obviously, as we talked just a few minutes ago, we are very pleased within the OMX up at the rate that I talked about earlier. We saw solid low single-digit growth in consumables, and sellout continues and actually is a fraction better than even our sell-in. So we always look at that sellout. We have good transparency with our distribution partners and we are encouraged by that. The Nobel implant systems business, mid-single-digit average daily sales growth in the quarter, we are pleased with that. The Armco business, the orthodontic business continues to do well and we are continuing to see on a geographic basis, as I mentioned, a couple of the high-growth markets, specifically our business in China, continuing to do well. On the flip side, on the equipment side, we have seen some challenges in Europe actually, and a couple in those high-growth markets where the equipment side has been held back a little bit more significantly. So I think as we annualize over some of those more challenging comps, we'll continue to see that growth improve during the course of this year."
265621,329307690,960455,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Analysts","Got it. And secondly, just on Test & Measurement, I wondered obviously that the trends year-on-year sort of similar Q1 as in [ph] Q4. I wondered if there was any specific end market you'd call out that's sort of dragging on the growth now. Obviously, you",67,"Got it. And secondly, just on Test & Measurement, I wondered obviously that the trends year-on-year sort of similar Q1 as in [ph] Q4. I wondered if there was any specific end market you'd call out that's sort of dragging on the growth now. Obviously, you do have some electronics exposure, for example, in T&M. Or if you thought it was sort of fairly broad-based, the weakness."
265621,329307690,960455,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","Well, there's certainly some broad-based weakness but if I had to call out a couple of the softer spots, it probably would be the end markets where Tek is most exposed. And then probably secondarily, it would be on the Fluke side, probably the U.S. point-",63,"Well, there's certainly some broad-based weakness but if I had to call out a couple of the softer spots, it probably would be the end markets where Tek is most exposed. And then probably secondarily, it would be on the Fluke side, probably the U.S. point-of-sale has been a weaker spot here through the quarter. Those would be the 2 I'd probably highlight."
265621,329307690,960455,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Analysts","And you're expecting those to be little changed in Q2?",11,"And you're expecting those to be little changed in Q2?"
265621,329307690,960455,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","We are, that's right. There's no indication right now of a pickup there. Obviously, we can always be optimistic, but we are not projecting for any improvement there certainly in the second quarter.",33,"We are, that's right. There's no indication right now of a pickup there. Obviously, we can always be optimistic, but we are not projecting for any improvement there certainly in the second quarter."
265621,329307690,960455,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Operator","I would now like to turn the call back to Mr. Matt Gugino for any additional or closing remarks.",19,"I would now like to turn the call back to Mr. Matt Gugino for any additional or closing remarks."
265621,329307690,960455,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","Thanks, Issa. And thanks, everyone, for joining us. We're around all day for questions.",14,"Thanks, Issa. And thanks, everyone, for joining us. We're around all day for questions."
265621,329307690,960455,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Operator","Thank you, ladies and gentlemen. That will conclude today's conference call. You may now disconnect.",15,"Thank you, ladies and gentlemen. That will conclude today's conference call. You may now disconnect."
265621,329307690,960696,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Operator","My name is Issa, and I will be your conference facilitator today. At this time, I would like to welcome everyone to the Danaher Corporation First Quarter 2016 Earnings Results Conference Call. [Operator Instructions] I will now turn the call over to Mr.",56,"My name is Issa, and I will be your conference facilitator today. At this time, I would like to welcome everyone to the Danaher Corporation First Quarter 2016 Earnings Results Conference Call. [Operator Instructions] 
I will now turn the call over to Mr. Matt Gugino, Vice President of Investor Relations. Mr. Gugino, please begin your conference."
265621,329307690,960696,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","Thank you, Issa, and good morning, everyone, and thanks for joining us on the call. With us today are Tom Joyce, our President and Chief Executive Officer; and Dan Comas, our Executive Vice President and Chief Financial Officer. I like to point out that",335,"Thank you, Issa, and good morning, everyone, and thanks for joining us on the call. With us today are Tom Joyce, our President and Chief Executive Officer; and Dan Comas, our Executive Vice President and Chief Financial Officer. 
I like to point out that our earnings release, the slide presentation supplementing today's call, our first quarter Form 10-Q and the reconciliations and other information required by SEC Regulation G relating to any non-GAAP financial measures provided during the call are all available on the Investors section of our website, www.danaher.com under the heading Financial Information. The audio portion of this call will be archived on the Investors section of our website later today under the heading Events & Presentations and will remain archived until our next quarterly call. A replay of this call will also be available until April 28, 2016. The replay number is (888) 203-1112 within the U.S. or (719) 457-0820 outside the U.S., and the confirmation code is 4643245. 
During the presentation, we will describe certain of the more significant factors that impact the year-over-year performance. The supplemental materials describe additional factors that impacted year-over-year performance. 
Unless otherwise noted, all references in these remarks and supplemental materials to company-specific financial metrics relate to the continuing operations of the company in the first quarter of 2016 and all references to period-to-period increases or decreases in financial metrics are year-over-year. 
During the call, we will make forward-looking statements within the meaning of the federal securities laws, including statements regarding events or developments that we believe or anticipate will or may occur in the future. These forward-looking statements are subject to a number of risks and uncertainties, including those set forth in our SEC filings, and actual results might differ materially from any forward-looking statements that we make today. These forward-looking statements speak only as of the date that they are made, and we do not assume any obligation to update any forward-looking statements. 
With that, I'd like to turn the call over to Tom."
265621,329307690,960696,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","Thanks, Matt, and good morning, everyone. We're pleased with our start to 2016, as our team continued to outperform in the face of uncertain and challenging economic conditions. In the quarter, we delivered high teens earnings growth, healthy operating ma",2371,"Thanks, Matt, and good morning, everyone. We're pleased with our start to 2016, as our team continued to outperform in the face of uncertain and challenging economic conditions. In the quarter, we delivered high teens earnings growth, healthy operating margin expansion and free cash flow that was up over 50% year-on-year. The Danaher Business System remained the driving force behind our performance, equipping our team with the tools to strengthen our competitive position, the focus to invest in high-impact growth opportunities and the flexibility to position our businesses for long-term success. 
This will be an exciting year as we anticipate the upcoming launch of Fortive Corporation, which we expect to spin out of Danaher in the third quarter. Since our last update in January, we continue to build a highly experienced leadership team that named additional members to Fortive's Board of Directors. The team has also made great progress solidifying Fortive's financial, legal and organizational structures. This separation is a unique opportunity for Danaher and Fortive to optimize our respective portfolios and build long-term shareholder value. We look forward to sharing more information with you at our investor and analyst event in May at Gilbarco Veeder-Root.
Now turning to the details of the quarter. Adjusted diluted net EPS was $1.08, an increase of 18.5% over last year. Sales grew 15% to $5.4 billion, and core revenue increased 50 basis points, as the number of our businesses were negatively impacted by tough prior year comparisons and 1 less selling day. 
Clearly, the economic environment remains challenging in many verticals and geographies, but we were encouraged by signs of sales and order stabilization through the quarter. Our team's focus on portfolio optimization and diligent execution using DBS helped improve and sustain many of our market-leading positions. Finally, the impact of currency translation eased this quarter but still decreased revenues by 2%, while acquisitions increased revenues by 16.5%.
Geographically, the developed markets grew slightly, with stability in the U.S. and Europe. High-growth markets were up low single digits, as continued growth in India was offset by declines in Latin America and Russia. In China, our teams are well positioned to compete in several attractive markets and delivered mid-single-digit core growth in the quarter.
Gross margin for the first quarter was 53.1%, an increase of 50 basis points from last year. Along with the productivity initiatives undertaken in 2015, our gross margin expansion has enabled us to sustain and expand our growth investments in new product development and sales and marketing.
Core operating margin expanded 45 basis points, with reported operating margin at 16.4%. 
Free cash flow is one of the most important metrics at Danaher, as it provides us with the agility to invest in both organic and inorganic growth initiatives across our entire portfolio. We had a strong quarter on this front, generated -- generating $622 million of free cash flow, a significant increase over last year.
Coming off a historic year of M&A, we closed 6 bolt-on acquisitions in the first quarter, deploying over $100 million in capital. These deals will strengthen our capabilities across many of our businesses. Both Danaher and Fortive have strong and active funnels, and we'll continue to focus on small and midsize transactions for both companies through the separation process.
Now let's take a look at our 5 operating segments, starting with Test & Measurement. Revenues decreased 5.5%, with core revenues down 5%. Core operating margin decreased 135 basis points, with reported operating margin coming in at 20.9%. Core revenues for our Instruments platform declined high single digits as we continue to face a challenging global market environment. All major geographies saw declines, except for China and India. Fluke core revenues decreased mid-single digits due to declines in the U.S., Western Europe and Latin America, partially offset by increases in China. 
While still a difficult environment, we did see some signs of stabilization in certain geographies and industrial end markets during the quarter. A few weeks ago, Fluke announced the launch of the Fluke 279 FC Thermal Multimeter, the world's first test tool that integrates a full-featured digital multimeter with a thermal camera in one device. This combination enables technicians to check for hotspots on high-voltage equipment and analyze problems at a safe distance. By combining these important test tools into one, Fluke is helping our customers troubleshoot electrical issues more quickly, safely and thoroughly.
At Tektronix, core revenues declined low double digits, as growth in China and India was more than offset by declines in all other major geographies. 
The Matco team continued to execute well, delivering high single-digit core growth in the quarter. Notably, Matco has posted mid-single-digit growth or better for 23 of the last 25 quarters and continues to improve its market position. In February, Matco hosted its annual tool expo in Las Vegas. The expo provides Matco franchisees with an opportunity to see new products, attend training sessions and stock their businesses for the upcoming year. This year, almost 3/4 of Matco's franchisees participated, resulting in record attendance and event-driven sales.
Turning to our Environmental segment. Revenues grew 4%, with core revenues up 3.5%. Reported operating margin declined 220 basis points to 17.3%. Core operating margin declined 155 basis points and was negatively impacted by incremental investments, including EMV-related spend at Gilbarco Veeder-Root. We anticipate segment margins to return to more normalized levels in the second quarter. 
The Water Quality platform's core revenues grew slightly, as 1 less selling day and a tough prior year comparison had a negative impact. 
At Hach, positive momentum in the U.S. municipal market continued, but softness in high-growth markets resulted in flat core growth for the quarter. 
Trojan also saw strong municipal demand globally and delivered another good quarter. 
Finally, at ChemTreat, the team grew revenue slightly in the quarter despite headwinds in its industrial- and commodity-oriented markets. 
One of the ways that we continue to augment growth, build our capabilities and better serve our customers is through M&A. Our Water Quality platform has acquired more than 40 businesses since 1996 and continued its healthy cadence of bolt-ons this quarter, with Hach's acquisition of Lufft Mess in January. Lufft's long-standing precision centers -- long-lasting precision centers are a key part of weather-measuring networks along roads, railways and airports and enable us to deliver value to a wider range of customers around the world. The Hach team does an exceptional job of implementing DBS in newly acquired businesses, and this is well underway already at Lufft. DBS lean and growth tools are helping us drive more efficient production, strengthen key account relationships and improve funnel management.
At Gilbarco Veeder-Root, core revenue grew high single digits for the third consecutive quarter. EMV-related demand in the U.S. drove double-digit growth in point-of-sale solutions and dispenser systems, and we believe we continue to gain share on both fronts. Many of our customers are still in the process of upgrading indoor payment systems for last October's credit card liability shift. Additionally, we're well positioned to benefit from the upcoming outdoor liability shift, and the Gilbarco team is already collaborating with a number of customers to phase in outdoor upgrades. You'll hear more about EMV and GVR's other opportunities at our investor and analyst event next month.
Moving now to Life Sciences & Diagnostics. Core revenues grew 2.5%, with reported revenues up 42%, largely due to our recent Pall and Microscan acquisitions. Core operating margin expanded 205 basis points, thanks to the team's solid execution using DBS. Core revenues in our Diagnostics platform increased low single digits, led by healthy demand in high-growth markets. 
At Beckman Coulter, core revenue increased at a low single-digit rate. We saw strong demand for our immunoassay solutions and used our well-established installed base to help drive increased sales in India and China. 
Our consumable streams remain solid, and we're seeing healthy utilization rates globally. Radiometer and Leica Biosystems both increased core revenues in the quarter, with growth in China and India offset by declines in other high-growth markets. 
Our team is focused on improving our customers' experience every day and shows that commitment by expanding our product offering through both innovation and adjacent bolt-on acquisitions. Beckman Coulter's first major bolt-on, Iris, closed in 2012 and extended our footprint beyond blood testing in the urinalysis. Since then, Iris has delivered double-digit growth and expanded operating margins over 1,000 basis points. More recently, the acquisition of Microscan expanded Beckman's already strong presence in hospital and reference labs into the microbiology space. It has been 1 year since we closed the deal, and we achieved double-digit core revenue growth in the quarter. Both Iris and Microscan are helping us serve our customers better, and we believe that adjacent acquisitions, combined with our consistent application of DBS, will continue to enhance our comprehensive workflow solutions across our diagnostic businesses. 
In our Life Science platform, core revenue was up low single digits, with growth in both developed and high-growth markets. Leica Microsystems core revenues were up low single digits, as strong performance in North America and China was offset by declines in Japan and Latin America.
At SCIEX, core revenues grew low single digits, driven by demand in China and the Middle East. We also saw healthy sales growth in certain applied end markets and our service business. The SCIEX team has placed a strong focus on improving our customers' experience by pairing service contracts with instrument sales. This has driven record contract capture rates, including over 500 basis points of improvement in year-over-year attachment rates in the first quarter alone. 
SCIEX is a great example of how we use new products to help our customers' most critical challenges. In the quarter, we launched the x500R, the first model within our X-Series product family, which was the SCIEX team's largest ever development project. The x500R is a robust instrument that was specifically designed to serve customers in food and environmental testing labs, 2 of the fastest-growing end markets in mass spectrometry. Going forward, we expect this to be a significant contributor to our future growth.
Turning to Pall. We are very pleased with our early progress. This quarter, the Pall team delivered mid-single-digit core revenue growth led by double-digit growth in our Life Science business due to demand for our biopharmaceutical solutions, including single-use technologies. Our Industrial business was down low single digits as we faced challenging market conditions. The team's enthusiastic application of DBS, including over 100 kaizen events since close, has led to meaningful process improvements and several new product introduction across Pall's Life Sciences and Industrial businesses. As a result of our growth and productivity initiatives, year-on-year operating margins were up over 250 basis points. 
As we move on to Dental, core revenues increased by 0.5% due to strong demand for consumables and implants in North America and the high-growth markets as well as healthy orthodontic sales in China. These gains were negatively impacted by 1 less selling day. Over the last several quarters, the Dental team's focus on execution and disciplined spending has paid off in margin expansion. This quarter, the team grew core operating margins by 250 basis points and reported operating margins by over 500 basis points to 14.5%. Our continued investments in innovation have resulted in a number of differentiated product offerings for our Dental customers. At the Chicago Midwinter Dental Show in February, we launched over 15 new products, including Maxcem Elite Chroma, a revolutionary new cement for dental restoration that changes color to indicate the correct time for a dentist to remove any excess material. The first-in-class color indicator simplifies the dentist's procedure and reduces clinical risk.
At Nobel Biocare, the team drove mid-single-digit average daily sales of implant systems this quarter. Since the acquisition closed, Nobel has achieved over 400 basis points of operating margin improvement and is focused on reinvesting those savings into future growth opportunities.
Moving now to Industrial Technologies. Revenues declined 1.5%, while core revenues were also down 1.5%. Despite the revenue decline, core operating margin expanded 25 basis points, while reported operating margin declined 30 basis points to 24.3%. The Automation platform's core revenues decreased at a high single-digit rate due to the weakness in global industrial markets and a difficult prior year comparison. While we expect this dynamic to largely persist in the near term, we were encouraged by signs of stabilization in the quarter. 
Product Identification core revenues grew at a low single-digit rate, as increased demand for marking and coding was offset by softer demand for the businesses packaging and color solutions. 
Videojet's core revenues increased mid-single digits, driven by what we believe to be continuing share gains in North America and Europe, while high-growth markets remain softer. The Videojet team has delivered mid-single-digit growth or better for 9 of the past 10 quarters.
Last quarter, we announced the acquisition of Laetus, which extends our Product ID offerings into track and trace inspection systems for pharmaceutical packaging plants. We're off to a good start with Laetus. The team's early adoption of DBS tools is already driving key process improvements, as quicker service deployment and improved on-time delivery are ensuring that our customers receive the best possible support.
So to wrap up, our team executed well in the face of challenging economic conditions, and we're pleased with our start to 2016. The Danaher Business System remained the driving force behind our performance this quarter, helping to deliver high teens earnings growth, healthy operating margin expansion and 50% year-on-year free cash flow growth. We're also off to a great start at Pall, where the team drove meaningful process improvements and delivered mid-single-digit revenue growth in the quarter. We continue to make progress preparing for the launch of Fortive Corporation, which remains on track to close in the third quarter. Our teams are excited about the unique opportunity to continue developing 2 separate portfolios of market-leading businesses that we believe will create shareholder value for years to come.
We're initiating second quarter adjusted diluted net EPS guidance between $1.19 and $1.23, which assumes approximately 2% core revenue growth. We are increasing our full year adjusted EPS guidance from $4.80 to $4.95 to $4.85 to $4.98, which would represent a 13% to 16% increase from 2015 adjusted EPS."
265621,329307690,960696,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","Thanks, Tom. That concludes our formal remarks. Issa, we're now ready to take questions.",14,"Thanks, Tom. That concludes our formal remarks. Issa, we're now ready to take questions."
265621,329307690,960696,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Operator","[Operator Instructions] We will now take our first question from Scott Davis from Barclays.",14,"[Operator Instructions] We will now take our first question from Scott Davis from Barclays."
265621,329307690,960696,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Analysts","China was up. Bright spot, for you guys, and I know last quarter was -- I mean, it tracked pretty comparable last quarter as well, but it sounded like things may have firmed up a little bit. I mean, Fluke -- is Fluke or canary in the coal mine in China ha",76,"China was up. Bright spot, for you guys, and I know last quarter was -- I mean, it tracked pretty comparable last quarter as well, but it sounded like things may have firmed up a little bit. I mean, Fluke -- is Fluke or canary in the coal mine in China having that business back in positive territory for the quarter? I'm just -- maybe just a little color on what you guys are seeing there."
265621,329307690,960696,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","Sure. Thanks, Scott. China, unquestionably, is -- remains a very good market for us. Despite much of the headlines that would certainly suggest that they're slowing in various areas, we were very pleased with the performance in China. And I think it was r",242,"Sure. Thanks, Scott. China, unquestionably, is -- remains a very good market for us. Despite much of the headlines that would certainly suggest that they're slowing in various areas, we were very pleased with the performance in China. And I think it was relatively broad based. If you looked at Danaher versus Fortive, let's say, Danaher was up high single digits in China, and Fortive was up mid-single digits in China. So I think a number of good examples where China remains a very attractive market for us. Relative to your specific question on Fluke, Fluke is just -- is an exceptional business overall. We've had a -- it's probably one of our most advanced businesses in terms of both go-to market as well as local production and product development in China. And while there's clearly still some softness around various industrial segments in the Chinese market, Fluke is a very strong brand in that market and has a very strong share position. So I think we're encouraged by some of the stabilization we see in some of the markets. And in other of those markets, we just continue to see very strong growth. Our Dental business continues to perform exceptionally well in China. Life Sciences & Diagnostics, broadly continuing to perform well there. So again, while clearly the headlines would show that, that market has pulled back a little bit in the aggregate, it's still a very good place to be."
265621,329307690,960696,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Analysts","Okay. It's helpful, Tom. And then just wanted to ask where you stand in Pall versus the deal model. Help us -- now that we're a year in or so, I mean, give us a sense of how you -- what's working? What's not working? What -- Industrial is probably far wea",106,"Okay. It's helpful, Tom. And then just wanted to ask where you stand in Pall versus the deal model. Help us -- now that we're a year in or so, I mean, give us a sense of how you -- what's working? What's not working? What -- Industrial is probably far weaker than you thought it was, but the Environmental or the, I should say, the Life Sciences side is probably far stronger than you thought it would be. So how are you managing that variability? And how does it all really stack up at the end of the day versus what your prior expectations were?"
265621,329307690,960696,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","Scott, we're in a -- it's Dan. We're off to a very good start there. We had mid-single-digit growth in the quarter. As Tom alluded, that was a combination of double-digit growth in the Life Science side and a slight decline on the Industrial side. Clearly",150,"Scott, we're in a -- it's Dan. We're off to a very good start there. We had mid-single-digit growth in the quarter. As Tom alluded, that was a combination of double-digit growth in the Life Science side and a slight decline on the Industrial side. Clearly, that would have been a contributor to our overall organic growth at Danaher. From a margin perspective, we are ahead of schedule. We talked about north of $100 million of benefit here this year on the margin side, continue to track very well to the ultimate target of $300 million. In addition to this, we are getting favorable mix, given the Life Science business is more profitable, and we really saw that play out exceedingly well in the first quarter. It'll likely create some opportunities, where we'll be able to accelerate some investments here at Pall during this year, given we're tracking so well."
265621,329307690,960696,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","Just to follow on Dan's comment a little bit, the team at Pall has just done a tremendous job. It's -- as we've mentioned before, it's a great combination of both some seasoned Danaher leaders as well as an exceptional group of folks who have been at Pall",138,"Just to follow on Dan's comment a little bit, the team at Pall has just done a tremendous job. It's -- as we've mentioned before, it's a great combination of both some seasoned Danaher leaders as well as an exceptional group of folks who have been at Pall for a long time, who, together, have really brought DBS to life in that business in rapid fashion. You heard me mention about the 100 kaizens that have gone on. Those have gone on literally around the world. And it's just one indication of the rapid rate at which the Pall team has adopted the tools of DBS. And really, that has truly contributed to not only the growth dynamics that we're seeing, but certainly has assisted in us getting ahead on the cost takeouts in the margin side."
265621,329307690,960696,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Operator","Our next question comes from Steve Tusa from JPMorgan.",9,"Our next question comes from Steve Tusa from JPMorgan."
265621,329307690,960696,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Analysts","Just back to Pall, just a follow-up on that. I think they were doing a little bit better than $100 million in R&D a year. And R&D year-over-year was up I think about $20 million. Is that a little bit of a decline in the core R&D? Or are you kind of gettin",97,"Just back to Pall, just a follow-up on that. I think they were doing a little bit better than $100 million in R&D a year. And R&D year-over-year was up I think about $20 million. Is that a little bit of a decline in the core R&D? Or are you kind of getting efficiencies there on the Pall side? You also mentioned you're kind of walking away from some business there I think in your 10-Q at Pall. Could you just give us a degree of magnitude on that front? And then I have one quick follow-up."
265621,329307690,960696,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","Steve, on walking away some business, that's something that Pall had started prior even to our acquisition. It's down to a relatively nominal amount here and will be I think largely done by the middle of this year.",38,"Steve, on walking away some business, that's something that Pall had started prior even to our acquisition. It's down to a relatively nominal amount here and will be I think largely done by the middle of this year."
265621,329307690,960696,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Analysts","Okay. And then on the R&D front, what was kind of Pall's R&D? I think it was greater than $100 million. Are you guys getting more efficiencies there? Do you expect to maintain that R&D budget? Increase it?",38,"Okay. And then on the R&D front, what was kind of Pall's R&D? I think it was greater than $100 million. Are you guys getting more efficiencies there? Do you expect to maintain that R&D budget? Increase it?"
265621,329307690,960696,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","I would -- right now, we're sustaining. And I suspect over time, that will get increased.",16,"I would -- right now, we're sustaining. And I suspect over time, that will get increased."
265621,329307690,960696,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","Steve, I would just add to that. And I think we'd mentioned this maybe once before. But if you think back to the playbook that we ran post the Beckman acquisition, I think the playbook here at Pall is very similar, which is there's a number of opportuniti",197,"Steve, I would just add to that. And I think we'd mentioned this maybe once before. But if you think back to the playbook that we ran post the Beckman acquisition, I think the playbook here at Pall is very similar, which is there's a number of opportunities to get cost out of the business broadly defined, and we're working on those obviously, start to see the margins coming up. But the playbook is to then redeploy some of that cost takeout into investments in sales and marketing and R&D. You see us do that broadly across Danaher with gross margins going up and sales and marketing and R&D on the quarter for the Danaher in total up 30 basis points. We did that at Pall -- at Beckman. R&D lifted over time. We started to get the innovation engine going. Innovation at Pall has always been a strong suit there, but we think we can take it up another level. And so some of those cost takeouts will ultimately translate into either higher spending or potentially more efficient spending as we find opportunities to do a better job innovating at the same cost rate. We'll see."
265621,329307690,960696,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Analysts","Okay. And then just lastly on the free cash flow, a very strong quarter. Obviously, you're paying down some debt, beginning to delever here a little bit. Is there anything about the timing of that free cash flow? Or should we think about kind of normal se",83,"Okay. And then just lastly on the free cash flow, a very strong quarter. Obviously, you're paying down some debt, beginning to delever here a little bit. Is there anything about the timing of that free cash flow? Or should we think about kind of normal seasonality off of that base? I know there were some accruals year-over-year. Accruals were less of a drag. Maybe there's just some timing. What's -- maybe bottom line is, what's kind of the annual free cash guide?"
265621,329307690,960696,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","Well, Steve, we don't give a specific guide, but we're off to a very good start. There was a little bit of timing benefit around some tax payments. But broadly, our cash flow was quite strong. As you know, we ended last year with a record number and a ver",85,"Well, Steve, we don't give a specific guide, but we're off to a very good start. There was a little bit of timing benefit around some tax payments. But broadly, our cash flow was quite strong. As you know, we ended last year with a record number and a very strong second half of free cash flow. We expect that trend to continue. We're not going to be up 40% year-on-year, but we'd expect a very healthy double-digit increase in free cash flow this year."
265621,329307690,960696,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","Our first quarter last year was [indiscernible].",7,"Our first quarter last year was [indiscernible]."
265621,329307690,960696,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","And we were a little bit light.",7,"And we were a little bit light."
265621,329307690,960696,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","A little lighter last first quarter, so a little bit of benefit there from a comp standpoint.",17,"A little lighter last first quarter, so a little bit of benefit there from a comp standpoint."
265621,329307690,960696,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Operator","Our next question comes from Nigel Coe from Morgan Stanley.",10,"Our next question comes from Nigel Coe from Morgan Stanley."
265621,329307690,960696,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Analysts","Tom, so you mentioned you're seeing signs of stability. I think that was in relation to Fluke, specifically. But maybe just broaden that to the conversation to maybe some of the more typical businesses within Industrial Tech, Tektronix. What are you seein",51,"Tom, so you mentioned you're seeing signs of stability. I think that was in relation to Fluke, specifically. But maybe just broaden that to the conversation to maybe some of the more typical businesses within Industrial Tech, Tektronix. What are you seeing today compared to what you saw back in January?"
265621,329307690,960696,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","Sure. Thanks, Nigel. Our comments about stability were not exclusively associated with Fluke. In fact, I think there are some pockets even around the Fluke business, where we've seen stability, but we've also seen still some real headwinds. But I think we",211,"Sure. Thanks, Nigel. Our comments about stability were not exclusively associated with Fluke. In fact, I think there are some pockets even around the Fluke business, where we've seen stability, but we've also seen still some real headwinds. But I think we have seen stability in some other areas. You asked specifically about -- on the Industrial Tech side. The Automation businesses, our Sensors and Controls businesses, as we looked at those throughout the course of the quarter, February and March, we saw indications of stability. We saw those order rates kind of firm up a little bit. And while we wouldn't call it an upward trajectory, we would call those a bit more stable than we had seen in the trajectory of the fourth quarter and maybe at the very opening of the year. You mentioned Tektronix. I wouldn't necessarily put Tektronix quite in that category yet. It had one of the more challenging quarters. It's in one of the tougher markets probably that we face today. And so I think while we're very encouraged by the new product flow at Tektronix and we expect to see that -- those new products drive some improved performance in the back half of the year, Tek remains in a pretty challenging environment."
265621,329307690,960696,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Analysts","Okay, that's helpful. And then switching to Environmental margins. Obviously, a lot of noise this quarter. You called out investment spending. I'm wondering if you can maybe help us size that impact. And it seems that this quarter, you had a negative mix",64,"Okay, that's helpful. And then switching to Environmental margins. Obviously, a lot of noise this quarter. You called out investment spending. I'm wondering if you can maybe help us size that impact. And it seems that this quarter, you had a negative mix of consumables versus GVR growth. Is that true? And would you expect that to normalize over the balance of the year?"
265621,329307690,960696,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","Well, I'll need you to clarify that last question. I'm not exactly sure what you meant by negative mix relative to GVR growth, unless you're talking about Water Quality versus GVR within Environmental. Is that what [indiscernible]?",37,"Well, I'll need you to clarify that last question. I'm not exactly sure what you meant by negative mix relative to GVR growth, unless you're talking about Water Quality versus GVR within Environmental. Is that what [indiscernible]?"
265621,329307690,960696,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Analysts","Exactly [indiscernible] GVR margin, yes.",5,"Exactly [indiscernible] GVR margin, yes."
265621,329307690,960696,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","Okay, sure, yes. No, absolutely right. Yes, thanks, Nigel. That's -- you're right on. If you look at Environmental, which, as all of you know, both has our GVR business as well as our Water Quality businesses, GVR had stronger growth during the course of",223,"Okay, sure, yes. No, absolutely right. Yes, thanks, Nigel. That's -- you're right on. If you look at Environmental, which, as all of you know, both has our GVR business as well as our Water Quality businesses, GVR had stronger growth during the course of the quarter, very encouraging signs of the EMV dynamic taking hold. And GVR comes through that with a lower margin mix relative to our Water Quality platform, which has higher margins and specifically, Hach. So a little bit softer Hach business, a little bit stronger GVR business during the course of the quarter together causes some of that headwind that you saw on the margin line there. The reference to investment spend is specific to what we need to do to build the capacity to step up to the demand associated with EMV. And so we see that in -- specifically in our GVR business. And those are investments that clearly will pay off as we continue to ramp our capabilities. And as we go into the second quarter and beyond, we would expect those margins overall in the segment to return closer to normal levels. Obviously, some continued investment there, but we expect Water Quality to come up a bit. So overall, I think there were just a couple of unique factors here in the first quarter."
265621,329307690,960696,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Operator","Our next question comes from Shannon O'Callaghan from UBS.",10,"Our next question comes from Shannon O'Callaghan from UBS."
265621,329307690,960696,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Analysts","Tom, you mentioned execution and disciplined spending at Dental with the big margin improvement there. I mean, that's a segment that you've always targeted getting to much higher margins over the year. It's been more of a challenge. I mean, is this someth",57,"Tom, you mentioned execution and disciplined spending at Dental with the big margin improvement there. I mean, that's a segment that you've always targeted getting to much higher margins over the year. It's been more of a challenge. I mean, is this something of a breakthrough here? Or how should we read the performance on those comments?"
265621,329307690,960696,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","Well, you're absolutely right, Shannon. It's been a challenge in the past. And we did set our sights and commit to making a difference there. We have some new leadership in place over the platform. Many of you have met Amir Aghdaei, who's lead a number of",208,"Well, you're absolutely right, Shannon. It's been a challenge in the past. And we did set our sights and commit to making a difference there. We have some new leadership in place over the platform. Many of you have met Amir Aghdaei, who's lead a number of our businesses over the last several years and some of our more challenging businesses. And he's really put a terrific team together. They've set their sights on specific margin improvements over time. There was some outstanding execution, some disciplined cost control. But similar to the comments I made earlier around the playbook, I made reference to the Beckman playbook and how that applies to Pall, while we'll continue to drive margin improvement at Dental, one of the team's leadership, we'll also take some of that improvement and continue to invest in sales and marketing and in R&D because we do have opportunities for improvement in terms of our innovation cadence. We saw some modest improvement there in our core growth and the platform during the quarter, but we know there's opportunities to continue to improve that. We expect it to continue to step up. But some additional investment over time with some of that cost takeout will certainly be a help."
265621,329307690,960696,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Analysts","Okay, great. And then, Dan, maybe a question for you on tax. Obviously, a lot of new tax policies being contemplated and put into place that impact a lot of multinationals. Any -- just thoughts on that in general and potential impacts on Danaher as well a",63,"Okay, great. And then, Dan, maybe a question for you on tax. Obviously, a lot of new tax policies being contemplated and put into place that impact a lot of multinationals. Any -- just thoughts on that in general and potential impacts on Danaher as well as how should we think about kind of the 2 NewCo tax rates and any differentials there?"
265621,329307690,960696,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","Sure, Shannon. Yes, obviously, it's something we're spending a lot of time on trying to understand better. I mean, our initial read of this is this is not going to be an impact to us -- a material impact to us in the near term. That over time, we could se",169,"Sure, Shannon. Yes, obviously, it's something we're spending a lot of time on trying to understand better. I mean, our initial read of this is this is not going to be an impact to us -- a material impact to us in the near term. That over time, we could see some rate creep because of it. Now that assumes nothing else happens and there's no other opportunities. And so sitting here right now, it's not something that worries us a great deal, but it's obviously a potential risk kind of going forward. I don't think there's a big change in how we think about the tax rates of the 2 entities. We've talked about Fortive likely coming out closer to kind of a high-20 tax rate. Again, I think as they begin to do some acquisitions, they'll have an opportunity to bring that down. And I would expect that Danaher would be at our current rate or lower. Danaher RemainCo would be at our current rate or lower."
265621,329307690,960696,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Operator","Our next question comes from Steven Winoker from Bernstein.",9,"Our next question comes from Steven Winoker from Bernstein."
265621,329307690,960696,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Analysts","Could you maybe just clarify? You talked about Fortive versus Danaher core growth in China. What was it globally for the quarter?",22,"Could you maybe just clarify? You talked about Fortive versus Danaher core growth in China. What was it globally for the quarter?"
265621,329307690,960696,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","The Danaher was up a couple points, and Fortive was down 1 to 2 points, 1.5%, I believe.",18,"The Danaher was up a couple points, and Fortive was down 1 to 2 points, 1.5%, I believe."
265621,329307690,960696,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Analysts","Okay. And, well, I guess everybody, what are you thinking about in terms of current thinking, I should say, on capital structure for the 2 entities? Were you still heading for that -- I know there have been some private conversations, but don't have a sen",51,"Okay. And, well, I guess everybody, what are you thinking about in terms of current thinking, I should say, on capital structure for the 2 entities? Were you still heading for that -- I know there have been some private conversations, but don't have a sense for where that is now."
265621,329307690,960696,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","I don't think much has changed versus what we communicated a year ago. We would expect Fortive to come out as an investment-grade company. Likely not -- they're not going to be an A-rated company, but a triple -- something in the BBB range, where they wou",62,"I don't think much has changed versus what we communicated a year ago. We would expect Fortive to come out as an investment-grade company. Likely not -- they're not going to be an A-rated company, but a triple -- something in the BBB range, where they would be strong investment-grade and clearly have a fair amount of latitude to execute M&A."
265621,329307690,960696,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Analysts","Okay, great. And if I could just -- one word. Tom, in terms of the R&D profile, I know you talked a little bit about it before, specifically with Pall. But I guess, overall, for the company, where is -- what level of R&D are we talking about for just -- f",79,"Okay, great. And if I could just -- one word. Tom, in terms of the R&D profile, I know you talked a little bit about it before, specifically with Pall. But I guess, overall, for the company, where is -- what level of R&D are we talking about for just -- for the new Danaher going forward? And do you see an opportunity to accelerate that at all as you think about also accelerating core growth in new Danaher?"
265621,329307690,960696,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","Sure. Thanks, Steve. I've said for a long time, I've always believed that there's no magic number for a business with the diverse portfolio that we have today. We really look at continuing to invest in R&D to certain levels, specifically at an operating c",216,"Sure. Thanks, Steve. I've said for a long time, I've always believed that there's no magic number for a business with the diverse portfolio that we have today. We really look at continuing to invest in R&D to certain levels, specifically at an operating company level. And that's obviously relevant for what -- relative to what's important to those markets, what's important for our competitiveness, what yields the greatest levels of competitive advantage from an innovation perspective. So we really look at it sort of operating company by operating company. Our track record is a great one, and it will continue of taking R&D up year-on-year pretty consistently. We've used our operating margin expansion that's been driven by improvements in gross margin to put some of that back into not only R&D, but into sales and marketing as well. And again, we've done that very consistently. I would expect that we will continue to do that. One of our 5 core values is Innovation Defines Our Future, and we represent that in our metrics by continuing to see that percent of R&D go up year-on-year. So again, it'll vary in terms of the number that we achieve year-on-year by operating company or even by platform, but using innovation to drive competitiveness is key to our strategy."
265621,329307690,960696,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Analysts","Okay. But what was it in the quarter, at least, just for the current -- or for the new Danaher?",20,"Okay. But what was it in the quarter, at least, just for the current -- or for the new Danaher?"
265621,329307690,960696,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","Probably in the same -- Steve, we have the dynamic around Pall where a lot of the application expertise they bring to their customers, which is a big part of their value add, they include in sales and marketing than R&D. So the fact that you saw R&D as a",109,"Probably in the same -- Steve, we have the dynamic around Pall where a lot of the application expertise they bring to their customers, which is a big part of their value add, they include in sales and marketing than R&D. So the fact that you saw R&D as a percent of our overall revenues go down 40, 50 basis points year-on-year, that's entirely driven by the Pall dynamic. But I would say, Danaher is probably in that zone where you've got some higher R&D businesses. But because of the way Pall accounts for their R&D, it probably averages to where Danaher is today around that 6% percent range."
265621,329307690,960696,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Operator","Our next question comes from Ross Muken from Evercore ISI.",10,"Our next question comes from Ross Muken from Evercore ISI."
265621,329307690,960696,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Analysts","Maybe on the Life Science business, just a little bit more color commentary. You called out pharma as sort of a strong end market. It seems like on the SCIEX side that market has been running hot for a while. I mean, how do you see the trajectory there? A",100,"Maybe on the Life Science business, just a little bit more color commentary. You called out pharma as sort of a strong end market. It seems like on the SCIEX side that market has been running hot for a while. I mean, how do you see the trajectory there? And then secondarily on the Pall side, biotech, there's obviously been a lot of concern in the market, particularly with the smaller companies on funding and the like. And have you seen anything in that side of the business, particularly with small to midsize biotechs in terms of any relevant slowdown?"
265621,329307690,960696,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","Thanks, Ross. Yes, no question, the pharma market is an important driver of our growth across the Life Science portfolio. And we have exposure to that growing market across virtually every one of our Life Science businesses. Pall, specific to your questio",224,"Thanks, Ross. Yes, no question, the pharma market is an important driver of our growth across the Life Science portfolio. And we have exposure to that growing market across virtually every one of our Life Science businesses. Pall, specific to your question around biotech and small and midsize, continues to perform exceptionally well across the biotech market. Just to go back and talk about a few things about what's going on in that market, Pall has a $1 billion business today that's oriented toward biopharmaceuticals. And the combination of the solutions that they've had for a number of years, along with the newer products and single-use technologies, continue to drive the exceptional growth that we see there. That growth, as I think many of you know, Ross, and others know, is really driven by this move, the growth and the transition from small molecule drugs to large molecule drugs. And not only are those the fastest-growing segment of the market, but they're also the drugs that are most significantly represented in the pipelines of both small as well as large pharmaceutical companies today. So we remain optimistic and bullish on that market. And I think there's every reason to believe that we'll continue to see good growth not only from Pall, but from our other Life Science business that have exposure to that market."
265621,329307690,960696,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Analysts","Great. And maybe just quickly on the capital allocation side. So a lot of equity market volatility to start the year. Private equity has probably been more of a net seller than buyer. I mean, how has it sort of impacted asset prices on the private side in",130,"Great. And maybe just quickly on the capital allocation side. So a lot of equity market volatility to start the year. Private equity has probably been more of a net seller than buyer. I mean, how has it sort of impacted asset prices on the private side in terms of what you're looking at? And does it make sellers more apt to maybe approach a process, given they saw equity prices up, down, up again, maybe they're afraid they go down again and so they want to take advantage of maybe an open and the sort of credit markets where larger companies can acquire? I mean, just trying to get a feel for kind of how all this volatility had maybe helped you a little bit on the deal front."
265621,329307690,960696,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","I mean, volatility is a net positive for us as a well-capitalized acquirer. Your comment about private equity, it's getting a little better for them, but it's -- the leverage markets are still pretty tough. So I think all those factors play to our benefit",80,"I mean, volatility is a net positive for us as a well-capitalized acquirer. Your comment about private equity, it's getting a little better for them, but it's -- the leverage markets are still pretty tough. So I think all those factors play to our benefit. Now granted there are other -- a number of other well-capitalized corporate player here, but we're happy to sort of compete in this sort of environment, where there's a little bit more volatility and uncertainty."
265621,329307690,960696,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Operator","Next question comes from Jeffrey Sprague from Vertical Research Partners.",10,"Next question comes from Jeffrey Sprague from Vertical Research Partners."
265621,329307690,960696,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Analysts","Just a couple. First on SG&A, I guess, Dan, you kind of partially answered it speaking to the Pall R&D. But the SG&A moving up as a percent of sales, is there anything to flag there? And do you expect that sort of upward pressure over the balance of the y",51,"Just a couple. First on SG&A, I guess, Dan, you kind of partially answered it speaking to the Pall R&D. But the SG&A moving up as a percent of sales, is there anything to flag there? And do you expect that sort of upward pressure over the balance of the year?"
265621,329307690,960696,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","Well, you -- if we first just take Pall out of the equation entirely, R&D as a percent of sales was flat year-on-year, but sales and marketing was up 30 basis points, and that was intentional. I mean, we've stepped up some investments. We've talked about",175,"Well, you -- if we first just take Pall out of the equation entirely, R&D as a percent of sales was flat year-on-year, but sales and marketing was up 30 basis points, and that was intentional. I mean, we've stepped up some investments. We've talked about some of the opportunities in high-growth markets, where we see people pulling back and we see there was some opportunity. I think some of the success Fortive is having in China right now is probably a little bit of an example of that. And Pall brings in a pretty high sales and marketing expense when you kind of layer that in. That probably sustains itself. We see that as an important part of their go-to market -- not only their go-to market, but, as I mentioned also, sort of part of their R&D as well. So we don't see ourselves sort of cutting back on those investments. If anything, given we've had a little bit more strength here early in the year, we may step some of that up."
265621,329307690,960696,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Analysts","And on tax, you mentioned creep and maybe there could be some offsets. Have you guys looked at this FASB change on stock comp and determined what, if any, benefit you'll have when you choose to adopt that?",38,"And on tax, you mentioned creep and maybe there could be some offsets. Have you guys looked at this FASB change on stock comp and determined what, if any, benefit you'll have when you choose to adopt that?"
265621,329307690,960696,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","We don't think it'd be meaningful.",7,"We don't think it'd be meaningful."
265621,329307690,960696,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Analysts","And then just finally, the 6 small deals, were any of those in Fortive? And if so, what?",18,"And then just finally, the 6 small deals, were any of those in Fortive? And if so, what?"
265621,329307690,960696,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","One was Fortive.",3,"One was Fortive."
265621,329307690,960696,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Analysts","What kind of asset?",4,"What kind of asset?"
265621,329307690,960696,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","It was an acquisition for Gilbarco.",6,"It was an acquisition for Gilbarco."
265621,329307690,960696,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","And that's on top of a couple more we did late last year. So in the last 4, 5 months, it's 3 deals, Jeff.",25,"And that's on top of a couple more we did late last year. So in the last 4, 5 months, it's 3 deals, Jeff."
265621,329307690,960696,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Operator","Our next question comes from Deane Dray from RBC.",9,"Our next question comes from Deane Dray from RBC."
265621,329307690,960696,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Analysts","Just like to go back to the 2016 guide. And just to clarify, has there been any change to the core revenue outlook for 2% to 3%? And then maybe a bit on the cadence of that through the year and how might that split with Fortive?",47,"Just like to go back to the 2016 guide. And just to clarify, has there been any change to the core revenue outlook for 2% to 3%? And then maybe a bit on the cadence of that through the year and how might that split with Fortive?"
265621,329307690,960696,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","Deane, no real change to our view of the full year, 2% to 3%. I think our comments referring to some stabilization that we've seen here in the last couple of months I think suggest -- as well as, by the way, how that was represented in the order rates, no",84,"Deane, no real change to our view of the full year, 2% to 3%. I think our comments referring to some stabilization that we've seen here in the last couple of months I think suggest -- as well as, by the way, how that was represented in the order rates, not just the sellout, but the order rates in the last couple of months, suggest that we still feel pretty good about the 2% to 3%. So I think we're going to stay there."
265621,329307690,960696,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Analysts","And how about the expectations for Fortive in the second quarter?",11,"And how about the expectations for Fortive in the second quarter?"
265621,329307690,960696,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","We would expect that Fortive would be in the same zone, maybe a little bit better. Danaher ex Fortive would be slightly better, and that would roll up to be approximately 2% versus the 0.5% of core we delivered in the first quarter.",43,"We would expect that Fortive would be in the same zone, maybe a little bit better. Danaher ex Fortive would be slightly better, and that would roll up to be approximately 2% versus the 0.5% of core we delivered in the first quarter."
265621,329307690,960696,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Analysts","Great. And then maybe some clarification on Hach. The softness in the high-growth markets, is there anything specific there? Is it tougher comps? Why might there be some slowing there?",30,"Great. And then maybe some clarification on Hach. The softness in the high-growth markets, is there anything specific there? Is it tougher comps? Why might there be some slowing there?"
265621,329307690,960696,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","Well, it certainly was a very challenging comp year-on-year. The platform, overall, I think comp did 10% versus last year, Deane. So it was probably among the platforms that we have -- it was probably the toughest comp perhaps across the entire corporatio",147,"Well, it certainly was a very challenging comp year-on-year. The platform, overall, I think comp did 10% versus last year, Deane. So it was probably among the platforms that we have -- it was probably the toughest comp perhaps across the entire corporation. So that was certainly a challenge. We have seen some delays in some key projects in a couple of the high-growth markets. So that was certainly a factor there. In certain of those high-growth markets, we actually have a little bit more industrial exposure than purely municipal exposure. And that, obviously, had an impact in those markets. Again, we don't -- that business, you know it well, Deane, is just one of our exceptional franchises. And we're confident that business continues to -- will continue to grow over time, and we'll see that business as core growth rate improve here in the second quarter."
265621,329307690,960696,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Analysts","Great. And then just last one, and still on the topic of Hach. I don't recall ever there being a time where Water Quality has been more front page news in the U.S. with Flint, Michigan. And just -- what's your expectation about the longer-term implication",56,"Great. And then just last one, and still on the topic of Hach. I don't recall ever there being a time where Water Quality has been more front page news in the U.S. with Flint, Michigan. And just -- what's your expectation about the longer-term implications on water quality, water test? And how is Hach positioned?"
265621,329307690,960696,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","Sure. Well, believe me, we wish we had an answer today to the infrastructure challenges that lead pipes represent in that situation. It's just terrible to see the challenges that, that community has gone through. But I think if we try to look on the brigh",141,"Sure. Well, believe me, we wish we had an answer today to the infrastructure challenges that lead pipes represent in that situation. It's just terrible to see the challenges that, that community has gone through. But I think if we try to look on the bright side from the standpoint of the overall market dynamics, situations like that always turn the spotlight up on the importance of regulatory oversight in municipalities around the country and frankly, throughout the world. And so as those regulatory drivers continue to be strengthened, to be pointed at the greatest vulnerabilities in municipal and industrial systems, that, again, while challenging for those communities, ultimately benefits consumers and certainly benefits us. Regulatory drivers have always been a key macro driver for that platform, and they will continue to be so for as long as we could anticipate."
265621,329307690,960696,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Operator","Our next question comes from Andrew Obin from Bank of America Merrill Lynch.",13,"Our next question comes from Andrew Obin from Bank of America Merrill Lynch."
265621,329307690,960696,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Analysts","I guess in the Q, you sort of indicated that you're still on track to pay the $3 billion dividend from Fortive to Danaher. Is there any flexibility around that number if Fortive discovers a good acquisition? How flexible are you there?",42,"I guess in the Q, you sort of indicated that you're still on track to pay the $3 billion dividend from Fortive to Danaher. Is there any flexibility around that number if Fortive discovers a good acquisition? How flexible are you there?"
265621,329307690,960696,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","Well, that's something obviously the board would need to determine depending on obviously the size of the acquisition in there, what else they have in the pipeline.",27,"Well, that's something obviously the board would need to determine depending on obviously the size of the acquisition in there, what else they have in the pipeline."
265621,329307690,960696,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Analysts","But it's fair to assume that there's some flexibility there?",11,"But it's fair to assume that there's some flexibility there?"
265621,329307690,960696,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","Nothing set until it's set.",6,"Nothing set until it's set."
265621,329307690,960696,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Analysts","And then just going back to GVR. The EMV investment and both growth and investment, is it fair to assume that investment is going to be front-end loaded Q1 and Q2, but you might see growth throughout the year? Is that the right way of thinking about it?",48,"And then just going back to GVR. The EMV investment and both growth and investment, is it fair to assume that investment is going to be front-end loaded Q1 and Q2, but you might see growth throughout the year? Is that the right way of thinking about it?"
265621,329307690,960696,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","Yes. There's clearly some upfront cost. And as Tom alluded, we also had some onetime items in the quarter, and that will normalize as we get through the year.",29,"Yes. There's clearly some upfront cost. And as Tom alluded, we also had some onetime items in the quarter, and that will normalize as we get through the year."
265621,329307690,960696,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Operator","We'll now take our next question from Julian Mitchell from Crdit Suisse.",13,"We'll now take our next question from Julian Mitchell from Crdit Suisse."
265621,329307690,960696,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Analysts","Just a question on Dental first. The growth rate was, I guess, lower than I thought, particularly as Nobel should have automatically pushed up the organic growth a little bit and the comp was pretty easy. So I saw you called out Middle East and Africa equ",70,"Just a question on Dental first. The growth rate was, I guess, lower than I thought, particularly as Nobel should have automatically pushed up the organic growth a little bit and the comp was pretty easy. So I saw you called out Middle East and Africa equipment, but I wouldn't have thought that was a very sizable piece of the business. So maybe just give a bit more color there."
265621,329307690,960696,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","Sure. Well, our Dental growth, overall, Julian, was -- at 0.5% was basically in line with our expectations, modest improvement from where we'd been over the last few quarters. And obviously, as we talked just a few minutes ago, we're very pleased with see",216,"Sure. Well, our Dental growth, overall, Julian, was -- at 0.5% was basically in line with our expectations, modest improvement from where we'd been over the last few quarters. And obviously, as we talked just a few minutes ago, we're very pleased with seeing the OMX up at the rate that I talked about earlier. We saw solid low single-digit growth in consumables, and sellout continues and actually is a fraction better than even our sell-in. So we always look at that sellout. We have good transparency with our distribution partners, and we're encouraged by that. The Nobel implant systems business, mid-single-digit average daily sales growth in the quarter, we're pleased with that. The Ormco business, the orthodontic business, continues to do well. And we're continuing to see on a geographic basis, as I mentioned, the -- a couple of the high-growth markets, specifically the -- our business in China, continuing to do well. On the flip side, on the equipment side, we have seen some challenges in Europe actually and a couple in those high-growth markets, where the equipment side has been held back a little bit more significantly. So I think as we annualize over some of those more challenging comps, we'll continue to see that growth improve during the course of this year."
265621,329307690,960696,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Analysts","Got it. And then secondly, just on Test & Measurement. I wondered -- obviously, the trends year-on-year are sort of similar Q1 as in Q4. I wondered if there was any specific end market you'd call out that's sort of dragging on the growth now. Obviously, y",68,"Got it. And then secondly, just on Test & Measurement. I wondered -- obviously, the trends year-on-year are sort of similar Q1 as in Q4. I wondered if there was any specific end market you'd call out that's sort of dragging on the growth now. Obviously, you do have some electronics exposure, for example, in T&M. Or if you thought it was sort of fairly broad-based, the weakness."
265621,329307690,960696,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","Well, there's certainly some broad-based weakness. But if I had to call out a couple of the softer spots, it probably would be the end markets where Tek is most exposed. And then probably secondarily, it would be in -- on the Fluke side. Probably, the U.S",65,"Well, there's certainly some broad-based weakness. But if I had to call out a couple of the softer spots, it probably would be the end markets where Tek is most exposed. And then probably secondarily, it would be in -- on the Fluke side. Probably, the U.S. point-of-sale has been a weaker spot here through the quarter. Those would be the 2 I'd probably highlight."
265621,329307690,960696,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Analysts","And you're expecting those to be little changed in Q2?",11,"And you're expecting those to be little changed in Q2?"
265621,329307690,960696,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","We are, that's right. There's no indication right now of a pickup there. Obviously, we can always be optimistic, but we're not projecting for any improvement there certainly in the second quarter.",32,"We are, that's right. There's no indication right now of a pickup there. Obviously, we can always be optimistic, but we're not projecting for any improvement there certainly in the second quarter."
265621,329307690,960696,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Operator","I would now like to turn the call back to Mr. Matt Gugino for any additional or closing remarks.",19,"I would now like to turn the call back to Mr. Matt Gugino for any additional or closing remarks."
265621,329307690,960696,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","Thanks, Issa, and thanks, everyone, for joining us. We're around all day for questions.",14,"Thanks, Issa, and thanks, everyone, for joining us. We're around all day for questions."
265621,329307690,960696,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Operator","Thank you, ladies and gentlemen. That will conclude today's conference call. You may now disconnect.",15,"Thank you, ladies and gentlemen. That will conclude today's conference call. You may now disconnect."
265621,329307690,960821,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Operator","My name is Issa, and I will be your conference facilitator today. At this time, I would like to welcome everyone to the Danaher Corporation First Quarter 2016 Earnings Results Conference Call. [Operator Instructions]   I will now turn the call over to",56,"My name is Issa, and I will be your conference facilitator today. At this time, I would like to welcome everyone to the Danaher Corporation First Quarter 2016 Earnings Results Conference Call. [Operator Instructions] 
 
 I will now turn the call over to Mr. Matt Gugino, Vice President of Investor Relations. Mr. Gugino, please begin your conference."
265621,329307690,960821,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","Thank you, Issa, and good morning, everyone, and thanks for joining us on the call. With us today are Tom Joyce, our President and Chief Executive Officer; and Dan Comas, our Executive Vice President and Chief Financial Officer.   I'd like to point ou",334,"Thank you, Issa, and good morning, everyone, and thanks for joining us on the call. With us today are Tom Joyce, our President and Chief Executive Officer; and Dan Comas, our Executive Vice President and Chief Financial Officer. 
 
 I'd like to point out that our earnings release, the slide presentation supplementing today's call, our first quarter Form 10-Q and the reconciliations and other information required by SEC Regulation G relating to any non-GAAP financial measures provided during the call are all available on the Investors section of our website, www.danaher.com, under the heading Financial Information. The audio portion of this call will be archived on the Investors section of our website later today under the heading Events & Presentations and will remain archived until our next quarterly call. A replay of this call will also be available until April 28, 2016. The replay number is (888) 203-1112 within the U.S. or (719) 457-0820 outside the U.S., and the confirmation code is 4643245. 
 
 During the presentation, we will describe certain of the more significant factors that impacted year-over-year performance. The supplemental materials describe additional factors that impacted year-over-year performance. 
 
 Unless otherwise noted, all references in these remarks and supplemental materials to company-specific financial metrics relate to the continuing operations of the company in the first quarter of 2016, and all references to period-to-period increases or decreases in financial metrics are year-over-year. 
 
 During the call, we will make forward-looking statements within the meaning of the federal securities laws, including statements regarding events or developments that we believe or anticipate will or may occur in the future. These forward-looking statements are subject to a number of risks and uncertainties, including those set forth in our SEC filings, and actual results might differ materially from any forward-looking statements that we make today. These forward-looking statements speak only as of the date that they are made, and we do not assume any obligation to update any forward-looking statements. 
 
 With that, I'd like to turn the call over to Tom."
265621,329307690,960821,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","Thanks, Matt, and good morning, everyone. We're pleased with our start to 2016, as our team continued to outperform in the face of uncertain and challenging economic conditions. In the quarter, we delivered high teens earnings growth, healthy operating ma",2368,"Thanks, Matt, and good morning, everyone. We're pleased with our start to 2016, as our team continued to outperform in the face of uncertain and challenging economic conditions. In the quarter, we delivered high teens earnings growth, healthy operating margin expansion and free cash flow that was up over 50% year-on-year. The Danaher Business System remains the driving force behind our performance, equipping our team with the tools to strengthen our competitive position, the focus to invest in high-impact growth opportunities and the flexibility to position our businesses for long-term success. 
 
 This will be an exciting year as we anticipate the upcoming launch of Fortive Corporation, which we expect to spin out of Danaher in the third quarter. Since our last update in January, we've continued to build a highly experienced leadership team that named additional members to Fortive's Board of Directors. The team has also made great progress solidifying Fortive's financial, legal and organizational structures. This separation is a unique opportunity for Danaher and Fortive to optimize our respective portfolios and build long-term shareholder value. We look forward to sharing more information with you at our investor and analyst event in May at Gilbarco Veeder-Root.
 
 Now turning to the details of the quarter. Adjusted diluted net EPS was $1.08, an increase of 18.5% over last year. Sales grew 15% to $5.4 billion, and core revenue increased 50 basis points, as a number of our businesses were negatively impacted by tough prior year comparisons and 1 less selling day. 
 
 Clearly, the economic environment remains challenging in many verticals and geographies, but we were encouraged by signs of sales and order stabilization through the quarter. Our team's focus on portfolio optimization and diligent execution using DBS helped improve and sustain many of our market-leading positions. Finally, the impact of currency translation eased this quarter but still decreased revenues by 2%, while acquisitions increased revenues by 16.5%.
 
 Geographically, the developed markets grew slightly, with stability in the U.S. and Europe. High-growth markets were up low single digits, as continued growth in India was offset by declines in Latin America and Russia. In China, our teams are well positioned to compete in several attractive markets and delivered mid-single-digit core growth in the quarter.
 
 Gross margin for the first quarter was 53.1%, an increase of 50 basis points from last year. Along with the productivity initiatives undertaken in 2015, our gross margin expansion has enabled us to sustain and expand our growth investments in new product development and sales and marketing.
 
 Core operating margin expanded 45 basis points, with reported operating margin at 16.4%. 
 
 Free cash flow is one of the most important metrics at Danaher, as it provides us with the agility to invest in both organic and inorganic growth initiatives across our entire portfolio. We had a strong quarter on this front, generated -- generating $622 million of free cash flow, a significant increase over last year.
 
 Coming off a historic year of M&A, we closed 6 bolt-on acquisitions in the first quarter, deploying over $100 million in capital. These deals will strengthen our capabilities across many of our businesses. Both Danaher and Fortive have strong and active funnels, and we'll continue to focus on small and midsize transactions for both companies through the separation process.
 
 Now let's take a look at our 5 operating segments, starting with Test & Measurement. Revenues decreased 5.5%, with core revenues down 5%. Core operating margin decreased 135 basis points, with reported operating margin coming in at 20.9%. Core revenues for our Instruments platform declined high single digits as we continue to face a challenging global market environment. All major geographies saw declines, except for China and India. Fluke core revenues decreased mid-single digits due to declines in the U.S., Western Europe and Latin America, partially offset by increases in China. 
 
 While still a difficult environment, we did see some signs of stabilization in certain geographies and industrial end markets during the quarter. A few weeks ago, Fluke announced the launch of the Fluke 279 FC Thermal Multimeter, the world's first test tool that integrates a full-featured digital multimeter with a thermal camera in one device. This combination enables technicians to check for hotspots on high-voltage equipment and analyze problems at a safe distance. By combining these important test tools into one, Fluke is helping our customers troubleshoot electrical issues more quickly, safely and thoroughly.
 
 At Tektronix, core revenues declined low double digits, as growth in China and India was more than offset by declines in all other major geographies. 
 
 The Matco team continued to execute well, delivering high single-digit core growth in the quarter. Notably, Matco has posted mid-single-digit growth or better for 23 of the last 25 quarters and continues to improve its market position. In February, Matco hosted its annual tool expo in Las Vegas. The expo provides Matco franchisees with an opportunity to see new products, attend training sessions and stock their businesses for the upcoming year. This year, almost 3/4 of Matco's franchisees participated, resulting in record attendance and event-driven sales.
 
 Turning to our Environmental segment. Revenues grew 4%, with core revenues up 3.5%. Reported operating margin declined 220 basis points to 17.3%. Core operating margin declined 155 basis points and was negatively impacted by incremental investments, including EMV-related spend at Gilbarco Veeder-Root. We anticipate segment margins to return to more normalized levels in the second quarter. 
 
 The Water Quality platform's core revenues grew slightly, as 1 less selling day and a tough prior year comparison had a negative impact. 
 
 At Hach, positive momentum in the U.S. municipal market continued, but softness in high-growth markets resulted in flat core growth for the quarter. 
 
 Trojan also saw strong municipal demand globally and delivered another good quarter. 
 
 Finally, at ChemTreat, the team grew revenue slightly in the quarter despite headwinds in its industrial- and commodity-oriented markets. 
 
 One of the ways that we continue to augment growth, build our capabilities and better serve our customers is through M&A. Our Water Quality platform has acquired more than 40 businesses since 1996 and continued its healthy cadence of bolt-ons this quarter, with Hach's acquisition of Lufft Mess in January. Lufft's long-standing precision sensors -- long-lasting precision sensors are a key part of weather-measuring networks along roads, railways and airports and enable us to deliver value to a wider range of customers around the world. The Hach team does an exceptional job of implementing DBS in newly acquired businesses, and this is well underway already at Lufft. DBS lean and growth tools are helping us drive more efficient production, strengthen key account relationships and improve funnel management.
 
 At Gilbarco Veeder-Root, core revenue grew high single digits for the third consecutive quarter. EMV-related demand in the U.S. drove double-digit growth in point-of-sale solutions and dispenser systems, and we believe we continue to gain share on both fronts. Many of our customers are still in the process of upgrading indoor payment systems for last October's credit card liability shift. Additionally, we're well positioned to benefit from the upcoming outdoor liability shift, and the Gilbarco team is already collaborating with a number of customers to phase in outdoor upgrades. You'll hear more about EMV and GVR's other opportunities at our investor and analyst event next month.
 
 Moving now to Life Sciences & Diagnostics. Core revenues grew 2.5%, with reported revenues up 42%, largely due to our recent Pall and Microscan acquisitions. Core operating margin expanded 205 basis points, thanks to the team's solid execution using DBS. Core revenues in our Diagnostics platform increased low single digits, led by healthy demand in high-growth markets. 
 
 At Beckman Coulter, core revenue increased at a low single-digit rate. We saw strong demand for our immunoassay solutions and used our well-established installed base to help drive increased sales in India and China. 
 
 Our consumable streams remain solid, and we're seeing healthy utilization rates globally. Radiometer and Leica Biosystems both increased core revenues in the quarter, with growth in China and India offset by declines in other high-growth markets. 
 
 Our team is focused on improving our customers' experience every day and shows that commitment by expanding our product offering through both innovation and adjacent bolt-on acquisitions. Beckman Coulter's first major bolt-on, Iris, closed in 2012 and extended our footprint beyond blood testing into urinalysis. Since then, Iris has delivered double-digit growth and expanded operating margins over 1,000 basis points. More recently, the acquisition of Microscan expanded Beckman's already strong presence in hospital and reference labs into the microbiology space. It has been 1 year since we closed the deal, and we achieved double-digit core revenue growth in the quarter. Both Iris and Microscan are helping us serve our customers better, and we believe that adjacent acquisitions, combined with our consistent application of DBS, will continue to enhance our comprehensive workflow solutions across our diagnostic businesses. 
 
 In our Life Science platform, core revenue was up low single digits, with growth in both developed and high-growth markets. Leica Microsystems core revenues were up low single digits, as strong performance in North America and China was offset by declines in Japan and Latin America.
 
 At SCIEX, core revenues grew low single digits, driven by demand in China and the Middle East. We also saw healthy sales growth in certain applied end markets and our service business. The SCIEX team has placed a strong focus on improving our customers' experience by pairing service contracts with instrument sales. This has driven record contract capture rates, including over 500 basis points of improvement in year-over-year attachment rates in the first quarter alone. 
 
 SCIEX is a great example of how we use new products to help our customers' most critical challenges. In the quarter, we launched the x500R, the first model within our X-Series product family, which was the SCIEX team's largest ever development project. The x500R is a robust instrument that was specifically designed to serve customers in food and environmental testing labs, 2 of the fastest-growing end markets in mass spectrometry. Going forward, we expect this to be a significant contributor to our future growth.
 
 Turning to Pall. We are very pleased with our early progress. This quarter, the Pall team delivered mid-single-digit core revenue growth, led by double-digit growth in our Life Science business due to demand for our biopharmaceutical solutions, including single-use technologies. Our Industrial business was down low single digits as we faced challenging market conditions. The team's enthusiastic application of DBS, including over 100 kaizen events since close, has led to meaningful process improvements and several new product introductions across Pall's Life Sciences and Industrial businesses. As a result of our growth and productivity initiatives, year-on-year operating margins were up over 250 basis points. 
 
 As we move on to Dental, core revenues increased by 0.5% due to strong demand for consumables and implants in North America and the high-growth markets as well as healthy orthodontic sales in China. These gains were negatively impacted by 1 less selling day. Over the last several quarters, the Dental team's focus on execution and disciplined spending has paid off in margin expansion. This quarter, the team grew core operating margins by 250 basis points and reported operating margins by over 500 basis points to 14.5%. Our continued investments in innovation have resulted in a number of differentiated product offerings for our Dental customers. At the Chicago Midwinter Dental Show in February, we launched over 15 new products, including Maxcem Elite Chroma, a revolutionary new cement for dental restoration that changes color to indicate the correct time for a dentist to remove any excess material. The first-in-class color indicator simplifies the dentist's procedure and reduces clinical risk.
 
 At Nobel Biocare, the team drove mid-single-digit average daily sales of implant systems this quarter. Since the acquisition closed, Nobel has achieved over 400 basis points of operating margin improvement and is focused on reinvesting those savings into future growth opportunities.
 
 Moving now to Industrial Technologies. Revenues declined 1.5%, while core revenues were also down 1.5%. Despite the revenue decline, core operating margin expanded 25 basis points, while reported operating margin declined 30 basis points to 24.3%. The Automation platform's core revenues decreased at a high single-digit rate due to the weakness in global industrial markets and a difficult prior year comparison. While we expect this dynamic to largely persist in the near term, we were encouraged by signs of stabilization in the quarter. 
 
 Product Identification core revenues grew at a low single-digit rate, as increased demand for marking and coding was offset by softer demand for the business's packaging and color solutions. 
 
 Videojet's core revenues increased mid-single digits, driven by what we believe to be continuing share gains in North America and Europe, while high-growth markets remain softer. The Videojet team has delivered mid-single-digit growth or better for 9 of the past 10 quarters.
 
 Last quarter, we announced the acquisition of Laetus, which extends our Product ID offerings into track-and-trace inspection systems for pharmaceutical packaging plants. We're off to a good start with Laetus. The team's early adoption of DBS tools is already driving key process improvements, as quicker service deployment and improved on-time delivery are ensuring that our customers receive the best possible support.
 
 So to wrap up, our team executed well in the face of challenging economic conditions, and we're pleased with our start to 2016. The Danaher Business System remained the driving force behind our performance this quarter, helping to deliver high teens earnings growth, healthy operating margin expansion and 50% year-on-year free cash flow growth. We're also off to a great start at Pall, where the team drove meaningful process improvements and delivered mid-single-digit revenue growth in the quarter. We continue to make progress preparing for the launch of Fortive Corporation, which remains on track to close in the third quarter. Our teams are excited about the unique opportunity to continue developing 2 separate portfolios of market-leading businesses that we believe will create shareholder value for years to come.
 
 We're initiating second quarter adjusted diluted net EPS guidance between $1.19 and $1.23, which assumes approximately 2% core revenue growth. We are increasing our full year adjusted EPS guidance from $4.80 to $4.95, to $4.85 to $4.98, which would represent a 13% to 16% increase from 2015 adjusted EPS."
265621,329307690,960821,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","Thanks, Tom. That concludes our formal remarks. Issa, we're now ready to take questions.",14,"Thanks, Tom. That concludes our formal remarks. Issa, we're now ready to take questions."
265621,329307690,960821,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Operator","[Operator Instructions] We will now take our first question from Scott Davis from Barclays.",14,"[Operator Instructions] We will now take our first question from Scott Davis from Barclays."
265621,329307690,960821,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Analysts","China was up. Bright spot for you guys, and I know last quarter was -- I mean, it tracked pretty comparable last quarter as well, but it sounded like things may have firmed up a little bit. I mean, Fluke -- is Fluke your canary in the coal mine in China h",76,"China was up. Bright spot for you guys, and I know last quarter was -- I mean, it tracked pretty comparable last quarter as well, but it sounded like things may have firmed up a little bit. I mean, Fluke -- is Fluke your canary in the coal mine in China having that business back in positive territory for the quarter? I'm just -- maybe just a little color on what you guys are seeing there."
265621,329307690,960821,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","Sure. Thanks, Scott. China, unquestionably, is -- remains a very good market for us. Despite much of the headlines that would certainly suggest that they're slowing in various areas, we were very pleased with the performance in China. And I think it was r",242,"Sure. Thanks, Scott. China, unquestionably, is -- remains a very good market for us. Despite much of the headlines that would certainly suggest that they're slowing in various areas, we were very pleased with the performance in China. And I think it was relatively broad based. If you looked at Danaher versus Fortive, let's say, Danaher was up high single digits in China, and Fortive was up mid-single digits in China. So I think a number of good examples where China remains a very attractive market for us. Relative to your specific question on Fluke, Fluke is just -- is an exceptional business overall. We've had a -- it's probably one of our most advanced businesses in terms of both go-to market as well as local production and product development in China. And while there's clearly still some softness around various industrial segments in the Chinese market, Fluke is a very strong brand in that market and has a very strong share position. So I think we're encouraged by some of the stabilization we see in some of the markets. And in other of those markets, we just continue to see very strong growth. Our Dental business continues to perform exceptionally well in China. Life Sciences & Diagnostics, broadly continuing to perform well there. So again, while clearly the headlines would show that, that market has pulled back a little bit in the aggregate, it's still a very good place to be."
265621,329307690,960821,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Analysts","Okay. It's helpful, Tom. And then just wanted to ask where you stand in Pall versus the deal model. Help us -- now that we're a year in or so, I mean, give us a sense of how you -- what's working? What's not working? What -- Industrial is probably far wea",106,"Okay. It's helpful, Tom. And then just wanted to ask where you stand in Pall versus the deal model. Help us -- now that we're a year in or so, I mean, give us a sense of how you -- what's working? What's not working? What -- Industrial is probably far weaker than you thought it was, but the Environmental or the, I should say, the Life Sciences side is probably far stronger than you thought it would be. So how are you managing that variability? And how does it all really stack up at the end of the day versus what your prior expectations were?"
265621,329307690,960821,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","Scott, we're in a -- it's Dan. We're off to a very good start there. We had mid-single-digit growth in the quarter. As Tom alluded, that was a combination of double-digit growth in the Life Science side and a slight decline on the Industrial side. Clearly",150,"Scott, we're in a -- it's Dan. We're off to a very good start there. We had mid-single-digit growth in the quarter. As Tom alluded, that was a combination of double-digit growth in the Life Science side and a slight decline on the Industrial side. Clearly, that would have been a contributor to our overall organic growth at Danaher. From a margin perspective, we are ahead of schedule. We talked about north of $100 million of benefit here this year on the margin side, continue to track very well to the ultimate target of $300 million. In addition to this, we are getting favorable mix, given the Life Science business is more profitable, and we really saw that play out exceedingly well in the first quarter. It'll likely create some opportunities, where we'll be able to accelerate some investments here at Pall during this year, given we're tracking so well."
265621,329307690,960821,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","Just to follow on Dan's comment a little bit, the team at Pall has just done a tremendous job. It's -- as we've mentioned before, it's a great combination of both some seasoned Danaher leaders as well as an exceptional group of folks who have been at Pall",138,"Just to follow on Dan's comment a little bit, the team at Pall has just done a tremendous job. It's -- as we've mentioned before, it's a great combination of both some seasoned Danaher leaders as well as an exceptional group of folks who have been at Pall for a long time, who, together, have really brought DBS to life in that business in rapid fashion. You heard me mention about the 100 kaizens that have gone on. Those have gone on literally around the world. And it's just one indication of the rapid rate at which the Pall team has adopted the tools of DBS. And really, that has truly contributed to not only the growth dynamics that we're seeing, but certainly has assisted in us getting ahead on the cost takeouts in the margin side."
265621,329307690,960821,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Operator","Our next question comes from Steve Tusa from JPMorgan.",9,"Our next question comes from Steve Tusa from JPMorgan."
265621,329307690,960821,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Analysts","Just back to Pall, just a follow-up on that. I think they were doing a little bit better than $100 million in R&D a year. And R&D year-over-year was up I think about $20 million. Is that a little bit of a decline in the core R&D? Or are you kind of gettin",97,"Just back to Pall, just a follow-up on that. I think they were doing a little bit better than $100 million in R&D a year. And R&D year-over-year was up I think about $20 million. Is that a little bit of a decline in the core R&D? Or are you kind of getting efficiencies there on the Pall side? You also mentioned you're kind of walking away from some business there, I think, in your 10-Q at Pall. Could you just give us a degree of magnitude on that front? And then I have one quick follow-up."
265621,329307690,960821,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","Steve, on walking away from some business, that's something that Pall had started prior even to our acquisition. It's down to a relatively nominal amount here and will be I think largely done by the middle of this year.",39,"Steve, on walking away from some business, that's something that Pall had started prior even to our acquisition. It's down to a relatively nominal amount here and will be I think largely done by the middle of this year."
265621,329307690,960821,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Analysts","Okay. And then on the R&D front, what was kind of Pall's R&D? I think it was greater than $100 million. Are you guys getting more efficiencies there? Do you expect to maintain that R&D budget? Increase it?",38,"Okay. And then on the R&D front, what was kind of Pall's R&D? I think it was greater than $100 million. Are you guys getting more efficiencies there? Do you expect to maintain that R&D budget? Increase it?"
265621,329307690,960821,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","I would -- right now, we're sustaining. And I suspect over time, that will get increased.",16,"I would -- right now, we're sustaining. And I suspect over time, that will get increased."
265621,329307690,960821,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","Steve, I would just add to that. And I think we'd mentioned this maybe once before. But if you think back to the playbook that we ran post the Beckman acquisition, I think the playbook here at Pall is very similar, which is there's a number of opportuniti",197,"Steve, I would just add to that. And I think we'd mentioned this maybe once before. But if you think back to the playbook that we ran post the Beckman acquisition, I think the playbook here at Pall is very similar, which is there's a number of opportunities to get cost out of the business broadly defined, and we're working on those obviously, start to see the margins coming up. But the playbook is to then redeploy some of that cost takeout into investments in sales and marketing and R&D. You see us do that broadly across Danaher, with gross margins going up and sales and marketing and R&D on the quarter for the Danaher in total up 30 basis points. We did that at Pall -- at Beckman. R&D lifted over time. We started to get the innovation engine going. Innovation at Pall has always been a strong suit there, but we think we can take it up another level. And so some of those cost takeouts will ultimately translate into either higher spending or potentially more efficient spending if we find opportunities to do a better job innovating at the same cost rate. We'll see."
265621,329307690,960821,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Analysts","Okay. And then just lastly on the free cash flow, a very strong quarter. Obviously, you're paying down some debt, beginning to delever here a little bit. Is there anything about the timing of that free cash flow? Or should we think about kind of normal se",83,"Okay. And then just lastly on the free cash flow, a very strong quarter. Obviously, you're paying down some debt, beginning to delever here a little bit. Is there anything about the timing of that free cash flow? Or should we think about kind of normal seasonality off of that base? I know there were some accruals. Year-over-year, accruals were less of a drag. Maybe there's just some timing. What's -- maybe bottom line is, what's kind of the annual free cash guide?"
265621,329307690,960821,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","Well, Steve, we don't give a specific guide, but we're off to a very good start. There was a little bit of timing benefit around some tax payments. But broadly, our cash flow was quite strong. As you know, we ended last year with a record number and a ver",85,"Well, Steve, we don't give a specific guide, but we're off to a very good start. There was a little bit of timing benefit around some tax payments. But broadly, our cash flow was quite strong. As you know, we ended last year with a record number and a very strong second half of free cash flow. We expect that trend to continue. We're not going to be up 40% year-on-year, but we'd expect a very healthy double-digit increase in free cash flow this year."
265621,329307690,960821,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","Our first quarter last year was [indiscernible].",7,"Our first quarter last year was [indiscernible]."
265621,329307690,960821,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","And we were a little bit light.",7,"And we were a little bit light."
265621,329307690,960821,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","A little lighter last first quarter, so a little bit of benefit there from a comp standpoint.",17,"A little lighter last first quarter, so a little bit of benefit there from a comp standpoint."
265621,329307690,960821,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Operator","Our next question comes from Nigel Coe from Morgan Stanley.",10,"Our next question comes from Nigel Coe from Morgan Stanley."
265621,329307690,960821,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Analysts","Tom, so you mentioned you're seeing signs of stability. I think that was in relation to Fluke, specifically. But maybe just broaden that to the conversation to maybe some of the more typical businesses within Industrial Tech, Tektronix. What are you seein",51,"Tom, so you mentioned you're seeing signs of stability. I think that was in relation to Fluke, specifically. But maybe just broaden that to the conversation to maybe some of the more typical businesses within Industrial Tech, Tektronix. What are you seeing today compared to what you saw back in January?"
265621,329307690,960821,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","Sure. Thanks, Nigel. Our comments about stability were not exclusively associated with Fluke. In fact, I think there are some pockets, even around the Fluke business, where we've seen stability, but we've also seen still some real headwinds. But I think w",211,"Sure. Thanks, Nigel. Our comments about stability were not exclusively associated with Fluke. In fact, I think there are some pockets, even around the Fluke business, where we've seen stability, but we've also seen still some real headwinds. But I think we have seen stability in some other areas. You asked specifically about -- on the Industrial Tech side. The Automation businesses, our Sensors and Controls businesses, as we looked at those throughout the course of the quarter, February and March, we saw indications of stability. We saw those order rates kind of firm up a little bit. And while we wouldn't call it an upward trajectory, we would call those a bit more stable than we had seen in the trajectory of the fourth quarter and maybe at the very opening of the year. You mentioned Tektronix. I wouldn't necessarily put Tektronix quite in that category yet. It had one of the more challenging quarters. It's in one of the tougher markets probably that we face today. And so I think while we're very encouraged by the new product flow at Tektronix and we expect to see that -- those new products drive some improved performance in the back half of the year, Tek remains in a pretty challenging environment."
265621,329307690,960821,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Analysts","Okay, that's helpful. And then switching to Environmental margins. Obviously, a lot of noise this quarter. You called out investment spending. I'm wondering if you can maybe help us size that impact. And it seems that this quarter, you had a negative mix",64,"Okay, that's helpful. And then switching to Environmental margins. Obviously, a lot of noise this quarter. You called out investment spending. I'm wondering if you can maybe help us size that impact. And it seems that this quarter, you had a negative mix of consumables versus GVR growth. Is that true? And would you expect that to normalize over the balance of the year?"
265621,329307690,960821,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","Well, I'll need you to clarify that last question. I'm not exactly sure what you meant by negative mix relative to GVR growth, unless you're talking about Water Quality versus GVR within Environmental. Is that what [indiscernible]?",37,"Well, I'll need you to clarify that last question. I'm not exactly sure what you meant by negative mix relative to GVR growth, unless you're talking about Water Quality versus GVR within Environmental. Is that what [indiscernible]?"
265621,329307690,960821,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Analysts","Exactly [indiscernible] GVR [indiscernible] margin, yes.",6,"Exactly [indiscernible] GVR [indiscernible] margin, yes."
265621,329307690,960821,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","Okay, sure, yes. No, absolutely right. Yes, thanks, Nigel. That's -- you're right on. If you look at Environmental, which, as all of you know, both has our GVR business as well as our Water Quality businesses, GVR had stronger growth during the course of",222,"Okay, sure, yes. No, absolutely right. Yes, thanks, Nigel. That's -- you're right on. If you look at Environmental, which, as all of you know, both has our GVR business as well as our Water Quality businesses, GVR had stronger growth during the course of the quarter, very encouraging signs of the EMV dynamic taking hold. And GVR comes through that with a lower-margin mix relative to our Water Quality platform, which has higher margins and specifically, Hach. So a little bit softer Hach business, a little bit stronger GVR business during the course of the quarter together causes some of that headwind that you saw on the margin line there. The reference to investment spend is specific to what we need to do to build the capacity to step up to the demand associated with EMV. And so we see that in -- specifically in our GVR business. And those are investments that clearly will pay off as we continue to ramp our capabilities. And as we go into the second quarter and beyond, we would expect those margins overall in the segment to return closer to normal levels. Obviously, some continued investment there, but we expect Water Quality to come up a bit. So overall, I think there were just a couple of unique factors here in the first quarter."
265621,329307690,960821,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Operator","Our next question comes from Shannon O'Callaghan from UBS.",10,"Our next question comes from Shannon O'Callaghan from UBS."
265621,329307690,960821,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Analysts","Tom, you mentioned execution and disciplined spending at Dental with the big margin improvement there. I mean, that's a segment that you've always targeted getting to much higher margins over the years, but it's been more of a challenge. I mean, is this s",58,"Tom, you mentioned execution and disciplined spending at Dental with the big margin improvement there. I mean, that's a segment that you've always targeted getting to much higher margins over the years, but it's been more of a challenge. I mean, is this something of a breakthrough here? Or how should we read the performance on those comments?"
265621,329307690,960821,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","Well, you're absolutely right, Shannon. It's been a challenge in the past. And we did set our sights and commit to making a difference there. We have some new leadership in place over the platform. Many of you have met Amir Aghdaei, who's led a number of",207,"Well, you're absolutely right, Shannon. It's been a challenge in the past. And we did set our sights and commit to making a difference there. We have some new leadership in place over the platform. Many of you have met Amir Aghdaei, who's led a number of our businesses over the last several years and some of our more challenging businesses. And he's really put a terrific team together. They've set their sights on specific margin improvements over time. There was some outstanding execution, some disciplined cost control. But similar to the comments I made earlier around the playbook, I made reference to the Beckman playbook and how that applies to Pall, while we'll continue to drive margin improvement at Dental under the team's leadership, we'll also take some of that improvement and continue to invest in sales and marketing and in R&D because we do have opportunities for improvement in terms of our innovation cadence. We saw some modest improvement there in our core growth in the platform during the quarter, but we know there's opportunities to continue to improve that. We expect it to continue to step up. But some additional investment over time with some of that cost takeout will certainly be a help."
265621,329307690,960821,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Analysts","Okay, great. And then, Dan, maybe a question for you on tax. Obviously, a lot of new tax policies being contemplated and put into place that impact a lot of multinationals. Any just thoughts on that in general and potential impacts on Danaher as well as h",62,"Okay, great. And then, Dan, maybe a question for you on tax. Obviously, a lot of new tax policies being contemplated and put into place that impact a lot of multinationals. Any just thoughts on that in general and potential impacts on Danaher as well as how should we think about kind of the 2 newco tax rates and any differentials there?"
265621,329307690,960821,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","Sure, Shannon. Yes, obviously, it's something we're spending a lot of time on, trying to understand better. I mean, our initial read of this is this is not going to be an impact to us -- a material impact to us in the near term. That over time, we could s",169,"Sure, Shannon. Yes, obviously, it's something we're spending a lot of time on, trying to understand better. I mean, our initial read of this is this is not going to be an impact to us -- a material impact to us in the near term. That over time, we could see some rate creep because of it. Now that assumes nothing else happens and there's no other opportunities. And so sitting here right now, it's not something that worries us a great deal, but it's obviously a potential risk kind of going forward. I don't think there's a big change in how we think about the tax rates of the 2 entities. We've talked about Fortive likely coming out closer to kind of a high-20 tax rate. Again, I think as they begin to do some acquisitions, they'll have an opportunity to bring that down. And I would expect that Danaher would be at our current rate or lower. Danaher remainco would be at our current rate or lower."
265621,329307690,960821,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Operator","Our next question comes from Steven Winoker from Bernstein.",9,"Our next question comes from Steven Winoker from Bernstein."
265621,329307690,960821,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Analysts","Could you maybe just clarify? You talked about Fortive versus Danaher core growth in China. What was it globally for the quarter?",22,"Could you maybe just clarify? You talked about Fortive versus Danaher core growth in China. What was it globally for the quarter?"
265621,329307690,960821,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","The Danaher was up a couple points, and Fortive was down 1 to 2 points, say 1.5%, I believe.",19,"The Danaher was up a couple points, and Fortive was down 1 to 2 points, say 1.5%, I believe."
265621,329307690,960821,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Analysts","Okay. And, well, I guess everybody, what are you thinking about in terms of current thinking, I should say, on capital structure for the 2 entities? Where are you still heading for that? I know there have been some private conversations, but don't have a",51,"Okay. And, well, I guess everybody, what are you thinking about in terms of current thinking, I should say, on capital structure for the 2 entities? Where are you still heading for that? I know there have been some private conversations, but don't have a sense for where that is now."
265621,329307690,960821,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","I don't think much has changed versus what we communicated a year ago. We would expect Fortive to come out as an investment-grade company. Likely not -- they're not going to be an A-rated company, but a triple -- something in the BBB range, where they wou",62,"I don't think much has changed versus what we communicated a year ago. We would expect Fortive to come out as an investment-grade company. Likely not -- they're not going to be an A-rated company, but a triple -- something in the BBB range, where they would be strong investment-grade and clearly have a fair amount of latitude to execute M&A."
265621,329307690,960821,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Analysts","Okay, great. And if I could just -- one more. Tom, in terms of the R&D profile, I know you talked a little bit about it before, specifically with Pall. But I guess, overall, for the company, where is -- what level of R&D are we talking about for just -- f",79,"Okay, great. And if I could just -- one more. Tom, in terms of the R&D profile, I know you talked a little bit about it before, specifically with Pall. But I guess, overall, for the company, where is -- what level of R&D are we talking about for just -- for the new Danaher going forward? And do you see an opportunity to accelerate that at all as you think about also accelerating core growth in new Danaher?"
265621,329307690,960821,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","Sure. Thanks, Steve. I've said for a long time, I've always believed that there's no magic number for a business with the diverse portfolio that we have today. We really look at continuing to invest in R&D to certain levels, specifically at an operating c",216,"Sure. Thanks, Steve. I've said for a long time, I've always believed that there's no magic number for a business with the diverse portfolio that we have today. We really look at continuing to invest in R&D to certain levels, specifically at an operating company level. And that's obviously relevant for what -- relative to what's important to those markets, what's important for our competitiveness, what yields the greatest levels of competitive advantage from an innovation perspective. So we really look at it sort of operating company by operating company. Our track record is a great one, and it will continue, of taking R&D up year-on-year pretty consistently. We've used our operating margin expansion that's been driven by improvements in gross margin to put some of that back into not only R&D, but into sales and marketing as well. And again, we've done that very consistently. I would expect that we will continue to do that. One of our 5 core values is Innovation Defines Our Future, and we represent that in our metrics by continuing to see that percent of R&D go up year-on-year. So again, it'll vary in terms of the number that we achieve year-on-year by operating company or even by platform, but using innovation to drive competitiveness is key to our strategy."
265621,329307690,960821,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Analysts","Okay. But what was it in the quarter, at least, just for the current -- or for the new Danaher?",20,"Okay. But what was it in the quarter, at least, just for the current -- or for the new Danaher?"
265621,329307690,960821,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","Probably in the same -- Steve, we have the dynamic around Pall, where a lot of the application expertise they bring to their customers, which is a big part of their value add, they include in sales and marketing than R&D. So the fact that you saw R&D as a",109,"Probably in the same -- Steve, we have the dynamic around Pall, where a lot of the application expertise they bring to their customers, which is a big part of their value add, they include in sales and marketing than R&D. So the fact that you saw R&D as a percent of our overall revenues go down 40, 50 basis points year-on-year, that's entirely driven by the Pall dynamic. But I would say, Danaher is probably in that zone where you've got some higher R&D businesses. But because of the way Pall accounts for their R&D, it probably averages to where Danaher is today, around that 6% percent range."
265621,329307690,960821,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Operator","Our next question comes from Ross Muken from Evercore ISI.",10,"Our next question comes from Ross Muken from Evercore ISI."
265621,329307690,960821,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Analysts","Maybe on the Life Science business, just a little bit more color commentary. You called out pharma as sort of a strong end market. It seems like on the SCIEX side that market has been running hot for a while. I mean, how do you see the trajectory there? A",100,"Maybe on the Life Science business, just a little bit more color commentary. You called out pharma as sort of a strong end market. It seems like on the SCIEX side that market has been running hot for a while. I mean, how do you see the trajectory there? And then secondarily on the Pall side, biotech, there's obviously been a lot of concern in the market, particularly with the smaller companies on funding and the like. And have you seen anything in that side of the business, particularly with small to midsize biotechs in terms of any relevant slowdown?"
265621,329307690,960821,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","Thanks, Ross. Yes, no question, the pharma market is an important driver of our growth across the Life Science portfolio. And we have exposure to that growing market across virtually every one of our Life Science businesses. Pall, specific to your questio",222,"Thanks, Ross. Yes, no question, the pharma market is an important driver of our growth across the Life Science portfolio. And we have exposure to that growing market across virtually every one of our Life Science businesses. Pall, specific to your question around biotech and small and midsize, continues to perform exceptionally well across the biotech market. Just to go back and talk about a few things about what's going on in that market, Pall has a $1 billion business today that's oriented toward biopharmaceuticals. And the combination of the solutions that they've had for a number of years, along with the newer products in single-use technologies, continue to drive the exceptional growth that we see there. That growth, as I think many of you know, Ross, and others know, is really driven by this move, the growth and the transition from small-molecule drugs to large-molecule drugs. And not only are those the fastest-growing segment of the market, but they're also the drugs that are most significantly represented in the pipelines of both small as well as large pharmaceutical companies today. So we remain optimistic and bullish on that market. And I think there's every reason to believe that we'll continue to see good growth not only from Pall, but from our other Life Science business that have exposure to that market."
265621,329307690,960821,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Analysts","Great. And maybe just quickly on the capital allocation side. So a lot of equity market volatility to start the year. Private equity has probably been more of a net seller than buyer. I mean, how has it sort of impacted asset prices on the private side in",130,"Great. And maybe just quickly on the capital allocation side. So a lot of equity market volatility to start the year. Private equity has probably been more of a net seller than buyer. I mean, how has it sort of impacted asset prices on the private side in terms of what you're looking at? And does it make sellers more apt to maybe approach a process, given they saw equity prices up, down, up again, maybe they're afraid they go down again and so they want to take advantage of maybe an open in the sort of credit markets where larger companies can acquire? I mean, just trying to get a feel for kind of how all this volatility had maybe helped you a little bit on the deal front."
265621,329307690,960821,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","I mean, volatility is a net positive for us as a well-capitalized acquirer. Your comment about private equity, it's getting a little better for them, but it's -- the leverage markets are still pretty tough. So I think all those factors play to our benefit",80,"I mean, volatility is a net positive for us as a well-capitalized acquirer. Your comment about private equity, it's getting a little better for them, but it's -- the leverage markets are still pretty tough. So I think all those factors play to our benefit. Now granted there are other -- a number of other well-capitalized corporate players here, but we're happy to sort of compete in this sort of environment, where there's a little bit more volatility and uncertainty."
265621,329307690,960821,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Operator","Next question comes from Jeffrey Sprague from Vertical Research Partners.",10,"Next question comes from Jeffrey Sprague from Vertical Research Partners."
265621,329307690,960821,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Analysts","Just a couple. First on SG&A, I guess, Dan, you kind of partially answered it speaking to the Pall R&D. But the SG&A moving up as a percent of sales, is there anything to flag there? And do you expect that sort of upward pressure over the balance of the y",51,"Just a couple. First on SG&A, I guess, Dan, you kind of partially answered it speaking to the Pall R&D. But the SG&A moving up as a percent of sales, is there anything to flag there? And do you expect that sort of upward pressure over the balance of the year?"
265621,329307690,960821,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","Well, you -- if we first just take Pall out of the equation entirely, R&D as a percent of sales was flat year-on-year, but sales and marketing was up 30 basis points, and that was intentional. I mean, we've stepped up some investments. We've talked about",174,"Well, you -- if we first just take Pall out of the equation entirely, R&D as a percent of sales was flat year-on-year, but sales and marketing was up 30 basis points, and that was intentional. I mean, we've stepped up some investments. We've talked about some of the opportunities in high-growth markets, where we see people pulling back and we see there was some opportunity. I think some of the success Fortive is having in China right now is probably a little bit of an example of that. And Pall brings in a pretty high sales and marketing expense when you kind of layer that in. That probably sustains itself. We see that as an important part of their go-to market, not only their go-to market, but, as I mentioned also, sort of part of their R&D as well. So we don't see ourselves sort of cutting back on those investments. If anything, given we've had a little bit more strength here early in the year, we may step some of that up."
265621,329307690,960821,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Analysts","And on tax, you mentioned creep and maybe there could be some offsets. Have you guys looked at this FASB change on stock comp and determined what, if any, benefit you'll have when you choose to adopt that?",38,"And on tax, you mentioned creep and maybe there could be some offsets. Have you guys looked at this FASB change on stock comp and determined what, if any, benefit you'll have when you choose to adopt that?"
265621,329307690,960821,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","We don't think it'd be meaningful.",7,"We don't think it'd be meaningful."
265621,329307690,960821,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Analysts","And then just finally, the 6 small deals, were any of those in Fortive? And if so, what?",18,"And then just finally, the 6 small deals, were any of those in Fortive? And if so, what?"
265621,329307690,960821,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","One was Fortive.",3,"One was Fortive."
265621,329307690,960821,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Analysts","What kind of asset?",4,"What kind of asset?"
265621,329307690,960821,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","It was an acquisition for Gilbarco.",6,"It was an acquisition for Gilbarco."
265621,329307690,960821,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","And that's on top of a couple more we did late last year. So in the last 4, 5 months, it's 3 deals, Jeff.",25,"And that's on top of a couple more we did late last year. So in the last 4, 5 months, it's 3 deals, Jeff."
265621,329307690,960821,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Operator","Our next question comes from Deane Dray from RBC.",9,"Our next question comes from Deane Dray from RBC."
265621,329307690,960821,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Analysts","Just like to go back to the 2016 guide. And just to clarify, has there been any change to the core revenue outlook for 2% to 3%? And then maybe a bit on the cadence of that through the year and how might that split with Fortive?",47,"Just like to go back to the 2016 guide. And just to clarify, has there been any change to the core revenue outlook for 2% to 3%? And then maybe a bit on the cadence of that through the year and how might that split with Fortive?"
265621,329307690,960821,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","Deane, no real change to our view of the full year at 2% to 3%. I think our comments referring to some stabilization that we've seen here in the last couple of months I think suggest -- as well as, by the way, how that was represented in the order rates,",85,"Deane, no real change to our view of the full year at 2% to 3%. I think our comments referring to some stabilization that we've seen here in the last couple of months I think suggest -- as well as, by the way, how that was represented in the order rates, not just the sellout, but the order rates in the last couple of months, suggest that we still feel pretty good about the 2% to 3%. So I think we're going to stay there."
265621,329307690,960821,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Analysts","And how about the expectations for Fortive in the second quarter?",11,"And how about the expectations for Fortive in the second quarter?"
265621,329307690,960821,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","We would expect that Fortive would be in the same zone, maybe a little bit better. Danaher ex Fortive would be slightly better, and that would roll up to be approximately 2% versus the 0.5% of core we delivered in the first quarter.",43,"We would expect that Fortive would be in the same zone, maybe a little bit better. Danaher ex Fortive would be slightly better, and that would roll up to be approximately 2% versus the 0.5% of core we delivered in the first quarter."
265621,329307690,960821,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Analysts","Great. And then maybe some clarification on Hach. The softness in the high-growth markets, is there anything specific there? Is it tougher comps? Why might there be some slowing there?",30,"Great. And then maybe some clarification on Hach. The softness in the high-growth markets, is there anything specific there? Is it tougher comps? Why might there be some slowing there?"
265621,329307690,960821,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","Well, it certainly was a very challenging comp year-on-year. The platform, overall, I think comp did 10% versus last year, Deane. So it was probably -- among the platforms that we have, it was probably the toughest comp perhaps across the entire corporati",146,"Well, it certainly was a very challenging comp year-on-year. The platform, overall, I think comp did 10% versus last year, Deane. So it was probably -- among the platforms that we have, it was probably the toughest comp perhaps across the entire corporation. So that was certainly a challenge. We have seen some delays in some key projects in a couple of the high-growth markets. So that was certainly a factor there. In certain of those high-growth markets, we actually have a little bit more industrial exposure than purely municipal exposure. And that, obviously, had an impact in those markets. Again, we don't -- that business, you know it well, Deane, is just one of our exceptional franchises. And we're confident that business continues to -- will continue to grow over time, and we'll see that business's core growth rate improve here in the second quarter."
265621,329307690,960821,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Analysts","Great. And then just last one, and still on the topic of Hach. I don't recall ever there being a time where Water Quality has been more front-page news in the U.S. with Flint, Michigan. And just -- what's your expectation about the longer-term implication",55,"Great. And then just last one, and still on the topic of Hach. I don't recall ever there being a time where Water Quality has been more front-page news in the U.S. with Flint, Michigan. And just -- what's your expectation about the longer-term implications on water quality, water test? And how is Hach positioned?"
265621,329307690,960821,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","Sure. Well, believe me, we wish we had an answer today to the infrastructure challenges that lead pipes represent in that situation. It's just terrible to see the challenges that, that community has gone through. But I think if we try to look on the brigh",141,"Sure. Well, believe me, we wish we had an answer today to the infrastructure challenges that lead pipes represent in that situation. It's just terrible to see the challenges that, that community has gone through. But I think if we try to look on the bright side from the standpoint of the overall market dynamics, situations like that always turn the spotlight up on the importance of regulatory oversight in municipalities around the country and frankly, throughout the world. And so as those regulatory drivers continue to be strengthened, to be pointed at the greatest vulnerabilities in municipal and industrial systems, that, again, while challenging for those communities, ultimately benefits consumers and certainly benefits us. Regulatory drivers have always been a key macro driver for that platform, and they will continue to be so for as long as we could anticipate."
265621,329307690,960821,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Operator","Our next question comes from Andrew Obin from Bank of America Merrill Lynch.",13,"Our next question comes from Andrew Obin from Bank of America Merrill Lynch."
265621,329307690,960821,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Analysts","I guess in the Q, you sort of indicated that you're still on track to pay the $3 billion dividend from Fortive to Danaher. Is there any flexibility around that number if Fortive discovers a good acquisition? How flexible are you there?",42,"I guess in the Q, you sort of indicated that you're still on track to pay the $3 billion dividend from Fortive to Danaher. Is there any flexibility around that number if Fortive discovers a good acquisition? How flexible are you there?"
265621,329307690,960821,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","Well, that's something obviously the board would need to determine depending on, obviously, the size of the acquisition and their -- what else they have in the pipeline.",28,"Well, that's something obviously the board would need to determine depending on, obviously, the size of the acquisition and their -- what else they have in the pipeline."
265621,329307690,960821,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Analysts","But it's fair to assume that there's some flexibility there?",11,"But it's fair to assume that there's some flexibility there?"
265621,329307690,960821,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","Nothing's said until it's said",6,"Nothing's said until it's said"
265621,329307690,960821,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Analysts","And then just going back to GVR. The EMV investment and -- both growth and investment, is it fair to assume that investment is going to be front-end loaded Q1 and Q2, but you might see growth throughout the year? Is that the right way of thinking about it",49,"And then just going back to GVR. The EMV investment and -- both growth and investment, is it fair to assume that investment is going to be front-end loaded Q1 and Q2, but you might see growth throughout the year? Is that the right way of thinking about it?"
265621,329307690,960821,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","Yes. There's clearly some upfront cost. And as Tom alluded, we also had some onetime items in the quarter, and that will normalize as we get through the year.",29,"Yes. There's clearly some upfront cost. And as Tom alluded, we also had some onetime items in the quarter, and that will normalize as we get through the year."
265621,329307690,960821,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Operator","We'll now take our next question from Julian Mitchell from Crdit Suisse.",13,"We'll now take our next question from Julian Mitchell from Crdit Suisse."
265621,329307690,960821,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Analysts","Just a question on Dental first. The growth rate was, I guess, lower than I thought, particularly as Nobel should have automatically pushed up the organic growth a little bit and the comp was pretty easy. So I saw you called out Middle East and Africa equ",70,"Just a question on Dental first. The growth rate was, I guess, lower than I thought, particularly as Nobel should have automatically pushed up the organic growth a little bit and the comp was pretty easy. So I saw you called out Middle East and Africa equipment, but I wouldn't have thought that was a very sizable piece of the business. So maybe just give a bit more color there."
265621,329307690,960821,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","Sure. Well, our Dental growth, overall, Julian, was -- at 0.5% was basically in line with our expectations, modest improvement from where we'd been over the last few quarters. And obviously, as we talked just a few minutes ago, we're very pleased with see",216,"Sure. Well, our Dental growth, overall, Julian, was -- at 0.5% was basically in line with our expectations, modest improvement from where we'd been over the last few quarters. And obviously, as we talked just a few minutes ago, we're very pleased with seeing the OMX up at the rate that I talked about earlier. We saw solid low single-digit growth in consumables, and sellout continues and actually is a fraction better than even our sell-in. So we always look at that sellout. We have good transparency with our distribution partners, and we're encouraged by that. The Nobel implant systems business, mid-single-digit average daily sales growth in the quarter, we're pleased with that. The Ormco business, the orthodontic business, continues to do well. And we're continuing to see on a geographic basis, as I mentioned, the -- a couple of the high-growth markets, specifically the -- our business in China, continuing to do well. On the flip side, on the equipment side, we have seen some challenges in Europe actually, and a couple in those high-growth markets, where the equipment side has been held back a little bit more significantly. So I think as we annualize over some of those more challenging comps, we'll continue to see that growth improve during the course of this year."
265621,329307690,960821,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Analysts","Got it. And then secondly, just on Test & Measurement. I wondered -- obviously, the trends year-on-year are sort of similar Q1 as in Q4. I wondered if there was any specific end market you'd call out that's sort of dragging on the growth now. Obviously, y",69,"Got it. And then secondly, just on Test & Measurement. I wondered -- obviously, the trends year-on-year are sort of similar Q1 as in Q4. I wondered if there was any specific end market you'd call out that's sort of dragging on the growth now. Obviously, you do have some electronics exposure, for example, in T&M. Or if you thought it was sort of fairly broad based, the weakness."
265621,329307690,960821,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","Well, there's certainly some broad-based weakness. But if I had to call out a couple of the softer spots, it probably would be the end markets where Tek is most exposed. And then probably secondarily, it would be in -- on the Fluke side. Probably, the U.S",65,"Well, there's certainly some broad-based weakness. But if I had to call out a couple of the softer spots, it probably would be the end markets where Tek is most exposed. And then probably secondarily, it would be in -- on the Fluke side. Probably, the U.S. point-of-sale has been a weaker spot here through the quarter. Those would be the 2 I'd probably highlight."
265621,329307690,960821,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Analysts","And you're expecting those to be little changed in Q2?",11,"And you're expecting those to be little changed in Q2?"
265621,329307690,960821,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","We are, that's right. There's no indication right now of a pickup there. Obviously, we can always be optimistic, but we're not projecting for any improvement there, certainly in the second quarter.",32,"We are, that's right. There's no indication right now of a pickup there. Obviously, we can always be optimistic, but we're not projecting for any improvement there, certainly in the second quarter."
265621,329307690,960821,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Operator","I would now like to turn the call back to Mr. Matt Gugino for any additional or closing remarks.",19,"I would now like to turn the call back to Mr. Matt Gugino for any additional or closing remarks."
265621,329307690,960821,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","Thanks, Issa, and thanks, everyone, for joining us. We're around all day for questions.",14,"Thanks, Issa, and thanks, everyone, for joining us. We're around all day for questions."
265621,329307690,960821,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Operator","Thank you, ladies and gentlemen. That will conclude today's conference call. You may now disconnect.",15,"Thank you, ladies and gentlemen. That will conclude today's conference call. You may now disconnect."
265621,329307690,960864,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Operator","My name is Issa, and I will be your conference facilitator today. At this time, I would like to welcome everyone to the Danaher Corporation First Quarter 2016 Earnings Results Conference Call. [Operator Instructions] I will now turn the call over to Mr.",56,"My name is Issa, and I will be your conference facilitator today. At this time, I would like to welcome everyone to the Danaher Corporation First Quarter 2016 Earnings Results Conference Call. [Operator Instructions] 
I will now turn the call over to Mr. Matt Gugino, Vice President of Investor Relations. Mr. Gugino, please begin your conference."
265621,329307690,960864,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","Thank you, Issa, and good morning, everyone, and thanks for joining us on the call. With us today are Tom Joyce, our President and Chief Executive Officer; and Dan Comas, our Executive Vice President and Chief Financial Officer. I'd like to point out th",334,"Thank you, Issa, and good morning, everyone, and thanks for joining us on the call. With us today are Tom Joyce, our President and Chief Executive Officer; and Dan Comas, our Executive Vice President and Chief Financial Officer. 
I'd like to point out that our earnings release, the slide presentation supplementing today's call, our first quarter Form 10-Q and the reconciliations and other information required by SEC Regulation G relating to any non-GAAP financial measures provided during the call are all available on the Investors section of our website, www.danaher.com, under the heading Financial Information. The audio portion of this call will be archived on the Investors section of our website later today under the heading Events & Presentations and will remain archived until our next quarterly call. A replay of this call will also be available until April 28, 2016. The replay number is (888) 203-1112 within the U.S. or (719) 457-0820 outside the U.S., and the confirmation code is 4643245. 
During the presentation, we will describe certain of the more significant factors that impacted year-over-year performance. The supplemental materials describe additional factors that impacted year-over-year performance. 
Unless otherwise noted, all references in these remarks and supplemental materials to company-specific financial metrics relate to the continuing operations of the company in the first quarter of 2016, and all references to period-to-period increases or decreases in financial metrics are year-over-year. 
During the call, we will make forward-looking statements within the meaning of the federal securities laws, including statements regarding events or developments that we believe or anticipate will or may occur in the future. These forward-looking statements are subject to a number of risks and uncertainties, including those set forth in our SEC filings, and actual results might differ materially from any forward-looking statements that we make today. These forward-looking statements speak only as of the date that they are made, and we do not assume any obligation to update any forward-looking statements. 
With that, I'd like to turn the call over to Tom."
265621,329307690,960864,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","Thanks, Matt, and good morning, everyone. We're pleased with our start to 2016, as our team continued to outperform in the face of uncertain and challenging economic conditions. In the quarter, we delivered high teens earnings growth, healthy operating ma",2368,"Thanks, Matt, and good morning, everyone. We're pleased with our start to 2016, as our team continued to outperform in the face of uncertain and challenging economic conditions. In the quarter, we delivered high teens earnings growth, healthy operating margin expansion and free cash flow that was up over 50% year-on-year. The Danaher Business System remains the driving force behind our performance, equipping our team with the tools to strengthen our competitive position, the focus to invest in high-impact growth opportunities and the flexibility to position our businesses for long-term success. 
This will be an exciting year as we anticipate the upcoming launch of Fortive Corporation, which we expect to spin out of Danaher in the third quarter. Since our last update in January, we've continued to build a highly experienced leadership team that named additional members to Fortive's Board of Directors. The team has also made great progress solidifying Fortive's financial, legal and organizational structures. This separation is a unique opportunity for Danaher and Fortive to optimize our respective portfolios and build long-term shareholder value. We look forward to sharing more information with you at our investor and analyst event in May at Gilbarco Veeder-Root.
Now turning to the details of the quarter. Adjusted diluted net EPS was $1.08, an increase of 18.5% over last year. Sales grew 15% to $5.4 billion, and core revenue increased 50 basis points, as a number of our businesses were negatively impacted by tough prior year comparisons and 1 less selling day. 
Clearly, the economic environment remains challenging in many verticals and geographies, but we were encouraged by signs of sales and order stabilization through the quarter. Our team's focus on portfolio optimization and diligent execution using DBS helped improve and sustain many of our market-leading positions. Finally, the impact of currency translation eased this quarter but still decreased revenues by 2%, while acquisitions increased revenues by 16.5%.
Geographically, the developed markets grew slightly, with stability in the U.S. and Europe. High-growth markets were up low single digits, as continued growth in India was offset by declines in Latin America and Russia. In China, our teams are well positioned to compete in several attractive markets and delivered mid-single-digit core growth in the quarter.
Gross margin for the first quarter was 53.1%, an increase of 50 basis points from last year. Along with the productivity initiatives undertaken in 2015, our gross margin expansion has enabled us to sustain and expand our growth investments in new product development and sales and marketing.
Core operating margin expanded 45 basis points, with reported operating margin at 16.4%. 
Free cash flow is one of the most important metrics at Danaher, as it provides us with the agility to invest in both organic and inorganic growth initiatives across our entire portfolio. We had a strong quarter on this front, generated -- generating $622 million of free cash flow, a significant increase over last year.
Coming off a historic year of M&A, we closed 6 bolt-on acquisitions in the first quarter, deploying over $100 million in capital. These deals will strengthen our capabilities across many of our businesses. Both Danaher and Fortive have strong and active funnels, and we'll continue to focus on small and midsize transactions for both companies through the separation process.
Now let's take a look at our 5 operating segments, starting with Test & Measurement. Revenues decreased 5.5%, with core revenues down 5%. Core operating margin decreased 135 basis points, with reported operating margin coming in at 20.9%. Core revenues for our Instruments platform declined high single digits as we continue to face a challenging global market environment. All major geographies saw declines, except for China and India. Fluke core revenues decreased mid-single digits due to declines in the U.S., Western Europe and Latin America, partially offset by increases in China. 
While still a difficult environment, we did see some signs of stabilization in certain geographies and industrial end markets during the quarter. A few weeks ago, Fluke announced the launch of the Fluke 279 FC Thermal Multimeter, the world's first test tool that integrates a full-featured digital multimeter with a thermal camera in one device. This combination enables technicians to check for hotspots on high-voltage equipment and analyze problems at a safe distance. By combining these important test tools into one, Fluke is helping our customers troubleshoot electrical issues more quickly, safely and thoroughly.
At Tektronix, core revenues declined low double digits, as growth in China and India was more than offset by declines in all other major geographies. 
The Matco team continued to execute well, delivering high single-digit core growth in the quarter. Notably, Matco has posted mid-single-digit growth or better for 23 of the last 25 quarters and continues to improve its market position. In February, Matco hosted its annual tool expo in Las Vegas. The expo provides Matco franchisees with an opportunity to see new products, attend training sessions and stock their businesses for the upcoming year. This year, almost 3/4 of Matco's franchisees participated, resulting in record attendance and event-driven sales.
Turning to our Environmental segment. Revenues grew 4%, with core revenues up 3.5%. Reported operating margin declined 220 basis points to 17.3%. Core operating margin declined 155 basis points and was negatively impacted by incremental investments, including EMV-related spend at Gilbarco Veeder-Root. We anticipate segment margins to return to more normalized levels in the second quarter. 
The Water Quality platform's core revenues grew slightly, as 1 less selling day and a tough prior year comparison had a negative impact. 
At Hach, positive momentum in the U.S. municipal market continued, but softness in high-growth markets resulted in flat core growth for the quarter. 
Trojan also saw strong municipal demand globally and delivered another good quarter. 
Finally, at ChemTreat, the team grew revenue slightly in the quarter despite headwinds in its industrial- and commodity-oriented markets. 
One of the ways that we continue to augment growth, build our capabilities and better serve our customers is through M&A. Our Water Quality platform has acquired more than 40 businesses since 1996 and continued its healthy cadence of bolt-ons this quarter, with Hach's acquisition of Lufft Mess in January. Lufft's long-standing precision sensors -- long-lasting precision sensors are a key part of weather-measuring networks along roads, railways and airports and enable us to deliver value to a wider range of customers around the world. The Hach team does an exceptional job of implementing DBS in newly acquired businesses, and this is well underway already at Lufft. DBS lean and growth tools are helping us drive more efficient production, strengthen key account relationships and improve funnel management.
At Gilbarco Veeder-Root, core revenue grew high single digits for the third consecutive quarter. EMV-related demand in the U.S. drove double-digit growth in point-of-sale solutions and dispenser systems, and we believe we continue to gain share on both fronts. Many of our customers are still in the process of upgrading indoor payment systems for last October's credit card liability shift. Additionally, we're well positioned to benefit from the upcoming outdoor liability shift, and the Gilbarco team is already collaborating with a number of customers to phase in outdoor upgrades. You'll hear more about EMV and GVR's other opportunities at our investor and analyst event next month.
Moving now to Life Sciences & Diagnostics. Core revenues grew 2.5%, with reported revenues up 42%, largely due to our recent Pall and Microscan acquisitions. Core operating margin expanded 205 basis points, thanks to the team's solid execution using DBS. Core revenues in our Diagnostics platform increased low single digits, led by healthy demand in high-growth markets. 
At Beckman Coulter, core revenue increased at a low single-digit rate. We saw strong demand for our immunoassay solutions and used our well-established installed base to help drive increased sales in India and China. 
Our consumable streams remain solid, and we're seeing healthy utilization rates globally. Radiometer and Leica Biosystems both increased core revenues in the quarter, with growth in China and India offset by declines in other high-growth markets. 
Our team is focused on improving our customers' experience every day and shows that commitment by expanding our product offering through both innovation and adjacent bolt-on acquisitions. Beckman Coulter's first major bolt-on, Iris, closed in 2012 and extended our footprint beyond blood testing into urinalysis. Since then, Iris has delivered double-digit growth and expanded operating margins over 1,000 basis points. More recently, the acquisition of Microscan expanded Beckman's already strong presence in hospital and reference labs into the microbiology space. It has been 1 year since we closed the deal, and we achieved double-digit core revenue growth in the quarter. Both Iris and Microscan are helping us serve our customers better, and we believe that adjacent acquisitions, combined with our consistent application of DBS, will continue to enhance our comprehensive workflow solutions across our diagnostic businesses. 
In our Life Science platform, core revenue was up low single digits, with growth in both developed and high-growth markets. Leica Microsystems core revenues were up low single digits, as strong performance in North America and China was offset by declines in Japan and Latin America.
At SCIEX, core revenues grew low single digits, driven by demand in China and the Middle East. We also saw healthy sales growth in certain applied end markets and our service business. The SCIEX team has placed a strong focus on improving our customers' experience by pairing service contracts with instrument sales. This has driven record contract capture rates, including over 500 basis points of improvement in year-over-year attachment rates in the first quarter alone. 
SCIEX is a great example of how we use new products to help our customers' most critical challenges. In the quarter, we launched the x500R, the first model within our X-Series product family, which was the SCIEX team's largest ever development project. The x500R is a robust instrument that was specifically designed to serve customers in food and environmental testing labs, 2 of the fastest-growing end markets in mass spectrometry. Going forward, we expect this to be a significant contributor to our future growth.
Turning to Pall. We are very pleased with our early progress. This quarter, the Pall team delivered mid-single-digit core revenue growth, led by double-digit growth in our Life Science business due to demand for our biopharmaceutical solutions, including single-use technologies. Our Industrial business was down low single digits as we faced challenging market conditions. The team's enthusiastic application of DBS, including over 100 kaizen events since close, has led to meaningful process improvements and several new product introductions across Pall's Life Sciences and Industrial businesses. As a result of our growth and productivity initiatives, year-on-year operating margins were up over 250 basis points. 
As we move on to Dental, core revenues increased by 0.5% due to strong demand for consumables and implants in North America and the high-growth markets as well as healthy orthodontic sales in China. These gains were negatively impacted by 1 less selling day. Over the last several quarters, the Dental team's focus on execution and disciplined spending has paid off in margin expansion. This quarter, the team grew core operating margins by 250 basis points and reported operating margins by over 500 basis points to 14.5%. Our continued investments in innovation have resulted in a number of differentiated product offerings for our Dental customers. At the Chicago Midwinter Dental Show in February, we launched over 15 new products, including Maxcem Elite Chroma, a revolutionary new cement for dental restoration that changes color to indicate the correct time for a dentist to remove any excess material. The first-in-class color indicator simplifies the dentist's procedure and reduces clinical risk.
At Nobel Biocare, the team drove mid-single-digit average daily sales of implant systems this quarter. Since the acquisition closed, Nobel has achieved over 400 basis points of operating margin improvement and is focused on reinvesting those savings into future growth opportunities.
Moving now to Industrial Technologies. Revenues declined 1.5%, while core revenues were also down 1.5%. Despite the revenue decline, core operating margin expanded 25 basis points, while reported operating margin declined 30 basis points to 24.3%. The Automation platform's core revenues decreased at a high single-digit rate due to the weakness in global industrial markets and a difficult prior year comparison. While we expect this dynamic to largely persist in the near term, we were encouraged by signs of stabilization in the quarter. 
Product Identification core revenues grew at a low single-digit rate, as increased demand for marking and coding was offset by softer demand for the business's packaging and color solutions. 
Videojet's core revenues increased mid-single digits, driven by what we believe to be continuing share gains in North America and Europe, while high-growth markets remain softer. The Videojet team has delivered mid-single-digit growth or better for 9 of the past 10 quarters.
Last quarter, we announced the acquisition of Laetus, which extends our Product ID offerings into track-and-trace inspection systems for pharmaceutical packaging plants. We're off to a good start with Laetus. The team's early adoption of DBS tools is already driving key process improvements, as quicker service deployment and improved on-time delivery are ensuring that our customers receive the best possible support.
So to wrap up, our team executed well in the face of challenging economic conditions, and we're pleased with our start to 2016. The Danaher Business System remained the driving force behind our performance this quarter, helping to deliver high teens earnings growth, healthy operating margin expansion and 50% year-on-year free cash flow growth. We're also off to a great start at Pall, where the team drove meaningful process improvements and delivered mid-single-digit revenue growth in the quarter. We continue to make progress preparing for the launch of Fortive Corporation, which remains on track to close in the third quarter. Our teams are excited about the unique opportunity to continue developing 2 separate portfolios of market-leading businesses that we believe will create shareholder value for years to come.
We're initiating second quarter adjusted diluted net EPS guidance between $1.19 and $1.23, which assumes approximately 2% core revenue growth. We are increasing our full year adjusted EPS guidance from $4.80 to $4.95, to $4.85 to $4.98, which would represent a 13% to 16% increase from 2015 adjusted EPS."
265621,329307690,960864,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","Thanks, Tom. That concludes our formal remarks. Issa, we're now ready to take questions.",14,"Thanks, Tom. That concludes our formal remarks. Issa, we're now ready to take questions."
265621,329307690,960864,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Operator","[Operator Instructions] We will now take our first question from Scott Davis from Barclays.",14,"[Operator Instructions] We will now take our first question from Scott Davis from Barclays."
265621,329307690,960864,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Analysts","China was up. Bright spot for you guys, and I know last quarter was -- I mean, it tracked pretty comparable last quarter as well, but it sounded like things may have firmed up a little bit. I mean, Fluke -- is Fluke your canary in the coal mine in China h",76,"China was up. Bright spot for you guys, and I know last quarter was -- I mean, it tracked pretty comparable last quarter as well, but it sounded like things may have firmed up a little bit. I mean, Fluke -- is Fluke your canary in the coal mine in China having that business back in positive territory for the quarter? I'm just -- maybe just a little color on what you guys are seeing there."
265621,329307690,960864,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","Sure. Thanks, Scott. China, unquestionably, is -- remains a very good market for us. Despite much of the headlines that would certainly suggest that they're slowing in various areas, we were very pleased with the performance in China. And I think it was r",242,"Sure. Thanks, Scott. China, unquestionably, is -- remains a very good market for us. Despite much of the headlines that would certainly suggest that they're slowing in various areas, we were very pleased with the performance in China. And I think it was relatively broad based. If you looked at Danaher versus Fortive, let's say, Danaher was up high single digits in China, and Fortive was up mid-single digits in China. So I think a number of good examples where China remains a very attractive market for us. Relative to your specific question on Fluke, Fluke is just -- is an exceptional business overall. We've had a -- it's probably one of our most advanced businesses in terms of both go-to market as well as local production and product development in China. And while there's clearly still some softness around various industrial segments in the Chinese market, Fluke is a very strong brand in that market and has a very strong share position. So I think we're encouraged by some of the stabilization we see in some of the markets. And in other of those markets, we just continue to see very strong growth. Our Dental business continues to perform exceptionally well in China. Life Sciences & Diagnostics, broadly continuing to perform well there. So again, while clearly the headlines would show that, that market has pulled back a little bit in the aggregate, it's still a very good place to be."
265621,329307690,960864,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Analysts","Okay. It's helpful, Tom. And then just wanted to ask where you stand in Pall versus the deal model. Help us -- now that we're a year in or so, I mean, give us a sense of how you -- what's working? What's not working? What -- Industrial is probably far wea",106,"Okay. It's helpful, Tom. And then just wanted to ask where you stand in Pall versus the deal model. Help us -- now that we're a year in or so, I mean, give us a sense of how you -- what's working? What's not working? What -- Industrial is probably far weaker than you thought it was, but the Environmental or the, I should say, the Life Sciences side is probably far stronger than you thought it would be. So how are you managing that variability? And how does it all really stack up at the end of the day versus what your prior expectations were?"
265621,329307690,960864,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","Scott, we're in a -- it's Dan. We're off to a very good start there. We had mid-single-digit growth in the quarter. As Tom alluded, that was a combination of double-digit growth in the Life Science side and a slight decline on the Industrial side. Clearly",150,"Scott, we're in a -- it's Dan. We're off to a very good start there. We had mid-single-digit growth in the quarter. As Tom alluded, that was a combination of double-digit growth in the Life Science side and a slight decline on the Industrial side. Clearly, that would have been a contributor to our overall organic growth at Danaher. From a margin perspective, we are ahead of schedule. We talked about north of $100 million of benefit here this year on the margin side, continue to track very well to the ultimate target of $300 million. In addition to this, we are getting favorable mix, given the Life Science business is more profitable, and we really saw that play out exceedingly well in the first quarter. It'll likely create some opportunities, where we'll be able to accelerate some investments here at Pall during this year, given we're tracking so well."
265621,329307690,960864,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","Just to follow on Dan's comment a little bit, the team at Pall has just done a tremendous job. It's -- as we've mentioned before, it's a great combination of both some seasoned Danaher leaders as well as an exceptional group of folks who have been at Pall",138,"Just to follow on Dan's comment a little bit, the team at Pall has just done a tremendous job. It's -- as we've mentioned before, it's a great combination of both some seasoned Danaher leaders as well as an exceptional group of folks who have been at Pall for a long time, who, together, have really brought DBS to life in that business in rapid fashion. You heard me mention about the 100 kaizens that have gone on. Those have gone on literally around the world. And it's just one indication of the rapid rate at which the Pall team has adopted the tools of DBS. And really, that has truly contributed to not only the growth dynamics that we're seeing, but certainly has assisted in us getting ahead on the cost takeouts in the margin side."
265621,329307690,960864,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Operator","Our next question comes from Steve Tusa from JPMorgan.",9,"Our next question comes from Steve Tusa from JPMorgan."
265621,329307690,960864,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Analysts","Just back to Pall, just a follow-up on that. I think they were doing a little bit better than $100 million in R&D a year. And R&D year-over-year was up I think about $20 million. Is that a little bit of a decline in the core R&D? Or are you kind of gettin",97,"Just back to Pall, just a follow-up on that. I think they were doing a little bit better than $100 million in R&D a year. And R&D year-over-year was up I think about $20 million. Is that a little bit of a decline in the core R&D? Or are you kind of getting efficiencies there on the Pall side? You also mentioned you're kind of walking away from some business there, I think, in your 10-Q at Pall. Could you just give us a degree of magnitude on that front? And then I have one quick follow-up."
265621,329307690,960864,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","Steve, on walking away from some business, that's something that Pall had started prior even to our acquisition. It's down to a relatively nominal amount here and will be I think largely done by the middle of this year.",39,"Steve, on walking away from some business, that's something that Pall had started prior even to our acquisition. It's down to a relatively nominal amount here and will be I think largely done by the middle of this year."
265621,329307690,960864,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Analysts","Okay. And then on the R&D front, what was kind of Pall's R&D? I think it was greater than $100 million. Are you guys getting more efficiencies there? Do you expect to maintain that R&D budget? Increase it?",38,"Okay. And then on the R&D front, what was kind of Pall's R&D? I think it was greater than $100 million. Are you guys getting more efficiencies there? Do you expect to maintain that R&D budget? Increase it?"
265621,329307690,960864,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","I would -- right now, we're sustaining. And I suspect over time, that will get increased.",16,"I would -- right now, we're sustaining. And I suspect over time, that will get increased."
265621,329307690,960864,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","Steve, I would just add to that. And I think we'd mentioned this maybe once before. But if you think back to the playbook that we ran post the Beckman acquisition, I think the playbook here at Pall is very similar, which is there's a number of opportuniti",197,"Steve, I would just add to that. And I think we'd mentioned this maybe once before. But if you think back to the playbook that we ran post the Beckman acquisition, I think the playbook here at Pall is very similar, which is there's a number of opportunities to get cost out of the business broadly defined, and we're working on those obviously, start to see the margins coming up. But the playbook is to then redeploy some of that cost takeout into investments in sales and marketing and R&D. You see us do that broadly across Danaher, with gross margins going up and sales and marketing and R&D on the quarter for the Danaher in total up 30 basis points. We did that at Pall -- at Beckman. R&D lifted over time. We started to get the innovation engine going. Innovation at Pall has always been a strong suit there, but we think we can take it up another level. And so some of those cost takeouts will ultimately translate into either higher spending or potentially more efficient spending if we find opportunities to do a better job innovating at the same cost rate. We'll see."
265621,329307690,960864,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Analysts","Okay. And then just lastly on the free cash flow, a very strong quarter. Obviously, you're paying down some debt, beginning to delever here a little bit. Is there anything about the timing of that free cash flow? Or should we think about kind of normal se",83,"Okay. And then just lastly on the free cash flow, a very strong quarter. Obviously, you're paying down some debt, beginning to delever here a little bit. Is there anything about the timing of that free cash flow? Or should we think about kind of normal seasonality off of that base? I know there were some accruals. Year-over-year, accruals were less of a drag. Maybe there's just some timing. What's -- maybe bottom line is, what's kind of the annual free cash guide?"
265621,329307690,960864,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","Well, Steve, we don't give a specific guide, but we're off to a very good start. There was a little bit of timing benefit around some tax payments. But broadly, our cash flow was quite strong. As you know, we ended last year with a record number and a ver",85,"Well, Steve, we don't give a specific guide, but we're off to a very good start. There was a little bit of timing benefit around some tax payments. But broadly, our cash flow was quite strong. As you know, we ended last year with a record number and a very strong second half of free cash flow. We expect that trend to continue. We're not going to be up 40% year-on-year, but we'd expect a very healthy double-digit increase in free cash flow this year."
265621,329307690,960864,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","Our first quarter last year was [indiscernible].",7,"Our first quarter last year was [indiscernible]."
265621,329307690,960864,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","And we were a little bit light.",7,"And we were a little bit light."
265621,329307690,960864,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","A little lighter last first quarter, so a little bit of benefit there from a comp standpoint.",17,"A little lighter last first quarter, so a little bit of benefit there from a comp standpoint."
265621,329307690,960864,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Operator","Our next question comes from Nigel Coe from Morgan Stanley.",10,"Our next question comes from Nigel Coe from Morgan Stanley."
265621,329307690,960864,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Analysts","Tom, so you mentioned you're seeing signs of stability. I think that was in relation to Fluke, specifically. But maybe just broaden that to the conversation to maybe some of the more typical businesses within Industrial Tech, Tektronix. What are you seein",51,"Tom, so you mentioned you're seeing signs of stability. I think that was in relation to Fluke, specifically. But maybe just broaden that to the conversation to maybe some of the more typical businesses within Industrial Tech, Tektronix. What are you seeing today compared to what you saw back in January?"
265621,329307690,960864,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","Sure. Thanks, Nigel. Our comments about stability were not exclusively associated with Fluke. In fact, I think there are some pockets, even around the Fluke business, where we've seen stability, but we've also seen still some real headwinds. But I think w",211,"Sure. Thanks, Nigel. Our comments about stability were not exclusively associated with Fluke. In fact, I think there are some pockets, even around the Fluke business, where we've seen stability, but we've also seen still some real headwinds. But I think we have seen stability in some other areas. You asked specifically about -- on the Industrial Tech side. The Automation businesses, our Sensors and Controls businesses, as we looked at those throughout the course of the quarter, February and March, we saw indications of stability. We saw those order rates kind of firm up a little bit. And while we wouldn't call it an upward trajectory, we would call those a bit more stable than we had seen in the trajectory of the fourth quarter and maybe at the very opening of the year. You mentioned Tektronix. I wouldn't necessarily put Tektronix quite in that category yet. It had one of the more challenging quarters. It's in one of the tougher markets probably that we face today. And so I think while we're very encouraged by the new product flow at Tektronix and we expect to see that -- those new products drive some improved performance in the back half of the year, Tek remains in a pretty challenging environment."
265621,329307690,960864,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Analysts","Okay, that's helpful. And then switching to Environmental margins. Obviously, a lot of noise this quarter. You called out investment spending. I'm wondering if you can maybe help us size that impact. And it seems that this quarter, you had a negative mix",64,"Okay, that's helpful. And then switching to Environmental margins. Obviously, a lot of noise this quarter. You called out investment spending. I'm wondering if you can maybe help us size that impact. And it seems that this quarter, you had a negative mix of consumables versus GVR growth. Is that true? And would you expect that to normalize over the balance of the year?"
265621,329307690,960864,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","Well, I'll need you to clarify that last question. I'm not exactly sure what you meant by negative mix relative to GVR growth, unless you're talking about Water Quality versus GVR within Environmental. Is that what [indiscernible]?",37,"Well, I'll need you to clarify that last question. I'm not exactly sure what you meant by negative mix relative to GVR growth, unless you're talking about Water Quality versus GVR within Environmental. Is that what [indiscernible]?"
265621,329307690,960864,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Analysts","Exactly [indiscernible] GVR [indiscernible] margin, yes.",6,"Exactly [indiscernible] GVR [indiscernible] margin, yes."
265621,329307690,960864,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","Okay, sure, yes. No, absolutely right. Yes, thanks, Nigel. That's -- you're right on. If you look at Environmental, which, as all of you know, both has our GVR business as well as our Water Quality businesses, GVR had stronger growth during the course of",222,"Okay, sure, yes. No, absolutely right. Yes, thanks, Nigel. That's -- you're right on. If you look at Environmental, which, as all of you know, both has our GVR business as well as our Water Quality businesses, GVR had stronger growth during the course of the quarter, very encouraging signs of the EMV dynamic taking hold. And GVR comes through that with a lower-margin mix relative to our Water Quality platform, which has higher margins and specifically, Hach. So a little bit softer Hach business, a little bit stronger GVR business during the course of the quarter together causes some of that headwind that you saw on the margin line there. The reference to investment spend is specific to what we need to do to build the capacity to step up to the demand associated with EMV. And so we see that in -- specifically in our GVR business. And those are investments that clearly will pay off as we continue to ramp our capabilities. And as we go into the second quarter and beyond, we would expect those margins overall in the segment to return closer to normal levels. Obviously, some continued investment there, but we expect Water Quality to come up a bit. So overall, I think there were just a couple of unique factors here in the first quarter."
265621,329307690,960864,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Operator","Our next question comes from Shannon O'Callaghan from UBS.",10,"Our next question comes from Shannon O'Callaghan from UBS."
265621,329307690,960864,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Analysts","Tom, you mentioned execution and disciplined spending at Dental with the big margin improvement there. I mean, that's a segment that you've always targeted getting to much higher margins over the years, but it's been more of a challenge. I mean, is this s",58,"Tom, you mentioned execution and disciplined spending at Dental with the big margin improvement there. I mean, that's a segment that you've always targeted getting to much higher margins over the years, but it's been more of a challenge. I mean, is this something of a breakthrough here? Or how should we read the performance on those comments?"
265621,329307690,960864,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","Well, you're absolutely right, Shannon. It's been a challenge in the past. And we did set our sights and commit to making a difference there. We have some new leadership in place over the platform. Many of you have met Amir Aghdaei, who's led a number of",207,"Well, you're absolutely right, Shannon. It's been a challenge in the past. And we did set our sights and commit to making a difference there. We have some new leadership in place over the platform. Many of you have met Amir Aghdaei, who's led a number of our businesses over the last several years and some of our more challenging businesses. And he's really put a terrific team together. They've set their sights on specific margin improvements over time. There was some outstanding execution, some disciplined cost control. But similar to the comments I made earlier around the playbook, I made reference to the Beckman playbook and how that applies to Pall, while we'll continue to drive margin improvement at Dental under the team's leadership, we'll also take some of that improvement and continue to invest in sales and marketing and in R&D because we do have opportunities for improvement in terms of our innovation cadence. We saw some modest improvement there in our core growth in the platform during the quarter, but we know there's opportunities to continue to improve that. We expect it to continue to step up. But some additional investment over time with some of that cost takeout will certainly be a help."
265621,329307690,960864,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Analysts","Okay, great. And then, Dan, maybe a question for you on tax. Obviously, a lot of new tax policies being contemplated and put into place that impact a lot of multinationals. Any just thoughts on that in general and potential impacts on Danaher as well as h",62,"Okay, great. And then, Dan, maybe a question for you on tax. Obviously, a lot of new tax policies being contemplated and put into place that impact a lot of multinationals. Any just thoughts on that in general and potential impacts on Danaher as well as how should we think about kind of the 2 NewCo tax rates and any differentials there?"
265621,329307690,960864,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","Sure, Shannon. Yes, obviously, it's something we're spending a lot of time on, trying to understand better. I mean, our initial read of this is this is not going to be an impact to us -- a material impact to us in the near term. That over time, we could s",169,"Sure, Shannon. Yes, obviously, it's something we're spending a lot of time on, trying to understand better. I mean, our initial read of this is this is not going to be an impact to us -- a material impact to us in the near term. That over time, we could see some rate creep because of it. Now that assumes nothing else happens and there's no other opportunities. And so sitting here right now, it's not something that worries us a great deal, but it's obviously a potential risk kind of going forward. I don't think there's a big change in how we think about the tax rates of the 2 entities. We've talked about Fortive likely coming out closer to kind of a high-20 tax rate. Again, I think as they begin to do some acquisitions, they'll have an opportunity to bring that down. And I would expect that Danaher would be at our current rate or lower. Danaher RemainCo would be at our current rate or lower."
265621,329307690,960864,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Operator","Our next question comes from Steven Winoker from Bernstein.",9,"Our next question comes from Steven Winoker from Bernstein."
265621,329307690,960864,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Analysts","Could you maybe just clarify? You talked about Fortive versus Danaher core growth in China. What was it globally for the quarter?",22,"Could you maybe just clarify? You talked about Fortive versus Danaher core growth in China. What was it globally for the quarter?"
265621,329307690,960864,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","The Danaher was up a couple points, and Fortive was down 1 to 2 points, say 1.5%, I believe.",19,"The Danaher was up a couple points, and Fortive was down 1 to 2 points, say 1.5%, I believe."
265621,329307690,960864,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Analysts","Okay. And, well, I guess everybody, what are you thinking about in terms of current thinking, I should say, on capital structure for the 2 entities? Where are you still heading for that? I know there have been some private conversations, but don't have a",51,"Okay. And, well, I guess everybody, what are you thinking about in terms of current thinking, I should say, on capital structure for the 2 entities? Where are you still heading for that? I know there have been some private conversations, but don't have a sense for where that is now."
265621,329307690,960864,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","I don't think much has changed versus what we communicated a year ago. We would expect Fortive to come out as an investment-grade company. Likely not -- they're not going to be an A-rated company, but a triple -- something in the BBB range, where they wou",62,"I don't think much has changed versus what we communicated a year ago. We would expect Fortive to come out as an investment-grade company. Likely not -- they're not going to be an A-rated company, but a triple -- something in the BBB range, where they would be strong investment-grade and clearly have a fair amount of latitude to execute M&A."
265621,329307690,960864,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Analysts","Okay, great. And if I could just -- one more. Tom, in terms of the R&D profile, I know you talked a little bit about it before, specifically with Pall. But I guess, overall, for the company, where is -- what level of R&D are we talking about for just -- f",79,"Okay, great. And if I could just -- one more. Tom, in terms of the R&D profile, I know you talked a little bit about it before, specifically with Pall. But I guess, overall, for the company, where is -- what level of R&D are we talking about for just -- for the new Danaher going forward? And do you see an opportunity to accelerate that at all as you think about also accelerating core growth in new Danaher?"
265621,329307690,960864,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","Sure. Thanks, Steve. I've said for a long time, I've always believed that there's no magic number for a business with the diverse portfolio that we have today. We really look at continuing to invest in R&D to certain levels, specifically at an operating c",216,"Sure. Thanks, Steve. I've said for a long time, I've always believed that there's no magic number for a business with the diverse portfolio that we have today. We really look at continuing to invest in R&D to certain levels, specifically at an operating company level. And that's obviously relevant for what -- relative to what's important to those markets, what's important for our competitiveness, what yields the greatest levels of competitive advantage from an innovation perspective. So we really look at it sort of operating company by operating company. Our track record is a great one, and it will continue, of taking R&D up year-on-year pretty consistently. We've used our operating margin expansion that's been driven by improvements in gross margin to put some of that back into not only R&D, but into sales and marketing as well. And again, we've done that very consistently. I would expect that we will continue to do that. One of our 5 core values is Innovation Defines Our Future, and we represent that in our metrics by continuing to see that percent of R&D go up year-on-year. So again, it'll vary in terms of the number that we achieve year-on-year by operating company or even by platform, but using innovation to drive competitiveness is key to our strategy."
265621,329307690,960864,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Analysts","Okay. But what was it in the quarter, at least, just for the current -- or for the new Danaher?",20,"Okay. But what was it in the quarter, at least, just for the current -- or for the new Danaher?"
265621,329307690,960864,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","Probably in the same -- Steve, we have the dynamic around Pall, where a lot of the application expertise they bring to their customers, which is a big part of their value add, they include in sales and marketing than R&D. So the fact that you saw R&D as a",109,"Probably in the same -- Steve, we have the dynamic around Pall, where a lot of the application expertise they bring to their customers, which is a big part of their value add, they include in sales and marketing than R&D. So the fact that you saw R&D as a percent of our overall revenues go down 40, 50 basis points year-on-year, that's entirely driven by the Pall dynamic. But I would say, Danaher is probably in that zone where you've got some higher R&D businesses. But because of the way Pall accounts for their R&D, it probably averages to where Danaher is today, around that 6% percent range."
265621,329307690,960864,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Operator","Our next question comes from Ross Muken from Evercore ISI.",10,"Our next question comes from Ross Muken from Evercore ISI."
265621,329307690,960864,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Analysts","Maybe on the Life Science business, just a little bit more color commentary. You called out pharma as sort of a strong end market. It seems like on the SCIEX side that market has been running hot for a while. I mean, how do you see the trajectory there? A",100,"Maybe on the Life Science business, just a little bit more color commentary. You called out pharma as sort of a strong end market. It seems like on the SCIEX side that market has been running hot for a while. I mean, how do you see the trajectory there? And then secondarily on the Pall side, biotech, there's obviously been a lot of concern in the market, particularly with the smaller companies on funding and the like. And have you seen anything in that side of the business, particularly with small to midsize biotechs in terms of any relevant slowdown?"
265621,329307690,960864,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","Thanks, Ross. Yes, no question, the pharma market is an important driver of our growth across the Life Science portfolio. And we have exposure to that growing market across virtually every one of our Life Science businesses. Pall, specific to your questio",222,"Thanks, Ross. Yes, no question, the pharma market is an important driver of our growth across the Life Science portfolio. And we have exposure to that growing market across virtually every one of our Life Science businesses. Pall, specific to your question around biotech and small and midsize, continues to perform exceptionally well across the biotech market. Just to go back and talk about a few things about what's going on in that market, Pall has a $1 billion business today that's oriented toward biopharmaceuticals. And the combination of the solutions that they've had for a number of years, along with the newer products in single-use technologies, continue to drive the exceptional growth that we see there. That growth, as I think many of you know, Ross, and others know, is really driven by this move, the growth and the transition from small-molecule drugs to large-molecule drugs. And not only are those the fastest-growing segment of the market, but they're also the drugs that are most significantly represented in the pipelines of both small as well as large pharmaceutical companies today. So we remain optimistic and bullish on that market. And I think there's every reason to believe that we'll continue to see good growth not only from Pall, but from our other Life Science business that have exposure to that market."
265621,329307690,960864,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Analysts","Great. And maybe just quickly on the capital allocation side. So a lot of equity market volatility to start the year. Private equity has probably been more of a net seller than buyer. I mean, how has it sort of impacted asset prices on the private side in",130,"Great. And maybe just quickly on the capital allocation side. So a lot of equity market volatility to start the year. Private equity has probably been more of a net seller than buyer. I mean, how has it sort of impacted asset prices on the private side in terms of what you're looking at? And does it make sellers more apt to maybe approach a process, given they saw equity prices up, down, up again, maybe they're afraid they go down again and so they want to take advantage of maybe an open in the sort of credit markets where larger companies can acquire? I mean, just trying to get a feel for kind of how all this volatility had maybe helped you a little bit on the deal front."
265621,329307690,960864,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","I mean, volatility is a net positive for us as a well-capitalized acquirer. Your comment about private equity, it's getting a little better for them, but it's -- the leverage markets are still pretty tough. So I think all those factors play to our benefit",80,"I mean, volatility is a net positive for us as a well-capitalized acquirer. Your comment about private equity, it's getting a little better for them, but it's -- the leverage markets are still pretty tough. So I think all those factors play to our benefit. Now granted there are other -- a number of other well-capitalized corporate players here, but we're happy to sort of compete in this sort of environment, where there's a little bit more volatility and uncertainty."
265621,329307690,960864,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Operator","Next question comes from Jeffrey Sprague from Vertical Research Partners.",10,"Next question comes from Jeffrey Sprague from Vertical Research Partners."
265621,329307690,960864,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Analysts","Just a couple. First on SG&A, I guess, Dan, you kind of partially answered it speaking to the Pall R&D. But the SG&A moving up as a percent of sales, is there anything to flag there? And do you expect that sort of upward pressure over the balance of the y",51,"Just a couple. First on SG&A, I guess, Dan, you kind of partially answered it speaking to the Pall R&D. But the SG&A moving up as a percent of sales, is there anything to flag there? And do you expect that sort of upward pressure over the balance of the year?"
265621,329307690,960864,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","Well, you -- if we first just take Pall out of the equation entirely, R&D as a percent of sales was flat year-on-year, but sales and marketing was up 30 basis points, and that was intentional. I mean, we've stepped up some investments. We've talked about",174,"Well, you -- if we first just take Pall out of the equation entirely, R&D as a percent of sales was flat year-on-year, but sales and marketing was up 30 basis points, and that was intentional. I mean, we've stepped up some investments. We've talked about some of the opportunities in high-growth markets, where we see people pulling back and we see there was some opportunity. I think some of the success Fortive is having in China right now is probably a little bit of an example of that. And Pall brings in a pretty high sales and marketing expense when you kind of layer that in. That probably sustains itself. We see that as an important part of their go-to market, not only their go-to market, but, as I mentioned also, sort of part of their R&D as well. So we don't see ourselves sort of cutting back on those investments. If anything, given we've had a little bit more strength here early in the year, we may step some of that up."
265621,329307690,960864,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Analysts","And on tax, you mentioned creep and maybe there could be some offsets. Have you guys looked at this FASB change on stock comp and determined what, if any, benefit you'll have when you choose to adopt that?",38,"And on tax, you mentioned creep and maybe there could be some offsets. Have you guys looked at this FASB change on stock comp and determined what, if any, benefit you'll have when you choose to adopt that?"
265621,329307690,960864,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","We don't think it'd be meaningful.",7,"We don't think it'd be meaningful."
265621,329307690,960864,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Analysts","And then just finally, the 6 small deals, were any of those in Fortive? And if so, what?",18,"And then just finally, the 6 small deals, were any of those in Fortive? And if so, what?"
265621,329307690,960864,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","One was Fortive.",3,"One was Fortive."
265621,329307690,960864,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Analysts","What kind of asset?",4,"What kind of asset?"
265621,329307690,960864,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","It was an acquisition for Gilbarco.",6,"It was an acquisition for Gilbarco."
265621,329307690,960864,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","And that's on top of a couple more we did late last year. So in the last 4, 5 months, it's 3 deals, Jeff.",25,"And that's on top of a couple more we did late last year. So in the last 4, 5 months, it's 3 deals, Jeff."
265621,329307690,960864,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Operator","Our next question comes from Deane Dray from RBC.",9,"Our next question comes from Deane Dray from RBC."
265621,329307690,960864,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Analysts","Just like to go back to the 2016 guide. And just to clarify, has there been any change to the core revenue outlook for 2% to 3%? And then maybe a bit on the cadence of that through the year and how might that split with Fortive?",47,"Just like to go back to the 2016 guide. And just to clarify, has there been any change to the core revenue outlook for 2% to 3%? And then maybe a bit on the cadence of that through the year and how might that split with Fortive?"
265621,329307690,960864,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","Deane, no real change to our view of the full year at 2% to 3%. I think our comments referring to some stabilization that we've seen here in the last couple of months I think suggest -- as well as, by the way, how that was represented in the order rates,",85,"Deane, no real change to our view of the full year at 2% to 3%. I think our comments referring to some stabilization that we've seen here in the last couple of months I think suggest -- as well as, by the way, how that was represented in the order rates, not just the sellout, but the order rates in the last couple of months, suggest that we still feel pretty good about the 2% to 3%. So I think we're going to stay there."
265621,329307690,960864,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Analysts","And how about the expectations for Fortive in the second quarter?",11,"And how about the expectations for Fortive in the second quarter?"
265621,329307690,960864,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","We would expect that Fortive would be in the same zone, maybe a little bit better. Danaher ex Fortive would be slightly better, and that would roll up to be approximately 2% versus the 0.5% of core we delivered in the first quarter.",43,"We would expect that Fortive would be in the same zone, maybe a little bit better. Danaher ex Fortive would be slightly better, and that would roll up to be approximately 2% versus the 0.5% of core we delivered in the first quarter."
265621,329307690,960864,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Analysts","Great. And then maybe some clarification on Hach. The softness in the high-growth markets, is there anything specific there? Is it tougher comps? Why might there be some slowing there?",30,"Great. And then maybe some clarification on Hach. The softness in the high-growth markets, is there anything specific there? Is it tougher comps? Why might there be some slowing there?"
265621,329307690,960864,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","Well, it certainly was a very challenging comp year-on-year. The platform, overall, I think comp did 10% versus last year, Deane. So it was probably -- among the platforms that we have, it was probably the toughest comp perhaps across the entire corporati",146,"Well, it certainly was a very challenging comp year-on-year. The platform, overall, I think comp did 10% versus last year, Deane. So it was probably -- among the platforms that we have, it was probably the toughest comp perhaps across the entire corporation. So that was certainly a challenge. We have seen some delays in some key projects in a couple of the high-growth markets. So that was certainly a factor there. In certain of those high-growth markets, we actually have a little bit more industrial exposure than purely municipal exposure. And that, obviously, had an impact in those markets. Again, we don't -- that business, you know it well, Deane, is just one of our exceptional franchises. And we're confident that business continues to -- will continue to grow over time, and we'll see that business's core growth rate improve here in the second quarter."
265621,329307690,960864,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Analysts","Great. And then just last one, and still on the topic of Hach. I don't recall ever there being a time where Water Quality has been more front-page news in the U.S. with Flint, Michigan. And just -- what's your expectation about the longer-term implication",55,"Great. And then just last one, and still on the topic of Hach. I don't recall ever there being a time where Water Quality has been more front-page news in the U.S. with Flint, Michigan. And just -- what's your expectation about the longer-term implications on water quality, water test? And how is Hach positioned?"
265621,329307690,960864,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","Sure. Well, believe me, we wish we had an answer today to the infrastructure challenges that lead pipes represent in that situation. It's just terrible to see the challenges that, that community has gone through. But I think if we try to look on the brigh",141,"Sure. Well, believe me, we wish we had an answer today to the infrastructure challenges that lead pipes represent in that situation. It's just terrible to see the challenges that, that community has gone through. But I think if we try to look on the bright side from the standpoint of the overall market dynamics, situations like that always turn the spotlight up on the importance of regulatory oversight in municipalities around the country and frankly, throughout the world. And so as those regulatory drivers continue to be strengthened, to be pointed at the greatest vulnerabilities in municipal and industrial systems, that, again, while challenging for those communities, ultimately benefits consumers and certainly benefits us. Regulatory drivers have always been a key macro driver for that platform, and they will continue to be so for as long as we could anticipate."
265621,329307690,960864,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Operator","Our next question comes from Andrew Obin from Bank of America Merrill Lynch.",13,"Our next question comes from Andrew Obin from Bank of America Merrill Lynch."
265621,329307690,960864,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Analysts","I guess in the Q, you sort of indicated that you're still on track to pay the $3 billion dividend from Fortive to Danaher. Is there any flexibility around that number if Fortive discovers a good acquisition? How flexible are you there?",42,"I guess in the Q, you sort of indicated that you're still on track to pay the $3 billion dividend from Fortive to Danaher. Is there any flexibility around that number if Fortive discovers a good acquisition? How flexible are you there?"
265621,329307690,960864,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","Well, that's something obviously the board would need to determine depending on, obviously, the size of the acquisition and their -- what else they have in the pipeline.",28,"Well, that's something obviously the board would need to determine depending on, obviously, the size of the acquisition and their -- what else they have in the pipeline."
265621,329307690,960864,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Analysts","But it's fair to assume that there's some flexibility there?",11,"But it's fair to assume that there's some flexibility there?"
265621,329307690,960864,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","Nothing's said until it's said",6,"Nothing's said until it's said"
265621,329307690,960864,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Analysts","And then just going back to GVR. The EMV investment and -- both growth and investment, is it fair to assume that investment is going to be front-end loaded Q1 and Q2, but you might see growth throughout the year? Is that the right way of thinking about it",49,"And then just going back to GVR. The EMV investment and -- both growth and investment, is it fair to assume that investment is going to be front-end loaded Q1 and Q2, but you might see growth throughout the year? Is that the right way of thinking about it?"
265621,329307690,960864,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","Yes. There's clearly some upfront cost. And as Tom alluded, we also had some onetime items in the quarter, and that will normalize as we get through the year.",29,"Yes. There's clearly some upfront cost. And as Tom alluded, we also had some onetime items in the quarter, and that will normalize as we get through the year."
265621,329307690,960864,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Operator","We'll now take our next question from Julian Mitchell from Crdit Suisse.",13,"We'll now take our next question from Julian Mitchell from Crdit Suisse."
265621,329307690,960864,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Analysts","Just a question on Dental first. The growth rate was, I guess, lower than I thought, particularly as Nobel should have automatically pushed up the organic growth a little bit and the comp was pretty easy. So I saw you called out Middle East and Africa equ",70,"Just a question on Dental first. The growth rate was, I guess, lower than I thought, particularly as Nobel should have automatically pushed up the organic growth a little bit and the comp was pretty easy. So I saw you called out Middle East and Africa equipment, but I wouldn't have thought that was a very sizable piece of the business. So maybe just give a bit more color there."
265621,329307690,960864,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","Sure. Well, our Dental growth, overall, Julian, was -- at 0.5% was basically in line with our expectations, modest improvement from where we'd been over the last few quarters. And obviously, as we talked just a few minutes ago, we're very pleased with see",216,"Sure. Well, our Dental growth, overall, Julian, was -- at 0.5% was basically in line with our expectations, modest improvement from where we'd been over the last few quarters. And obviously, as we talked just a few minutes ago, we're very pleased with seeing the OMX up at the rate that I talked about earlier. We saw solid low single-digit growth in consumables, and sellout continues and actually is a fraction better than even our sell-in. So we always look at that sellout. We have good transparency with our distribution partners, and we're encouraged by that. The Nobel implant systems business, mid-single-digit average daily sales growth in the quarter, we're pleased with that. The Ormco business, the orthodontic business, continues to do well. And we're continuing to see on a geographic basis, as I mentioned, the -- a couple of the high-growth markets, specifically the -- our business in China, continuing to do well. On the flip side, on the equipment side, we have seen some challenges in Europe actually, and a couple in those high-growth markets, where the equipment side has been held back a little bit more significantly. So I think as we annualize over some of those more challenging comps, we'll continue to see that growth improve during the course of this year."
265621,329307690,960864,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Analysts","Got it. And then secondly, just on Test & Measurement. I wondered -- obviously, the trends year-on-year are sort of similar Q1 as in Q4. I wondered if there was any specific end market you'd call out that's sort of dragging on the growth now. Obviously, y",69,"Got it. And then secondly, just on Test & Measurement. I wondered -- obviously, the trends year-on-year are sort of similar Q1 as in Q4. I wondered if there was any specific end market you'd call out that's sort of dragging on the growth now. Obviously, you do have some electronics exposure, for example, in T&M. Or if you thought it was sort of fairly broad based, the weakness."
265621,329307690,960864,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","Well, there's certainly some broad-based weakness. But if I had to call out a couple of the softer spots, it probably would be the end markets where Tek is most exposed. And then probably secondarily, it would be in -- on the Fluke side. Probably, the U.S",65,"Well, there's certainly some broad-based weakness. But if I had to call out a couple of the softer spots, it probably would be the end markets where Tek is most exposed. And then probably secondarily, it would be in -- on the Fluke side. Probably, the U.S. point-of-sale has been a weaker spot here through the quarter. Those would be the 2 I'd probably highlight."
265621,329307690,960864,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Analysts","And you're expecting those to be little changed in Q2?",11,"And you're expecting those to be little changed in Q2?"
265621,329307690,960864,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","We are, that's right. There's no indication right now of a pickup there. Obviously, we can always be optimistic, but we're not projecting for any improvement there, certainly in the second quarter.",32,"We are, that's right. There's no indication right now of a pickup there. Obviously, we can always be optimistic, but we're not projecting for any improvement there, certainly in the second quarter."
265621,329307690,960864,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Operator","I would now like to turn the call back to Mr. Matt Gugino for any additional or closing remarks.",19,"I would now like to turn the call back to Mr. Matt Gugino for any additional or closing remarks."
265621,329307690,960864,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Executives","Thanks, Issa, and thanks, everyone, for joining us. We're around all day for questions.",14,"Thanks, Issa, and thanks, everyone, for joining us. We're around all day for questions."
265621,329307690,960864,"Danaher Corp., Q1 2016 Earnings Call, Apr 21, 2016",2016-04-21,"Earnings Calls","Danaher Corporation","Operator","Thank you, ladies and gentlemen. That will conclude today's conference call. You may now disconnect.",15,"Thank you, ladies and gentlemen. That will conclude today's conference call. You may now disconnect."
265621,368081405,1011232,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Operator","My name is Ashley, and I will be your conference facilitator today. At this time, I would like to welcome everyone to the Danaher Corporation, Second Quarter 2016 Earnings Results Conference Call. [Operator Instructions] I will now turn the conference ove",57,"My name is Ashley, and I will be your conference facilitator today. At this time, I would like to welcome everyone to the Danaher Corporation, Second Quarter 2016 Earnings Results Conference Call. [Operator Instructions] I will now turn the conference over to Mr. Matt Gugino, Vice President of Investor Relations. Mr. Gugino, you may begin your conference."
265621,368081405,1011232,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Executives","Thanks, Ashley. Good morning, everyone, and thanks for joining us on the call. With us today are Tom Joyce, our President and Chief Executive Officer; and Dan Comas, our Executive Vice President and Chief Financial Officer. I'd like to point out that our",328,"Thanks, Ashley. Good morning, everyone, and thanks for joining us on the call. With us today are Tom Joyce, our President and Chief Executive Officer; and Dan Comas, our Executive Vice President and Chief Financial Officer. I'd like to point out that our earnings release, the slide presentation supplementing today's call, our second quarter Form 10-Q and the reconciliations and other information required by SEC Regulation G relating to any non-GAAP financial measures provided during the call are all available on the Investors' section of our website, www.danaher.com, under the heading Financial Information. The audio portion of this call will be archived on the Investors' section of our website later today under the heading Events & Presentations and will remain archived until our next quarterly call. A replay of this call will also be available until August 1, 2016. 
During the presentation, we will describe certain of the more significant factors that impacted year-over-year performance. The supplemental materials describe additional factors that impacted year-over-year performance. Unless otherwise noted, all references in these remarks and supplemental materials to company-specific financial metrics relate to continuing operations of the company in the second quarter of 2016, and all references to period-to-period increases or decreases in financial metrics are year-over-year. 
We may also describe certain products and devices which have applications submitted and pending for certain regulatory approvals. 
During the call, we will make forward-looking statements within the meaning of the federal securities laws, including statements regarding events or developments that we believe or anticipate will or may occur in the future. These forward-looking statements are subject to a number of risks and uncertainties, including those set forth in our SEC filings, and actual results may differ materially from any forward-looking statement that we make today. These forward-looking statements speak only as of the date that they are made, and we do not assume any obligation to update any forward-looking statement. 
With that, I'd like to turn the call over to Tom."
265621,368081405,1011232,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Executives","Thanks, Matt, and good morning, everyone. The second quarter was a busy and exciting one for Danaher. Despite challenging economic conditions, we are pleased with our performance as the team's consistent focus on execution helped deliver solid core revenu",2343,"Thanks, Matt, and good morning, everyone. The second quarter was a busy and exciting one for Danaher. Despite challenging economic conditions, we are pleased with our performance as the team's consistent focus on execution helped deliver solid core revenue growth, high-teens adjusted earnings per share growth and strong free cash flow performance. 
On July 2, we successfully completed the spin-off of Fortive Corporation, a new industrial growth company. The earlier-than-expected completion of the separation is a testament to our process orientation, execution focus and exceptional teamwork. We continue to believe that the separation will provide significant opportunities for both Danaher and Fortive to independently build even greater shareholder value in the years ahead. Since we owned Fortive through the end of the quarter, will start with financial highlights that reflect the combined Danaher and Fortive results.  We'll then provide detail for the businesses remaining with Danaher, outline our planned new putting segments and provide guidance for Danaher's continuing operations, excluding Fortive, for the third quarter and the full year. Since the Fortive team will be reporting their second quarter results separately next week, we ask that you please save any questions about the Fortive businesses until then. 
Now, turning to the details of the second quarter. Adjusted diluted net earnings per share from continuing operations was $1.25, an increase of 17% over last year and our third consecutive quarter of mid-teens or better adjusted EPS growth. Sales grew 16.5% to $5.8 billion, and core revenue increased 2%. The impact of currency translation eased this quarter but still decreased revenues by 0.5%, while acquisitions increased revenues by 15%. Danaher remainco [ph] core revenue was up 3%, while Fortive core revenue was down slightly. 
Geographically, high-growth market revenues were up mid-single digits, led by double-digit growth in China and India. We saw better sequential performance in Latin America and Russia, in part because of easier prior-year comparisons. Developed market core revenues were up low single-digits led by growth in Western Europe. The U.S. remained roughly flat, and we saw a decline in Japan during the quarter. 
Gross margin for the second quarter was 54.4%, an increase of 110 basis points from last year. Reported operating margins were 17.9%, with core operating margins down 30 basis points. More than 80 basis points of core margin improvement were -- we had more than 80 basis points of core margin improvement at both Dental and Life Sciences & Diagnostics. This was offset by declines in Test & Measurement and Environmental segments. 
Free cash flow continues to be one of our most important financial metrics, enabling us to pursue organic and inorganic growth initiatives across our entire portfolio. We generated $1.1 billion in free cash flow from continuing operations in the quarter, up 14%, and our free cash flow to net income conversion ratio was over 150%. 
Now let's take a look at more detailed results across the Danaher portfolio. In Life Sciences, core revenue increased mid-single digits led by strength in high-growth markets in Western Europe. At Beckman Life Sciences, we continued to outperform high-single digit core growth in the quarter was driven by strong demand in flow cytometry, particularly in North America and China. The robust growth in flow cytometry was largely driven by demand for our new Cytoflex [ph] product based on the breakthrough technology which we acquired as part of the Cytogen acquisition in 2014. This bolt-on acquisition has been a tremendous success, and this is a great example of how we incorporate novel technology into our portfolio to enhance our offering and expand our customer base. Cytoflex has been a significant contributor to recent share gains in our flow cytometry business. 
At Leica Microsystems, we saw improved results versus previous quarters, as recent new product introductions helped drive low single-digit core revenue growth. Two such new product introductions included our Leica DVM [ph] digital microscope launched at the end of 2015 and our new Leica M530 neurosurgery microscope, which is off to a great start in China after successful launches in Europe and North America last year. The M530 is a standout combination of our high-resolution optics technology with improved ergonomics, helping neurosurgeons stay focused during their demanding high precision procedures. 
Core revenues at SCIEX were up mid-single digits as we saw continued strength in pharmaceutical, food and environmental end markets. We had another very strong quarter in China, as new regulations from the Chinese Food Drug & Administration help drive increased demand around drug testing and food safety. 
In June, SCIEX announced a number of new workflow solutions at ASMS, the American Society of Mass Spectrometry Annual Meeting. These solutions are geared toward fast-growing markets such as biologics, [indiscernible], food and environmental testing. We showcased the latest Qtrap [ph] 6500 plus mass spectrometer that provides enhance sensitivity and selectivity to create a powerful workflow solution for biologics analysis. 
We also rolled out Biopharmaview Software 2.0, which accelerates automated data processing and simplifies reporting, enabling biopharma researchers to make better decisions faster. 
At Pall, core revenues were up mid single digits for the quarter compared to last year as a standalone company. Continued strong demand in biopharma, particularly single-use technologies, led to double-digit core revenue growth in Pall life sciences. In Pall industrial, revenues were down low single-digits, but we're continuing to see some signs of stabilization in those end markets. 
Pall continues to ramp exceedingly well across a number of key metrics. The team's commitment to the Danaher Business System has resulted in on-time delivery improving by more than 1,500 basis points with greater productivity and quality, driving improved customer satisfaction. Since acquisition, faster-than-expected cost savings and meaningful operational gains have contributed to sizable growth and operating margin improvements. As a result of the team's impressive start, we've been able to redirect some of that benefit into R&D and sales and marketing investments. By pursuing these combination of margin enhancement and growth opportunities, we believe we can continue to drive innovation and improve Pall's competitive advantage. 
The Pall team showcased a number of innovations such as acoustic wave separation and our new single-use bioreactor at the Interfax biomanufacturing tradeshow in April. Our expanded single-use product offering has enhanced our competitive position as pharmaceutical companies look to shift from traditional large infrastructure stainless steel systems to more efficient production processes. Pall's bioprocessing solutions help our customers save significant time, energy and money while greatly reducing cross-contamination risk, which provides the flexibility to easily and safely make multiple products in one facility. 
Moving now to Diagnostics. Core revenues increased low single-digits, with double-digit gains in China and India partially offset by weakness in the Middle East and the Americas. At Beckman Coulter, core revenues were up low single-digits driven primarily by strength in high-growth markets. This past June  marked the fifth anniversary of the Beckman acquisition. We made tremendous progress since then, significantly improving quality, delivery and our overall customer experience, while using productivity gains to help fund new product development and add feet on the street. Another quarter of good execution by the Beckman team contributed to healthy core operating margin expansion, and we continue to reinvest in high-impact growth opportunities. New menu additions are gaining traction, including our vitamin D and AMH fertility tests in our immunoassay business. 
Our recently launched molecular diagnostic platform, Veris, continues to gain early traction in Europe. New product developments like these, combined with opportunities at recent bolt-on acquisitions like Microscan, will continue to help build meaningful runway for growth at Beckman going forward. 
Radiometer achieved mid-single digit revenue growth, with healthy performance in Western Europe and China, partially offset by weakness in Latin America and the Middle East. Our growing installed base of blood gas instrument and ATT analyzers contributed to solid consumable sales in the quarter. The Radiometer team also recently launched the TCM 5 flex, a new transcutaneous monitor design. This noninvasive monitor measures ventilation for patients in critical condition, and the TCM 5 updated design is easy to use and reliable, providing nurses and doctors with improved usability while maintaining accuracy and precision. 
At Leica Biosystems, core revenues grew mid-single digits. Results were driven by a combination of strength in high-growth markets and continued growth of instrument placements in advanced staining and core histology. 
Moving now over to our Dental segment. Core revenues were up mid-single digits, with growth across consumables, equipment and implants. We saw particular strength in our restorative and [indiscernible] product lines. Geographically, China had another strong quarter, with double-digit growth, and we maintain positive momentum in North America and Western Europe. 
Nobel had another good quarter, with mid-single-digit core revenue growth. We've improved operating margins at Nobel by more than 500 basis points since acquisition, enabling us to direct some of our savings into expanded product offerings and accelerate its sales and marketing efforts. This is similar to what you've seen as achieved at other large acquisitions like Beckman and Pall, where operational improvements helped fuel renewed focus on new product development and go-to-market initiatives. 
The Nobel team has launched more than 20 new products since acquisition and featured a number of these recent innovations at the Nobel Biocare Global Symposium in June. Nobel's new On one implant-based remains in position during the entire restorative workflow, from implant placement to finalization and for the lifetime of the restoration. This helps simplify the dental surgeons' workflow and allows for an improved patient experience. 
And our new Nobel parallel CC implant is a straightforward highly versatile implant system, providing an efficient treatment flow that can be used in a wide variety of implant cases. Both of these new innovations help us serve our customers with better solutions to improve their patients' experience and treatment. 
Turning to Product Identification. Core revenues increased low single-digits. We saw increased demand for marking and coding equipment and related consumables across most major geographies, partially offset by softness in some of our packaging and color solutions offerings. 
Videojet's substantial and growing installed base contributed to mid-single-digit core revenue growth in the quarter. Strong market performance in North America, Latin America and Western Europe offset softness in certain high-growth markets. Videojet recently introduced a new service offering that enables our technicians to remotely gather data from a printer that's experiencing a fault or a failure condition. This helps our customers return to normal operations much faster, often without a site visit. With our range of comprehensive, preventive services, we're able to improve end-user productivity over the course of the printer's lifespan, ultimately reduce operating costs and enhancing customer satisfaction. 
In June, Esko successfully launched a number of new products and innovations at DRUBA [ph] , the world's largest printing equipment exhibition, which is held every 4 year in Germany. This is the most important tradeshow in the industry. Esco introduced more than a dozen significant hardware and software innovations at DRUBA this year, including a suite of powerful new software tool that help customers simplify, automate and integrate their complex packaging and label production workflows. We originated a record number of leads and orders at DRUB A, which we expect to help drive improved growth at Esko and across the product ID platform in the second half of the year. 
Lastly, turning to Water Quality. Core revenues grew low single-digits with strength in Western Europe, India and China partially offset by lower demand in Japan and Eastern Europe. Hach had a solid quarter with mid-single-digit core revenue growth. Results were driven by strength in U.S. municipal markets and Western Europe. We saw improved growth in China as Hach continues to benefit from ongoing regulations around water quality monitoring and analysis in the region. 
Hach's online water monitoring solutions are in place in Rio de Janeiro, Brazil for next month's Summer Olympics. Our solutions are installed at the majority of event's sites, including the largest soccer stadium in the world. We'll apply our expertise to monitor water quality in order to help Brazil execute a successful Olympic Games. After the events wrap up, Hach systems will be transferred to municipal water plants across the country, benefiting local communities for many years to come. 
At Trojan, high-single digit core revenue growth in the quarter was a result of a number of project wins in North America, Western Europe and Australia, as well as robust demand in municipal markets. 
And finally, at ChemTreat, core revenues grew low single-digits, despite exposure to weaker industrial and commodity-oriented end markets. 
So to wrap up, the Danaher team executed well in a challenging macro environment. The thoughtful application of DBS continued to drive results, with meaningful process improvements enabling reinvestment in high-impact growth initiatives. Danaher's core values is innovation defines our future, and the successful new product launches we've seen across the portfolio demonstrates our commitment to providing customers with truly differentiated technology to strengthen our collective competitive advantage. 
Following the launch of Fortive, Danaher will be a diversified multi-industry science and technology company, united by common business models and the power of DBS. We remain focused on improving growth, margins and cash flow, and we'll continue to pursue meaningful organic and inorganic opportunities to strengthen our market-leading portfolio of businesses. 
Going forward, Danaher's businesses will be organized across 4 segments:  Life sciences, including all of Pall; Diagnostics; Dental; and Environmental and Applied Solutions, which includes our Water Quality and Product Identification businesses. For further details, please refer to the supplemental information that we posted on our website this morning. 
This marks the start of an exciting new chapter for Danaher, and we look forward to the exciting opportunities we see in the years ahead. We are initiating third quarter guidance for adjusted diluted net EPS from continuing operations of $0.80 to $0.84. We are assuming third quarter core revenue growth of 3% or better. For the full year 2016, we are anticipating adjusted diluted net EPS from continuing operations to be in the range of $3.53 to $3.60, which at the midpoint would represent an increase of approximately 20% from 2015. Both our third quarter and full year guidance exclude the impact of Fortive."
265621,368081405,1011232,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Executives","Thanks, Tom. That concludes our formal remarks. Ashley, we're now ready for questions [Operator Instructions]",15,"Thanks, Tom. That concludes our formal remarks. Ashley, we're now ready for questions [Operator Instructions]"
265621,368081405,1011232,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Operator","[Operator Instructions] We will take our first question from Nigel Coe with Morgan Stanley.",14,"[Operator Instructions] We will take our first question from Nigel Coe with Morgan Stanley."
265621,368081405,1011232,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Analysts","So I just wanted to just fill in the gaps on the FY guidance. You said 3% or better for 3Q. Is that the worker assumption for 4Q as well? And then what assumptions are you making in terms of the corporate synergies in the back half of the year? Obviously,",84,"So I just wanted to just fill in the gaps on the FY guidance. You said 3% or better for 3Q. Is that the worker assumption for 4Q as well? And then what assumptions are you making in terms of the corporate synergies in the back half of the year? Obviously, there's a corporate line isn't allocated, but there some corporate answer been the segment, I'm just wondering how that impacts margins in the second half of the year. Any color will be helpful."
265621,368081405,1011232,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Executives","Nigel, this is Dan. So Q3 we're talking about 3% or better core. I think if we, in that zone in part, a little bit of easier comparison in the fourth quarter core could be a little bit higher than that. Regarding the corporate on a combined basis, we've t",90,"Nigel, this is Dan. So Q3 we're talking about 3% or better core. I think if we, in that zone in part, a little bit of easier comparison in the fourth quarter core could be a little bit higher than that. Regarding the corporate on a combined basis, we've talked since the beginning and we're still sort of in that zone of about $70 million to $80 million of corporate synergies from the 2 entities. And go forward, corporate will remain in that kind of the low 40s for Danaher."
265621,368081405,1011232,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Analysts","Okay. And then does that impact the segment line as well, Dan? Or is it just within that line? So I guess what I'm saying is the 2Q 1Q pro forma segments numbers for new Danaher, is that a good base for the second half of the year?",48,"Okay. And then does that impact the segment line as well, Dan? Or is it just within that line? So I guess what I'm saying is the 2Q 1Q pro forma segments numbers for new Danaher, is that a good base for the second half of the year?"
265621,368081405,1011232,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Executives","Yes.",1,"Yes."
265621,368081405,1011232,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Analysts","Okay, great. And then just on Dental, you gave some details on the moving parts work better in 2Q. Just I'm just wondering given the pre-fillers acceleration from 1Q, 2Q, was there any pull forward or pull back from 1Q to 2Q different channel volatility?",57,"Okay, great. And then just on Dental, you gave some details on the moving parts work better in 2Q. Just I'm just wondering given the pre-fillers acceleration from 1Q, 2Q, was there any pull forward or pull back from 1Q to 2Q different channel volatility? Or is it just natural volatility we'll see from time to time?"
265621,368081405,1011232,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Executives","Nigel, we did see some core improvement without a doubt in Dental. 4% core growth in dental. And a good part of that was clearly around better execution, and to some extent, a little bit easier comp. We saw good performance in the implants and equipment a",243,"Nigel, we did see some core improvement without a doubt in Dental. 4% core growth in dental. And a good part of that was clearly around better execution, and to some extent, a little bit easier comp. We saw good performance in the implants and equipment at mid-single-digit growth consumables, more like low single-digit, terrific performance in China continued. You've heard us talk to double-digit growth in China, and we saw that continuing. U.S. and EU, getting a little bit better. And the high-growth market is still challenging for sure, but we are rounding around some easier comps. You heard me talk about good solid performance at Nobel. That continued. That said, relative to your question about any impact, there may have been a little bit of pull forward of revenues just based on the nature of the calendar and the way that calendar worked on the end of the quarter. But in general, I think we are very pleased with the performance. Given seasonality, we could see some moderation in the Q3 growth rates at low single-digits, that's typically a function of more European exposure and the summer tends to be a little bit slower. So we won't necessarily see a straight line to the improved performance, but we were very, very pleased with execution of the second quarter, and we think we got a very good trajectory behind us to -- that bodes well, I think, for the quarters to come."
265621,368081405,1011232,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Operator","And our next question comes from Steven Winoker with Bernstein.",10,"And our next question comes from Steven Winoker with Bernstein."
265621,368081405,1011232,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Analysts","Tom, just on the segmentation, the new segmentation front. A couple of questions here. One, why is Pall industrial stuck in Life Sciences? And secondly, on Environmental and Applied solutions, I thought maybe Water Quality and Product ID will be standalon",63,"Tom, just on the segmentation, the new segmentation front. A couple of questions here. One, why is Pall industrial stuck in Life Sciences? And secondly, on Environmental and Applied solutions, I thought maybe Water Quality and Product ID will be standalone or they're just big enough yet or strategic thought here number of segments? I mean how are you thinking about those two?"
265621,368081405,1011232,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Executives","Sure. Relative to Pall, we did think it was important to keep those together in a single segment. Obviously, the life science part of the Pall portfolio is the larger part of the portfolio. There's commonality internally at Danaher from a reporting standp",227,"Sure. Relative to Pall, we did think it was important to keep those together in a single segment. Obviously, the life science part of the Pall portfolio is the larger part of the portfolio. There's commonality internally at Danaher from a reporting standpoint in terms of both businesses, both sides of the business reporting into Pall as well as EVP, overseeing all of Life Sciences. There's also commonality across R&D and supply chain and operations. So there's a lot of reasons operationally to keep the businesses together and, therefore, somewhat from a reporting standpoint as well. I mean, realistically, we probably could have split them up, but I think we would probably reevaluate that over time and see how we might run the businesses in the years to come. But I think for right now, this is probably, probably the best approach to keep them together. In terms of Environmental and PID, I think those businesses do share some commonality in terms of serving some different applied end markets. We could have kept them separately, they would have been far smaller segments. So I think we felt that those kind of went together and provided some flexibility for us as we defined ourselves to remain with the industry company their obviously is some flexibility maintain in terms of how we might add to that segment over time."
265621,368081405,1011232,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Analysts","Okay. And I suppose taking on the same M&A or the same scene here in an M&A, I know it's bumpy, but you did 6 last quarter, I guess, and 0 this quarter. Was it -- were you busy of separation? Things just didn't come together? How's the pipeline looking fo",70,"Okay. And I suppose taking on the same M&A or the same scene here in an M&A, I know it's bumpy, but you did 6 last quarter, I guess, and 0 this quarter. Was it -- were you busy of separation? Things just didn't come together? How's the pipeline looking for going forward? What should be we kind of expect in terms of momentum or pace on the M&A front?"
265621,368081405,1011232,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Executives","Steve, didn't have anything to do with being busy or in any way focused on other things. Acquisition volume kind of ebbs and flows over time, and so we think the pipeline, we know the pipelines remain quite good. We have active conversations in each one o",80,"Steve, didn't have anything to do with being busy or in any way focused on other things. Acquisition volume kind of ebbs and flows over time, and so we think the pipeline, we know the pipelines remain quite good. We have active conversations in each one of the platforms. So we feel very good about where we are. We have obviously a terrific balance sheet to work with, and I think we'll see good things in the quarters to come."
265621,368081405,1011232,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Analysts","And you emphasized, the multiindustry diversified nature as well as science technology, but I mean, is that -- are you as optimistic on the Environmental and Applied Solutions as supposed industrial front as you are into other parts of the business?",41,"And you emphasized, the multiindustry diversified nature as well as science technology, but I mean, is that -- are you as optimistic on the Environmental and Applied Solutions as supposed industrial front as you are into other parts of the business?"
265621,368081405,1011232,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Executives","We are. We continue to have teams that focus, as we always have, in each one of the operating companies and in each one of the platforms, focused on developing funnels, ensuring that we have active cultivations and, yes, we remain bias towards applying ou",57,"We are. We continue to have teams that focus, as we always have, in each one of the operating companies and in each one of the platforms, focused on developing funnels, ensuring that we have active cultivations and, yes, we remain bias towards applying our free cash flow to each one of the businesses across the portfolio."
265621,368081405,1011232,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Operator","Next, we will take Jeffrey Sprague with Vertical Research Partners.",10,"Next, we will take Jeffrey Sprague with Vertical Research Partners."
265621,368081405,1011232,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Analysts","Congrats on getting Fortive done. Just maybe a couple of business-related questions drilling in a little bit. Tom, can you elaborate a little bit on what's going on in Environmental core markets in the quarter? Why are they under pressure and kind of what",49,"Congrats on getting Fortive done. Just maybe a couple of business-related questions drilling in a little bit. Tom, can you elaborate a little bit on what's going on in Environmental core markets in the quarter? Why are they under pressure and kind of what the trajectory is looking forward?"
265621,368081405,1011232,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Executives","Jeff, thanks for the question. In general, we feel very good about where those businesses are. I'll speeak specifically to the Hach business. We have very good performance in the prior quarter, in the same quarter last year. In addition, we're making some",99,"Jeff, thanks for the question. In general, we feel very good about where those businesses are. I'll speeak specifically to the Hach business. We have very good performance in the prior quarter, in the same quarter last year. In addition, we're making some investments from a growth standpoint in those businesses. So I think we're continuing to see margin expansion from the water side of the Environmental segment. And I think those investments overall are going to pay off in terms of good growth rates in the quarters to come. So it's not an area of concern for us."
265621,368081405,1011232,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Executives","And Jeff, 2 things to add. One is Gilbarco had better growth than the Water business, so there's some negative mix in there for the segment. And we had our best -- that segment was Q2 last year was probably 150, 200 basis points better than any other quar",80,"And Jeff, 2 things to add. One is Gilbarco had better growth than the Water business, so there's some negative mix in there for the segment. And we had our best -- that segment was Q2 last year was probably 150, 200 basis points better than any other quarter we had in 2015, so a little bit of a comp issue as well. But as Tom alluded to, we are investing pretty heavily right now in the Water business organically."
265621,368081405,1011232,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Analysts","Speaking of investment, maybe just kind of total new Danaher question, but the idea is kind of restructuring being quiet or otherwise, is that likely part of the equation here as you progress through the year? And can you give us some idea on how to think",49,"Speaking of investment, maybe just kind of total new Danaher question, but the idea is kind of restructuring being quiet or otherwise, is that likely part of the equation here as you progress through the year? And can you give us some idea on how to think about that?"
265621,368081405,1011232,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Executives","Jeff, as we, I think, showed last quarter, we've established a cadence of restructuring that has gone on. You might say quietly, but I would say more consistently and appropriately throughout the course of the year. As opportunities have  come up, we've t",111,"Jeff, as we, I think, showed last quarter, we've established a cadence of restructuring that has gone on. You might say quietly, but I would say more consistently and appropriately throughout the course of the year. As opportunities have  come up, we've taken advantage of those, I mean, in each of the quarters. And so we still have opportunities for some level of restructuring in the third and fourth quarter. But in general, we've been more balanced through the course of the year, and I think that has served us well in terms of the operating margin expansion that you've seen over time late last year and this year as well."
265621,368081405,1011232,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Analysts","And then finally, just back to Environmental and Water, specifically in the muni market. So we've been kind of hearing for a couple of quarters that things are gaining traction, obviously had a strong quarter at Trojan. Can you speak a little bit to the f",67,"And then finally, just back to Environmental and Water, specifically in the muni market. So we've been kind of hearing for a couple of quarters that things are gaining traction, obviously had a strong quarter at Trojan. Can you speak a little bit to the forward visibility there, what's going on in order activity? Do you have top line topline visibility into that business now into '17?"
265621,368081405,1011232,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Executives","Jeff, it's probably a little bit early to kind of comment on '17. The muni strength continues to be broad-based, both the Trojan and the Hach business. And at the Hach base, we are seeing it both in Europe and in U.S., very consistent and healthy spending",72,"Jeff, it's probably a little bit early to kind of comment on '17. The muni strength continues to be broad-based, both the Trojan and the Hach business. And at the Hach base, we are seeing it both in Europe and in U.S., very consistent and healthy spending there. The offset is that both for Hach and ChemTreat is where we serve the industry were any comp commodity oriented markets, they've been challenging."
265621,368081405,1011232,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Operator","Our next question is from Shannon O'Callaghan with UBS.",10,"Our next question is from Shannon O'Callaghan with UBS."
265621,368081405,1011232,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Analysts","Just on this emphasis on reinvesting some of the synergy upside at Nobel and at Pall into new products, go-to-market investments. What kind of lag are you expecting from that? I mean, when do you expect that to translate into improving organic growth for",51,"Just on this emphasis on reinvesting some of the synergy upside at Nobel and at Pall into new products, go-to-market investments. What kind of lag are you expecting from that? I mean, when do you expect that to translate into improving organic growth for those businesses and just what you're seeing."
265621,368081405,1011232,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Executives","Shannon, it varies depending on where we direct those funds. I think in some cases when we put investment directly into say feet on the street, in either a developed market or a high-growth market, we tend to see those investments pay off in just a quarte",215,"Shannon, it varies depending on where we direct those funds. I think in some cases when we put investment directly into say feet on the street, in either a developed market or a high-growth market, we tend to see those investments pay off in just a quarter or 2. If we're talking about investments that go into new product development, those tend to have much more of a lag time, as projects get kicked off into early business case-oriented tollgates, you could have several quarters to it, at times even a couple of years, before you might see the impacts of the new product investment, again depending on how early or late stage an existing project might be in the pipeline. So it's varied. I think in the case of Nobel, just to talk to one of the businesses, we've seen those investments pay off relatively quickly. You've seen that in core revenue growth consistently in that business. They have relatively shorter cycle times in terms of new product development. In businesses like Beckman, for example, and at Pall, product development cycles are longer, certainly significantly longer at a place like Beckman, where oftentimes we'll have clinical trials and/or regulatory clearances. And so those new product investments can be -- can take some time, obviously."
265621,368081405,1011232,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Analysts","Okay, great. Then maybe a follow-up to that. In terms of in Diagnostics, you talked about Beckman's growth being driven by high-growth markets. What's going on in the developed markets? And maybe gets some of your comments you just made their sellout what",56,"Okay, great. Then maybe a follow-up to that. In terms of in Diagnostics, you talked about Beckman's growth being driven by high-growth markets. What's going on in the developed markets? And maybe gets some of your comments you just made their sellout what's going to take to get some better growth in developed markets for Beckman?"
265621,368081405,1011232,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Executives","Sure. Yes, a little bit slower growth in developed markets. I mean, in general, the developed markets, from an overall perspective, are slower growth markets to begin with. We've always seen better market growth in the overall in places like China and Ind",119,"Sure. Yes, a little bit slower growth in developed markets. I mean, in general, the developed markets, from an overall perspective, are slower growth markets to begin with. We've always seen better market growth in the overall in places like China and India and the Middle East. So in general, I think we're tracking closer to the market growth rates than anything else. Still have work to do, there's no question about it. We have improved our retention rates and our competitive win rates, but there's still work to do in terms of both go-to-market as well as new product development. And over time, we do believe those will pay off in better growth rates in the developed markets."
265621,368081405,1011232,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Operator","And our next question is coming from Tycho Peterson with JPMorgan.",11,"And our next question is coming from Tycho Peterson with JPMorgan."
265621,368081405,1011232,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Analysts","Tom, just wondering if you can talk about some of the gives and takes where you're feeling a little more constructive by segment in the back half of the year. You talk to the gives and takes on Dental, so maybe you can pass on that. But is Pall industrial",99,"Tom, just wondering if you can talk about some of the gives and takes where you're feeling a little more constructive by segment in the back half of the year. You talk to the gives and takes on Dental, so maybe you can pass on that. But is Pall industrial kind of bottoming out there? Can you see some improvement there? Obviously, the academic fund those may pick up in the back half of the year, that could help SCIEX. Could you just talk by division where you're feeling a little more constructive for the next couple of quarters?"
265621,368081405,1011232,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Executives","Sure. We do think that, as you mentioned, we've seen good performance in Dental, again not necessarily a straight line, but we're very encouraged by the performance we're seeing. In terms of the other businesses across the second half, I think we'll see c",158,"Sure. We do think that, as you mentioned, we've seen good performance in Dental, again not necessarily a straight line, but we're very encouraged by the performance we're seeing. In terms of the other businesses across the second half, I think we'll see continuing better performance across the Diagnostic businesses, in particular. We're starting to see the benefit of a number of the investments across those businesses. I think we'll see continuing good performance from Water Quality. PID has been pretty consistent along the way, so I think we will see that continue. Our Life Science businesses have also performed well, particularly SCIEX, as well as Beckman Life Science, so I think we'd see some modest incremental growth there. I would also remind you that we are coming around through some easier comps in the second half as well, and so we will get a little bit of benefit from those easier comps really across the entire portfolio."
265621,368081405,1011232,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Analysts","And since you called out Europe as a source of strength for Life Science and radiometer, are you kind of comfortable with the macro in the back half of the year for those markets?",34,"And since you called out Europe as a source of strength for Life Science and radiometer, are you kind of comfortable with the macro in the back half of the year for those markets?"
265621,368081405,1011232,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Executives","Well, I think the Brexit situation certainly has created uncertainty around not just the U.K. But across European theater at large. Uncertainty is rarely a good thing for markets in terms of people's willingness to make investments, particularly in Instru",64,"Well, I think the Brexit situation certainly has created uncertainty around not just the U.K. But across European theater at large. Uncertainty is rarely a good thing for markets in terms of people's willingness to make investments, particularly in Instrumentation and higher-cost instrumentation. So I think that uncertainty could potentially result in some slowness in the second half, but it's very early to tell."
265621,368081405,1011232,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Executives","Tycho, just add on Western Europe. We've been consistently in kind of a pretty healthy low single-digit number across Western Europe. It's been pretty broad-based. It is an area where because of some of the uncertainties the last couple of years, we've pr",96,"Tycho, just add on Western Europe. We've been consistently in kind of a pretty healthy low single-digit number across Western Europe. It's been pretty broad-based. It is an area where because of some of the uncertainties the last couple of years, we've probably taken a fair amount of share, as we've seen some people kind of pulled back in Western Europe over the last couple of years. So it's been a good market for us. And while and we also see doing Pall doing quite well in Europe, those obviously not in the core numbers yet."
265621,368081405,1011232,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Analysts","Okay. And then just lastly on the capital deployment question earlier. You touched on the framework a little bit. Can you just remind us where you're comfortable taking up leverage? And maybe just any comments on what you're seeing in terms of valuation g",50,"Okay. And then just lastly on the capital deployment question earlier. You touched on the framework a little bit. Can you just remind us where you're comfortable taking up leverage? And maybe just any comments on what you're seeing in terms of valuation given how much this space has run?"
265621,368081405,1011232,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Executives","Well Tycho, we've obviously spent the last year in a significant effort on deleveraging, we're in really good shape. We're south of 2.5x at this point. Initially, we were close to 4x leverage. So we're back to a motive spending our free cash flow plus, an",84,"Well Tycho, we've obviously spent the last year in a significant effort on deleveraging, we're in really good shape. We're south of 2.5x at this point. Initially, we were close to 4x leverage. So we're back to a motive spending our free cash flow plus, and we've talked about a couple of billion of capacity for this year. But going into next year you're back to more of $3 billion to $4 billion of capacity per year. And that's without really stretching balance sheet."
265621,368081405,1011232,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Operator","Our next question is coming from Ross Muken with Evercore ISI.",11,"Our next question is coming from Ross Muken with Evercore ISI."
265621,368081405,1011232,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Analysts","So appreciate, I know you gave us already some color on Pall single use and on SCIEX. But I'd love if you could tease out at all sort of pharma demand based on sort of customer types, sort of separate it maybe pharma from biotech or emerging biotech to se",96,"So appreciate, I know you gave us already some color on Pall single use and on SCIEX. But I'd love if you could tease out at all sort of pharma demand based on sort of customer types, sort of separate it maybe pharma from biotech or emerging biotech to see if there's any sort of discernible trend you've seen amongst. I mean it's clear Pall obviously having pretty strong growth across the board, but I was wondering if any of the end markets, whether it's generic or CRO, et cetera, you've seen any change in demand."
265621,368081405,1011232,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Executives","SCIEX is probably the best business to think about when you think about the -- your question about pharma versus say biotech. SCIEX has exposure to both those end markets, and we are seeing good performance, healthy demand and fairly consistent demand fro",132,"SCIEX is probably the best business to think about when you think about the -- your question about pharma versus say biotech. SCIEX has exposure to both those end markets, and we are seeing good performance, healthy demand and fairly consistent demand from both sides of the house there. I'd have to do some follow-up to get you some detail on anything to do with the generics or the CROs specifically. But clearly, in the aggregate, these markets are doing quite well. Pall, as you mentioned, we talked about the growth that we are seeing in the life science side, specifically around our single-use technology product offering, where we're seeing continued double-digit growth rate an area. That clearly is associated with the growth in biopharmaceuticals, specifically in growth in large molecule drugs."
265621,368081405,1011232,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Analysts","I guess what I'm getting is more on the CRO drugs. Maybe I'll ask it differently, in terms of high-growth markets, and it's clear China has been good, but outside of China, how would you sort of characterize the rest of the key markets, obviously LatAM is",65,"I guess what I'm getting is more on the CRO drugs. Maybe I'll ask it differently, in terms of high-growth markets, and it's clear China has been good, but outside of China, how would you sort of characterize the rest of the key markets, obviously LatAM is kind of a mixed bag overall, but India and some of the other geography -- key geographies."
265621,368081405,1011232,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Executives","I'd say China, in particular, India as well, are very good markets for us. But I would say that there's still a long runway ahead for those markets. Some of the generic and the CRO movement into those markets have been on balance positive, but there are a",86,"I'd say China, in particular, India as well, are very good markets for us. But I would say that there's still a long runway ahead for those markets. Some of the generic and the CRO movement into those markets have been on balance positive, but there are also components of the market that are still relatively nascent, particularly in terms of what might be going on there in the future relative to large molecule drugs. So I think there's still a pretty good runway ahead."
265621,368081405,1011232,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Operator","Our next question comes from Derik De Bruin with Bank of America Merrill Lynch.",14,"Our next question comes from Derik De Bruin with Bank of America Merrill Lynch."
265621,368081405,1011232,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Analysts","So could you talk a little bit about capital deployment? I'm just curious now that sort of Fortive has spun out, how do you sort of view your overall strategy in the Life Sciences space? Do you still feel like you want to stay focused on the core your sta",82,"So could you talk a little bit about capital deployment? I'm just curious now that sort of Fortive has spun out, how do you sort of view your overall strategy in the Life Sciences space? Do you still feel like you want to stay focused on the core your standalone core brand? Or do you feel the need to sort of become a more integrated provider in the space? Are you thinking to add anything into your Life Sciences or Diagnostics armament?"
265621,368081405,1011232,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Executives","Derik, I think, first of all starting at Danaher level, our bias towards M&A is not -- and use of our free cash flow to M&A is not specifically skewed towards any of the 4 segments that I mentioned. We've had a consistent track record of capital allocatio",275,"Derik, I think, first of all starting at Danaher level, our bias towards M&A is not -- and use of our free cash flow to M&A is not specifically skewed towards any of the 4 segments that I mentioned. We've had a consistent track record of capital allocation across each of those 4 segments that we'll be reporting on in the future. And I think you'll continue to see us do that. Specifically to your question about Life Sciences and Diagnostics, what you've seen us do in Life Sciences is continue to broaden our product offering over time, and I think you'll continue to see us do that. We have had bias and we'll continue to need to have a bias towards businesses with not only strong brands and significant installed basis, but installed basis that drive the good, consistent, recurring revenue and consumables growth. Diagnostics businesses is inherently that way, typically, and you've seen us buy businesses with those same characteristics, strong brand, significant installed basis and strong recurring revenue and consumable streams. I think, you'd see us continue to do that. We think there is certainly room to continue to expand our Diagnostic product offering and provide hospitals with broader bundles of products. Today, we provide products obviously into the central laboratory, the core clinical laboratories, as well as the anatomical pathology and to the acute care areas of the hospital. And with the expansion of microscan into microbiology, with Iris opening up urinalysis for us, I think those types of expansion of our footprint would certainly be characteristic of the types of things that we would hope to do in the future."
265621,368081405,1011232,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Analysts","That's really helpful. It's been a year since you launched the Veris platform and . Can you talk a little bit about what you see in terms of installed base and competitive blends and essentially where is that going, what's the customer type and then if yo",71,"That's really helpful. It's been a year since you launched the Veris platform and . Can you talk a little bit about what you see in terms of installed base and competitive blends and essentially where is that going, what's the customer type and then if you're taking share from people in those hospitals all your platforms that size. Can you just talk a little bit more color on that?"
265621,368081405,1011232,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Executives","Sure. Just for everyone's benefit, the Veris platform is a high-volume random-access molecular diagnostics instrument that was commercialized for the first time in Europe in the second half of last year. That product line serves the core or central clinic",217,"Sure. Just for everyone's benefit, the Veris platform is a high-volume random-access molecular diagnostics instrument that was commercialized for the first time in Europe in the second half of last year. That product line serves the core or central clinical laboratory of major hospitals. And again, as I mentioned, it's a high-volume platform. We're very pleased with the early traction that we've gotten, it is still early. During the first year of a significant new product introduction like that, the first of its kind by Beckman Coulter, it does take a while to build the funnel, but we've been very happy with how that funnel has built, sales opportunity funnel in the last year. The installations that we've had thus far are running very well. We have 4 assays in the market right now, but the 4 assays really are just the beginning. There's a significant roadmap of assay development ahead that will ultimately be commercialized, both in Europe as well as in the U.S. That product will need to go through regulatory clearance in the U.S. So it will be some time before we see the volumes ramp beyond the early days here in Europe. But the feedback from customers has been very, very -- strongly positive, and we feel good about the start we have."
265621,368081405,1011232,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Analysts","Great. And when is the approval expected?",7,"Great. And when is the approval expected?"
265621,368081405,1011232,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Executives","I usually hesitate to try to put any bets on FDA clearance. There's a fair amount of work to do even before we file for that clearance, so I'll probably have a better sense of that in the quarters to come, but wouldn't -- I couldn't put a date on it today",52,"I usually hesitate to try to put any bets on FDA clearance. There's a fair amount of work to do even before we file for that clearance, so I'll probably have a better sense of that in the quarters to come, but wouldn't -- I couldn't put a date on it today."
265621,368081405,1011232,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Operator","Our next question comes from Julian Mitchell with Crdit Suisse.",10,"Our next question comes from Julian Mitchell with Crdit Suisse."
265621,368081405,1011232,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Analysts","Just a question on margins, firstly. So the core margin in total Danaher fell about 30 bps in Q2. Could you give that comparable number for the remaining business? And then maybe and how you think that will trend in the second half? And tied to that, I gu",87,"Just a question on margins, firstly. So the core margin in total Danaher fell about 30 bps in Q2. Could you give that comparable number for the remaining business? And then maybe and how you think that will trend in the second half? And tied to that, I guess, going back to the Environmental and Applied Solutions segment, the headline margin there was down 300 bps plus in Q2. Should we see that coming back in the second half as the comps on margins get much easier?"
265621,368081405,1011232,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Executives","Sure, Julian. On the last one you asked, as I mentioned earlier, part of the Environmental issue was a comp issue that margins on a historical restated basis for the Environmental Applied Solutions were 200 basis points higher in Q2 a year ago. So you exp",113,"Sure, Julian. On the last one you asked, as I mentioned earlier, part of the Environmental issue was a comp issue that margins on a historical restated basis for the Environmental Applied Solutions were 200 basis points higher in Q2 a year ago. So you expect that to sort of normalize. Core margins were relatively flat for Danaher ex Fortive, that was, again, somewhat of a function of the prior-year compare. For our full year, we continue to expect 50 to 75 basis points of core margin expansion for Danaher ex Fortive, and you'll see better performance. So very good forms in the first quarter, you'll see better performance in Q3 and Q4."
265621,368081405,1011232,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Analysts","Great. And then just on Pall industrial. You called out the overall organic sales trend year-on-year. Is there any sort of color you'd give there on specific verticals or markets within that any changes?",34,"Great. And then just on Pall industrial. You called out the overall organic sales trend year-on-year. Is there any sort of color you'd give there on specific verticals or markets within that any changes?"
265621,368081405,1011232,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Executives","No. I wouldn't say we've seen necessarily any changes, Julian. I think, to the extent that there's good news there, I think that it would be that we've seen some stability found in those markets. We continue to make some excellent progress in terms of our",162,"No. I wouldn't say we've seen necessarily any changes, Julian. I think, to the extent that there's good news there, I think that it would be that we've seen some stability found in those markets. We continue to make some excellent progress in terms of our go-to-market initiatives. We've done over 40 growth-related Keizens [ph] at Pall since we acquired the business. And a number of those Kaizens have been going on in the industrial markets, and that involve installing DBS tools, such as funnel management and transformative marketing, that we think is improving our execution in those markets. So I think the combination of seeing some stability across each one of those end markets, in combination with the application of DBS tools, I think, has gotten us to a pretty good place. So I would hope to see some incrementally better performance late this year and certainly entering next year. But I think, in general, we're pleased that things have stabilized."
265621,368081405,1011232,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Operator","Our final question is coming from Isaac Ro with Goldman Sachs.",11,"Our final question is coming from Isaac Ro with Goldman Sachs."
265621,368081405,1011232,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Analysts","I just want to ask another question on Pall industrial. If we look back, prior to the acquisition, that business was obviously going a little slower than the Life Science side. But curious if you could maybe take a bigger step back and give us a sense of",76,"I just want to ask another question on Pall industrial. If we look back, prior to the acquisition, that business was obviously going a little slower than the Life Science side. But curious if you could maybe take a bigger step back and give us a sense of what you think it will take for industrial to return to growth? Is it mostly a function of end markets or is it more of an execution issue?"
265621,368081405,1011232,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Executives","Isaac, I think it's both. As I was just mentioning to Julian, I think we've seen the markets themselves, from a macro standpoint, stabilize a bit, in other words not get any worse, and we will need to see some improvement in the macro environment to see s",154,"Isaac, I think it's both. As I was just mentioning to Julian, I think we've seen the markets themselves, from a macro standpoint, stabilize a bit, in other words not get any worse, and we will need to see some improvement in the macro environment to see some meaningful or a step function improvement and growth. But we're not waiting for that. Our focus is on ensuring that we have the best sales team on the field, that we provide those teams with exceptional new product development, that we got our coverage set up appropriately across geographies and across each one of those verticals. And I think the combination of good market coverage DBS tools, new product development and some improvement in those end markets is what it's going to take. Obviously, the majority of that, we hope to be in our control, but a little help from the end markets certainly would help."
265621,368081405,1011232,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Analysts","That's helpful. And then one question on Beckman. If we just kind of square up what we saw last week with some of the peer groups in Diagnostics with what you said you obviously got Veris and Cytoflex helping out. If we pull those out, just trying to get",76,"That's helpful. And then one question on Beckman. If we just kind of square up what we saw last week with some of the peer groups in Diagnostics with what you said you obviously got Veris and Cytoflex helping out. If we pull those out, just trying to get a better sense of how you think you're pacing versus the overall market for Diagnostics. And any color there, especially in North America, would be helpful."
265621,368081405,1011232,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Executives","Sure. Well, as you know, we have come from behind here from the standpoint of the big 5 in the overall market. I think from a pacing standpoint, we've now gotten to a point where we are very close to, if not at market growth rates, with a couple of the co",205,"Sure. Well, as you know, we have come from behind here from the standpoint of the big 5 in the overall market. I think from a pacing standpoint, we've now gotten to a point where we are very close to, if not at market growth rates, with a couple of the competitors, as you mentioned, reported last week posting better growth rates. And in doing so, in some cases it's a function of their positions in certain higher-growth markets. But in other cases, we simply have work to do in terms of continuing to drive our new product development and our go-to-market initiatives. We are ahead of a couple of other competitors in that market, and we have demonstrated where, from a competitive win perspective, we've become far more competitive in the overall market. So I think we've made a ton of progress, but clearly, work to do. And that work is as you've referenced, is represented by some folks that are still putting up some pretty good numbers. So I think we've got the initiatives and the investment levels in the right place. We continue to make progress, and it'll take a little bit of time, but I think we're on the right track."
265621,368081405,1011232,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Operator","And that concludes our question-and-answer session. I would like to turn the conference back over to Matt Gugino for any additional or closing remarks.",25,"And that concludes our question-and-answer session. I would like to turn the conference back over to Matt Gugino for any additional or closing remarks."
265621,368081405,1011232,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Executives","Thanks, everyone, for joining us. We're around all day for questions.",11,"Thanks, everyone, for joining us. We're around all day for questions."
265621,368081405,1011232,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Operator","And that concludes today's presentation. We thank you all for your participation.",13,"And that concludes today's presentation. We thank you all for your participation."
265621,368081405,1011291,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Operator","My name is Ashley, and I will be your conference facilitator today. At this time, I would like to welcome everyone to the Danaher Corporation Second Quarter 2016 Earnings Results Conference Call. [Operator Instructions] I will now turn the conference ov",57,"My name is Ashley, and I will be your conference facilitator today. At this time, I would like to welcome everyone to the Danaher Corporation Second Quarter 2016 Earnings Results Conference Call. [Operator Instructions] 
I will now turn the conference over to Mr. Matt Gugino, Vice President of Investor Relations. Mr. Gugino, you may begin your conference."
265621,368081405,1011291,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Executives","Thanks, Ashley. Good morning, everyone, and thanks for joining us on the call. With us today are Tom Joyce, our President and Chief Executive Officer; and Dan Comas, our Executive Vice President and Chief Financial Officer. I'd like to point out that ou",331,"Thanks, Ashley. Good morning, everyone, and thanks for joining us on the call. With us today are Tom Joyce, our President and Chief Executive Officer; and Dan Comas, our Executive Vice President and Chief Financial Officer. 
I'd like to point out that our earnings release, the slide presentation supplementing today's call, our second quarter Form 10-Q and the reconciliations and other information required by SEC Regulation G relating to any non-GAAP financial measures provided during the call are all available on the Investors section of our website, www.danaher.com, under the heading Financial Information. The audio portion of this call will be archived on the Investors section of our website later today under the heading Events & Presentations and will remain archived until our next quarterly call. A replay of this call will also be available until August 1, 2016. 
During the presentation, we will describe certain of the more significant factors that impacted year-over-year performance. The supplemental materials describe additional factors that impacted year-over-year performance. Unless otherwise noted, all references in these remarks and supplemental materials to company-specific financial metrics relate to the continuing operations of the company in the second quarter of 2016, and all references to period-to-period increases or decreases in financial metrics are year over year. 
We may also describe certain products and devices, which have applications submitted and pending for certain regulatory approvals. 
During the call, we will make forward-looking statements within the meaning of the federal securities laws, including statements regarding events or developments that we believe or anticipate will or may occur in the future. These forward-looking statements are subject to a number of risks and uncertainties, including those set forth in our SEC filings, and actual results may differ materially from any forward-looking statements that we make today. These forward-looking statements speak only as of the date that they are made, and we do not assume any obligation to update any forward-looking statements. 
With that, I'd like to turn the call over to Tom."
265621,368081405,1011291,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Executives","Thanks, Matt, and good morning, everyone. The second quarter was a busy and exciting one for Danaher. Despite challenging economic conditions, we're pleased with our performance as the team's consistent focus on execution helped deliver solid core revenue",2340,"Thanks, Matt, and good morning, everyone. The second quarter was a busy and exciting one for Danaher. Despite challenging economic conditions, we're pleased with our performance as the team's consistent focus on execution helped deliver solid core revenue growth, high-teens adjusted earnings per share growth and strong free cash flow performance. 
On July 2, we successfully completed the spin-off of Fortive Corporation, a new industrial growth company. The earlier-than-expected completion of the separation is a testament to our process orientation, execution focus and exceptional teamwork. We continue to believe that the separation will provide significant opportunities for both Danaher and Fortive to independently build even greater shareholder value in the years ahead. Since we owned Fortive through the end of the second quarter, we will start with financial highlights that reflect the combined Danaher and Fortive results. We'll then provide detail for the businesses remaining with Danaher, outline our planned new reporting segments and provide guidance for Danaher's continuing operations, excluding Fortive, for the third quarter and the full year. Since the Fortive team will be reporting their second quarter results separately next week, we'd ask that you please save any questions about the Fortive businesses until then. 
Now turning to the details of the second quarter. Adjusted diluted net earnings per share from continuing operations was $1.25, an increase of 17% over last year and our third consecutive quarter of mid-teens or better adjusted EPS growth. Sales grew 16.5% to $5.8 billion, and core revenue increased 2%. The impact of currency translation eased this quarter but still decreased revenues by 0.5%, while acquisitions increased revenues by 15%. Danaher RemainCo core revenue was up 3%, while Fortive core revenue was down slightly. 
Geographically, high-growth market revenues were up mid-single digits, led by double-digit growth in China and India. We saw better sequential performance in Latin America and Russia, in part because of easier prior-year comparisons. Developed market core revenues were up low single digits, led by growth in Western Europe. The U.S. remained roughly flat, and we saw declines in Japan during the quarter. 
Gross margin for the second quarter was 54.4%, an increase of 110 basis points from last year. Reported operating margins were 17.9%, with core operating margins down 30 basis points. More than 80 basis points of core margin improvement were -- we had more than 80 basis points of core margin improvement at both Dental and Life Sciences & Diagnostics, which was offset by declines in Test & Measurement and Environmental segments. 
Free cash flow continues to be one of our most important financial metrics, enabling us to pursue organic and inorganic growth initiatives across our entire portfolio. We generated $1.1 billion in free cash flow from continuing operations in the quarter, up 14%, and our free cash flow to net income conversion ratio was over 150%. 
Now let's take a look at more detailed results across the Danaher portfolio. In Life Sciences, core revenue increased mid-single digits, led by strength in high-growth markets and Western Europe. At Beckman Life Sciences, we continued to outperform. High-single digit core growth in the quarter was driven by strong demand in flow cytometry, particularly in North America and China. The robust growth in flow cytometry was largely driven by demand for our new CytoFLEX product based on the breakthrough technology, which we acquired as part of the Xitogen acquisition in 2014. This bolt-on acquisition has been a tremendous success and is a great example of how we incorporate novel technology into our portfolio to enhance our offering and expand our customer base. CytoFLEX has been a significant contributor to recent share gains in our flow cytometry business. 
At Leica Microsystems, we saw improved results versus previous quarters, as recent new product introductions helped drive low single-digit core revenue growth. Two such new product introductions included our Leica DVM6 digital microscope launched at the end of 2015 and our new Leica M530 neurosurgery microscope, which is off to a great start in China after successful launches in Europe and North America last year. The M530 is a standout combination of our high-resolution optics technology with improved ergonomics, helping neurosurgeons stay focused during their demanding high-precision procedures. 
Core revenues at SCIEX were up mid-single digits as we saw continued strength in pharmaceutical, food and environmental end markets. We had another very strong quarter in China as new regulations from the Chinese Food Drug and Administration helped drive increased demand around drug testing and food safety. 
In June, SCIEX announced a number of new workflow solutions at ASMS, the American Society of Mass Spectrometry Annual Meeting. These solutions are geared toward fast-growing markets such as biologics, proteomics, food and environmental testing. We showcased the latest QTRAP 6500+ mass spectrometer that provides enhanced sensitivity and selectivity to create a powerful workflow solution for biologics analysis. 
We also rolled out BioPharmaView Software 2.0, which accelerates automated data processing and simplifies reporting, enabling biopharma researchers to make better decisions faster. 
At Pall, core revenues were up mid-single digits for the quarter compared to last year as a stand-alone company. Continued strong demand in biopharma, particularly single-use technologies, led to double-digit core revenue growth in Pall Life Sciences. In Pall Industrial, revenues were down low single digits, but we're continuing to see some signs of stabilization in those end markets. 
Pall continues to ramp exceedingly well across a number of key metrics. The team's commitment to the Danaher Business System has resulted in on-time delivery improving by more than 1,500 basis points with greater productivity and quality, driving improved customer satisfaction. Since acquisition, faster-than-expected cost savings and meaningful operational gains have contributed to sizable growth and operating margin improvements. As a result of the team's impressive start, we've been able to redirect some of that benefit into R&D and sales and marketing investments. By pursuing this combination of margin enhancement and growth opportunities, we believe we can continue to drive innovation and improve Pall's competitive advantage. 
The Pall team showcased a number of innovations, such as acoustic wave separation and our new single-use bioreactor at the Interfax biomanufacturing trade show in April. Our expanded single-use product offering has enhanced our competitive position, as pharmaceutical companies look to shift from traditional large infrastructure stainless steel systems to more efficient production processes. Pall's bioprocessing solutions help our customers save significant time, energy and money while greatly reducing cross-contamination risk, which provides the flexibility to easily and safely make multiple products in one facility. 
Moving now to Diagnostics. Core revenues increased low single digits, with double-digit gains in China and India partially offset by weakness in the Middle East and the Americas. At Beckman Coulter, core revenues were up low single digits, driven primarily by strength in high-growth markets. This past June marked the fifth anniversary of the Beckman acquisition. We'd made tremendous progress since then, significantly improving quality, delivery and our overall customer experience while using productivity gains to help fund new product development and add feet on the street. Another quarter of good execution by the Beckman team contributed to healthy core operating margin expansion, and we continue to reinvest in high-impact growth opportunities. New menu additions are gaining traction, including our vitamin D and AMH fertility tests in our immunoassay business. 
Our recently launched molecular diagnostic platform, Veris, continues to gain early traction in Europe. New product developments like these, combined with opportunities at recent bolt-on acquisitions like Microscan, will continue to help build meaningful runway for growth at Beckman going forward. 
Radiometer achieved mid-single-digit revenue growth, with healthy performance in Western Europe and China partially offset by weakness in Latin America and the Middle East. Our growing installed base of blood gas instruments and AQT analyzers contributed to solid consumable sales in the quarter. The Radiometer team also recently launched the TCM5 FLEX, a new transcutaneous monitor design. This noninvasive monitor measures ventilation for patients in critical condition. And the TCM5's updated design is easy to use and reliable, providing nurses and doctors with improved usability while maintaining accuracy and precision. 
At Leica Biosystems, core revenues grew mid-single digits. Results were driven by a combination of strength in high-growth markets and continued growth of instrument placements in advanced staining and core histology. 
Moving now over to our Dental segment. Core revenues were up mid-single digits, with growth across consumables, equipment and implants. We saw particular strength in our restorative and Ormco product lines. Geographically, China had another strong quarter with double-digit growth, and we maintain positive momentum in North America and Western Europe. 
Nobel had another good quarter with mid-single-digit core revenue growth. We've improved operating margins at Nobel by more than 500 basis points since acquisition, enabling us to direct some of our savings into expanded product offerings and accelerated sales and marketing efforts. This is similar to what you've seen us achieve at other large acquisitions like Beckman and Pall, where operational improvements helped fuel renewed focus on new product development and go-to-market initiatives. 
The Nobel team has launched more than 20 new products since acquisition and featured a number of these recent innovations at the Nobel Biocare Global Symposium in June. Nobel's new On1 implant base remains in position during the entire restorative workflow, from implant placement to finalization and for the lifetime of the restoration. This helps simplify the dental surgeon's workflow and allows for an improved patient experience. 
And our new NobelParallel CC implant is a straightforward highly versatile implant system, providing an efficient treatment flow that can be used in a wide variety of implant cases. Both of these new innovations help us serve our customers with better solutions to improve their patients' experience and treatment. 
Turning to Product Identification. Core revenues increased low single digits. We saw increased demand for marking and coding equipment and related consumables across most major geographies, partially offset by softness in some of our packaging and color solutions offerings. 
Videojet's substantial and growing installed base contributed to mid-single-digit core revenue growth in the quarter. Strong market performance in North America, Latin America and Western Europe offset softness in certain high-growth markets. Videojet recently introduced a new service offering that enables our technicians to remotely gather data from a printer that's experiencing a fault or a failure condition. This helps our customers return to normal operation much faster, often without a site visit. With our range of comprehensive preventive services, we're able to improve end user productivity over the course of a printers' life span, ultimately reducing operating costs and enhancing customer satisfaction. 
In June, Esko successfully launched a number of new products and innovations at drupa, the world's largest printing equipment exhibition, which is held every 4 years in Germany. This is the most important trade show in the industry. Esko introduced more than a dozen significant hardware and software innovations at drupa this year, including a suite of powerful new software tools that help customers simplify, automate and integrate their complex packaging and label production workflows. We originated a record number of leads and orders at drupa, which we expect to help drive improved growth at Esko and across the product ID platform in the second half of the year. 
Lastly, turning to Water Quality. Core revenues grew low single digits, with strength in Western Europe India and China partially offset by lower demand in Japan and Eastern Europe. Hach had a solid quarter with mid-single-digit core revenue growth. Results were driven by strength in U.S. municipal markets and Western Europe. We saw improved growth in China as Hach continues to benefit from ongoing regulations around water quality monitoring and analysis in the region. 
Hach's online water monitoring solutions are in place in Rio de Janeiro, Brazil for next month's Summer Olympics. Our solutions are installed at the majority of event sites, including the largest soccer stadium in the world. We'll apply our expertise to monitor water quality in order to help Brazil execute a successful Olympic Games. After the events wrap up, the Hach systems will be transferred to municipal water plants across the country, benefiting local communities for many years to come. 
At Trojan, high-single digit core revenue growth in the quarter was a result of a number of project wins in North America, Western Europe and Australia as well as robust demand in municipal markets. 
And finally, at ChemTreat, core revenues grew low single digits despite exposure to weaker industrial- and commodity-oriented end markets. 
So to wrap up, the Danaher team executed well in a challenging macro environment. The thoughtful application of DBS continue to drive results, with meaningful process improvements enabling reinvestment in high-impact growth initiatives. One of Danaher's core values is innovation defines our future, and the successful new product launches we've seen across the portfolio demonstrate our commitment to providing customers with truly differentiated technology to strengthen our collective competitive advantage. 
Following the launch of Fortive, Danaher will be a diversified multi-industry science and technology company united by common business models and the power of DBS. We remain focused on improving growth, margins and cash flow, and we'll continue to pursue meaningful organic and inorganic opportunities to strengthen our market-leading portfolio of businesses. 
Going forward, Danaher's businesses will be organized across 4 segments: Life Sciences, including all of Pall; Diagnostics; Dental; and Environmental & Applied Solutions, which includes our Water Quality and Product Identification businesses. For further details, please refer to the supplemental information that we posted on our website this morning. 
This marks the start of an exciting new chapter for Danaher, and we look forward to the exciting opportunities we see in the years ahead. We are initiating third quarter guidance for adjusted diluted net EPS from continuing operations of $0.80 to $0.84. We are assuming third quarter core revenue growth of 3% or better. For the full year 2016, we're anticipating adjusted diluted net EPS from continuing operations to be in the range of $3.53 to $3.60, which, at the midpoint, would represent an increase of approximately 20% from 2015. Both our third quarter and full year guidance exclude the impact of Fortive."
265621,368081405,1011291,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Executives","Thanks, Tom. That concludes our formal remarks. Ashley, we're now ready for questions. [Operator Instructions]",15,"Thanks, Tom. That concludes our formal remarks. Ashley, we're now ready for questions. [Operator Instructions]"
265621,368081405,1011291,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Operator","[Operator Instructions] We will take our first question from Nigel Coe with Morgan Stanley.",14,"[Operator Instructions] We will take our first question from Nigel Coe with Morgan Stanley."
265621,368081405,1011291,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Analysts","So I just wanted to just fill in the gaps on the FY guide. You said 3% or better for 3Q. Is that the working assumption for 4Q as well? And then what assumptions are you making in terms of the corporate synergies in the back half of the year? I mean, obvi",89,"So I just wanted to just fill in the gaps on the FY guide. You said 3% or better for 3Q. Is that the working assumption for 4Q as well? And then what assumptions are you making in terms of the corporate synergies in the back half of the year? I mean, obviously, there's a corporate line which is unallocated, but then there are some corporate absorbed by the segments. I'm just wondering how that impacts margins in the second half of the year. Any color will be helpful."
265621,368081405,1011291,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Executives","So Nigel, this is Dan. So Q3, we're talking about 3% or better core. I think if we -- in that zone, in part because we a little bit of easier comparison in the fourth quarter, core could be a little bit higher than that. Regarding the corporate on a combi",92,"So Nigel, this is Dan. So Q3, we're talking about 3% or better core. I think if we -- in that zone, in part because we a little bit of easier comparison in the fourth quarter, core could be a little bit higher than that. Regarding the corporate on a combined basis, we've talked since the beginning and we're still sort of in that zone about $70 million to $80 million of corporate dissynergies from the 2 entities. And go-forward, corporate will remain in that kind of the low 40s for Danaher."
265621,368081405,1011291,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Analysts","Okay. And then does that impact the segment line as well, Dan? Or is it just within that unallocated line? So -- well, I guess, what I'm saying is the 2Q, 1Q pro forma segments numbers for new Danaher, is that a good base for the second half of the year?",51,"Okay. And then does that impact the segment line as well, Dan? Or is it just within that unallocated line? So -- well, I guess, what I'm saying is the 2Q, 1Q pro forma segments numbers for new Danaher, is that a good base for the second half of the year?"
265621,368081405,1011291,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Executives","Yes.",1,"Yes."
265621,368081405,1011291,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Analysts","Okay, great. And then just on Dental, you gave some details on the moving parts, will work up better in 2Q. But just -- I'm just wondering, given the pretty fast acceleration from 1Q to 2Q, was there any pull forward or pull back from 1Q to 2Q? Were there",67,"Okay, great. And then just on Dental, you gave some details on the moving parts, will work up better in 2Q. But just -- I'm just wondering, given the pretty fast acceleration from 1Q to 2Q, was there any pull forward or pull back from 1Q to 2Q? Were there some channel volatility? Or is this just natural volatility that we will see from time to time?"
265621,368081405,1011291,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Executives","Nigel, we did see some core improvement, without a doubt, in Dental. 4% core growth in Dental. And a good part of that was clearly around better execution and to some extent, a little bit easier comp. We saw good performance in implants and equipment at m",245,"Nigel, we did see some core improvement, without a doubt, in Dental. 4% core growth in Dental. And a good part of that was clearly around better execution and to some extent, a little bit easier comp. We saw good performance in implants and equipment at mid-single-digit growth consumables, more like low single digit. Terrific performance in China continued. You've heard us talk to double-digit growth in China, and we saw that continuing. U.S. and EU, getting a little bit better. And the high-growth market is still challenging, for sure, but we are rounding around some easier comps. You heard me talk about good solid performance at Nobel. That continued. That said, relative to your question about any impact, there may have been a little bit of pull forward on some revenues just based on the nature of the calendar and the way the calendar worked on the end of the quarter. But in general, I think we're very pleased with the performance. Given seasonality, we could see some moderation in the Q3 growth rates at low single digits. That's typically a function of more European exposure, and the summer tends to be a little bit slower. So we won't necessarily see a straight line to the improved performance, but we were very, very pleased with the execution in the second quarter. And we think we've got a very good trajectory behind us to -- that bodes well for, I think, the quarters to come."
265621,368081405,1011291,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Operator","And our next question comes from Steven Winoker with Bernstein.",10,"And our next question comes from Steven Winoker with Bernstein."
265621,368081405,1011291,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Analysts","Tom, just on the segmentation -- or the new segmentation front. A couple of questions here. One, why is Pall Industrial stuck in Life Sciences? And then secondly, on Environmental & Applied Solutions, I thought maybe Water Quality and Product ID would be",71,"Tom, just on the segmentation -- or the new segmentation front. A couple of questions here. One, why is Pall Industrial stuck in Life Sciences? And then secondly, on Environmental & Applied Solutions, I thought maybe Water Quality and Product ID would be stand-alone. Are they just not big enough yet? Or is there a strategic thought here, a number of segments? I mean, how are you thinking about those 2?"
265621,368081405,1011291,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Executives","Sure. Thanks, Steve. Relative to Pall, we did think it was important to keep those together in a single segment. Obviously, the life science part of the Pall portfolio is the larger part of the portfolio. There's commonality internally at Danaher from a r",236,"Sure. Thanks, Steve. Relative to Pall, we did think it was important to keep those together in a single segment. Obviously, the life science part of the Pall portfolio is the larger part of the portfolio. There's commonality internally at Danaher from a reporting standpoint, both -- in terms of both businesses -- both sides of the business reporting into a president at Pall as well as an EVP overseeing all of Life Sciences. There's also commonality across R&D and supply chain and operations. So there's a lot of reasons operationally to keep the businesses together and therefore, somewhat from a reporting standpoint as well. I mean, realistically, we probably could have split them up, but I think we would probably reevaluate that over time and see how we might run the businesses in the years to come. But I think for right now, that's -- probably the best approach is to keep them together. In terms of Environmental and PID, I think those businesses do share some commonality in terms of serving some different applied end markets. We could have kept them separately. They would have been far smaller segments. So I think we felt that those kind of went together and provided some flexibility for us. As we defined ourselves as remaining a multi-industry company, there obviously is some flexibility to maintain in terms of how we might add to that segment over time."
265621,368081405,1011291,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Analysts","Okay. And then I suppose sticking in the -- on the same M&A -- or the same theme here. On M&A, I know it's bumpy, but you did 6 last quarter, I guess, and 0 this quarter. Was it you're busy of separation? Things just didn't come together? Where -- how's t",72,"Okay. And then I suppose sticking in the -- on the same M&A -- or the same theme here. On M&A, I know it's bumpy, but you did 6 last quarter, I guess, and 0 this quarter. Was it you're busy of separation? Things just didn't come together? Where -- how's the pipeline looking going forward? What should we kind of expect in terms of momentum or pace on the M&A front?"
265621,368081405,1011291,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Executives","Steve, it didn't have anything to do with being busy or in any way focused on other things. Acquisition volume kind of ebbs and flows over time, and so we think the pipeline -- we know the pipelines remain quite good. We have active conversations in each",82,"Steve, it didn't have anything to do with being busy or in any way focused on other things. Acquisition volume kind of ebbs and flows over time, and so we think the pipeline -- we know the pipelines remain quite good. We have active conversations in each one of the platforms. So we feel very good about where we are. We have, obviously, a terrific balance sheet to work with, and I think we'll see good things in the quarters to come."
265621,368081405,1011291,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Analysts","And you emphasized the multi-industry diversified nature as well as science and technology. But I mean, does that -- are you as optimistic on the Environmental & Applied Solutions, I suppose, and Pall Industrial front as you are on the other parts of the",46,"And you emphasized the multi-industry diversified nature as well as science and technology. But I mean, does that -- are you as optimistic on the Environmental & Applied Solutions, I suppose, and Pall Industrial front as you are on the other parts of the business?"
265621,368081405,1011291,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Executives","We are. Well, we continue to have teams that focus, as we always have, in each one of the operating companies and in each one of the platforms, focused on developing funnels, ensuring that we have active cultivations. And yes, we remain biased towards app",58,"We are. Well, we continue to have teams that focus, as we always have, in each one of the operating companies and in each one of the platforms, focused on developing funnels, ensuring that we have active cultivations. And yes, we remain biased towards applying our free cash flow to each one of the businesses across the portfolio."
265621,368081405,1011291,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Operator","Next, we will take Jeffrey Sprague with Vertical Research Partners.",10,"Next, we will take Jeffrey Sprague with Vertical Research Partners."
265621,368081405,1011291,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Analysts","Congrats on getting Fortive done. Just maybe a couple business-related questions drilling in a little bit. Tom, can you elaborate a little bit what was going on in Environmental core margins in the quarter, why they're under pressure and kind of what the",47,"Congrats on getting Fortive done. Just maybe a couple business-related questions drilling in a little bit. Tom, can you elaborate a little bit what was going on in Environmental core margins in the quarter, why they're under pressure and kind of what the trajectory is looking forward?"
265621,368081405,1011291,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Executives","Jeff, thanks for the question. In general, we feel very good about where those businesses are. I'll speak specifically to the Hach business. We had very good performance in the prior quarter -- in the same quarter last year. In addition, we're making some",100,"Jeff, thanks for the question. In general, we feel very good about where those businesses are. I'll speak specifically to the Hach business. We had very good performance in the prior quarter -- in the same quarter last year. In addition, we're making some investments from a growth standpoint in those businesses. So I think we're continuing to see margin expansion from the water side of the Environmental segment, and I think those investments overall are going to pay off in terms of good growth rates in the quarters to come. So it's not an area of concern for us."
265621,368081405,1011291,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Executives","And Jeff, 2 things to add. One is Gilbarco had better growth than the Water business, so there's some negative mix in there for the segment. And we had our best -- that segment was -- Q2 last year was probably 150, 200 basis points better than any other q",81,"And Jeff, 2 things to add. One is Gilbarco had better growth than the Water business, so there's some negative mix in there for the segment. And we had our best -- that segment was -- Q2 last year was probably 150, 200 basis points better than any other quarter we had in 2015. So a little bit of a comp issue as well. But as Tom alluded to, we are investing pretty heavily right now in the Water business organically."
265621,368081405,1011291,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Analysts","Speaking of investment, maybe just kind of a total new Danaher question. But the idea of kind of restructuring, be it quiet or otherwise, is that a likely part of the equation here as you progress through the year? And can you give us some idea how to thi",51,"Speaking of investment, maybe just kind of a total new Danaher question. But the idea of kind of restructuring, be it quiet or otherwise, is that a likely part of the equation here as you progress through the year? And can you give us some idea how to think about that?"
265621,368081405,1011291,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Executives","Jeff, as we, I think, showed last year, we've established a cadence of restructuring that has gone on. You might say quietly, but I would say more consistently and appropriately throughout the course of the year. As opportunities have come up, we've taken",109,"Jeff, as we, I think, showed last year, we've established a cadence of restructuring that has gone on. You might say quietly, but I would say more consistently and appropriately throughout the course of the year. As opportunities have come up, we've taken advantage of those in each of the quarters. And so we still have opportunities for some level of restructuring in the third and fourth quarter. But in general, we've been more balanced through the course of the year, and I think that has served us well in terms of the operating margin expansion that you've seen over time late last year and this year as well."
265621,368081405,1011291,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Analysts","And then finally, just back to Environmental and Water specifically in the muni market. So we've been kind of hearing for a couple quarters that things are gaining traction. Obviously, you had a strong quarter at Trojan. Can you speak a little bit to the",66,"And then finally, just back to Environmental and Water specifically in the muni market. So we've been kind of hearing for a couple quarters that things are gaining traction. Obviously, you had a strong quarter at Trojan. Can you speak a little bit to the forward visibility there? What's going on in order activity? Do you have top line visibility into that business now into '17?"
265621,368081405,1011291,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Executives","Jeff, it's probably a little bit early to kind of comment on '17. The muni strength continues to be broad-based, both the Trojan and the Hach business. And at the Hach business, we're seeing it both in Europe and the U.S. Very consistent and healthy spend",70,"Jeff, it's probably a little bit early to kind of comment on '17. The muni strength continues to be broad-based, both the Trojan and the Hach business. And at the Hach business, we're seeing it both in Europe and the U.S. Very consistent and healthy spending there. The offset is that both for Hach and ChemTreat is where we serve the industrial or any comp commodity-oriented markets, they've been challenging."
265621,368081405,1011291,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Operator","Our next question is from Shannon O'Callaghan with UBS.",10,"Our next question is from Shannon O'Callaghan with UBS."
265621,368081405,1011291,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Analysts","Just on this emphasis on reinvesting some of the synergy upside at Nobel and at Pall into new products, go-to-market investments. What kind of lag are you expecting from that? I mean, when do you expect that to translate into improving organic growth for",51,"Just on this emphasis on reinvesting some of the synergy upside at Nobel and at Pall into new products, go-to-market investments. What kind of lag are you expecting from that? I mean, when do you expect that to translate into improving organic growth for those businesses and just what you're seeing?"
265621,368081405,1011291,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Executives","Shannon, it varies depending on where we direct those funds. I think, in some cases, when we put investment directly into, say, feet on the street, in either a developed market or a high-growth market, we tend to see those investments pay off in just a qu",215,"Shannon, it varies depending on where we direct those funds. I think, in some cases, when we put investment directly into, say, feet on the street, in either a developed market or a high-growth market, we tend to see those investments pay off in just a quarter or 2. If we're talking about investments that go into new product development, those tend to have much more of a lag time. As projects get kicked off into early business case-oriented tollgates, you could have several quarters to it, at times even a couple of years, before you might see the impact of a new product investment, again, depending on how early or late-stage an existing project might be in the pipeline. So it's varied. I think in the case of Nobel, just to talk to one of the businesses, we've seen those investments pay off relatively quickly. You've seen it in core revenue growth consistently in that business. They have relatively shorter cycle times in terms of new product development. In businesses like Beckman, for example, and at Pall, the product development cycles are longer, certainly significantly longer at a place like Beckman, where, oftentimes, we'll have clinical trials and/or regulatory clearances. And so those new product investments can be -- can take some time, obviously."
265621,368081405,1011291,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Analysts","Okay, great. And then, yes, maybe a follow-up to that. I mean, in terms of -- in Diagnostics, you talked about Beckman's growth being driven by high-growth markets. What's going on in the developed markets? And maybe to get to some of your comments you ju",67,"Okay, great. And then, yes, maybe a follow-up to that. I mean, in terms of -- in Diagnostics, you talked about Beckman's growth being driven by high-growth markets. What's going on in the developed markets? And maybe to get to some of your comments you just made there with a sellout, what is it going to take to get some better growth in developed markets for Beckman?"
265621,368081405,1011291,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Executives","Sure. Yes, a little bit slower growth in developed markets. I mean, in general, the developed markets, from an overall perspective, are slower-growth markets to begin with. We've always seen better market growth in the -- overall in places like China and",119,"Sure. Yes, a little bit slower growth in developed markets. I mean, in general, the developed markets, from an overall perspective, are slower-growth markets to begin with. We've always seen better market growth in the -- overall in places like China and India and the Middle East. So in general, I think we're tracking closer to the market growth rates than anything else. Still have work to do. There's no question about it. We have improved our retention rates and our competitive win rates, but there's still work to do in terms of both go-to-market as well as new product development. And over time, we do believe those will pay off in better growth rates in the developed markets."
265621,368081405,1011291,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Operator","And our next question is coming from Tycho Peterson with JPMorgan.",11,"And our next question is coming from Tycho Peterson with JPMorgan."
265621,368081405,1011291,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Analysts","Tom, just wondering if you can talk about some of the gives and takes where you're feeling a little more constructive by segment in the back half of the year. You talked to the gives and takes on Dental, so maybe you can pass on that. But is Pall Industri",99,"Tom, just wondering if you can talk about some of the gives and takes where you're feeling a little more constructive by segment in the back half of the year. You talked to the gives and takes on Dental, so maybe you can pass on that. But is Pall Industrial kind of bottoming out here? Could you see some improvement there? Obviously, the academic fund flows may pick up in the back half of the year, and that could help SCIEX. So could you just talk by division where you're feeling more constructive for the next couple of quarters?"
265621,368081405,1011291,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Executives","Sure. Thanks for the question. We do think that we're -- as you mentioned, we've seen good performance in Dental. Again, not necessarily a straight line, but we're very encouraged by the performance we're seeing. In terms of the other businesses across th",163,"Sure. Thanks for the question. We do think that we're -- as you mentioned, we've seen good performance in Dental. Again, not necessarily a straight line, but we're very encouraged by the performance we're seeing. In terms of the other businesses across the second half, I think we'll see continuing better performance across the Diagnostic businesses, in particular. We're starting to see the benefit of a number of the investments across those businesses. I think we'll see continuing good performance from Water Quality. PID has been pretty consistent along the way, so I think we will see that continue. Our Life Science businesses have also performed well, particularly SCIEX, as well as Beckman Life Science, so I think we'd see some modest incremental growth there. I would also remind you that we're coming around through some easier comps in the second half as well, and so we will get a little bit of benefit from those easier comps really across the entire portfolio."
265621,368081405,1011291,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Analysts","And since you called out Europe as a source of strength for Life Sciences and Radiometer, are you kind of comfortable with the macro in the back half of the year for those markets?",34,"And since you called out Europe as a source of strength for Life Sciences and Radiometer, are you kind of comfortable with the macro in the back half of the year for those markets?"
265621,368081405,1011291,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Executives","Well, I think the Brexit situation certainly has created uncertainty around not just the U.K. but across European theater at large. Uncertainty is rarely a good thing for markets in terms of people's willingness to make investments, particularly in instru",64,"Well, I think the Brexit situation certainly has created uncertainty around not just the U.K. but across European theater at large. Uncertainty is rarely a good thing for markets in terms of people's willingness to make investments, particularly in instrumentation and higher-cost instrumentation. So I think that uncertainty could potentially result in some slowness in the second half, but it's very early to tell."
265621,368081405,1011291,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Executives","Tycho, we've been -- just to add on Western Europe. We've been consistently in kind of a pretty healthy low single-digit number across Western Europe. It's been pretty broad-based. It is an area where -- because of some of the uncertainties the last coupl",103,"Tycho, we've been -- just to add on Western Europe. We've been consistently in kind of a pretty healthy low single-digit number across Western Europe. It's been pretty broad-based. It is an area where -- because of some of the uncertainties the last couple of years, we've probably taken a fair amount of share, as we've seen some people kind of pull back in Western Europe over the last couple of years. So it's been a good market for us. And while -- and we also see doing Pall doing quite well in Europe. Those, obviously, are not in the core numbers yet."
265621,368081405,1011291,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Analysts","Okay. And then just lastly on the capital deployment question earlier. You touched on the framework a little bit. Can you just remind us where you're comfortable taking up leverage? And maybe just any comments on what you're seeing in terms of valuation,",50,"Okay. And then just lastly on the capital deployment question earlier. You touched on the framework a little bit. Can you just remind us where you're comfortable taking up leverage? And maybe just any comments on what you're seeing in terms of valuation, given how much this space has run?"
265621,368081405,1011291,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Executives","Well, Tycho, we've obviously spent the last year in a significant effort on deleveraging. We're in really good shape. We're south of 2.5x at this point. Initially, we're close to 4x leverage. So we're back to a mode of spending our free cash flow plus, an",87,"Well, Tycho, we've obviously spent the last year in a significant effort on deleveraging. We're in really good shape. We're south of 2.5x at this point. Initially, we're close to 4x leverage. So we're back to a mode of spending our free cash flow plus, and we've talked about a couple billion of capacity for this year. But going into next year, you're back to more $3 billion to $4 billion of capacity per year. And that's not without -- that's without really stretching the balance sheet."
265621,368081405,1011291,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Operator","Our next question is coming from Ross Muken with Evercore ISI.",11,"Our next question is coming from Ross Muken with Evercore ISI."
265621,368081405,1011291,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Analysts","So appreciate, I know you gave us already some color on Pall single-use and on SCIEX, but I'd love it if you could tease out at all sort of pharma demand based on sort of customer types, so sort of separating maybe pharma from biotech or emerging biotech",96,"So appreciate, I know you gave us already some color on Pall single-use and on SCIEX, but I'd love it if you could tease out at all sort of pharma demand based on sort of customer types, so sort of separating maybe pharma from biotech or emerging biotech to see if there's any sort of discernible trend you've seen amongst. I mean, it's clear Pall, obviously, having pretty strong growth across the board, but I was wondering if any of the end markets, whether it's generic or CRO, et cetera, you're seeing any change in demand."
265621,368081405,1011291,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Executives","SCIEX is probably the best business to think about when you think about the -- your question about pharma versus, say, biotech. SCIEX has exposure to both those end markets, and we're seeing good performance, healthy demand and fairly consistent demand fr",131,"SCIEX is probably the best business to think about when you think about the -- your question about pharma versus, say, biotech. SCIEX has exposure to both those end markets, and we're seeing good performance, healthy demand and fairly consistent demand from both sides of the house there. I'd have to do some follow-up to get you some detail on anything to do with the generics or the CROs, specifically. But clearly, in the aggregate, these markets are doing quite well. Pall, as you mentioned, we've talked about the growth that we're seeing in the life science side, specifically around our single-use technology product offering, where we're seeing continued double-digit growth rates in that area. And that clearly is associated with the growth in biopharmaceuticals, specifically the growth in large-molecule drugs."
265621,368081405,1011291,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Analysts","Great. I guess, what I was getting at is more on the CRO, generic side. Maybe I'll ask it differently. In terms of just high-growth markets, I mean, it's clear China has been good. But outside of China, how would you sort of characterize the rest of the k",69,"Great. I guess, what I was getting at is more on the CRO, generic side. Maybe I'll ask it differently. In terms of just high-growth markets, I mean, it's clear China has been good. But outside of China, how would you sort of characterize the rest of the key markets? Obviously, LatAm has kind of been a mixed bag overall, but India and some of the other key geographies."
265621,368081405,1011291,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Executives","I'd say China, in particular, India as well, are very good markets for us. But I would say that there's still a long runway ahead for those markets. Some of the generic and the CRO movement into those markets has been, on balance, positive. But there are",85,"I'd say China, in particular, India as well, are very good markets for us. But I would say that there's still a long runway ahead for those markets. Some of the generic and the CRO movement into those markets has been, on balance, positive. But there are also components of the market that are still relatively nascent, particularly in terms of what might be going on there in the future relative to large-molecule drugs. So I think there's still a pretty good runway ahead."
265621,368081405,1011291,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Operator","Our next question comes from Derik De Bruin with Bank of America Merrill Lynch.",14,"Our next question comes from Derik De Bruin with Bank of America Merrill Lynch."
265621,368081405,1011291,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Analysts","So could you talk a little bit about capital deployment? I'm just curious, now that sort of Fortive is spun out, how do you sort of view your overall strategy in the life sciences space? Do you still feel like you want to stay focused on the core -- stand",84,"So could you talk a little bit about capital deployment? I'm just curious, now that sort of Fortive is spun out, how do you sort of view your overall strategy in the life sciences space? Do you still feel like you want to stay focused on the core -- stand-alone core brands? Or do you feel the need to sort of become a more integrated provider in the space? Do you think you need to add anything to your Life Sciences or Diagnostics armament?"
265621,368081405,1011291,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Executives","Well, Derik, I think, first of all, starting at a Danaher level, our bias towards M&A is not -- and the use of our free cash flow to M&A is not specifically skewed towards any of the 4 segments that I mentioned. We've had a consistent track record of capi",278,"Well, Derik, I think, first of all, starting at a Danaher level, our bias towards M&A is not -- and the use of our free cash flow to M&A is not specifically skewed towards any of the 4 segments that I mentioned. We've had a consistent track record of capital allocation across each of those 4 segments that we'll be reporting on in the future, and I think you'll continue to see us do that. Now specifically to your question around Life Sciences and Diagnostics, what you've seen us do in Life Sciences is continue to broaden our product offering over time, and I think you'll continue to see us do that. We have had a bias and would continue to have a bias towards businesses with not only strong brands and significant installed bases, but installed bases that drive good, consistent recurring revenue and consumables growth. The Diagnostics business is inherently that way, typically, and you've seen us buy businesses with those same characteristics, strong brands, significant installed bases and strong recurring revenue and consumable streams. I think you'd see us continue to do that. We think there is certainly room to continue to expand our Diagnostic product offering and provide hospitals with broader bundles of product. Today, we provide products, obviously, to the central laboratory, the core clinical laboratory, as well as the anatomical pathology and to the acute care areas of the hospital. And with the expansion of Microscan into microbiology, with Iris opening up urinalysis for us, I think those types of expansions of our footprint would certainly be characteristic of the types of things that we would hope to do in the future."
265621,368081405,1011291,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Analysts","Great. That's really helpful. And just one quick follow-up. It's been a year since you launched the Veris platform and Molecular. Could you talk a little bit about what you've seen in terms of installed base and competitive wins? And essentially, where is",83,"Great. That's really helpful. And just one quick follow-up. It's been a year since you launched the Veris platform and Molecular. Could you talk a little bit about what you've seen in terms of installed base and competitive wins? And essentially, where is that going? What's the customer type? And then if you're -- I assume you're taking share from people since most hospitals have molecular platforms of that size. Can you just talk a little bit more -- some color on that?"
265621,368081405,1011291,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Executives","Sure. Thanks, Derik. Just for everyone's benefit, the Veris platform is a high-volume, random-access molecular diagnostics instrument that was commercialized for the first time in Europe in the second half of last year. That product line serves the core -",224,"Sure. Thanks, Derik. Just for everyone's benefit, the Veris platform is a high-volume, random-access molecular diagnostics instrument that was commercialized for the first time in Europe in the second half of last year. That product line serves the core -- or central clinical laboratory of major hospitals. And again, as I mentioned, it is a -- it's a high-volume platform. We're very pleased with the early traction that we'd gotten. It is still early. During the first year of a significant new product introduction like that, the first of its kind by Beckman Coulter, it does take a while to build the funnel, but we've been very happy with how that funnel has built, the sales opportunity funnel in the last year. The installations that we have thus far are running very well. We have 4 assays in the market right now, but the 4 assays really are just the beginning. There's a significant road map of assay development ahead that will ultimately be commercialized, both in Europe as well as in the U.S. That product will need to go through regulatory clearance in the U.S., so it'll be some time before we see the volumes ramp beyond the early days here in Europe. But the feedback from customers has been very -- strongly positive, and we feel good about the start we have."
265621,368081405,1011291,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Analysts","Great. And when is FDA approval expected?",7,"Great. And when is FDA approval expected?"
265621,368081405,1011291,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Executives","I usually hesitate to try to put any bets on FDA clearance. There's a fair amount of work to do even before we file for that clearance, so I'll probably have a better sense of that in the quarters to come. But wouldn't -- I couldn't put a date on it today",52,"I usually hesitate to try to put any bets on FDA clearance. There's a fair amount of work to do even before we file for that clearance, so I'll probably have a better sense of that in the quarters to come. But wouldn't -- I couldn't put a date on it today."
265621,368081405,1011291,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Operator","Our next question comes from Julian Mitchell with Crdit Suisse.",10,"Our next question comes from Julian Mitchell with Crdit Suisse."
265621,368081405,1011291,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Analysts","Just a question on margins, firstly. So the core margin in total Danaher fell about 30 bps in Q2. Could you give that comparable number for the remaining business? And then maybe -- and how you think that will trend in the second half? And tied to that, I",88,"Just a question on margins, firstly. So the core margin in total Danaher fell about 30 bps in Q2. Could you give that comparable number for the remaining business? And then maybe -- and how you think that will trend in the second half? And tied to that, I guess, going back to the Environmental & Applied Solutions segment. The headline margin there was down 300 bps plus in Q2. Should we see that coming back in the second half as the comps on margins get much easier?"
265621,368081405,1011291,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Executives","Sure, Julian. On the last one you asked, and I -- as I mentioned earlier, part of the Environmental issue was a comp issue that margins on a historical restated basis for the Environmental & Applied Solutions were 200 basis points higher in Q2 a year ago.",118,"Sure, Julian. On the last one you asked, and I -- as I mentioned earlier, part of the Environmental issue was a comp issue that margins on a historical restated basis for the Environmental & Applied Solutions were 200 basis points higher in Q2 a year ago. So you expect that to sort of normalize. Core margins were relatively flat for Danaher ex Fortive. That was, again, somewhat of a function of the prior-year compare. For our full year, we continue to expect 50 to 75 basis points of core margin expansion for Danaher ex Fortive, and you'll see better performance. So a very good performance in the first quarter. You'll see better performance in Q3 and Q4."
265621,368081405,1011291,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Analysts","Great. And then just on Pall Industrial. You called out the overall organic sales trend year-on-year. Is there any sort of color you'd give there on specific verticals or markets within that? Any changes?",34,"Great. And then just on Pall Industrial. You called out the overall organic sales trend year-on-year. Is there any sort of color you'd give there on specific verticals or markets within that? Any changes?"
265621,368081405,1011291,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Executives","No. I wouldn't say we've seen necessarily any changes, Julian. I think if -- to the extent that there's good news there, I think it would be that we've seen some stability found in those markets. We continue to make some excellent progress in terms of our",162,"No. I wouldn't say we've seen necessarily any changes, Julian. I think if -- to the extent that there's good news there, I think it would be that we've seen some stability found in those markets. We continue to make some excellent progress in terms of our go-to-market initiatives. We've done over 40 growth-related kaizens at Pall since we acquired the business. And a number of those kaizens have been going on in the industrial markets. And that involves installing DBS tools, such as funnel management and transformative marketing, that, we think, is improving our execution in those markets. So I think the combination of seeing some stability across each one of those end markets, in combination with the application of DBS tools, I think, has gotten us to a pretty good place. So I would hope to see some incrementally better performance late this year and certainly, entering next year. But I think, in general, we're pleased that things have stabilized."
265621,368081405,1011291,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Operator","Our final question is coming from Isaac Ro with Goldman Sachs.",11,"Our final question is coming from Isaac Ro with Goldman Sachs."
265621,368081405,1011291,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Analysts","I just want to ask another question on Pall Industrial. If we look back prior to the acquisition, that business was obviously growing a little slower than the Life Science side. But curious if you could maybe take a bigger step back and give us a sense of",77,"I just want to ask another question on Pall Industrial. If we look back prior to the acquisition, that business was obviously growing a little slower than the Life Science side. But curious if you could maybe take a bigger step back and give us a sense of what you think it will take for Industrial to return to growth. Is it mostly a function of end markets? Or is there really more of an execution issue?"
265621,368081405,1011291,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Executives","I think it's both. As I was just mentioning to Julian, I think we've seen the markets themselves, from a macro standpoint, stabilize a bit. In other words, not get any worse. And we will need to see some improvement in the macro environment to see some me",154,"I think it's both. As I was just mentioning to Julian, I think we've seen the markets themselves, from a macro standpoint, stabilize a bit. In other words, not get any worse. And we will need to see some improvement in the macro environment to see some meaningful or a step function improvement and growth. But we're not waiting for that. Our focus is on ensuring that we have the best sales team on the field, that we're providing those teams with exceptional new product development, that we've got our coverage set up appropriately across geographies and across each one of those verticals. And I think the combination of good market coverage, DBS tools, new product development and some improvement in those end markets is what it's going to take. Obviously, the majority of that, we hope to be in our control, but a little help from the end markets certainly wouldn't hurt."
265621,368081405,1011291,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Analysts","Got it. That's helpful. And then one other question on Beckman. If we -- if you just try to square up kind of what we saw last week with some of the peer groups in Diagnostics with what you said, you -- obviously, you've got Veris and CytoFLEX helping out",85,"Got it. That's helpful. And then one other question on Beckman. If we -- if you just try to square up kind of what we saw last week with some of the peer groups in Diagnostics with what you said, you -- obviously, you've got Veris and CytoFLEX helping out. If we pull those out, just trying to get a better sense of how you think you're pacing versus the overall market for Diagnostics. And any color there, especially in North America, would be helpful."
265621,368081405,1011291,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Executives","Sure. Thanks, Isaac. Well, as you know, we had to come from behind here from the standpoint of the big 5 in the overall market. I think from a pacing standpoint, we've now gotten to a point where we are very close to, if not at, market growth rates, with",206,"Sure. Thanks, Isaac. Well, as you know, we had to come from behind here from the standpoint of the big 5 in the overall market. I think from a pacing standpoint, we've now gotten to a point where we are very close to, if not at, market growth rates, with a couple of the competitors, as you mentioned, that reported last week posting better growth rates. And in doing so -- in some cases, it's a function of their positions in certain higher-growth markets. But in other cases, we simply have work to do in terms of continuing to drive our new product development and our go-to-market initiatives. We're ahead of a couple other competitors in that market, and we have demonstrated where, from a competitive win perspective, we've become far more competitive in the overall market. So I think we've made a ton of progress. But clearly, work to do. And that work, as you've referenced, is represented by some folks that are still putting up some pretty good numbers. So I think we've got the initiatives and the investment levels in the right place. We continue to make progress. And it'll take a bit of time, but I think we're on the right track."
265621,368081405,1011291,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Operator","And that concludes our question-and-answer session. I would like to turn the conference back over to Matt Gugino for any additional or closing remarks.",25,"And that concludes our question-and-answer session. I would like to turn the conference back over to Matt Gugino for any additional or closing remarks."
265621,368081405,1011291,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Executives","Thanks, everyone, for joining us. We're around all day for questions.",11,"Thanks, everyone, for joining us. We're around all day for questions."
265621,368081405,1011291,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Operator","And that concludes today's presentation. We thank you all for your participation.",13,"And that concludes today's presentation. We thank you all for your participation."
265621,368081405,1011371,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Operator","My name is Ashley, and I will be your conference facilitator today. At this time, I would like to welcome everyone to the Danaher Corporation Second Quarter 2016 Earnings Results Conference Call. [Operator Instructions] I will now turn the conference ov",57,"My name is Ashley, and I will be your conference facilitator today. At this time, I would like to welcome everyone to the Danaher Corporation Second Quarter 2016 Earnings Results Conference Call. [Operator Instructions] 
I will now turn the conference over to Mr. Matt Gugino, Vice President of Investor Relations. Mr. Gugino, you may begin your conference."
265621,368081405,1011371,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Executives","Thanks, Ashley. Good morning, everyone, and thanks for joining us on the call. With us today are Tom Joyce, our President and Chief Executive Officer; and Dan Comas, our Executive Vice President and Chief Financial Officer. I'd like to point out that ou",331,"Thanks, Ashley. Good morning, everyone, and thanks for joining us on the call. With us today are Tom Joyce, our President and Chief Executive Officer; and Dan Comas, our Executive Vice President and Chief Financial Officer. 
I'd like to point out that our earnings release, the slide presentation supplementing today's call, our second quarter Form 10-Q and the reconciliations and other information required by SEC Regulation G relating to any non-GAAP financial measures provided during the call are all available on the Investors section of our website, www.danaher.com, under the heading Financial Information. The audio portion of this call will be archived on the Investors section of our website later today under the heading Events & Presentations and will remain archived until our next quarterly call. A replay of this call will also be available until August 1, 2016. 
During the presentation, we will describe certain of the more significant factors that impacted year-over-year performance. The supplemental materials describe additional factors that impacted year-over-year performance. Unless otherwise noted, all references in these remarks and supplemental materials to company-specific financial metrics relate to the continuing operations of the company in the second quarter of 2016, and all references to period-to-period increases or decreases in financial metrics are year over year. 
We may also describe certain products and devices, which have applications submitted and pending for certain regulatory approvals. 
During the call, we will make forward-looking statements within the meaning of the federal securities laws, including statements regarding events or developments that we believe or anticipate will or may occur in the future. These forward-looking statements are subject to a number of risks and uncertainties, including those set forth in our SEC filings, and actual results may differ materially from any forward-looking statements that we make today. These forward-looking statements speak only as of the date that they are made, and we do not assume any obligation to update any forward-looking statements. 
With that, I'd like to turn the call over to Tom."
265621,368081405,1011371,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Executives","Thanks, Matt, and good morning, everyone. The second quarter was a busy and exciting one for Danaher. Despite challenging economic conditions, we were pleased with our performance as the team's consistent focus on execution helped deliver solid core reven",2343,"Thanks, Matt, and good morning, everyone. The second quarter was a busy and exciting one for Danaher. Despite challenging economic conditions, we were pleased with our performance as the team's consistent focus on execution helped deliver solid core revenue growth, high-teens adjusted earnings per share growth and strong free cash flow performance. 
On July 2, we successfully completed the spin-off of Fortive Corporation, a new industrial growth company. The earlier-than-expected completion of the separation is a testament to our process orientation, execution focus and exceptional teamwork. We continue to believe that the separation will provide significant opportunities for both Danaher and Fortive to independently build even greater shareholder value in the years ahead. Since we owned Fortive through the end of the second quarter, we will start with financial highlights that reflect the combined Danaher and Fortive results. We'll then provide detail for the businesses remaining with Danaher, outline our planned new reporting segments and provide guidance for Danaher's continuing operations, excluding Fortive, for the third quarter and the full year. Since the Fortive team will be reporting their second quarter results separately next week, we'd ask that you please save any questions about the Fortive businesses until then. 
Now turning to the details of the second quarter. Adjusted diluted net earnings per share from continuing operations was $1.25, an increase of 17% over last year and our third consecutive quarter of mid-teens or better adjusted EPS growth. Sales grew 16.5% to $5.8 billion, and core revenue increased 2%. The impact of currency translation eased this quarter but still decreased revenues by 0.5%, while acquisitions increased revenues by 15%. Danaher RemainCo core revenue was up 3%, while Fortive core revenue was down slightly. 
Geographically, high-growth market revenues were up mid-single digits, led by double-digit growth in China and India. We saw better sequential performance in Latin America and Russia, in part because of easier prior-year comparisons. Developed market core revenues were up low single digits, led by growth in Western Europe. The U.S. remained roughly flat, and we saw declines in Japan during the quarter. 
Gross margin for the second quarter was 54.4%, an increase of 110 basis points from last year. Reported operating margins were 17.9%, with core operating margins down 30 basis points. More than 80 basis points of core margin improvement were -- we had more than 80 basis points of core margin improvement at both Dental and Life Sciences & Diagnostics, which was offset by declines in Test & Measurement and Environmental segments. 
Free cash flow continues to be one of our most important financial metrics, enabling us to pursue organic and inorganic growth initiatives across our entire portfolio. We generated $1.1 billion of free cash flow from continuing operations in the quarter, up 14%, and our free cash flow to net income conversion ratio was over 150%. 
Now let's take a look at more detailed results across the Danaher portfolio. In Life Sciences, core revenue increased mid-single digits, led by strength in high-growth markets and Western Europe. At Beckman Life Sciences, we continued to outperform. High-single digit core growth in the quarter was driven by strong demand in flow cytometry, particularly in North America and China. The robust growth in flow cytometry was largely driven by demand for our new CytoFLEX product based on the breakthrough technology, which we acquired as part of the Xitogen acquisition in 2014. This bolt-on acquisition has been a tremendous success and is a great example of how we incorporate novel technology into our portfolio to enhance our offering and expand our customer base. CytoFLEX has been a significant contributor to recent share gains in our flow cytometry business. 
At Leica Microsystems, we saw improved results versus previous quarters, as recent new product introductions helped drive low single-digit core revenue growth. Two such new product introductions included our Leica DVM6 digital microscope launched at the end of 2015 and our new Leica M530 neurosurgery microscope, which is off to a great start in China after successful launches in Europe and North America last year. The M530 is a standout combination of our high-resolution optics technology with improved ergonomics, helping neurosurgeons stay focused during their demanding high-precision procedures. 
Core revenues at SCIEX were up mid-single digits as we saw continued strength in pharmaceutical, food and environmental end markets. We had another very strong quarter in China as new regulations from the Chinese Food and Drug Administration helped drive increased demand around drug testing and food safety. 
In June, SCIEX announced a number of new workflow solutions at ASMS, the American Society of Mass Spectrometry Annual Meeting. These solutions are geared toward fast-growing markets such as biologics, proteomics, food and environmental testing. We showcased the latest QTRAP 6500+ mass spectrometer that provides enhanced sensitivity and selectivity to create a powerful workflow solution for biologics analysis. 
We also rolled out BioPharmaView Software 2.0, which accelerates automated data processing and simplifies reporting, enabling biopharma researchers to make better decisions faster. 
At Pall, core revenues were up mid-single digits for the quarter compared to last year as a stand-alone company. Continued strong demand in biopharma, particularly single-use technologies, led to double-digit core revenue growth in Pall Life Sciences. In Pall Industrial, revenues were down low single digits, but we're continuing to see some signs of stabilization in those end markets. 
Pall continues to ramp exceedingly well across a number of key metrics. The team's commitment to the Danaher Business System has resulted in on-time delivery improving by more than 1,500 basis points with greater productivity and quality, driving improved customer satisfaction. Since acquisition, faster-than-expected cost savings and meaningful operational gains have contributed to sizable gross and operating margin improvements. As a result of the team's impressive start, we've been able to redirect some of that benefit into R&D and sales and marketing investments. By pursuing this combination of margin enhancement and growth opportunities, we believe we can continue to drive innovation and improve Pall's competitive advantage. 
The Pall team showcased a number of innovations, such as acoustic wave separation and our new single-use bioreactor at the Interfax biomanufacturing trade show in April. Our expanded single-use product offering has enhanced our competitive position, as pharmaceutical companies look to shift from traditional large infrastructure stainless steel systems to more efficient production processes. Pall's bioprocessing solutions help our customers save significant time, energy and money while greatly reducing cross-contamination risk, which provides the flexibility to easily and safely make multiple products in one facility. 
Moving now to Diagnostics. Core revenues increased low single digits, with double-digit gains in China and India partially offset by weakness in the Middle East and the Americas. At Beckman Coulter, core revenues were up low single digits, driven primarily by strength in high-growth markets. This past June marked the fifth anniversary of the Beckman acquisition. We've made tremendous progress since then, significantly improving quality, delivery and our overall customer experience while using productivity gains to help fund new product development and add feet on the street. Another quarter of good execution by the Beckman team contributed to healthy core operating margin expansion, and we continued to reinvest in high-impact growth opportunities. New menu additions are gaining traction, including our vitamin D and AMH fertility tests in our immunoassay business. 
Our recently launched molecular diagnostic platform, Veris, continues to gain early traction in Europe. New product developments like these, combined with opportunities at recent bolt-on acquisitions like Microscan, will continue to help build meaningful runway for growth at Beckman going forward. 
Radiometer achieved mid-single-digit revenue growth, with healthy performance in Western Europe and China partially offset by weakness in Latin America and the Middle East. Our growing installed base of blood gas instruments and AQT analyzers contributed to solid consumable sales in the quarter. The Radiometer team also recently launched the TCM5 FLEX, a new transcutaneous monitor design. This noninvasive monitor measures ventilation for patients in critical condition. And the TCM5's updated design is easy to use and reliable, providing nurses and doctors with improved usability while maintaining accuracy and precision. 
At Leica Biosystems, core revenues grew mid-single digits. Results were driven by a combination of strength in high-growth markets and continued growth of instrument placements in advanced staining and core histology. 
Moving now over to our Dental segment. Core revenues were up mid-single digits, with growth across consumables, equipment and implants. We saw particular strength in our restorative and Ormco product lines. Geographically, China had another strong quarter with double-digit growth, and we maintain positive momentum in North America and Western Europe. 
Nobel had another good quarter with mid-single-digit core revenue growth. We've improved operating margins at Nobel by more than 500 basis points since acquisition, enabling us to direct some of our savings into expanded product offerings and accelerated sales and marketing efforts. This is similar to what you've seen us achieve at other large acquisitions like Beckman and Pall, where operational improvements helped fuel a renewed focus on new product development and go-to-market initiatives. 
The Nobel team has launched more than 20 new products since acquisition and featured a number of these recent innovations at the Nobel Biocare Global Symposium in June. Nobel's new On1 implant base remains in position during the entire restorative workflow, from implant placement to finalization and for the lifetime of the restoration. This helps simplify the dental surgeon's workflow and allows for an improved patient experience. 
And our new NobelParallel CC implant is a straightforward highly versatile implant system, providing an efficient treatment flow that can be used in a wide variety of implant cases. Both of these new innovations help us serve our customers with better solutions to improve their patients' experience and treatment. 
Turning to Product Identification. Core revenues increased low single digits. We saw increased demand for marking and coding equipment and related consumables across most major geographies, partially offset by softness in some of our packaging and color solutions offerings. 
Videojet's substantial and growing installed base contributed to mid-single-digit core revenue growth in the quarter. Strong market performance in North America, Latin America and Western Europe offset softness in certain high-growth markets. Videojet recently introduced a new service offering that enables our technicians to remotely gather data from a printer that's experiencing a fault or a failure condition. This helps our customers return to normal operation much faster, often without a site visit. With our range of comprehensive preventive services, we're able to improve end user productivity over the course of a printers' life span, ultimately reducing operating costs and enhancing customer satisfaction. 
In June, Esko successfully launched a number of new products and innovations at drupa, the world's largest printing equipment exhibition, which is held every 4 years in Germany. This is the most important trade show in the industry. Esko introduced more than a dozen significant hardware and software innovations at drupa this year, including a suite of powerful new software tools that help customers simplify, automate and integrate their complex packaging and label production workflows. We originated a record number of leads and orders at drupa, which we expect to help drive improved growth at Esko and across the product ID platform in the second half of the year. 
Lastly, turning to Water Quality. Core revenues grew low single digits, with strength in Western Europe, India and China partially offset by lower demand in Japan and Eastern Europe. Hach had a solid quarter with mid-single-digit core revenue growth. Results were driven by strength in U.S. municipal markets and Western Europe. We saw improved growth in China as Hach continues to benefit from ongoing regulations around water quality monitoring and analysis in the region. 
Hach's online water monitoring solutions are in place in Rio de Janeiro, Brazil for next month's Summer Olympics. Our solutions are installed at the majority of event sites, including the largest soccer stadium in the world. We'll apply our expertise to monitor water quality in order to help Brazil execute a successful Olympic Games. After the events wrap up, the Hach systems will be transferred to municipal water plants across the country, benefiting local communities for many years to come. 
At Trojan, high-single digit core revenue growth in the quarter was a result of a number of project wins in North America, Western Europe and Australia as well as robust demand in municipal markets. 
And finally, at ChemTreat, core revenues grew low single digits despite exposure to weaker industrial- and commodity-oriented end markets. 
So to wrap up, the Danaher team executed well in a challenging macro environment. The thoughtful application of DBS continued to drive results, with meaningful process improvements enabling reinvestment in high-impact growth initiatives. One of Danaher's core values is innovation defines our future, and the successful new product launches we've seen across the portfolio demonstrate our commitment to providing customers with truly differentiated technology to strengthen our collective competitive advantage. 
Following the launch of Fortive, Danaher will be a diversified multi-industry science and technology company united by common business models and the power of DBS. We remain focused on improving growth, margins and cash flow, and we'll continue to pursue meaningful organic and inorganic opportunities to strengthen our market-leading portfolio of businesses. 
Going forward, Danaher's businesses will be organized across 4 segments: Life Sciences, including all of Pall; Diagnostics; Dental; and Environmental & Applied Solutions, which includes our Water Quality and Product Identification businesses. For further details, please refer to the supplemental information that we posted on our website this morning. 
This marks the start of an exciting new chapter for Danaher, and we look forward to the exciting opportunities we see in the years ahead. We are initiating third quarter guidance for adjusted diluted net EPS from continuing operations of $0.80 to $0.84. We are assuming third quarter core revenue growth of 3% or better. For the full year 2016, we are anticipating adjusted diluted net EPS from continuing operations to be in the range of $3.53 to $3.60, which, at the midpoint, would represent an increase of approximately 20% from 2015. Both our third quarter and full year guidance exclude the impact of Fortive."
265621,368081405,1011371,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Executives","Thanks, Tom. That concludes our formal remarks. Ashley, we're now ready for questions. [Operator Instructions]",15,"Thanks, Tom. That concludes our formal remarks. Ashley, we're now ready for questions. [Operator Instructions]"
265621,368081405,1011371,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Operator","[Operator Instructions] We will take our first question from Nigel Coe with Morgan Stanley.",14,"[Operator Instructions] We will take our first question from Nigel Coe with Morgan Stanley."
265621,368081405,1011371,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Analysts","So I just wanted to just fill in the gaps on the FY guide. You said 3% or better for 3Q. Is that the work [ph] assumption for 4Q as well? And then what assumptions are you making in terms of the corporate synergies in the back half of the year? I mean, ob",90,"So I just wanted to just fill in the gaps on the FY guide. You said 3% or better for 3Q. Is that the work [ph] assumption for 4Q as well? And then what assumptions are you making in terms of the corporate synergies in the back half of the year? I mean, obviously, there's a corporate line which is unallocated, but then there is some corporate absorbed by the segments. I'm just wondering how that impacts margins in the second half of the year. Any color would be helpful."
265621,368081405,1011371,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Executives","So Nigel, this is Dan. So Q3, we're talking about 3% or better core. I think if we -- in that zone, in part because we a little bit of easier comparison in the fourth quarter, core could be a little bit higher than that. Regarding the corporate on a combi",93,"So Nigel, this is Dan. So Q3, we're talking about 3% or better core. I think if we -- in that zone, in part because we a little bit of easier comparison in the fourth quarter, core could be a little bit higher than that. Regarding the corporate on a combined basis, we've talked since the beginning and we're still sort of in that zone of about $70 million to $80 million of corporate dissynergies from the 2 entities. And go-forward, corporate will remain in the kind of the low 40s for Danaher."
265621,368081405,1011371,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Analysts","Okay. And then does that impact the segment line as well, Dan? Or is it just within that unallocated line? So, I guess, what I'm saying is the 2Q, 1Q pro forma segments numbers for new Danaher, is that a good base for the second half of the year?",49,"Okay. And then does that impact the segment line as well, Dan? Or is it just within that unallocated line? So, I guess, what I'm saying is the 2Q, 1Q pro forma segments numbers for new Danaher, is that a good base for the second half of the year?"
265621,368081405,1011371,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Executives","Yes.",1,"Yes."
265621,368081405,1011371,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Analysts","Okay, great. And then just on Dental, you gave some details on the moving parts, what woke [ph] up better in 2Q. But just -- I'm just wondering, given the pretty fast acceleration from 1Q to 2Q, was there any pull forward or pull back from 1Q to 2Q? Was t",67,"Okay, great. And then just on Dental, you gave some details on the moving parts, what woke [ph] up better in 2Q. But just -- I'm just wondering, given the pretty fast acceleration from 1Q to 2Q, was there any pull forward or pull back from 1Q to 2Q? Was there some channel volatility? Or is this just natural volatility that we'll see from time to time?"
265621,368081405,1011371,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Executives","Nigel, we did see some core improvement, without a doubt, in Dental. 4% core growth in Dental. And a good part of that was clearly around better execution and to some extent, a little bit easier comp. We saw good performance in implants and equipment at m",245,"Nigel, we did see some core improvement, without a doubt, in Dental. 4% core growth in Dental. And a good part of that was clearly around better execution and to some extent, a little bit easier comp. We saw good performance in implants and equipment at mid-single-digit growth; consumables, more like low single digit. Terrific performance in China continued. You've heard us talk to double-digit growth in China, and we saw that continuing. U.S. and EU, getting a little bit better. And the high-growth markets, still challenging, for sure, but we are rounding around some easier comps. You heard me talk about good solid performance at Nobel. That continued. That said, relative to your question about any impact, there may have been a little bit of pull forward on some revenues just based on the nature of the calendar and the way the calendar worked on the end of the quarter. But in general, I think we were very pleased with the performance. Given seasonality, we could see some moderation in the Q3 growth rates at low single digits. That's typically a function of more European exposure, and the summer tends to be a little bit slower. So we won't necessarily see a straight line to the improved performance, but we were very, very pleased with the execution in the second quarter. And we think we've got a very good trajectory behind us to -- that bodes well for, I think, the quarters to come."
265621,368081405,1011371,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Operator","And our next question comes from Steven Winoker with Bernstein.",10,"And our next question comes from Steven Winoker with Bernstein."
265621,368081405,1011371,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Analysts","Tom, just on the segmentation -- or the new segmentation front. A couple of questions here. One, why is Pall Industrial stuck in Life Sciences? And then secondly, on Environmental & Applied Solutions, I thought maybe Water Quality and Product ID would be",71,"Tom, just on the segmentation -- or the new segmentation front. A couple of questions here. One, why is Pall Industrial stuck in Life Sciences? And then secondly, on Environmental & Applied Solutions, I thought maybe Water Quality and Product ID would be stand-alone. Are they just not big enough yet? Or is there a strategic thought here, a number of segments? I mean, how are you thinking about those 2?"
265621,368081405,1011371,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Executives","Sure. Thanks, Steve. Relative to Pall, we did think it was important to keep those together in a single segment. Obviously, the life science part of the Pall portfolio is the larger part of the portfolio. There's commonality internally at Danaher from a r",235,"Sure. Thanks, Steve. Relative to Pall, we did think it was important to keep those together in a single segment. Obviously, the life science part of the Pall portfolio is the larger part of the portfolio. There's commonality internally at Danaher from a reporting standpoint, both -- in terms of both businesses -- both sides of the business reporting into a president at Pall as well as an EVP overseeing all of Life Sciences. There's also commonality across R&D and supply chain and operations. So there's a lot of reasons operationally to keep the businesses together and therefore, somewhat from a reporting standpoint as well. I mean, realistically, we probably could have split them up, but I think we would probably reevaluate that over time and see how we might run the businesses in the years to come. But I think for right now, that's probably the best approach is to keep them together. In terms of Environmental and PID, I think those businesses do share some commonality in terms of serving some different applied end markets. We could have kept them separately. They would have been far smaller segments. So I think we felt that those kind of went together and provided some flexibility for us. As we've defined ourselves as remaining a multi-industry company, there obviously is some flexibility to maintain in terms of how we might add to that segment over time."
265621,368081405,1011371,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Analysts","Okay. And then I suppose sticking in the same -- on the same M&A -- or the same theme here. On M&A, I know it's bumpy, but you did 6 last quarter, I guess, and 0 this quarter. Was it -- were you busy with separation? Things just didn't come together? Wher",75,"Okay. And then I suppose sticking in the same -- on the same M&A -- or the same theme here. On M&A, I know it's bumpy, but you did 6 last quarter, I guess, and 0 this quarter. Was it -- were you busy with separation? Things just didn't come together? Where -- how's the pipeline looking going forward? What should we kind of expect in terms of momentum or pace on the M&A front?"
265621,368081405,1011371,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Executives","Steve, it didn't have anything to do with being busy or in any way focused on other things. Acquisition volume kind of ebbs and flows over time, and so we think the pipeline -- we know the pipelines remain quite good. We have active conversations in each",82,"Steve, it didn't have anything to do with being busy or in any way focused on other things. Acquisition volume kind of ebbs and flows over time, and so we think the pipeline -- we know the pipelines remain quite good. We have active conversations in each one of the platforms. So we feel very good about where we are. We have, obviously, a terrific balance sheet to work with, and I think we'll see good things in the quarters to come."
265621,368081405,1011371,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Analysts","And you emphasized the multi-industry diversified nature as well as science and technology. But I mean, does that -- are you as optimistic on the Environmental & Applied Solutions, I suppose, and Pall Industrial front as you are on the other parts of the",46,"And you emphasized the multi-industry diversified nature as well as science and technology. But I mean, does that -- are you as optimistic on the Environmental & Applied Solutions, I suppose, and Pall Industrial front as you are on the other parts of the business?"
265621,368081405,1011371,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Executives","We are. Well, we continue to have teams that focus, as we always have, in each one of the operating companies and in each one of the platforms, focused on developing funnels, ensuring that we have active cultivations. And yes, we remain biased towards app",58,"We are. Well, we continue to have teams that focus, as we always have, in each one of the operating companies and in each one of the platforms, focused on developing funnels, ensuring that we have active cultivations. And yes, we remain biased towards applying our free cash flow to each one of the businesses across the portfolio."
265621,368081405,1011371,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Operator","Next, we will take Jeffrey Sprague with Vertical Research Partners.",10,"Next, we will take Jeffrey Sprague with Vertical Research Partners."
265621,368081405,1011371,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Analysts","Congrats on getting Fortive done. Just maybe a couple business-related questions drilling in a little bit. Tom, can you elaborate a little bit what was going on in Environmental core margins in the quarter, why they were under pressure and kind of what th",48,"Congrats on getting Fortive done. Just maybe a couple business-related questions drilling in a little bit. Tom, can you elaborate a little bit what was going on in Environmental core margins in the quarter, why they were under pressure and kind of what the trajectory is looking forward?"
265621,368081405,1011371,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Executives","Jeff, thanks for the question. In general, we feel very good about where those businesses are. I'll speak specifically to the Hach business. We had very good performance in the prior quarter -- in the same quarter last year. In addition, we're making some",100,"Jeff, thanks for the question. In general, we feel very good about where those businesses are. I'll speak specifically to the Hach business. We had very good performance in the prior quarter -- in the same quarter last year. In addition, we're making some investments from a growth standpoint in those businesses. So I think we'll continue to see margin expansion from the water side of the Environmental segment, and I think those investments overall are going to pay off in terms of good growth rates in the quarters to come. So it's not an area of concern for us."
265621,368081405,1011371,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Executives","And Jeff, 2 things to add. One is Gilbarco had better growth than the Water business, so there's some negative mix in there for the segment. And we had our best -- that segment was -- Q2 last year was probably 150, 200 basis points better than any other q",83,"And Jeff, 2 things to add. One is Gilbarco had better growth than the Water business, so there's some negative mix in there for the segment. And we had our best -- that segment was -- Q2 last year was probably 150, 200 basis points better than any other quarter we had in 2015. So it was a little bit of a comp issue as well. But as Tom alluded to, we are investing pretty heavily right now in the Water business organically."
265621,368081405,1011371,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Analysts","Speaking of investment, maybe just kind of a total new Danaher question. But the idea of kind of restructuring, be it quiet or otherwise, is that a likely part of the equation here as you progress through the year? And can you give us some idea how to thi",51,"Speaking of investment, maybe just kind of a total new Danaher question. But the idea of kind of restructuring, be it quiet or otherwise, is that a likely part of the equation here as you progress through the year? And can you give us some idea how to think about that?"
265621,368081405,1011371,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Executives","Jeff, as we, I think, showed last year, we've established a cadence of restructuring that has gone on. You might say quietly, but I would say more consistently and appropriately throughout the course of the year. As opportunities have come up, we've taken",109,"Jeff, as we, I think, showed last year, we've established a cadence of restructuring that has gone on. You might say quietly, but I would say more consistently and appropriately throughout the course of the year. As opportunities have come up, we've taken advantage of those in each of the quarters. And so we still have opportunities for some level of restructuring in the third and fourth quarter. But in general, we've been more balanced through the course of the year, and I think that has served us well in terms of the operating margin expansion that you've seen over time late last year and this year as well."
265621,368081405,1011371,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Analysts","And then finally, just back to Environmental and Water specifically in the muni market. So we've been kind of hearing for a couple quarters that things are gaining traction. Obviously, you had a strong quarter at Trojan. Can you speak a little bit to the",66,"And then finally, just back to Environmental and Water specifically in the muni market. So we've been kind of hearing for a couple quarters that things are gaining traction. Obviously, you had a strong quarter at Trojan. Can you speak a little bit to the forward visibility there? What's going on in order activity? Do you have top line visibility into that business now into '17?"
265621,368081405,1011371,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Executives","Jeff, it's probably a little bit early to kind of comment on '17. The muni strength continues to be broad-based, both at Trojan and in the Hach business. And at the Hach business, we're seeing it both in Europe and the U.S. Very consistent and healthy spe",70,"Jeff, it's probably a little bit early to kind of comment on '17. The muni strength continues to be broad-based, both at Trojan and in the Hach business. And at the Hach business, we're seeing it both in Europe and the U.S. Very consistent and healthy spending there. The offset to that, both for Hach and ChemTreat, is where we serve the industrial or any commodity-oriented markets, they've been challenging."
265621,368081405,1011371,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Operator","Our next question is from Shannon O'Callaghan with UBS.",10,"Our next question is from Shannon O'Callaghan with UBS."
265621,368081405,1011371,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Analysts","Just on this emphasis on reinvesting some of the synergy upside at Nobel and at Pall into new products, go-to-market investments. What kind of lag are you expecting from that? I mean, when do you expect that to translate into improving organic growth for",51,"Just on this emphasis on reinvesting some of the synergy upside at Nobel and at Pall into new products, go-to-market investments. What kind of lag are you expecting from that? I mean, when do you expect that to translate into improving organic growth for those businesses and just what you're seeing?"
265621,368081405,1011371,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Executives","Shannon, it varies depending on where we direct those funds. I think, in some cases, when we put investment directly into, say, feet on the street, in either a developed market or a high-growth market, we tend to see those investments pay off in just a qu",216,"Shannon, it varies depending on where we direct those funds. I think, in some cases, when we put investment directly into, say, feet on the street, in either a developed market or a high-growth market, we tend to see those investments pay off in just a quarter or 2. If we're talking about investments that go into new product development, those tend to have much more of a lag time. As projects get kicked off into early business case-oriented tollgates, you could have several quarters to it, at times even a couple of years, before you might see the impact of a new product investment, again, depending on how early or late-stage an existing project might be in the pipeline. So it's varied. I think in the case of Nobel, just to talk to one of the businesses, we've seen those investments pay off relatively quickly. You've seen it in good core revenue growth consistently in that business. They have relatively shorter cycle times in terms of new product development. In businesses like Beckman, for example, and at Pall, the product development cycles are longer, certainly significantly longer at a place like Beckman, where, oftentimes, we'll have clinical trials and/or regulatory clearances. And so those new product investments can be -- can take some time, obviously."
265621,368081405,1011371,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Analysts","Okay, great. And then, yes, maybe a follow-up to that. I mean, in terms of -- in Diagnostics, you talked about Beckman's growth being driven by high-growth markets. What's going on in the developed markets? And maybe, I guess, to some of your comments you",68,"Okay, great. And then, yes, maybe a follow-up to that. I mean, in terms of -- in Diagnostics, you talked about Beckman's growth being driven by high-growth markets. What's going on in the developed markets? And maybe, I guess, to some of your comments you just made there with maybe [ph] sellout, what is it going to take to get some better growth in developed markets for Beckman?"
265621,368081405,1011371,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Executives","Sure. Yes, a little bit slower growth in the developed markets. I mean, in general, the developed markets, from an overall perspective, are slower-growth markets to begin with. We've always seen better market growth in the -- overall in places like China",120,"Sure. Yes, a little bit slower growth in the developed markets. I mean, in general, the developed markets, from an overall perspective, are slower-growth markets to begin with. We've always seen better market growth in the -- overall in places like China and India and the Middle East. So in general, I think we're tracking closer to the market growth rates than anything else. Still have work to do. There's no question about it. We have improved our retention rates and our competitive win rates, but there's still work to do in terms of both go-to-market as well as new product development. And over time, we do believe those will pay off in better growth rates in the developed markets."
265621,368081405,1011371,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Operator","And our next question is coming from Tycho Peterson with JPMorgan.",11,"And our next question is coming from Tycho Peterson with JPMorgan."
265621,368081405,1011371,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Analysts","Tom, just wondering if you can talk about some of the gives and takes where you're feeling a little more constructive by segment in the back half of the year. You talked to the gives and takes on Dental, so maybe you can pass on that. But is Pall Industri",99,"Tom, just wondering if you can talk about some of the gives and takes where you're feeling a little more constructive by segment in the back half of the year. You talked to the gives and takes on Dental, so maybe you can pass on that. But is Pall Industrial kind of bottoming out here? Could you see some improvement there? Obviously, the academic fund flows may pick up in the back half of the year, and that could help SCIEX. So could you just talk by division where you're feeling more constructive for the next couple of quarters?"
265621,368081405,1011371,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Executives","Sure. Thanks for the question. We do think that we're -- as you mentioned, we've seen good performance in Dental. Again, not necessarily a straight line, but we're very encouraged by the performance we're seeing. In terms of the other businesses across th",163,"Sure. Thanks for the question. We do think that we're -- as you mentioned, we've seen good performance in Dental. Again, not necessarily a straight line, but we're very encouraged by the performance we're seeing. In terms of the other businesses across the second half, I think we'll see continuing better performance across the Diagnostic businesses, in particular. We're starting to see the benefit of a number of the investments across those businesses. I think we'll see continuing good performance from Water Quality. PID has been pretty consistent along the way, so I think we will see that continue. Our Life Science businesses have also performed well, particularly SCIEX, as well as Beckman Life Science, so I think we'd see some modest incremental growth there. I would also remind you that we're coming around through some easier comps in the second half as well, and so we will get a little bit of benefit from those easier comps really across the entire portfolio."
265621,368081405,1011371,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Analysts","And since you called out Europe as a source of strength for Life Sciences and Radiometer, are you kind of comfortable with the macro in the back half of the year for those markets?",34,"And since you called out Europe as a source of strength for Life Sciences and Radiometer, are you kind of comfortable with the macro in the back half of the year for those markets?"
265621,368081405,1011371,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Executives","Well, I think the Brexit situation certainly has created uncertainty around, not just the U.K. but across the European theater at large. Uncertainty is rarely a good thing for markets in terms of people's willingness to make investments, particularly in i",65,"Well, I think the Brexit situation certainly has created uncertainty around, not just the U.K. but across the European theater at large. Uncertainty is rarely a good thing for markets in terms of people's willingness to make investments, particularly in instrumentation and higher-cost instrumentation. So I think that uncertainty could potentially result in some slowness in the second half, but it's very early to tell."
265621,368081405,1011371,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Executives","Tycho, we've been -- maybe just on Western Europe. We've been consistently in kind of a pretty healthy low single-digit number across Western Europe. It's been pretty broad-based. It is an area where, I think, because of some of the uncertainties the last",103,"Tycho, we've been -- maybe just on Western Europe. We've been consistently in kind of a pretty healthy low single-digit number across Western Europe. It's been pretty broad-based. It is an area where, I think, because of some of the uncertainties the last couple of years, we've probably taken a fair amount of share, as we've seen some people kind of pull back in Western Europe over the last couple of years. So it's been a good market for us. And while -- and we also see doing Pall doing quite well in Europe, though those, obviously, not in the core numbers yet."
265621,368081405,1011371,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Analysts","Okay. And then just lastly on the capital deployment question. Earlier, you touched on the framework a little bit. Can you just remind us where you're comfortable taking up leverage? And maybe just any comments on what you're seeing in terms of valuation,",50,"Okay. And then just lastly on the capital deployment question. Earlier, you touched on the framework a little bit. Can you just remind us where you're comfortable taking up leverage? And maybe just any comments on what you're seeing in terms of valuation, given how much the space has run?"
265621,368081405,1011371,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Executives","Well, Tycho, we've obviously spent the last year in a significant effort on deleveraging. We're in really good shape. We're south of 2.5x at this point. Initially, we were close to 4x leverage. So we're back to a mode of spending our free cash flow plus,",88,"Well, Tycho, we've obviously spent the last year in a significant effort on deleveraging. We're in really good shape. We're south of 2.5x at this point. Initially, we were close to 4x leverage. So we're back to a mode of spending our free cash flow plus, and we've talked about a couple billion of capacity for this year. But going into next year, you're back to more $3 billion to $4 billion of capacity per year. And that's not without -- that's without really stretching the balance sheet."
265621,368081405,1011371,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Operator","Our next question is coming from Ross Muken with Evercore ISI.",11,"Our next question is coming from Ross Muken with Evercore ISI."
265621,368081405,1011371,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Analysts","So appreciate, I know you gave us already some color on Pall single-use and on SCIEX, but I'd love it if you could tease out at all sort of pharma demand based on sort of customer types, so sort of separating maybe pharma from biotech or emerging biotech",97,"So appreciate, I know you gave us already some color on Pall single-use and on SCIEX, but I'd love it if you could tease out at all sort of pharma demand based on sort of customer types, so sort of separating maybe pharma from biotech or emerging biotech to see if there's any sort of discernible trend you've seen amongst. I mean, it's clear at Pall, obviously, having pretty strong growth across the board, but I was wondering if any of the end markets, whether it's generic or CRO, et cetera, you're seeing any change in demand."
265621,368081405,1011371,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Executives","SCIEX is probably the best business to think about when you think about the -- your question about pharma versus, say, biotech. SCIEX has exposure to both those end markets, and we're seeing good performance, healthy demand and fairly consistent demand fr",131,"SCIEX is probably the best business to think about when you think about the -- your question about pharma versus, say, biotech. SCIEX has exposure to both those end markets, and we're seeing good performance, healthy demand and fairly consistent demand from both sides of the house there. I'd have to do some follow-up to get you some detail on anything to do with the generics or the CROs, specifically. But clearly, in the aggregate, these markets are doing quite well. Pall, as you mentioned, we've talked about the growth that we're seeing in the life science side, specifically around our single-use technology product offering, where we're seeing continued double-digit growth rates in that area. And that clearly is associated with the growth in biopharmaceuticals, specifically the growth in large-molecule drugs."
265621,368081405,1011371,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Analysts","Great. I guess, what I was getting at is more on the CRO, generic side. Maybe I'll ask it differently. In terms of just high-growth markets, I mean, it's clear China has been good. But outside of China, how would you sort of characterize the rest of the k",69,"Great. I guess, what I was getting at is more on the CRO, generic side. Maybe I'll ask it differently. In terms of just high-growth markets, I mean, it's clear China has been good. But outside of China, how would you sort of characterize the rest of the key markets? Obviously, LatAm has kind of been a mixed bag overall, but India and some of the other key geographies."
265621,368081405,1011371,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Executives","I'd say China, in particular, India as well, are very good markets for us. But I would say that there's still a long runway ahead for those markets. Some of the generic and the CRO movement into those markets has been, on balance, a positive. But there ar",86,"I'd say China, in particular, India as well, are very good markets for us. But I would say that there's still a long runway ahead for those markets. Some of the generic and the CRO movement into those markets has been, on balance, a positive. But there are also components of the market that are still relatively nascent, particularly in terms of what might be going on there in the future relative to large-molecule drugs. So I think there's still a pretty good runway ahead."
265621,368081405,1011371,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Operator","Our next question comes from Derik De Bruin with Bank of America Merrill Lynch.",14,"Our next question comes from Derik De Bruin with Bank of America Merrill Lynch."
265621,368081405,1011371,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Analysts","So could you talk a little bit about capital deployment? I'm just curious, now that sort of Fortive is spun out, how do you sort of view your overall strategy in the life sciences space? Do you still feel like you want to stay focused on the core -- stand",84,"So could you talk a little bit about capital deployment? I'm just curious, now that sort of Fortive is spun out, how do you sort of view your overall strategy in the life sciences space? Do you still feel like you want to stay focused on the core -- stand-alone core brands? Or do you feel the need to sort of become a more integrated provider in the space? Do you think you need to add anything to your Life Sciences or Diagnostics armament?"
265621,368081405,1011371,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Executives","Well, Derik, I think, first of all, starting at a Danaher level, our bias towards M&A is not -- and the use of our free cash flow to M&A is not specifically skewed towards any of the 4 segments that I mentioned. We've had a consistent track record of capi",278,"Well, Derik, I think, first of all, starting at a Danaher level, our bias towards M&A is not -- and the use of our free cash flow to M&A is not specifically skewed towards any of the 4 segments that I mentioned. We've had a consistent track record of capital allocation across each of those 4 segments that we'll be reporting on in the future, and I think you'll continue to see us do that. Now specifically to your question around Life Sciences and Diagnostics, what you've seen us do in Life Sciences is continue to broaden our product offering over time, and I think you'll continue to see us do that. We have had a bias and would continue to have a bias towards businesses with not only strong brands and significant installed bases, but installed bases that drive good, consistent recurring revenue and consumables growth. The Diagnostics business is inherently that way, typically, and you've seen us buy businesses with those same characteristics, strong brands, significant installed bases and strong recurring revenue and consumable streams. I think you'd see us continue to do that. We think there is certainly room to continue to expand our Diagnostic product offering and provide hospitals with broader bundles of product. Today, we provide products, obviously, to the central laboratory, the core clinical laboratory, as well as to anatomical pathology and to the acute care areas of the hospital. And with the expansion of Microscan, into microbiology, with Iris opening up urinalysis for us, I think those types of expansions of our footprint would certainly be characteristic of the types of things that we would hope to do in the future."
265621,368081405,1011371,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Analysts","Great. That's really helpful. And just one quick follow-up. It's been a year since you launched the Veris platform in Molecular. Could you talk a little bit about what you see in terms of installed base and competitive wins? And essentially, where is that",84,"Great. That's really helpful. And just one quick follow-up. It's been a year since you launched the Veris platform in Molecular. Could you talk a little bit about what you see in terms of installed base and competitive wins? And essentially, where is that going? What's the customer type? And then if you're -- I assume you're taking share from people since most hospitals have molecular [ph] platforms of that size. Can you just talk a little bit more -- some color on that?"
265621,368081405,1011371,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Executives","Sure. Thanks, Derik. Just for everyone's benefit, the Veris platform is a high-volume, random-access molecular diagnostics instrument that was commercialized for the first time in Europe in the second half of last year. That product line serves the core -",224,"Sure. Thanks, Derik. Just for everyone's benefit, the Veris platform is a high-volume, random-access molecular diagnostics instrument that was commercialized for the first time in Europe in the second half of last year. That product line serves the core -- or central clinical laboratory of major hospitals. And again, as I mentioned, it is a -- it's a high-volume platform. We're very pleased with the early traction that we'd gotten. It is still early. During the first year of a significant new product introduction like that, the first of its kind by Beckman Coulter, it does take a while to build the funnel, but we've been very happy with how that funnel has built, the sales opportunity funnel in the last year. The installations that we have thus far are running very well. We have 4 assays in the market right now, but the 4 assays really are just the beginning. There's a significant road map of assay development ahead that will ultimately be commercialized, both in Europe as well as in the U.S. That product will need to go through regulatory clearance in the U.S., so it'll be some time before we see the volumes ramp beyond the early days here in Europe. But the feedback from customers has been very -- strongly positive, and we feel good about the start we have."
265621,368081405,1011371,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Analysts","Great. And when is FDA approval expected?",7,"Great. And when is FDA approval expected?"
265621,368081405,1011371,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Executives","I usually hesitate to try to put any bets on FDA clearance. There's a fair amount of work to do even before we file for that clearance, so I'll probably have a better sense of that in the quarters to come. But wouldn't -- I couldn't put a date on it today",52,"I usually hesitate to try to put any bets on FDA clearance. There's a fair amount of work to do even before we file for that clearance, so I'll probably have a better sense of that in the quarters to come. But wouldn't -- I couldn't put a date on it today."
265621,368081405,1011371,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Operator","Our next question comes from Julian Mitchell with Crdit Suisse.",10,"Our next question comes from Julian Mitchell with Crdit Suisse."
265621,368081405,1011371,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Analysts","Just a question on margins, firstly. So the core margin in total Danaher fell about 30 bps in Q2. Could you give that comparable number for the remaining business? And then maybe -- and how you think that will trend in the second half? And tied to that, I",88,"Just a question on margins, firstly. So the core margin in total Danaher fell about 30 bps in Q2. Could you give that comparable number for the remaining business? And then maybe -- and how you think that will trend in the second half? And tied to that, I guess, going back to the Environmental & Applied Solutions segment. The headline margin there was down 300 bps plus in Q2. Should we see that coming back in the second half as the comps on margins get much easier?"
265621,368081405,1011371,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Executives","Sure, Julian. On the last one you asked, and I -- as I mentioned earlier, part of the Environmental issue was a comp issue that margins on a historical restated basis for the Environmental & Applied Solutions were 200 basis points higher in Q2 a year ago.",118,"Sure, Julian. On the last one you asked, and I -- as I mentioned earlier, part of the Environmental issue was a comp issue that margins on a historical restated basis for the Environmental & Applied Solutions were 200 basis points higher in Q2 a year ago. So you expect that to sort of normalize. Core margins were relatively flat for Danaher ex Fortive. That was, again, somewhat of a function of the prior-year compare. For our full year, we continue to expect 50 to 75 basis points of core margin expansion for Danaher ex Fortive, and you'll see better performance. You saw very good performance in the first quarter. You'll see better performance in Q3 and Q4."
265621,368081405,1011371,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Analysts","Great. And then just on Pall Industrial. You called out the overall organic sales trend year-on-year. Is there any sort of color you'd give there on specific verticals or markets within that? Any changes?",34,"Great. And then just on Pall Industrial. You called out the overall organic sales trend year-on-year. Is there any sort of color you'd give there on specific verticals or markets within that? Any changes?"
265621,368081405,1011371,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Executives","No. I wouldn't say we've seen necessarily any changes, Julian. I think if -- to the extent that there's good news there, I think it would be that we've seen some stability found in those markets. We continue to make some excellent progress in terms of our",162,"No. I wouldn't say we've seen necessarily any changes, Julian. I think if -- to the extent that there's good news there, I think it would be that we've seen some stability found in those markets. We continue to make some excellent progress in terms of our go-to-market initiatives. We've done over 40 growth-related kaizens at Pall since we acquired the business. And a number of those kaizens have been going on in the industrial markets. And that involves installing DBS tools, such as funnel management and transformative marketing that we think is improving our execution in those markets. So I think the combination of seeing some stability across each one of those end markets, in combination with the application of DBS tools, I think, has gotten us to a pretty good place. So I would hope to see some incrementally better performance late this year and certainly, entering next year. But I think, in general, we're pleased that things have stabilized."
265621,368081405,1011371,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Operator","Our final question is coming from Isaac Ro with Goldman Sachs.",11,"Our final question is coming from Isaac Ro with Goldman Sachs."
265621,368081405,1011371,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Analysts","I just want to ask another question on Pall Industrial. If we look back prior to the acquisition, that business was obviously growing a little slower than the Life Science side. But curious if you could maybe take a bigger step back and give us a sense of",77,"I just want to ask another question on Pall Industrial. If we look back prior to the acquisition, that business was obviously growing a little slower than the Life Science side. But curious if you could maybe take a bigger step back and give us a sense of what you think it will take for Industrial to return to growth. Is it mostly a function of end markets? Or is there really more of an execution issue?"
265621,368081405,1011371,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Executives","I think it's both. As I was just mentioning to Julian, I think we've seen the markets themselves, from a macro standpoint, stabilize a bit. In other words, not get any worse. And we will need to see some improvement in the macro environment to see some me",153,"I think it's both. As I was just mentioning to Julian, I think we've seen the markets themselves, from a macro standpoint, stabilize a bit. In other words, not get any worse. And we will need to see some improvement in the macro environment to see some meaningful or step function improvement in growth. But we're not waiting for that. Our focus is on ensuring that we have the best sales team on the field, that we're providing those teams with exceptional new product development, that we've got our coverage set up appropriately across geographies and across each one of those verticals. And I think the combination of good market coverage, DBS tools, new product development and some improvement in those end markets is what it's going to take. Obviously, the majority of that, we hope to be in our control, but a little help from the end markets certainly wouldn't hurt."
265621,368081405,1011371,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Analysts","Got it. That's helpful. And then one other question on Beckman. If we -- just trying to square up kind of what we saw last week with some of the peer groups in Diagnostics with what you said, you -- obviously, you've got Veris and CytoFLEX helping out. If",83,"Got it. That's helpful. And then one other question on Beckman. If we -- just trying to square up kind of what we saw last week with some of the peer groups in Diagnostics with what you said, you -- obviously, you've got Veris and CytoFLEX helping out. If we pull those out, just trying to get a better sense of how you think you're pacing versus the overall market for Diagnostics. And any color there, especially in North America, would be helpful."
265621,368081405,1011371,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Executives","Sure. Thanks, Isaac. Well, as you know, we had to -- we had to come from behind here from the standpoint of the big 5 in the overall market. I think from a pacing standpoint, we've now gotten to a point where we are very close to, if not at, market growth",210,"Sure. Thanks, Isaac. Well, as you know, we had to -- we had to come from behind here from the standpoint of the big 5 in the overall market. I think from a pacing standpoint, we've now gotten to a point where we are very close to, if not at, market growth rates, with a couple of the competitors, as you mentioned, that reported last week posting better growth rates. And in doing so -- in some cases, it's a function of their positions in certain higher-growth markets. But in other cases, we simply have work to do in terms of continuing to drive our new product development and our go-to-market initiatives. We're ahead of a couple other competitors in that market, and we have demonstrated where, from a competitive win perspective, we've become far more competitive in the overall market. So I think we've made a ton of progress. But clearly, work to do. And that work, as you've referenced, is represented by some folks that are still putting up some pretty good numbers. So I think we've got the initiatives and the investment levels in the right place. We continue to make progress. And it'll take a bit of time, but I think we're on the right track."
265621,368081405,1011371,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Operator","And that concludes our question-and-answer session. I would like to turn the conference back over to Matt Gugino for any additional or closing remarks.",25,"And that concludes our question-and-answer session. I would like to turn the conference back over to Matt Gugino for any additional or closing remarks."
265621,368081405,1011371,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Executives","Thanks, everyone, for joining us. We're around all day for questions.",11,"Thanks, everyone, for joining us. We're around all day for questions."
265621,368081405,1011371,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Operator","And that concludes today's presentation. We thank you all for your participation.",13,"And that concludes today's presentation. We thank you all for your participation."
265621,368081405,1011544,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Operator","My name is Ashley, and I will be your conference facilitator today. At this time, I would like to welcome everyone to the Danaher Corporation Second Quarter 2016 Earnings Results Conference Call. [Operator Instructions] I will now turn the conference ov",57,"My name is Ashley, and I will be your conference facilitator today. At this time, I would like to welcome everyone to the Danaher Corporation Second Quarter 2016 Earnings Results Conference Call. [Operator Instructions] 
I will now turn the conference over to Mr. Matt Gugino, Vice President of Investor Relations. Mr. Gugino, you may begin your conference."
265621,368081405,1011544,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Executives","Thanks, Ashley. Good morning, everyone, and thanks for joining us on the call. With us today are Tom Joyce, our President and Chief Executive Officer; and Dan Comas, our Executive Vice President and Chief Financial Officer. I'd like to point out that ou",331,"Thanks, Ashley. Good morning, everyone, and thanks for joining us on the call. With us today are Tom Joyce, our President and Chief Executive Officer; and Dan Comas, our Executive Vice President and Chief Financial Officer. 
I'd like to point out that our earnings release, the slide presentation supplementing today's call, our second quarter Form 10-Q and the reconciliations and other information required by SEC Regulation G relating to any non-GAAP financial measures provided during the call are all available on the Investors section of our website, www.danaher.com, under the heading Financial Information. The audio portion of this call will be archived on the Investors section of our website later today under the heading Events & Presentations and will remain archived until our next quarterly call. A replay of this call will also be available until August 1, 2016. 
During the presentation, we will describe certain of the more significant factors that impacted year-over-year performance. The supplemental materials describe additional factors that impacted year-over-year performance. Unless otherwise noted, all references in these remarks and supplemental materials to company-specific financial metrics relate to the continuing operations of the company in the second quarter of 2016, and all references to period-to-period increases or decreases in financial metrics are year over year. 
We may also describe certain products and devices, which have applications submitted and pending for certain regulatory approvals. 
During the call, we will make forward-looking statements within the meaning of the federal securities laws, including statements regarding events or developments that we believe or anticipate will or may occur in the future. These forward-looking statements are subject to a number of risks and uncertainties, including those set forth in our SEC filings, and actual results may differ materially from any forward-looking statements that we make today. These forward-looking statements speak only as of the date that they are made, and we do not assume any obligation to update any forward-looking statements. 
With that, I'd like to turn the call over to Tom."
265621,368081405,1011544,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Executives","Thanks, Matt, and good morning, everyone. The second quarter was a busy and exciting one for Danaher. Despite challenging economic conditions, we were pleased with our performance as the team's consistent focus on execution helped deliver solid core reven",2344,"Thanks, Matt, and good morning, everyone. The second quarter was a busy and exciting one for Danaher. Despite challenging economic conditions, we were pleased with our performance as the team's consistent focus on execution helped deliver solid core revenue growth, high-teens adjusted earnings per share growth and strong free cash flow performance. 
On July 2, we successfully completed the spin-off of Fortive Corporation, a new industrial growth company. The earlier-than-expected completion of the separation is a testament to our process orientation, execution focus and exceptional teamwork. We continue to believe that the separation will provide significant opportunities for both Danaher and Fortive to independently build even greater shareholder value in the years ahead. Since we owned Fortive through the end of the second quarter, we will start with financial highlights that reflect the combined Danaher and Fortive results. We'll then provide detail for the businesses remaining with Danaher, outline our planned new reporting segments and provide guidance for Danaher's continuing operations, excluding Fortive, for the third quarter and the full year. Since the Fortive team will be reporting their second quarter results separately next week, we'd ask that you please save any questions about the Fortive businesses until then. 
Now turning to the details of the second quarter. Adjusted diluted net earnings per share from continuing operations was $1.25, an increase of 17% over last year and our third consecutive quarter of mid-teens or better adjusted EPS growth. Sales grew 16.5% to $5.8 billion, and core revenue increased 2%. The impact of currency translation eased this quarter but still decreased revenues by 0.5%, while acquisitions increased revenues by 15%. Danaher RemainCo core revenue was up 3%, while Fortive core revenue was down slightly. 
Geographically, high-growth market revenues were up mid-single digits, led by double-digit growth in China and India. We saw better sequential performance in Latin America and Russia, in part because of easier prior year comparisons. Developed market core revenues were up low single digits, led by growth in Western Europe. The U.S. remained roughly flat, and we saw declines in Japan during the quarter. 
Gross margin for the second quarter was 54.4%, an increase of 110 basis points from last year. Reported operating margins were 17.9%, with core operating margins down 30 basis points. More than 80 basis points of core margin improvement were -- we had more than 80 basis points of core margin improvement at both Dental and Life Sciences & Diagnostics, which was offset by declines in Test & Measurement and Environmental segments. 
Free cash flow continues to be one of our most important financial metrics, enabling us to pursue organic and inorganic growth initiatives across our entire portfolio. We generated $1.1 billion of free cash flow from continuing operations in the quarter, up 14%, and our free cash flow to net income conversion ratio was over 150%. 
Now let's take a look at more detailed results across the Danaher portfolio. In Life Sciences, core revenue increased mid-single digits, led by strength in high-growth markets and Western Europe. At Beckman Life Sciences, we continued to outperform. High-single digit core growth in the quarter was driven by strong demand in flow cytometry, particularly in North America and China. The robust growth in flow cytometry was largely driven by demand for our new CytoFLEX product based on the breakthrough technology, which we acquired as part of the Xitogen acquisition in 2014. This bolt-on acquisition has been a tremendous success and is a great example of how we incorporate novel technology into our portfolio to enhance our offering and expand our customer base. CytoFLEX has been a significant contributor to recent share gains in our flow cytometry business. 
At Leica Microsystems, we saw improved results versus previous quarters, as recent new product introductions helped drive low single-digit core revenue growth. Two such new product introductions included our Leica DVM6 digital microscope launched at the end of 2015 and our new Leica M530 neurosurgery microscope, which is off to a great start in China after successful launches in Europe and North America last year. The M530 is a standout combination of our high-resolution optics technology with improved ergonomics, helping neurosurgeons stay focused during their demanding high-precision procedures. 
Core revenues at SCIEX were up mid-single digits as we saw continued strength in pharmaceutical, food and environmental end markets. We had another very strong quarter in China as new regulations from the Chinese Food and Drug Administration helped drive increased demand around drug testing and food safety. 
In June, SCIEX announced a number of new workflow solutions at ASMS, the American Society of Mass Spectrometry Annual Meeting. These solutions are geared toward fast-growing markets such as biologics, proteomics, food and environmental testing. We showcased the latest QTRAP 6500+ mass spectrometer that provides enhanced sensitivity and selectivity to create a powerful workflow solution for biologics analysis. 
We also rolled out BioPharmaView Software 2.0, which accelerates automated data processing and simplifies reporting, enabling biopharma researchers to make better decisions faster. 
At Pall, core revenues were up mid-single digits for the quarter compared to last year as a stand-alone company. Continued strong demand in biopharma, particularly single-use technologies, led to double-digit core revenue growth in Pall Life Sciences. In Pall Industrial, revenues were down low single digits, but we're continuing to see some signs of stabilization in those end markets. 
Pall continues to ramp exceedingly well across a number of key metrics. The team's commitment to the Danaher Business System has resulted in on-time delivery improving by more than 1,500 basis points with greater productivity and quality, driving improved customer satisfaction. Since acquisition, faster-than-expected cost savings and meaningful operational gains have contributed to sizable gross and operating margin improvements. As a result of the team's impressive start, we've been able to redirect some of that benefit into R&D and sales and marketing investments. By pursuing this combination of margin enhancement and growth opportunities, we believe we can continue to drive innovation and improve Pall's competitive advantage. 
The Pall team showcased a number of innovations, such as acoustic wave separation and our new single-use bioreactor at the Interfax biomanufacturing trade show in April. Our expanded single-use product offering has enhanced our competitive position, as pharmaceutical companies look to shift from traditional large infrastructure stainless steel systems to more efficient production processes. Pall's bioprocessing solutions help our customers save significant time, energy and money while greatly reducing cross-contamination risk, which provides the flexibility to easily and safely make multiple products in one facility. 
Moving now to Diagnostics. Core revenues increased low single digits, with double-digit gains in China and India partially offset by weakness in the Middle East and the Americas. At Beckman Coulter, core revenues were up low single digits, driven primarily by strength in high-growth markets. This past June marked the fifth anniversary of the Beckman acquisition. We've made tremendous progress since then, significantly improving quality, delivery and our overall customer experience while using productivity gains to help fund new product development and add feet on the street. Another quarter of good execution by the Beckman team contributed to healthy core operating margin expansion, and we continued to reinvest in high-impact growth opportunities. New menu additions are gaining traction, including our vitamin D and AMH fertility tests in our immunoassay business. 
Our recently launched molecular diagnostic platform, Veris, continues to gain early traction in Europe. New product developments like these, combined with opportunities at recent bolt-on acquisitions like Microscan, will continue to help build meaningful runway for growth at Beckman going forward. 
Radiometer achieved mid-single-digit revenue growth, with healthy performance in Western Europe and China partially offset by weakness in Latin America and the Middle East. Our growing installed base of blood gas instruments and AQT analyzers contributed to solid consumable sales in the quarter. The Radiometer team also recently launched the TCM5 FLEX, a new transcutaneous monitor design. This noninvasive monitor measures ventilation for patients in critical condition. And the TCM5's updated design is easy to use and reliable, providing nurses and doctors with improved usability while maintaining accuracy and precision. 
At Leica Biosystems, core revenues grew mid-single digits. Results were driven by a combination of strength in high-growth markets and continued growth of instrument placements in advanced staining and core histology. 
Moving now over to our Dental segment. Core revenues were up mid-single digits, with growth across consumables, equipment and implants. We saw particular strength in our restorative and Ormco product lines. Geographically, China had another strong quarter with double-digit growth, and we maintain positive momentum in North America and Western Europe. 
Nobel had another good quarter with mid-single-digit core revenue growth. We've improved operating margins at Nobel by more than 500 basis points since acquisition, enabling us to direct some of our savings into expanded product offerings and accelerated sales and marketing efforts. This is similar to what you've seen us achieve at other large acquisitions like Beckman and Pall, where operational improvements helped fuel a renewed focus on new product development and go-to-market initiatives. 
The Nobel team has launched more than 20 new products since acquisition and featured a number of these recent innovations at the Nobel Biocare Global Symposium in June. Nobel's new On1 implant base remains in position during the entire restorative workflow, from implant placement to finalization and for the lifetime of the restoration. This helps simplify the dental surgeon's workflow and allows for an improved patient experience. 
And our new NobelParallel CC implant is a straightforward highly versatile implant system, providing an efficient treatment flow that can be used in a wide variety of implant cases. Both of these new innovations help us serve our customers with better solutions to improve their patients' experience and treatment. 
Turning to Product Identification. Core revenues increased low single digits. We saw increased demand for marking and coding equipment and related consumables across most major geographies, partially offset by softness in some of our packaging and color solutions offerings. 
Videojet's substantial and growing installed base contributed to mid-single-digit core revenue growth in the quarter. Strong market performance in North America, Latin America and Western Europe offset softness in certain high-growth markets. Videojet recently introduced a new service offering that enables our technicians to remotely gather data from a printer that's experiencing a fault or a failure condition. This helps our customers return to normal operation much faster, often without a site visit. With our range of comprehensive preventive services, we're able to improve end user productivity over the course of a printers' life span, ultimately reducing operating costs and enhancing customer satisfaction. 
In June, Esko successfully launched a number of new products and innovations at drupa, the world's largest printing equipment exhibition, which is held every 4 years in Germany. This is the most important trade show in the industry. Esko introduced more than a dozen significant hardware and software innovations at drupa this year, including a suite of powerful new software tools that help customers simplify, automate and integrate their complex packaging and label production workflows. We originated a record number of leads and orders at drupa, which we expect to help drive improved growth at Esko and across the product ID platform in the second half of the year. 
Lastly, turning to Water Quality. Core revenues grew low single digits, with strength in Western Europe, India and China partially offset by lower demand in Japan and Eastern Europe. Hach had a solid quarter with mid-single-digit core revenue growth. Results were driven by strength in U.S. municipal markets and Western Europe. We saw improved growth in China as Hach continues to benefit from ongoing regulations around water quality monitoring and analysis in the region. 
Hach's online water monitoring solutions are in place in Rio de Janeiro, Brazil for next month's Summer Olympics. Our solutions are installed at the majority of event sites, including the largest soccer stadium in the world. We'll apply our expertise to monitor water quality in order to help Brazil execute a successful Olympic Games. After the events wrap up, the Hach systems will be transferred to municipal water plants across the country, benefiting local communities for many years to come. 
At Trojan, high-single digit core revenue growth in the quarter was a result of a number of project wins in North America, Western Europe and Australia as well as robust demand in municipal markets. 
And finally, at ChemTreat, core revenues grew low single digits despite exposure to weaker industrial- and commodity-oriented end markets. 
So to wrap up, the Danaher team executed well in a challenging macro environment. The thoughtful application of DBS continued to drive results, with meaningful process improvements enabling reinvestment in high-impact growth initiatives. One of Danaher's core values is innovation defines our future, and the successful new product launches we've seen across the portfolio demonstrate our commitment to providing customers with truly differentiated technology to strengthen our collective competitive advantage. 
Following the launch of Fortive, Danaher will be a diversified multi-industry science and technology company united by common business models and the power of DBS. We remain focused on improving growth, margins and cash flow, and we'll continue to pursue meaningful organic and inorganic opportunities to strengthen our market-leading portfolio of businesses. 
Going forward, Danaher's businesses will be organized across 4 segments: Life Sciences, including all of Pall; Diagnostics; Dental; and Environmental & Applied Solutions, which includes our Water Quality and Product Identification businesses. For further details, please refer to the supplemental information that we posted on our website this morning. 
This marks the start of an exciting new chapter for Danaher, and we look forward to the exciting opportunities we see in the years ahead. We are initiating third quarter guidance for adjusted diluted net EPS from continuing operations of $0.80 to $0.84. We are assuming third quarter core revenue growth of 3% or better. For the full year 2016, we are anticipating adjusted diluted net EPS from continuing operations to be in the range of $3.53 to $3.60, which, at the midpoint, would represent an increase of approximately 20% from 2015. Both our third quarter and full year guidance exclude the impact of Fortive."
265621,368081405,1011544,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Executives","Thanks, Tom. That concludes our formal remarks. Ashley, we're now ready for questions. [Operator Instructions]",15,"Thanks, Tom. That concludes our formal remarks. Ashley, we're now ready for questions. [Operator Instructions]"
265621,368081405,1011544,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Operator","[Operator Instructions] We will take our first question from Nigel Coe with Morgan Stanley.",14,"[Operator Instructions] We will take our first question from Nigel Coe with Morgan Stanley."
265621,368081405,1011544,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Analysts","So I just wanted to just fill in the gaps on the FY guide. You said 3% or better for 3Q. Is that the work [ph] assumption for 4Q as well? And then what assumptions are you making in terms of the corporate synergies in the back half of the year? I mean, ob",90,"So I just wanted to just fill in the gaps on the FY guide. You said 3% or better for 3Q. Is that the work [ph] assumption for 4Q as well? And then what assumptions are you making in terms of the corporate synergies in the back half of the year? I mean, obviously, there's a corporate line which is unallocated, but then there is some corporate absorbed by the segments. I'm just wondering how that impacts margins in the second half of the year. Any color would be helpful."
265621,368081405,1011544,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Executives","So Nigel, this is Dan. So Q3, we're talking about 3% or better core. I think if we -- in that zone, in part because we a little bit of easier comparison in the fourth quarter, core could be a little bit higher than that. Regarding the corporate on a combi",93,"So Nigel, this is Dan. So Q3, we're talking about 3% or better core. I think if we -- in that zone, in part because we a little bit of easier comparison in the fourth quarter, core could be a little bit higher than that. Regarding the corporate on a combined basis, we've talked since the beginning and we're still sort of in that zone of about $70 million to $80 million of corporate dissynergies from the 2 entities. And go-forward, corporate will remain in the kind of the low 40s for Danaher."
265621,368081405,1011544,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Analysts","Okay. And then does that impact the segment line as well, Dan? Or is it just within that unallocated line? So I guess, what I'm saying is the 2Q, 1Q pro forma segments numbers for new Danaher, is that a good base for the second half of the year?",49,"Okay. And then does that impact the segment line as well, Dan? Or is it just within that unallocated line? So I guess, what I'm saying is the 2Q, 1Q pro forma segments numbers for new Danaher, is that a good base for the second half of the year?"
265621,368081405,1011544,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Executives","Yes.",1,"Yes."
265621,368081405,1011544,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Analysts","Okay, great. And then just on Dental, you gave some details on the moving parts, what woke [ph] up better in 2Q. But just -- I'm just wondering, given the pretty fast acceleration from 1Q to 2Q, was there any pull forward or pull back from 1Q to 2Q? Was t",67,"Okay, great. And then just on Dental, you gave some details on the moving parts, what woke [ph] up better in 2Q. But just -- I'm just wondering, given the pretty fast acceleration from 1Q to 2Q, was there any pull forward or pull back from 1Q to 2Q? Was there some channel volatility? Or is this just natural volatility that we'll see from time to time?"
265621,368081405,1011544,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Executives","Nigel, we did see some core improvement, without a doubt, in Dental. 4% core growth in Dental. And a good part of that was clearly around better execution and to some extent, a little bit easier comp. We saw good performance in implants and equipment at m",245,"Nigel, we did see some core improvement, without a doubt, in Dental. 4% core growth in Dental. And a good part of that was clearly around better execution and to some extent, a little bit easier comp. We saw good performance in implants and equipment at mid-single-digit growth; consumables, more like low single digit. Terrific performance in China continued. You've heard us talk to double-digit growth in China, and we saw that continuing. U.S. and EU, getting a little bit better. And the high-growth markets, still challenging, for sure, but we are rounding around some easier comps. You heard me talk about good solid performance at Nobel. That continued. That said, relative to your question about any impact, there may have been a little bit of pull forward on some revenues just based on the nature of the calendar and the way the calendar worked on the end of the quarter. But in general, I think we were very pleased with the performance. Given seasonality, we could see some moderation in the Q3 growth rates at low single digits. That's typically a function of more European exposure, and the summer tends to be a little bit slower. So we won't necessarily see a straight line to the improved performance, but we were very, very pleased with the execution in the second quarter. And we think we've got a very good trajectory behind us to -- that bodes well for, I think, the quarters to come."
265621,368081405,1011544,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Operator","And our next question comes from Steven Winoker with Bernstein.",10,"And our next question comes from Steven Winoker with Bernstein."
265621,368081405,1011544,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Analysts","Tom, just on the segmentation -- or the new segmentation front. A couple of questions here. One, why is Pall Industrial stuck in Life Sciences? And then secondly, on Environmental & Applied Solutions, I thought maybe Water Quality and Product ID would be",71,"Tom, just on the segmentation -- or the new segmentation front. A couple of questions here. One, why is Pall Industrial stuck in Life Sciences? And then secondly, on Environmental & Applied Solutions, I thought maybe Water Quality and Product ID would be stand-alone. Are they just not big enough yet? Or is there a strategic thought here, a number of segments? I mean, how are you thinking about those 2?"
265621,368081405,1011544,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Executives","Sure. Thanks, Steve. Relative to Pall, we did think it was important to keep those together in a single segment. Obviously, the life science part of the Pall portfolio is the larger part of the portfolio. There's commonality internally at Danaher from a r",235,"Sure. Thanks, Steve. Relative to Pall, we did think it was important to keep those together in a single segment. Obviously, the life science part of the Pall portfolio is the larger part of the portfolio. There's commonality internally at Danaher from a reporting standpoint, both -- in terms of both businesses -- both sides of the business reporting into a president at Pall as well as an EVP overseeing all of Life Sciences. There's also commonality across R&D and supply chain and operations. So there's a lot of reasons operationally to keep the businesses together and therefore, somewhat from a reporting standpoint as well. I mean, realistically, we probably could have split them up, but I think we would probably reevaluate that over time and see how we might run the businesses in the years to come. But I think for right now, that's probably the best approach is to keep them together. In terms of Environmental and PID, I think those businesses do share some commonality in terms of serving some different applied end markets. We could have kept them separately. They would have been far smaller segments. So I think we felt that those kind of went together and provided some flexibility for us. As we've defined ourselves as remaining a multi-industry company, there obviously is some flexibility to maintain in terms of how we might add to that segment over time."
265621,368081405,1011544,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Analysts","Okay. And then I suppose sticking in the same -- on the same M&A -- or the same theme here. On M&A, I know it's bumpy, but you did 6 last quarter, I guess, and 0 this quarter. Was it -- were you busy with separation? Things just didn't come together? Wher",75,"Okay. And then I suppose sticking in the same -- on the same M&A -- or the same theme here. On M&A, I know it's bumpy, but you did 6 last quarter, I guess, and 0 this quarter. Was it -- were you busy with separation? Things just didn't come together? Where -- how's the pipeline looking going forward? What should we kind of expect in terms of momentum or pace on the M&A front?"
265621,368081405,1011544,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Executives","Steve, it didn't have anything to do with being busy or in any way focused on other things. Acquisition volume kind of ebbs and flows over time, and so we think the pipeline -- we know the pipelines remain quite good. We have active conversations in each",82,"Steve, it didn't have anything to do with being busy or in any way focused on other things. Acquisition volume kind of ebbs and flows over time, and so we think the pipeline -- we know the pipelines remain quite good. We have active conversations in each one of the platforms. So we feel very good about where we are. We have, obviously, a terrific balance sheet to work with, and I think we'll see good things in the quarters to come."
265621,368081405,1011544,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Analysts","And you emphasized the multi-industry diversified nature as well as science and technology. But I mean, does that -- are you as optimistic on the Environmental & Applied Solutions, I suppose, and Pall Industrial front as you are on the other parts of the",46,"And you emphasized the multi-industry diversified nature as well as science and technology. But I mean, does that -- are you as optimistic on the Environmental & Applied Solutions, I suppose, and Pall Industrial front as you are on the other parts of the business?"
265621,368081405,1011544,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Executives","We are. Well, we continue to have teams that focus, as we always have, in each one of the operating companies and in each one of the platforms, focused on developing funnels, ensuring that we have active cultivations. And yes, we remain biased towards app",58,"We are. Well, we continue to have teams that focus, as we always have, in each one of the operating companies and in each one of the platforms, focused on developing funnels, ensuring that we have active cultivations. And yes, we remain biased towards applying our free cash flow to each one of the businesses across the portfolio."
265621,368081405,1011544,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Operator","Next, we will take Jeffrey Sprague with Vertical Research Partners.",10,"Next, we will take Jeffrey Sprague with Vertical Research Partners."
265621,368081405,1011544,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Analysts","Congrats on getting Fortive done. Just maybe a couple business-related questions drilling in a little bit. Tom, can you elaborate a little bit what was going on in Environmental core margins in the quarter, why they were under pressure and kind of what th",48,"Congrats on getting Fortive done. Just maybe a couple business-related questions drilling in a little bit. Tom, can you elaborate a little bit what was going on in Environmental core margins in the quarter, why they were under pressure and kind of what the trajectory is looking forward?"
265621,368081405,1011544,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Executives","Jeff, thanks for the question. In general, we feel very good about where those businesses are. I'll speak specifically to the Hach business. We had very good performance in the prior quarter -- in the same quarter last year. In addition, we're making some",100,"Jeff, thanks for the question. In general, we feel very good about where those businesses are. I'll speak specifically to the Hach business. We had very good performance in the prior quarter -- in the same quarter last year. In addition, we're making some investments from a growth standpoint in those businesses. So I think we'll continue to see margin expansion from the water side of the Environmental segment, and I think those investments overall are going to pay off in terms of good growth rates in the quarters to come. So it's not an area of concern for us."
265621,368081405,1011544,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Executives","And Jeff, 2 things to add. One is Gilbarco had better growth than the Water business, so there's some negative mix in there for the segment. And we had our best -- that segment was -- Q2 last year was probably 150, 200 basis points better than any other q",83,"And Jeff, 2 things to add. One is Gilbarco had better growth than the Water business, so there's some negative mix in there for the segment. And we had our best -- that segment was -- Q2 last year was probably 150, 200 basis points better than any other quarter we had in 2015. So it was a little bit of a comp issue as well. But as Tom alluded to, we are investing pretty heavily right now in the Water business organically."
265621,368081405,1011544,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Analysts","Speaking of investment, maybe just kind of a total new Danaher question. But the idea of kind of restructuring, be it quiet or otherwise, is that a likely part of the equation here as you progress through the year? And can you give us some idea how to thi",51,"Speaking of investment, maybe just kind of a total new Danaher question. But the idea of kind of restructuring, be it quiet or otherwise, is that a likely part of the equation here as you progress through the year? And can you give us some idea how to think about that?"
265621,368081405,1011544,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Executives","Jeff, as we, I think, showed last year, we've established a cadence of restructuring that has gone on. You might say quietly, but I would say more consistently and appropriately throughout the course of the year. As opportunities have come up, we've taken",109,"Jeff, as we, I think, showed last year, we've established a cadence of restructuring that has gone on. You might say quietly, but I would say more consistently and appropriately throughout the course of the year. As opportunities have come up, we've taken advantage of those in each of the quarters. And so we still have opportunities for some level of restructuring in the third and fourth quarter. But in general, we've been more balanced through the course of the year, and I think that has served us well in terms of the operating margin expansion that you've seen over time late last year and this year as well."
265621,368081405,1011544,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Analysts","And then finally, just back to Environmental and Water specifically in the muni market. So we've been kind of hearing for a couple quarters that things are gaining traction. Obviously, you had a strong quarter at Trojan. Can you speak a little bit to the",66,"And then finally, just back to Environmental and Water specifically in the muni market. So we've been kind of hearing for a couple quarters that things are gaining traction. Obviously, you had a strong quarter at Trojan. Can you speak a little bit to the forward visibility there? What's going on in order activity? Do you have top line visibility into that business now into '17?"
265621,368081405,1011544,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Executives","Jeff, it's probably a little bit early to kind of comment on '17. The muni strength continues to be broad-based, both at Trojan and in the Hach business. And at the Hach business, we're seeing it both in Europe and the U.S. Very consistent and healthy spe",70,"Jeff, it's probably a little bit early to kind of comment on '17. The muni strength continues to be broad-based, both at Trojan and in the Hach business. And at the Hach business, we're seeing it both in Europe and the U.S. Very consistent and healthy spending there. The offset to that, both for Hach and ChemTreat, is where we serve the industrial or any commodity-oriented markets, they've been challenging."
265621,368081405,1011544,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Operator","Our next question is from Shannon O'Callaghan with UBS.",10,"Our next question is from Shannon O'Callaghan with UBS."
265621,368081405,1011544,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Analysts","Just on this emphasis on reinvesting some of the synergy upside at Nobel and at Pall into new products, go-to-market investments. What kind of lag are you expecting from that? I mean, when do you expect that to translate into improving organic growth for",51,"Just on this emphasis on reinvesting some of the synergy upside at Nobel and at Pall into new products, go-to-market investments. What kind of lag are you expecting from that? I mean, when do you expect that to translate into improving organic growth for those businesses and just what you're seeing?"
265621,368081405,1011544,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Executives","Shannon, it varies depending on where we direct those funds. I think, in some cases, when we put investment directly into, say, feet on the street, in either a developed market or a high-growth market, we tend to see those investments pay off in just a qu",216,"Shannon, it varies depending on where we direct those funds. I think, in some cases, when we put investment directly into, say, feet on the street, in either a developed market or a high-growth market, we tend to see those investments pay off in just a quarter or 2. If we're talking about investments that go into new product development, those tend to have much more of a lag time. As projects get kicked off into early business case-oriented tollgates, you could have several quarters to it, at times even a couple of years, before you might see the impact of a new product investment, again, depending on how early or late-stage an existing project might be in the pipeline. So it's varied. I think in the case of Nobel, just to talk to one of the businesses, we've seen those investments pay off relatively quickly. You've seen it in good core revenue growth consistently in that business. They have relatively shorter cycle times in terms of new product development. In businesses like Beckman, for example, and at Pall, the product development cycles are longer, certainly significantly longer at a place like Beckman, where, oftentimes, we'll have clinical trials and/or regulatory clearances. And so those new product investments can be -- can take some time, obviously."
265621,368081405,1011544,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Analysts","Okay, great. And then, yes, maybe a follow-up to that. I mean, in terms of -- in Diagnostics, you talked about Beckman's growth being driven by high-growth markets. What's going on in the developed markets? And maybe, I guess, to some of your comments you",68,"Okay, great. And then, yes, maybe a follow-up to that. I mean, in terms of -- in Diagnostics, you talked about Beckman's growth being driven by high-growth markets. What's going on in the developed markets? And maybe, I guess, to some of your comments you just made there with maybe [ph] sellout, what is it going to take to get some better growth in developed markets for Beckman?"
265621,368081405,1011544,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Executives","Sure. Yes, a little bit slower growth in the developed markets. I mean, in general, the developed markets, from an overall perspective, are slower-growth markets to begin with. We've always seen better market growth in the -- overall in places like China",120,"Sure. Yes, a little bit slower growth in the developed markets. I mean, in general, the developed markets, from an overall perspective, are slower-growth markets to begin with. We've always seen better market growth in the -- overall in places like China and India and the Middle East. So in general, I think we're tracking closer to the market growth rates than anything else. Still have work to do. There's no question about it. We have improved our retention rates and our competitive win rates, but there's still work to do in terms of both go-to-market as well as new product development. And over time, we do believe those will pay off in better growth rates in the developed markets."
265621,368081405,1011544,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Operator","And our next question is coming from Tycho Peterson with JPMorgan.",11,"And our next question is coming from Tycho Peterson with JPMorgan."
265621,368081405,1011544,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Analysts","Tom, just wondering if you can talk about some of the gives and takes where you're feeling a little more constructive by segment in the back half of the year. You talked to the gives and takes on Dental, so maybe you can pass on that. But is Pall Industri",99,"Tom, just wondering if you can talk about some of the gives and takes where you're feeling a little more constructive by segment in the back half of the year. You talked to the gives and takes on Dental, so maybe you can pass on that. But is Pall Industrial kind of bottoming out here? Could you see some improvement there? Obviously, the academic fund flows may pick up in the back half of the year, and that could help SCIEX. So could you just talk by division where you're feeling more constructive for the next couple of quarters?"
265621,368081405,1011544,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Executives","Sure. Thanks for the question. We do think that we're -- as you mentioned, we've seen good performance in Dental. Again, not necessarily a straight line, but we're very encouraged by the performance we're seeing. In terms of the other businesses across th",163,"Sure. Thanks for the question. We do think that we're -- as you mentioned, we've seen good performance in Dental. Again, not necessarily a straight line, but we're very encouraged by the performance we're seeing. In terms of the other businesses across the second half, I think we'll see continuing better performance across the Diagnostic businesses, in particular. We're starting to see the benefit of a number of the investments across those businesses. I think we'll see continuing good performance from Water Quality. PID has been pretty consistent along the way, so I think we will see that continue. Our Life Science businesses have also performed well, particularly SCIEX, as well as Beckman Life Science, so I think we'd see some modest incremental growth there. I would also remind you that we're coming around through some easier comps in the second half as well, and so we will get a little bit of benefit from those easier comps really across the entire portfolio."
265621,368081405,1011544,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Analysts","And since you called out Europe as a source of strength for Life Sciences and Radiometer, are you kind of comfortable with the macro in the back half of the year for those markets?",34,"And since you called out Europe as a source of strength for Life Sciences and Radiometer, are you kind of comfortable with the macro in the back half of the year for those markets?"
265621,368081405,1011544,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Executives","Well, I think the Brexit situation certainly has created uncertainty around, not just the U.K. but across the European theater at large. Uncertainty is rarely a good thing for markets in terms of people's willingness to make investments, particularly in i",65,"Well, I think the Brexit situation certainly has created uncertainty around, not just the U.K. but across the European theater at large. Uncertainty is rarely a good thing for markets in terms of people's willingness to make investments, particularly in instrumentation and higher-cost instrumentation. So I think that uncertainty could potentially result in some slowness in the second half, but it's very early to tell."
265621,368081405,1011544,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Executives","Tycho, we've been -- maybe just on Western Europe. We've been consistently in kind of a pretty healthy low single-digit number across Western Europe. It's been pretty broad-based. It is an area where, I think, because of some of the uncertainties the last",103,"Tycho, we've been -- maybe just on Western Europe. We've been consistently in kind of a pretty healthy low single-digit number across Western Europe. It's been pretty broad-based. It is an area where, I think, because of some of the uncertainties the last couple of years, we've probably taken a fair amount of share, as we've seen some people kind of pull back in Western Europe over the last couple of years. So it's been a good market for us. And while -- and we also see doing Pall doing quite well in Europe, though those, obviously, not in the core numbers yet."
265621,368081405,1011544,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Analysts","Okay. And then just lastly on the capital deployment question. Earlier, you touched on the framework a little bit. Can you just remind us where you're comfortable taking up leverage? And maybe just any comments on what you're seeing in terms of valuation,",50,"Okay. And then just lastly on the capital deployment question. Earlier, you touched on the framework a little bit. Can you just remind us where you're comfortable taking up leverage? And maybe just any comments on what you're seeing in terms of valuation, given how much the space has run?"
265621,368081405,1011544,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Executives","Well, Tycho, we've obviously spent the last year in a significant effort on deleveraging. We're in really good shape. We're south of 2.5x at this point. Initially, we were close to 4x leverage. So we're back to a mode of spending our free cash flow plus,",88,"Well, Tycho, we've obviously spent the last year in a significant effort on deleveraging. We're in really good shape. We're south of 2.5x at this point. Initially, we were close to 4x leverage. So we're back to a mode of spending our free cash flow plus, and we've talked about a couple billion of capacity for this year. But going into next year, you're back to more $3 billion to $4 billion of capacity per year. And that's not without -- that's without really stretching the balance sheet."
265621,368081405,1011544,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Operator","Our next question is coming from Ross Muken with Evercore ISI.",11,"Our next question is coming from Ross Muken with Evercore ISI."
265621,368081405,1011544,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Analysts","So appreciate, I know you gave us already some color on Pall single-use and on SCIEX, but I'd love it if you could tease out at all sort of pharma demand based on sort of customer types, so sort of separating maybe pharma from biotech or emerging biotech",97,"So appreciate, I know you gave us already some color on Pall single-use and on SCIEX, but I'd love it if you could tease out at all sort of pharma demand based on sort of customer types, so sort of separating maybe pharma from biotech or emerging biotech to see if there's any sort of discernible trend you've seen amongst. I mean, it's clear at Pall, obviously, having pretty strong growth across the board, but I was wondering if any of the end markets, whether it's generic or CRO, et cetera, you're seeing any change in demand."
265621,368081405,1011544,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Executives","SCIEX is probably the best business to think about when you think about the -- your question about pharma versus, say, biotech. SCIEX has exposure to both those end markets, and we're seeing good performance, healthy demand and fairly consistent demand fr",131,"SCIEX is probably the best business to think about when you think about the -- your question about pharma versus, say, biotech. SCIEX has exposure to both those end markets, and we're seeing good performance, healthy demand and fairly consistent demand from both sides of the house there. I'd have to do some follow-up to get you some detail on anything to do with the generics or the CROs, specifically. But clearly, in the aggregate, these markets are doing quite well. Pall, as you mentioned, we've talked about the growth that we're seeing in the life science side, specifically around our single-use technology product offering, where we're seeing continued double-digit growth rates in that area. And that clearly is associated with the growth in biopharmaceuticals, specifically the growth in large-molecule drugs."
265621,368081405,1011544,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Analysts","Great. I guess, what I was getting at is more on the CRO, generic side. Maybe I'll ask it differently. In terms of just high-growth markets, I mean, it's clear China has been good. But outside of China, how would you sort of characterize the rest of the k",69,"Great. I guess, what I was getting at is more on the CRO, generic side. Maybe I'll ask it differently. In terms of just high-growth markets, I mean, it's clear China has been good. But outside of China, how would you sort of characterize the rest of the key markets? Obviously, LatAm has kind of been a mixed bag overall, but India and some of the other key geographies."
265621,368081405,1011544,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Executives","I'd say China, in particular, India as well, are very good markets for us. But I would say that there's still a long runway ahead for those markets. Some of the generic and the CRO movement into those markets has been, on balance, a positive. But there ar",86,"I'd say China, in particular, India as well, are very good markets for us. But I would say that there's still a long runway ahead for those markets. Some of the generic and the CRO movement into those markets has been, on balance, a positive. But there are also components of the market that are still relatively nascent, particularly in terms of what might be going on there in the future relative to large-molecule drugs. So I think there's still a pretty good runway ahead."
265621,368081405,1011544,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Operator","Our next question comes from Derik De Bruin with Bank of America Merrill Lynch.",14,"Our next question comes from Derik De Bruin with Bank of America Merrill Lynch."
265621,368081405,1011544,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Analysts","So could you talk a little bit about capital deployment? I'm just curious, now that sort of Fortive is spun out, how do you sort of view your overall strategy in the life sciences space? Do you still feel like you want to stay focused on the core -- stand",84,"So could you talk a little bit about capital deployment? I'm just curious, now that sort of Fortive is spun out, how do you sort of view your overall strategy in the life sciences space? Do you still feel like you want to stay focused on the core -- stand-alone core brands? Or do you feel the need to sort of become a more integrated provider in the space? Do you think you need to add anything to your Life Sciences or Diagnostics armament?"
265621,368081405,1011544,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Executives","Well, Derik, I think, first of all, starting at a Danaher level, our bias towards M&A is not -- and the use of our free cash flow to M&A is not specifically skewed towards any of the 4 segments that I mentioned. We've had a consistent track record of capi",278,"Well, Derik, I think, first of all, starting at a Danaher level, our bias towards M&A is not -- and the use of our free cash flow to M&A is not specifically skewed towards any of the 4 segments that I mentioned. We've had a consistent track record of capital allocation across each of those 4 segments that we'll be reporting on in the future, and I think you'll continue to see us do that. Now specifically to your question around Life Sciences and Diagnostics, what you've seen us do in Life Sciences is continue to broaden our product offering over time, and I think you'll continue to see us do that. We have had a bias and would continue to have a bias towards businesses with not only strong brands and significant installed bases, but installed bases that drive good, consistent recurring revenue and consumables growth. The Diagnostics business is inherently that way, typically, and you've seen us buy businesses with those same characteristics, strong brands, significant installed bases and strong recurring revenue and consumable streams. I think you'd see us continue to do that. We think there is certainly room to continue to expand our Diagnostic product offering and provide hospitals with broader bundles of product. Today, we provide products, obviously, to the central laboratory, the core clinical laboratory as well as to anatomical pathology and to the acute care areas of the hospital. And with the expansion of Microscan, into microbiology, with Iris opening up urinalysis for us, I think those types of expansions of our footprint would certainly be characteristic of the types of things that we would hope to do in the future."
265621,368081405,1011544,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Analysts","Great. That's really helpful. And just one quick follow-up. It's been a year since you launched the Veris platform in Molecular. Could you talk a little bit about what you see in terms of installed base and competitive wins? And essentially, where is that",84,"Great. That's really helpful. And just one quick follow-up. It's been a year since you launched the Veris platform in Molecular. Could you talk a little bit about what you see in terms of installed base and competitive wins? And essentially, where is that going? What's the customer type? And then if you're -- I assume you're taking share from people since most hospitals have molecular [ph] platforms of that size. Can you just talk a little bit more -- some color on that?"
265621,368081405,1011544,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Executives","Sure. Thanks, Derik. Just for everyone's benefit, the Veris platform is a high-volume, random-access molecular diagnostics instrument that was commercialized for the first time in Europe in the second half of last year. That product line serves the core -",224,"Sure. Thanks, Derik. Just for everyone's benefit, the Veris platform is a high-volume, random-access molecular diagnostics instrument that was commercialized for the first time in Europe in the second half of last year. That product line serves the core -- or central clinical laboratory of major hospitals. And again, as I mentioned, it is a -- it's a high-volume platform. We're very pleased with the early traction that we'd gotten. It is still early. During the first year of a significant new product introduction like that, the first of its kind by Beckman Coulter, it does take a while to build the funnel, but we've been very happy with how that funnel has built, the sales opportunity funnel in the last year. The installations that we have thus far are running very well. We have 4 assays in the market right now, but the 4 assays really are just the beginning. There's a significant road map of assay development ahead that will ultimately be commercialized, both in Europe as well as in the U.S. That product will need to go through regulatory clearance in the U.S., so it'll be some time before we see the volumes ramp beyond the early days here in Europe. But the feedback from customers has been very -- strongly positive, and we feel good about the start we have."
265621,368081405,1011544,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Analysts","Great. And when is FDA approval expected?",7,"Great. And when is FDA approval expected?"
265621,368081405,1011544,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Executives","I usually hesitate to try to put any bets on FDA clearance. There's a fair amount of work to do even before we file for that clearance, so I'll probably have a better sense of that in the quarters to come. But wouldn't -- I couldn't put a date on it today",52,"I usually hesitate to try to put any bets on FDA clearance. There's a fair amount of work to do even before we file for that clearance, so I'll probably have a better sense of that in the quarters to come. But wouldn't -- I couldn't put a date on it today."
265621,368081405,1011544,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Operator","Our next question comes from Julian Mitchell with Crdit Suisse.",10,"Our next question comes from Julian Mitchell with Crdit Suisse."
265621,368081405,1011544,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Analysts","Just a question on margins, firstly. So the core margin in total Danaher fell about 30 bps in Q2. Could you give that comparable number for the remaining business? And then maybe -- and how you think that will trend in the second half? And tied to that, I",88,"Just a question on margins, firstly. So the core margin in total Danaher fell about 30 bps in Q2. Could you give that comparable number for the remaining business? And then maybe -- and how you think that will trend in the second half? And tied to that, I guess, going back to the Environmental & Applied Solutions segment. The headline margin there was down 300 bps plus in Q2. Should we see that coming back in the second half as the comps on margins get much easier?"
265621,368081405,1011544,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Executives","Sure, Julian. On the last one you asked, and I -- as I mentioned earlier, part of the Environmental issue was a comp issue that margins on a historical restated basis for the Environmental & Applied Solutions were 200 basis points higher in Q2 a year ago.",119,"Sure, Julian. On the last one you asked, and I -- as I mentioned earlier, part of the Environmental issue was a comp issue that margins on a historical restated basis for the Environmental & Applied Solutions were 200 basis points higher in Q2 a year ago. So you expect that to sort of normalize. Core margins were relatively flat for Danaher ex Fortive. That was, again, somewhat of a function of the prior year compare. For our full year, we continue to expect 50 to 75 basis points of core margin expansion for Danaher ex Fortive, and you'll see better performance. You saw very good performance in the first quarter. You'll see better performance in Q3 and Q4."
265621,368081405,1011544,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Analysts","Great. And then just on Pall Industrial. You called out the overall organic sales trend year-on-year. Is there any sort of color you'd give there on specific verticals or markets within that? Any changes?",34,"Great. And then just on Pall Industrial. You called out the overall organic sales trend year-on-year. Is there any sort of color you'd give there on specific verticals or markets within that? Any changes?"
265621,368081405,1011544,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Executives","No. I wouldn't say we've seen necessarily any changes, Julian. I think if -- to the extent that there's good news there, I think it would be that we've seen some stability found in those markets. We continue to make some excellent progress in terms of our",162,"No. I wouldn't say we've seen necessarily any changes, Julian. I think if -- to the extent that there's good news there, I think it would be that we've seen some stability found in those markets. We continue to make some excellent progress in terms of our go-to-market initiatives. We've done over 40 growth-related kaizens at Pall since we acquired the business. And a number of those kaizens have been going on in the industrial markets. And that involves installing DBS tools, such as funnel management and transformative marketing that we think is improving our execution in those markets. So I think the combination of seeing some stability across each one of those end markets, in combination with the application of DBS tools, I think, has gotten us to a pretty good place. So I would hope to see some incrementally better performance late this year and certainly, entering next year. But I think, in general, we're pleased that things have stabilized."
265621,368081405,1011544,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Operator","Our final question is coming from Isaac Ro with Goldman Sachs.",11,"Our final question is coming from Isaac Ro with Goldman Sachs."
265621,368081405,1011544,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Analysts","I just want to ask another question on Pall Industrial. If we look back prior to the acquisition, that business was obviously growing a little slower than the Life Science side. But curious if you could maybe take a bigger step back and give us a sense of",77,"I just want to ask another question on Pall Industrial. If we look back prior to the acquisition, that business was obviously growing a little slower than the Life Science side. But curious if you could maybe take a bigger step back and give us a sense of what you think it will take for Industrial to return to growth. Is it mostly a function of end markets? Or is there really more of an execution issue?"
265621,368081405,1011544,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Executives","I think it's both. As I was just mentioning to Julian, I think we've seen the markets themselves, from a macro standpoint, stabilize a bit. In other words, not get any worse. And we will need to see some improvement in the macro environment to see some me",153,"I think it's both. As I was just mentioning to Julian, I think we've seen the markets themselves, from a macro standpoint, stabilize a bit. In other words, not get any worse. And we will need to see some improvement in the macro environment to see some meaningful or step function improvement in growth. But we're not waiting for that. Our focus is on ensuring that we have the best sales team on the field, that we're providing those teams with exceptional new product development, that we've got our coverage set up appropriately across geographies and across each one of those verticals. And I think the combination of good market coverage, DBS tools, new product development and some improvement in those end markets is what it's going to take. Obviously, the majority of that, we hope to be in our control, but a little help from the end markets certainly wouldn't hurt."
265621,368081405,1011544,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Analysts","Got it. That's helpful. And then one other question on Beckman. If we -- just trying to square up kind of what we saw last week with some of the peer groups in Diagnostics with what you said, you -- obviously, you've got Veris and CytoFLEX helping out. If",83,"Got it. That's helpful. And then one other question on Beckman. If we -- just trying to square up kind of what we saw last week with some of the peer groups in Diagnostics with what you said, you -- obviously, you've got Veris and CytoFLEX helping out. If we pull those out, just trying to get a better sense of how you think you're pacing versus the overall market for Diagnostics. And any color there, especially in North America, would be helpful."
265621,368081405,1011544,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Executives","Sure. Thanks, Isaac. Well, as you know, we had to -- we had to come from behind here from the standpoint of the big 5 in the overall market. I think from a pacing standpoint, we've now gotten to a point where we are very close to, if not at, market growth",210,"Sure. Thanks, Isaac. Well, as you know, we had to -- we had to come from behind here from the standpoint of the big 5 in the overall market. I think from a pacing standpoint, we've now gotten to a point where we are very close to, if not at, market growth rates, with a couple of the competitors, as you mentioned, that reported last week posting better growth rates. And in doing so -- in some cases, it's a function of their positions in certain higher-growth markets. But in other cases, we simply have work to do in terms of continuing to drive our new product development and our go-to-market initiatives. We're ahead of a couple other competitors in that market, and we have demonstrated where, from a competitive win perspective, we've become far more competitive in the overall market. So I think we've made a ton of progress. But clearly, work to do. And that work, as you've referenced, is represented by some folks that are still putting up some pretty good numbers. So I think we've got the initiatives and the investment levels in the right place. We continue to make progress. And it'll take a bit of time, but I think we're on the right track."
265621,368081405,1011544,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Operator","And that concludes our question-and-answer session. I would like to turn the conference back over to Matt Gugino for any additional or closing remarks.",25,"And that concludes our question-and-answer session. I would like to turn the conference back over to Matt Gugino for any additional or closing remarks."
265621,368081405,1011544,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Executives","Thanks, everyone, for joining us. We're around all day for questions.",11,"Thanks, everyone, for joining us. We're around all day for questions."
265621,368081405,1011544,"Danaher Corp., Q2 2016 Earnings Call, Jul 25, 2016",2016-07-25,"Earnings Calls","Danaher Corporation","Operator","And that concludes today's presentation. We thank you all for your participation.",13,"And that concludes today's presentation. We thank you all for your participation."
265621,402034332,1057366,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Operator","My name is Erica, and I will be your conference facilitator this morning. At this time, I would like to welcome everyone to Danaher Corporation's Third Quarter 2016 Earning Results Conference Call. [Operator Instructions] I will now turn the call over t",56,"My name is Erica, and I will be your conference facilitator this morning. At this time, I would like to welcome everyone to Danaher Corporation's Third Quarter 2016 Earning Results Conference Call. [Operator Instructions] 
I will now turn the call over to Mr. Gugino, Vice President of Investor Relations. Mr. Gugino, you may begin your conference."
265621,402034332,1057366,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Executives","Thanks, Erica. Good morning, everyone, and thanks for joining us on the call. With us today are Tom Joyce, our President and Chief Executive Officer; and Dan Comas, our Executive Vice President and Chief Financial Officer. I'd like to point out that our",366,"Thanks, Erica. Good morning, everyone, and thanks for joining us on the call. With us today are Tom Joyce, our President and Chief Executive Officer; and Dan Comas, our Executive Vice President and Chief Financial Officer. 
I'd like to point out that our earnings release, the slide presentation supplementing today's call, our third quarter Form 10-Q and the reconciliations and other information required by SEC Regulation G relating to any non-GAAP financial measures provided during the call are all available on the Investors section of our website, www.danaher.com, under the heading Financial Information. The audio portion of this call will be archived on the Investors section of our website later today under the heading Events & Presentations and will remain archived until our next quarterly call. A replay of this call will also be available until October 27, 2016. 
During the presentation, we will describe certain of the more significant factors that impacted year-over-year performance. The supplemental materials describe additional factors that impacted year-over-year performance. Unless otherwise noted, all references in these remarks and supplemental materials to company-specific financial metrics relate to the continuing operations of the company in the third quarter of 2016, and all references to period-to-period increases or decreases in financial metrics are year-over-year. 
Today, we'll be discussing 2 recently announced acquisitions of Cepheid and Phenomenex. Both acquisitions are subject to customary closing condition, including receipt of applicable regulatory approval; and, in the case of Cepheid, approval of the Cepheid shareholders. We may also describe certain products and devices which have applications submitted and pending for certain regulatory approvals. 
During the call, we will make forward-looking statements within the meaning of the federal securities laws, including statements regarding events or developments that we believe or anticipate will or may occur in the future. These forward-looking statements are subject to a number of risks and uncertainties, including those set forth in our SEC filings, and actual results might differ materially from any forward-looking statement that we make today. These forward-looking statements speak only as of the date that they are made, and we do not assume any obligation to update any forward-looking statement. 
With that, I'd like to turn the call over to Tom."
265621,402034332,1057366,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Executives","Thank you, Matt. Good morning, everyone. We're pleased with our third quarter results as our team continued to execute well despite the macroeconomic environment. We delivered solid core revenue growth with very strong adjusted earnings per share growth a",2290,"Thank you, Matt. Good morning, everyone. We're pleased with our third quarter results as our team continued to execute well despite the macroeconomic environment. We delivered solid core revenue growth with very strong adjusted earnings per share growth and free cash flow performance. The diversity and strength of our businesses has served us well in this modest growth environment. The recent separation of Fortive was an important step towards optimizing our portfolio, and we continue to strategically position Danaher for strong long-term growth through M&A. 
Since July, we have announced over $4.8 billion of acquisitions that will strengthen our Life Sciences and Diagnostics segments. In September, we announced the acquisition of Cepheid, a global leader in molecular diagnostics, and we recently announced the acquisition of Phenomenex, an outstanding chromatography consumables business that will be highly complementary to our Life Sciences portfolio. Combined with the execution benefits of DBS, we believe these exciting strategic additions will contribute to Danaher's growth trajectory and superior returns. We look forward to welcoming the Cepheid and Phenomenex teams to Danaher. 
With that as a backdrop, let's turn to the details of the third quarter. This morning, we reported adjusted diluted net earnings per share from continuing operations of $0.87, an increase of more than 20% over last year. Sales grew 17.5% to $4.1 billion, with core revenue increasing 3%. Core growth was consistent across the portfolio, as each of our 4 reporting segments achieved at least 3% core revenue growth in the quarter. Currency translation had minimal impact while acquisitions increased revenues by 14.5%. 
Geographically, the high-growth markets led the way, driven by high single-digit growth in China and high-teens growth in India. Developed market core revenues were up low single digits. Modest growth in the U.S. and Western Europe was partially offset by declines in Japan. 
Gross margin for the third quarter was 55.3%, an increase of 140 basis points from last year. This increase in gross profit enabled us to increase our sales and marketing and R&D spend meaningfully in the quarter. Core operating margins were up 155 basis points in the quarter and 90 basis points year-to-date. This strong margin expansion helped to drive double-digit adjusted net earnings growth in the third quarter. During the quarter, we generated approximately $700 million of free cash flow from continuing operations, up 35%, and our free cash flow to net income conversion ratio was over 150%. 
Now let's take a more detailed look at the results across the portfolio. In Life Sciences, core revenues were up 3% and reported revenues grew over 60%, largely due to the Pall acquisition. Core operating margin increased 180 basis points, and the reported operating profit margin increased to 15.4%. 
At Beckman Life Sciences, low single-digit core growth in the quarter was driven by momentum in China while developed markets were essentially flat. The backdrop of government investment in health care in China, coupled with Beckman's strong execution, contributed to double-digit gains in that region.  Beckman's particle counting and characterization business had another good quarter, with double-digit growth driven by global biopharmaceutical demand. 
The team also launched a new product that supports drug discovery and development. The Vi-CELL MetaFLEX is a biochemistry analyzer that resulted from a collaboration with one of our Diagnostic businesses, Radiometer. Beckman incorporated the technology behind Radiometer's blood gas analyzer to create the Vi-CELL MetaFLEX, which analyzes cell cultures, a crucial component in biotherapy production. This cross-pollination between Beckman and Radiometer is a powerful example of the unique opportunities we have at Danaher to bring greater value to customers by collaborating across the portfolio. 
Leica Microsystems core revenue declined in the quarter. Growth was impacted by weakness in the academic and industrial end markets, particularly in North America and Western Europe. This was partially offset by double-digit gains in the high-growth markets as China continued to be a bright spot, particularly for our confocal business. 
SCIEX posted another quarter of mid-single-digit core revenue growth, led by global strength in pharmaceuticals and food as well as environmental testing. Geographically, we saw declines in Japan and in Europe, where academic weakness impacted results. In the high-growth markets, China and India each maintained strong double-digit growth. Our service offering continues to be a differentiator at SCIEX as the team drove further improvements in contract renewals and attachment rates in the quarter. 
As I mentioned at the start of the call, we recently announced our acquisition of Phenomenex, a leading player in chromatography consumables that supports a variety of analytical testing applications in the health, research and environmental segments. Phenomenex is 100% consumables, a high-margin business in an attractive mid-single-digit growth industry that is adjacent to where SCIEX participates. We expect to achieve a double-digit return on our investment in less than 5 years and believe that Phenomenex will help us to continue creating long-term value as part of our Life Sciences portfolio. 
Pall delivered another quarter of good growth and execution. Continued strength in biopharmaceutical end markets and demand for single-use technologies underpinned strong growth at Pall Life Sciences. Pall's market-leading solutions are at the forefront of the biopharma evolution, and 9 of the 12 new biologic drugs cleared by the FDA last year specified Pall products in their processes. This is a tremendous testament to the quality and reliability that Pall provides to its customers every day. 
Pall Industrial revenue was down in the quarter with solid gains in aerospace and microelectronics offset by declines in energy and machinery as heavy industrial end markets remained challenging. August marked the 1-year anniversary of our acquisition of Pall Corporation, and the team's exceptional implementation of DBS has been a critical driver of what we've been able to accomplish thus far. Since the beginning of the year, Pall has achieved more than 150 basis points of gross margin expansion and improved operating margins by over 350 basis points. 
At the same time, we've been able to put some of that benefit back into sales and marketing and R&D. This reinvestment, combined with the team's thoughtful use of DBS growth tools, like accelerated product development and [indiscernible], has resulted in a number of key new products launching ahead of schedule this year. By delivering these impactful new solutions to the market sooner, we can deliver greater value to our customers and further enhance Pall's growth trajectory. 
Moving now to Diagnostics. Both reported and core revenues increased 3%. The team's solid execution generated 250 basis points of core operating margin expansion, and reported operating margins increased to 16%. Sustained strength in China and India was complemented by modest growth in the developed markets. 
Core revenue at Beckman Coulter Diagnostics was up low single digits, with growth in emerging markets partially offset by softer demand in North America and Europe. Recent installed base growth in China contributed to strong immunoassay performance in the quarter, with the business achieving double-digit recurring revenue in the region. 
One of our 5 core values at Danaher is: Customers talk, we listen. And Beckman Diagnostics recognizes the importance of helping customers drive performance across multiple labs with different needs and different test volumes. One of the ways we differentiate our offering is to partner with customers and help them integrate Danaher Business System tools and processes into their labs and workflows. The result can be tremendously impactful: better speed to results, operational efficiency and ultimately improved clinician workflows. 
The effectiveness of one such collaboration was recently highlighted by a customer that operates one of the largest regional lab networks in the Midwestern United States. Within 6 months, Beckman helped them implement over 180 analyzers and 4 automation lines at 30 different hospitals and lab locations without any patient disruption. This customer was recently awarded a prestigious ADVANCE Laboratory of the Year award for 2016 and has mentioned their partnership with Beckman and the adoption of DBS tools as a key factor in their labs' transformational success. 
Radiometer achieved mid-single-digit core revenue growth, led by continued double-digit growth in both China and India and solid performance in the developed markets. We saw robust demand for consumables across our portfolio of acute care diagnostic instruments. 
At Leica Biosystems, core revenues grew mid-single digits in the quarter, led by high single-digit growth in North America. An expanding installed base and strong consumable sales contributed to double-digit growth in our advanced staining business. 
Back in September, we announced our acquisition of Cepheid, a leading molecular diagnostics innovator in the fastest-growing segment of diagnostics. Cepheid has the largest global installed base of molecular diagnostics instruments, combined with the broadest test menu available. We expect this highly complementary addition to our Diagnostics portfolio to accelerate our growth strategy and further differentiate Danaher's diagnostics offering. We also foresee tremendous opportunities with the application of DBS at Cepheid, which we believe will help drive better top and bottom line performance. 
Turning now to our Dental segment. Reported revenues increased 3.5%, and reported operating margin increased slightly to 15%, with 20 basis points of core margin expansion. Core revenues were up 3%, driven by our equipment, implant and orthodontic product lines, while we saw softer demand for consumables in the quarter. Positive gains in North America were offset by weakness in Western Europe. Strength in high-growth markets was supported by another quarter of double-digit growth in China across all of our major dental product lines. 
Since 2010, we've grown our Dental revenues in China from $15 million to over $150 million today, and we're now positioned as one of the leading players in the region. We've evolved our business model as well in China to position ourselves as more of a localized player by expanding our R&D teams, increasing local commercial coverage and establishing manufacturing capabilities in the region. This approach, combined with our comprehensive product suite, enables us to provide a full service China-centric offering that enhances our customers' experiences and positions us well for continued growth in this market. 
Let's turn to Nobel Biocare. Nobel Biocare's core revenue grew at a low single-digit rate, with demand for implant systems and regeneratives driven by recently launched new products that have quickly gained traction with customers. Similar to what we saw across our other Dental businesses in the quarter, sales in Western Europe softened at Nobel while China continued to do well. The benefit of the team's operational and cost improvements using DBS continues to help fuel Nobel's new product and innovation engine. 
Turning to our Environmental & Applied Solutions segment. Core revenues grew 3.5% with reported revenues up 4.5%. Core operating margin expanded 60 basis points, and reported operating margin was down slightly at 24.3%. 
In Product Identification, core revenues increased at a mid-single-digit rate, and we saw strong demand for marking and coding equipment and related consumables across most major geographies. Sales growth of our packaging and color solutions offerings improved sequentially and was led primarily by increased demand in the U.S. and Latin America. 
Videojet showed solid growth performance, delivering mid-single-digit core revenue growth in the quarter. Strength in developed markets and Latin America was modestly offset by declines in China, primarily due to industrial end market weakness. Videojet continued to grow the number of connected printers in the market, expanding our remote solutions offering for customers and driving high single-digit service revenue growth. 
Core revenue grew low single digits at Esko, led by increased demand at MediaBeacon, which we acquired in 2015. As a reminder, MediaBeacon provide digital asset management software that brand owners and packaging managers use to ensure accuracy and compliance. With the help of DBS tools like funnel management and transformative marketing, MediaBeacon has generated greater market awareness and demand for our integrated solutions, which support customers across their full brand and packaging workflows. At X-Rite, core revenue grew low single digits, with strong performance in North America and China partially offset by the rest of Asia. 
Lastly, turning to Water Quality. Core revenue growth for the platform increased at a low single-digit rate. Hach's core revenue declined slightly in the quarter as industrial end market weakness contributed to softer demand in North America and China. We saw similarly lackluster activity in Eastern Europe as constrained government funding and political instability affected municipal projects. We anticipate better core growth at Hach in the fourth quarter. 
ChemTreat core revenue grew at a mid-single-digit rate as the team delivered solid commercial execution and expanded their customer base in the U.S. Strength in North America and the food and beverage end markets was partially offset by lower demand in Latin America, particularly in the more commodity-oriented markets. 
At Trojan, core revenue increased double digits, driven by consistent municipal demand across developed and emerging markets. Our increased municipal systems' installed base contributed to strong replacement growth, and bidding activity was up low single digits globally. A few key municipal project wins materialized in Asia as ultraviolet water treatment solutions have gained interest in the region. 
So to wrap up, we're pleased with our performance in the current macroeconomic environment. We believe that the steps we've taken to reshape our portfolio positions us well for stronger growth and value creation. The diversity and strength of our businesses, combined with our team's focused execution using the Danaher Business System, is what sustains our competitive advantage. We believe that this combination will continue to serve both our customers and our shareholders as well. 
We are initiating fourth quarter guidance for adjusted diluted net EPS from continuing operations of $1.01 to $1.05, which assumes fourth quarter core revenue growth comparable to the third quarter of 2016. For the full year 2016, we're raising our adjusted diluted net EPS from continuing operations guidance to $3.57 to $3.61, which, at the midpoint, would represent an increase of approximately 20% from 2015."
265621,402034332,1057366,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Executives","Thanks, Tom. That concludes our formal comments. Erica, we're now ready for questions.",13,"Thanks, Tom. That concludes our formal comments. Erica, we're now ready for questions."
265621,402034332,1057366,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Operator","[Operator Instructions] We'll go first to the line of Scott Davis with Barclays.",13,"[Operator Instructions] We'll go first to the line of Scott Davis with Barclays."
265621,402034332,1057366,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Analysts","I could see the pattern that since you hired Gugino, you started to put up these big numbers.",18,"I could see the pattern that since you hired Gugino, you started to put up these big numbers."
265621,402034332,1057366,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Executives","He's got a big team supporting him, Scott. We love him, but big team, big team, broad-based.",18,"He's got a big team supporting him, Scott. We love him, but big team, big team, broad-based."
265621,402034332,1057366,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Analysts","Yes. Well, anyways, I'm intrigued by -- it's your 1-year anniversary of Pall, and I'm intrigued on how does that -- have your results matched up with the deal model? And more kind of specifically, what time -- or what type of return on capital are you sit",62,"Yes. Well, anyways, I'm intrigued by -- it's your 1-year anniversary of Pall, and I'm intrigued on how does that -- have your results matched up with the deal model? And more kind of specifically, what time -- or what type of return on capital are you sitting on kind of as you look point in time right now in that deal?"
265621,402034332,1057366,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Executives","Sure. Scott, we're very, very pleased with the performance of the team, both the Danaher team that has joined the team at Pall as well as the legacy Pall associates. The combination of those 2 teams has gotten the business off to a tremendous start in the",293,"Sure. Scott, we're very, very pleased with the performance of the team, both the Danaher team that has joined the team at Pall as well as the legacy Pall associates. The combination of those 2 teams has gotten the business off to a tremendous start in the first year. DBS has played a huge role in the progress that we've made there. As you might recall, that team had sort of began the journey before we arrived on the scene, but the combination of the Danaher team that's gone in, in the Pall team have really accelerated the pace of progress. There have been over 350 kaizens that have been completed both on operational side as well as on the commercial side. We've seen the tremendous lift in core operating margins in that business. And as I mentioned in my remarks, we're now seeing the investment in some of the sales and marketing and the new product areas start to make a real difference in terms of getting new products not only launched but commercialized on time and effectively. So we're off to a good start. You know we took the improvements from a cost standpoint up from $60 million in the first year to $100 million. So we're a little bit ahead of schedule in that respect. And I think, obviously, that lifts the returns here in the near term. Relative to where we'll end up on a 4-, 5-year basis and beyond, I think, again, we're off to a very good start. I think we have a lot of opportunity to lift those returns, but it's still early days. And there's a lot of hard work to be done in the months and quarters and years ahead, but a great start."
265621,402034332,1057366,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Analysts","And when -- and just thinking about Pall. When Pall Industrial comes back -- and I'd love to hear your view on when you think you move into positive territory there, but when Pall Industrial comes back, would you expect outsized operating leverage on the",64,"And when -- and just thinking about Pall. When Pall Industrial comes back -- and I'd love to hear your view on when you think you move into positive territory there, but when Pall Industrial comes back, would you expect outsized operating leverage on the cost-out? Or how would you think about it if you -- I guess, if you were in our shoes?"
265621,402034332,1057366,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Executives","Yes. Well, first of all, I think we've seen while not a -- the beginnings of growth on the industrial side, I think we haven't seen -- we have not seen another leg down. In other words, we've seen some stability. The industrial side was still down mid-sin",202,"Yes. Well, first of all, I think we've seen while not a -- the beginnings of growth on the industrial side, I think we haven't seen -- we have not seen another leg down. In other words, we've seen some stability. The industrial side was still down mid-single digits in the quarter while the Life Science side was up mid-single digits. And so as those businesses begin to improve both from the standpoint of our execution, and DBS is playing a role there from a new product execution standpoint and a commercialization perspective, when those improvements kick in and we get some lift from the macro, I think the big benefit you're going to see is in terms of the core growth of that business and the readthrough on an operating margin basis from that core growth. I don't know that it necessarily changes trajectory from a cost-out perspective. We're working on the cost structures, both on the Life Science side and on the industrial side as well as across the horizontal components of G&A. So I think the real lift comes when we start to see that core growth turn positive and we start to see the readthrough from that growth."
265621,402034332,1057366,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Operator","And we'll take our next question from Steve Winoker from Bernstein.",12,"And we'll take our next question from Steve Winoker from Bernstein."
265621,402034332,1057366,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Analysts","And to echo Scott, I wouldn't -- Matt and his team is important, but don't forget Matt in all these, okay? So listen, I want to just start with the actual fourth quarter core growth that you just talked about at about the same as third quarter. Just looki",112,"And to echo Scott, I wouldn't -- Matt and his team is important, but don't forget Matt in all these, okay? So listen, I want to just start with the actual fourth quarter core growth that you just talked about at about the same as third quarter. Just looking for where you might see signs of acceleration, how you think about that trending into next year. I know, if I look at 2015, the third quarter was up year-on-year 3%. The fourth quarter was up only 1.5%. So just wondering, is this conservative in terms of how you're seeing [ph] -- give us some sense of the fourth quarter, if you could."
265621,402034332,1057366,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Executives","Yes. I wouldn't describe it as conservative, Steve. I do think, though, there's a number of considerations that go into how we look at the fourth quarter. I mean it starts with how pleased we are with the performance at this point in the third quarter, wi",245,"Yes. I wouldn't describe it as conservative, Steve. I do think, though, there's a number of considerations that go into how we look at the fourth quarter. I mean it starts with how pleased we are with the performance at this point in the third quarter, with all 4 segments driving at least 3% core growth. And I think now with a portfolio where greater than 60% of the revenues are in the aftermarket and where there's some stability in these markets but not necessarily anything positive to write home about macroeconomically, I think there is cause for some degree of caution in the outlook. You're reading the same macroeconomic news that everybody else is and, certainly, that we are. There's a number of sources of uncertainty in the market today, whether that's the election uncertainty in the U.S.; the Brexit uncertainty throughout Europe; the questions around turns in some of the high-growth markets or previously known as high-growth markets, as I sometimes say, around places like Latin America, the Middle East, Russia, and particularly those markets with a good deal of commodity exposure and certainly those with a high degree of industrial exposure. So it's hard not to be appropriately concerned with some of that sources of uncertainty. But that being said, we think we've got an incredibly resilient portfolio right now, again, underpinned by that level of aftermarket position and a portfolio we think that will continue to perform well despite those uncertainties."
265621,402034332,1057366,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Analysts","And as you think about extending that through next year, what would be the biggest things that would drive you from that 3% level to, say, something higher, even another 50 basis points? What are the few things we should be looking for?",43,"And as you think about extending that through next year, what would be the biggest things that would drive you from that 3% level to, say, something higher, even another 50 basis points? What are the few things we should be looking for?"
265621,402034332,1057366,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Executives","Well, we -- first of all, we still have plenty of work to do left here in 2016 before we get into 2017, and we'll be going through a process here in the fourth quarter around budgets and be in a much better position to give you some specifics when we're t",218,"Well, we -- first of all, we still have plenty of work to do left here in 2016 before we get into 2017, and we'll be going through a process here in the fourth quarter around budgets and be in a much better position to give you some specifics when we're together in December. But if you really stand back and you look at us today, I just mentioned the strength of the portfolio and the repositioning and the level of aftermarket that gives us a strong foundation, but I think we're encouraged about the continued improvement in performance at Pall, with the addition of Cepheid and Phenomenex coming into the Life Sciences and Diagnostics portfolio and continuing to help us from -- both from a growth rate standpoint as well as from an operating margin lift. And then as we've mentioned before, we think there's plenty of opportunity for continued improvement in growth in our Diagnostics business, in our Life Science -- in a number of our Life Science business as well as in Dental. So clearly, we could use a little bit of macroeconomic headwind, but I think there's -- excuse me, tailwind, but I think we have plenty of opportunities to play offense and make our own way in a good deal of the portfolio."
265621,402034332,1057366,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Executives","And Steve, just to add a few things. One, on a year-to-date basis, Pall is up mid-single digits. That's not been in the core number, as Tom alluded to. That's with no benefit from the industrial side of Pall. So even if industrial stabilizes a little bit,",134,"And Steve, just to add a few things. One, on a year-to-date basis, Pall is up mid-single digits. That's not been in the core number, as Tom alluded to. That's with no benefit from the industrial side of Pall. So even if industrial stabilizes a little bit, Pall should be a net contributor, adder to our core growth next year. Our industrial instrumentation business at Hach has been weak. Our experience, that tends to not last very long. I think that would be -- we would expect sort of better numbers out of Hach here in the fourth quarter going into next year. So given those 2 items, even before Cepheid comes in -- again, Cepheid won't impact our reported core number but will help our pro forma core number in 2017 as well."
265621,402034332,1057366,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Operator","And we'll go next to the side of Jeff Sprague from Vertical Research.",14,"And we'll go next to the side of Jeff Sprague from Vertical Research."
265621,402034332,1057366,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Analysts","Could we fill a little bit more on your discussion about the uptick in activity? It feels like that has been building for a couple of quarters now. And I just wonder if you could give us a little bit more color on, geographically, what's going on, and kin",66,"Could we fill a little bit more on your discussion about the uptick in activity? It feels like that has been building for a couple of quarters now. And I just wonder if you could give us a little bit more color on, geographically, what's going on, and kind of what the pipeline of business looks here to the next call it 6 to 12 months?"
265621,402034332,1057366,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Executives","And Jeff, specifically on the Muni world?",7,"And Jeff, specifically on the Muni world?"
265621,402034332,1057366,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Analysts","Yes, Muni world.",3,"Yes, Muni world."
265621,402034332,1057366,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Executives","Sure, sure. I think the brightest spot that we've seen in the municipal world around water, our municipal water business has been at Trojan, where we've seen good performance this year, where we've seen double-digit growth in the last quarter, we've seen",219,"Sure, sure. I think the brightest spot that we've seen in the municipal world around water, our municipal water business has been at Trojan, where we've seen good performance this year, where we've seen double-digit growth in the last quarter, we've seen increasing win rates and a reasonable lift in bidding activity. But I wouldn't say that, that bidding activity necessarily suggests that, that double-digit growth rate is a sustainable one. This is more of a probably a mid-single-digit type of market, but we have been very encouraged by the performance at Trojan. Their competitiveness I think is read through in terms of their win rates and so we're -- in a reasonable market right now, I think we're winning share. So I think that's encouraging from an equipment and an  infrastructure perspective, and we're seeing that globally. I think on -- there's a different side of the story though, which is on the municipal business in North America, the day-to-day consumables business is not showing the kind of strength that I just represented at Trojan. We are seeing low single-digit growth in that market right now, still a very good market, and Hach continues to be gaining share there, but not nearly at the rate that we're seeing some of the infrastructure build out in certain other markets."
265621,402034332,1057366,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Analysts","And then just on Phenomenex, I don't know a lot about the company, obviously. But interesting that it's 100% consumables, and I always think about the strength of your consumable business being tied to the inherent strength near platform and equipment bus",93,"And then just on Phenomenex, I don't know a lot about the company, obviously. But interesting that it's 100% consumables, and I always think about the strength of your consumable business being tied to the inherent strength near platform and equipment businesses. Are there other assets like this that are kind of tuck-ins? are these 100% consumable companies under strategic and competitive threat as folks like yourself build an equipment business? Just any perspective on how to think about just kind of the dynamics of that company and how [indiscernible] landscape is there."
265621,402034332,1057366,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Executives","Sure. Sure. Well, Phenomenex's a great franchise, and it is a virtually 100% consumables business with great gross margins, gross margins in the 70% neighborhood and mid-20s operating margins, but still with opportunities for improvement via DBS. And we'r",288,"Sure. Sure. Well, Phenomenex's a great franchise, and it is a virtually 100% consumables business with great gross margins, gross margins in the 70% neighborhood and mid-20s operating margins, but still with opportunities for improvement via DBS. And we're thrilled to be able to acquire this asset. We've admired that business for a long time. We were able to acquire it at an attractive valuation, and I think for those who've asked us about return thresholds in the past, this is, clearly, a business that we believe we will achieve double-digit return on invested capital in less than 5 years. And so -- and that obviously for us is very typical for a large bolt-on or a midsize adjacency deal and really opens up a number of other possibilities. Jeff, this is a business, to your point about installed base versus consumables, where Phenomenex is -- has become the leader they are largely because they actually are equipment-agnostic, and they focus on specific applications and workflows that address unique customer problems, and therefore, create unique customer value. We've got a partnership with Phenomenex at SCIEX for a number of years, and it's been a very successful one. But as some of you may recall, we are also consumables-agnostic in the sense of chromatography columns at SCIEX. And so what this allows us to do essentially is bring a greater variety, a broader set of solutions to our customers without necessarily having to have those consumables be captive by that installed base. Obviously, that can be very attractive strategically when you have it, but in the particular case of the Life Science world, being able to customize solutions for these unique applications customer challenges is a real competitive advantage."
265621,402034332,1057366,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Analysts","And Tom, that doesn't create a channel conflict for all the other folks that we're agnostic with and simply do we on the other businesses as a result of it?",30,"And Tom, that doesn't create a channel conflict for all the other folks that we're agnostic with and simply do we on the other businesses as a result of it?"
265621,402034332,1057366,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Executives","It really doesn't, Jeff. Again, we have excellent relationships with other partners in the consumables world in Life Sciences. We had sourced from multiple -- actually, I shouldn't even say source, we had customized solutions for customers across a number",83,"It really doesn't, Jeff. Again, we have excellent relationships with other partners in the consumables world in Life Sciences. We had sourced from multiple -- actually, I shouldn't even say source, we had customized solutions for customers across a number of different consumable suppliers for a long period of time, and we expect to maintain those relationships and continued to be focused on what are the specific needs of the customer -- the customers today and how do we serve them best."
265621,402034332,1057366,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Operator","And we'll go next to the side of Tycho Peterson from JPMorgan.",13,"And we'll go next to the side of Tycho Peterson from JPMorgan."
265621,402034332,1057366,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Analysts","Tom, wondering if you can comment on the academic market. NIH data was pretty negative for September, I think budget's down about 13%. And I know you called out some softness for Leica Microsystems. So can you maybe just talk a little bit about what you'r",52,"Tom, wondering if you can comment on the academic market. NIH data was pretty negative for September, I think budget's down about 13%. And I know you called out some softness for Leica Microsystems. So can you maybe just talk a little bit about what you're seeing on the academic market specifically?"
265621,402034332,1057366,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Executives","Sure. We certainly participate in the academic market in our Life Sciences businesses, but it's -- we don't have enormous direct exposure to NIH. If you really look at the direct exposure across a number of our businesses, we're probably in the $150 milli",173,"Sure. We certainly participate in the academic market in our Life Sciences businesses, but it's -- we don't have enormous direct exposure to NIH. If you really look at the direct exposure across a number of our businesses, we're probably in the $150 million or less with direct exposure to NIH funding. Now there's more than that in terms of indirect funding, but I would say that, that funding issue that you mentioned clearly has had an impact on a broad basis when you talk about a variety of things that are indirectly funded or go through a number of different stages before they ultimately get to a supplier like us. We have seen weakness in that market. We have not seen any particular cause for optimism in the academic market, particularly in the U.S. Europe has hang in their in pockets. Japan is weak and certainly continues to be that way. So it's not an area of strength right now and, clearly, the NIH funding issues have not been that particularly helpful."
265621,402034332,1057366,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Executives","And Tycho, I would add that we probably saw a little more of a bifurcation in Life Science in the quarter, meaning that biopharma remained very strong, traditional farm, food and environmental remain solid, consistent with what we saw in the first half, b",62,"And Tycho, I would add that we probably saw a little more of a bifurcation in Life Science in the quarter, meaning that biopharma remained very strong, traditional farm, food and environmental remain solid, consistent with what we saw in the first half, but we did see both academic and sort of industrial markets, particularly at Leica, weaken in the third quarter."
265621,402034332,1057366,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Analysts","That's helpful. And then on Beckman, if I go back to your comments last quarter, I think you talked about growing at a market rate. If we look at the results from some of the peers, they're still going a little bit faster, including in the high-single dig",78,"That's helpful. And then on Beckman, if I go back to your comments last quarter, I think you talked about growing at a market rate. If we look at the results from some of the peers, they're still going a little bit faster, including in the high-single digit range or one of them. Can you maybe just talk a little bit about your view of whether you can get Beckman back to maybe a single-digit growth trajectory?"
265621,402034332,1057366,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Executives","We absolutely believe that we can do that, Tycho. We've made terrific progress thus far. We've seen improvement certainly in our clinical chemistry and in our immunoassay business. Urinalysis business continues to perform very, very well. That business is",117,"We absolutely believe that we can do that, Tycho. We've made terrific progress thus far. We've seen improvement certainly in our clinical chemistry and in our immunoassay business. Urinalysis business continues to perform very, very well. That business is up double digits in the third quarter. And I think with the addition of Cepheid and a broader position in molecular diagnostics, particularly with the potential growth that's available in -- at the point of care and potentially ultimately in the physician office lab, we do believe that both the core legacy business of Beckman will improve its growth trajectory over time with addition of those higher-growth segments that we've acquired will be accretive to that growth profile."
265621,402034332,1057366,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Analysts","Okay. And then just one last quick one, can you quantify the biopharma growth from Pall that you saw in the quarter?",22,"Okay. And then just one last quick one, can you quantify the biopharma growth from Pall that you saw in the quarter?"
265621,402034332,1057366,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Executives","The life Science businesses overall was up mid-single-digits on the quarter and the single-use business continues to grow at a double-digit rate. And so we continue to see good and consistent performance on the biopharma side.",37,"The life Science businesses overall was up mid-single-digits on the quarter and the single-use business continues to grow at a double-digit rate. And so we continue to see good and consistent performance on the biopharma side."
265621,402034332,1057366,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Operator","And we'll go next to the line of Ross Muken from Evercore ISI.",14,"And we'll go next to the line of Ross Muken from Evercore ISI."
265621,402034332,1057366,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Analysts","So on Dental, it's sort of interesting. The macro has been all right, I would guess, in the U.S. but it feels like on North American consumables, we are seeing a little bit of choppiness. Curious that sort of your thoughts for that. And then conversely, i",124,"So on Dental, it's sort of interesting. The macro has been all right, I would guess, in the U.S. but it feels like on North American consumables, we are seeing a little bit of choppiness. Curious that sort of your thoughts for that. And then conversely, it seems like overall the segment is doing quite well, but it's equipment, which, I guess, doesn't sort of correspond with the macro question. And then on the implant side, where it seems like you're doing quite well with the Nobel acquisition. So help us kind of make sense of what you're seeing in the segment and how much is market-related and how much is better execution on your end and some of the segments that are outperforming."
265621,402034332,1057366,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Executives","Sure. We're pleased with how the Dental business, the segment performed in the quarter, at up -- up 3%. And there was clearly some better execution on our side in a number of different areas, and you heard us speak in the past about some of the changes th",368,"Sure. We're pleased with how the Dental business, the segment performed in the quarter, at up -- up 3%. And there was clearly some better execution on our side in a number of different areas, and you heard us speak in the past about some of the changes that we've made a both organizationally and operationally. We have realigned our investments into some key areas from a new product perspective, and we're seeing the benefits there. Relative to the specific portions of the business that you mentioned, we are seeing strength in our equipment business, up mid-single digits and, yes, the consumable business, up more like low single-digits. And really, I think that have to do with a couple of different factors. We are executing well in the equipment side. We have new product initiatives that are making a difference there. And overall, I think we're well positioned from a portfolio perspective. You've heard the narrative from a number of different folks in the market around some softness during the course of July and August. I think, we, as the quarter came to a close in September, we started to certainly see some of that play through, and I think that absolutely varies by geography as well. I mentioned double-digit growth in places like China and India, but the U.S., much slower, and certainly we're seeing some softness in Europe as well as Latin America and the Middle East. So definitely a tale of 2 cities. You asked also about the equipment -- the implant side. Nobel continues to perform very well. They've got a number of new products in the market right now, which are helping in that growth rate. And they're executing well just on a commercial basis day in and day out. And some of that obviously has been a function of the implementation of DBS on the cost side where we've been able to reallocate some of those funds into investments in sales and marketing as well as in R&D. Particularly in the third quarter, we made some significant investments in sales and marketing, and I think will pay off -- that will continue to pay off at Nobel with even improving growth rates."
265621,402034332,1057366,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Analysts","Great. And maybe just moving back to the capital allocation, you guys have obviously been quite busy and obviously since you've taken over, there's been a distinct bias towards growth. I guess what should we learn about your vision of what Danaher will be",119,"Great. And maybe just moving back to the capital allocation, you guys have obviously been quite busy and obviously since you've taken over, there's been a distinct bias towards growth. I guess what should we learn about your vision of what Danaher will be over the next 5 or 10 years based on these assets? You've obviously gotten some real crown jewels within the tools, complex and Phenomenex and Pall and obviously and Cepheid you got a high growth potential. So how should we think about how you're sort of reshaping this portfolio and what the -- I'm not looking for quantitative, but maybe more qualitatively, how do you think about the evolution of these assets at this point?"
265621,402034332,1057366,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Executives","Sure. Well, Ross, we have gotten quite a bit done here in the last couple of years with the separation that took place with Fortive and getting Fortive off to a great start, but then making some very important and strategic acquisitions to shore up really",300,"Sure. Well, Ross, we have gotten quite a bit done here in the last couple of years with the separation that took place with Fortive and getting Fortive off to a great start, but then making some very important and strategic acquisitions to shore up really what were 3 of the most important strategic needs or opportunities that we had: Nobel, on the implant and consumable side; as you mentioned, Pall, to enhance our Life Sciences, specifically biopharmaceutical production position; and then Cepheid, to improve our position relative to molecular diagnostics. We've had a focus strategically on the consumable side of Life Science and Phenomenex to use your term, a crown jewel in the consumable side of Life Science. I think we feel very good about where we are right now. I wouldn't trade our portfolio, the 4 segments that we have today of Diagnostics, Life Science, Dental and Environmental and Applied Solutions for any portfolio in the market. And I think the game plan in the years ahead, as it has been in the past, is continue to deploy our free cash flow strategically with a strong bias towards M&A into these highly attractive segments. And I think the game plan, at least in the near term here, given the current position of the balance sheet and all that we have to do operationally with these acquisitions is to focus on probably small or midsize bolt-ons that are strategically important to our position, that hopefully will, as these have done, will be accretive to our growth rates and improve our growth trajectories and hopefully, that will be the case certainly on the margin side, if not initially, certainly over time. So I think that's the game going forward, and it's been the plan over the last couple of years."
265621,402034332,1057366,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Operator","And we'll go next to the line of Doug Schenkel from Cowen.",13,"And we'll go next to the line of Doug Schenkel from Cowen."
265621,402034332,1057366,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Analysts","My first question is on high-growth market trends. In the third quarter, high-growth market revenue growth was, I think, around, I think, you said mid-single digits. As you described, there continue to be some headwinds relative to what we've seen at leas",82,"My first question is on high-growth market trends. In the third quarter, high-growth market revenue growth was, I think, around, I think, you said mid-single digits. As you described, there continue to be some headwinds relative to what we've seen at least compared to historical trends. Recognizing a lot of this is out of control, I'm just wondering if you'd speak a little bit about the actions and investments you're taking to better position these markets for better growth in 2017."
265621,402034332,1057366,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Executives","Sure. I think we've -- as we look at the high-growth markets today, I'm not sure we would necessarily say that there was much of a change recently in those markets. We've continued to see strength in China across a number of our businesses, if not all bus",266,"Sure. I think we've -- as we look at the high-growth markets today, I'm not sure we would necessarily say that there was much of a change recently in those markets. We've continued to see strength in China across a number of our businesses, if not all business in China is up high single-digits. Real strength in Life Science, in Dental, in Diagnostics, some softness in Videojet. Those are businesses where that softness largely comes from equipment and more industrially oriented end markets. And you've heard me mention a number of times, the strength that we have seen in India, which has been very consistent level strength over the last couple of years. And with those 2 markets being what they are, both the scale of those markets, the inherent growth rates in those markets and the strength of our positions, those are really where a great deal of our investment are going. We're largely doubling down in the markets where we have the greatest opportunities for growth in the near term. We -- what improvement we've seen, and that's been very modest in places like Latin America, Brazil specifically and Russia, are really more about easier comps than materially improved market conditions. And the Middle East continues to be weak. And so while we've sustained our positions there in terms of our feet on the street and our investments in commercializing new products in those markets, those have not been markets where we are significantly accelerating our investments today. Instead, the biggest incremental investments are going into those markets where we are seeing continued strength."
265621,402034332,1057366,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Analysts","Great, that's helpful and insightful. My second question is on Diagnostic core margins, they improved 250 basis points year-over-year in the quarter yet there are some nice improvement in the first half of about 210 basis points year-over-year. So it got",80,"Great, that's helpful and insightful. My second question is on Diagnostic core margins, they improved 250 basis points year-over-year in the quarter yet there are some nice improvement in the first half of about 210 basis points year-over-year. So it got even better in Q3. Some of this may be a function of comps but to the extent it isn't, could you provide a bit more detail on what's really driving, accelerating improvement? And how should we think about sustainability?"
265621,402034332,1057366,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Executives","Well, we're certainly seeing continued improvement in the margin performance at Beckman Diagnostics. Across our Diagnostics portfolio, you have Radiometer, Leica Biosystems, both businesses we've owned for a number of years and have made tremendous progre",100,"Well, we're certainly seeing continued improvement in the margin performance at Beckman Diagnostics. Across our Diagnostics portfolio, you have Radiometer, Leica Biosystems, both businesses we've owned for a number of years and have made tremendous progress in enhancing their operating margins. Beckman, obviously a more recent acquisition, but still 5 years ago, we've seen great lift in those operating margins to this point. But as I mentioned, Beckman represents a large business. Still has quite a bit of headroom for margin improvement. And so we've seen at this point, but we think there's more runway ahead. So really, should you..."
265621,402034332,1057366,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Executives","Doug, it's Dan. We did benefit in Q3 with a slightly easier comp despited having said that, again, it was a very strong quarter of core margin expansion. What we are seeing is continued increase in the gross margin side, continued leverage on the G&A side",87,"Doug, it's Dan. We did benefit in Q3 with a slightly easier comp despited having said that, again, it was a very strong quarter of core margin expansion. What we are seeing is continued increase in the gross margin side, continued leverage on the G&A side while we're also stepping up R&D and sales and marketing. So we are seeing the mix you'd like to see from a margin perspective where we're getting the expansion, where we're taking part of that, putting that into more growth investments."
265621,402034332,1057366,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Analysts","That's great, that's kind of what was I'm getting at. Is a continuation of trend which has been good or things actually getting a little bit even better which it kind of sounds like they are. Last one, there' is clearly been a lot of questions about what'",115,"That's great, that's kind of what was I'm getting at. Is a continuation of trend which has been good or things actually getting a little bit even better which it kind of sounds like they are. Last one, there' is clearly been a lot of questions about what's going on in different geographies and different end markets, and you guys have been great at providing a lot of directional qualitative information to help us out there. I just figured I would ask, in case you guys will be willing to whether or not you can just give us core revenue growth by end market and by developed geography in the quarter across all businesses."
265621,402034332,1057366,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Executives","Well, we don't give quite that level of detail, but we did talk about continued double-digit kind of mid-teens growth in India, high-single digit growth in China. Both the U.S. and Western Europe were up low single-digits, that's been pretty consistent. I",123,"Well, we don't give quite that level of detail, but we did talk about continued double-digit kind of mid-teens growth in India, high-single digit growth in China. Both the U.S. and Western Europe were up low single-digits, that's been pretty consistent. I would add as a footnote, probably seeing some incremental signs of weakness in Western Europe where our overall numbers in Q3 were pretty comparable to what we had in the first half. Tom alluded to the academic comment, seeing a little bit of that industrial weakness in places like Hach, not a big change, but probably on the margin the tone is a little bit cautious is in Western Europe. And Japan, we continue to be down low to mid-single digits."
265621,402034332,1057366,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Operator","We'll go next to the line of Derik De Bruin with Bank of America.",15,"We'll go next to the line of Derik De Bruin with Bank of America."
265621,402034332,1057366,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Analysts","So before I ask another geography question, I just wanted to ask a Diagnostics question. So it's been -- you've closed the Cepheid -- you haven't closed, but you've announced the Cepheid transaction, you had a little bit more time to think about it. Any f",87,"So before I ask another geography question, I just wanted to ask a Diagnostics question. So it's been -- you've closed the Cepheid -- you haven't closed, but you've announced the Cepheid transaction, you had a little bit more time to think about it. Any further additional thoughts on where you think you can ultimately get the gross margin on the Cepheid products, that was sort of a topic when we did the call the last time, I'm wondering if you have any further thoughts on it."
265621,402034332,1057366,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Executives","Derik, I don't know that we've had a lot more to offer. During due diligence, we were able to spend a good deal of time with the team and understand the roadmap that they had laid out for gross margin. You've heard a lot of that from the business in terms",147,"Derik, I don't know that we've had a lot more to offer. During due diligence, we were able to spend a good deal of time with the team and understand the roadmap that they had laid out for gross margin. You've heard a lot of that from the business in terms of the opportunities around improving the cost structure of the cartridge. We think those are -- that's very credible. We think they got a solid roadmap for executing on those improvements. And obviously, once we've closed the transaction, we can engage directly with them, we'll be bringing the tools of the Danaher Business System that we've used successfully in a number of other businesses to improve gross margin. You just heard Dan commented what we've done at Beckman and we'll obviously bring that to bear at Cepheid, and I think you'll see those improvements come through."
265621,402034332,1057366,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Analysts","Great. And just wondered, one more question your question. Are you seeing -- is it budget delays that you're seeing or people just canceling orders? Or people just hesitating on spending? Just a little more color on what's going on in terms of specific tr",60,"Great. And just wondered, one more question your question. Are you seeing -- is it budget delays that you're seeing or people just canceling orders? Or people just hesitating on spending? Just a little more color on what's going on in terms of specific trends, if there's anything sort of you can draw from what you're seeing across the businesses."
265621,402034332,1057366,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Executives","Was that a Europe question?",5,"Was that a Europe question?"
265621,402034332,1057366,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Analysts","The Western Europe question, yes.",5,"The Western Europe question, yes."
265621,402034332,1057366,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Executives","Yes. Much more in terms of delays, event cancellations, we tend to see both at the tendering level as well as at the purchase order level folks hanging back. In certain cases, because budgets haven't been fully approved yet. In other cases, they're just t",70,"Yes. Much more in terms of delays, event cancellations, we tend to see both at the tendering level as well as at the purchase order level folks hanging back. In certain cases, because budgets haven't been fully approved yet. In other cases, they're just trying to get paper work through approvals. And normally, that's a circumstance where, because of some levels of austerity, that folks are just slowing things down."
265621,402034332,1057366,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Operator","And our final question comes from Nigel Coe with Morgan Stanley.",11,"And our final question comes from Nigel Coe with Morgan Stanley."
265621,402034332,1057366,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Analysts","So we covered a lot of ground, so I will keep this relatively quick. But I did want to come back to Dental, there's obviously a lot of noise from competitive regarding the U.S. channel. So I'm just wondering, given the vocabulary we've seen lots recovery",70,"So we covered a lot of ground, so I will keep this relatively quick. But I did want to come back to Dental, there's obviously a lot of noise from competitive regarding the U.S. channel. So I'm just wondering, given the vocabulary we've seen lots recovery we've seen core growth in dental, how confident are you, you can sustain this level of growth in the sort of 3% plus bracket?"
265621,402034332,1057366,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Executives","Well, clearly, there's some cause for concern or caution around that given some of the narrative that we heard from the channel during the course of the quarter. We saw some of that in the month of September come through in terms of the order rates on the",105,"Well, clearly, there's some cause for concern or caution around that given some of the narrative that we heard from the channel during the course of the quarter. We saw some of that in the month of September come through in terms of the order rates on the consumable side. So I think we feel pretty good about continuing to improve our own execution particularly on the equipment side, also at Nobel. But I think on the consumables side, we need to make sure that we are seeing some improvement in the sellout, either from a programmatic perspective or just from an overall macroeconomic perspective."
265621,402034332,1057366,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Analysts","Great. Okay, and then Diagnostics, we don't have a great history on the quarterly performance of Diagnostics. But it does feel like last year, we saw some maybe an unusually large Q over Q stepdown in margins in 3Q followed by a pretty big pickup in 4Q. W",106,"Great. Okay, and then Diagnostics, we don't have a great history on the quarterly performance of Diagnostics. But it does feel like last year, we saw some maybe an unusually large Q over Q stepdown in margins in 3Q followed by a pretty big pickup in 4Q. Would you expect to see a similar 4Q buildup out of 3Q? And then more broadly on 4Q restructuring across the portfolio, in the past, Dan had very heavy restructuring actions in 4Q, I know this year is not going to be anywhere like that, but maybe just comment on how you see 4Q restructuring actions across the portfolio."
265621,402034332,1057366,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Executives","Yes, Nigel, on Diagnostics first. Seasonally, Q3 tends to be a little lighter, so that played out again this year, big improvement versus Q3 a year ago, and we do expect a nice, seasonal pickup in Q4, I would expect margins above where they were a year ag",99,"Yes, Nigel, on Diagnostics first. Seasonally, Q3 tends to be a little lighter, so that played out again this year, big improvement versus Q3 a year ago, and we do expect a nice, seasonal pickup in Q4, I would expect margins above where they were a year ago Q4, which was north of 18%. Regarding restructuring, we continue to take actions throughout the year. We don't really kind of call those out. I would expect our overall restructuring spend to be in the same ballpark as last year, again probably a little bit more evenly distributed through the year."
265621,402034332,1057366,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Operator","And at this time, we would like to thank everybody for their participation on today's conference call. Please feel free to disconnect your line at any time.",27,"And at this time, we would like to thank everybody for their participation on today's conference call. Please feel free to disconnect your line at any time."
265621,402034332,1057455,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Operator","My name is Erica, and I will be your conference facilitator this morning. At this time, I would like to welcome everyone to Danaher Corporation's Third Quarter 2016 Earning Results Conference Call. [Operator Instructions] I will now turn the call over t",56,"My name is Erica, and I will be your conference facilitator this morning. At this time, I would like to welcome everyone to Danaher Corporation's Third Quarter 2016 Earning Results Conference Call. [Operator Instructions] 
I will now turn the call over to Mr. Gugino, Vice President of Investor Relations. Mr. Gugino, you may begin your conference."
265621,402034332,1057455,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Executives","Thanks, Erica. Good morning, everyone, and thanks for joining us on the call. With us today are Tom Joyce, our President and Chief Executive Officer; and Dan Comas, our Executive Vice President and Chief Financial Officer. I'd like to point out that our",366,"Thanks, Erica. Good morning, everyone, and thanks for joining us on the call. With us today are Tom Joyce, our President and Chief Executive Officer; and Dan Comas, our Executive Vice President and Chief Financial Officer. 
I'd like to point out that our earnings release, the slide presentation supplementing today's call, our third quarter Form 10-Q and the reconciliations and other information required by SEC Regulation G relating to any non-GAAP financial measures provided during the call are all available on the Investors section of our website, www.danaher.com, under the heading Financial Information. The audio portion of this call will be archived on the Investors section of our website later today under the heading Events & Presentations and will remain archived until our next quarterly call. A replay of this call will also be available until October 27, 2016. 
During the presentation, we will describe certain of the more significant factors that impacted year-over-year performance. The supplemental materials describe additional factors that impacted year-over-year performance. Unless otherwise noted, all references in these remarks and supplemental materials to company-specific financial metrics relate to the continuing operations of the company in the third quarter of 2016, and all references to period-to-period increases or decreases in financial metrics are year-over-year. 
Today, we'll be discussing 2 recently announced acquisitions of Cepheid and Phenomenex. Both acquisitions are subject to customary closing condition, including receipt of applicable regulatory approval; and, in the case of Cepheid, approval of the Cepheid shareholders. We may also describe certain products and devices which have applications submitted and pending for certain regulatory approvals. 
During the call, we will make forward-looking statements within the meaning of the federal securities laws, including statements regarding events or developments that we believe or anticipate will or may occur in the future. These forward-looking statements are subject to a number of risks and uncertainties, including those set forth in our SEC filings, and actual results might differ materially from any forward-looking statement that we make today. These forward-looking statements speak only as of the date that they are made, and we do not assume any obligation to update any forward-looking statement. 
With that, I'd like to turn the call over to Tom."
265621,402034332,1057455,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Executives","Thank you, Matt. Good morning, everyone. We're pleased with our third quarter results as our team continued to execute well despite the macroeconomic environment. We delivered solid core revenue growth with very strong adjusted earnings per share growth a",2290,"Thank you, Matt. Good morning, everyone. We're pleased with our third quarter results as our team continued to execute well despite the macroeconomic environment. We delivered solid core revenue growth with very strong adjusted earnings per share growth and free cash flow performance. The diversity and strength of our businesses has served us well in this modest growth environment. The recent separation of Fortive was an important step towards optimizing our portfolio, and we continue to strategically position Danaher for strong long-term growth through M&A. 
Since July, we have announced over $4.8 billion of acquisitions that will strengthen our Life Sciences and Diagnostics segments. In September, we announced the acquisition of Cepheid, a global leader in molecular diagnostics, and we recently announced the acquisition of Phenomenex, an outstanding chromatography consumables business that will be highly complementary to our Life Sciences portfolio. Combined with the execution benefits of DBS, we believe these exciting strategic additions will contribute to Danaher's growth trajectory and superior returns. We look forward to welcoming the Cepheid and Phenomenex teams to Danaher. 
With that as a backdrop, let's turn to the details of the third quarter. This morning, we reported adjusted diluted net earnings per share from continuing operations of $0.87, an increase of more than 20% over last year. Sales grew 17.5% to $4.1 billion, with core revenue increasing 3%. Core growth was consistent across the portfolio, as each of our 4 reporting segments achieved at least 3% core revenue growth in the quarter. Currency translation had minimal impact while acquisitions increased revenues by 14.5%. 
Geographically, the high-growth markets led the way, driven by high single-digit growth in China and high-teens growth in India. Developed market core revenues were up low single digits. Modest growth in the U.S. and Western Europe was partially offset by declines in Japan. 
Gross margin for the third quarter was 55.3%, an increase of 140 basis points from last year. This increase in gross profit enabled us to increase our sales and marketing and R&D spend meaningfully in the quarter. Core operating margins were up 155 basis points in the quarter and 90 basis points year-to-date. This strong margin expansion helped to drive double-digit adjusted net earnings growth in the third quarter. During the quarter, we generated approximately $700 million of free cash flow from continuing operations, up 35%, and our free cash flow to net income conversion ratio was over 150%. 
Now let's take a more detailed look at the results across the portfolio. In Life Sciences, core revenues were up 3% and reported revenues grew over 60%, largely due to the Pall acquisition. Core operating margin increased 180 basis points, and the reported operating profit margin increased to 15.4%. 
At Beckman Life Sciences, low single-digit core growth in the quarter was driven by momentum in China while developed markets were essentially flat. The backdrop of government investment in health care in China, coupled with Beckman's strong execution, contributed to double-digit gains in that region.  Beckman's particle counting and characterization business had another good quarter, with double-digit growth driven by global biopharmaceutical demand. 
The team also launched a new product that supports drug discovery and development. The Vi-CELL MetaFLEX is a biochemistry analyzer that resulted from a collaboration with one of our Diagnostic businesses, Radiometer. Beckman incorporated the technology behind Radiometer's blood gas analyzer to create the Vi-CELL MetaFLEX, which analyzes cell cultures, a crucial component in biotherapy production. This cross-pollination between Beckman and Radiometer is a powerful example of the unique opportunities we have at Danaher to bring greater value to customers by collaborating across the portfolio. 
Leica Microsystems core revenue declined in the quarter. Growth was impacted by weakness in the academic and industrial end markets, particularly in North America and Western Europe. This was partially offset by double-digit gains in the high-growth markets as China continued to be a bright spot, particularly for our confocal business. 
SCIEX posted another quarter of mid-single-digit core revenue growth, led by global strength in pharmaceuticals and food as well as environmental testing. Geographically, we saw declines in Japan and in Europe, where academic weakness impacted results. In the high-growth markets, China and India each maintained strong double-digit growth. Our service offering continues to be a differentiator at SCIEX as the team drove further improvements in contract renewals and attachment rates in the quarter. 
As I mentioned at the start of the call, we recently announced our acquisition of Phenomenex, a leading player in chromatography consumables that supports a variety of analytical testing applications in the health, research and environmental segments. Phenomenex is 100% consumables, a high-margin business in an attractive mid-single-digit growth industry that is adjacent to where SCIEX participates. We expect to achieve a double-digit return on our investment in less than 5 years and believe that Phenomenex will help us to continue creating long-term value as part of our Life Sciences portfolio. 
Pall delivered another quarter of good growth and execution. Continued strength in biopharmaceutical end markets and demand for single-use technologies underpinned strong growth at Pall Life Sciences. Pall's market-leading solutions are at the forefront of the biopharma evolution, and 9 of the 12 new biologic drugs cleared by the FDA last year specified Pall products in their processes. This is a tremendous testament to the quality and reliability that Pall provides to its customers every day. 
Pall Industrial revenue was down in the quarter with solid gains in aerospace and microelectronics offset by declines in energy and machinery as heavy industrial end markets remained challenging. August marked the 1-year anniversary of our acquisition of Pall Corporation, and the team's exceptional implementation of DBS has been a critical driver of what we've been able to accomplish thus far. Since the beginning of the year, Pall has achieved more than 150 basis points of gross margin expansion and improved operating margins by over 350 basis points. 
At the same time, we've been able to put some of that benefit back into sales and marketing and R&D. This reinvestment, combined with the team's thoughtful use of DBS growth tools, like accelerated product development and [indiscernible], has resulted in a number of key new products launching ahead of schedule this year. By delivering these impactful new solutions to the market sooner, we can deliver greater value to our customers and further enhance Pall's growth trajectory. 
Moving now to Diagnostics. Both reported and core revenues increased 3%. The team's solid execution generated 250 basis points of core operating margin expansion, and reported operating margins increased to 16%. Sustained strength in China and India was complemented by modest growth in the developed markets. 
Core revenue at Beckman Coulter Diagnostics was up low single digits, with growth in emerging markets partially offset by softer demand in North America and Europe. Recent installed base growth in China contributed to strong immunoassay performance in the quarter, with the business achieving double-digit recurring revenue in the region. 
One of our 5 core values at Danaher is: Customers talk, we listen. And Beckman Diagnostics recognizes the importance of helping customers drive performance across multiple labs with different needs and different test volumes. One of the ways we differentiate our offering is to partner with customers and help them integrate Danaher Business System tools and processes into their labs and workflows. The result can be tremendously impactful: better speed to results, operational efficiency and ultimately improved clinician workflows. 
The effectiveness of one such collaboration was recently highlighted by a customer that operates one of the largest regional lab networks in the Midwestern United States. Within 6 months, Beckman helped them implement over 180 analyzers and 4 automation lines at 30 different hospitals and lab locations without any patient disruption. This customer was recently awarded a prestigious ADVANCE Laboratory of the Year award for 2016 and has mentioned their partnership with Beckman and the adoption of DBS tools as a key factor in their labs' transformational success. 
Radiometer achieved mid-single-digit core revenue growth, led by continued double-digit growth in both China and India and solid performance in the developed markets. We saw robust demand for consumables across our portfolio of acute care diagnostic instruments. 
At Leica Biosystems, core revenues grew mid-single digits in the quarter, led by high single-digit growth in North America. An expanding installed base and strong consumable sales contributed to double-digit growth in our advanced staining business. 
Back in September, we announced our acquisition of Cepheid, a leading molecular diagnostics innovator in the fastest-growing segment of diagnostics. Cepheid has the largest global installed base of molecular diagnostics instruments, combined with the broadest test menu available. We expect this highly complementary addition to our Diagnostics portfolio to accelerate our growth strategy and further differentiate Danaher's diagnostics offering. We also foresee tremendous opportunities with the application of DBS at Cepheid, which we believe will help drive better top and bottom line performance. 
Turning now to our Dental segment. Reported revenues increased 3.5%, and reported operating margin increased slightly to 15%, with 20 basis points of core margin expansion. Core revenues were up 3%, driven by our equipment, implant and orthodontic product lines, while we saw softer demand for consumables in the quarter. Positive gains in North America were offset by weakness in Western Europe. Strength in high-growth markets was supported by another quarter of double-digit growth in China across all of our major dental product lines. 
Since 2010, we've grown our Dental revenues in China from $15 million to over $150 million today, and we're now positioned as one of the leading players in the region. We've evolved our business model as well in China to position ourselves as more of a localized player by expanding our R&D teams, increasing local commercial coverage and establishing manufacturing capabilities in the region. This approach, combined with our comprehensive product suite, enables us to provide a full service China-centric offering that enhances our customers' experiences and positions us well for continued growth in this market. 
Let's turn to Nobel Biocare. Nobel Biocare's core revenue grew at a low single-digit rate, with demand for implant systems and regeneratives driven by recently launched new products that have quickly gained traction with customers. Similar to what we saw across our other Dental businesses in the quarter, sales in Western Europe softened at Nobel while China continued to do well. The benefit of the team's operational and cost improvements using DBS continues to help fuel Nobel's new product and innovation engine. 
Turning to our Environmental & Applied Solutions segment. Core revenues grew 3.5% with reported revenues up 4.5%. Core operating margin expanded 60 basis points, and reported operating margin was down slightly at 24.3%. 
In Product Identification, core revenues increased at a mid-single-digit rate, and we saw strong demand for marking and coding equipment and related consumables across most major geographies. Sales growth of our packaging and color solutions offerings improved sequentially and was led primarily by increased demand in the U.S. and Latin America. 
Videojet showed solid growth performance, delivering mid-single-digit core revenue growth in the quarter. Strength in developed markets and Latin America was modestly offset by declines in China, primarily due to industrial end market weakness. Videojet continued to grow the number of connected printers in the market, expanding our remote solutions offering for customers and driving high single-digit service revenue growth. 
Core revenue grew low single digits at Esko, led by increased demand at MediaBeacon, which we acquired in 2015. As a reminder, MediaBeacon provide digital asset management software that brand owners and packaging managers use to ensure accuracy and compliance. With the help of DBS tools like funnel management and transformative marketing, MediaBeacon has generated greater market awareness and demand for our integrated solutions, which support customers across their full brand and packaging workflows. At X-Rite, core revenue grew low single digits, with strong performance in North America and China partially offset by the rest of Asia. 
Lastly, turning to Water Quality. Core revenue growth for the platform increased at a low single-digit rate. Hach's core revenue declined slightly in the quarter as industrial end market weakness contributed to softer demand in North America and China. We saw similarly lackluster activity in Eastern Europe as constrained government funding and political instability affected municipal projects. We anticipate better core growth at Hach in the fourth quarter. 
ChemTreat core revenue grew at a mid-single-digit rate as the team delivered solid commercial execution and expanded their customer base in the U.S. Strength in North America and the food and beverage end markets was partially offset by lower demand in Latin America, particularly in the more commodity-oriented markets. 
At Trojan, core revenue increased double digits, driven by consistent municipal demand across developed and emerging markets. Our increased municipal systems' installed base contributed to strong replacement growth, and bidding activity was up low single digits globally. A few key municipal project wins materialized in Asia as ultraviolet water treatment solutions have gained interest in the region. 
So to wrap up, we're pleased with our performance in the current macroeconomic environment. We believe that the steps we've taken to reshape our portfolio positions us well for stronger growth and value creation. The diversity and strength of our businesses, combined with our team's focused execution using the Danaher Business System, is what sustains our competitive advantage. We believe that this combination will continue to serve both our customers and our shareholders as well. 
We are initiating fourth quarter guidance for adjusted diluted net EPS from continuing operations of $1.01 to $1.05, which assumes fourth quarter core revenue growth comparable to the third quarter of 2016. For the full year 2016, we're raising our adjusted diluted net EPS from continuing operations guidance to $3.57 to $3.61, which, at the midpoint, would represent an increase of approximately 20% from 2015."
265621,402034332,1057455,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Executives","Thanks, Tom. That concludes our formal comments. Erica, we're now ready for questions.",13,"Thanks, Tom. That concludes our formal comments. Erica, we're now ready for questions."
265621,402034332,1057455,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Operator","[Operator Instructions] We'll go first to the line of Scott Davis with Barclays.",13,"[Operator Instructions] We'll go first to the line of Scott Davis with Barclays."
265621,402034332,1057455,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Analysts","I could see the pattern that since you hired Gugino, you started to put up these big numbers.",18,"I could see the pattern that since you hired Gugino, you started to put up these big numbers."
265621,402034332,1057455,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Executives","He's got a big team supporting him, Scott. We love him, but big team, big team, broad-based.",18,"He's got a big team supporting him, Scott. We love him, but big team, big team, broad-based."
265621,402034332,1057455,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Analysts","Yes. Well, anyways, I'm intrigued by -- it's your 1-year anniversary of Pall, and I'm intrigued on how does that -- have your results matched up with the deal model? And more kind of specifically, what time -- or what type of return on capital are you sit",62,"Yes. Well, anyways, I'm intrigued by -- it's your 1-year anniversary of Pall, and I'm intrigued on how does that -- have your results matched up with the deal model? And more kind of specifically, what time -- or what type of return on capital are you sitting on kind of as you look point in time right now in that deal?"
265621,402034332,1057455,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Executives","Sure. Scott, we're very, very pleased with the performance of the team, both the Danaher team that has joined the team at Pall as well as the legacy Pall associates. The combination of those 2 teams has gotten the business off to a tremendous start in the",293,"Sure. Scott, we're very, very pleased with the performance of the team, both the Danaher team that has joined the team at Pall as well as the legacy Pall associates. The combination of those 2 teams has gotten the business off to a tremendous start in the first year. DBS has played a huge role in the progress that we've made there. As you might recall, that team had sort of began the journey before we arrived on the scene, but the combination of the Danaher team that's gone in, in the Pall team have really accelerated the pace of progress. There have been over 350 kaizens that have been completed both on operational side as well as on the commercial side. We've seen the tremendous lift in core operating margins in that business. And as I mentioned in my remarks, we're now seeing the investment in some of the sales and marketing and the new product areas start to make a real difference in terms of getting new products not only launched but commercialized on time and effectively. So we're off to a good start. You know we took the improvements from a cost standpoint up from $60 million in the first year to $100 million. So we're a little bit ahead of schedule in that respect. And I think, obviously, that lifts the returns here in the near term. Relative to where we'll end up on a 4-, 5-year basis and beyond, I think, again, we're off to a very good start. I think we have a lot of opportunity to lift those returns, but it's still early days. And there's a lot of hard work to be done in the months and quarters and years ahead, but a great start."
265621,402034332,1057455,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Analysts","And when -- and just thinking about Pall. When Pall Industrial comes back -- and I'd love to hear your view on when you think you move into positive territory there, but when Pall Industrial comes back, would you expect outsized operating leverage on the",64,"And when -- and just thinking about Pall. When Pall Industrial comes back -- and I'd love to hear your view on when you think you move into positive territory there, but when Pall Industrial comes back, would you expect outsized operating leverage on the cost-out? Or how would you think about it if you -- I guess, if you were in our shoes?"
265621,402034332,1057455,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Executives","Yes. Well, first of all, I think we've seen while not a -- the beginnings of growth on the industrial side, I think we haven't seen -- we have not seen another leg down. In other words, we've seen some stability. The industrial side was still down mid-sin",202,"Yes. Well, first of all, I think we've seen while not a -- the beginnings of growth on the industrial side, I think we haven't seen -- we have not seen another leg down. In other words, we've seen some stability. The industrial side was still down mid-single digits in the quarter while the Life Science side was up mid-single digits. And so as those businesses begin to improve both from the standpoint of our execution, and DBS is playing a role there from a new product execution standpoint and a commercialization perspective, when those improvements kick in and we get some lift from the macro, I think the big benefit you're going to see is in terms of the core growth of that business and the readthrough on an operating margin basis from that core growth. I don't know that it necessarily changes trajectory from a cost-out perspective. We're working on the cost structures, both on the Life Science side and on the industrial side as well as across the horizontal components of G&A. So I think the real lift comes when we start to see that core growth turn positive and we start to see the readthrough from that growth."
265621,402034332,1057455,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Operator","And we'll take our next question from Steve Winoker from Bernstein.",12,"And we'll take our next question from Steve Winoker from Bernstein."
265621,402034332,1057455,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Analysts","And to echo Scott, I wouldn't -- Matt and his team is important, but don't forget Matt in all these, okay? So listen, I want to just start with the actual fourth quarter core growth that you just talked about at about the same as third quarter. Just looki",111,"And to echo Scott, I wouldn't -- Matt and his team is important, but don't forget Matt in all these, okay? So listen, I want to just start with the actual fourth quarter core growth that you just talked about at about the same as third quarter. Just looking for where you might see signs of acceleration, how you think about that trending into next year. I know, if I look at 2015, the third quarter was up year-on-year 3%. The fourth quarter was up only 1.5%. So just wondering, is this conservative in terms of how you're seeing -- give us some sense of the fourth quarter, if you could."
265621,402034332,1057455,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Executives","Yes. I wouldn't describe it as conservative, Steve. I do think, though, there's a number of considerations that go into how we look at the fourth quarter. I mean it starts with how pleased we are with the performance at this point in the third quarter, wi",245,"Yes. I wouldn't describe it as conservative, Steve. I do think, though, there's a number of considerations that go into how we look at the fourth quarter. I mean it starts with how pleased we are with the performance at this point in the third quarter, with all 4 segments driving at least 3% core growth. And I think now with a portfolio where greater than 60% of the revenues are in the aftermarket and where there's some stability in these markets but not necessarily anything positive to write home about macroeconomically, I think there is cause for some degree of caution in the outlook. You're reading the same macroeconomic news that everybody else is and, certainly, that we are. There's a number of sources of uncertainty in the market today, whether that's the election uncertainty in the U.S.; the Brexit uncertainty throughout Europe; the questions around turns in some of the high-growth markets or previously known as high-growth markets, as I sometimes say, around places like Latin America, the Middle East, Russia, and particularly those markets with a good deal of commodity exposure and certainly those with a high degree of industrial exposure. So it's hard not to be appropriately concerned with some of that sources of uncertainty. But that being said, we think we've got an incredibly resilient portfolio right now, again, underpinned by that level of aftermarket position and a portfolio we think that will continue to perform well despite those uncertainties."
265621,402034332,1057455,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Analysts","And as you think about extending that through next year, what would be the biggest things that would drive you from that 3% level to, say, something higher, even another 50 basis points? What are the few things we should be looking for?",43,"And as you think about extending that through next year, what would be the biggest things that would drive you from that 3% level to, say, something higher, even another 50 basis points? What are the few things we should be looking for?"
265621,402034332,1057455,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Executives","Well, we -- first of all, we still have plenty of work to do left here in 2016 before we get into 2017, and we'll be going through a process here in the fourth quarter around budgets and be in a much better position to give you some specifics when we're t",218,"Well, we -- first of all, we still have plenty of work to do left here in 2016 before we get into 2017, and we'll be going through a process here in the fourth quarter around budgets and be in a much better position to give you some specifics when we're together in December. But if you really stand back and you look at us today, I just mentioned the strength of the portfolio and the repositioning and the level of aftermarket that gives us a strong foundation, but I think we're encouraged about the continued improvement in performance at Pall, with the addition of Cepheid and Phenomenex coming into the Life Sciences and Diagnostics portfolio and continuing to help us from -- both from a growth rate standpoint as well as from an operating margin lift. And then as we've mentioned before, we think there's plenty of opportunity for continued improvement in growth in our Diagnostics business, in our Life Science -- in a number of our Life Science business as well as in Dental. So clearly, we could use a little bit of macroeconomic headwind, but I think there's -- excuse me, tailwind, but I think we have plenty of opportunities to play offense and make our own way in a good deal of the portfolio."
265621,402034332,1057455,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Executives","And Steve, just to add a few things. One, on a year-to-date basis, Pall is up mid-single digits. That's not been in the core number, as Tom alluded to. That's with no benefit from the industrial side of Pall. So even if industrial stabilizes a little bit,",134,"And Steve, just to add a few things. One, on a year-to-date basis, Pall is up mid-single digits. That's not been in the core number, as Tom alluded to. That's with no benefit from the industrial side of Pall. So even if industrial stabilizes a little bit, Pall should be a net contributor, adder to our core growth next year. Our industrial instrumentation business at Hach has been weak. Our experience, that tends to not last very long. I think that would be -- we would expect sort of better numbers out of Hach here in the fourth quarter going into next year. So given those 2 items, even before Cepheid comes in -- again, Cepheid won't impact our reported core number but will help our pro forma core number in 2017 as well."
265621,402034332,1057455,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Operator","And we'll go next to the side of Jeffrey Sprague from Vertical Research.",14,"And we'll go next to the side of Jeffrey Sprague from Vertical Research."
265621,402034332,1057455,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Analysts","Could we field a little bit more on your discussion about the uptick in muni activity? It feels like that has been building for a couple of quarters now. And I just wonder if you could give us a little bit more color on, geographically, what's going on an",67,"Could we field a little bit more on your discussion about the uptick in muni activity? It feels like that has been building for a couple of quarters now. And I just wonder if you could give us a little bit more color on, geographically, what's going on and kind of what the pipeline of business looks here for the next, call it, 6 to 12 months."
265621,402034332,1057455,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Executives","And Jeff, specifically on -- in the muni world?",9,"And Jeff, specifically on -- in the muni world?"
265621,402034332,1057455,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Analysts","Yes, muni world.",3,"Yes, muni world."
265621,402034332,1057455,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Executives","Sure, sure. Well, I think the brightest spot that we've seen in the municipal world around water -- our municipal water business has been at Trojan, where we've seen good performance this year, where we've seen double-digit growth in the last quarter. We'",224,"Sure, sure. Well, I think the brightest spot that we've seen in the municipal world around water -- our municipal water business has been at Trojan, where we've seen good performance this year, where we've seen double-digit growth in the last quarter. We've seen increasing win rates and a reasonable lift in bidding activity. But I wouldn't say that, that bidding activity necessarily suggests that, that double-digit growth rate is a sustainable one. This is more of a -- probably a mid-single-digit type of market. But we have been very encouraged by the performance at Trojan. Their competitiveness, I think, is -- has read through in terms of their win rates. And so we're -- in a reasonable market right now, I think we're winning share. So I think that's encouraging from an equipment and an infrastructure perspective, and we're seeing that globally. I think on the -- there's a different side of the story though, which is on the municipal business in North America, the day-to-day consumables business is not showing the kind of strength that I just represented at Trojan. We're seeing low single-digit growth in that market right now. It's still a very good market, and Hach continues to be gaining share there, but not nearly at the rate that we're seeing some of the infrastructure build out in certain markets."
265621,402034332,1057455,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Analysts","Great. And then just on Phenomenex, I don't know a lot about the company, obviously. But interesting that it's 100% consumables, and I always think about the strength of your consumable business being tied to the inherent strength in your platform and equ",96,"Great. And then just on Phenomenex, I don't know a lot about the company, obviously. But interesting that it's 100% consumables, and I always think about the strength of your consumable business being tied to the inherent strength in your platform and equipment businesses. Are there other assets like this that are kind of tuck-ins? Are these 100% consumable companies under strategic and competitive threat as folks like yourself build an equipment business? Just any perspective on how to think about just kind of the dynamics of that company and how [indiscernible] the landscape is there."
265621,402034332,1057455,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Executives","Sure, sure. Well, it's a -- Phenomenex is a great franchise, and it is a virtually 100% consumables business with great gross margins, gross margins in the 70% neighborhood and mid-20s operating margins, but still with opportunities for improvement via DB",294,"Sure, sure. Well, it's a -- Phenomenex is a great franchise, and it is a virtually 100% consumables business with great gross margins, gross margins in the 70% neighborhood and mid-20s operating margins, but still with opportunities for improvement via DBS. And we're thrilled to be able to acquire this asset. We've admired that business for a long time. We were able to acquire it at an attractive valuation. And I think for those who've asked us about return thresholds in the past, this is clearly a business that we believe we will achieve double-digit return on invested capital in less than 5 years. And so -- and that, obviously, for us is very typical for a large bolt-on or a midsize adjacency deal and really opens up a number of other possibilities. Jeff, this is a business, to your point about installed base versus consumables, where Phenomenex is -- has become the leader they are largely because they actually are equipment-agnostic and they focus on specific applications and workflows that address unique customer problems and, therefore, create unique customer value. We've had a partnership with Phenomenex at SCIEX for a number of years, and it's been a very successful one. But as some of you may recall, we're also consumables-agnostic in the sense of chromatography columns at SCIEX. And so what this allows us to do essentially is bring a greater variety, a broader set of solutions to our customers without necessarily having to have those consumables be captive by that installed base. Obviously, that can be very attractive strategically when you have it, but in the particular case of the Life Science world, being able to customize solutions to -- for these unique applications and customer challenges is a real competitive advantage."
265621,402034332,1057455,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Analysts","And Tom, that doesn't create a channel conflict for all the other folks they were agnostic with and there's some bleed away on their other business as a result of it?",31,"And Tom, that doesn't create a channel conflict for all the other folks they were agnostic with and there's some bleed away on their other business as a result of it?"
265621,402034332,1057455,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Executives","It really doesn't, Jeff. Again, we have excellent relationships with other partners in the consumables world in Life Sciences. We had sourced from multiple -- I shouldn't even say source. We had customized solutions for customers across a number of differ",82,"It really doesn't, Jeff. Again, we have excellent relationships with other partners in the consumables world in Life Sciences. We had sourced from multiple -- I shouldn't even say source. We had customized solutions for customers across a number of different consumables suppliers for a long period of time, and we expect to maintain those relationships and continue to be focused on what are the specific needs of the customer -- the customers today and how do we serve them best."
265621,402034332,1057455,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Operator","And we'll go next to the side of Tycho Peterson from JPMorgan.",13,"And we'll go next to the side of Tycho Peterson from JPMorgan."
265621,402034332,1057455,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Analysts","Tom, wondering if you can comment on the academic market. The NIH data was pretty negative for September. I think budget's down about 13%. And I know you called out some softness for Leica Microsystems. So can you maybe just talk a little bit about what y",53,"Tom, wondering if you can comment on the academic market. The NIH data was pretty negative for September. I think budget's down about 13%. And I know you called out some softness for Leica Microsystems. So can you maybe just talk a little bit about what you're seeing on the academic market specifically?"
265621,402034332,1057455,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Executives","Sure, Tycho. We certainly participate in the academic market in our Life Science businesses, but it's -- we don't have enormous direct exposure to NIH. If you really looked at the direct exposure across a number of our businesses, we're probably in the $1",174,"Sure, Tycho. We certainly participate in the academic market in our Life Science businesses, but it's -- we don't have enormous direct exposure to NIH. If you really looked at the direct exposure across a number of our businesses, we're probably in the $150 million or less with direct exposure to NIH funding. Now there's more than that in terms of indirect funding, but I would say that, that funding issue that you mentioned clearly has had an impact on a broad basis when you talk about a variety of things that are indirectly funded or go through a number of different stages before they ultimately get to a supplier like us. We have seen weakness in that market. We have not seen any particular cause for optimism in the academic market, particularly in the U.S. Europe has hang in there in pockets. Japan is weak and certainly continues to be that way. So it's not an area of strength right now, and clearly, the NIH funding issues have not been net particularly helpful."
265621,402034332,1057455,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Executives","And Tycho, I would add that we probably saw a little more of a bifurcation in Life Science in the quarter, meaning that biopharma remained very strong; traditional farm, food and environmental remained solid, consistent with what we saw in the first half.",62,"And Tycho, I would add that we probably saw a little more of a bifurcation in Life Science in the quarter, meaning that biopharma remained very strong; traditional farm, food and environmental remained solid, consistent with what we saw in the first half. But we did see both academic and sort of industrial markets, particularly at Leica, weaken in the third quarter."
265621,402034332,1057455,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Analysts","Okay, that's helpful. And then on Beckman, if I kind of go back to your comments last quarter, I think you'd talked about growing at a market rate. If we look at the results from some of the peers, they're still growing a little bit faster, including in t",80,"Okay, that's helpful. And then on Beckman, if I kind of go back to your comments last quarter, I think you'd talked about growing at a market rate. If we look at the results from some of the peers, they're still growing a little bit faster, including in the high single-digit range for one of them. Can you maybe just talk a little bit about your view of whether you can get Beckman back to maybe a mid-single-digit growth trajectory?"
265621,402034332,1057455,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Executives","We absolutely believe that we can do that, Tycho. We've made terrific progress thus far. We've seen improvement certainly in our clinical chemistry and in our immunoassay business. Our urinalysis business continues to perform very, very well. That busines",119,"We absolutely believe that we can do that, Tycho. We've made terrific progress thus far. We've seen improvement certainly in our clinical chemistry and in our immunoassay business. Our urinalysis business continues to perform very, very well. That business is up double digits in the third quarter. And I think with the addition of Cepheid and a broader position in molecular diagnostics, particularly with the potential growth that's available in -- at the point of care and potentially, ultimately, in the physician office lab, we do believe that both the core legacy business of Beckman will improve its growth trajectory over time, but the addition of those higher-growth segments that we've acquired will be accretive to that growth profile."
265621,402034332,1057455,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Analysts","Okay. And then just one last quick one. Can you quantify the biopharma growth from Pall that you saw in the quarter?",22,"Okay. And then just one last quick one. Can you quantify the biopharma growth from Pall that you saw in the quarter?"
265621,402034332,1057455,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Executives","Well, the Life Science business overall was up mid-single digits on the quarter, and the single-use business continues to grow at a double-digit rate. And so that -- we continue to see good and consistent performance on the biopharma side.",40,"Well, the Life Science business overall was up mid-single digits on the quarter, and the single-use business continues to grow at a double-digit rate. And so that -- we continue to see good and consistent performance on the biopharma side."
265621,402034332,1057455,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Operator","And we'll go next to the line of Ross Muken from Evercore ISI.",14,"And we'll go next to the line of Ross Muken from Evercore ISI."
265621,402034332,1057455,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Analysts","So on Dental, it's sort of interesting. I mean the macro has been all right, I would guess, in the U.S., but it feels like on North American consumables, we're seeing a little bit of choppiness. Curious at sort of your thoughts for that. And then, convers",126,"So on Dental, it's sort of interesting. I mean the macro has been all right, I would guess, in the U.S., but it feels like on North American consumables, we're seeing a little bit of choppiness. Curious at sort of your thoughts for that. And then, conversely, it seems like overall, the segment is doing quite well, but it's equipment, which, I guess, doesn't sort of correspond with the macro question; and then on the implant side, where it seems like you're doing quite well with the Nobel acquisition. So help us kind of make sense of what you're seeing in the segment. And how much is market-related? And then how much is better execution on your end in some of the segments that are outperforming?"
265621,402034332,1057455,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Executives","Sure. Thanks, Ross. We're pleased with how the Dental business, the segment performed in the quarter at up 3%. And there was clearly some better execution on our side in a number of different areas, and you've heard us speak in the past about some of the",369,"Sure. Thanks, Ross. We're pleased with how the Dental business, the segment performed in the quarter at up 3%. And there was clearly some better execution on our side in a number of different areas, and you've heard us speak in the past about some of the changes that we've made both organizationally and operationally. We have realigned our investments into some key areas from a new product perspective, and we're seeing the benefits there. Relative to the specific portions of the business that you mentioned, we are seeing strength in our equipment business, up mid-single digits; and, yes, the consumable business, up more like low single digits. And really, I think that had to do with a couple of different factors. We are executing well in the equipment side. We have new product initiatives that are making a difference there. And overall, I think we're well positioned from a portfolio perspective. You've heard the narrative from a number of different folks in the market around some softness during the course of July and August. I think we -- as the quarter came to a close in September, we started to certainly see some of that play through, and I think that absolutely varies by geography as well. I mentioned double-digit growth in places like China and India; but the U.S., much slower. And certainly, we're seeing some softness in Europe as well as Latin America and the Middle East. So definitely, a tale of 2 cities. You asked also about the equipment -- the implant side. Nobel continues to perform very well. They've got a number of new products in the market right now, which are helping in that growth rate, and they're executing well just on a commercial basis day in and day out. And some of that obviously has been a function of the implementation of DBS on the cost side, where we've been able to reallocate some of those funds into investments in sales and marketing as well as in R&D. Particularly in the third quarter, we made some significant investments in sales and marketing, and I think will pay off -- that will continue to pay off at Nobel with even improving growth rates."
265621,402034332,1057455,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Analysts","Great. And maybe just moving back to the capital allocation, you guys have obviously been quite busy. And obviously, since you've taken over, there's been a distinct bias towards growth. I guess, what should we learn about your vision of what Danaher will",117,"Great. And maybe just moving back to the capital allocation, you guys have obviously been quite busy. And obviously, since you've taken over, there's been a distinct bias towards growth. I guess, what should we learn about your vision of what Danaher will be over the next 5 or 10 years based on these assets? You've obviously gotten some real crown jewels within the tools, complex and Phenomenex and Pall. And obviously, in Cepheid, you get a high-growth potential. So how should we think about how you're sort of reshaping this portfolio? And what the -- I'm not looking for quantitative, but maybe more qualitatively how you think about the evolution of these assets at this point."
265621,402034332,1057455,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Executives","Sure. Well, Ross, we have gotten quite a bit done here in the last couple of years with the separation that took place with Fortive and getting Fortive off to a great start, but then making some very important and strategic acquisitions to shore up really",302,"Sure. Well, Ross, we have gotten quite a bit done here in the last couple of years with the separation that took place with Fortive and getting Fortive off to a great start, but then making some very important and strategic acquisitions to shore up really what were 3 of the most important strategic needs or opportunities that we had: Nobel on the implant and consumable side; as you mentioned, Pall, to enhance our Life Sciences, specifically biopharmaceutical production position; and then Cepheid, to improve our position relative to molecular diagnostics. We've had a focus strategically on the consumable side of Life Science and Phenomenex, to use your term, a crown jewel in the consumable side of Life Science. So I think we feel very good about where we are right now. I wouldn't trade our portfolio, the 4 segments that we have today of Diagnostics, Life Science, Dental and Environmental & Applied Solutions, for any portfolio in the market. And I think the game plan in the years ahead, as it has been in the past, is continue to deploy our free cash flow strategically, with a strong bias towards M&A, into these highly attractive segments. And I think the game plan, at least in the near term here, given the current position of the balance sheet and all that we have to do operationally with these acquisitions, is to focus on probably small or midsize bolt-ons that are strategically important to our position, that hopefully will -- as these have done, will be accretive to our growth rates and improve our growth trajectories. And hopefully, that would be the case certainly on the margin side, if not initially, certainly over time. So I think that's the game going forward, and it's been the plan over the last couple of years."
265621,402034332,1057455,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Operator","And we'll go next to the line of Doug Schenkel from Cowen.",13,"And we'll go next to the line of Doug Schenkel from Cowen."
265621,402034332,1057455,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Analysts","My first question is on high-growth market trends. In the third quarter, high-growth market revenue growth was I think around -- I think you said mid-single digits. As you describe it, there continue to be some headwinds relative to what we've seen at lea",84,"My first question is on high-growth market trends. In the third quarter, high-growth market revenue growth was I think around -- I think you said mid-single digits. As you describe it, there continue to be some headwinds relative to what we've seen at least compared to historical trends. Recognizing a lot of this is out of control, I'm just wondering if you'd speak a little bit about the actions and investments you're taking to better position these markets for better growth in 2017."
265621,402034332,1057455,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Executives","Sure. Thanks for that question. I think we've -- as we look at the high-growth markets today, I'm not sure we would necessarily say that there was much of a change recently in those markets. We've continued to see strength in China across a number of our",271,"Sure. Thanks for that question. I think we've -- as we look at the high-growth markets today, I'm not sure we would necessarily say that there was much of a change recently in those markets. We've continued to see strength in China across a number of our businesses, if not all. Business in China is up high single digits, real strength in Life Science, in Dental, in Diagnostics; some softness in Hach and Videojet. Those are businesses where that softness largely comes from equipment and more industrially-oriented end markets. And you've heard me mention a number of times the strength that we've seen in India, which has been very consistent level of strength over the last couple of years. And with those 2 markets being what they are, both the scale of those markets, the inherent growth rates in those markets and the strength of our positions, those are really where a great deal of our investment are going. We're largely doubling down in the markets where we have the greatest opportunities for growth in the near term. We -- what improvement we've seen, and it's been very modest, in places like Latin America, Brazil specifically and Russia are really more about easier comps than materially improved market conditions. And the Middle East continues to be weak. And so while we've sustained our positions there in terms of our feet on the street and our investments in commercializing new products in those markets, those have not been markets where we are significantly accelerating our investments today. Instead, the biggest incremental investments are going into those markets where we're seeing continued strength."
265621,402034332,1057455,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Analysts","Great. That's helpful and insightful. My second question is on Diagnostic core margins. They improved 250 basis points year-over-year in the quarter. Yes, there were some nice improvement in the first half of about 210 basis points year-over-year, so it g",81,"Great. That's helpful and insightful. My second question is on Diagnostic core margins. They improved 250 basis points year-over-year in the quarter. Yes, there were some nice improvement in the first half of about 210 basis points year-over-year, so it got even better in Q3. Some of this may be a function of comps, but to the extent it isn't, could you provide a bit more detail on what's really driving -- accelerating improvement and how should we think about sustainability?"
265621,402034332,1057455,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Executives","Well, we're certainly seeing continued improvement in the margin performance at Beckman Diagnostics. Across our Diagnostics portfolio, you have Radiometer and Leica Biosystems. Both businesses we've owned for a number of years and have made tremendous pro",99,"Well, we're certainly seeing continued improvement in the margin performance at Beckman Diagnostics. Across our Diagnostics portfolio, you have Radiometer and Leica Biosystems. Both businesses we've owned for a number of years and have made tremendous progress in enhancing their operating margins. Beckman, obviously a more recent acquisition, but still, 5 years ago, we've seen great lift in those operating margins to this point. But as I mentioned, Beckman represents a large business. It still has quite a bit of headroom for margin improvement. And so we've seen it at this point, but we think there's more runway ahead."
265621,402034332,1057455,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Analysts","So really, it should -- sorry.",6,"So really, it should -- sorry."
265621,402034332,1057455,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Executives","Yes. I mean -- yes. Doug, it's Dan. It's -- we did benefit in Q3 with a slightly easier comp. Despite -- having said that, again, it was a very strong quarter of core margin expansion. What we are seeing is a continued increase in the gross margin side, c",96,"Yes. I mean -- yes. Doug, it's Dan. It's -- we did benefit in Q3 with a slightly easier comp. Despite -- having said that, again, it was a very strong quarter of core margin expansion. What we are seeing is a continued increase in the gross margin side, continued leverage on the G&A side while we're also stepping up R&D and sales and marketing. So we're seeing the mix you'd like to see from a margin perspective, where we're getting the expansion but we're taking part of that and putting that into more growth investments."
265621,402034332,1057455,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Analysts","No, that's great. That's kind of what I was getting at, is, is it a continuation of trend which has been good or are things actually getting a little bit even better, which it kind of sounds like they are. Last one. There's clearly been a lot of questions",117,"No, that's great. That's kind of what I was getting at, is, is it a continuation of trend which has been good or are things actually getting a little bit even better, which it kind of sounds like they are. Last one. There's clearly been a lot of questions about what's going on in different geographies and different end markets, and you guys have been great at providing a lot of directional qualitative information to help us out there. I just figured I would ask, in case you guys would be willing to, whether or not you could just give us core revenue growth by end market and by developed geography in the quarter across all businesses."
265621,402034332,1057455,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Executives","Well, we don't give quite that level of detail, but we did talk about continued double-digit kind of mid-teens growth in India, high single-digit growth in China. Both the U.S. and Western Europe were up low single digits. That's been pretty consistent. I",123,"Well, we don't give quite that level of detail, but we did talk about continued double-digit kind of mid-teens growth in India, high single-digit growth in China. Both the U.S. and Western Europe were up low single digits. That's been pretty consistent. I would add as a footnote probably seeing some incremental signs of weakness in Western Europe, where our overall numbers in Q3 were pretty comparable to what we had in the first half. Tom alluded to the academic comment, seeing a little bit of that industrial weakness in places like Hach. Not a big change, but probably on the margin, the tone is a little bit cautious in Western Europe. And Japan, we continue to be down low to mid-single digits."
265621,402034332,1057455,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Operator","We'll go next to the line of Derik De Bruin from Bank of America.",15,"We'll go next to the line of Derik De Bruin from Bank of America."
265621,402034332,1057455,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Analysts","So before I ask another geography question, I just wanted to ask a Diagnostics question. So it's been -- you've closed the Cepheid -- or you haven't closed it, but you've announced the Cepheid transaction. You've had a little bit more time to think about",90,"So before I ask another geography question, I just wanted to ask a Diagnostics question. So it's been -- you've closed the Cepheid -- or you haven't closed it, but you've announced the Cepheid transaction. You've had a little bit more time to think about it. Any further additional thoughts on where you think you can ultimately get the gross margin on the Cepheid products? That was sort of a topic when we did the call the last time. I just wondered if you have any further thoughts on it."
265621,402034332,1057455,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Executives","Derik, thanks. I don't know that we have a lot more to offer. During due diligence, we were able to spend a good deal of time with the team and understand the road map that they had laid out for gross margin. You've heard a lot of that from the business i",150,"Derik, thanks. I don't know that we have a lot more to offer. During due diligence, we were able to spend a good deal of time with the team and understand the road map that they had laid out for gross margin. You've heard a lot of that from the business in terms of the opportunities around improving the cost structure of the cartridge. We think those are very credible. We think they've got a solid road map for executing on those improvements. And obviously, once we've closed the transaction and we can engage directly with them, we'll be bringing the tools of the Danaher Business System that we've used successfully in a number of other businesses to improve gross margin. You just heard Dan comment about what we've done at Beckman. And we'll obviously bring that to bear at Cepheid, and I think you'll see those improvements come through."
265621,402034332,1057455,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Analysts","Great. And just wondered -- one more question, Europe question. Are you seeing -- is it budget delays that you're seeing or people just canceling orders or people just hesitating on spending? Just a little bit more color on what's going on in terms of spe",63,"Great. And just wondered -- one more question, Europe question. Are you seeing -- is it budget delays that you're seeing or people just canceling orders or people just hesitating on spending? Just a little bit more color on what's going on in terms of specific just trends, if there's anything you can sort of draw from what you're seeing across the businesses."
265621,402034332,1057455,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Executives","Derik, was that a Europe question, I'm sorry?",8,"Derik, was that a Europe question, I'm sorry?"
265621,402034332,1057455,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Analysts","It's a Western Europe question, yes.",7,"It's a Western Europe question, yes."
265621,402034332,1057455,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Executives","Yes. Much more, in terms of delays, event cancellations, we tend to see, both at the tendering level as well as at the purchase order level, folks hanging back. In certain cases, it's because budgets haven't been fully approved yet. In other cases, they'r",70,"Yes. Much more, in terms of delays, event cancellations, we tend to see, both at the tendering level as well as at the purchase order level, folks hanging back. In certain cases, it's because budgets haven't been fully approved yet. In other cases, they're just trying to get paper work through approvals. And normally, that's a circumstance where, because of some levels of austerity, folks are just slowing things down."
265621,402034332,1057455,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Operator","And our final question comes from Nigel Coe with Morgan Stanley.",11,"And our final question comes from Nigel Coe with Morgan Stanley."
265621,402034332,1057455,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Analysts","So we covered a lot of ground so I want to keep this relatively quick. But on -- I did want to come back to Dental. There's obviously a lot of noise from your competitors regarding the U.S. channel. So I'm just wondering, given the recovery we've seen --",77,"So we covered a lot of ground so I want to keep this relatively quick. But on -- I did want to come back to Dental. There's obviously a lot of noise from your competitors regarding the U.S. channel. So I'm just wondering, given the recovery we've seen -- the large recovery we've seen in core growth rates in Dental, how confident are you, you can sustain this level of growth in the sort of 3%-plus bracket?"
265621,402034332,1057455,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Executives","Well, clearly, there's some cause for concern or caution around that, given some of the narrative that we heard from the channel during the course of the quarter. We saw some of that in the month of September come through in terms of the order rates on th",104,"Well, clearly, there's some cause for concern or caution around that, given some of the narrative that we heard from the channel during the course of the quarter. We saw some of that in the month of September come through in terms of the order rates on the consumable side. So I think we feel pretty good about continuing to improve our own execution, particularly on the equipment side, also at Nobel. But I think on the consumable side, we'll need to make sure that we're seeing some improvement in the sellout, either from a programmatic perspective or just from an overall macroeconomic perspective."
265621,402034332,1057455,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Analysts","Great, okay. And then Diagnostics, we don't have a great history on the quarterly performance of Diagnostics. But it does feel like, last year, we saw maybe an unusually large Q-over-Q step down in margins in 3Q, followed by a pretty big pickup in 4Q. Wou",106,"Great, okay. And then Diagnostics, we don't have a great history on the quarterly performance of Diagnostics. But it does feel like, last year, we saw maybe an unusually large Q-over-Q step down in margins in 3Q, followed by a pretty big pickup in 4Q. Would you expect to see a similar 4Q buildup as the 3Q? And then more broadly on 4Q restructuring across the portfolio. In the past, Danaher was -- had very heavy restructuring actions in 4Q. I know this year is not going to be anywhere like that, but maybe just comment on how you see 4Q restructuring actions across the portfolio."
265621,402034332,1057455,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Executives","Yes. Nigel, on Diagnostics first. Seasonally, Q3 tends to be a little lighter, so that played out again. This year there was a big improvement versus Q3 a year ago, and we do expect a nice seasonal pickup in Q4. I would expect margins above where they wer",104,"Yes. Nigel, on Diagnostics first. Seasonally, Q3 tends to be a little lighter, so that played out again. This year there was a big improvement versus Q3 a year ago, and we do expect a nice seasonal pickup in Q4. I would expect margins above where they were a year ago Q4, which were -- was north of 18%. Regarding restructuring, we continue to take actions throughout the year. We don't really kind of call those out. I would expect our overall restructuring spend to be in the same ballpark as last year, again probably a little bit more evenly distributed through the year."
265621,402034332,1057455,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Operator","And at this time, we would like to thank everybody for their participation on today's conference call. Please feel free to disconnect your line at any time.",27,"And at this time, we would like to thank everybody for their participation on today's conference call. Please feel free to disconnect your line at any time."
265621,402034332,1057710,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Operator","My name is Erica, and I will be your conference facilitator this morning. At this time, I would like to welcome everyone to Danaher Corporation's Third Quarter 2016 Earning Results Conference Call. [Operator Instructions] I will now turn the call over t",56,"My name is Erica, and I will be your conference facilitator this morning. At this time, I would like to welcome everyone to Danaher Corporation's Third Quarter 2016 Earning Results Conference Call. [Operator Instructions] 
I will now turn the call over to Mr. Gugino, Vice President of Investor Relations. Mr. Gugino, you may begin your conference."
265621,402034332,1057710,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Executives","Thanks, Erica. Good morning, everyone, and thanks for joining us on the call. With us today are Tom Joyce, our President and Chief Executive Officer; and Dan Comas, our Executive Vice President and Chief Financial Officer. I'd like to point out that our",366,"Thanks, Erica. Good morning, everyone, and thanks for joining us on the call. With us today are Tom Joyce, our President and Chief Executive Officer; and Dan Comas, our Executive Vice President and Chief Financial Officer. 
I'd like to point out that our earnings release, the slide presentation supplementing today's call, our third quarter Form 10-Q and the reconciliations and other information required by SEC Regulation G relating to any non-GAAP financial measures provided during the call are all available on the Investors section of our website, www.danaher.com, under the heading Financial Information. The audio portion of this call will be archived on the Investors section of our website later today under the heading Events & Presentations and will remain archived until our next quarterly call. A replay of this call will also be available until October 27, 2016. 
During the presentation, we will describe certain of the more significant factors that impacted year-over-year performance. The supplemental materials describe additional factors that impacted year-over-year performance. Unless otherwise noted, all references in these remarks and supplemental materials to company-specific financial metrics relate to the continuing operations of the company in the third quarter of 2016, and all references to period-to-period increases or decreases in financial metrics are year-over-year. 
Today, we'll be discussing 2 recently announced acquisitions of Cepheid and Phenomenex. Both acquisitions are subject to customary closing conditions, including receipt of applicable regulatory approvals; and, in the case of Cepheid, approval of the Cepheid shareholders. We may also describe certain products and devices which have applications submitted and pending for certain regulatory approvals. 
During the call, we will make forward-looking statements within the meaning of the federal securities laws, including statements regarding events or developments that we believe or anticipate will or may occur in the future. These forward-looking statements are subject to a number of risks and uncertainties, including those set forth in our SEC filings, and actual results might differ materially from any forward-looking statement that we make today. These forward-looking statements speak only as of the date that they are made, and we do not assume any obligation to update any forward-looking statement. 
With that, I'd like to turn the call over to Tom."
265621,402034332,1057710,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Executives","Thank you, Matt. Good morning, everyone. We're pleased with our third quarter results as our team continued to execute well despite the macroeconomic environment. We delivered solid core revenue growth with very strong adjusted earnings per share growth a",2290,"Thank you, Matt. Good morning, everyone. We're pleased with our third quarter results as our team continued to execute well despite the macroeconomic environment. We delivered solid core revenue growth with very strong adjusted earnings per share growth and free cash flow performance. The diversity and strength of our businesses has served us well in this modest growth environment. The recent separation of Fortive was an important step towards optimizing our portfolio, and we continue to strategically position Danaher for strong long-term growth through M&A. 
Since July, we have announced over $4.8 billion of acquisitions that will strengthen our Life Sciences and Diagnostics segments. In September, we announced the acquisition of Cepheid, a global leader in molecular diagnostics, and we recently announced the acquisition of Phenomenex, an outstanding chromatography consumables business that will be highly complementary to our Life Sciences portfolio. Combined with the execution benefits of DBS, we believe these exciting strategic additions will contribute to Danaher's growth trajectory and superior returns. We look forward to welcoming the Cepheid and Phenomenex teams to Danaher. 
With that as a backdrop, let's turn to the details of the third quarter. This morning, we reported adjusted diluted net earnings per share from continuing operations of $0.87, an increase of more than 20% over last year. Sales grew 17.5% to $4.1 billion, with core revenue increasing 3%. Core growth was consistent across the portfolio, as each of our 4 reporting segments achieved at least 3% core revenue growth in the quarter. Currency translation had minimal impact while acquisitions increased revenues by 14.5%. 
Geographically, the high-growth markets led the way, driven by high single-digit growth in China and high-teens growth in India. Developed market core revenues were up low single digits. Modest growth in the U.S. and Western Europe was partially offset by declines in Japan. 
Gross margin for the third quarter was 55.3%, an increase of 140 basis points from last year. This increase in gross profit enabled us to increase our sales and marketing and R&D spend meaningfully in the quarter. Core operating margins were up 155 basis points in the quarter and 90 basis points year-to-date. This strong margin expansion helped to drive double-digit adjusted net earnings growth in the third quarter. During the quarter, we generated approximately $700 million of free cash flow from continuing operations, up 35%, and our free cash flow to net income conversion ratio was over 150%. 
Now let's take a more detailed look at the results across the portfolio. In Life Sciences, core revenues were up 3% and reported revenues grew over 60%, largely due to the Pall acquisition. Core operating margin increased 180 basis points, and the reported operating profit margin increased to 15.4%. 
At Beckman Life Sciences, low single-digit core growth in the quarter was driven by momentum in China while developed markets were essentially flat. The backdrop of government investment in health care in China, coupled with Beckman's strong execution, contributed to double-digit gains in that region.  Beckman's particle counting and characterization business had another good quarter, with double-digit growth driven by global biopharmaceutical demand. 
The team also launched a new product that supports drug discovery and development. The Vi-CELL MetaFLEX is a biochemistry analyzer that resulted from a collaboration with one of our Diagnostic businesses, Radiometer. Beckman incorporated the technology behind Radiometer's blood gas analyzer to create the Vi-CELL MetaFLEX, which analyzes cell cultures, a crucial component in biotherapy production. This cross-pollination between Beckman and Radiometer is a powerful example of the unique opportunities we have at Danaher to bring greater value to customers by collaborating across the portfolio. 
Leica Microsystems core revenue declined in the quarter. Growth was impacted by weakness in the academic and industrial end markets, particularly in North America and Western Europe. This was partially offset by double-digit gains in the high-growth markets as China continued to be a bright spot, particularly for our confocal business. 
SCIEX posted another quarter of mid-single-digit core revenue growth, led by global strength in pharmaceuticals and food as well as environmental testing. Geographically, we saw declines in Japan and in Europe, where academic weakness impacted results. In the high-growth markets, China and India each maintained strong double-digit growth. Our service offering continues to be a differentiator at SCIEX as the team drove further improvements in contract renewals and attachment rates in the quarter. 
As I mentioned at the start of the call, we recently announced our acquisition of Phenomenex, a leading player in chromatography consumables that supports a variety of analytical testing applications in the health, research and environmental segments. Phenomenex is 100% consumables, a high-margin business in an attractive mid-single-digit growth industry that is adjacent to where SCIEX participates. We expect to achieve a double-digit return on our investment in less than 5 years and believe that Phenomenex will help us to continue creating long-term value as part of our Life Sciences portfolio. 
Pall delivered another quarter of good growth and execution. Continued strength in biopharmaceutical end markets and demand for single-use technologies underpinned strong growth at Pall Life Sciences. Pall's market-leading solutions are at the forefront of the biopharma evolution, and 9 of the 12 new biologic drugs cleared by the FDA last year specified Pall products in their processes. This is a tremendous testament to the quality and reliability that Pall provides to its customers every day. 
Pall Industrial revenue was down in the quarter with solid gains in aerospace and microelectronics offset by declines in energy and machinery as heavy industrial end markets remained challenging. August marked the 1-year anniversary of our acquisition of Pall Corporation, and the team's exceptional implementation of DBS has been a critical driver of what we've been able to accomplish thus far. Since the beginning of the year, Pall has achieved more than 150 basis points of gross margin expansion and improved operating margins by over 350 basis points. 
At the same time, we've been able to put some of that benefit back into sales and marketing and R&D. This reinvestment, combined with the team's thoughtful use of DBS growth tools, like accelerated product development and Obeya Rooms, has resulted in a number of key new products launching ahead of schedule this year. By delivering these impactful new solutions to the market sooner, we can deliver greater value to our customers and further enhance Pall's growth trajectory. 
Moving now to Diagnostics. Both reported and core revenues increased 3%. The team's solid execution generated 250 basis points of core operating margin expansion, and reported operating margins increased to 16%. Sustained strength in China and India was complemented by modest growth in the developed markets. 
Core revenue at Beckman Coulter Diagnostics was up low single digits, with growth in emerging markets partially offset by softer demand in North America and Europe. Recent installed base growth in China contributed to strong immunoassay performance in the quarter, with the business achieving double-digit recurring revenue in the region. 
One of our 5 core values at Danaher is: Customers talk, we listen. And Beckman Diagnostics recognizes the importance of helping customers drive performance across multiple labs with different needs and different test volumes. One of the ways we differentiate our offering is to partner with customers and help them integrate Danaher Business System tools and processes into their labs and workflows. The result can be tremendously impactful: better speed to results, operational efficiency and ultimately improved clinician workflows. 
The effectiveness of one such collaboration was recently highlighted by a customer that operates one of the largest regional lab networks in the Midwestern United States. Within 6 months, Beckman helped them implement over 180 analyzers and 4 automation lines at 30 different hospitals and lab locations without any patient disruption. This customer was recently awarded the prestigious ADVANCE Laboratory of the Year award for 2016 and has mentioned their partnership with Beckman and the adoption of DBS tools as a key factor in their labs' transformational success. 
Radiometer achieved mid-single-digit core revenue growth, led by continued double-digit growth in both China and India and solid performance in the developed markets. We saw robust demand for consumables across our portfolio of acute care diagnostic instruments. 
At Leica Biosystems, core revenues grew mid-single digits in the quarter, led by high single-digit growth in North America. An expanding installed base and strong consumable sales contributed to double-digit growth in our advanced staining business. 
Back in September, we announced our acquisition of Cepheid, a leading molecular diagnostics innovator in the fastest-growing segment of diagnostics. Cepheid has the largest global installed base of molecular diagnostics instruments, combined with the broadest test menu available. We expect this highly complementary addition to our Diagnostics portfolio to accelerate our growth strategy and further differentiate Danaher's diagnostics offering. We also foresee tremendous opportunities with the application of DBS at Cepheid, which we believe will help drive better top and bottom line performance. 
Turning now to our Dental segment. Reported revenues increased 3.5%, and reported operating margin increased slightly to 15%, with 20 basis points of core margin expansion. Core revenues were up 3%, driven by our equipment, implant and orthodontic product lines, while we saw softer demand for consumables in the quarter. Positive gains in North America were offset by weakness in Western Europe. Strength in high-growth markets was supported by another quarter of double-digit growth in China across all of our major dental product lines. 
Since 2010, we've grown our Dental revenues in China from $15 million to over $150 million today, and we're now positioned as one of the leading players in the region. We've evolved our business model as well in China to position ourselves as more of a localized player by expanding our R&D teams, increasing local commercial coverage and establishing manufacturing capabilities in the region. This approach, combined with our comprehensive product suite, enables us to provide a full service China-centric offering that enhances our customers' experiences and positions us well for continued growth in this market. 
Let's turn to Nobel Biocare. Nobel Biocare's core revenue grew at a low single-digit rate, with demand for implant systems and regeneratives driven by recently launched new products that have quickly gained traction with customers. Similar to what we saw across our other Dental businesses in the quarter, sales in Western Europe softened at Nobel while China continued to do well. The benefit of the team's operational and cost improvements using DBS continues to help fuel Nobel's new product and innovation engine. 
Turning to our Environmental & Applied Solutions segment. Core revenues grew 3.5% with reported revenues up 4.5%. Core operating margin expanded 60 basis points, and reported operating margin was down slightly at 24.3%. 
In Product Identification, core revenues increased at a mid-single-digit rate, and we saw strong demand for marking and coding equipment and related consumables across most major geographies. Sales growth of our packaging and color solutions offerings improved sequentially and was led primarily by increased demand in the U.S. and Latin America. 
Videojet showed solid growth performance, delivering mid-single-digit core revenue growth in the quarter. Strength in developed markets and Latin America was modestly offset by declines in China, primarily due to industrial end market weakness. Videojet continued to grow the number of connected printers in the market, expanding our remote solutions offering for customers and driving high single-digit service revenue growth. 
Core revenue grew low single digits at Esko, led by increased demand at MediaBeacon, which we acquired in 2015. As a reminder, MediaBeacon provides digital asset management software that brand owners and packaging managers use to ensure accuracy and compliance. With the help of DBS tools like funnel management and transformative marketing, MediaBeacon has generated greater market awareness and demand for our integrated solutions, which support customers across their full brand and packaging workflows. At X-Rite, core revenue grew low single digits, with strong performance in North America and China partially offset by the rest of Asia. 
Lastly, turning to Water Quality. Core revenue growth for the platform increased at a low single-digit rate. Hach's core revenue declined slightly in the quarter as industrial end market weakness contributed to softer demand in North America and China. We saw similarly lackluster activity in Eastern Europe as constrained government funding and political instability affected municipal projects. We anticipate better core growth at Hach in the fourth quarter. 
ChemTreat core revenue grew at a mid-single-digit rate as the team delivered solid commercial execution and expanded their customer base in the U.S. Strength in North America and the food and beverage end markets was partially offset by lower demand in Latin America, particularly in the more commodity-oriented markets. 
At Trojan, core revenue increased double digits, driven by consistent municipal demand across developed and emerging markets. Our increased municipal systems installed base contributed to strong replacement growth, and bidding activity was up low single digits globally. A few key municipal project wins materialized in Asia as ultraviolet water treatment solutions have gained interest in the region. 
So to wrap up, we're pleased with our performance in the current macroeconomic environment. We believe that the steps we've taken to reshape our portfolio positions us well for stronger growth and value creation. The diversity and strength of our businesses, combined with our team's focused execution using the Danaher Business System, is what sustains our competitive advantage. We believe that this combination will continue to serve both our customers and our shareholders well. 
We are initiating fourth quarter guidance for adjusted diluted net EPS from continuing operations of $1.01 to $1.05, which assumes fourth quarter core revenue growth comparable to the third quarter of 2016. For the full year 2016, we're raising our adjusted diluted net EPS from continuing operations guidance to $3.57 to $3.61, which, at the midpoint, would represent an increase of approximately 20% from 2015."
265621,402034332,1057710,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Executives","Thanks, Tom. That concludes our formal comments. Erica, we're now ready for questions.",13,"Thanks, Tom. That concludes our formal comments. Erica, we're now ready for questions."
265621,402034332,1057710,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Operator","[Operator Instructions] We'll go first to the line of Scott Davis with Barclays.",13,"[Operator Instructions] We'll go first to the line of Scott Davis with Barclays."
265621,402034332,1057710,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Analysts","I could see the pattern that since you hired Gugino, you started to put up these big numbers.",18,"I could see the pattern that since you hired Gugino, you started to put up these big numbers."
265621,402034332,1057710,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Executives","He's got a big team supporting him, Scott. We love him, but big team, big team, broad-based.",18,"He's got a big team supporting him, Scott. We love him, but big team, big team, broad-based."
265621,402034332,1057710,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Analysts","Yes. Well, anyways, I'm intrigued by -- it's your 1-year anniversary of Pall, and I'm intrigued on how does that -- have your results matched up with the deal model? And more kind of specifically, what time -- or what type of return on capital are you sit",62,"Yes. Well, anyways, I'm intrigued by -- it's your 1-year anniversary of Pall, and I'm intrigued on how does that -- have your results matched up with the deal model? And more kind of specifically, what time -- or what type of return on capital are you sitting on kind of as you look point in time right now in that deal?"
265621,402034332,1057710,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Executives","Sure. Scott, we're very, very pleased with the performance of the team, both the Danaher team that has joined the team at Pall as well as the legacy Pall associates. The combination of those 2 teams has gotten the business off to a tremendous start in the",293,"Sure. Scott, we're very, very pleased with the performance of the team, both the Danaher team that has joined the team at Pall as well as the legacy Pall associates. The combination of those 2 teams has gotten the business off to a tremendous start in the first year. DBS has played a huge role in the progress that we've made there. As you might recall, that team had sort of begun the journey before we arrived on the scene, but the combination of the Danaher team that's gone in and the Pall team have really accelerated the pace of progress. There have been over 350 kaizens that have been completed both on operational side as well as on the commercial side. We've seen the tremendous lift in core operating margins in that business. And as I mentioned in my remarks, we're now seeing the investment in some of the sales and marketing and the new product areas start to make a real difference in terms of getting new products not only launched but commercialized on time and effectively. So we're off to a good start. You know we took the improvements from a cost standpoint up from $60 million in the first year to $100 million. So we're a little bit ahead of schedule in that respect. And I think, obviously, that lifts the returns here in the near term. Relative to where we'll end up on a 4-, 5-year basis and beyond, I think, again, we're off to a very good start. I think we have a lot of opportunity to lift those returns, but it's still early days. And there's a lot of hard work to be done in the months and quarters and years ahead, but a great start."
265621,402034332,1057710,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Analysts","And when -- and just thinking about Pall -- when Pall Industrial comes back -- and I'd love to hear your view on when you think you move into positive territory there, but when Pall Industrial comes back, would you expect outsized operating leverage on th",65,"And when -- and just thinking about Pall -- when Pall Industrial comes back -- and I'd love to hear your view on when you think you move into positive territory there, but when Pall Industrial comes back, would you expect outsized operating leverage on the cost-out? Or how would you think about it if you -- I guess, if you were in our shoes?"
265621,402034332,1057710,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Executives","Yes. Well, first of all, I think we've seen while not a -- the beginnings of growth on the industrial side, I think we haven't seen -- we have not seen another leg down. In other words, we've seen some stability. The industrial side was still down mid-sin",202,"Yes. Well, first of all, I think we've seen while not a -- the beginnings of growth on the industrial side, I think we haven't seen -- we have not seen another leg down. In other words, we've seen some stability. The industrial side was still down mid-single digits in the quarter while the Life Science side was up mid-single digits. And so as those businesses begin to improve both from the standpoint of our execution, and DBS is playing a role there from a new product execution standpoint and a commercialization perspective, when those improvements kick in and we get some lift from the macro, I think the big benefit you're going to see is in terms of the core growth of that business and the readthrough on an operating margin basis from that core growth. I don't know that it necessarily changes trajectory from a cost-out perspective. We're working on the cost structures, both on the Life Science side and on the industrial side as well as across the horizontal components of G&A. So I think the real lift comes when we start to see that core growth turn positive and we start to see the readthrough from that growth."
265621,402034332,1057710,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Operator","And we'll take our next question from Steve Winoker from Bernstein.",12,"And we'll take our next question from Steve Winoker from Bernstein."
265621,402034332,1057710,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Analysts","And to echo Scott, I wouldn't -- Matt -- his team is important, but don't forget Matt in all this, okay? So listen, I want to just start with the actual fourth quarter core growth that you just talked about at about the same as third quarter. Just looking",111,"And to echo Scott, I wouldn't -- Matt -- his team is important, but don't forget Matt in all this, okay? So listen, I want to just start with the actual fourth quarter core growth that you just talked about at about the same as third quarter. Just looking for where you might see signs of acceleration, how you think about that trending into next year. I know, if I look at 2015, the third quarter was up year-on-year 3%. The fourth quarter was up only 1.5%. So just wondering, is this conservative in terms of how you're seeing -- give us some sense of the fourth quarter, if you could."
265621,402034332,1057710,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Executives","Yes. I wouldn't describe it as conservative, Steve. I do think, though, there's a number of considerations that go into how we look at the fourth quarter. I mean it starts with how pleased we are with the performance to this point in the third quarter, wi",247,"Yes. I wouldn't describe it as conservative, Steve. I do think, though, there's a number of considerations that go into how we look at the fourth quarter. I mean it starts with how pleased we are with the performance to this point in the third quarter, with all 4 segments driving at least 3% core growth. And I think now with a portfolio where greater than 60% of the revenues are in the aftermarket and where there's some stability in these markets but not necessarily anything positive to write home about macroeconomically, I think there is cause for some degree of caution in the outlook. You're reading the same macroeconomic news that everybody else is and, certainly, that we are. There's a number of sources of uncertainty in the market today, whether that's the election uncertainty in the U.S.; the Brexit uncertainty throughout Europe; the questions around turns in some of the high-growth markets or previously known as high-growth markets, as I sometimes say, around places like Latin America, the Middle East, Russia, and particularly those markets with a good deal of commodity exposure and certainly those with a high degree of industrial exposure. So it's hard not to be appropriately concerned with some of that -- those sources of uncertainty. But that being said, we think we've got an incredibly resilient portfolio right now, again, underpinned by that level of aftermarket position and a portfolio we think that will continue to perform well despite those uncertainties."
265621,402034332,1057710,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Analysts","And as you think about extending that through next year, what would be the biggest things that would drive you from that 3% level to, say, something higher, even another 50 basis points? What are the few things we should be looking for?",43,"And as you think about extending that through next year, what would be the biggest things that would drive you from that 3% level to, say, something higher, even another 50 basis points? What are the few things we should be looking for?"
265621,402034332,1057710,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Executives","Well, we -- first of all, we still have plenty of work to do left here in 2016 before we get into 2017, and we'll be going through a process here in the fourth quarter around budgets and be in a much better position to give you some specifics when we're t",218,"Well, we -- first of all, we still have plenty of work to do left here in 2016 before we get into 2017, and we'll be going through a process here in the fourth quarter around budgets and be in a much better position to give you some specifics when we're together in December. But if you really stand back and you look at us today, I just mentioned the strength of the portfolio and the repositioning and the level of aftermarket that gives us a strong foundation, but I think we're encouraged about the continued improvement in performance at Pall, with the addition of Cepheid and Phenomenex coming into the Life Sciences and Diagnostics portfolio and continuing to help us from -- both from a growth rate standpoint as well as from an operating margin lift. And then as we've mentioned before, we think there's plenty of opportunity for continued improvement in growth in our Diagnostics business, in our Life Science -- in a number of our Life Science businesses as well as in Dental. So clearly, we could use a little bit of macroeconomic headwind, but I think there's -- excuse me, tailwind, but I think we have plenty of opportunities to play offense and make our own way in a good deal of the portfolio."
265621,402034332,1057710,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Executives","And Steve, just to add a few things. One, on a year-to-date basis, Pall is up mid-single digits. That's not been in the core number, as Tom alluded to. That's with no benefit from the industrial side of Pall. So even if industrial stabilizes a little bit,",134,"And Steve, just to add a few things. One, on a year-to-date basis, Pall is up mid-single digits. That's not been in the core number, as Tom alluded to. That's with no benefit from the industrial side of Pall. So even if industrial stabilizes a little bit, Pall should be a net contributor, adder to our core growth next year. Our industrial instrumentation business at Hach has been weak. Our experience, that tends to not last very long. I think that would be -- we would expect sort of better numbers out of Hach here in the fourth quarter going into next year. So even those 2 items, even before Cepheid comes in -- again, Cepheid won't impact our reported core number but will help our pro forma core number in 2017 as well."
265621,402034332,1057710,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Operator","And we'll go next to the side of Jeffrey Sprague from Vertical Research.",14,"And we'll go next to the side of Jeffrey Sprague from Vertical Research."
265621,402034332,1057710,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Analysts","Could we field a little bit more on your discussion about the uptick in muni activity? It feels like that has been building for a couple of quarters now. And I just wonder if you could give us a little bit more color on, geographically, what's going on an",67,"Could we field a little bit more on your discussion about the uptick in muni activity? It feels like that has been building for a couple of quarters now. And I just wonder if you could give us a little bit more color on, geographically, what's going on and kind of what the pipeline of business looks here for the next, call it, 6 to 12 months."
265621,402034332,1057710,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Executives","And Jeff, specifically on -- in the muni world?",9,"And Jeff, specifically on -- in the muni world?"
265621,402034332,1057710,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Analysts","Yes, muni world.",3,"Yes, muni world."
265621,402034332,1057710,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Executives","Sure, sure. Well, I think the brightest spot that we've seen in the municipal world around water -- our municipal water business has been at Trojan, where we've seen good performance this year, where we've seen double-digit growth in the last quarter. We'",224,"Sure, sure. Well, I think the brightest spot that we've seen in the municipal world around water -- our municipal water business has been at Trojan, where we've seen good performance this year, where we've seen double-digit growth in the last quarter. We've seen increasing win rates and a reasonable lift in bidding activity. But I wouldn't say that, that bidding activity necessarily suggests that, that double-digit growth rate is a sustainable one. This is more of a -- probably a mid-single-digit type of market. But we have been very encouraged by the performance at Trojan. Their competitiveness, I think, is -- has read through in terms of their win rates. And so we're -- in a reasonable market right now, I think we're winning share. So I think that's encouraging from an equipment and an infrastructure perspective, and we're seeing that globally. I think on the -- there's a different side of the story though, which is on the municipal business in North America, the day-to-day consumables business is not showing the kind of strength that I just represented at Trojan. We're seeing low single-digit growth in that market right now. It's still a very good market, and Hach continues to be gaining share there, but not nearly at the rate that we're seeing some of the infrastructure build out in certain markets."
265621,402034332,1057710,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Analysts","Great. And then just on Phenomenex, I don't know a lot about the company, obviously. But interesting that it's 100% consumables, and I always think about the strength of your consumable business being tied to the inherent strength in your platform and equ",96,"Great. And then just on Phenomenex, I don't know a lot about the company, obviously. But interesting that it's 100% consumables, and I always think about the strength of your consumable business being tied to the inherent strength in your platform and equipment businesses. Are there other assets like this that are kind of tuck-ins? Are these 100% consumable companies under strategic and competitive threat as folks like yourself build an equipment business? Just any perspective on how to think about just kind of the dynamics of that company and how [indiscernible] the landscape is there."
265621,402034332,1057710,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Executives","Sure, sure. Well, it's a -- Phenomenex is a great franchise, and it is a virtually 100% consumables business with great gross margins, gross margins in the 70% neighborhood and mid-20s operating margins, but still with opportunities for improvement via DB",294,"Sure, sure. Well, it's a -- Phenomenex is a great franchise, and it is a virtually 100% consumables business with great gross margins, gross margins in the 70% neighborhood and mid-20s operating margins, but still with opportunities for improvement via DBS. And we're thrilled to be able to acquire this asset. We've admired that business for a long time. We were able to acquire it at an attractive valuation. And I think for those who've asked us about return thresholds in the past, this is clearly a business that we believe we will achieve double-digit return on invested capital in less than 5 years. And so -- and that, obviously, for us is very typical for a large bolt-on or a midsize adjacency deal and really opens up a number of other possibilities. Jeff, this is a business, to your point about installed base versus consumables, where Phenomenex is -- has become the leader they are largely because they actually are equipment-agnostic and they focus on specific applications and workflows that address unique customer problems and, therefore, create unique customer value. We've had a partnership with Phenomenex at SCIEX for a number of years, and it's been a very successful one. But as some of you may recall, we're also consumables-agnostic in the sense of chromatography columns at SCIEX. And so what this allows us to do essentially is bring a greater variety, a broader set of solutions to our customers without necessarily having to have those consumables be captive by that install base. Obviously, that can be very attractive strategically when you have it, but in the particular case of the Life Science world, being able to customize solutions to -- for these unique applications and customer challenges is a real competitive advantage."
265621,402034332,1057710,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Analysts","And Tom, that doesn't create a channel conflict for all the other folks they were agnostic with and there's some bleed away on their other business as a result of it?",31,"And Tom, that doesn't create a channel conflict for all the other folks they were agnostic with and there's some bleed away on their other business as a result of it?"
265621,402034332,1057710,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Executives","It really doesn't, Jeff. Again, we have excellent relationships with other partners in the consumables world in Life Sciences. We had sourced from multiple -- I shouldn't even say source. We had customized solutions for customers across a number of differ",82,"It really doesn't, Jeff. Again, we have excellent relationships with other partners in the consumables world in Life Sciences. We had sourced from multiple -- I shouldn't even say source. We had customized solutions for customers across a number of different consumables suppliers for a long period of time, and we expect to maintain those relationships and continue to be focused on what are the specific needs of the customer -- the customers today and how do we serve them best."
265621,402034332,1057710,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Operator","And we'll go next to the side of Tycho Peterson from JPMorgan.",13,"And we'll go next to the side of Tycho Peterson from JPMorgan."
265621,402034332,1057710,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Analysts","Tom, wondering if you can comment on the academic market. The NIH data was pretty negative for September. I think budget's down about 13%. And I know you called out some softness for Leica Microsystems. So can you maybe just talk a little bit about what y",53,"Tom, wondering if you can comment on the academic market. The NIH data was pretty negative for September. I think budget's down about 13%. And I know you called out some softness for Leica Microsystems. So can you maybe just talk a little bit about what you're seeing on the academic market specifically?"
265621,402034332,1057710,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Executives","Sure, Tycho. We certainly participate in the academic market in our Life Science businesses, but it's -- we don't have enormous direct exposure to NIH. If you really looked at the direct exposure across a number of our businesses, we're probably in the $1",174,"Sure, Tycho. We certainly participate in the academic market in our Life Science businesses, but it's -- we don't have enormous direct exposure to NIH. If you really looked at the direct exposure across a number of our businesses, we're probably in the $150 million or less with direct exposure to NIH funding. Now there's more than that in terms of indirect funding, but I would say that, that funding issue that you mentioned clearly has had an impact on a broad basis when you talk about a variety of things that are indirectly funded or go through a number of different stages before they ultimately get to a supplier like us. We have seen weakness in that market. We have not seen any particular cause for optimism in the academic market, particularly in the U.S. Europe has hung in there in pockets. Japan is weak and certainly continues to be that way. So it's not an area of strength right now, and clearly, the NIH funding issues have not been net particularly helpful."
265621,402034332,1057710,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Executives","And Tycho, I would add that we probably saw a little more of a bifurcation in Life Science in the quarter, meaning that biopharma remained very strong; traditional farm, food and environmental remained solid, consistent with what we saw in the first half.",62,"And Tycho, I would add that we probably saw a little more of a bifurcation in Life Science in the quarter, meaning that biopharma remained very strong; traditional farm, food and environmental remained solid, consistent with what we saw in the first half. But we did see both academic and sort of industrial markets, particularly at Leica, weaken in the third quarter."
265621,402034332,1057710,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Analysts","Okay, that's helpful. And then on Beckman, if I kind of go back to your comments last quarter, I think you'd talked about growing at a market rate. If we look at the results from some of the peers, they're still growing a little bit faster, including in t",80,"Okay, that's helpful. And then on Beckman, if I kind of go back to your comments last quarter, I think you'd talked about growing at a market rate. If we look at the results from some of the peers, they're still growing a little bit faster, including in the high single-digit range for one of them. Can you maybe just talk a little bit about your view of whether you can get Beckman back to maybe a mid-single-digit growth trajectory?"
265621,402034332,1057710,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Executives","We absolutely believe that we can do that, Tycho. We've made terrific progress thus far. We've seen improvement certainly in our clinical chemistry and in our immunoassay business. Our urinalysis business continues to perform very, very well. That busines",119,"We absolutely believe that we can do that, Tycho. We've made terrific progress thus far. We've seen improvement certainly in our clinical chemistry and in our immunoassay business. Our urinalysis business continues to perform very, very well. That business is up double digits in the third quarter. And I think with the addition of Cepheid and a broader position in molecular diagnostics, particularly with the potential growth that's available in -- at the point of care and potentially, ultimately, in the physician office lab, we do believe that both the core legacy business of Beckman will improve its growth trajectory over time, but the addition of those higher-growth segments that we've acquired will be accretive to that growth profile."
265621,402034332,1057710,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Analysts","Okay. And then just one last quick one. Can you quantify the biopharma growth from Pall that you saw in the quarter?",22,"Okay. And then just one last quick one. Can you quantify the biopharma growth from Pall that you saw in the quarter?"
265621,402034332,1057710,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Executives","Well, the Life Science business overall was up mid-single digits on the quarter, and the single-use business continues to grow at a double-digit rate. And so that -- we continue to see good and consistent performance on the biopharma side.",40,"Well, the Life Science business overall was up mid-single digits on the quarter, and the single-use business continues to grow at a double-digit rate. And so that -- we continue to see good and consistent performance on the biopharma side."
265621,402034332,1057710,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Operator","And we'll go next to the line of Ross Muken from Evercore ISI.",14,"And we'll go next to the line of Ross Muken from Evercore ISI."
265621,402034332,1057710,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Analysts","So on Dental, it's sort of interesting. I mean the macro has been all right, I would guess, in the U.S., but it feels like on North American consumables, we're seeing a little bit of choppiness. Curious of sort of your thoughts for that. And then, convers",126,"So on Dental, it's sort of interesting. I mean the macro has been all right, I would guess, in the U.S., but it feels like on North American consumables, we're seeing a little bit of choppiness. Curious of sort of your thoughts for that. And then, conversely, it seems like overall, the segment is doing quite well, but it's equipment, which, I guess, doesn't sort of correspond with the macro question; and then on the implant side, where it seems like you're doing quite well with the Nobel acquisition. So help us kind of make sense of what you're seeing in the segment. And how much is market-related? And then how much is better execution on your end in some of the segments that are outperforming?"
265621,402034332,1057710,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Executives","Sure. Thanks, Ross. We're pleased with how the Dental business, the segment performed in the quarter at up 3%. And there was clearly some better execution on our side in a number of different areas, and you've heard us speak in the past about some of the",369,"Sure. Thanks, Ross. We're pleased with how the Dental business, the segment performed in the quarter at up 3%. And there was clearly some better execution on our side in a number of different areas, and you've heard us speak in the past about some of the changes that we've made both organizationally and operationally. We have realigned our investments into some key areas from a new product perspective, and we're seeing the benefits there. Relative to the specific portions of the business that you mentioned, we are seeing strength in our equipment business, up mid-single digits; and, yes, the consumables business, up more like low single digits. And really, I think that has to do with a couple of different factors. We are executing well in the equipment side. We have new product initiatives that are making a difference there. And overall, I think we're well positioned from a portfolio perspective. You've heard the narrative from a number of different folks in the market around some softness during the course of July and August. I think we -- as the quarter came to a close in September, we started to certainly see some of that play through, and I think that absolutely varies by geography as well. I mentioned double-digit growth in places like China and India; but the U.S., much slower. And certainly, we're seeing some softness in Europe as well as Latin America and the Middle East. So definitely, a tale of 2 cities. You asked also about the equipment -- the implant side. Nobel continues to perform very well. They've got a number of new products in the market right now, which are helping in that growth rate, and they're executing well just on a commercial basis day in and day out. And some of that obviously has been a function of the implementation of DBS on the cost side, where we've been able to reallocate some of those funds into investments in sales and marketing as well as in R&D. Particularly in the third quarter, we made some significant investments in sales and marketing, and I think will pay off -- that will continue to pay off at Nobel with even improving growth rates."
265621,402034332,1057710,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Analysts","Great. And maybe just moving back to the capital allocation, you guys have obviously been quite busy. And obviously, since you've taken over, there's been a distinct bias towards growth. I guess, what should we learn about your vision of what Danaher will",117,"Great. And maybe just moving back to the capital allocation, you guys have obviously been quite busy. And obviously, since you've taken over, there's been a distinct bias towards growth. I guess, what should we learn about your vision of what Danaher will be over the next 5 or 10 years based on these assets? You've obviously gotten some real crown jewels within the tools, complex and Phenomenex and Pall. And obviously, in Cepheid, you get a high-growth potential. So how should we think about how you're sort of reshaping this portfolio? And what the -- I'm not looking for quantitative, but maybe more qualitatively how you think about the evolution of these assets at this point."
265621,402034332,1057710,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Executives","Sure. Well, Ross, we have gotten quite a bit done here in the last couple of years with the separation that took place with Fortive and getting Fortive off to a great start, but then making some very important and strategic acquisitions to shore up really",302,"Sure. Well, Ross, we have gotten quite a bit done here in the last couple of years with the separation that took place with Fortive and getting Fortive off to a great start, but then making some very important and strategic acquisitions to shore up really what were 3 of the most important strategic needs or opportunities that we had: Nobel on the implant and consumable side; as you mentioned, Pall, to enhance our Life Sciences, specifically biopharmaceutical production position; and then Cepheid, to improve our position relative to molecular diagnostics. We've had a focus strategically on the consumable side of Life Science and Phenomenex, to use your term, a crown jewel in the consumable side of Life Science. So I think we feel very good about where we are right now. I wouldn't trade our portfolio, the 4 segments that we have today of Diagnostics, Life Science, Dental and Environmental & Applied Solutions, for any portfolio in the market. And I think the game plan in the years ahead, as it has been in the past, is continue to deploy our free cash flow strategically, with a strong bias towards M&A, into these highly attractive segments. And I think the game plan, at least in the near term here, given the current position of the balance sheet and all that we have to do operationally with these acquisitions, is to focus on probably small or midsize bolt-ons that are strategically important to our position, that hopefully will -- as these have done, will be accretive to our growth rates and improve our growth trajectories. And hopefully, that would be the case certainly on the margin side, if not initially, certainly over time. So I think that's the game going forward, and it's been the plan over the last couple of years."
265621,402034332,1057710,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Operator","And we'll go next to the line of Doug Schenkel from Cowen.",13,"And we'll go next to the line of Doug Schenkel from Cowen."
265621,402034332,1057710,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Analysts","My first question is on high-growth market trends. In the third quarter, high-growth market revenue growth was I think around -- I think you said mid-single digits. As you describe it, there continue to be some headwinds relative to what we've seen at lea",84,"My first question is on high-growth market trends. In the third quarter, high-growth market revenue growth was I think around -- I think you said mid-single digits. As you describe it, there continue to be some headwinds relative to what we've seen at least compared to historical trends. Recognizing a lot of this is out of control, I'm just wondering if you'd speak a little bit about the actions and investments you're taking to better position these markets for better growth in 2017."
265621,402034332,1057710,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Executives","Sure. Thanks for that question. I think we've -- as we look at the high-growth markets today, I'm not sure we would necessarily say that there was much of a change recently in those markets. We've continued to see strength in China across a number of our",271,"Sure. Thanks for that question. I think we've -- as we look at the high-growth markets today, I'm not sure we would necessarily say that there was much of a change recently in those markets. We've continued to see strength in China across a number of our businesses, if not all. Business in China is up high single digits, real strength in Life Science, in Dental, in Diagnostics; some softness in Hach and Videojet. Those are businesses where that softness largely comes from equipment and more industrially-oriented end markets. And you've heard me mention a number of times the strength that we've seen in India, which has been very consistent level of strength over the last couple of years. And with those 2 markets being what they are, both the scale of those markets, the inherent growth rates in those markets and the strength of our positions, those are really where a great deal of our investment are going. We're largely doubling down in the markets where we have the greatest opportunities for growth in the near term. We -- what improvement we've seen, and it's been very modest, in places like Latin America, Brazil specifically and Russia are really more about easier comps than materially improved market conditions. And the Middle East continues to be weak. And so while we've sustained our positions there in terms of our feet on the street and our investments in commercializing new products in those markets, those have not been markets where we are significantly accelerating our investments today. Instead, the biggest incremental investments are going into those markets where we're seeing continued strength."
265621,402034332,1057710,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Analysts","Great. That's helpful and insightful. My second question is on Diagnostic core margins. They improved 250 basis points year-over-year in the quarter. Yes, there were some nice improvement in the first half of about 210 basis points year-over-year, so it g",81,"Great. That's helpful and insightful. My second question is on Diagnostic core margins. They improved 250 basis points year-over-year in the quarter. Yes, there were some nice improvement in the first half of about 210 basis points year-over-year, so it got even better in Q3. Some of this may be a function of comps, but to the extent it isn't, could you provide a bit more detail on what's really driving -- accelerating improvement and how should we think about sustainability?"
265621,402034332,1057710,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Executives","Well, we're certainly seeing continued improvement in the margin performance at Beckman Diagnostics. Across our Diagnostics portfolio, you have Radiometer and Leica Biosystems. Both businesses we've owned for a number of years and have made tremendous pro",99,"Well, we're certainly seeing continued improvement in the margin performance at Beckman Diagnostics. Across our Diagnostics portfolio, you have Radiometer and Leica Biosystems. Both businesses we've owned for a number of years and have made tremendous progress in enhancing their operating margins. Beckman, obviously a more recent acquisition, but still, 5 years ago, we've seen great lift in those operating margins to this point. But as I mentioned, Beckman represents a large business. It still has quite a bit of headroom for margin improvement. And so we've seen it at this point, but we think there's more runway ahead."
265621,402034332,1057710,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Analysts","So really, it should -- sorry.",6,"So really, it should -- sorry."
265621,402034332,1057710,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Executives","Yes. I mean -- yes. Doug, it's Dan. It's -- we did benefit in Q3 with a slightly easier comp. Despite -- having said that, again, it was a very strong quarter of core margin expansion. What we are seeing is a continued increase in the gross margin side, c",96,"Yes. I mean -- yes. Doug, it's Dan. It's -- we did benefit in Q3 with a slightly easier comp. Despite -- having said that, again, it was a very strong quarter of core margin expansion. What we are seeing is a continued increase in the gross margin side, continued leverage on the G&A side while we're also stepping up R&D and sales and marketing. So we're seeing the mix you'd like to see from a margin perspective, where we're getting the expansion but we're taking part of that and putting that into more growth investments."
265621,402034332,1057710,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Analysts","No, that's great. That's kind of what I was getting at, is, is it a continuation of trend which has been good or are things actually getting a little bit even better, which it kind of sounds like they are. Last one. There's clearly been a lot of questions",117,"No, that's great. That's kind of what I was getting at, is, is it a continuation of trend which has been good or are things actually getting a little bit even better, which it kind of sounds like they are. Last one. There's clearly been a lot of questions about what's going on in different geographies and different end markets, and you guys have been great at providing a lot of directional qualitative information to help us out there. I just figured I would ask, in case you guys would be willing to, whether or not you could just give us core revenue growth by end market and by developed geography in the quarter across all businesses."
265621,402034332,1057710,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Executives","Well, we don't give quite that level of detail, but we did talk about continued double-digit kind of mid-teens growth in India, high single-digit growth in China. Both the U.S. and Western Europe were up low single digits. That's been pretty consistent. I",123,"Well, we don't give quite that level of detail, but we did talk about continued double-digit kind of mid-teens growth in India, high single-digit growth in China. Both the U.S. and Western Europe were up low single digits. That's been pretty consistent. I would add as a footnote probably seeing some incremental signs of weakness in Western Europe, where our overall numbers in Q3 were pretty comparable to what we had in the first half. Tom alluded to the academic comment, seeing a little bit of that industrial weakness in places like Hach. Not a big change, but probably on the margin, the tone is a little bit cautious in Western Europe. And Japan, we continue to be down low to mid-single digits."
265621,402034332,1057710,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Operator","We'll go next to the line of Derik De Bruin from Bank of America.",15,"We'll go next to the line of Derik De Bruin from Bank of America."
265621,402034332,1057710,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Analysts","So before I ask another geography question, I just wanted to ask a Diagnostics question. So it's been -- you've closed the Cepheid -- or you haven't closed it, but you've announced the Cepheid transaction. You've had a little bit more time to think about",90,"So before I ask another geography question, I just wanted to ask a Diagnostics question. So it's been -- you've closed the Cepheid -- or you haven't closed it, but you've announced the Cepheid transaction. You've had a little bit more time to think about it. Any further additional thoughts on where you think you can ultimately get the gross margin on the Cepheid products? That was sort of a topic when we did the call the last time. I just wondered if you have any further thoughts on it."
265621,402034332,1057710,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Executives","Derik, thanks. I don't know that we have a lot more to offer. During due diligence, we were able to spend a good deal of time with the team and understand the road map that they had laid out for gross margin. You've heard a lot of that from the business i",150,"Derik, thanks. I don't know that we have a lot more to offer. During due diligence, we were able to spend a good deal of time with the team and understand the road map that they had laid out for gross margin. You've heard a lot of that from the business in terms of the opportunities around improving the cost structure of the cartridge. We think those are very credible. We think they've got a solid road map for executing on those improvements. And obviously, once we've closed the transaction and we can engage directly with them, we'll be bringing the tools of the Danaher Business System that we've used successfully in a number of other businesses to improve gross margin. You just heard Dan comment about what we've done at Beckman. And we'll obviously bring that to bear at Cepheid, and I think you'll see those improvements come through."
265621,402034332,1057710,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Analysts","Great. And just wondered -- one more question, Europe question. Are you seeing -- is it budget delays that you're seeing or people just canceling orders or people just hesitating on spending? Just a little bit more color on what's going on in terms of spe",63,"Great. And just wondered -- one more question, Europe question. Are you seeing -- is it budget delays that you're seeing or people just canceling orders or people just hesitating on spending? Just a little bit more color on what's going on in terms of specific just trends, if there's anything you can sort of draw from what you're seeing across the businesses."
265621,402034332,1057710,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Executives","Derik, was that a Europe question, I'm sorry?",8,"Derik, was that a Europe question, I'm sorry?"
265621,402034332,1057710,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Analysts","It's a Western Europe question, yes.",7,"It's a Western Europe question, yes."
265621,402034332,1057710,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Executives","Yes. Much more in terms of delays than cancellations, we tend to see, both at the tendering level as well as at the purchase order level, folks hanging back. In certain cases, it's because budgets haven't been fully approved yet. In other cases, they're j",70,"Yes. Much more in terms of delays than cancellations, we tend to see, both at the tendering level as well as at the purchase order level, folks hanging back. In certain cases, it's because budgets haven't been fully approved yet. In other cases, they're just trying to get paper work through approvals. And normally, that's a circumstance where, because of some levels of austerity, folks are just slowing things down."
265621,402034332,1057710,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Operator","And our final question comes from Nigel Coe with Morgan Stanley.",11,"And our final question comes from Nigel Coe with Morgan Stanley."
265621,402034332,1057710,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Analysts","So we covered a lot of ground so I want to keep this relatively quick. But on -- I did want to come back to Dental. There's obviously a lot of noise from some of your competitors regarding the U.S. channel. So I'm just wondering, given the recovery we've",79,"So we covered a lot of ground so I want to keep this relatively quick. But on -- I did want to come back to Dental. There's obviously a lot of noise from some of your competitors regarding the U.S. channel. So I'm just wondering, given the recovery we've seen -- the large recovery we've seen in core growth rates in Dental, how confident are you, you can sustain this level of growth in the sort of 3%-plus bracket?"
265621,402034332,1057710,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Executives","Well, clearly, there's some cause for concern or caution around that, given some of the narrative that we heard from the channel during the course of the quarter. We saw some of that in the month of September come through in terms of the order rates on th",104,"Well, clearly, there's some cause for concern or caution around that, given some of the narrative that we heard from the channel during the course of the quarter. We saw some of that in the month of September come through in terms of the order rates on the consumable side. So I think we feel pretty good about continuing to improve our own execution, particularly on the equipment side, also at Nobel. But I think on the consumable side, we'll need to make sure that we're seeing some improvement in the sellout, either from a programmatic perspective or just from an overall macroeconomic perspective."
265621,402034332,1057710,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Analysts","Great, okay. And then Diagnostics, we don't have a great history on the quarterly performance of Diagnostics. But it does feel like, last year, we saw maybe an unusually large Q-over-Q step down in margins in 3Q, followed by a pretty big pickup in 4Q. Wou",106,"Great, okay. And then Diagnostics, we don't have a great history on the quarterly performance of Diagnostics. But it does feel like, last year, we saw maybe an unusually large Q-over-Q step down in margins in 3Q, followed by a pretty big pickup in 4Q. Would you expect to see a similar 4Q buildup as the 3Q? And then more broadly on 4Q restructuring across the portfolio. In the past, Danaher was -- had very heavy restructuring actions in 4Q. I know this year is not going to be anywhere like that, but maybe just comment on how you see 4Q restructuring actions across the portfolio."
265621,402034332,1057710,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Executives","Yes. Nigel, on Diagnostics first. Seasonally, Q3 tends to be a little lighter, so that played out again. This year there was a big improvement versus Q3 a year ago, and we do expect a nice seasonal pickup in Q4. I would expect margins above where they wer",104,"Yes. Nigel, on Diagnostics first. Seasonally, Q3 tends to be a little lighter, so that played out again. This year there was a big improvement versus Q3 a year ago, and we do expect a nice seasonal pickup in Q4. I would expect margins above where they were a year ago Q4, which were -- was north of 18%. Regarding restructuring, we continue to take actions throughout the year. We don't really kind of call those out. I would expect our overall restructuring spend to be in the same ballpark as last year, again probably a little bit more evenly distributed through the year."
265621,402034332,1057710,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Operator","And at this time, we would like to thank everybody for their participation on today's conference call. Please feel free to disconnect your line at any time.",27,"And at this time, we would like to thank everybody for their participation on today's conference call. Please feel free to disconnect your line at any time."
265621,402034332,1058402,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Operator","My name is Erica, and I will be your conference facilitator this morning. At this time, I would like to welcome everyone to Danaher Corporation's Third Quarter 2016 Earning Results Conference Call. [Operator Instructions] I will now turn the call over t",56,"My name is Erica, and I will be your conference facilitator this morning. At this time, I would like to welcome everyone to Danaher Corporation's Third Quarter 2016 Earning Results Conference Call. [Operator Instructions] 
I will now turn the call over to Mr. Gugino, Vice President of Investor Relations. Mr. Gugino, you may begin your conference."
265621,402034332,1058402,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Executives","Thanks, Erica. Good morning, everyone, and thanks for joining us on the call. With us today are Tom Joyce, our President and Chief Executive Officer; and Dan Comas, our Executive Vice President and Chief Financial Officer. I'd like to point out that our",366,"Thanks, Erica. Good morning, everyone, and thanks for joining us on the call. With us today are Tom Joyce, our President and Chief Executive Officer; and Dan Comas, our Executive Vice President and Chief Financial Officer. 
I'd like to point out that our earnings release, the slide presentation supplementing today's call, our third quarter Form 10-Q and the reconciliations and other information required by SEC Regulation G relating to any non-GAAP financial measures provided during the call are all available on the Investors section of our website, www.danaher.com, under the heading Financial Information. The audio portion of this call will be archived on the Investors section of our website later today under the heading Events & Presentations and will remain archived until our next quarterly call. A replay of this call will also be available until October 27, 2016. 
During the presentation, we will describe certain of the more significant factors that impacted year-over-year performance. The supplemental materials describe additional factors that impacted year-over-year performance. Unless otherwise noted, all references in these remarks and supplemental materials to company-specific financial metrics relate to the continuing operations of the company in the third quarter of 2016, and all references to period-to-period increases or decreases in financial metrics are year-over-year. 
Today, we'll be discussing 2 recently announced acquisitions of Cepheid and Phenomenex. Both acquisitions are subject to customary closing conditions, including receipt of applicable regulatory approvals; and, in the case of Cepheid, approval of the Cepheid shareholders. We may also describe certain products and devices which have applications submitted and pending for certain regulatory approvals. 
During the call, we will make forward-looking statements within the meaning of the federal securities laws, including statements regarding events or developments that we believe or anticipate will or may occur in the future. These forward-looking statements are subject to a number of risks and uncertainties, including those set forth in our SEC filings, and actual results might differ materially from any forward-looking statement that we make today. These forward-looking statements speak only as of the date that they are made, and we do not assume any obligation to update any forward-looking statement. 
With that, I'd like to turn the call over to Tom."
265621,402034332,1058402,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Executives","Thank you, Matt. Good morning, everyone. We're pleased with our third quarter results as our team continued to execute well despite the macroeconomic environment. We delivered solid core revenue growth with very strong adjusted earnings per share growth a",2290,"Thank you, Matt. Good morning, everyone. We're pleased with our third quarter results as our team continued to execute well despite the macroeconomic environment. We delivered solid core revenue growth with very strong adjusted earnings per share growth and free cash flow performance. The diversity and strength of our businesses has served us well in this modest growth environment. The recent separation of Fortive was an important step towards optimizing our portfolio, and we continue to strategically position Danaher for strong long-term growth through M&A. 
Since July, we have announced over $4.8 billion of acquisitions that will strengthen our Life Sciences and Diagnostics segments. In September, we announced the acquisition of Cepheid, a global leader in molecular diagnostics, and we recently announced the acquisition of Phenomenex, an outstanding chromatography consumables business that will be highly complementary to our Life Sciences portfolio. Combined with the execution benefits of DBS, we believe these exciting strategic additions will contribute to Danaher's growth trajectory and superior returns. We look forward to welcoming the Cepheid and Phenomenex teams to Danaher. 
With that as a backdrop, let's turn to the details of the third quarter. This morning, we reported adjusted diluted net earnings per share from continuing operations of $0.87, an increase of more than 20% over last year. Sales grew 17.5% to $4.1 billion, with core revenue increasing 3%. Core growth was consistent across the portfolio, as each of our 4 reporting segments achieved at least 3% core revenue growth in the quarter. Currency translation had minimal impact while acquisitions increased revenues by 14.5%. 
Geographically, the high-growth markets led the way, driven by high single-digit growth in China and high-teens growth in India. Developed market core revenues were up low single digits. Modest growth in the U.S. and Western Europe was partially offset by declines in Japan. 
Gross margin for the third quarter was 55.3%, an increase of 140 basis points from last year. This increase in gross profit enabled us to increase our sales and marketing and R&D spend meaningfully in the quarter. Core operating margins were up 155 basis points in the quarter and 90 basis points year-to-date. This strong margin expansion helped to drive double-digit adjusted net earnings growth in the third quarter. During the quarter, we generated approximately $700 million of free cash flow from continuing operations, up 35%, and our free cash flow to net income conversion ratio was over 150%. 
Now let's take a more detailed look at the results across the portfolio. In Life Sciences, core revenues were up 3% and reported revenues grew over 60%, largely due to the Pall acquisition. Core operating margin increased 180 basis points, and the reported operating profit margin increased to 15.4%. 
At Beckman Life Sciences, low single-digit core growth in the quarter was driven by momentum in China while developed markets were essentially flat. The backdrop of government investment in health care in China, coupled with Beckman's strong execution, contributed to double-digit gains in that region.  Beckman's particle counting and characterization business had another good quarter, with double-digit growth driven by global biopharmaceutical demand. 
The team also launched a new product that supports drug discovery and development. The Vi-CELL MetaFLEX is a biochemistry analyzer that resulted from a collaboration with one of our Diagnostic businesses, Radiometer. Beckman incorporated the technology behind Radiometer's blood gas analyzer to create the Vi-CELL MetaFLEX, which analyzes cell cultures, a crucial component in biotherapy production. This cross-pollination between Beckman and Radiometer is a powerful example of the unique opportunities we have at Danaher to bring greater value to customers by collaborating across the portfolio. 
Leica Microsystems core revenue declined in the quarter. Growth was impacted by weakness in the academic and industrial end markets, particularly in North America and Western Europe. This was partially offset by double-digit gains in the high-growth markets as China continued to be a bright spot, particularly for our confocal business. 
SCIEX posted another quarter of mid-single-digit core revenue growth, led by global strength in pharmaceuticals and food as well as environmental testing. Geographically, we saw declines in Japan and in Europe, where academic weakness impacted results. In the high-growth markets, China and India each maintained strong double-digit growth. Our service offering continues to be a differentiator at SCIEX as the team drove further improvements in contract renewals and attachment rates in the quarter. 
As I mentioned at the start of the call, we recently announced our acquisition of Phenomenex, a leading player in chromatography consumables that supports a variety of analytical testing applications in the health, research and environmental segments. Phenomenex is 100% consumables, a high-margin business in an attractive mid-single-digit growth industry that is adjacent to where SCIEX participates. We expect to achieve a double-digit return on our investment in less than 5 years and believe that Phenomenex will help us to continue creating long-term value as part of our Life Sciences portfolio. 
Pall delivered another quarter of good growth and execution. Continued strength in biopharmaceutical end markets and demand for single-use technologies underpinned strong growth at Pall Life Sciences. Pall's market-leading solutions are at the forefront of the biopharma evolution, and 9 of the 12 new biologic drugs cleared by the FDA last year specified Pall products in their processes. This is a tremendous testament to the quality and reliability that Pall provides to its customers every day. 
Pall Industrial revenue was down in the quarter with solid gains in aerospace and microelectronics offset by declines in energy and machinery as heavy industrial end markets remained challenging. August marked the 1-year anniversary of our acquisition of Pall Corporation, and the team's exceptional implementation of DBS has been a critical driver of what we've been able to accomplish thus far. Since the beginning of the year, Pall has achieved more than 150 basis points of gross margin expansion and improved operating margins by over 350 basis points. 
At the same time, we've been able to put some of that benefit back into sales and marketing and R&D. This reinvestment, combined with the team's thoughtful use of DBS growth tools, like accelerated product development and Obeya Rooms, has resulted in a number of key new products launching ahead of schedule this year. By delivering these impactful new solutions to the market sooner, we can deliver greater value to our customers and further enhance Pall's growth trajectory. 
Moving now to Diagnostics. Both reported and core revenues increased 3%. The team's solid execution generated 250 basis points of core operating margin expansion, and reported operating margins increased to 16%. Sustained strength in China and India was complemented by modest growth in the developed markets. 
Core revenue at Beckman Coulter Diagnostics was up low single digits, with growth in emerging markets partially offset by softer demand in North America and Europe. Recent installed base growth in China contributed to strong immunoassay performance in the quarter, with the business achieving double-digit recurring revenue in the region. 
One of our 5 core values at Danaher is: Customers talk, we listen. And Beckman Diagnostics recognizes the importance of helping customers drive performance across multiple labs with different needs and different test volumes. One of the ways we differentiate our offering is to partner with customers and help them integrate Danaher Business System tools and processes into their labs and workflows. The result can be tremendously impactful: better speed to results, operational efficiency and ultimately improved clinician workflows. 
The effectiveness of one such collaboration was recently highlighted by a customer that operates one of the largest regional lab networks in the Midwestern United States. Within 6 months, Beckman helped them implement over 180 analyzers and 4 automation lines at 30 different hospitals and lab locations without any patient disruption. This customer was recently awarded the prestigious ADVANCE Laboratory of the Year award for 2016 and has mentioned their partnership with Beckman and the adoption of DBS tools as a key factor in their labs' transformational success. 
Radiometer achieved mid-single-digit core revenue growth, led by continued double-digit growth in both China and India and solid performance in the developed markets. We saw robust demand for consumables across our portfolio of acute care diagnostic instruments. 
At Leica Biosystems, core revenues grew mid-single digits in the quarter, led by high single-digit growth in North America. An expanding installed base and strong consumable sales contributed to double-digit growth in our advanced staining business. 
Back in September, we announced our acquisition of Cepheid, a leading molecular diagnostics innovator in the fastest-growing segment of diagnostics. Cepheid has the largest global installed base of molecular diagnostics instruments, combined with the broadest test menu available. We expect this highly complementary addition to our Diagnostics portfolio to accelerate our growth strategy and further differentiate Danaher's diagnostics offering. We also foresee tremendous opportunities with the application of DBS at Cepheid, which we believe will help drive better top and bottom line performance. 
Turning now to our Dental segment. Reported revenues increased 3.5%, and reported operating margin increased slightly to 15%, with 20 basis points of core margin expansion. Core revenues were up 3%, driven by our equipment, implant and orthodontic product lines, while we saw softer demand for consumables in the quarter. Positive gains in North America were offset by weakness in Western Europe. Strength in high-growth markets was supported by another quarter of double-digit growth in China across all of our major dental product lines. 
Since 2010, we've grown our Dental revenues in China from $15 million to over $150 million today, and we're now positioned as one of the leading players in the region. We've evolved our business model as well in China to position ourselves as more of a localized player by expanding our R&D teams, increasing local commercial coverage and establishing manufacturing capabilities in the region. This approach, combined with our comprehensive product suite, enables us to provide a full service China-centric offering that enhances our customers' experiences and positions us well for continued growth in this market. 
Let's turn to Nobel Biocare. Nobel Biocare's core revenue grew at a low single-digit rate, with demand for implant systems and regeneratives driven by recently launched new products that have quickly gained traction with customers. Similar to what we saw across our other Dental businesses in the quarter, sales in Western Europe softened at Nobel while China continued to do well. The benefit of the team's operational and cost improvements using DBS continues to help fuel Nobel's new product and innovation engine. 
Turning to our Environmental & Applied Solutions segment. Core revenues grew 3.5% with reported revenues up 4.5%. Core operating margin expanded 60 basis points, and reported operating margin was down slightly at 24.3%. 
In Product Identification, core revenues increased at a mid-single-digit rate, and we saw strong demand for marking and coding equipment and related consumables across most major geographies. Sales growth of our packaging and color solutions offerings improved sequentially and was led primarily by increased demand in the U.S. and Latin America. 
Videojet showed solid growth performance, delivering mid-single-digit core revenue growth in the quarter. Strength in developed markets and Latin America was modestly offset by declines in China, primarily due to industrial end market weakness. Videojet continued to grow the number of connected printers in the market, expanding our remote solutions offering for customers and driving high single-digit service revenue growth. 
Core revenue grew low single digits at Esko, led by increased demand at MediaBeacon, which we acquired in 2015. As a reminder, MediaBeacon provides digital asset management software that brand owners and packaging managers use to ensure accuracy and compliance. With the help of DBS tools like funnel management and transformative marketing, MediaBeacon has generated greater market awareness and demand for our integrated solutions, which support customers across their full brand and packaging workflows. At X-Rite, core revenue grew low single digits, with strong performance in North America and China partially offset by the rest of Asia. 
Lastly, turning to Water Quality. Core revenue growth for the platform increased at a low single-digit rate. Hach's core revenue declined slightly in the quarter as industrial end market weakness contributed to softer demand in North America and China. We saw similarly lackluster activity in Eastern Europe as constrained government funding and political instability affected municipal projects. We anticipate better core growth at Hach in the fourth quarter. 
ChemTreat core revenue grew at a mid-single-digit rate as the team delivered solid commercial execution and expanded their customer base in the U.S. Strength in North America and the food and beverage end markets was partially offset by lower demand in Latin America, particularly in the more commodity-oriented markets. 
At Trojan, core revenue increased double digits, driven by consistent municipal demand across developed and emerging markets. Our increased municipal systems installed base contributed to strong replacement growth, and bidding activity was up low single digits globally. A few key municipal project wins materialized in Asia as ultraviolet water treatment solutions have gained interest in the region. 
So to wrap up, we're pleased with our performance in the current macroeconomic environment. We believe that the steps we've taken to reshape our portfolio positions us well for stronger growth and value creation. The diversity and strength of our businesses, combined with our team's focused execution using the Danaher Business System, is what sustains our competitive advantage. We believe that this combination will continue to serve both our customers and our shareholders well. 
We are initiating fourth quarter guidance for adjusted diluted net EPS from continuing operations of $1.01 to $1.05, which assumes fourth quarter core revenue growth comparable to the third quarter of 2016. For the full year 2016, we're raising our adjusted diluted net EPS from continuing operations guidance to $3.57 to $3.61, which, at the midpoint, would represent an increase of approximately 20% from 2015."
265621,402034332,1058402,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Executives","Thanks, Tom. That concludes our formal comments. Erica, we're now ready for questions.",13,"Thanks, Tom. That concludes our formal comments. Erica, we're now ready for questions."
265621,402034332,1058402,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Operator","[Operator Instructions] We'll go first to the line of Scott Davis with Barclays.",13,"[Operator Instructions] We'll go first to the line of Scott Davis with Barclays."
265621,402034332,1058402,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Analysts","I could see the pattern that since you hired Gugino, you started to put up these big numbers.",18,"I could see the pattern that since you hired Gugino, you started to put up these big numbers."
265621,402034332,1058402,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Executives","He's got a big team supporting him, Scott. We love him, but big team, big team, broad-based.",18,"He's got a big team supporting him, Scott. We love him, but big team, big team, broad-based."
265621,402034332,1058402,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Analysts","Yes. Well, anyways, I'm intrigued by -- it's your 1-year anniversary of Pall, and I'm intrigued on how does that -- have your results matched up with the deal model? And more kind of specifically, what time -- or what type of return on capital are you sit",62,"Yes. Well, anyways, I'm intrigued by -- it's your 1-year anniversary of Pall, and I'm intrigued on how does that -- have your results matched up with the deal model? And more kind of specifically, what time -- or what type of return on capital are you sitting on kind of as you look point in time right now in that deal?"
265621,402034332,1058402,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Executives","Sure. Scott, we're very, very pleased with the performance of the team, both the Danaher team that has joined the team at Pall as well as the legacy Pall associates. The combination of those 2 teams has gotten the business off to a tremendous start in the",293,"Sure. Scott, we're very, very pleased with the performance of the team, both the Danaher team that has joined the team at Pall as well as the legacy Pall associates. The combination of those 2 teams has gotten the business off to a tremendous start in the first year. DBS has played a huge role in the progress that we've made there. As you might recall, that team had sort of begun the journey before we arrived on the scene, but the combination of the Danaher team that's gone in and the Pall team have really accelerated the pace of progress. There have been over 350 kaizens that have been completed both on operational side as well as on the commercial side. We've seen the tremendous lift in core operating margins in that business. And as I mentioned in my remarks, we're now seeing the investment in some of the sales and marketing and the new product areas start to make a real difference in terms of getting new products not only launched but commercialized on time and effectively. So we're off to a good start. You know we took the improvements from a cost standpoint up from $60 million in the first year to $100 million. So we're a little bit ahead of schedule in that respect. And I think, obviously, that lifts the returns here in the near term. Relative to where we'll end up on a 4-, 5-year basis and beyond, I think, again, we're off to a very good start. I think we have a lot of opportunity to lift those returns, but it's still early days. And there's a lot of hard work to be done in the months and quarters and years ahead, but a great start."
265621,402034332,1058402,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Analysts","And when -- and just thinking about Pall -- when Pall Industrial comes back -- and I'd love to hear your view on when you think you move into positive territory there, but when Pall Industrial comes back, would you expect outsized operating leverage on th",65,"And when -- and just thinking about Pall -- when Pall Industrial comes back -- and I'd love to hear your view on when you think you move into positive territory there, but when Pall Industrial comes back, would you expect outsized operating leverage on the cost-out? Or how would you think about it if you -- I guess, if you were in our shoes?"
265621,402034332,1058402,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Executives","Yes. Well, first of all, I think we've seen while not a -- the beginnings of growth on the industrial side, I think we haven't seen -- we have not seen another leg down. In other words, we've seen some stability. The industrial side was still down mid-sin",202,"Yes. Well, first of all, I think we've seen while not a -- the beginnings of growth on the industrial side, I think we haven't seen -- we have not seen another leg down. In other words, we've seen some stability. The industrial side was still down mid-single digits in the quarter while the Life Science side was up mid-single digits. And so as those businesses begin to improve both from the standpoint of our execution, and DBS is playing a role there from a new product execution standpoint and a commercialization perspective, when those improvements kick in and we get some lift from the macro, I think the big benefit you're going to see is in terms of the core growth of that business and the readthrough on an operating margin basis from that core growth. I don't know that it necessarily changes trajectory from a cost-out perspective. We're working on the cost structures, both on the Life Science side and on the industrial side as well as across the horizontal components of G&A. So I think the real lift comes when we start to see that core growth turn positive and we start to see the readthrough from that growth."
265621,402034332,1058402,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Operator","And we'll take our next question from Steve Winoker from Bernstein.",12,"And we'll take our next question from Steve Winoker from Bernstein."
265621,402034332,1058402,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Analysts","And to echo Scott, I wouldn't -- Matt -- his team is important, but don't forget Matt in all this, okay? So listen, I want to just start with the actual fourth quarter core growth that you just talked about at about the same as third quarter. Just looking",111,"And to echo Scott, I wouldn't -- Matt -- his team is important, but don't forget Matt in all this, okay? So listen, I want to just start with the actual fourth quarter core growth that you just talked about at about the same as third quarter. Just looking for where you might see signs of acceleration, how you think about that trending into next year. I know, if I look at 2015, the third quarter was up year-on-year 3%. The fourth quarter was up only 1.5%. So just wondering, is this conservative in terms of how you're seeing -- give us some sense of the fourth quarter, if you could."
265621,402034332,1058402,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Executives","Yes. I wouldn't describe it as conservative, Steve. I do think, though, there's a number of considerations that go into how we look at the fourth quarter. I mean it starts with how pleased we are with the performance to this point in the third quarter, wi",247,"Yes. I wouldn't describe it as conservative, Steve. I do think, though, there's a number of considerations that go into how we look at the fourth quarter. I mean it starts with how pleased we are with the performance to this point in the third quarter, with all 4 segments driving at least 3% core growth. And I think now with a portfolio where greater than 60% of the revenues are in the aftermarket and where there's some stability in these markets but not necessarily anything positive to write home about macroeconomically, I think there is cause for some degree of caution in the outlook. You're reading the same macroeconomic news that everybody else is and, certainly, that we are. There's a number of sources of uncertainty in the market today, whether that's the election uncertainty in the U.S.; the Brexit uncertainty throughout Europe; the questions around turns in some of the high-growth markets or previously known as high-growth markets, as I sometimes say, around places like Latin America, the Middle East, Russia, and particularly those markets with a good deal of commodity exposure and certainly those with a high degree of industrial exposure. So it's hard not to be appropriately concerned with some of that -- those sources of uncertainty. But that being said, we think we've got an incredibly resilient portfolio right now, again, underpinned by that level of aftermarket position and a portfolio we think that will continue to perform well despite those uncertainties."
265621,402034332,1058402,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Analysts","And as you think about extending that through next year, what would be the biggest things that would drive you from that 3% level to, say, something higher, even another 50 basis points? What are the few things we should be looking for?",43,"And as you think about extending that through next year, what would be the biggest things that would drive you from that 3% level to, say, something higher, even another 50 basis points? What are the few things we should be looking for?"
265621,402034332,1058402,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Executives","Well, we -- first of all, we still have plenty of work to do left here in 2016 before we get into 2017, and we'll be going through a process here in the fourth quarter around budgets and be in a much better position to give you some specifics when we're t",218,"Well, we -- first of all, we still have plenty of work to do left here in 2016 before we get into 2017, and we'll be going through a process here in the fourth quarter around budgets and be in a much better position to give you some specifics when we're together in December. But if you really stand back and you look at us today, I just mentioned the strength of the portfolio and the repositioning and the level of aftermarket that gives us a strong foundation, but I think we're encouraged about the continued improvement in performance at Pall, with the addition of Cepheid and Phenomenex coming into the Life Sciences and Diagnostics portfolio and continuing to help us from -- both from a growth rate standpoint as well as from an operating margin lift. And then as we've mentioned before, we think there's plenty of opportunity for continued improvement in growth in our Diagnostics business, in our Life Science -- in a number of our Life Science businesses as well as in Dental. So clearly, we could use a little bit of macroeconomic headwind, but I think there's -- excuse me, tailwind, but I think we have plenty of opportunities to play offense and make our own way in a good deal of the portfolio."
265621,402034332,1058402,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Executives","And Steve, just to add a few things. One, on a year-to-date basis, Pall is up mid-single digits. That's not been in the core number, as Tom alluded to. That's with no benefit from the industrial side of Pall. So even if industrial stabilizes a little bit,",134,"And Steve, just to add a few things. One, on a year-to-date basis, Pall is up mid-single digits. That's not been in the core number, as Tom alluded to. That's with no benefit from the industrial side of Pall. So even if industrial stabilizes a little bit, Pall should be a net contributor, adder to our core growth next year. Our industrial instrumentation business at Hach has been weak. Our experience, that tends to not last very long. I think that would be -- we would expect sort of better numbers out of Hach here in the fourth quarter going into next year. So even those 2 items, even before Cepheid comes in -- again, Cepheid won't impact our reported core number but will help our pro forma core number in 2017 as well."
265621,402034332,1058402,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Operator","And we'll go next to the side of Jeffrey Sprague from Vertical Research.",14,"And we'll go next to the side of Jeffrey Sprague from Vertical Research."
265621,402034332,1058402,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Analysts","Could we field a little bit more on your discussion about the uptick in muni activity? It feels like that has been building for a couple of quarters now. And I just wonder if you could give us a little bit more color on, geographically, what's going on an",67,"Could we field a little bit more on your discussion about the uptick in muni activity? It feels like that has been building for a couple of quarters now. And I just wonder if you could give us a little bit more color on, geographically, what's going on and kind of what the pipeline of business looks here for the next, call it, 6 to 12 months."
265621,402034332,1058402,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Executives","And Jeff, specifically on -- in the muni world?",9,"And Jeff, specifically on -- in the muni world?"
265621,402034332,1058402,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Analysts","Yes, muni world.",3,"Yes, muni world."
265621,402034332,1058402,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Executives","Sure, sure. Well, I think the brightest spot that we've seen in the municipal world around water -- our municipal water business has been at Trojan, where we've seen good performance this year, where we've seen double-digit growth in the last quarter. We'",224,"Sure, sure. Well, I think the brightest spot that we've seen in the municipal world around water -- our municipal water business has been at Trojan, where we've seen good performance this year, where we've seen double-digit growth in the last quarter. We've seen increasing win rates and a reasonable lift in bidding activity. But I wouldn't say that, that bidding activity necessarily suggests that, that double-digit growth rate is a sustainable one. This is more of a -- probably a mid-single-digit type of market. But we have been very encouraged by the performance at Trojan. Their competitiveness, I think, is -- has read through in terms of their win rates. And so we're -- in a reasonable market right now, I think we're winning share. So I think that's encouraging from an equipment and an infrastructure perspective, and we're seeing that globally. I think on the -- there's a different side of the story though, which is on the municipal business in North America, the day-to-day consumables business is not showing the kind of strength that I just represented at Trojan. We're seeing low single-digit growth in that market right now. It's still a very good market, and Hach continues to be gaining share there, but not nearly at the rate that we're seeing some of the infrastructure build out in certain markets."
265621,402034332,1058402,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Analysts","Great. And then just on Phenomenex, I don't know a lot about the company, obviously. But interesting that it's 100% consumables, and I always think about the strength of your consumable business being tied to the inherent strength in your platform and equ",96,"Great. And then just on Phenomenex, I don't know a lot about the company, obviously. But interesting that it's 100% consumables, and I always think about the strength of your consumable business being tied to the inherent strength in your platform and equipment businesses. Are there other assets like this that are kind of tuck-ins? Are these 100% consumable companies under strategic and competitive threat as folks like yourself build an equipment business? Just any perspective on how to think about just kind of the dynamics of that company and how [indiscernible] the landscape is there."
265621,402034332,1058402,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Executives","Sure, sure. Well, it's a -- Phenomenex is a great franchise, and it is a virtually 100% consumables business with great gross margins, gross margins in the 70% neighborhood and mid-20s operating margins, but still with opportunities for improvement via DB",294,"Sure, sure. Well, it's a -- Phenomenex is a great franchise, and it is a virtually 100% consumables business with great gross margins, gross margins in the 70% neighborhood and mid-20s operating margins, but still with opportunities for improvement via DBS. And we're thrilled to be able to acquire this asset. We've admired that business for a long time. We were able to acquire it at an attractive valuation. And I think for those who've asked us about return thresholds in the past, this is clearly a business that we believe we will achieve double-digit return on invested capital in less than 5 years. And so -- and that, obviously, for us is very typical for a large bolt-on or a midsize adjacency deal and really opens up a number of other possibilities. Jeff, this is a business, to your point about installed base versus consumables, where Phenomenex is -- has become the leader they are largely because they actually are equipment-agnostic and they focus on specific applications and workflows that address unique customer problems and, therefore, create unique customer value. We've had a partnership with Phenomenex at SCIEX for a number of years, and it's been a very successful one. But as some of you may recall, we're also consumables-agnostic in the sense of chromatography columns at SCIEX. And so what this allows us to do essentially is bring a greater variety, a broader set of solutions to our customers without necessarily having to have those consumables be captive by that install base. Obviously, that can be very attractive strategically when you have it, but in the particular case of the Life Science world, being able to customize solutions to -- for these unique applications and customer challenges is a real competitive advantage."
265621,402034332,1058402,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Analysts","And Tom, that doesn't create a channel conflict for all the other folks they were agnostic with and there's some bleed away on their other business as a result of it?",31,"And Tom, that doesn't create a channel conflict for all the other folks they were agnostic with and there's some bleed away on their other business as a result of it?"
265621,402034332,1058402,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Executives","It really doesn't, Jeff. Again, we have excellent relationships with other partners in the consumables world in Life Sciences. We had sourced from multiple -- I shouldn't even say source. We had customized solutions for customers across a number of differ",82,"It really doesn't, Jeff. Again, we have excellent relationships with other partners in the consumables world in Life Sciences. We had sourced from multiple -- I shouldn't even say source. We had customized solutions for customers across a number of different consumables suppliers for a long period of time, and we expect to maintain those relationships and continue to be focused on what are the specific needs of the customer -- the customers today and how do we serve them best."
265621,402034332,1058402,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Operator","And we'll go next to the side of Tycho Peterson from JPMorgan.",13,"And we'll go next to the side of Tycho Peterson from JPMorgan."
265621,402034332,1058402,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Analysts","Tom, wondering if you can comment on the academic market. The NIH data was pretty negative for September. I think budget's down about 13%. And I know you called out some softness for Leica Microsystems. So can you maybe just talk a little bit about what y",53,"Tom, wondering if you can comment on the academic market. The NIH data was pretty negative for September. I think budget's down about 13%. And I know you called out some softness for Leica Microsystems. So can you maybe just talk a little bit about what you're seeing on the academic market specifically?"
265621,402034332,1058402,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Executives","Sure, Tycho. We certainly participate in the academic market in our Life Science businesses, but it's -- we don't have enormous direct exposure to NIH. If you really looked at the direct exposure across a number of our businesses, we're probably in the $1",174,"Sure, Tycho. We certainly participate in the academic market in our Life Science businesses, but it's -- we don't have enormous direct exposure to NIH. If you really looked at the direct exposure across a number of our businesses, we're probably in the $150 million or less with direct exposure to NIH funding. Now there's more than that in terms of indirect funding, but I would say that, that funding issue that you mentioned clearly has had an impact on a broad basis when you talk about a variety of things that are indirectly funded or go through a number of different stages before they ultimately get to a supplier like us. We have seen weakness in that market. We have not seen any particular cause for optimism in the academic market, particularly in the U.S. Europe has hung in there in pockets. Japan is weak and certainly continues to be that way. So it's not an area of strength right now, and clearly, the NIH funding issues have not been net particularly helpful."
265621,402034332,1058402,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Executives","And Tycho, I would add that we probably saw a little more of a bifurcation in Life Science in the quarter, meaning that biopharma remained very strong; traditional farm, food and environmental remained solid, consistent with what we saw in the first half.",62,"And Tycho, I would add that we probably saw a little more of a bifurcation in Life Science in the quarter, meaning that biopharma remained very strong; traditional farm, food and environmental remained solid, consistent with what we saw in the first half. But we did see both academic and sort of industrial markets, particularly at Leica, weaken in the third quarter."
265621,402034332,1058402,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Analysts","Okay, that's helpful. And then on Beckman, if I kind of go back to your comments last quarter, I think you'd talked about growing at a market rate. If we look at the results from some of the peers, they're still growing a little bit faster, including in t",80,"Okay, that's helpful. And then on Beckman, if I kind of go back to your comments last quarter, I think you'd talked about growing at a market rate. If we look at the results from some of the peers, they're still growing a little bit faster, including in the high single-digit range for one of them. Can you maybe just talk a little bit about your view of whether you can get Beckman back to maybe a mid-single-digit growth trajectory?"
265621,402034332,1058402,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Executives","We absolutely believe that we can do that, Tycho. We've made terrific progress thus far. We've seen improvement certainly in our clinical chemistry and in our immunoassay business. Our urinalysis business continues to perform very, very well. That busines",119,"We absolutely believe that we can do that, Tycho. We've made terrific progress thus far. We've seen improvement certainly in our clinical chemistry and in our immunoassay business. Our urinalysis business continues to perform very, very well. That business is up double digits in the third quarter. And I think with the addition of Cepheid and a broader position in molecular diagnostics, particularly with the potential growth that's available in -- at the point of care and potentially, ultimately, in the physician office lab, we do believe that both the core legacy business of Beckman will improve its growth trajectory over time, but the addition of those higher-growth segments that we've acquired will be accretive to that growth profile."
265621,402034332,1058402,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Analysts","Okay. And then just one last quick one. Can you quantify the biopharma growth from Pall that you saw in the quarter?",22,"Okay. And then just one last quick one. Can you quantify the biopharma growth from Pall that you saw in the quarter?"
265621,402034332,1058402,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Executives","Well, the Life Science business overall was up mid-single digits on the quarter, and the single-use business continues to grow at a double-digit rate. And so that -- we continue to see good and consistent performance on the biopharma side.",40,"Well, the Life Science business overall was up mid-single digits on the quarter, and the single-use business continues to grow at a double-digit rate. And so that -- we continue to see good and consistent performance on the biopharma side."
265621,402034332,1058402,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Operator","And we'll go next to the line of Ross Muken from Evercore ISI.",14,"And we'll go next to the line of Ross Muken from Evercore ISI."
265621,402034332,1058402,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Analysts","So on Dental, it's sort of interesting. I mean the macro has been all right, I would guess, in the U.S., but it feels like on North American consumables, we're seeing a little bit of choppiness. Curious of sort of your thoughts for that. And then, convers",126,"So on Dental, it's sort of interesting. I mean the macro has been all right, I would guess, in the U.S., but it feels like on North American consumables, we're seeing a little bit of choppiness. Curious of sort of your thoughts for that. And then, conversely, it seems like overall, the segment is doing quite well, but it's equipment, which, I guess, doesn't sort of correspond with the macro question; and then on the implant side, where it seems like you're doing quite well with the Nobel acquisition. So help us kind of make sense of what you're seeing in the segment. And how much is market-related? And then how much is better execution on your end in some of the segments that are outperforming?"
265621,402034332,1058402,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Executives","Sure. Thanks, Ross. We're pleased with how the Dental business, the segment performed in the quarter at up 3%. And there was clearly some better execution on our side in a number of different areas, and you've heard us speak in the past about some of the",369,"Sure. Thanks, Ross. We're pleased with how the Dental business, the segment performed in the quarter at up 3%. And there was clearly some better execution on our side in a number of different areas, and you've heard us speak in the past about some of the changes that we've made both organizationally and operationally. We have realigned our investments into some key areas from a new product perspective, and we're seeing the benefits there. Relative to the specific portions of the business that you mentioned, we are seeing strength in our equipment business, up mid-single digits; and, yes, the consumables business, up more like low single digits. And really, I think that has to do with a couple of different factors. We are executing well in the equipment side. We have new product initiatives that are making a difference there. And overall, I think we're well positioned from a portfolio perspective. You've heard the narrative from a number of different folks in the market around some softness during the course of July and August. I think we -- as the quarter came to a close in September, we started to certainly see some of that play through, and I think that absolutely varies by geography as well. I mentioned double-digit growth in places like China and India; but the U.S., much slower. And certainly, we're seeing some softness in Europe as well as Latin America and the Middle East. So definitely, a tale of 2 cities. You asked also about the equipment -- the implant side. Nobel continues to perform very well. They've got a number of new products in the market right now, which are helping in that growth rate, and they're executing well just on a commercial basis day in and day out. And some of that obviously has been a function of the implementation of DBS on the cost side, where we've been able to reallocate some of those funds into investments in sales and marketing as well as in R&D. Particularly in the third quarter, we made some significant investments in sales and marketing, and I think will pay off -- that will continue to pay off at Nobel with even improving growth rates."
265621,402034332,1058402,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Analysts","Great. And maybe just moving back to the capital allocation, you guys have obviously been quite busy. And obviously, since you've taken over, there's been a distinct bias towards growth. I guess, what should we learn about your vision of what Danaher will",117,"Great. And maybe just moving back to the capital allocation, you guys have obviously been quite busy. And obviously, since you've taken over, there's been a distinct bias towards growth. I guess, what should we learn about your vision of what Danaher will be over the next 5 or 10 years based on these assets? You've obviously gotten some real crown jewels within the tools, complex and Phenomenex and Pall. And obviously, in Cepheid, you get a high-growth potential. So how should we think about how you're sort of reshaping this portfolio? And what the -- I'm not looking for quantitative, but maybe more qualitatively how you think about the evolution of these assets at this point."
265621,402034332,1058402,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Executives","Sure. Well, Ross, we have gotten quite a bit done here in the last couple of years with the separation that took place with Fortive and getting Fortive off to a great start, but then making some very important and strategic acquisitions to shore up really",302,"Sure. Well, Ross, we have gotten quite a bit done here in the last couple of years with the separation that took place with Fortive and getting Fortive off to a great start, but then making some very important and strategic acquisitions to shore up really what were 3 of the most important strategic needs or opportunities that we had: Nobel on the implant and consumable side; as you mentioned, Pall, to enhance our Life Sciences, specifically biopharmaceutical production position; and then Cepheid, to improve our position relative to molecular diagnostics. We've had a focus strategically on the consumable side of Life Science and Phenomenex, to use your term, a crown jewel in the consumable side of Life Science. So I think we feel very good about where we are right now. I wouldn't trade our portfolio, the 4 segments that we have today of Diagnostics, Life Science, Dental and Environmental & Applied Solutions, for any portfolio in the market. And I think the game plan in the years ahead, as it has been in the past, is continue to deploy our free cash flow strategically, with a strong bias towards M&A, into these highly attractive segments. And I think the game plan, at least in the near term here, given the current position of the balance sheet and all that we have to do operationally with these acquisitions, is to focus on probably small or midsize bolt-ons that are strategically important to our position, that hopefully will -- as these have done, will be accretive to our growth rates and improve our growth trajectories. And hopefully, that would be the case certainly on the margin side, if not initially, certainly over time. So I think that's the game going forward, and it's been the plan over the last couple of years."
265621,402034332,1058402,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Operator","And we'll go next to the line of Doug Schenkel from Cowen.",13,"And we'll go next to the line of Doug Schenkel from Cowen."
265621,402034332,1058402,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Analysts","My first question is on high-growth market trends. In the third quarter, high-growth market revenue growth was I think around -- I think you said mid-single digits. As you describe it, there continue to be some headwinds relative to what we've seen at lea",84,"My first question is on high-growth market trends. In the third quarter, high-growth market revenue growth was I think around -- I think you said mid-single digits. As you describe it, there continue to be some headwinds relative to what we've seen at least compared to historical trends. Recognizing a lot of this is out of control, I'm just wondering if you'd speak a little bit about the actions and investments you're taking to better position these markets for better growth in 2017."
265621,402034332,1058402,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Executives","Sure. Thanks for that question. I think we've -- as we look at the high-growth markets today, I'm not sure we would necessarily say that there was much of a change recently in those markets. We've continued to see strength in China across a number of our",271,"Sure. Thanks for that question. I think we've -- as we look at the high-growth markets today, I'm not sure we would necessarily say that there was much of a change recently in those markets. We've continued to see strength in China across a number of our businesses, if not all. Business in China is up high single digits, real strength in Life Science, in Dental, in Diagnostics; some softness in Hach and Videojet. Those are businesses where that softness largely comes from equipment and more industrially-oriented end markets. And you've heard me mention a number of times the strength that we've seen in India, which has been very consistent level of strength over the last couple of years. And with those 2 markets being what they are, both the scale of those markets, the inherent growth rates in those markets and the strength of our positions, those are really where a great deal of our investment are going. We're largely doubling down in the markets where we have the greatest opportunities for growth in the near term. We -- what improvement we've seen, and it's been very modest, in places like Latin America, Brazil specifically and Russia are really more about easier comps than materially improved market conditions. And the Middle East continues to be weak. And so while we've sustained our positions there in terms of our feet on the street and our investments in commercializing new products in those markets, those have not been markets where we are significantly accelerating our investments today. Instead, the biggest incremental investments are going into those markets where we're seeing continued strength."
265621,402034332,1058402,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Analysts","Great. That's helpful and insightful. My second question is on Diagnostic core margins. They improved 250 basis points year-over-year in the quarter. Yes, there were some nice improvement in the first half of about 210 basis points year-over-year, so it g",81,"Great. That's helpful and insightful. My second question is on Diagnostic core margins. They improved 250 basis points year-over-year in the quarter. Yes, there were some nice improvement in the first half of about 210 basis points year-over-year, so it got even better in Q3. Some of this may be a function of comps, but to the extent it isn't, could you provide a bit more detail on what's really driving -- accelerating improvement and how should we think about sustainability?"
265621,402034332,1058402,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Executives","Well, we're certainly seeing continued improvement in the margin performance at Beckman Diagnostics. Across our Diagnostics portfolio, you have Radiometer and Leica Biosystems. Both businesses we've owned for a number of years and have made tremendous pro",99,"Well, we're certainly seeing continued improvement in the margin performance at Beckman Diagnostics. Across our Diagnostics portfolio, you have Radiometer and Leica Biosystems. Both businesses we've owned for a number of years and have made tremendous progress in enhancing their operating margins. Beckman, obviously a more recent acquisition, but still, 5 years ago, we've seen great lift in those operating margins to this point. But as I mentioned, Beckman represents a large business. It still has quite a bit of headroom for margin improvement. And so we've seen it at this point, but we think there's more runway ahead."
265621,402034332,1058402,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Analysts","So really, it should -- sorry.",6,"So really, it should -- sorry."
265621,402034332,1058402,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Executives","Yes. I mean -- yes. Doug, it's Dan. It's -- we did benefit in Q3 with a slightly easier comp. Despite -- having said that, again, it was a very strong quarter of core margin expansion. What we are seeing is a continued increase in the gross margin side, c",96,"Yes. I mean -- yes. Doug, it's Dan. It's -- we did benefit in Q3 with a slightly easier comp. Despite -- having said that, again, it was a very strong quarter of core margin expansion. What we are seeing is a continued increase in the gross margin side, continued leverage on the G&A side while we're also stepping up R&D and sales and marketing. So we're seeing the mix you'd like to see from a margin perspective, where we're getting the expansion but we're taking part of that and putting that into more growth investments."
265621,402034332,1058402,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Analysts","No, that's great. That's kind of what I was getting at, is, is it a continuation of trend which has been good or are things actually getting a little bit even better, which it kind of sounds like they are. Last one. There's clearly been a lot of questions",117,"No, that's great. That's kind of what I was getting at, is, is it a continuation of trend which has been good or are things actually getting a little bit even better, which it kind of sounds like they are. Last one. There's clearly been a lot of questions about what's going on in different geographies and different end markets, and you guys have been great at providing a lot of directional qualitative information to help us out there. I just figured I would ask, in case you guys would be willing to, whether or not you could just give us core revenue growth by end market and by developed geography in the quarter across all businesses."
265621,402034332,1058402,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Executives","Well, we don't give quite that level of detail, but we did talk about continued double-digit kind of mid-teens growth in India, high single-digit growth in China. Both the U.S. and Western Europe were up low single digits. That's been pretty consistent. I",123,"Well, we don't give quite that level of detail, but we did talk about continued double-digit kind of mid-teens growth in India, high single-digit growth in China. Both the U.S. and Western Europe were up low single digits. That's been pretty consistent. I would add as a footnote probably seeing some incremental signs of weakness in Western Europe, where our overall numbers in Q3 were pretty comparable to what we had in the first half. Tom alluded to the academic comment, seeing a little bit of that industrial weakness in places like Hach. Not a big change, but probably on the margin, the tone is a little bit cautious in Western Europe. And Japan, we continue to be down low to mid-single digits."
265621,402034332,1058402,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Operator","We'll go next to the line of Derik De Bruin from Bank of America.",15,"We'll go next to the line of Derik De Bruin from Bank of America."
265621,402034332,1058402,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Analysts","So before I ask another geography question, I just wanted to ask a Diagnostics question. So it's been -- you've closed the Cepheid -- or you haven't closed it, but you've announced the Cepheid transaction. You've had a little bit more time to think about",90,"So before I ask another geography question, I just wanted to ask a Diagnostics question. So it's been -- you've closed the Cepheid -- or you haven't closed it, but you've announced the Cepheid transaction. You've had a little bit more time to think about it. Any further additional thoughts on where you think you can ultimately get the gross margin on the Cepheid products? That was sort of a topic when we did the call the last time. I just wondered if you have any further thoughts on it."
265621,402034332,1058402,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Executives","Derik, thanks. I don't know that we have a lot more to offer. During due diligence, we were able to spend a good deal of time with the team and understand the road map that they had laid out for gross margin. You've heard a lot of that from the business i",150,"Derik, thanks. I don't know that we have a lot more to offer. During due diligence, we were able to spend a good deal of time with the team and understand the road map that they had laid out for gross margin. You've heard a lot of that from the business in terms of the opportunities around improving the cost structure of the cartridge. We think those are very credible. We think they've got a solid road map for executing on those improvements. And obviously, once we've closed the transaction and we can engage directly with them, we'll be bringing the tools of the Danaher Business System that we've used successfully in a number of other businesses to improve gross margin. You just heard Dan comment about what we've done at Beckman. And we'll obviously bring that to bear at Cepheid, and I think you'll see those improvements come through."
265621,402034332,1058402,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Analysts","Great. And just wondered -- one more question, Europe question. Are you seeing -- is it budget delays that you're seeing or people just canceling orders or people just hesitating on spending? Just a little bit more color on what's going on in terms of spe",63,"Great. And just wondered -- one more question, Europe question. Are you seeing -- is it budget delays that you're seeing or people just canceling orders or people just hesitating on spending? Just a little bit more color on what's going on in terms of specific just trends, if there's anything you can sort of draw from what you're seeing across the businesses."
265621,402034332,1058402,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Executives","Derik, was that a Europe question, I'm sorry?",8,"Derik, was that a Europe question, I'm sorry?"
265621,402034332,1058402,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Analysts","It's a Western Europe question, yes.",7,"It's a Western Europe question, yes."
265621,402034332,1058402,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Executives","Yes. Much more in terms of delays than cancellations, we tend to see, both at the tendering level as well as at the purchase order level, folks hanging back. In certain cases, it's because budgets haven't been fully approved yet. In other cases, they're j",70,"Yes. Much more in terms of delays than cancellations, we tend to see, both at the tendering level as well as at the purchase order level, folks hanging back. In certain cases, it's because budgets haven't been fully approved yet. In other cases, they're just trying to get paper work through approvals. And normally, that's a circumstance where, because of some levels of austerity, folks are just slowing things down."
265621,402034332,1058402,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Operator","And our final question comes from Nigel Coe with Morgan Stanley.",11,"And our final question comes from Nigel Coe with Morgan Stanley."
265621,402034332,1058402,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Analysts","So we covered a lot of ground so I want to keep this relatively quick. But on -- I did want to come back to Dental. There's obviously a lot of noise from some of your competitors regarding the U.S. channel. So I'm just wondering, given the recovery we've",79,"So we covered a lot of ground so I want to keep this relatively quick. But on -- I did want to come back to Dental. There's obviously a lot of noise from some of your competitors regarding the U.S. channel. So I'm just wondering, given the recovery we've seen -- the large recovery we've seen in core growth rates in Dental, how confident are you, you can sustain this level of growth in the sort of 3%-plus bracket?"
265621,402034332,1058402,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Executives","Well, clearly, there's some cause for concern or caution around that, given some of the narrative that we heard from the channel during the course of the quarter. We saw some of that in the month of September come through in terms of the order rates on th",104,"Well, clearly, there's some cause for concern or caution around that, given some of the narrative that we heard from the channel during the course of the quarter. We saw some of that in the month of September come through in terms of the order rates on the consumable side. So I think we feel pretty good about continuing to improve our own execution, particularly on the equipment side, also at Nobel. But I think on the consumable side, we'll need to make sure that we're seeing some improvement in the sellout, either from a programmatic perspective or just from an overall macroeconomic perspective."
265621,402034332,1058402,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Analysts","Great, okay. And then Diagnostics, we don't have a great history on the quarterly performance of Diagnostics. But it does feel like, last year, we saw maybe an unusually large Q-over-Q step down in margins in 3Q, followed by a pretty big pickup in 4Q. Wou",106,"Great, okay. And then Diagnostics, we don't have a great history on the quarterly performance of Diagnostics. But it does feel like, last year, we saw maybe an unusually large Q-over-Q step down in margins in 3Q, followed by a pretty big pickup in 4Q. Would you expect to see a similar 4Q buildup as the 3Q? And then more broadly on 4Q restructuring across the portfolio. In the past, Danaher was -- had very heavy restructuring actions in 4Q. I know this year is not going to be anywhere like that, but maybe just comment on how you see 4Q restructuring actions across the portfolio."
265621,402034332,1058402,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Executives","Yes. Nigel, on Diagnostics first. Seasonally, Q3 tends to be a little lighter, so that played out again. This year there was a big improvement versus Q3 a year ago, and we do expect a nice seasonal pickup in Q4. I would expect margins above where they wer",104,"Yes. Nigel, on Diagnostics first. Seasonally, Q3 tends to be a little lighter, so that played out again. This year there was a big improvement versus Q3 a year ago, and we do expect a nice seasonal pickup in Q4. I would expect margins above where they were a year ago Q4, which were -- was north of 18%. Regarding restructuring, we continue to take actions throughout the year. We don't really kind of call those out. I would expect our overall restructuring spend to be in the same ballpark as last year, again probably a little bit more evenly distributed through the year."
265621,402034332,1058402,"Danaher Corp., Q3 2016 Earnings Call, Oct 20, 2016",2016-10-20,"Earnings Calls","Danaher Corporation","Operator","And at this time, we would like to thank everybody for their participation on today's conference call. Please feel free to disconnect your line at any time.",27,"And at this time, we would like to thank everybody for their participation on today's conference call. Please feel free to disconnect your line at any time."
